NIBR DRUG-seq U2OS MoA Box Gene Expression Profiles Dataset

Description Drug perturbation signatures created by profiling 4343 small molecules in the U2-OS cell line with the DRUG-seq platform
Measurement gene expression by RNA-seq
Association gene-drug perturbation associations by differential expression of gene following drug perturbation
Category transcriptomics
Resource Novartis Institutes for Biomedical Research
Citation(s)
Last Updated Thu Apr 17 00:00:00 UTC 2025
Stats
  1. 12895 genes
  2. 15960 drug perturbations
  3. 2391032 gene-drug perturbation associations

Data Access

API
Script

Visualizations

  • Gene Attribute

  • Gene Similarity

  • Attribute Similarity

  • UMAP

drug perturbation Gene Sets

15960 sets of genes differentially expressed following drug perturbation from the NIBR DRUG-seq U2OS MoA Box dataset.

Gene Set Description
AA-01-JO26_0.01uM Dose=0.01uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
AA-01-JO26_0.1uM Dose=0.1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
AA-01-JO26_10uM Dose=10uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
AA-01-JO26_1uM Dose=1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
AA-01-PS31_0.01uM Dose=0.01uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11
AA-01-PS31_0.1uM Dose=0.1uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11
AA-01-PS31_10uM Dose=10uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11
AA-01-PS31_1uM Dose=1uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11
AA-01-XV28_0.01uM Dose=0.01uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2
AA-01-XV28_0.1uM Dose=0.1uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2
AA-01-XV28_10uM Dose=10uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2
AA-01-XV28_1uM Dose=1uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2
AA-02-FS13_0.01uM Dose=0.01uM, Benzylhydrazine
AA-02-FS13_0.1uM Dose=0.1uM, Benzylhydrazine
AA-02-FS13_10uM Dose=10uM, Benzylhydrazine
AA-02-FS13_1uM Dose=1uM, Benzylhydrazine
AA-03-QM41_0.01uM Dose=0.01uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R
AA-03-QM41_0.1uM Dose=0.1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R
AA-03-QM41_10uM Dose=10uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R
AA-03-QM41_1uM Dose=1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R
AA-07-BW60_0.01uM Dose=0.01uM, Moclobemide, MAO-A Inhibitors targeting MAOA
AA-07-BW60_0.1uM Dose=0.1uM, Moclobemide, MAO-A Inhibitors targeting MAOA
AA-07-BW60_10uM Dose=10uM, Moclobemide, MAO-A Inhibitors targeting MAOA
AA-07-BW60_1uM Dose=1uM, Moclobemide, MAO-A Inhibitors targeting MAOA
AA-07-FZ97_0.01uM Dose=0.01uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1
AA-07-FZ97_0.1uM Dose=0.1uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1
AA-07-FZ97_10uM Dose=10uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1
AA-07-FZ97_1uM Dose=1uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1
AA-09-HG96_0.01uM Dose=0.01uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA
AA-09-HG96_0.1uM Dose=0.1uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA
AA-09-HG96_10uM Dose=10uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA
AA-09-HG96_1uM Dose=1uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA
AA-10-BH32_0.01uM Dose=0.01uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP
AA-10-BH32_0.1uM Dose=0.1uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP
AA-10-BH32_10uM Dose=10uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP
AA-10-BH32_1uM Dose=1uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP
AA-10-VR76_0.01uM Dose=0.01uM, Hexachlorophene, Autotaxin) Inhibitors;Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2, SDHD
AA-10-VR76_0.1uM Dose=0.1uM, Hexachlorophene, Autotaxin) Inhibitors;Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2, SDHD
AA-10-VR76_10uM Dose=10uM, Hexachlorophene, Autotaxin) Inhibitors;Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2, SDHD
AA-11-RO46_0.01uM Dose=0.01uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6
AA-11-RO46_0.1uM Dose=0.1uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6
AA-11-RO46_10uM Dose=10uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6
AA-11-RO46_1uM Dose=1uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6
AA-12-SS68_0.01uM Dose=0.01uM
AA-12-SS68_0.1uM Dose=0.1uM
AA-12-SS68_10uM Dose=10uM
AA-12-SS68_1uM Dose=1uM
AA-12-VW53_0.01uM Dose=0.01uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1
AA-12-VW53_0.1uM Dose=0.1uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1
AA-12-VW53_10uM Dose=10uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1
AA-12-VW53_1uM Dose=1uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1
AA-13-DN24_0.01uM Dose=0.01uM, Eliprodil, NMDA Antagonists targeting GRIN1
AA-13-DN24_0.1uM Dose=0.1uM, Eliprodil, NMDA Antagonists targeting GRIN1
AA-13-DN24_10uM Dose=10uM, Eliprodil, NMDA Antagonists targeting GRIN1
AA-13-DN24_1uM Dose=1uM, Eliprodil, NMDA Antagonists targeting GRIN1
AA-13-FM86_0.01uM Dose=0.01uM, Alagebrium
AA-13-FM86_1uM Dose=1uM, Alagebrium
AA-14-DQ28_0.01uM Dose=0.01uM, Estradiol
AA-14-DQ28_0.1uM Dose=0.1uM, Estradiol
AA-14-DQ28_10uM Dose=10uM, Estradiol
AA-14-DQ28_1uM Dose=1uM, Estradiol
AA-14-SG39_0.01uM Dose=0.01uM, (2R)-2-[(4-phenoxyphenyl)sulfonylamino]-5-(1,1,3-trioxo-1,2-benzothiazol-2-yl)pentanoic acid
AA-14-SG39_0.1uM Dose=0.1uM, (2R)-2-[(4-phenoxyphenyl)sulfonylamino]-5-(1,1,3-trioxo-1,2-benzothiazol-2-yl)pentanoic acid
AA-14-SG39_10uM Dose=10uM, (2R)-2-[(4-phenoxyphenyl)sulfonylamino]-5-(1,1,3-trioxo-1,2-benzothiazol-2-yl)pentanoic acid
AA-14-VK39_0.01uM Dose=0.01uM, N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide
AA-14-VK39_0.1uM Dose=0.1uM, N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide
AA-14-VK39_10uM Dose=10uM, N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide
AA-15-HO31_0.1uM Dose=0.1uM, Batimastat, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting FCER2, MMP14, MMP16, MMP11, FCER1A, MS4A2, MMP15, MMP17, MMP19, MMP23A, MMP20, MS4A7, MMP27, MMP28, MMP21
AA-15-HO31_10uM Dose=10uM, Batimastat, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting FCER2, MMP14, MMP16, MMP11, FCER1A, MS4A2, MMP15, MMP17, MMP19, MMP23A, MMP20, MS4A7, MMP27, MMP28, MMP21
AA-15-HO31_1uM Dose=1uM, Batimastat, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting FCER2, MMP14, MMP16, MMP11, FCER1A, MS4A2, MMP15, MMP17, MMP19, MMP23A, MMP20, MS4A7, MMP27, MMP28, MMP21
AA-15-VA57_0.01uM Dose=0.01uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG
AA-15-VA57_0.1uM Dose=0.1uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG
AA-15-VA57_10uM Dose=10uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG
AA-15-VA57_1uM Dose=1uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG
AA-16-HV95_0.01uM Dose=0.01uM
AA-16-HV95_0.1uM Dose=0.1uM
AA-16-HV95_10uM Dose=10uM
AA-16-HV95_1uM Dose=1uM
AA-17-RC87_0.01uM Dose=0.01uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1
AA-17-RC87_0.1uM Dose=0.1uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1
AA-17-RC87_10uM Dose=10uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1
AA-17-RC87_1uM Dose=1uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1
AA-18-BW97_0.01uM Dose=0.01uM, Phentolamine, alpha-Adrenoceptor Antagonists targeting ADRA1B
AA-18-BW97_10uM Dose=10uM, Phentolamine, alpha-Adrenoceptor Antagonists targeting ADRA1B
AA-18-BW97_1uM Dose=1uM, Phentolamine, alpha-Adrenoceptor Antagonists targeting ADRA1B
AA-18-GQ83_0.01uM Dose=0.01uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide
AA-18-GQ83_0.1uM Dose=0.1uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide
AA-18-GQ83_10uM Dose=10uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide
AA-18-GQ83_1uM Dose=1uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide
AA-19-EX72_0.01uM Dose=0.01uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A
AA-19-EX72_0.1uM Dose=0.1uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A
AA-19-EX72_10uM Dose=10uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A
AA-19-EX72_1uM Dose=1uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A
AA-19-SX47_0.01uM Dose=0.01uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1
AA-19-SX47_0.1uM Dose=0.1uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1
AA-19-SX47_10uM Dose=10uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1
AA-19-SX47_1uM Dose=1uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1
AA-20-DK54_0.01uM Dose=0.01uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
AA-20-DK54_0.1uM Dose=0.1uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
AA-20-DK54_10uM Dose=10uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
AA-20-DK54_1uM Dose=1uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
AA-22-FS33_0.01uM Dose=0.01uM, Vatalanib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors;VEGFR-1 (Flt-1) Inhibitors;KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways;Aromatase Inhibitors;Angiogenesis Inhibitors targeting FLT1, KDR, KIT
AA-22-FS33_10uM Dose=10uM, Vatalanib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors;VEGFR-1 (Flt-1) Inhibitors;KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways;Aromatase Inhibitors;Angiogenesis Inhibitors targeting FLT1, KDR, KIT
AA-22-PQ14_0.01uM Dose=0.01uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A
AA-22-PQ14_0.1uM Dose=0.1uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A
AA-22-PQ14_10uM Dose=10uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A
AA-22-PQ14_1uM Dose=1uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A
AA-22-SF72_0.01uM Dose=0.01uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET
AA-22-SF72_0.1uM Dose=0.1uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET
AA-22-SF72_10uM Dose=10uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET
AA-22-SF72_1uM Dose=1uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET
AA-22-UI44_0.01uM Dose=0.01uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AA-22-UI44_0.1uM Dose=0.1uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AA-22-UI44_10uM Dose=10uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AA-22-UI44_1uM Dose=1uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AA-23-FM46_0.01uM Dose=0.01uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AA-23-FM46_0.1uM Dose=0.1uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AA-23-FM46_10uM Dose=10uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AA-23-FM46_1uM Dose=1uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AA-24-EN31_0.01uM Dose=0.01uM, (5R,8S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-7-[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]amino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AA-24-EN31_10uM Dose=10uM, (5R,8S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-7-[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]amino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AA-24-EN31_1uM Dose=1uM, (5R,8S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-7-[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]amino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AA-24-SQ13_0.01uM Dose=0.01uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1
AA-24-SQ13_0.1uM Dose=0.1uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1
AA-24-SQ13_10uM Dose=10uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1
AA-24-SQ13_1uM Dose=1uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1
AA-24-UO04_0.01uM Dose=0.01uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F
AA-24-UO04_0.1uM Dose=0.1uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F
AA-24-UO04_10uM Dose=10uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F
AA-24-UO04_1uM Dose=1uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F
AA-27-LG62_0.01uM Dose=0.01uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG
AA-27-LG62_0.1uM Dose=0.1uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG
AA-27-LG62_10uM Dose=10uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG
AA-27-LG62_1uM Dose=1uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG
AA-27-TF89_0.01uM Dose=0.01uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B
AA-27-TF89_0.1uM Dose=0.1uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B
AA-27-TF89_10uM Dose=10uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B
AA-27-TF89_1uM Dose=1uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B
AA-28-PM33_0.01uM Dose=0.01uM, Cromolyn, Mediator Release Inhibitors targeting S100P
AA-28-PM33_0.1uM Dose=0.1uM, Cromolyn, Mediator Release Inhibitors targeting S100P
AA-28-PM33_10uM Dose=10uM, Cromolyn, Mediator Release Inhibitors targeting S100P
AA-28-PM33_1uM Dose=1uM, Cromolyn, Mediator Release Inhibitors targeting S100P
AA-29-ZN08_0.01uM Dose=0.01uM, 1-[2-(2-Ethyltetrazol-5-yl)ethyl]-3-[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]urea, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
AA-29-ZN08_0.1uM Dose=0.1uM, 1-[2-(2-Ethyltetrazol-5-yl)ethyl]-3-[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]urea, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
AA-29-ZN08_10uM Dose=10uM, 1-[2-(2-Ethyltetrazol-5-yl)ethyl]-3-[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]urea, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
AA-29-ZN08_1uM Dose=1uM, 1-[2-(2-Ethyltetrazol-5-yl)ethyl]-3-[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]urea, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
AA-30-BE85_10uM Dose=10uM, 4,7-Dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one, EWS-FLI1 Inhibitors targeting EWSR1, FLI1
AA-30-BE85_1uM Dose=1uM, 4,7-Dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one, EWS-FLI1 Inhibitors targeting EWSR1, FLI1
AA-31-NO26_0.01uM Dose=0.01uM, Carbamazepine, Sodium Channel Blockers targeting SCN5A, SCN10A
AA-31-NO26_0.1uM Dose=0.1uM, Carbamazepine, Sodium Channel Blockers targeting SCN5A, SCN10A
AA-31-NO26_1uM Dose=1uM, Carbamazepine, Sodium Channel Blockers targeting SCN5A, SCN10A
AA-31-OE22_0.01uM Dose=0.01uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione
AA-31-OE22_0.1uM Dose=0.1uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione
AA-31-OE22_10uM Dose=10uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione
AA-31-OE22_1uM Dose=1uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione
AA-31-YE07_0.01uM Dose=0.01uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
AA-31-YE07_0.1uM Dose=0.1uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
AA-31-YE07_10uM Dose=10uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
AA-31-YE07_1uM Dose=1uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
AA-32-DP01_0.1uM Dose=0.1uM, 1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea, SIK1 gene inhibitor targeting SIK2, SIK3, SIK1
AA-32-DP01_10uM Dose=10uM, 1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea, SIK1 gene inhibitor targeting SIK2, SIK3, SIK1
AA-32-DP01_1uM Dose=1uM, 1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea, SIK1 gene inhibitor targeting SIK2, SIK3, SIK1
AA-33-DN24_0.01uM Dose=0.01uM, Olprinone
AA-33-DN24_0.1uM Dose=0.1uM, Olprinone
AA-33-DN24_10uM Dose=10uM, Olprinone
AA-33-DN24_1uM Dose=1uM, Olprinone
AA-33-TW45_0.01uM Dose=0.01uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL
AA-33-TW45_0.1uM Dose=0.1uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL
AA-33-TW45_10uM Dose=10uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL
AA-33-TW45_1uM Dose=1uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL
AA-34-SG19_0.01uM Dose=0.01uM, Abitesartan, Angiotensin AT1 Antagonists targeting AGTR1
AA-34-SG19_10uM Dose=10uM, Abitesartan, Angiotensin AT1 Antagonists targeting AGTR1
AA-34-SG19_1uM Dose=1uM, Abitesartan, Angiotensin AT1 Antagonists targeting AGTR1
AA-35-LB45_0.01uM Dose=0.01uM, Amoxapine, 5-HT Reuptake Inhibitors;5-HT2A Antagonists;Norepinephrine Reuptake Inhibitors targeting HTR2A, SLC6A2, SLC6A4
AA-35-LB45_10uM Dose=10uM, Amoxapine, 5-HT Reuptake Inhibitors;5-HT2A Antagonists;Norepinephrine Reuptake Inhibitors targeting HTR2A, SLC6A2, SLC6A4
AA-35-LB45_1uM Dose=1uM, Amoxapine, 5-HT Reuptake Inhibitors;5-HT2A Antagonists;Norepinephrine Reuptake Inhibitors targeting HTR2A, SLC6A2, SLC6A4
AA-35-QK71_0.01uM Dose=0.01uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH
AA-35-QK71_0.1uM Dose=0.1uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH
AA-35-QK71_10uM Dose=10uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH
AA-35-QK71_1uM Dose=1uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH
AA-35-VH74_0.01uM Dose=0.01uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3
AA-35-VH74_0.1uM Dose=0.1uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3
AA-35-VH74_10uM Dose=10uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3
AA-35-VH74_1uM Dose=1uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3
AA-36-YV45_0.01uM Dose=0.01uM, 5-Nitrosalicylaldehyde, Glucose-6-phosphatase Inhibitors targeting G6PC
AA-36-YV45_0.1uM Dose=0.1uM, 5-Nitrosalicylaldehyde, Glucose-6-phosphatase Inhibitors targeting G6PC
AA-36-YV45_10uM Dose=10uM, 5-Nitrosalicylaldehyde, Glucose-6-phosphatase Inhibitors targeting G6PC
AA-36-YV45_1uM Dose=1uM, 5-Nitrosalicylaldehyde, Glucose-6-phosphatase Inhibitors targeting G6PC
AA-38-TT50_0.01uM Dose=0.01uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55
AA-38-TT50_0.1uM Dose=0.1uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55
AA-38-TT50_10uM Dose=10uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55
AA-38-TT50_1uM Dose=1uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55
AA-39-BD24_0.01uM Dose=0.01uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1
AA-39-BD24_0.1uM Dose=0.1uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1
AA-39-BD24_10uM Dose=10uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1
AA-39-BD24_1uM Dose=1uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1
AA-39-ZQ15_0.01uM Dose=0.01uM, Phenylbutyric acid, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers targeting HDAC3
AA-39-ZQ15_0.1uM Dose=0.1uM, Phenylbutyric acid, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers targeting HDAC3
AA-39-ZQ15_10uM Dose=10uM, Phenylbutyric acid, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers targeting HDAC3
AA-39-ZQ15_1uM Dose=1uM, Phenylbutyric acid, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers targeting HDAC3
AA-40-IA00_0.01uM Dose=0.01uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1
AA-40-IA00_0.1uM Dose=0.1uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1
AA-40-IA00_10uM Dose=10uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1
AA-40-IA00_1uM Dose=1uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1
AA-42-JP76_0.01uM Dose=0.01uM, Imiquimod, Interferon Inducers;TLR7 Receptor Agonists targeting NQO2, TLR7
AA-42-JP76_10uM Dose=10uM, Imiquimod, Interferon Inducers;TLR7 Receptor Agonists targeting NQO2, TLR7
AA-42-XZ05_0.01uM Dose=0.01uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4
AA-42-XZ05_0.1uM Dose=0.1uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4
AA-42-XZ05_10uM Dose=10uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4
AA-42-XZ05_1uM Dose=1uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4
AA-43-BW50_0.01uM Dose=0.01uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3
AA-43-BW50_0.1uM Dose=0.1uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3
AA-43-BW50_10uM Dose=10uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3
AA-43-BW50_1uM Dose=1uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3
AA-43-TW35_0.01uM Dose=0.01uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B
AA-43-TW35_0.1uM Dose=0.1uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B
AA-43-TW35_10uM Dose=10uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B
AA-43-TW35_1uM Dose=1uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B
AA-44-BX20_0.01uM Dose=0.01uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid
AA-44-BX20_0.1uM Dose=0.1uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid
AA-44-BX20_10uM Dose=10uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid
AA-44-BX20_1uM Dose=1uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid
AA-45-AA67_0.01uM Dose=0.01uM, Fluorouracil, thymidylate synthase targeting TYMS
AA-45-AA67_0.1uM Dose=0.1uM, Fluorouracil, thymidylate synthase targeting TYMS
AA-45-AA67_10uM Dose=10uM, Fluorouracil, thymidylate synthase targeting TYMS
AA-45-AA67_1uM Dose=1uM, Fluorouracil, thymidylate synthase targeting TYMS
AA-45-BL29_0.01uM Dose=0.01uM, DL-Tyrosine
AA-45-BL29_0.1uM Dose=0.1uM, DL-Tyrosine
AA-45-BL29_10uM Dose=10uM, DL-Tyrosine
AA-45-SU80_0.01uM Dose=0.01uM, Phenylpiperazine
AA-45-SU80_0.1uM Dose=0.1uM, Phenylpiperazine
AA-45-SU80_10uM Dose=10uM, Phenylpiperazine
AA-45-SU80_1uM Dose=1uM, Phenylpiperazine
AA-46-GL76_0.01uM Dose=0.01uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3
AA-46-GL76_0.1uM Dose=0.1uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3
AA-46-GL76_10uM Dose=10uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3
AA-46-GL76_1uM Dose=1uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3
AA-46-HS88_0.01uM Dose=0.01uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3
AA-46-HS88_0.1uM Dose=0.1uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3
AA-46-HS88_10uM Dose=10uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3
AA-46-HS88_1uM Dose=1uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3
AA-47-BS40_0.01uM Dose=0.01uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B
AA-47-BS40_0.1uM Dose=0.1uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B
AA-47-BS40_10uM Dose=10uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B
AA-47-BS40_1uM Dose=1uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B
AA-47-MP58_0.01uM Dose=0.01uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119
AA-47-MP58_0.1uM Dose=0.1uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119
AA-47-MP58_10uM Dose=10uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119
AA-47-MP58_1uM Dose=1uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119
AA-48-GT70_0.01uM Dose=0.01uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT
AA-48-GT70_0.1uM Dose=0.1uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT
AA-48-GT70_10uM Dose=10uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT
AA-48-GT70_1uM Dose=1uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT
AA-48-XT80_0.01uM Dose=0.01uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine
AA-48-XT80_0.1uM Dose=0.1uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine
AA-48-XT80_10uM Dose=10uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine
AA-48-XT80_1uM Dose=1uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine
AA-49-BD04_0.1uM Dose=0.1uM, Purvalanol A, CDK1/Cyclin B Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase (DYRK) Inhibitors;CDK2/Cyclin A Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK2/Cyclin E Inhibitors;CDK5 Inhibitors targeting CHUK, CCNA1, CCNB2, CCNE2, CCNB3
AA-49-BD04_10uM Dose=10uM, Purvalanol A, CDK1/Cyclin B Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase (DYRK) Inhibitors;CDK2/Cyclin A Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK2/Cyclin E Inhibitors;CDK5 Inhibitors targeting CHUK, CCNA1, CCNB2, CCNE2, CCNB3
AA-49-BD04_1uM Dose=1uM, Purvalanol A, CDK1/Cyclin B Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase (DYRK) Inhibitors;CDK2/Cyclin A Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK2/Cyclin E Inhibitors;CDK5 Inhibitors targeting CHUK, CCNA1, CCNB2, CCNE2, CCNB3
AA-49-HG46_0.01uM Dose=0.01uM
AA-49-HG46_0.1uM Dose=0.1uM
AA-49-HG46_10uM Dose=10uM
AA-49-HG46_1uM Dose=1uM
AA-50-FY68_0.01uM Dose=0.01uM
AA-50-FY68_0.1uM Dose=0.1uM
AA-50-FY68_10uM Dose=10uM
AA-50-FY68_1uM Dose=1uM
AA-50-HR61_0.01uM Dose=0.01uM, Rifampin, RNA Polymerase (Bacterial) Inhibitors;Enzyme Inducers;DNA-Directed RNA Polymerase Inhibitors targeting NR1I2, SLCO1B1, POLRMT
AA-50-HR61_0.1uM Dose=0.1uM, Rifampin, RNA Polymerase (Bacterial) Inhibitors;Enzyme Inducers;DNA-Directed RNA Polymerase Inhibitors targeting NR1I2, SLCO1B1, POLRMT
AA-50-HR61_10uM Dose=10uM, Rifampin, RNA Polymerase (Bacterial) Inhibitors;Enzyme Inducers;DNA-Directed RNA Polymerase Inhibitors targeting NR1I2, SLCO1B1, POLRMT
AA-51-RY00_0.01uM Dose=0.01uM, Chlorambucil
AA-51-RY00_0.1uM Dose=0.1uM, Chlorambucil
AA-51-RY00_10uM Dose=10uM, Chlorambucil
AA-51-RY00_1uM Dose=1uM, Chlorambucil
AA-52-JS03_0.01uM Dose=0.01uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
AA-52-JS03_0.1uM Dose=0.1uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
AA-52-JS03_10uM Dose=10uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
AA-52-JS03_1uM Dose=1uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
AA-54-WG39_0.01uM Dose=0.01uM, 4-Aminobenzamide
AA-54-WG39_0.1uM Dose=0.1uM, 4-Aminobenzamide
AA-54-WG39_10uM Dose=10uM, 4-Aminobenzamide
AA-54-WG39_1uM Dose=1uM, 4-Aminobenzamide
AA-56-AB37_0.01uM Dose=0.01uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1
AA-56-AB37_0.1uM Dose=0.1uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1
AA-56-AB37_10uM Dose=10uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1
AA-56-AB37_1uM Dose=1uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1
AA-56-DV95_0.01uM Dose=0.01uM
AA-56-DV95_0.1uM Dose=0.1uM
AA-56-DV95_10uM Dose=10uM
AA-56-DV95_1uM Dose=1uM
AA-56-JY17_0.01uM Dose=0.01uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1
AA-56-JY17_0.1uM Dose=0.1uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1
AA-56-JY17_10uM Dose=10uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1
AA-56-JY17_1uM Dose=1uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1
AA-56-KV80_0.01uM Dose=0.01uM, Almorexant, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
AA-56-KV80_0.1uM Dose=0.1uM, Almorexant, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
AA-56-KV80_10uM Dose=10uM, Almorexant, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
AA-56-KV80_1uM Dose=1uM, Almorexant, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
AA-56-QO38_0.01uM Dose=0.01uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B
AA-56-QO38_0.1uM Dose=0.1uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B
AA-56-QO38_10uM Dose=10uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B
AA-56-QO38_1uM Dose=1uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B
AA-57-CF49_0.01uM Dose=0.01uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1
AA-57-CF49_0.1uM Dose=0.1uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1
AA-57-CF49_10uM Dose=10uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1
AA-57-CF49_1uM Dose=1uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1
AA-57-FZ47_0.01uM Dose=0.01uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3
AA-57-FZ47_0.1uM Dose=0.1uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3
AA-57-FZ47_10uM Dose=10uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3
AA-57-FZ47_1uM Dose=1uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3
AA-58-BW57_0.01uM Dose=0.01uM, Niguldipine, Adrenergic receptor modulator;Calcium Channel Blockers targeting ADRA1B, CACNA1I, CACNA1H, CACNA1G
AA-58-BW57_10uM Dose=10uM, Niguldipine, Adrenergic receptor modulator;Calcium Channel Blockers targeting ADRA1B, CACNA1I, CACNA1H, CACNA1G
AA-58-BW57_1uM Dose=1uM, Niguldipine, Adrenergic receptor modulator;Calcium Channel Blockers targeting ADRA1B, CACNA1I, CACNA1H, CACNA1G
AA-58-FJ71_0.01uM Dose=0.01uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4
AA-58-FJ71_0.1uM Dose=0.1uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4
AA-58-FJ71_10uM Dose=10uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4
AA-58-FJ71_1uM Dose=1uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4
AA-58-JC44_0.01uM Dose=0.01uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2
AA-58-JC44_0.1uM Dose=0.1uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2
AA-58-JC44_10uM Dose=10uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2
AA-58-JC44_1uM Dose=1uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2
AA-59-HG56_0.01uM Dose=0.01uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B
AA-59-HG56_0.1uM Dose=0.1uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B
AA-59-HG56_10uM Dose=10uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B
AA-59-HG56_1uM Dose=1uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B
AA-61-KE62_0.01uM Dose=0.01uM, 3-[2-[[6-(2-Methoxyethoxy)pyrazin-2-yl]amino]-5-(1,2,4-triazol-1-yl)-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3
AA-61-KE62_0.1uM Dose=0.1uM, 3-[2-[[6-(2-Methoxyethoxy)pyrazin-2-yl]amino]-5-(1,2,4-triazol-1-yl)-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3
AA-61-KE62_10uM Dose=10uM, 3-[2-[[6-(2-Methoxyethoxy)pyrazin-2-yl]amino]-5-(1,2,4-triazol-1-yl)-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3
AA-62-HP31_0.01uM Dose=0.01uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG
AA-62-HP31_0.1uM Dose=0.1uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG
AA-62-HP31_10uM Dose=10uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG
AA-62-HP31_1uM Dose=1uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG
AA-62-JP26_0.1uM Dose=0.1uM, (7R)-2-amino-7-[4-fluoro-2-(2-methoxy-1,3-thiazol-4-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
AA-62-JP26_10uM Dose=10uM, (7R)-2-amino-7-[4-fluoro-2-(2-methoxy-1,3-thiazol-4-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
AA-62-JP26_1uM Dose=1uM, (7R)-2-amino-7-[4-fluoro-2-(2-methoxy-1,3-thiazol-4-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
AA-62-OC45_0.01uM Dose=0.01uM
AA-62-OC45_10uM Dose=10uM
AA-62-OC45_1uM Dose=1uM
AA-62-XS38_0.01uM Dose=0.01uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2
AA-62-XS38_0.1uM Dose=0.1uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2
AA-62-XS38_10uM Dose=10uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2
AA-62-XS38_1uM Dose=1uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2
AA-64-WG29_0.01uM Dose=0.01uM, Cgs-27023, Matrix metalloproteinase inhibitor;MMP-9 (Gelatinase B) Inhibitors;Angiogenesis Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP8, MMP9, MMP14, MMP16, MMP11, MMP15, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
AA-64-WG29_10uM Dose=10uM, Cgs-27023, Matrix metalloproteinase inhibitor;MMP-9 (Gelatinase B) Inhibitors;Angiogenesis Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP8, MMP9, MMP14, MMP16, MMP11, MMP15, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
AA-64-WG29_1uM Dose=1uM, Cgs-27023, Matrix metalloproteinase inhibitor;MMP-9 (Gelatinase B) Inhibitors;Angiogenesis Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP8, MMP9, MMP14, MMP16, MMP11, MMP15, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
AA-66-PC55_0.1uM Dose=0.1uM, 9-Azapaullone, CDK9/Cyclin T1 Inhibitors;Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting CCNT1, CDK9, GSK3A
AA-66-PC55_10uM Dose=10uM, 9-Azapaullone, CDK9/Cyclin T1 Inhibitors;Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting CCNT1, CDK9, GSK3A
AA-66-YY32_0.1uM Dose=0.1uM, Serazapine, 5-HT2A Antagonists targeting HTR2A
AA-66-YY32_10uM Dose=10uM, Serazapine, 5-HT2A Antagonists targeting HTR2A
AA-66-YY32_1uM Dose=1uM, Serazapine, 5-HT2A Antagonists targeting HTR2A
AA-67-FZ57_10uM Dose=10uM, Isothiourea-1a, HIV Attachment Inhibitors;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4
AA-67-FZ57_1uM Dose=1uM, Isothiourea-1a, HIV Attachment Inhibitors;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4
AA-67-JI21_0.01uM Dose=0.01uM, Tryptamine
AA-67-JI21_0.1uM Dose=0.1uM, Tryptamine
AA-67-JI21_10uM Dose=10uM, Tryptamine
AA-67-JI21_1uM Dose=1uM, Tryptamine
AA-67-TF79_0.01uM Dose=0.01uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1
AA-67-TF79_0.1uM Dose=0.1uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1
AA-67-TF79_10uM Dose=10uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1
AA-67-TF79_1uM Dose=1uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1
AA-67-TP08_0.01uM Dose=0.01uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1
AA-67-TP08_0.1uM Dose=0.1uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1
AA-67-TP08_10uM Dose=10uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1
AA-67-TP08_1uM Dose=1uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1
AA-68-MW92_0.01uM Dose=0.01uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4
AA-68-MW92_0.1uM Dose=0.1uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4
AA-68-MW92_10uM Dose=10uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4
AA-68-MW92_1uM Dose=1uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4
AA-68-OJ16_0.01uM Dose=0.01uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine
AA-68-OJ16_0.1uM Dose=0.1uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine
AA-68-OJ16_10uM Dose=10uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine
AA-68-OJ16_1uM Dose=1uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine
AA-69-TD29_0.01uM Dose=0.01uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1
AA-69-TD29_0.1uM Dose=0.1uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1
AA-69-TD29_10uM Dose=10uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1
AA-69-TD29_1uM Dose=1uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1
AA-70-DH87_0.01uM Dose=0.01uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B
AA-70-DH87_0.1uM Dose=0.1uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B
AA-70-DH87_10uM Dose=10uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B
AA-70-DH87_1uM Dose=1uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B
AA-70-VU13_0.01uM Dose=0.01uM
AA-70-VU13_0.1uM Dose=0.1uM
AA-70-VU13_10uM Dose=10uM
AA-70-VU13_1uM Dose=1uM
AA-71-XO01_0.01uM Dose=0.01uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38
AA-71-XO01_0.1uM Dose=0.1uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38
AA-71-XO01_10uM Dose=10uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38
AA-71-XO01_1uM Dose=1uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38
AA-72-JP86_0.01uM Dose=0.01uM, Delamanid
AA-72-JP86_0.1uM Dose=0.1uM, Delamanid
AA-72-JP86_10uM Dose=10uM, Delamanid
AA-72-JP86_1uM Dose=1uM, Delamanid
AA-72-QI84_0.01uM Dose=0.01uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1
AA-72-QI84_0.1uM Dose=0.1uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1
AA-72-QI84_10uM Dose=10uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1
AA-72-QI84_1uM Dose=1uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1
AA-74-OG49_0.01uM Dose=0.01uM, Aminoglutethimide, Antiglucocorticoids;Aromatase Inhibitors targeting CYP11A1, CYP19A1, NR3C1
AA-74-OG49_0.1uM Dose=0.1uM, Aminoglutethimide, Antiglucocorticoids;Aromatase Inhibitors targeting CYP11A1, CYP19A1, NR3C1
AA-74-OG49_10uM Dose=10uM, Aminoglutethimide, Antiglucocorticoids;Aromatase Inhibitors targeting CYP11A1, CYP19A1, NR3C1
AA-74-ON06_0.01uM Dose=0.01uM, (2S,4S,5S,7S)-5-amino-4-hydroxy-N-[(1S,2S)-2-hydroxycyclopentyl]-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide
AA-74-ON06_0.1uM Dose=0.1uM, (2S,4S,5S,7S)-5-amino-4-hydroxy-N-[(1S,2S)-2-hydroxycyclopentyl]-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide
AA-74-ON06_10uM Dose=10uM, (2S,4S,5S,7S)-5-amino-4-hydroxy-N-[(1S,2S)-2-hydroxycyclopentyl]-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide
AA-74-ON06_1uM Dose=1uM, (2S,4S,5S,7S)-5-amino-4-hydroxy-N-[(1S,2S)-2-hydroxycyclopentyl]-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide
AA-75-JH89_0.01uM Dose=0.01uM, BAY-598 R-isomer
AA-75-JH89_0.1uM Dose=0.1uM, BAY-598 R-isomer
AA-75-JH89_10uM Dose=10uM, BAY-598 R-isomer
AA-75-JH89_1uM Dose=1uM, BAY-598 R-isomer
AA-76-CL76_0.01uM Dose=0.01uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
AA-76-CL76_0.1uM Dose=0.1uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
AA-76-CL76_10uM Dose=10uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
AA-76-CL76_1uM Dose=1uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
AA-76-VE74_0.01uM Dose=0.01uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2
AA-76-VE74_0.1uM Dose=0.1uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2
AA-76-VE74_10uM Dose=10uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2
AA-76-VE74_1uM Dose=1uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2
AA-77-MP68_0.01uM Dose=0.01uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5
AA-77-MP68_0.1uM Dose=0.1uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5
AA-77-MP68_10uM Dose=10uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5
AA-77-MP68_1uM Dose=1uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5
AA-77-RI81_0.01uM Dose=0.01uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B
AA-77-RI81_0.1uM Dose=0.1uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B
AA-77-RI81_10uM Dose=10uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B
AA-77-RI81_1uM Dose=1uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B
AA-79-SX47_0.01uM Dose=0.01uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2
AA-79-SX47_0.1uM Dose=0.1uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2
AA-79-SX47_10uM Dose=10uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2
AA-79-SX47_1uM Dose=1uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2
AA-80-IA90_0.01uM Dose=0.01uM, Ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3
AA-80-IA90_0.1uM Dose=0.1uM, Ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3
AA-80-IA90_10uM Dose=10uM, Ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3
AA-80-IA90_1uM Dose=1uM, Ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3
AA-80-XK94_0.01uM Dose=0.01uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AA-80-XK94_0.1uM Dose=0.1uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AA-80-XK94_10uM Dose=10uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AA-80-XK94_1uM Dose=1uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AA-81-CY65_0.01uM Dose=0.01uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3
AA-81-CY65_0.1uM Dose=0.1uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3
AA-81-CY65_10uM Dose=10uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3
AA-81-CY65_1uM Dose=1uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3
AA-81-IB40_0.01uM Dose=0.01uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE
AA-81-IB40_0.1uM Dose=0.1uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE
AA-81-IB40_10uM Dose=10uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE
AA-81-IB40_1uM Dose=1uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE
AA-82-RM29_0.01uM Dose=0.01uM, Ascomycin, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA
AA-82-RM29_10uM Dose=10uM, Ascomycin, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA
AA-82-RM29_1uM Dose=1uM, Ascomycin, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA
AA-83-TW85_0.01uM Dose=0.01uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2
AA-83-TW85_0.1uM Dose=0.1uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2
AA-83-TW85_1uM Dose=1uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2
AA-83-YJ04_0.01uM Dose=0.01uM
AA-83-YJ04_0.1uM Dose=0.1uM
AA-83-YJ04_10uM Dose=10uM
AA-83-YJ04_1uM Dose=1uM
AA-84-BX70_0.01uM Dose=0.01uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN
AA-84-BX70_0.1uM Dose=0.1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN
AA-84-BX70_10uM Dose=10uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN
AA-84-BX70_1uM Dose=1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN
AA-84-PX05_0.01uM Dose=0.01uM, 2-Methylsulfinyl-8-pentan-3-ylpyrido[2,3-d]pyrimidin-7-one
AA-84-PX05_0.1uM Dose=0.1uM, 2-Methylsulfinyl-8-pentan-3-ylpyrido[2,3-d]pyrimidin-7-one
AA-84-PX05_10uM Dose=10uM, 2-Methylsulfinyl-8-pentan-3-ylpyrido[2,3-d]pyrimidin-7-one
AA-85-KR83_0.01uM Dose=0.01uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35
AA-85-KR83_0.1uM Dose=0.1uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35
AA-85-KR83_10uM Dose=10uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35
AA-85-KR83_1uM Dose=1uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35
AA-85-LB25_0.01uM Dose=0.01uM, Floxuridine, Pyrimidine Antagonists targeting TYMS
AA-85-LB25_0.1uM Dose=0.1uM, Floxuridine, Pyrimidine Antagonists targeting TYMS
AA-85-LB25_10uM Dose=10uM, Floxuridine, Pyrimidine Antagonists targeting TYMS
AA-85-LB25_1uM Dose=1uM, Floxuridine, Pyrimidine Antagonists targeting TYMS
AA-86-YV75_0.01uM Dose=0.01uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1
AA-86-YV75_0.1uM Dose=0.1uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1
AA-86-YV75_10uM Dose=10uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1
AA-86-YV75_1uM Dose=1uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1
AA-86-YY62_0.01uM Dose=0.01uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12
AA-86-YY62_0.1uM Dose=0.1uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12
AA-86-YY62_10uM Dose=10uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12
AA-86-YY62_1uM Dose=1uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12
AA-87-EI21_0.01uM Dose=0.01uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A
AA-87-EI21_0.1uM Dose=0.1uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A
AA-87-EI21_10uM Dose=10uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A
AA-87-EI21_1uM Dose=1uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A
AA-87-MP18_0.1uM Dose=0.1uM, N-(2-Chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)phenyl)-6-methylpyridin-3-amine, mglu5 Receptor (mgluR5) Ligands targeting GRM5
AA-87-MP18_10uM Dose=10uM, N-(2-Chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)phenyl)-6-methylpyridin-3-amine, mglu5 Receptor (mgluR5) Ligands targeting GRM5
AA-87-MP18_1uM Dose=1uM, N-(2-Chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)phenyl)-6-methylpyridin-3-amine, mglu5 Receptor (mgluR5) Ligands targeting GRM5
AA-88-PJ86_0.01uM Dose=0.01uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5
AA-88-PJ86_0.1uM Dose=0.1uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5
AA-88-PJ86_10uM Dose=10uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5
AA-88-PJ86_1uM Dose=1uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5
AA-89-HG56_0.01uM Dose=0.01uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A
AA-89-HG56_0.1uM Dose=0.1uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A
AA-89-HG56_10uM Dose=10uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A
AA-89-HG56_1uM Dose=1uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A
AA-90-AU53_0.01uM Dose=0.01uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F
AA-90-AU53_0.1uM Dose=0.1uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F
AA-90-AU53_10uM Dose=10uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F
AA-90-AU53_1uM Dose=1uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F
AA-90-YI00_0.01uM Dose=0.01uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
AA-90-YI00_0.1uM Dose=0.1uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
AA-90-YI00_10uM Dose=10uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
AA-90-YI00_1uM Dose=1uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
AA-91-SB25_0.01uM Dose=0.01uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK
AA-91-SB25_0.1uM Dose=0.1uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK
AA-91-SB25_10uM Dose=10uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK
AA-91-SB25_1uM Dose=1uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK
AA-91-WB95_0.01uM Dose=0.01uM
AA-91-WB95_0.1uM Dose=0.1uM
AA-91-WB95_10uM Dose=10uM
AA-91-WB95_1uM Dose=1uM
AA-91-XV98_0.01uM Dose=0.01uM, Tolfenamic acid
AA-91-XV98_0.1uM Dose=0.1uM, Tolfenamic acid
AA-91-XV98_10uM Dose=10uM, Tolfenamic acid
AA-92-NW83_0.01uM Dose=0.01uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1
AA-92-NW83_0.1uM Dose=0.1uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1
AA-92-NW83_10uM Dose=10uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1
AA-92-NW83_1uM Dose=1uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1
AA-94-OG89_0.01uM Dose=0.01uM, Detrothyronine targeting THRA
AA-94-OG89_0.1uM Dose=0.1uM, Detrothyronine targeting THRA
AA-94-OG89_10uM Dose=10uM, Detrothyronine targeting THRA
AA-94-TU18_0.01uM Dose=0.01uM
AA-94-TU18_0.1uM Dose=0.1uM
AA-94-TU18_10uM Dose=10uM
AA-94-TU18_1uM Dose=1uM
AA-97-XP63_0.01uM Dose=0.01uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4
AA-97-XP63_0.1uM Dose=0.1uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4
AA-97-XP63_10uM Dose=10uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4
AA-97-XP63_1uM Dose=1uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4
AA-98-FJ71_0.01uM Dose=0.01uM, Anisindione, gamma carboxylation inhibitor targeting GGCX
AA-98-FJ71_0.1uM Dose=0.1uM, Anisindione, gamma carboxylation inhibitor targeting GGCX
AA-98-FJ71_10uM Dose=10uM, Anisindione, gamma carboxylation inhibitor targeting GGCX
AA-98-FJ71_1uM Dose=1uM, Anisindione, gamma carboxylation inhibitor targeting GGCX
AA-98-HX85_0.01uM Dose=0.01uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide
AA-98-HX85_0.1uM Dose=0.1uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide
AA-98-HX85_10uM Dose=10uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide
AA-98-HX85_1uM Dose=1uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide
AA-98-MW52_0.01uM Dose=0.01uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2
AA-98-MW52_0.1uM Dose=0.1uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2
AA-98-MW52_10uM Dose=10uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2
AA-98-MW52_1uM Dose=1uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2
AA-98-PM63_0.01uM Dose=0.01uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5
AA-98-PM63_0.1uM Dose=0.1uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5
AA-98-PM63_10uM Dose=10uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5
AA-98-PM63_1uM Dose=1uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5
AA-99-HG56_0.01uM Dose=0.01uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3
AA-99-HG56_0.1uM Dose=0.1uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3
AA-99-HG56_10uM Dose=10uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3
AA-99-HG56_1uM Dose=1uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3
AA-99-HG96_0.01uM Dose=0.01uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F
AA-99-HG96_0.1uM Dose=0.1uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F
AA-99-HG96_10uM Dose=10uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F
AA-99-HG96_1uM Dose=1uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F
AA-99-HO76_0.01uM Dose=0.01uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1
AA-99-HO76_0.1uM Dose=0.1uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1
AA-99-HO76_10uM Dose=10uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1
AA-99-HO76_1uM Dose=1uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1
AA-99-OX27_0.01uM Dose=0.01uM, Tolnaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE
AA-99-OX27_1uM Dose=1uM, Tolnaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE
AA-99-PN83_0.01uM Dose=0.01uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide
AA-99-PN83_10uM Dose=10uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide
AA-99-PN83_1uM Dose=1uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide
AB-00-HA50_0.01uM Dose=0.01uM
AB-00-HA50_0.1uM Dose=0.1uM
AB-00-HA50_1uM Dose=1uM
AB-00-IL62_0.01uM Dose=0.01uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5
AB-00-IL62_0.1uM Dose=0.1uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5
AB-00-IL62_10uM Dose=10uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5
AB-00-IL62_1uM Dose=1uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5
AB-00-VH52_0.01uM Dose=0.01uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119
AB-00-VH52_0.1uM Dose=0.1uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119
AB-00-VH52_10uM Dose=10uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119
AB-00-VH52_1uM Dose=1uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119
AB-01-NB05_0.01uM Dose=0.01uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG
AB-01-NB05_0.1uM Dose=0.1uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG
AB-01-NB05_10uM Dose=10uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG
AB-01-NB05_1uM Dose=1uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG
AB-01-UY50_0.01uM Dose=0.01uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F
AB-01-UY50_0.1uM Dose=0.1uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F
AB-01-UY50_10uM Dose=10uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F
AB-01-UY50_1uM Dose=1uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F
AB-02-CF97_0.01uM Dose=0.01uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1
AB-02-CF97_0.1uM Dose=0.1uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1
AB-02-CF97_10uM Dose=10uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1
AB-02-CF97_1uM Dose=1uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1
AB-02-TI14_0.01uM Dose=0.01uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
AB-02-TI14_0.1uM Dose=0.1uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
AB-02-TI14_10uM Dose=10uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
AB-02-TI14_1uM Dose=1uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
AB-04-HG24_0.01uM Dose=0.01uM
AB-04-HG24_0.1uM Dose=0.1uM
AB-04-HG24_1uM Dose=1uM
AB-04-MQ83_0.01uM Dose=0.01uM
AB-04-MQ83_0.1uM Dose=0.1uM
AB-04-MQ83_10uM Dose=10uM
AB-04-MQ83_1uM Dose=1uM
AB-04-NN16_0.01uM Dose=0.01uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G
AB-04-NN16_0.1uM Dose=0.1uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G
AB-04-NN16_10uM Dose=10uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G
AB-04-NN16_1uM Dose=1uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G
AB-05-FB25_0.01uM Dose=0.01uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1
AB-05-FB25_0.1uM Dose=0.1uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1
AB-05-FB25_10uM Dose=10uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1
AB-05-FB25_1uM Dose=1uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1
AB-05-JR93_0.1uM Dose=0.1uM, Ketoprofen, Non-Steroidal Antiinflammatory Drugs targeting PTGS2
AB-05-JR93_10uM Dose=10uM, Ketoprofen, Non-Steroidal Antiinflammatory Drugs targeting PTGS2
AB-05-JR93_1uM Dose=1uM, Ketoprofen, Non-Steroidal Antiinflammatory Drugs targeting PTGS2
AB-06-KB32_0.01uM Dose=0.01uM
AB-06-KB32_0.1uM Dose=0.1uM
AB-06-KB32_10uM Dose=10uM
AB-06-KB32_1uM Dose=1uM
AB-07-AZ97_0.1uM Dose=0.1uM, CB1R antagonist 1, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM
AB-07-AZ97_1uM Dose=1uM, CB1R antagonist 1, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM
AB-07-KC02_0.1uM Dose=0.1uM, PT2399, HIF2A/EPAS1 inhibitor targeting EPAS1
AB-07-KC02_10uM Dose=10uM, PT2399, HIF2A/EPAS1 inhibitor targeting EPAS1
AB-07-KC02_1uM Dose=1uM, PT2399, HIF2A/EPAS1 inhibitor targeting EPAS1
AB-07-WP43_0.01uM Dose=0.01uM, Cidoxepin, Histamine H1 Receptor Antagonists;5-HT Reuptake Inhibitors;Histamine H2 Receptor Antagonists;Norepinephrine Reuptake Inhibitors targeting HRH1
AB-07-WP43_0.1uM Dose=0.1uM, Cidoxepin, Histamine H1 Receptor Antagonists;5-HT Reuptake Inhibitors;Histamine H2 Receptor Antagonists;Norepinephrine Reuptake Inhibitors targeting HRH1
AB-07-WP43_1uM Dose=1uM, Cidoxepin, Histamine H1 Receptor Antagonists;5-HT Reuptake Inhibitors;Histamine H2 Receptor Antagonists;Norepinephrine Reuptake Inhibitors targeting HRH1
AB-08-HT45_0.01uM Dose=0.01uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1
AB-08-HT45_0.1uM Dose=0.1uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1
AB-08-HT45_10uM Dose=10uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1
AB-08-HT45_1uM Dose=1uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1
AB-09-AD74_0.01uM Dose=0.01uM, (1S,3S)-3-[[3-[2-(3,5-dimethylpyrazol-1-yl)pyridin-4-yl]imidazo[1,2-a]pyridin-6-yl]amino]cyclohexan-1-ol, Activin Receptor Like Kinase 5 (ALK5 TbetaR-I) Inhibitors targeting TGFBR1
AB-09-EA37_0.01uM Dose=0.01uM
AB-09-EA37_0.1uM Dose=0.1uM
AB-09-EA37_10uM Dose=10uM
AB-09-EA37_1uM Dose=1uM
AB-09-JN93_0.01uM Dose=0.01uM
AB-09-JN93_0.1uM Dose=0.1uM
AB-09-JN93_10uM Dose=10uM
AB-09-NX37_0.01uM Dose=0.01uM, 6-{4-[(2-methoxyethoxy)methyl]phenyl}-5-methyl-3-phenyl-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one, Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2, NURR1) Agonists targeting NR4A2
AB-09-NX37_10uM Dose=10uM, 6-{4-[(2-methoxyethoxy)methyl]phenyl}-5-methyl-3-phenyl-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one, Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2, NURR1) Agonists targeting NR4A2
AB-09-NX37_1uM Dose=1uM, 6-{4-[(2-methoxyethoxy)methyl]phenyl}-5-methyl-3-phenyl-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one, Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2, NURR1) Agonists targeting NR4A2
AB-09-PR28_0.01uM Dose=0.01uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE
AB-09-PR28_0.1uM Dose=0.1uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE
AB-09-PR28_10uM Dose=10uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE
AB-09-PR28_1uM Dose=1uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE
AB-09-YX02_0.01uM Dose=0.01uM, p-Coumaric acid
AB-09-YX02_0.1uM Dose=0.1uM, p-Coumaric acid
AB-09-YX02_10uM Dose=10uM, p-Coumaric acid
AB-09-YX02_1uM Dose=1uM, p-Coumaric acid
AB-10-RE65_0.01uM Dose=0.01uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-10-RE65_0.1uM Dose=0.1uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-10-RE65_10uM Dose=10uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-10-RE65_1uM Dose=1uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-11-AY75_0.01uM Dose=0.01uM, 5-(2,5-Dimethyl-pyrrol-1-yl)-2-hydroxy-benzoic acid, Pin1 Inhibitors targeting PIN1
AB-11-AY75_0.1uM Dose=0.1uM, 5-(2,5-Dimethyl-pyrrol-1-yl)-2-hydroxy-benzoic acid, Pin1 Inhibitors targeting PIN1
AB-11-AY75_10uM Dose=10uM, 5-(2,5-Dimethyl-pyrrol-1-yl)-2-hydroxy-benzoic acid, Pin1 Inhibitors targeting PIN1
AB-11-MO96_0.01uM Dose=0.01uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A
AB-11-MO96_0.1uM Dose=0.1uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A
AB-11-MO96_10uM Dose=10uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A
AB-11-MO96_1uM Dose=1uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A
AB-11-QV43_0.01uM Dose=0.01uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1
AB-11-QV43_0.1uM Dose=0.1uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1
AB-11-QV43_10uM Dose=10uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1
AB-11-QV43_1uM Dose=1uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1
AB-11-VI02_0.01uM Dose=0.01uM, Amlodipine
AB-11-VI02_0.1uM Dose=0.1uM, Amlodipine
AB-11-VI02_1uM Dose=1uM, Amlodipine
AB-12-IS33_0.01uM Dose=0.01uM, Melphalan
AB-12-IS33_10uM Dose=10uM, Melphalan
AB-12-IS33_1uM Dose=1uM, Melphalan
AB-12-PP61_0.01uM Dose=0.01uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2
AB-12-PP61_0.1uM Dose=0.1uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2
AB-12-PP61_10uM Dose=10uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2
AB-12-PP61_1uM Dose=1uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2
AB-13-HC37_0.01uM Dose=0.01uM, 2-{[4-(3-chloro-propoxy)-benzenesulfonyl]-(4-methoxy-benzyl)amino}-N-hydroxy-acetamide
AB-13-HC37_0.1uM Dose=0.1uM, 2-{[4-(3-chloro-propoxy)-benzenesulfonyl]-(4-methoxy-benzyl)amino}-N-hydroxy-acetamide
AB-13-HC37_1uM Dose=1uM, 2-{[4-(3-chloro-propoxy)-benzenesulfonyl]-(4-methoxy-benzyl)amino}-N-hydroxy-acetamide
AB-14-GQ48_0.01uM Dose=0.01uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3
AB-14-GQ48_0.1uM Dose=0.1uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3
AB-14-GQ48_10uM Dose=10uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3
AB-14-GQ48_1uM Dose=1uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3
AB-14-QA30_0.01uM Dose=0.01uM
AB-14-QA30_0.1uM Dose=0.1uM
AB-14-QA30_10uM Dose=10uM
AB-14-QA30_1uM Dose=1uM
AB-15-FB25_0.01uM Dose=0.01uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1
AB-15-FB25_0.1uM Dose=0.1uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1
AB-15-FB25_10uM Dose=10uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1
AB-15-FB25_1uM Dose=1uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1
AB-15-XR48_0.01uM Dose=0.01uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B
AB-15-XR48_0.1uM Dose=0.1uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B
AB-15-XR48_10uM Dose=10uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B
AB-15-XR48_1uM Dose=1uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B
AB-16-HE44_0.01uM Dose=0.01uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
AB-16-HE44_0.1uM Dose=0.1uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
AB-16-HE44_10uM Dose=10uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
AB-16-HE44_1uM Dose=1uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
AB-16-LY07_0.01uM Dose=0.01uM, Nortriptyline, K(ir) 4.1 Blockers targeting KCNJ10
AB-16-LY07_10uM Dose=10uM, Nortriptyline, K(ir) 4.1 Blockers targeting KCNJ10
AB-16-SB72_0.01uM Dose=0.01uM, 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid, ADH5) Inhibitors;Alcohol Dehydrogenase class-3 (GSNOR targeting ADH5
AB-16-SB72_0.1uM Dose=0.1uM, 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid, ADH5) Inhibitors;Alcohol Dehydrogenase class-3 (GSNOR targeting ADH5
AB-17-DF74_0.01uM Dose=0.01uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL
AB-17-DF74_0.1uM Dose=0.1uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL
AB-17-DF74_10uM Dose=10uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL
AB-17-DF74_1uM Dose=1uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL
AB-17-LS35_0.01uM Dose=0.01uM, Prostanoid TP Antagonists
AB-17-LS35_0.1uM Dose=0.1uM, Prostanoid TP Antagonists
AB-17-LS35_1uM Dose=1uM, Prostanoid TP Antagonists
AB-17-WP43_0.01uM Dose=0.01uM, Loperamide, mu-Opioid Agonists targeting OPRM1
AB-17-WP43_0.1uM Dose=0.1uM, Loperamide, mu-Opioid Agonists targeting OPRM1
AB-17-WP43_10uM Dose=10uM, Loperamide, mu-Opioid Agonists targeting OPRM1
AB-17-WP43_1uM Dose=1uM, Loperamide, mu-Opioid Agonists targeting OPRM1
AB-17-ZZ77_0.01uM Dose=0.01uM, Estradiol Valerate
AB-17-ZZ77_0.1uM Dose=0.1uM, Estradiol Valerate
AB-17-ZZ77_10uM Dose=10uM, Estradiol Valerate
AB-17-ZZ77_1uM Dose=1uM, Estradiol Valerate
AB-18-YN11_0.01uM Dose=0.01uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10
AB-18-YN11_0.1uM Dose=0.1uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10
AB-18-YN11_10uM Dose=10uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10
AB-18-YN11_1uM Dose=1uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10
AB-21-CI37_0.1uM Dose=0.1uM, Deferoxamine
AB-21-CI37_10uM Dose=10uM, Deferoxamine
AB-21-CI37_1uM Dose=1uM, Deferoxamine
AB-21-MV93_0.01uM Dose=0.01uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4
AB-21-MV93_0.1uM Dose=0.1uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4
AB-21-MV93_10uM Dose=10uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4
AB-21-MV93_1uM Dose=1uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4
AB-21-VE32_0.01uM Dose=0.01uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-21-VE32_0.1uM Dose=0.1uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-21-VE32_10uM Dose=10uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-21-VE32_1uM Dose=1uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-22-AI49_0.01uM Dose=0.01uM, Arbaclofen, GABA(B) Agonists targeting GABBR1, GABBR2
AB-22-AI49_0.1uM Dose=0.1uM, Arbaclofen, GABA(B) Agonists targeting GABBR1, GABBR2
AB-22-AI49_10uM Dose=10uM, Arbaclofen, GABA(B) Agonists targeting GABBR1, GABBR2
AB-22-AI49_1uM Dose=1uM, Arbaclofen, GABA(B) Agonists targeting GABBR1, GABBR2
AB-23-MN29_0.01uM Dose=0.01uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A
AB-23-MN29_0.1uM Dose=0.1uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A
AB-23-MN29_10uM Dose=10uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A
AB-23-MN29_1uM Dose=1uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A
AB-23-UX23_0.1uM Dose=0.1uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1
AB-23-UX23_10uM Dose=10uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1
AB-23-UX23_1uM Dose=1uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1
AB-25-MR13_0.01uM Dose=0.01uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2
AB-25-MR13_0.1uM Dose=0.1uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2
AB-25-MR13_10uM Dose=10uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2
AB-25-MR13_1uM Dose=1uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2
AB-25-NK66_0.01uM Dose=0.01uM, Adh-1, N-cadherin Inhibitor targeting CDH2
AB-25-NK66_10uM Dose=10uM, Adh-1, N-cadherin Inhibitor targeting CDH2
AB-25-NK66_1uM Dose=1uM, Adh-1, N-cadherin Inhibitor targeting CDH2
AB-25-XU75_0.01uM Dose=0.01uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA
AB-25-XU75_0.1uM Dose=0.1uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA
AB-25-XU75_10uM Dose=10uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA
AB-25-XU75_1uM Dose=1uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA
AB-26-BE29_0.01uM Dose=0.01uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2
AB-26-BE29_0.1uM Dose=0.1uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2
AB-26-BE29_10uM Dose=10uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2
AB-26-BE29_1uM Dose=1uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2
AB-27-LS15_0.01uM Dose=0.01uM, bisindolylmaleimide VIII, Protein Kinase C (PKC) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CAMK2D, PRKCA
AB-27-LS15_0.1uM Dose=0.1uM, bisindolylmaleimide VIII, Protein Kinase C (PKC) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CAMK2D, PRKCA
AB-27-LS15_10uM Dose=10uM, bisindolylmaleimide VIII, Protein Kinase C (PKC) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CAMK2D, PRKCA
AB-28-BT90_0.01uM Dose=0.01uM, N-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]quinoline-8-sulfonamide, Angiogenesis Inhibitors;Aquaporin 1 (AQP1) Inhibitors targeting AQP1
AB-28-BT90_10uM Dose=10uM, N-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]quinoline-8-sulfonamide, Angiogenesis Inhibitors;Aquaporin 1 (AQP1) Inhibitors targeting AQP1
AB-28-BT90_1uM Dose=1uM, N-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]quinoline-8-sulfonamide, Angiogenesis Inhibitors;Aquaporin 1 (AQP1) Inhibitors targeting AQP1
AB-30-CR11_0.01uM Dose=0.01uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4
AB-30-CR11_0.1uM Dose=0.1uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4
AB-30-CR11_10uM Dose=10uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4
AB-30-CR11_1uM Dose=1uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4
AB-30-DA10_0.01uM Dose=0.01uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2
AB-30-DA10_0.1uM Dose=0.1uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2
AB-30-DA10_10uM Dose=10uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2
AB-30-DA10_1uM Dose=1uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2
AB-31-VZ28_0.01uM Dose=0.01uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A
AB-31-VZ28_0.1uM Dose=0.1uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A
AB-31-VZ28_10uM Dose=10uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A
AB-31-VZ28_1uM Dose=1uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A
AB-32-QZ50_0.01uM Dose=0.01uM
AB-32-QZ50_0.1uM Dose=0.1uM
AB-32-QZ50_10uM Dose=10uM
AB-32-QZ50_1uM Dose=1uM
AB-32-WM54_0.01uM Dose=0.01uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG
AB-32-WM54_0.1uM Dose=0.1uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG
AB-32-WM54_10uM Dose=10uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG
AB-32-WM54_1uM Dose=1uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG
AB-33-EM56_0.01uM Dose=0.01uM
AB-33-EM56_0.1uM Dose=0.1uM
AB-33-EM56_10uM Dose=10uM
AB-33-EM56_1uM Dose=1uM
AB-33-VM36_0.01uM Dose=0.01uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS
AB-33-VM36_0.1uM Dose=0.1uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS
AB-33-VM36_10uM Dose=10uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS
AB-33-VM36_1uM Dose=1uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS
AB-34-DD27_0.01uM Dose=0.01uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
AB-34-DD27_0.1uM Dose=0.1uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
AB-34-DD27_10uM Dose=10uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
AB-34-DD27_1uM Dose=1uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
AB-34-RQ73_0.01uM Dose=0.01uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2
AB-34-RQ73_0.1uM Dose=0.1uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2
AB-34-RQ73_10uM Dose=10uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2
AB-34-RQ73_1uM Dose=1uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2
AB-35-RU30_0.01uM Dose=0.01uM
AB-35-RU30_0.1uM Dose=0.1uM
AB-35-RU30_10uM Dose=10uM
AB-35-RU30_1uM Dose=1uM
AB-36-NS83_0.01uM Dose=0.01uM, 3-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(thiophen-2-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A
AB-36-NS83_0.1uM Dose=0.1uM, 3-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(thiophen-2-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A
AB-37-JM16_0.01uM Dose=0.01uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB
AB-37-JM16_0.1uM Dose=0.1uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB
AB-37-JM16_10uM Dose=10uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB
AB-37-JM16_1uM Dose=1uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB
AB-38-CX25_0.01uM Dose=0.01uM, Methiothepin targeting HTR1E, HTR1F
AB-38-CX25_10uM Dose=10uM, Methiothepin targeting HTR1E, HTR1F
AB-39-ED84_0.01uM Dose=0.01uM, (+)-Ketoconazole, Antifungal;CYP inhibitor targeting CYP2D6, CYP3A5, CYP24A1, CYP21A2
AB-39-ED84_0.1uM Dose=0.1uM, (+)-Ketoconazole, Antifungal;CYP inhibitor targeting CYP2D6, CYP3A5, CYP24A1, CYP21A2
AB-39-ED84_10uM Dose=10uM, (+)-Ketoconazole, Antifungal;CYP inhibitor targeting CYP2D6, CYP3A5, CYP24A1, CYP21A2
AB-40-HA80_0.01uM Dose=0.01uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2
AB-40-HA80_0.1uM Dose=0.1uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2
AB-40-HA80_10uM Dose=10uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2
AB-40-HA80_1uM Dose=1uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2
AB-41-IO16_0.01uM Dose=0.01uM
AB-41-IO16_0.1uM Dose=0.1uM
AB-41-IO16_10uM Dose=10uM
AB-41-IO16_1uM Dose=1uM
AB-41-VZ28_0.01uM Dose=0.01uM, Neostigmine, Acetylcholinesterase Inhibitors targeting ACHE
AB-41-VZ28_0.1uM Dose=0.1uM, Neostigmine, Acetylcholinesterase Inhibitors targeting ACHE
AB-41-VZ28_10uM Dose=10uM, Neostigmine, Acetylcholinesterase Inhibitors targeting ACHE
AB-42-AI99_0.01uM Dose=0.01uM, NS 1619, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
AB-42-AI99_0.1uM Dose=0.1uM, NS 1619, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
AB-42-AI99_1uM Dose=1uM, NS 1619, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
AB-43-XJ34_0.01uM Dose=0.01uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-43-XJ34_0.1uM Dose=0.1uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-43-XJ34_10uM Dose=10uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-43-XJ34_1uM Dose=1uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
AB-44-GQ28_0.01uM Dose=0.01uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A
AB-44-GQ28_0.1uM Dose=0.1uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A
AB-44-GQ28_10uM Dose=10uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A
AB-44-GQ28_1uM Dose=1uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A
AB-46-GB72_0.01uM Dose=0.01uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B
AB-46-GB72_0.1uM Dose=0.1uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B
AB-46-GB72_10uM Dose=10uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B
AB-46-GB72_1uM Dose=1uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B
AB-47-BS00_0.01uM Dose=0.01uM, Hydroxyurea, Ribonucleoside-Diphosphate Reductase Inhibitors;Antimetabolites;Nitric oxide donor targeting RRM1
AB-47-BS00_10uM Dose=10uM, Hydroxyurea, Ribonucleoside-Diphosphate Reductase Inhibitors;Antimetabolites;Nitric oxide donor targeting RRM1
AB-47-BS00_1uM Dose=1uM, Hydroxyurea, Ribonucleoside-Diphosphate Reductase Inhibitors;Antimetabolites;Nitric oxide donor targeting RRM1
AB-50-OH27_0.01uM Dose=0.01uM, methyl 2-[(1R,2S,4S,7E,10R,12R,13R,14E,16R)-2,12-dihydroxy-4-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-1,13-dimethyl-6-oxo-5,17-dioxabicyclo[14.1.0]heptadeca-7,14-dien-10-yl]acetate, tubulin antagonist targeting TUBB
AB-50-OH27_0.1uM Dose=0.1uM, methyl 2-[(1R,2S,4S,7E,10R,12R,13R,14E,16R)-2,12-dihydroxy-4-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-1,13-dimethyl-6-oxo-5,17-dioxabicyclo[14.1.0]heptadeca-7,14-dien-10-yl]acetate, tubulin antagonist targeting TUBB
AB-50-OH27_1uM Dose=1uM, methyl 2-[(1R,2S,4S,7E,10R,12R,13R,14E,16R)-2,12-dihydroxy-4-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-1,13-dimethyl-6-oxo-5,17-dioxabicyclo[14.1.0]heptadeca-7,14-dien-10-yl]acetate, tubulin antagonist targeting TUBB
AB-51-WV08_0.01uM Dose=0.01uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1
AB-51-WV08_0.1uM Dose=0.1uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1
AB-51-WV08_10uM Dose=10uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1
AB-51-WV08_1uM Dose=1uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1
AB-53-AW00_0.01uM Dose=0.01uM, Deferasirox
AB-53-AW00_0.1uM Dose=0.1uM, Deferasirox
AB-53-AW00_10uM Dose=10uM, Deferasirox
AB-53-AW00_1uM Dose=1uM, Deferasirox
AB-55-DE17_10uM Dose=10uM, (R)-6-((3-Chloro-5-cyanopyridin-2-yl)amino)-4-(cyclopropylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide, interleukin 1 receptor associated kinase 4 targeting IRAK4
AB-55-DE17_1uM Dose=1uM, (R)-6-((3-Chloro-5-cyanopyridin-2-yl)amino)-4-(cyclopropylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide, interleukin 1 receptor associated kinase 4 targeting IRAK4
AB-55-HO71_0.01uM Dose=0.01uM, Pirfenidone, TGFb pathway inhibitor;antifibrotic;TNF alpha synthesis inhibitor targeting TNF
AB-55-HO71_0.1uM Dose=0.1uM, Pirfenidone, TGFb pathway inhibitor;antifibrotic;TNF alpha synthesis inhibitor targeting TNF
AB-55-HO71_1uM Dose=1uM, Pirfenidone, TGFb pathway inhibitor;antifibrotic;TNF alpha synthesis inhibitor targeting TNF
AB-57-IZ37_0.01uM Dose=0.01uM
AB-57-IZ37_0.1uM Dose=0.1uM
AB-57-IZ37_10uM Dose=10uM
AB-57-IZ37_1uM Dose=1uM
AB-61-FY15_0.01uM Dose=0.01uM
AB-61-FY15_0.1uM Dose=0.1uM
AB-61-FY15_10uM Dose=10uM
AB-61-FY15_1uM Dose=1uM
AB-61-VZ28_0.01uM Dose=0.01uM, Phenylephrine, alpha1-Adrenoceptor Agonists;alpha1A-Adrenoceptor Ligands targeting ADRA1A
AB-61-VZ28_0.1uM Dose=0.1uM, Phenylephrine, alpha1-Adrenoceptor Agonists;alpha1A-Adrenoceptor Ligands targeting ADRA1A
AB-61-VZ28_1uM Dose=1uM, Phenylephrine, alpha1-Adrenoceptor Agonists;alpha1A-Adrenoceptor Ligands targeting ADRA1A
AB-62-TF27_0.01uM Dose=0.01uM, (2S,4R)-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-4-[(4-chlorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide
AB-62-TF27_0.1uM Dose=0.1uM, (2S,4R)-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-4-[(4-chlorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide
AB-62-TF27_1uM Dose=1uM, (2S,4R)-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-4-[(4-chlorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide
AB-63-HD20_0.01uM Dose=0.01uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3
AB-63-HD20_0.1uM Dose=0.1uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3
AB-63-HD20_10uM Dose=10uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3
AB-63-HD20_1uM Dose=1uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3
AB-63-OW35_0.1uM Dose=0.1uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A
AB-63-OW35_10uM Dose=10uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A
AB-63-OW35_1uM Dose=1uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A
AB-63-UJ99_0.01uM Dose=0.01uM, Jak1 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor
AB-63-UJ99_0.1uM Dose=0.1uM, Jak1 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor
AB-63-UJ99_10uM Dose=10uM, Jak1 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor
AB-63-UJ99_1uM Dose=1uM, Jak1 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor
AB-63-UX23_0.01uM Dose=0.01uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
AB-63-UX23_0.1uM Dose=0.1uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
AB-63-UX23_10uM Dose=10uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
AB-63-UX23_1uM Dose=1uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
AB-64-HD87_0.01uM Dose=0.01uM
AB-64-HD87_0.1uM Dose=0.1uM
AB-64-HD87_10uM Dose=10uM
AB-64-HD87_1uM Dose=1uM
AB-64-NN66_0.01uM Dose=0.01uM, [1-(2-Chloro-4-ethanesulfonyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid, CRTh2 antagonist targeting PTGDR2
AB-64-NN66_0.1uM Dose=0.1uM, [1-(2-Chloro-4-ethanesulfonyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid, CRTh2 antagonist targeting PTGDR2
AB-64-NN66_1uM Dose=1uM, [1-(2-Chloro-4-ethanesulfonyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid, CRTh2 antagonist targeting PTGDR2
AB-64-ZX70_0.01uM Dose=0.01uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D
AB-64-ZX70_0.1uM Dose=0.1uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D
AB-64-ZX70_10uM Dose=10uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D
AB-64-ZX70_1uM Dose=1uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D
AB-66-IL06_0.01uM Dose=0.01uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13
AB-66-IL06_0.1uM Dose=0.1uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13
AB-66-IL06_10uM Dose=10uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13
AB-66-IL06_1uM Dose=1uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13
AB-67-SF89_0.01uM Dose=0.01uM
AB-67-SF89_0.1uM Dose=0.1uM
AB-67-SF89_10uM Dose=10uM
AB-67-SF89_1uM Dose=1uM
AB-68-SC09_0.01uM Dose=0.01uM, Bicifadine, Norepinephrine Transporter (NET) Inhibitors;NMDA Antagonists;Serotonin Transporter (SERT) Inhibitors targeting SLC6A2, SLC6A4
AB-68-SC09_0.1uM Dose=0.1uM, Bicifadine, Norepinephrine Transporter (NET) Inhibitors;NMDA Antagonists;Serotonin Transporter (SERT) Inhibitors targeting SLC6A2, SLC6A4
AB-68-SC09_10uM Dose=10uM, Bicifadine, Norepinephrine Transporter (NET) Inhibitors;NMDA Antagonists;Serotonin Transporter (SERT) Inhibitors targeting SLC6A2, SLC6A4
AB-68-SC09_1uM Dose=1uM, Bicifadine, Norepinephrine Transporter (NET) Inhibitors;NMDA Antagonists;Serotonin Transporter (SERT) Inhibitors targeting SLC6A2, SLC6A4
AB-70-GR31_0.01uM Dose=0.01uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA
AB-70-GR31_0.1uM Dose=0.1uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA
AB-70-GR31_10uM Dose=10uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA
AB-70-GR31_1uM Dose=1uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA
AB-71-CI37_0.01uM Dose=0.01uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2
AB-71-CI37_0.1uM Dose=0.1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2
AB-71-CI37_10uM Dose=10uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2
AB-71-CI37_1uM Dose=1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2
AB-71-NB55_0.01uM Dose=0.01uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14
AB-71-NB55_0.1uM Dose=0.1uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14
AB-71-NB55_10uM Dose=10uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14
AB-71-NB55_1uM Dose=1uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14
AB-71-UV73_0.01uM Dose=0.01uM, (3S)-3-amino-4-[5-[4-(4-chlorophenoxy)phenyl]tetrazol-2-yl]butanoic acid, inhibitor of leukotriene A4 hydrolase targeting LTA4H
AB-71-UV73_0.1uM Dose=0.1uM, (3S)-3-amino-4-[5-[4-(4-chlorophenoxy)phenyl]tetrazol-2-yl]butanoic acid, inhibitor of leukotriene A4 hydrolase targeting LTA4H
AB-71-UV73_1uM Dose=1uM, (3S)-3-amino-4-[5-[4-(4-chlorophenoxy)phenyl]tetrazol-2-yl]butanoic acid, inhibitor of leukotriene A4 hydrolase targeting LTA4H
AB-71-VZ28_0.01uM Dose=0.01uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2
AB-71-VZ28_0.1uM Dose=0.1uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2
AB-71-VZ28_10uM Dose=10uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2
AB-71-VZ28_1uM Dose=1uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2
AB-72-EP76_0.01uM Dose=0.01uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2
AB-72-EP76_0.1uM Dose=0.1uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2
AB-72-EP76_10uM Dose=10uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2
AB-72-EP76_1uM Dose=1uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2
AB-73-SW45_0.01uM Dose=0.01uM, Citalopram, 5-HT Reuptake Inhibitors targeting SLC6A4
AB-73-SW45_0.1uM Dose=0.1uM, Citalopram, 5-HT Reuptake Inhibitors targeting SLC6A4
AB-73-SW45_10uM Dose=10uM, Citalopram, 5-HT Reuptake Inhibitors targeting SLC6A4
AB-73-ZX03_0.01uM Dose=0.01uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5
AB-73-ZX03_0.1uM Dose=0.1uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5
AB-73-ZX03_10uM Dose=10uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5
AB-73-ZX03_1uM Dose=1uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5
AB-74-VK99_0.01uM Dose=0.01uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2
AB-74-VK99_0.1uM Dose=0.1uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2
AB-74-VK99_10uM Dose=10uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2
AB-74-VK99_1uM Dose=1uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2
AB-78-RM53_0.01uM Dose=0.01uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1
AB-78-RM53_0.1uM Dose=0.1uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1
AB-78-RM53_10uM Dose=10uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1
AB-78-RM53_1uM Dose=1uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1
AB-79-ZD24_0.01uM Dose=0.01uM, Dopamine D4 receptor antagonist-1, DRD4 antagonist targeting DRD4
AB-79-ZD24_0.1uM Dose=0.1uM, Dopamine D4 receptor antagonist-1, DRD4 antagonist targeting DRD4
AB-79-ZD24_10uM Dose=10uM, Dopamine D4 receptor antagonist-1, DRD4 antagonist targeting DRD4
AB-80-CK34_0.01uM Dose=0.01uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4
AB-80-CK34_0.1uM Dose=0.1uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4
AB-80-CK34_10uM Dose=10uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4
AB-80-CK34_1uM Dose=1uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4
AB-82-EP26_0.01uM Dose=0.01uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14
AB-82-EP26_0.1uM Dose=0.1uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14
AB-82-EP26_10uM Dose=10uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14
AB-82-EP26_1uM Dose=1uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14
AB-82-ES53_0.01uM Dose=0.01uM, Quercetin targeting SULT1A1
AB-82-ES53_0.1uM Dose=0.1uM, Quercetin targeting SULT1A1
AB-82-ES53_10uM Dose=10uM, Quercetin targeting SULT1A1
AB-82-ES53_1uM Dose=1uM, Quercetin targeting SULT1A1
AB-83-EW00_0.01uM Dose=0.01uM, 1,3-Dipropyl-7-methylxanthine
AB-83-EW00_0.1uM Dose=0.1uM, 1,3-Dipropyl-7-methylxanthine
AB-83-EW00_10uM Dose=10uM, 1,3-Dipropyl-7-methylxanthine
AB-83-EW00_1uM Dose=1uM, 1,3-Dipropyl-7-methylxanthine
AB-84-PK04_0.01uM Dose=0.01uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED
AB-84-PK04_0.1uM Dose=0.1uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED
AB-84-PK04_10uM Dose=10uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED
AB-84-PK04_1uM Dose=1uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED
AB-85-JR73_0.01uM Dose=0.01uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13
AB-85-JR73_0.1uM Dose=0.1uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13
AB-85-JR73_10uM Dose=10uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13
AB-85-JR73_1uM Dose=1uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13
AB-85-YK41_0.1uM Dose=0.1uM, Racecadotril, Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME
AB-85-YK41_10uM Dose=10uM, Racecadotril, Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME
AB-85-YK41_1uM Dose=1uM, Racecadotril, Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME
AB-86-GB42_0.01uM Dose=0.01uM, 3-(3-(2-(4-Fluorophenyl)pyridin-4-yl)imidazo[1,2-a]pyridin-7-yl)-N-methylbenzamide, ALK5 inhibitor targeting TGFBR1
AB-86-GB42_10uM Dose=10uM, 3-(3-(2-(4-Fluorophenyl)pyridin-4-yl)imidazo[1,2-a]pyridin-7-yl)-N-methylbenzamide, ALK5 inhibitor targeting TGFBR1
AB-86-GB42_1uM Dose=1uM, 3-(3-(2-(4-Fluorophenyl)pyridin-4-yl)imidazo[1,2-a]pyridin-7-yl)-N-methylbenzamide, ALK5 inhibitor targeting TGFBR1
AB-86-XY72_0.01uM Dose=0.01uM
AB-86-XY72_0.1uM Dose=0.1uM
AB-86-XY72_10uM Dose=10uM
AB-86-XY72_1uM Dose=1uM
AB-87-II61_0.01uM Dose=0.01uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2
AB-87-II61_0.1uM Dose=0.1uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2
AB-87-II61_10uM Dose=10uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2
AB-87-II61_1uM Dose=1uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2
AB-87-KC82_0.01uM Dose=0.01uM, 4-(4-Methylphenoxy)-2-phenylthieno[3,2-d]pyrimidine, Prostanoid EP4 Agonists targeting PTGER4
AB-87-KC82_0.1uM Dose=0.1uM, 4-(4-Methylphenoxy)-2-phenylthieno[3,2-d]pyrimidine, Prostanoid EP4 Agonists targeting PTGER4
AB-87-KC82_10uM Dose=10uM, 4-(4-Methylphenoxy)-2-phenylthieno[3,2-d]pyrimidine, Prostanoid EP4 Agonists targeting PTGER4
AB-87-LJ34_0.01uM Dose=0.01uM, (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid targeting KRAS, AXIN1
AB-87-LJ34_0.1uM Dose=0.1uM, (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid targeting KRAS, AXIN1
AB-87-LJ34_10uM Dose=10uM, (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid targeting KRAS, AXIN1
AB-87-LJ34_1uM Dose=1uM, (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid targeting KRAS, AXIN1
AB-90-NH82_0.01uM Dose=0.01uM, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1;Gardos channel, SK41, IK1) Channel Activators;Small Conductance SK(Ca) 2.1 (SK1, SKCa1) Channel Activators;Small Conductance SK(Ca) 2.2 (SK2, SKCa2) Channel Activators targeting KCNN1, KCNN2, KCNN3
AB-90-NH82_0.1uM Dose=0.1uM, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1;Gardos channel, SK41, IK1) Channel Activators;Small Conductance SK(Ca) 2.1 (SK1, SKCa1) Channel Activators;Small Conductance SK(Ca) 2.2 (SK2, SKCa2) Channel Activators targeting KCNN1, KCNN2, KCNN3
AB-90-NH82_10uM Dose=10uM, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1;Gardos channel, SK41, IK1) Channel Activators;Small Conductance SK(Ca) 2.1 (SK1, SKCa1) Channel Activators;Small Conductance SK(Ca) 2.2 (SK2, SKCa2) Channel Activators targeting KCNN1, KCNN2, KCNN3
AB-90-YR46_0.01uM Dose=0.01uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1
AB-90-YR46_0.1uM Dose=0.1uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1
AB-90-YR46_10uM Dose=10uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1
AB-90-YR46_1uM Dose=1uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1
AB-92-GP61_0.01uM Dose=0.01uM, JTE-607 free base
AB-92-GP61_0.1uM Dose=0.1uM, JTE-607 free base
AB-92-GP61_10uM Dose=10uM, JTE-607 free base
AB-92-GP61_1uM Dose=1uM, JTE-607 free base
AB-92-LS83_0.01uM Dose=0.01uM, Flurbiprofen targeting SC5D
AB-92-LS83_0.1uM Dose=0.1uM, Flurbiprofen targeting SC5D
AB-92-LS83_10uM Dose=10uM, Flurbiprofen targeting SC5D
AB-92-LS83_1uM Dose=1uM, Flurbiprofen targeting SC5D
AB-95-LH34_0.01uM Dose=0.01uM, Benzamide, N-[3-[6-amino-5-[[1-(1-oxo-2-propen-1-yl)-3-azetidinyl]oxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-, irreversible, covalent inhibitor of BTK;Btk tyrosine kinase inhibitor targeting BTK
AB-95-LH34_0.1uM Dose=0.1uM, Benzamide, N-[3-[6-amino-5-[[1-(1-oxo-2-propen-1-yl)-3-azetidinyl]oxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-, irreversible, covalent inhibitor of BTK;Btk tyrosine kinase inhibitor targeting BTK
AB-95-LH34_10uM Dose=10uM, Benzamide, N-[3-[6-amino-5-[[1-(1-oxo-2-propen-1-yl)-3-azetidinyl]oxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-, irreversible, covalent inhibitor of BTK;Btk tyrosine kinase inhibitor targeting BTK
AB-96-JV50_0.01uM Dose=0.01uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2
AB-96-JV50_0.1uM Dose=0.1uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2
AB-96-JV50_10uM Dose=10uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2
AB-96-JV50_1uM Dose=1uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2
AB-96-XV75_0.01uM Dose=0.01uM, Dapsone
AB-96-XV75_0.1uM Dose=0.1uM, Dapsone
AB-96-XV75_10uM Dose=10uM, Dapsone
AB-96-XV75_1uM Dose=1uM, Dapsone
AB-97-BI36_0.01uM Dose=0.01uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide
AB-97-BI36_0.1uM Dose=0.1uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide
AB-97-BI36_10uM Dose=10uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide
AB-97-BI36_1uM Dose=1uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide
AB-98-HT45_0.01uM Dose=0.01uM, Capsaicin, Vanilloid receptor agonist targeting TRPV1
AB-98-HT45_0.1uM Dose=0.1uM, Capsaicin, Vanilloid receptor agonist targeting TRPV1
AB-98-HT45_1uM Dose=1uM, Capsaicin, Vanilloid receptor agonist targeting TRPV1
AB-99-PR28_0.1uM Dose=0.1uM, Ribavirin, Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Hepatitis C virus inhibitor targeting IMPDH1
AB-99-PR28_10uM Dose=10uM, Ribavirin, Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Hepatitis C virus inhibitor targeting IMPDH1
AB-99-PR28_1uM Dose=1uM, Ribavirin, Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Hepatitis C virus inhibitor targeting IMPDH1
AC-00-BR21_0.01uM Dose=0.01uM
AC-00-BR21_0.1uM Dose=0.1uM
AC-00-BR21_10uM Dose=10uM
AC-00-BR21_1uM Dose=1uM
AC-00-KV26_0.01uM Dose=0.01uM, N,N,N-trimethylglycinium
AC-00-KV26_0.1uM Dose=0.1uM, N,N,N-trimethylglycinium
AC-00-KV26_10uM Dose=10uM, N,N,N-trimethylglycinium
AC-00-KV26_1uM Dose=1uM, N,N,N-trimethylglycinium
AC-02-SI74_0.01uM Dose=0.01uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E
AC-02-SI74_0.1uM Dose=0.1uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E
AC-02-SI74_10uM Dose=10uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E
AC-02-SI74_1uM Dose=1uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E
AC-05-MR83_0.01uM Dose=0.01uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3
AC-05-MR83_0.1uM Dose=0.1uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3
AC-05-MR83_10uM Dose=10uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3
AC-05-MR83_1uM Dose=1uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3
AC-06-FB12_0.01uM Dose=0.01uM, 2,2,2-Trifluoro-N-(4-(2-methoxyphenoxy)phenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide, mgluR2 Agonists targeting GRM2
AC-06-FB12_10uM Dose=10uM, 2,2,2-Trifluoro-N-(4-(2-methoxyphenoxy)phenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide, mgluR2 Agonists targeting GRM2
AC-06-FB12_1uM Dose=1uM, 2,2,2-Trifluoro-N-(4-(2-methoxyphenoxy)phenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide, mgluR2 Agonists targeting GRM2
AC-06-PO03_0.1uM Dose=0.1uM, Erythromycin, NF-kappaB (NFKB) Activation Inhibitors;Motilin Receptor Agonists targeting MLNR
AC-06-PO03_10uM Dose=10uM, Erythromycin, NF-kappaB (NFKB) Activation Inhibitors;Motilin Receptor Agonists targeting MLNR
AC-06-PO03_1uM Dose=1uM, Erythromycin, NF-kappaB (NFKB) Activation Inhibitors;Motilin Receptor Agonists targeting MLNR
AC-09-DD24_1uM Dose=1uM, 2-[2-(2-Bromo-4-methylphenoxy)ethylsulfanyl]pyrimidine, PRKA gene stimulator;AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1, PRKAB2
AC-10-JK64_0.01uM Dose=0.01uM
AC-10-JK64_0.1uM Dose=0.1uM
AC-10-JK64_10uM Dose=10uM
AC-10-JK64_1uM Dose=1uM
AC-10-PK69_0.01uM Dose=0.01uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2
AC-10-PK69_0.1uM Dose=0.1uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2
AC-10-PK69_10uM Dose=10uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2
AC-10-PK69_1uM Dose=1uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2
AC-11-BO01_0.01uM Dose=0.01uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1
AC-11-BO01_0.1uM Dose=0.1uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1
AC-11-BO01_10uM Dose=10uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1
AC-11-BO01_1uM Dose=1uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1
AC-11-SE07_0.01uM Dose=0.01uM, Asimadoline, kappa-Opioid Agonists targeting OPRK1
AC-11-SE07_10uM Dose=10uM, Asimadoline, kappa-Opioid Agonists targeting OPRK1
AC-11-SE07_1uM Dose=1uM, Asimadoline, kappa-Opioid Agonists targeting OPRK1
AC-12-PZ00_0.01uM Dose=0.01uM
AC-12-PZ00_0.1uM Dose=0.1uM
AC-12-PZ00_1uM Dose=1uM
AC-14-FX35_0.01uM Dose=0.01uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2
AC-14-FX35_0.1uM Dose=0.1uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2
AC-14-FX35_10uM Dose=10uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2
AC-14-FX35_1uM Dose=1uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2
AC-14-JQ68_0.01uM Dose=0.01uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562)
AC-14-JQ68_0.1uM Dose=0.1uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562)
AC-14-JQ68_10uM Dose=10uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562)
AC-14-JQ68_1uM Dose=1uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562)
AC-17-PC87_0.01uM Dose=0.01uM, Chk2 Inhibitor II targeting CHEK2
AC-17-PC87_0.1uM Dose=0.1uM, Chk2 Inhibitor II targeting CHEK2
AC-17-PC87_10uM Dose=10uM, Chk2 Inhibitor II targeting CHEK2
AC-17-PC87_1uM Dose=1uM, Chk2 Inhibitor II targeting CHEK2
AC-17-PI61_0.01uM Dose=0.01uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6
AC-17-PI61_0.1uM Dose=0.1uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6
AC-17-PI61_10uM Dose=10uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6
AC-17-PI61_1uM Dose=1uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6
AC-18-DC84_0.01uM Dose=0.01uM, 7-Nitroindazole
AC-18-DC84_0.1uM Dose=0.1uM, 7-Nitroindazole
AC-18-DC84_10uM Dose=10uM, 7-Nitroindazole
AC-18-DC84_1uM Dose=1uM, 7-Nitroindazole
AC-19-TH24_0.1uM Dose=0.1uM, Vigabatrin, GABA Aminotransferase Inhibitors targeting ABAT
AC-19-TH24_10uM Dose=10uM, Vigabatrin, GABA Aminotransferase Inhibitors targeting ABAT
AC-19-TH24_1uM Dose=1uM, Vigabatrin, GABA Aminotransferase Inhibitors targeting ABAT
AC-20-SO29_0.01uM Dose=0.01uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4
AC-20-SO29_0.1uM Dose=0.1uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4
AC-20-SO29_10uM Dose=10uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4
AC-20-SO29_1uM Dose=1uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4
AC-21-IE62_0.01uM Dose=0.01uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1
AC-21-IE62_0.1uM Dose=0.1uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1
AC-21-IE62_10uM Dose=10uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1
AC-21-IE62_1uM Dose=1uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1
AC-21-PO16_0.01uM Dose=0.01uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate
AC-21-PO16_0.1uM Dose=0.1uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate
AC-21-PO16_10uM Dose=10uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate
AC-21-PO16_1uM Dose=1uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate
AC-22-PZ30_0.01uM Dose=0.01uM, Eed226, PRC2/EED targeting EED
AC-22-PZ30_0.1uM Dose=0.1uM, Eed226, PRC2/EED targeting EED
AC-22-PZ30_10uM Dose=10uM, Eed226, PRC2/EED targeting EED
AC-22-PZ30_1uM Dose=1uM, Eed226, PRC2/EED targeting EED
AC-24-NX95_0.01uM Dose=0.01uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10
AC-24-NX95_0.1uM Dose=0.1uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10
AC-24-NX95_10uM Dose=10uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10
AC-24-NX95_1uM Dose=1uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10
AC-24-QG69_0.01uM Dose=0.01uM, Myricetin, Cytochrome P450 CYP3A4 Inhibitors;Androgen Receptor Ligands;Antioxidants targeting AR, CYP3A4
AC-24-QG69_0.1uM Dose=0.1uM, Myricetin, Cytochrome P450 CYP3A4 Inhibitors;Androgen Receptor Ligands;Antioxidants targeting AR, CYP3A4
AC-24-QG69_10uM Dose=10uM, Myricetin, Cytochrome P450 CYP3A4 Inhibitors;Androgen Receptor Ligands;Antioxidants targeting AR, CYP3A4
AC-24-QG69_1uM Dose=1uM, Myricetin, Cytochrome P450 CYP3A4 Inhibitors;Androgen Receptor Ligands;Antioxidants targeting AR, CYP3A4
AC-28-IT60_10uM Dose=10uM, US10934285, Example 23, SHP2 allosteric inhibitor targeting PTPN11
AC-28-IT60_1uM Dose=1uM, US10934285, Example 23, SHP2 allosteric inhibitor targeting PTPN11
AC-28-RT00_0.01uM Dose=0.01uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
AC-28-RT00_0.1uM Dose=0.1uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
AC-28-RT00_10uM Dose=10uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
AC-28-RT00_1uM Dose=1uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
AC-29-ZR23_0.01uM Dose=0.01uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4
AC-29-ZR23_0.1uM Dose=0.1uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4
AC-29-ZR23_10uM Dose=10uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4
AC-29-ZR23_1uM Dose=1uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4
AC-30-XU83_0.01uM Dose=0.01uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8
AC-30-XU83_0.1uM Dose=0.1uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8
AC-30-XU83_10uM Dose=10uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8
AC-30-XU83_1uM Dose=1uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8
AC-31-AY35_0.01uM Dose=0.01uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
AC-31-AY35_0.1uM Dose=0.1uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
AC-31-AY35_10uM Dose=10uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
AC-31-AY35_1uM Dose=1uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
AC-31-PL89_0.01uM Dose=0.01uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2
AC-31-PL89_0.1uM Dose=0.1uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2
AC-31-PL89_10uM Dose=10uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2
AC-31-PL89_1uM Dose=1uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2
AC-31-SL44_0.01uM Dose=0.01uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B
AC-31-SL44_0.1uM Dose=0.1uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B
AC-31-SL44_10uM Dose=10uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B
AC-31-SL44_1uM Dose=1uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B
AC-33-YJ09_0.01uM Dose=0.01uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
AC-33-YJ09_0.1uM Dose=0.1uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
AC-33-YJ09_10uM Dose=10uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
AC-33-YJ09_1uM Dose=1uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
AC-35-CK01_10uM Dose=10uM, Mitonafide
AC-35-CK01_1uM Dose=1uM, Mitonafide
AC-35-JA42_0.01uM Dose=0.01uM, Terbutaline, beta2-Adrenoceptor Agonists targeting ADRB2
AC-35-JA42_0.1uM Dose=0.1uM, Terbutaline, beta2-Adrenoceptor Agonists targeting ADRB2
AC-35-JA42_10uM Dose=10uM, Terbutaline, beta2-Adrenoceptor Agonists targeting ADRB2
AC-35-JA42_1uM Dose=1uM, Terbutaline, beta2-Adrenoceptor Agonists targeting ADRB2
AC-36-FB52_0.01uM Dose=0.01uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AC-36-FB52_0.1uM Dose=0.1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AC-36-FB52_10uM Dose=10uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AC-36-FB52_1uM Dose=1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AC-36-SY22_0.01uM Dose=0.01uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4
AC-36-SY22_0.1uM Dose=0.1uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4
AC-36-SY22_10uM Dose=10uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4
AC-36-SY22_1uM Dose=1uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4
AC-36-TL21_0.01uM Dose=0.01uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1
AC-36-TL21_0.1uM Dose=0.1uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1
AC-36-TL21_10uM Dose=10uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1
AC-36-TL21_1uM Dose=1uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1
AC-37-OZ52_0.01uM Dose=0.01uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3
AC-37-OZ52_0.1uM Dose=0.1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3
AC-37-OZ52_10uM Dose=10uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3
AC-37-OZ52_1uM Dose=1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3
AC-38-WM38_0.01uM Dose=0.01uM
AC-38-WM38_0.1uM Dose=0.1uM
AC-38-WM38_10uM Dose=10uM
AC-38-WM38_1uM Dose=1uM
AC-40-DU58_0.01uM Dose=0.01uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP
AC-40-DU58_0.1uM Dose=0.1uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP
AC-40-DU58_10uM Dose=10uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP
AC-40-DU58_1uM Dose=1uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP
AC-40-KV26_0.01uM Dose=0.01uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1
AC-40-KV26_0.1uM Dose=0.1uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1
AC-40-KV26_10uM Dose=10uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1
AC-40-KV26_1uM Dose=1uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1
AC-40-PV46_0.01uM Dose=0.01uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1
AC-40-PV46_0.1uM Dose=0.1uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1
AC-40-PV46_10uM Dose=10uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1
AC-40-PV46_1uM Dose=1uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1
AC-41-IB85_0.01uM Dose=0.01uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA
AC-41-IB85_0.1uM Dose=0.1uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA
AC-41-IB85_10uM Dose=10uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA
AC-41-IB85_1uM Dose=1uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA
AC-41-MB45_0.01uM Dose=0.01uM
AC-41-MB45_10uM Dose=10uM
AC-41-MB45_1uM Dose=1uM
AC-42-LW33_0.01uM Dose=0.01uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one
AC-42-LW33_10uM Dose=10uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one
AC-42-LW33_1uM Dose=1uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one
AC-42-SI74_0.01uM Dose=0.01uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF
AC-42-SI74_0.1uM Dose=0.1uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF
AC-42-SI74_10uM Dose=10uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF
AC-42-SI74_1uM Dose=1uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF
AC-43-YW30_10uM Dose=10uM, Pindolol, beta-Adrenoceptor Antagonists targeting ADRB1
AC-43-ZC52_0.01uM Dose=0.01uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3
AC-43-ZC52_0.1uM Dose=0.1uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3
AC-43-ZC52_10uM Dose=10uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3
AC-43-ZC52_1uM Dose=1uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3
AC-44-UR36_0.01uM Dose=0.01uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT
AC-44-UR36_0.1uM Dose=0.1uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT
AC-44-UR36_10uM Dose=10uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT
AC-44-UR36_1uM Dose=1uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT
AC-45-EE32_0.01uM Dose=0.01uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid
AC-45-EE32_0.1uM Dose=0.1uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid
AC-45-EE32_10uM Dose=10uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid
AC-45-EE32_1uM Dose=1uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid
AC-45-YY00_0.01uM Dose=0.01uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol
AC-45-YY00_0.1uM Dose=0.1uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol
AC-45-YY00_10uM Dose=10uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol
AC-45-YY00_1uM Dose=1uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol
AC-47-YZ27_0.01uM Dose=0.01uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2
AC-47-YZ27_0.1uM Dose=0.1uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2
AC-47-YZ27_10uM Dose=10uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2
AC-47-YZ27_1uM Dose=1uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2
AC-47-ZI16_0.1uM Dose=0.1uM, Beta-Aminopropionitrile, LOX inhibitor targeting LOX, LOXL2
AC-47-ZI16_10uM Dose=10uM, Beta-Aminopropionitrile, LOX inhibitor targeting LOX, LOXL2
AC-49-NG46_0.01uM Dose=0.01uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5
AC-49-NG46_0.1uM Dose=0.1uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5
AC-49-NG46_10uM Dose=10uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5
AC-49-NG46_1uM Dose=1uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5
AC-49-ZR23_0.01uM Dose=0.01uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C
AC-49-ZR23_0.1uM Dose=0.1uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C
AC-49-ZR23_10uM Dose=10uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C
AC-49-ZR23_1uM Dose=1uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C
AC-50-FR41_0.01uM Dose=0.01uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
AC-50-FR41_0.1uM Dose=0.1uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
AC-50-FR41_10uM Dose=10uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
AC-50-FR41_1uM Dose=1uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
AC-50-JK54_0.01uM Dose=0.01uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4
AC-50-JK54_0.1uM Dose=0.1uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4
AC-50-JK54_10uM Dose=10uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4
AC-50-JK54_1uM Dose=1uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4
AC-50-TU13_0.01uM Dose=0.01uM, 1,4-Dihydroxy-2-naphthoic acid, Tau Aggregation Inhibitors targeting MAPT
AC-50-TU13_0.1uM Dose=0.1uM, 1,4-Dihydroxy-2-naphthoic acid, Tau Aggregation Inhibitors targeting MAPT
AC-50-TU13_10uM Dose=10uM, 1,4-Dihydroxy-2-naphthoic acid, Tau Aggregation Inhibitors targeting MAPT
AC-51-PY60_0.01uM Dose=0.01uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO
AC-51-PY60_0.1uM Dose=0.1uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO
AC-51-PY60_10uM Dose=10uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO
AC-51-PY60_1uM Dose=1uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO
AC-51-PY70_0.01uM Dose=0.01uM, FPL-55712 free base, Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1, CYSLTR2
AC-51-PY70_0.1uM Dose=0.1uM, FPL-55712 free base, Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1, CYSLTR2
AC-51-PY70_10uM Dose=10uM, FPL-55712 free base, Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1, CYSLTR2
AC-51-PY70_1uM Dose=1uM, FPL-55712 free base, Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1, CYSLTR2
AC-51-WE57_0.01uM Dose=0.01uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1
AC-51-WE57_0.1uM Dose=0.1uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1
AC-51-WE57_10uM Dose=10uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1
AC-51-WE57_1uM Dose=1uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1
AC-53-HJ29_0.01uM Dose=0.01uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6
AC-53-HJ29_0.1uM Dose=0.1uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6
AC-53-HJ29_10uM Dose=10uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6
AC-53-HJ29_1uM Dose=1uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6
AC-53-OM41_0.01uM Dose=0.01uM, Prucalopride, 5-HT4 Agonists targeting HTR4
AC-53-OM41_0.1uM Dose=0.1uM, Prucalopride, 5-HT4 Agonists targeting HTR4
AC-53-OM41_10uM Dose=10uM, Prucalopride, 5-HT4 Agonists targeting HTR4
AC-53-OM41_1uM Dose=1uM, Prucalopride, 5-HT4 Agonists targeting HTR4
AC-53-RC32_0.01uM Dose=0.01uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide
AC-53-RC32_0.1uM Dose=0.1uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide
AC-53-RC32_10uM Dose=10uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide
AC-53-RC32_1uM Dose=1uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide
AC-53-YM36_0.01uM Dose=0.01uM, N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[1-(2-methoxy-ethyl)-piperidin-4-yl]-benzamide, Cathepsin K Inhibitors targeting CTSK
AC-53-YM36_0.1uM Dose=0.1uM, N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[1-(2-methoxy-ethyl)-piperidin-4-yl]-benzamide, Cathepsin K Inhibitors targeting CTSK
AC-53-YM36_1uM Dose=1uM, N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[1-(2-methoxy-ethyl)-piperidin-4-yl]-benzamide, Cathepsin K Inhibitors targeting CTSK
AC-54-FR31_0.01uM Dose=0.01uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG
AC-54-FR31_0.1uM Dose=0.1uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG
AC-54-FR31_10uM Dose=10uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG
AC-54-FR31_1uM Dose=1uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG
AC-54-UG49_0.01uM Dose=0.01uM, Proadifen, Cytochrome P450 Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Potassium Channel Blockers targeting NOS1
AC-54-UG49_0.1uM Dose=0.1uM, Proadifen, Cytochrome P450 Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Potassium Channel Blockers targeting NOS1
AC-54-UG49_10uM Dose=10uM, Proadifen, Cytochrome P450 Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Potassium Channel Blockers targeting NOS1
AC-54-UG49_1uM Dose=1uM, Proadifen, Cytochrome P450 Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Potassium Channel Blockers targeting NOS1
AC-55-CK61_0.01uM Dose=0.01uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2
AC-55-CK61_0.1uM Dose=0.1uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2
AC-55-CK61_10uM Dose=10uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2
AC-55-CK61_1uM Dose=1uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2
AC-55-GO91_0.01uM Dose=0.01uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG
AC-55-GO91_0.1uM Dose=0.1uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG
AC-55-GO91_10uM Dose=10uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG
AC-55-GO91_1uM Dose=1uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG
AC-55-XA97_0.01uM Dose=0.01uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
AC-55-XA97_0.1uM Dose=0.1uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
AC-55-XA97_10uM Dose=10uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
AC-55-XA97_1uM Dose=1uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
AC-56-ZV05_0.01uM Dose=0.01uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK
AC-56-ZV05_0.1uM Dose=0.1uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK
AC-56-ZV05_10uM Dose=10uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK
AC-56-ZV05_1uM Dose=1uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK
AC-57-ZF49_0.01uM Dose=0.01uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6
AC-57-ZF49_0.1uM Dose=0.1uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6
AC-57-ZF49_10uM Dose=10uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6
AC-57-ZF49_1uM Dose=1uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6
AC-58-RM63_0.01uM Dose=0.01uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2
AC-58-RM63_0.1uM Dose=0.1uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2
AC-58-RM63_10uM Dose=10uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2
AC-58-RM63_1uM Dose=1uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2
AC-59-ZD79_0.01uM Dose=0.01uM, N6-Methyladenosine
AC-59-ZD79_0.1uM Dose=0.1uM, N6-Methyladenosine
AC-59-ZD79_10uM Dose=10uM, N6-Methyladenosine
AC-59-ZD79_1uM Dose=1uM, N6-Methyladenosine
AC-60-EU98_0.01uM Dose=0.01uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT
AC-60-EU98_0.1uM Dose=0.1uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT
AC-60-EU98_10uM Dose=10uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT
AC-60-EU98_1uM Dose=1uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT
AC-61-ZY25_10uM Dose=10uM, EP (PGE2) Receptor Antagonists;EP (PGE1) Receptor Antagonists;EP (PGE2) Receptor Antagonists;EP (PGE1) Receptor Antagonists
AC-61-ZY25_1uM Dose=1uM, EP (PGE2) Receptor Antagonists;EP (PGE1) Receptor Antagonists;EP (PGE2) Receptor Antagonists;EP (PGE1) Receptor Antagonists
AC-63-DM46_0.01uM Dose=0.01uM
AC-63-DM46_0.1uM Dose=0.1uM
AC-63-DM46_10uM Dose=10uM
AC-63-DM46_1uM Dose=1uM
AC-63-OM41_0.01uM Dose=0.01uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P
AC-63-OM41_0.1uM Dose=0.1uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P
AC-63-OM41_10uM Dose=10uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P
AC-63-OM41_1uM Dose=1uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P
AC-65-TK51_0.01uM Dose=0.01uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D
AC-65-TK51_0.1uM Dose=0.1uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D
AC-65-TK51_1uM Dose=1uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D
AC-67-PZ77_0.01uM Dose=0.01uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1
AC-67-PZ77_0.1uM Dose=0.1uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1
AC-67-PZ77_10uM Dose=10uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1
AC-67-PZ77_1uM Dose=1uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1
AC-67-TM11_0.01uM Dose=0.01uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48
AC-67-TM11_0.1uM Dose=0.1uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48
AC-67-TM11_10uM Dose=10uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48
AC-67-TM11_1uM Dose=1uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48
AC-67-ZF49_0.01uM Dose=0.01uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A
AC-67-ZF49_0.1uM Dose=0.1uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A
AC-67-ZF49_10uM Dose=10uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A
AC-67-ZF49_1uM Dose=1uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A
AC-70-KV26_0.01uM Dose=0.01uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F
AC-70-KV26_0.1uM Dose=0.1uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F
AC-70-KV26_10uM Dose=10uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F
AC-70-KV26_1uM Dose=1uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F
AC-71-VV28_0.01uM Dose=0.01uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119
AC-71-VV28_0.1uM Dose=0.1uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119
AC-71-VV28_10uM Dose=10uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119
AC-71-VV28_1uM Dose=1uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119
AC-71-YF45_0.01uM Dose=0.01uM
AC-71-YF45_0.1uM Dose=0.1uM
AC-71-YF45_10uM Dose=10uM
AC-71-YF45_1uM Dose=1uM
AC-72-HZ80_0.01uM Dose=0.01uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
AC-72-HZ80_0.1uM Dose=0.1uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
AC-72-HZ80_10uM Dose=10uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
AC-72-HZ80_1uM Dose=1uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
AC-73-DW50_0.01uM Dose=0.01uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1
AC-73-DW50_0.1uM Dose=0.1uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1
AC-73-DW50_10uM Dose=10uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1
AC-73-DW50_1uM Dose=1uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1
AC-73-GJ74_0.01uM Dose=0.01uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM
AC-73-GJ74_0.1uM Dose=0.1uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM
AC-73-GJ74_10uM Dose=10uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM
AC-73-GJ74_1uM Dose=1uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM
AC-74-BQ48_0.01uM Dose=0.01uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R
AC-74-BQ48_0.1uM Dose=0.1uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R
AC-74-BQ48_10uM Dose=10uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R
AC-74-BQ48_1uM Dose=1uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R
AC-74-UR36_0.01uM Dose=0.01uM, Apixaban, Known FactorXa inhibitor targeting F10
AC-74-UR36_0.1uM Dose=0.1uM, Apixaban, Known FactorXa inhibitor targeting F10
AC-74-UR36_10uM Dose=10uM, Apixaban, Known FactorXa inhibitor targeting F10
AC-74-UR36_1uM Dose=1uM, Apixaban, Known FactorXa inhibitor targeting F10
AC-74-ZA35_0.01uM Dose=0.01uM, Golgicide A, Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitors targeting GBF1
AC-74-ZA35_10uM Dose=10uM, Golgicide A, Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitors targeting GBF1
AC-74-ZA35_1uM Dose=1uM, Golgicide A, Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitors targeting GBF1
AC-75-CE67_0.01uM Dose=0.01uM
AC-75-CE67_10uM Dose=10uM
AC-75-CE67_1uM Dose=1uM
AC-75-LR63_0.01uM Dose=0.01uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10
AC-75-LR63_0.1uM Dose=0.1uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10
AC-75-LR63_10uM Dose=10uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10
AC-75-LR63_1uM Dose=1uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10
AC-76-BB02_0.01uM Dose=0.01uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14
AC-76-BB02_0.1uM Dose=0.1uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14
AC-76-BB02_10uM Dose=10uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14
AC-76-BB02_1uM Dose=1uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14
AC-76-BB72_0.01uM Dose=0.01uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1
AC-76-BB72_0.1uM Dose=0.1uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1
AC-76-BB72_10uM Dose=10uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1
AC-76-BB72_1uM Dose=1uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1
AC-76-JB92_0.01uM Dose=0.01uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2
AC-76-JB92_0.1uM Dose=0.1uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2
AC-76-JB92_10uM Dose=10uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2
AC-76-JB92_1uM Dose=1uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2
AC-77-BC52_0.01uM Dose=0.01uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine
AC-77-BC52_0.1uM Dose=0.1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine
AC-77-BC52_10uM Dose=10uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine
AC-77-BC52_1uM Dose=1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine
AC-77-VS60_0.01uM Dose=0.01uM, Reserpine, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors;Norepinephrine Uptake Inhibitor targeting SLC18A1, SLC18A2
AC-77-VS60_0.1uM Dose=0.1uM, Reserpine, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors;Norepinephrine Uptake Inhibitor targeting SLC18A1, SLC18A2
AC-77-VS60_10uM Dose=10uM, Reserpine, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors;Norepinephrine Uptake Inhibitor targeting SLC18A1, SLC18A2
AC-78-GT35_0.01uM Dose=0.01uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1
AC-78-GT35_0.1uM Dose=0.1uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1
AC-78-GT35_10uM Dose=10uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1
AC-78-GT35_1uM Dose=1uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1
AC-79-CQ25_0.01uM Dose=0.01uM, 1-(1-Acetylpyrazol-3-yl)-6,6-dimethyl-3-methylsulfanyl-5,7-dihydro-2-benzothiophen-4-one targeting GABRA5
AC-79-CQ25_0.1uM Dose=0.1uM, 1-(1-Acetylpyrazol-3-yl)-6,6-dimethyl-3-methylsulfanyl-5,7-dihydro-2-benzothiophen-4-one targeting GABRA5
AC-79-CQ25_10uM Dose=10uM, 1-(1-Acetylpyrazol-3-yl)-6,6-dimethyl-3-methylsulfanyl-5,7-dihydro-2-benzothiophen-4-one targeting GABRA5
AC-79-CQ25_1uM Dose=1uM, 1-(1-Acetylpyrazol-3-yl)-6,6-dimethyl-3-methylsulfanyl-5,7-dihydro-2-benzothiophen-4-one targeting GABRA5
AC-80-DI95_0.01uM Dose=0.01uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10
AC-80-DI95_0.1uM Dose=0.1uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10
AC-80-DI95_1uM Dose=1uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10
AC-82-PZ00_0.01uM Dose=0.01uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C
AC-82-PZ00_0.1uM Dose=0.1uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C
AC-82-PZ00_10uM Dose=10uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C
AC-82-PZ00_1uM Dose=1uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C
AC-83-LN99_0.01uM Dose=0.01uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3
AC-83-LN99_0.1uM Dose=0.1uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3
AC-83-LN99_10uM Dose=10uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3
AC-83-LN99_1uM Dose=1uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3
AC-84-QG99_0.01uM Dose=0.01uM
AC-84-QG99_0.1uM Dose=0.1uM
AC-84-QG99_10uM Dose=10uM
AC-84-QG99_1uM Dose=1uM
AC-85-MR73_0.01uM Dose=0.01uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C
AC-85-MR73_0.1uM Dose=0.1uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C
AC-85-MR73_10uM Dose=10uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C
AC-85-MR73_1uM Dose=1uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C
AC-86-KF37_0.01uM Dose=0.01uM, Capzimin, Proteasome inhibitor targeting PSMD14
AC-86-KF37_0.1uM Dose=0.1uM, Capzimin, Proteasome inhibitor targeting PSMD14
AC-86-KF37_10uM Dose=10uM, Capzimin, Proteasome inhibitor targeting PSMD14
AC-86-KF37_1uM Dose=1uM, Capzimin, Proteasome inhibitor targeting PSMD14
AC-86-XI84_0.01uM Dose=0.01uM
AC-86-XI84_0.1uM Dose=0.1uM
AC-86-XI84_10uM Dose=10uM
AC-86-XI84_1uM Dose=1uM
AC-90-GY03_0.01uM Dose=0.01uM
AC-90-GY03_0.1uM Dose=0.1uM
AC-90-GY03_10uM Dose=10uM
AC-90-GY03_1uM Dose=1uM
AC-90-QA75_0.01uM Dose=0.01uM, Benzenesulfonamide, 4-amino-3,5-dichloro-
AC-90-QA75_0.1uM Dose=0.1uM, Benzenesulfonamide, 4-amino-3,5-dichloro-
AC-90-QA75_10uM Dose=10uM, Benzenesulfonamide, 4-amino-3,5-dichloro-
AC-90-QA75_1uM Dose=1uM, Benzenesulfonamide, 4-amino-3,5-dichloro-
AC-91-AV48_0.01uM Dose=0.01uM
AC-91-AV48_0.1uM Dose=0.1uM
AC-91-AV48_10uM Dose=10uM
AC-91-AV48_1uM Dose=1uM
AC-91-ME22_0.01uM Dose=0.01uM, (R)-Aminoglutethimide
AC-91-ME22_0.1uM Dose=0.1uM, (R)-Aminoglutethimide
AC-91-ME22_10uM Dose=10uM, (R)-Aminoglutethimide
AC-91-ME22_1uM Dose=1uM, (R)-Aminoglutethimide
AC-91-TS36_0.01uM Dose=0.01uM
AC-91-TS36_0.1uM Dose=0.1uM
AC-91-TS36_10uM Dose=10uM
AC-91-TS36_1uM Dose=1uM
AC-91-WE67_0.01uM Dose=0.01uM, Acetovanillone, NADPH Oxidase Inhibitors targeting NOX3, NOX1
AC-91-WE67_0.1uM Dose=0.1uM, Acetovanillone, NADPH Oxidase Inhibitors targeting NOX3, NOX1
AC-91-WE67_10uM Dose=10uM, Acetovanillone, NADPH Oxidase Inhibitors targeting NOX3, NOX1
AC-91-WE67_1uM Dose=1uM, Acetovanillone, NADPH Oxidase Inhibitors targeting NOX3, NOX1
AC-92-HS43_0.01uM Dose=0.01uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4
AC-92-HS43_0.1uM Dose=0.1uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4
AC-92-HS43_10uM Dose=10uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4
AC-92-HS43_1uM Dose=1uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4
AC-92-ZW28_0.01uM Dose=0.01uM
AC-92-ZW28_10uM Dose=10uM
AC-92-ZW28_1uM Dose=1uM
AC-93-LT43_0.01uM Dose=0.01uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2
AC-93-LT43_0.1uM Dose=0.1uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2
AC-93-LT43_10uM Dose=10uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2
AC-93-LT43_1uM Dose=1uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2
AC-93-OJ74_0.01uM Dose=0.01uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2
AC-93-OJ74_0.1uM Dose=0.1uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2
AC-93-OJ74_10uM Dose=10uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2
AC-93-OJ74_1uM Dose=1uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2
AC-93-QD45_0.01uM Dose=0.01uM, targeting CGAS
AC-93-QD45_0.1uM Dose=0.1uM, targeting CGAS
AC-93-QD45_10uM Dose=10uM, targeting CGAS
AC-93-QD45_1uM Dose=1uM, targeting CGAS
AC-94-JQ48_0.1uM Dose=0.1uM, 5-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-2-fluoro-benzoic acid, Cathepsin B Inhibitors targeting CTSB
AC-94-JQ48_10uM Dose=10uM, 5-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-2-fluoro-benzoic acid, Cathepsin B Inhibitors targeting CTSB
AC-94-JQ48_1uM Dose=1uM, 5-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-2-fluoro-benzoic acid, Cathepsin B Inhibitors targeting CTSB
AC-94-SN51_0.01uM Dose=0.01uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1
AC-94-SN51_0.1uM Dose=0.1uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1
AC-94-SN51_10uM Dose=10uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1
AC-94-SN51_1uM Dose=1uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1
AC-94-YX80_0.01uM Dose=0.01uM, Loratadine
AC-94-YX80_0.1uM Dose=0.1uM, Loratadine
AC-94-YX80_10uM Dose=10uM, Loratadine
AC-94-YX80_1uM Dose=1uM, Loratadine
AC-95-MR73_0.01uM Dose=0.01uM, Cyclizine, Drugs Acting on Histamine Receptors targeting HRH1, SULT1E1
AC-95-MR73_0.1uM Dose=0.1uM, Cyclizine, Drugs Acting on Histamine Receptors targeting HRH1, SULT1E1
AC-95-MR73_10uM Dose=10uM, Cyclizine, Drugs Acting on Histamine Receptors targeting HRH1, SULT1E1
AC-95-MR73_1uM Dose=1uM, Cyclizine, Drugs Acting on Histamine Receptors targeting HRH1, SULT1E1
AC-95-MU00_0.01uM Dose=0.01uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A
AC-95-MU00_0.1uM Dose=0.1uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A
AC-95-MU00_10uM Dose=10uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A
AC-95-MU00_1uM Dose=1uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A
AC-95-NR38_0.01uM Dose=0.01uM
AC-95-NR38_0.1uM Dose=0.1uM
AC-95-NR38_10uM Dose=10uM
AC-95-NR38_1uM Dose=1uM
AC-95-TK81_0.01uM Dose=0.01uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4
AC-95-TK81_0.1uM Dose=0.1uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4
AC-95-TK81_10uM Dose=10uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4
AC-95-TK81_1uM Dose=1uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4
AC-96-OO08_0.01uM Dose=0.01uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
AC-96-OO08_0.1uM Dose=0.1uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
AC-96-OO08_10uM Dose=10uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
AC-96-OO08_1uM Dose=1uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
AC-97-KP88_0.01uM Dose=0.01uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD
AC-97-KP88_0.1uM Dose=0.1uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD
AC-97-KP88_10uM Dose=10uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD
AC-97-KP88_1uM Dose=1uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD
AC-98-QW77_0.01uM Dose=0.01uM, CGC-11047 free base
AC-98-QW77_0.1uM Dose=0.1uM, CGC-11047 free base
AC-98-QW77_10uM Dose=10uM, CGC-11047 free base
AC-98-QW77_1uM Dose=1uM, CGC-11047 free base
AC-98-UW57_0.01uM Dose=0.01uM, Suplatast
AC-98-UW57_0.1uM Dose=0.1uM, Suplatast
AC-98-UW57_10uM Dose=10uM, Suplatast
AC-98-UW57_1uM Dose=1uM, Suplatast
AC-99-ZN13_0.01uM Dose=0.01uM, Ethoxzolamide, CA2 inhibitor;CA4 inhibitor;CA1 inhibitor;CA7 inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10
AC-99-ZN13_10uM Dose=10uM, Ethoxzolamide, CA2 inhibitor;CA4 inhibitor;CA1 inhibitor;CA7 inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10
AC-99-ZN13_1uM Dose=1uM, Ethoxzolamide, CA2 inhibitor;CA4 inhibitor;CA1 inhibitor;CA7 inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10
AD-00-WA10_0.1uM Dose=0.1uM, 1-{4-[N-(2-isopropyloxyethyl)-N-chloroacetylamino]benzoyl}-4-[2-(4-chlorophenyl)ethyl]piperazine
AD-00-WA10_10uM Dose=10uM, 1-{4-[N-(2-isopropyloxyethyl)-N-chloroacetylamino]benzoyl}-4-[2-(4-chlorophenyl)ethyl]piperazine
AD-00-WA10_1uM Dose=1uM, 1-{4-[N-(2-isopropyloxyethyl)-N-chloroacetylamino]benzoyl}-4-[2-(4-chlorophenyl)ethyl]piperazine
AD-00-ZK94_0.01uM Dose=0.01uM, 3-[(2,4-Dichlorophenyl)methylsulfanyl]-1,6-dimethylpyridazino[4,5-e][1,3,4]thiadiazin-5-one targeting GPR65
AD-00-ZK94_0.1uM Dose=0.1uM, 3-[(2,4-Dichlorophenyl)methylsulfanyl]-1,6-dimethylpyridazino[4,5-e][1,3,4]thiadiazin-5-one targeting GPR65
AD-00-ZK94_10uM Dose=10uM, 3-[(2,4-Dichlorophenyl)methylsulfanyl]-1,6-dimethylpyridazino[4,5-e][1,3,4]thiadiazin-5-one targeting GPR65
AD-02-XI19_0.01uM Dose=0.01uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT
AD-02-XI19_0.1uM Dose=0.1uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT
AD-02-XI19_10uM Dose=10uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT
AD-02-XI19_1uM Dose=1uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT
AD-06-OB47_0.01uM Dose=0.01uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19
AD-06-OB47_0.1uM Dose=0.1uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19
AD-06-OB47_10uM Dose=10uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19
AD-06-OB47_1uM Dose=1uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19
AD-07-US30_0.01uM Dose=0.01uM, Emodin, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B
AD-07-US30_0.1uM Dose=0.1uM, Emodin, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B
AD-07-US30_10uM Dose=10uM, Emodin, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B
AD-07-US30_1uM Dose=1uM, Emodin, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B
AD-07-YF79_0.01uM Dose=0.01uM, N-(4-fluoro-2-methylphenyl)-3-methyl-N-[(2-methyl-1H-indol-4-yl)methyl]pyridine-4-carboxamide, GPBAR1 agonist;TGR5 agonist targeting GPBAR1
AD-07-YF79_1uM Dose=1uM, N-(4-fluoro-2-methylphenyl)-3-methyl-N-[(2-methyl-1H-indol-4-yl)methyl]pyridine-4-carboxamide, GPBAR1 agonist;TGR5 agonist targeting GPBAR1
AD-09-MD49_0.01uM Dose=0.01uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR
AD-09-MD49_0.1uM Dose=0.1uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR
AD-09-MD49_10uM Dose=10uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR
AD-09-MD49_1uM Dose=1uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR
AD-09-TD34_0.01uM Dose=0.01uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(5-isopropyl-4-methoxypyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN
AD-09-TD34_0.1uM Dose=0.1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(5-isopropyl-4-methoxypyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN
AD-09-TD34_1uM Dose=1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(5-isopropyl-4-methoxypyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN
AD-10-TH32_0.01uM Dose=0.01uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1
AD-10-TH32_0.1uM Dose=0.1uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1
AD-10-TH32_10uM Dose=10uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1
AD-10-TH32_1uM Dose=1uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1
AD-10-ZS64_0.01uM Dose=0.01uM, Ivabradine
AD-10-ZS64_0.1uM Dose=0.1uM, Ivabradine
AD-10-ZS64_10uM Dose=10uM, Ivabradine
AD-10-ZS64_1uM Dose=1uM, Ivabradine
AD-11-FZ23_0.01uM Dose=0.01uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B
AD-11-FZ23_0.1uM Dose=0.1uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B
AD-11-FZ23_10uM Dose=10uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B
AD-11-FZ23_1uM Dose=1uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B
AD-11-HV98_0.01uM Dose=0.01uM, Balicatib, Cathepsin K Inhibitors targeting CTSK
AD-11-HV98_0.1uM Dose=0.1uM, Balicatib, Cathepsin K Inhibitors targeting CTSK
AD-11-HV98_10uM Dose=10uM, Balicatib, Cathepsin K Inhibitors targeting CTSK
AD-11-HV98_1uM Dose=1uM, Balicatib, Cathepsin K Inhibitors targeting CTSK
AD-11-RL84_0.01uM Dose=0.01uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1
AD-11-RL84_0.1uM Dose=0.1uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1
AD-11-RL84_10uM Dose=10uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1
AD-11-RL84_1uM Dose=1uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1
AD-11-VE17_0.01uM Dose=0.01uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5
AD-11-VE17_0.1uM Dose=0.1uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5
AD-11-VE17_10uM Dose=10uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5
AD-12-YF12_0.01uM Dose=0.01uM, Umbelliferone, Carbonic Anhydrase Type XII Inhibitors;Cyclooxygenase-2 Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Antioxidants targeting CA9, CA12, PTGS2
AD-12-YF12_0.1uM Dose=0.1uM, Umbelliferone, Carbonic Anhydrase Type XII Inhibitors;Cyclooxygenase-2 Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Antioxidants targeting CA9, CA12, PTGS2
AD-12-YF12_10uM Dose=10uM, Umbelliferone, Carbonic Anhydrase Type XII Inhibitors;Cyclooxygenase-2 Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Antioxidants targeting CA9, CA12, PTGS2
AD-14-QD12_0.01uM Dose=0.01uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2
AD-14-QD12_0.1uM Dose=0.1uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2
AD-14-QD12_10uM Dose=10uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2
AD-14-QD12_1uM Dose=1uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2
AD-15-VR38_0.01uM Dose=0.01uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14
AD-15-VR38_0.1uM Dose=0.1uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14
AD-15-VR38_10uM Dose=10uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14
AD-15-VR38_1uM Dose=1uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14
AD-16-HL96_0.01uM Dose=0.01uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1
AD-16-HL96_0.1uM Dose=0.1uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1
AD-16-HL96_10uM Dose=10uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1
AD-16-HL96_1uM Dose=1uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1
AD-16-OE34_0.01uM Dose=0.01uM, Octopamine
AD-16-OE34_0.1uM Dose=0.1uM, Octopamine
AD-16-OE34_10uM Dose=10uM, Octopamine
AD-16-OE34_1uM Dose=1uM, Octopamine
AD-18-VX25_0.01uM Dose=0.01uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18
AD-18-VX25_0.1uM Dose=0.1uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18
AD-18-VX25_10uM Dose=10uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18
AD-18-VX25_1uM Dose=1uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18
AD-18-XC14_0.01uM Dose=0.01uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1
AD-18-XC14_0.1uM Dose=0.1uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1
AD-18-XC14_10uM Dose=10uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1
AD-18-XC14_1uM Dose=1uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1
AD-19-GH34_0.01uM Dose=0.01uM, Gsk-lsd1, KDM1A/B targeting KDM1A
AD-19-GH34_0.1uM Dose=0.1uM, Gsk-lsd1, KDM1A/B targeting KDM1A
AD-19-GH34_10uM Dose=10uM, Gsk-lsd1, KDM1A/B targeting KDM1A
AD-20-AA40_0.01uM Dose=0.01uM, Cdc2-like kinase inhibitor, CDC-like kinase-1 inhibitors targeting CLK1, CLK2, CLK4
AD-20-AA40_10uM Dose=10uM, Cdc2-like kinase inhibitor, CDC-like kinase-1 inhibitors targeting CLK1, CLK2, CLK4
AD-20-AA40_1uM Dose=1uM, Cdc2-like kinase inhibitor, CDC-like kinase-1 inhibitors targeting CLK1, CLK2, CLK4
AD-20-CH42_0.01uM Dose=0.01uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42
AD-20-CH42_0.1uM Dose=0.1uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42
AD-20-CH42_10uM Dose=10uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42
AD-20-CH42_1uM Dose=1uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42
AD-20-KA75_10uM Dose=10uM, 1H-1,4-Diazepine, hexahydro-1-((5-iodo-1-naphthalenyl)sulfonyl)-, Myosin Light Chain Kinase (MLCK) Inhibitors targeting MYLK, MYLK2, MYLK3, MYLK4
AD-20-KA75_1uM Dose=1uM, 1H-1,4-Diazepine, hexahydro-1-((5-iodo-1-naphthalenyl)sulfonyl)-, Myosin Light Chain Kinase (MLCK) Inhibitors targeting MYLK, MYLK2, MYLK3, MYLK4
AD-20-YO14_0.01uM Dose=0.01uM, Ars-1620 targeting KRAS
AD-20-YO14_0.1uM Dose=0.1uM, Ars-1620 targeting KRAS
AD-20-YO14_10uM Dose=10uM, Ars-1620 targeting KRAS
AD-20-YO14_1uM Dose=1uM, Ars-1620 targeting KRAS
AD-21-WS76_0.01uM Dose=0.01uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide
AD-21-WS76_0.1uM Dose=0.1uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide
AD-21-WS76_10uM Dose=10uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide
AD-21-WS76_1uM Dose=1uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide
AD-23-AN14_0.01uM Dose=0.01uM, Tranilast, Urate Transporter 1 (URAT1) Inhibitors;Indoleamine 2,3-dioxygenase Activators;IFN-gamma Production Inhibitors;IL-2 Production Inhibitors;TNF-alpha Production Inhibitors;IL-10 Production Enhancers;IL-4 Modulators;Signal Transduction Modulators targeting HEXB, IDO1, TRPV2, SLC22A12
AD-23-AN14_0.1uM Dose=0.1uM, Tranilast, Urate Transporter 1 (URAT1) Inhibitors;Indoleamine 2,3-dioxygenase Activators;IFN-gamma Production Inhibitors;IL-2 Production Inhibitors;TNF-alpha Production Inhibitors;IL-10 Production Enhancers;IL-4 Modulators;Signal Transduction Modulators targeting HEXB, IDO1, TRPV2, SLC22A12
AD-23-AN14_10uM Dose=10uM, Tranilast, Urate Transporter 1 (URAT1) Inhibitors;Indoleamine 2,3-dioxygenase Activators;IFN-gamma Production Inhibitors;IL-2 Production Inhibitors;TNF-alpha Production Inhibitors;IL-10 Production Enhancers;IL-4 Modulators;Signal Transduction Modulators targeting HEXB, IDO1, TRPV2, SLC22A12
AD-24-KU93_0.01uM Dose=0.01uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone
AD-24-KU93_0.1uM Dose=0.1uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone
AD-24-KU93_10uM Dose=10uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone
AD-24-KU93_1uM Dose=1uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone
AD-26-RY42_0.01uM Dose=0.01uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
AD-26-RY42_0.1uM Dose=0.1uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
AD-26-RY42_10uM Dose=10uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
AD-26-RY42_1uM Dose=1uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
AD-26-SL71_0.1uM Dose=0.1uM, 6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide, Adenosine A2A Agonists targeting ADORA2A
AD-26-SL71_10uM Dose=10uM, 6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide, Adenosine A2A Agonists targeting ADORA2A
AD-26-SL71_1uM Dose=1uM, 6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide, Adenosine A2A Agonists targeting ADORA2A
AD-27-JS45_0.01uM Dose=0.01uM, 4-Methylhistamine, HRH4 agonist targeting HRH4
AD-27-JS45_0.1uM Dose=0.1uM, 4-Methylhistamine, HRH4 agonist targeting HRH4
AD-27-JS45_10uM Dose=10uM, 4-Methylhistamine, HRH4 agonist targeting HRH4
AD-27-JS45_1uM Dose=1uM, 4-Methylhistamine, HRH4 agonist targeting HRH4
AD-28-GJ71_0.01uM Dose=0.01uM, 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine, Adenosine A2A Agonists targeting ADORA2A
AD-28-GJ71_0.1uM Dose=0.1uM, 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine, Adenosine A2A Agonists targeting ADORA2A
AD-28-GJ71_10uM Dose=10uM, 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine, Adenosine A2A Agonists targeting ADORA2A
AD-29-IG16_0.01uM Dose=0.01uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1
AD-29-IG16_0.1uM Dose=0.1uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1
AD-29-IG16_10uM Dose=10uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1
AD-29-IG16_1uM Dose=1uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1
AD-29-MQ00_0.01uM Dose=0.01uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid
AD-29-MQ00_0.1uM Dose=0.1uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid
AD-29-MQ00_10uM Dose=10uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid
AD-29-MQ00_1uM Dose=1uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid
AD-30-OK99_0.01uM Dose=0.01uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A
AD-30-OK99_0.1uM Dose=0.1uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A
AD-30-OK99_10uM Dose=10uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A
AD-30-OK99_1uM Dose=1uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A
AD-30-SU93_0.01uM Dose=0.01uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A
AD-30-SU93_0.1uM Dose=0.1uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A
AD-30-SU93_10uM Dose=10uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A
AD-30-SU93_1uM Dose=1uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A
AD-30-TH52_0.01uM Dose=0.01uM, 5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole, Phosphodiesterase PDE4D Inhibitors;TNF-alpha Production Inhibitors targeting PDE4D
AD-30-TH52_10uM Dose=10uM, 5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole, Phosphodiesterase PDE4D Inhibitors;TNF-alpha Production Inhibitors targeting PDE4D
AD-30-TH52_1uM Dose=1uM, 5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole, Phosphodiesterase PDE4D Inhibitors;TNF-alpha Production Inhibitors targeting PDE4D
AD-30-TH82_0.1uM Dose=0.1uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1
AD-30-TH82_10uM Dose=10uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1
AD-30-TH82_1uM Dose=1uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1
AD-30-VB23_10uM Dose=10uM, Rotenone, Apoptosis Inducers;NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitors;Non-Steroidal Antiinflammatory Drugs;Electron Transport Chain Inhibitors;Electron transport chain inhibitor targeting NDUFS1, NOX4, NOX5
AD-30-VB23_1uM Dose=1uM, Rotenone, Apoptosis Inducers;NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitors;Non-Steroidal Antiinflammatory Drugs;Electron Transport Chain Inhibitors;Electron transport chain inhibitor targeting NDUFS1, NOX4, NOX5
AD-31-GO06_0.01uM Dose=0.01uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one
AD-31-GO06_0.1uM Dose=0.1uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one
AD-31-GO06_10uM Dose=10uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one
AD-31-GO06_1uM Dose=1uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one
AD-31-PI82_0.01uM Dose=0.01uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2
AD-31-PI82_0.1uM Dose=0.1uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2
AD-31-PI82_10uM Dose=10uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2
AD-31-PI82_1uM Dose=1uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2
AD-32-RF17_0.01uM Dose=0.01uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN
AD-32-RF17_0.1uM Dose=0.1uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN
AD-32-RF17_10uM Dose=10uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN
AD-32-RF17_1uM Dose=1uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN
AD-33-YW85_0.01uM Dose=0.01uM, (3-Aminopropyl)(n-butyl)phosphinic acid
AD-33-YW85_0.1uM Dose=0.1uM, (3-Aminopropyl)(n-butyl)phosphinic acid
AD-33-YW85_10uM Dose=10uM, (3-Aminopropyl)(n-butyl)phosphinic acid
AD-33-YW85_1uM Dose=1uM, (3-Aminopropyl)(n-butyl)phosphinic acid
AD-34-TG29_0.01uM Dose=0.01uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP
AD-34-TG29_0.1uM Dose=0.1uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP
AD-34-TG29_10uM Dose=10uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP
AD-34-TG29_1uM Dose=1uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP
AD-34-WD27_0.01uM Dose=0.01uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT
AD-34-WD27_0.1uM Dose=0.1uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT
AD-34-WD27_10uM Dose=10uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT
AD-34-WD27_1uM Dose=1uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT
AD-37-DF79_0.01uM Dose=0.01uM, mGluR4-PAM-1, MGLUR4 positive allosteric modulator targeting GRM4
AD-37-DF79_0.1uM Dose=0.1uM, mGluR4-PAM-1, MGLUR4 positive allosteric modulator targeting GRM4
AD-37-DF79_10uM Dose=10uM, mGluR4-PAM-1, MGLUR4 positive allosteric modulator targeting GRM4
AD-37-DF79_1uM Dose=1uM, mGluR4-PAM-1, MGLUR4 positive allosteric modulator targeting GRM4
AD-37-UF49_0.01uM Dose=0.01uM, (S)-N1-(4-Methyl-5-(2-(1-methylcyclopropyl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
AD-37-UF49_0.1uM Dose=0.1uM, (S)-N1-(4-Methyl-5-(2-(1-methylcyclopropyl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
AD-37-UF49_10uM Dose=10uM, (S)-N1-(4-Methyl-5-(2-(1-methylcyclopropyl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
AD-38-OG44_0.01uM Dose=0.01uM, Bempedoic Acid, ATP citrate lyase inhibitor targeting ACLY
AD-38-OG44_0.1uM Dose=0.1uM, Bempedoic Acid, ATP citrate lyase inhibitor targeting ACLY
AD-38-OG44_10uM Dose=10uM, Bempedoic Acid, ATP citrate lyase inhibitor targeting ACLY
AD-38-OG44_1uM Dose=1uM, Bempedoic Acid, ATP citrate lyase inhibitor targeting ACLY
AD-39-JN68_0.01uM Dose=0.01uM, PI3K|A inhibitor 4, PI3 kinase p85 regulatory subunit gamma inhibitor targeting PIK3CG
AD-39-JN68_0.1uM Dose=0.1uM, PI3K|A inhibitor 4, PI3 kinase p85 regulatory subunit gamma inhibitor targeting PIK3CG
AD-39-JN68_10uM Dose=10uM, PI3K|A inhibitor 4, PI3 kinase p85 regulatory subunit gamma inhibitor targeting PIK3CG
AD-39-JN68_1uM Dose=1uM, PI3K|A inhibitor 4, PI3 kinase p85 regulatory subunit gamma inhibitor targeting PIK3CG
AD-39-QQ00_0.01uM Dose=0.01uM, S-Methyl-L-thiocitrulline, Nitric Oxide Synthase Inhibitors targeting NOS3
AD-39-QQ00_0.1uM Dose=0.1uM, S-Methyl-L-thiocitrulline, Nitric Oxide Synthase Inhibitors targeting NOS3
AD-39-QQ00_1uM Dose=1uM, S-Methyl-L-thiocitrulline, Nitric Oxide Synthase Inhibitors targeting NOS3
AD-40-WB93_0.01uM Dose=0.01uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1
AD-40-WB93_0.1uM Dose=0.1uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1
AD-40-WB93_10uM Dose=10uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1
AD-40-WB93_1uM Dose=1uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1
AD-41-WB70_0.01uM Dose=0.01uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
AD-41-WB70_0.1uM Dose=0.1uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
AD-41-WB70_10uM Dose=10uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
AD-41-WB70_1uM Dose=1uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
AD-42-OW73_0.01uM Dose=0.01uM, SB 415286 targeting GSK3A, GSK3B
AD-42-OW73_0.1uM Dose=0.1uM, SB 415286 targeting GSK3A, GSK3B
AD-42-OW73_10uM Dose=10uM, SB 415286 targeting GSK3A, GSK3B
AD-42-OW73_1uM Dose=1uM, SB 415286 targeting GSK3A, GSK3B
AD-42-US78_0.01uM Dose=0.01uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3
AD-42-US78_0.1uM Dose=0.1uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3
AD-42-US78_10uM Dose=10uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3
AD-42-US78_1uM Dose=1uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3
AD-42-VF57_0.01uM Dose=0.01uM, [[[[(2R,3S,4R,5R)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-dichloromethyl]phosphonic acid, P2RY12 (P2T) Antagonists targeting P2RY12
AD-42-VF57_0.1uM Dose=0.1uM, [[[[(2R,3S,4R,5R)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-dichloromethyl]phosphonic acid, P2RY12 (P2T) Antagonists targeting P2RY12
AD-43-EQ11_0.01uM Dose=0.01uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one
AD-43-EQ11_0.1uM Dose=0.1uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one
AD-43-EQ11_10uM Dose=10uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one
AD-43-EQ11_1uM Dose=1uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one
AD-43-WX13_0.01uM Dose=0.01uM, (2e,3ar,14as)-9-Bromo-2-Imino-1,2,3,5,6,14a-Hexahydro-4h,8h-Imidazo[4',5':5,6]pyrrolo[1',2':4,5]pyrazino[1,2-A]indol-8-One, Proteasome beta-5 subunit inhibitor targeting PSMB5
AD-43-WX13_10uM Dose=10uM, (2e,3ar,14as)-9-Bromo-2-Imino-1,2,3,5,6,14a-Hexahydro-4h,8h-Imidazo[4',5':5,6]pyrrolo[1',2':4,5]pyrazino[1,2-A]indol-8-One, Proteasome beta-5 subunit inhibitor targeting PSMB5
AD-43-XJ59_0.01uM Dose=0.01uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG
AD-43-XJ59_0.1uM Dose=0.1uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG
AD-43-XJ59_10uM Dose=10uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG
AD-43-XJ59_1uM Dose=1uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG
AD-45-DA82_10uM Dose=10uM, Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;Cholesterol Absorption Inhibitors
AD-45-YB25_0.01uM Dose=0.01uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A
AD-45-YB25_0.1uM Dose=0.1uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A
AD-45-YB25_10uM Dose=10uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A
AD-45-YB25_1uM Dose=1uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A
AD-49-MG76_0.01uM Dose=0.01uM, Clozapine, 5-HT2 Antagonists;Dopamine D4 Antagonists;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD4, HTR1E, HTR1F
AD-49-MG76_0.1uM Dose=0.1uM, Clozapine, 5-HT2 Antagonists;Dopamine D4 Antagonists;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD4, HTR1E, HTR1F
AD-49-MG76_10uM Dose=10uM, Clozapine, 5-HT2 Antagonists;Dopamine D4 Antagonists;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD4, HTR1E, HTR1F
AD-50-WA90_0.01uM Dose=0.01uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
AD-50-WA90_0.1uM Dose=0.1uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
AD-50-WA90_10uM Dose=10uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
AD-50-WA90_1uM Dose=1uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
AD-51-BB90_0.01uM Dose=0.01uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA
AD-51-BB90_0.1uM Dose=0.1uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA
AD-51-BB90_10uM Dose=10uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA
AD-51-BB90_1uM Dose=1uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA
AD-51-FB60_0.01uM Dose=0.01uM, 1-C-Ethylaminoadamantane
AD-51-FB60_0.1uM Dose=0.1uM, 1-C-Ethylaminoadamantane
AD-51-FB60_10uM Dose=10uM, 1-C-Ethylaminoadamantane
AD-51-FB60_1uM Dose=1uM, 1-C-Ethylaminoadamantane
AD-51-LE62_0.01uM Dose=0.01uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B
AD-51-LE62_0.1uM Dose=0.1uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B
AD-51-LE62_10uM Dose=10uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B
AD-51-LE62_1uM Dose=1uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B
AD-51-SS86_0.01uM Dose=0.01uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2
AD-51-SS86_0.1uM Dose=0.1uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2
AD-51-SS86_10uM Dose=10uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2
AD-51-SS86_1uM Dose=1uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2
AD-51-ZE47_0.01uM Dose=0.01uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2
AD-51-ZE47_0.1uM Dose=0.1uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2
AD-51-ZE47_10uM Dose=10uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2
AD-51-ZE47_1uM Dose=1uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2
AD-52-UZ45_0.01uM Dose=0.01uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2
AD-52-UZ45_0.1uM Dose=0.1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2
AD-52-UZ45_10uM Dose=10uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2
AD-52-UZ45_1uM Dose=1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2
AD-53-VC77_0.01uM Dose=0.01uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-[[(6S)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
AD-53-VC77_10uM Dose=10uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-[[(6S)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
AD-53-VC77_1uM Dose=1uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-[[(6S)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
AD-54-FG24_0.01uM Dose=0.01uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB
AD-54-FG24_0.1uM Dose=0.1uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB
AD-54-FG24_10uM Dose=10uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB
AD-54-IH37_0.01uM Dose=0.01uM, Entacapone, COMT Inhibitors targeting COMT
AD-54-IH37_0.1uM Dose=0.1uM, Entacapone, COMT Inhibitors targeting COMT
AD-54-IH37_10uM Dose=10uM, Entacapone, COMT Inhibitors targeting COMT
AD-54-IH37_1uM Dose=1uM, Entacapone, COMT Inhibitors targeting COMT
AD-55-EA62_0.01uM Dose=0.01uM, D-AP4
AD-55-EA62_0.1uM Dose=0.1uM, D-AP4
AD-55-EA62_10uM Dose=10uM, D-AP4
AD-55-EA62_1uM Dose=1uM, D-AP4
AD-55-HH69_0.01uM Dose=0.01uM, 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
AD-55-HH69_0.1uM Dose=0.1uM, 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
AD-55-HH69_10uM Dose=10uM, 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
AD-55-HH69_1uM Dose=1uM, 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
AD-55-WK61_0.01uM Dose=0.01uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1
AD-55-WK61_0.1uM Dose=0.1uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1
AD-55-WK61_10uM Dose=10uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1
AD-55-WK61_1uM Dose=1uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1
AD-56-VO78_0.01uM Dose=0.01uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E
AD-56-VO78_0.1uM Dose=0.1uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E
AD-56-VO78_10uM Dose=10uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E
AD-56-VO78_1uM Dose=1uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E
AD-58-PW17_0.01uM Dose=0.01uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB
AD-58-PW17_0.1uM Dose=0.1uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB
AD-58-PW17_10uM Dose=10uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB
AD-58-PW17_1uM Dose=1uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB
AD-59-IN33_0.01uM Dose=0.01uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14
AD-59-IN33_0.1uM Dose=0.1uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14
AD-59-IN33_10uM Dose=10uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14
AD-59-IN33_1uM Dose=1uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14
AD-65-WK61_0.01uM Dose=0.01uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P
AD-65-WK61_0.1uM Dose=0.1uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P
AD-65-WK61_10uM Dose=10uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P
AD-65-WK61_1uM Dose=1uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P
AD-66-NO48_0.01uM Dose=0.01uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9
AD-66-NO48_0.1uM Dose=0.1uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9
AD-66-NO48_10uM Dose=10uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9
AD-66-NO48_1uM Dose=1uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9
AD-66-NV75_0.01uM Dose=0.01uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3
AD-66-NV75_0.1uM Dose=0.1uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3
AD-66-NV75_10uM Dose=10uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3
AD-66-NV75_1uM Dose=1uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3
AD-70-DU18_0.01uM Dose=0.01uM
AD-70-DU18_0.1uM Dose=0.1uM
AD-70-DU18_10uM Dose=10uM
AD-70-DU18_1uM Dose=1uM
AD-70-LA75_0.01uM Dose=0.01uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6
AD-70-LA75_0.1uM Dose=0.1uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6
AD-70-LA75_10uM Dose=10uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6
AD-70-LA75_1uM Dose=1uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6
AD-70-TH82_0.01uM Dose=0.01uM, (4R)-2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1
AD-70-TH82_10uM Dose=10uM, (4R)-2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1
AD-70-TH82_1uM Dose=1uM, (4R)-2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1
AD-72-MJ27_0.01uM Dose=0.01uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN
AD-72-MJ27_0.1uM Dose=0.1uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN
AD-72-MJ27_10uM Dose=10uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN
AD-72-MJ27_1uM Dose=1uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN
AD-72-OW33_0.01uM Dose=0.01uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid
AD-72-OW33_0.1uM Dose=0.1uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid
AD-72-OW33_10uM Dose=10uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid
AD-72-OW33_1uM Dose=1uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid
AD-72-RI24_0.01uM Dose=0.01uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
AD-72-RI24_0.1uM Dose=0.1uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
AD-72-RI24_10uM Dose=10uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
AD-72-RI24_1uM Dose=1uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
AD-77-UF99_0.01uM Dose=0.01uM, (R)-1-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)pyrimidin-2-yl)pyrrolidin-3-ol, TRKB Inhibitors;ALK Inhibitors;TRKA Inhibitors targeting ALK, NTRK1, NTRK2
AD-77-UF99_10uM Dose=10uM, (R)-1-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)pyrimidin-2-yl)pyrrolidin-3-ol, TRKB Inhibitors;ALK Inhibitors;TRKA Inhibitors targeting ALK, NTRK1, NTRK2
AD-77-UF99_1uM Dose=1uM, (R)-1-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)pyrimidin-2-yl)pyrrolidin-3-ol, TRKB Inhibitors;ALK Inhibitors;TRKA Inhibitors targeting ALK, NTRK1, NTRK2
AD-79-UU60_0.01uM Dose=0.01uM, Het0016, 20-HETE receptor antagonist targeting CYP4A11
AD-79-UU60_10uM Dose=10uM, Het0016, 20-HETE receptor antagonist targeting CYP4A11
AD-79-UU60_1uM Dose=1uM, Het0016, 20-HETE receptor antagonist targeting CYP4A11
AD-82-AM64_0.01uM Dose=0.01uM
AD-82-AM64_10uM Dose=10uM
AD-82-AM64_1uM Dose=1uM
AD-82-OW73_0.01uM Dose=0.01uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2
AD-82-OW73_0.1uM Dose=0.1uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2
AD-82-OW73_10uM Dose=10uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2
AD-82-OW73_1uM Dose=1uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2
AD-83-MW95_0.01uM Dose=0.01uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA
AD-83-MW95_0.1uM Dose=0.1uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA
AD-83-MW95_10uM Dose=10uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA
AD-83-MW95_1uM Dose=1uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA
AD-84-LG49_0.01uM Dose=0.01uM
AD-84-LG49_0.1uM Dose=0.1uM
AD-84-LG49_10uM Dose=10uM
AD-84-LG49_1uM Dose=1uM
AD-85-ME82_0.01uM Dose=0.01uM, 15-O-Desmethylascomycin
AD-85-ME82_0.1uM Dose=0.1uM, 15-O-Desmethylascomycin
AD-85-ME82_10uM Dose=10uM, 15-O-Desmethylascomycin
AD-85-ME82_1uM Dose=1uM, 15-O-Desmethylascomycin
AD-86-ES28_0.01uM Dose=0.01uM, LY2033298, M4 positive allosteric modulator targeting CHRM4
AD-86-ES28_0.1uM Dose=0.1uM, LY2033298, M4 positive allosteric modulator targeting CHRM4
AD-86-ES28_10uM Dose=10uM, LY2033298, M4 positive allosteric modulator targeting CHRM4
AD-86-ES28_1uM Dose=1uM, LY2033298, M4 positive allosteric modulator targeting CHRM4
AD-86-OB47_0.01uM Dose=0.01uM, Icilin, TRPM8 agonist;Induction of Brown Adipose Tissue (BAT) thermogenesis;TRPA1 Agonists targeting TRPA1, TRPM8
AD-86-OB47_0.1uM Dose=0.1uM, Icilin, TRPM8 agonist;Induction of Brown Adipose Tissue (BAT) thermogenesis;TRPA1 Agonists targeting TRPA1, TRPM8
AD-86-OB47_10uM Dose=10uM, Icilin, TRPM8 agonist;Induction of Brown Adipose Tissue (BAT) thermogenesis;TRPA1 Agonists targeting TRPA1, TRPM8
AD-86-OB87_0.01uM Dose=0.01uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2
AD-86-OB87_0.1uM Dose=0.1uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2
AD-86-OB87_10uM Dose=10uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2
AD-86-OB87_1uM Dose=1uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2
AD-86-XL96_0.01uM Dose=0.01uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
AD-86-XL96_0.1uM Dose=0.1uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
AD-86-XL96_10uM Dose=10uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
AD-86-XL96_1uM Dose=1uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
AD-88-WG84_0.01uM Dose=0.01uM, 2-Bromo-N-(3-butyramidophenyl)benzamide, PAR-1 antagonist targeting F2R
AD-88-WG84_10uM Dose=10uM, 2-Bromo-N-(3-butyramidophenyl)benzamide, PAR-1 antagonist targeting F2R
AD-88-WG84_1uM Dose=1uM, 2-Bromo-N-(3-butyramidophenyl)benzamide, PAR-1 antagonist targeting F2R
AD-89-ID99_0.01uM Dose=0.01uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B
AD-89-ID99_0.1uM Dose=0.1uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B
AD-89-ID99_10uM Dose=10uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B
AD-89-ID99_1uM Dose=1uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B
AD-89-LX67_0.01uM Dose=0.01uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AD-89-LX67_0.1uM Dose=0.1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AD-89-LX67_10uM Dose=10uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AD-89-LX67_1uM Dose=1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
AD-89-XG11_0.01uM Dose=0.01uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2
AD-89-XG11_0.1uM Dose=0.1uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2
AD-89-XG11_10uM Dose=10uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2
AD-89-XG11_1uM Dose=1uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2
AD-90-PA45_0.01uM Dose=0.01uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5
AD-90-PA45_0.1uM Dose=0.1uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5
AD-90-PA45_10uM Dose=10uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5
AD-90-PA45_1uM Dose=1uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5
AD-91-FB70_0.1uM Dose=0.1uM, LPA2 antagonist 1, Lysophosphatidate-2 receptor antagonist targeting LPAR2
AD-91-FB70_10uM Dose=10uM, LPA2 antagonist 1, Lysophosphatidate-2 receptor antagonist targeting LPAR2
AD-91-FB70_1uM Dose=1uM, LPA2 antagonist 1, Lysophosphatidate-2 receptor antagonist targeting LPAR2
AD-91-FZ23_0.01uM Dose=0.01uM, Piracetam, AMPA Receptor Postiive Allosteric Modulators;Nootropic targeting GRIA1, GRIA2, GRIA3, GRIA4
AD-91-FZ23_0.1uM Dose=0.1uM, Piracetam, AMPA Receptor Postiive Allosteric Modulators;Nootropic targeting GRIA1, GRIA2, GRIA3, GRIA4
AD-91-FZ23_10uM Dose=10uM, Piracetam, AMPA Receptor Postiive Allosteric Modulators;Nootropic targeting GRIA1, GRIA2, GRIA3, GRIA4
AD-91-LE02_0.01uM Dose=0.01uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A
AD-91-LE02_0.1uM Dose=0.1uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A
AD-91-LE02_10uM Dose=10uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A
AD-91-LE02_1uM Dose=1uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A
AD-92-AP11_0.1uM Dose=0.1uM, Chenodiol, Farnesoid X Receptor (FXR) Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, NR1H4
AD-92-AP11_10uM Dose=10uM, Chenodiol, Farnesoid X Receptor (FXR) Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, NR1H4
AD-92-QZ55_0.01uM Dose=0.01uM, Tmc-353121
AD-92-QZ55_0.1uM Dose=0.1uM, Tmc-353121
AD-92-QZ55_10uM Dose=10uM, Tmc-353121
AD-92-QZ55_1uM Dose=1uM, Tmc-353121
AD-93-VC77_0.01uM Dose=0.01uM, 4-(1-((1-Naphthyl)methyl)benzimidazole-2-ylthio)butyric acid, Known Chymase inhibitor targeting CMA1
AD-93-VC77_0.1uM Dose=0.1uM, 4-(1-((1-Naphthyl)methyl)benzimidazole-2-ylthio)butyric acid, Known Chymase inhibitor targeting CMA1
AD-93-VC77_10uM Dose=10uM, 4-(1-((1-Naphthyl)methyl)benzimidazole-2-ylthio)butyric acid, Known Chymase inhibitor targeting CMA1
AD-93-VC77_1uM Dose=1uM, 4-(1-((1-Naphthyl)methyl)benzimidazole-2-ylthio)butyric acid, Known Chymase inhibitor targeting CMA1
AD-94-EX35_0.01uM Dose=0.01uM, Pretomanid
AD-94-EX35_0.1uM Dose=0.1uM, Pretomanid
AD-94-EX35_10uM Dose=10uM, Pretomanid
AD-94-EX35_1uM Dose=1uM, Pretomanid
AD-94-TN76_0.01uM Dose=0.01uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN
AD-94-TN76_0.1uM Dose=0.1uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN
AD-94-TN76_10uM Dose=10uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN
AD-94-TN76_1uM Dose=1uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN
AD-98-UM13_0.01uM Dose=0.01uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E
AD-98-UM13_0.1uM Dose=0.1uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E
AD-98-UM13_10uM Dose=10uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E
AD-98-UM13_1uM Dose=1uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E
AD-99-SN88_0.01uM Dose=0.01uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2
AD-99-SN88_0.1uM Dose=0.1uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2
AD-99-SN88_10uM Dose=10uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2
AD-99-SN88_1uM Dose=1uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2
AE-00-DK14_10uM Dose=10uM, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists
AE-00-NY23_0.01uM Dose=0.01uM, Englerin A, TRPC4 gene stimulator targeting TRPC4
AE-00-NY23_0.1uM Dose=0.1uM, Englerin A, TRPC4 gene stimulator targeting TRPC4
AE-00-NY23_10uM Dose=10uM, Englerin A, TRPC4 gene stimulator targeting TRPC4
AE-00-NY23_1uM Dose=1uM, Englerin A, TRPC4 gene stimulator targeting TRPC4
AE-00-WU78_0.01uM Dose=0.01uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E
AE-00-WU78_0.1uM Dose=0.1uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E
AE-00-WU78_10uM Dose=10uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E
AE-00-WU78_1uM Dose=1uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E
AE-00-YK74_0.1uM Dose=0.1uM, ApoB Secretion Inhibitors
AE-02-OC25_0.01uM Dose=0.01uM, Caffeic Acid Phenethyl Ester
AE-02-OC25_0.1uM Dose=0.1uM, Caffeic Acid Phenethyl Ester
AE-02-OC25_10uM Dose=10uM, Caffeic Acid Phenethyl Ester
AE-02-OC25_1uM Dose=1uM, Caffeic Acid Phenethyl Ester
AE-03-BM76_0.01uM Dose=0.01uM, Gamma-Aminobutyric Acid targeting GABRR1
AE-03-BM76_0.1uM Dose=0.1uM, Gamma-Aminobutyric Acid targeting GABRR1
AE-03-BM76_10uM Dose=10uM, Gamma-Aminobutyric Acid targeting GABRR1
AE-03-BM76_1uM Dose=1uM, Gamma-Aminobutyric Acid targeting GABRR1
AE-03-MJ64_0.01uM Dose=0.01uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD
AE-03-MJ64_0.1uM Dose=0.1uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD
AE-03-MJ64_10uM Dose=10uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD
AE-03-MJ64_1uM Dose=1uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD
AE-04-DX45_0.01uM Dose=0.01uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5
AE-04-DX45_0.1uM Dose=0.1uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5
AE-04-DX45_10uM Dose=10uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5
AE-04-SN76_0.01uM Dose=0.01uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6
AE-04-SN76_0.1uM Dose=0.1uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6
AE-04-SN76_10uM Dose=10uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6
AE-04-SN76_1uM Dose=1uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6
AE-05-CB45_0.01uM Dose=0.01uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6
AE-05-CB45_0.1uM Dose=0.1uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6
AE-05-CB45_10uM Dose=10uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6
AE-05-CB45_1uM Dose=1uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6
AE-05-GR23_0.1uM Dose=0.1uM, Gnf-5, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, ABL2
AE-05-GR23_10uM Dose=10uM, Gnf-5, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, ABL2
AE-05-GR23_1uM Dose=1uM, Gnf-5, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, ABL2
AE-05-HA92_0.1uM Dose=0.1uM, 12-(4-methylpiperazin-1-yl)-6H-indolo[2,1-c][1,4]benzodiazepine, Mediator Release Inhibitors;GnRH (LHRH) Antagonists targeting GNRHR, GNRH1
AE-05-HA92_10uM Dose=10uM, 12-(4-methylpiperazin-1-yl)-6H-indolo[2,1-c][1,4]benzodiazepine, Mediator Release Inhibitors;GnRH (LHRH) Antagonists targeting GNRHR, GNRH1
AE-05-HA92_1uM Dose=1uM, 12-(4-methylpiperazin-1-yl)-6H-indolo[2,1-c][1,4]benzodiazepine, Mediator Release Inhibitors;GnRH (LHRH) Antagonists targeting GNRHR, GNRH1
AE-06-FY47_0.01uM Dose=0.01uM, Xamoterol, ADRB1 agonist targeting ADRB1
AE-06-FY47_0.1uM Dose=0.1uM, Xamoterol, ADRB1 agonist targeting ADRB1
AE-06-FY47_10uM Dose=10uM, Xamoterol, ADRB1 agonist targeting ADRB1
AE-06-FY47_1uM Dose=1uM, Xamoterol, ADRB1 agonist targeting ADRB1
AE-06-JY57_0.01uM Dose=0.01uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1
AE-06-JY57_0.1uM Dose=0.1uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1
AE-06-JY57_10uM Dose=10uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1
AE-06-JY57_1uM Dose=1uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1
AE-07-IZ32_0.01uM Dose=0.01uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2
AE-07-IZ32_0.1uM Dose=0.1uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2
AE-07-IZ32_10uM Dose=10uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2
AE-07-IZ32_1uM Dose=1uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2
AE-09-IN08_0.01uM Dose=0.01uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3
AE-09-IN08_0.1uM Dose=0.1uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3
AE-09-IN08_10uM Dose=10uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3
AE-09-IN08_1uM Dose=1uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3
AE-09-SG21_0.01uM Dose=0.01uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP
AE-09-SG21_0.1uM Dose=0.1uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP
AE-09-SG21_10uM Dose=10uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP
AE-09-SG21_1uM Dose=1uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP
AE-10-FH02_0.01uM Dose=0.01uM, Baz2-icr, Dual BAZ2A/BAZ2B inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B
AE-10-FH02_0.1uM Dose=0.1uM, Baz2-icr, Dual BAZ2A/BAZ2B inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B
AE-10-FH02_10uM Dose=10uM, Baz2-icr, Dual BAZ2A/BAZ2B inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B
AE-11-BF25_0.01uM Dose=0.01uM, Pentamidine
AE-11-BF25_0.1uM Dose=0.1uM, Pentamidine
AE-11-BF25_10uM Dose=10uM, Pentamidine
AE-11-VB80_0.1uM Dose=0.1uM, N-[(2s,3r)-3-Hydroxy-1-(Hydroxyamino)-1-Oxobutan-2-Yl]-4-(Phenylethynyl)benzamide
AE-11-VB80_10uM Dose=10uM, N-[(2s,3r)-3-Hydroxy-1-(Hydroxyamino)-1-Oxobutan-2-Yl]-4-(Phenylethynyl)benzamide
AE-11-VB80_1uM Dose=1uM, N-[(2s,3r)-3-Hydroxy-1-(Hydroxyamino)-1-Oxobutan-2-Yl]-4-(Phenylethynyl)benzamide
AE-13-CX28_0.01uM Dose=0.01uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3
AE-13-CX28_0.1uM Dose=0.1uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3
AE-13-CX28_10uM Dose=10uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3
AE-13-CX28_1uM Dose=1uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3
AE-13-WW30_0.01uM Dose=0.01uM, CID 14403147, 5-HT3 Antagonists targeting HTR3A
AE-13-WW30_0.1uM Dose=0.1uM, CID 14403147, 5-HT3 Antagonists targeting HTR3A
AE-13-WW30_1uM Dose=1uM, CID 14403147, 5-HT3 Antagonists targeting HTR3A
AE-14-NN26_0.01uM Dose=0.01uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1
AE-14-NN26_0.1uM Dose=0.1uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1
AE-14-NN26_10uM Dose=10uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1
AE-14-NN26_1uM Dose=1uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1
AE-15-HA32_10uM Dose=10uM, (3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopenten-1-yl)oxy-3,4-dihydrochromene-6-carbonitrile
AE-15-HA32_1uM Dose=1uM, (3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopenten-1-yl)oxy-3,4-dihydrochromene-6-carbonitrile
AE-15-KH69_0.01uM Dose=0.01uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3
AE-15-KH69_0.1uM Dose=0.1uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3
AE-15-KH69_10uM Dose=10uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3
AE-15-KH69_1uM Dose=1uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3
AE-17-IZ62_0.01uM Dose=0.01uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide
AE-17-IZ62_0.1uM Dose=0.1uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide
AE-17-IZ62_10uM Dose=10uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide
AE-17-IZ62_1uM Dose=1uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide
AE-18-RD27_0.01uM Dose=0.01uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E
AE-18-RD27_0.1uM Dose=0.1uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E
AE-18-RD27_10uM Dose=10uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E
AE-18-RD27_1uM Dose=1uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E
AE-18-ZM98_0.01uM Dose=0.01uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3
AE-18-ZM98_0.1uM Dose=0.1uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3
AE-18-ZM98_10uM Dose=10uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3
AE-18-ZM98_1uM Dose=1uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3
AE-19-BK71_0.01uM Dose=0.01uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1
AE-19-BK71_0.1uM Dose=0.1uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1
AE-19-BK71_10uM Dose=10uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1
AE-19-BK71_1uM Dose=1uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1
AE-19-XO96_10uM Dose=10uM, Nlrp3-IN-5
AE-19-ZK31_0.01uM Dose=0.01uM, Prinomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9, MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
AE-19-ZK31_0.1uM Dose=0.1uM, Prinomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9, MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
AE-19-ZK31_1uM Dose=1uM, Prinomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9, MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
AE-21-BF25_0.01uM Dose=0.01uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8
AE-21-BF25_0.1uM Dose=0.1uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8
AE-21-BF25_10uM Dose=10uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8
AE-21-BF25_1uM Dose=1uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8
AE-21-GE72_0.01uM Dose=0.01uM, Ozagrel, Thromboxane Synthase Inhibitors targeting TBXAS1
AE-21-GE72_0.1uM Dose=0.1uM, Ozagrel, Thromboxane Synthase Inhibitors targeting TBXAS1
AE-21-GE72_1uM Dose=1uM, Ozagrel, Thromboxane Synthase Inhibitors targeting TBXAS1
AE-22-QI24_0.1uM Dose=0.1uM, Mozavaptan, Vasopressin (AVP) V2 Antagonists targeting AVPR2
AE-22-QI24_10uM Dose=10uM, Mozavaptan, Vasopressin (AVP) V2 Antagonists targeting AVPR2
AE-26-JY57_0.01uM Dose=0.01uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R
AE-26-JY57_0.1uM Dose=0.1uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R
AE-26-JY57_10uM Dose=10uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R
AE-26-JY57_1uM Dose=1uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R
AE-28-IQ88_0.01uM Dose=0.01uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2
AE-28-IQ88_0.1uM Dose=0.1uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2
AE-28-IQ88_10uM Dose=10uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2
AE-28-IQ88_1uM Dose=1uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2
AE-28-LX10_0.01uM Dose=0.01uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A
AE-28-LX10_0.1uM Dose=0.1uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A
AE-28-LX10_10uM Dose=10uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A
AE-28-LX10_1uM Dose=1uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A
AE-28-WC14_0.01uM Dose=0.01uM, Trichlorfon, Butyrylcholinesterase Inhibitors targeting BCHE
AE-28-WC14_0.1uM Dose=0.1uM, Trichlorfon, Butyrylcholinesterase Inhibitors targeting BCHE
AE-28-WC14_10uM Dose=10uM, Trichlorfon, Butyrylcholinesterase Inhibitors targeting BCHE
AE-32-DP61_0.01uM Dose=0.01uM, Cpi-203, BRD4 gene inhibitor targeting BRD4
AE-32-DP61_0.1uM Dose=0.1uM, Cpi-203, BRD4 gene inhibitor targeting BRD4
AE-32-DP61_10uM Dose=10uM, Cpi-203, BRD4 gene inhibitor targeting BRD4
AE-32-DP61_1uM Dose=1uM, Cpi-203, BRD4 gene inhibitor targeting BRD4
AE-32-NZ70_0.01uM Dose=0.01uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2
AE-32-NZ70_0.1uM Dose=0.1uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2
AE-32-NZ70_10uM Dose=10uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2
AE-32-UP21_0.01uM Dose=0.01uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1
AE-32-UP21_0.1uM Dose=0.1uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1
AE-32-UP21_10uM Dose=10uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1
AE-32-UP21_1uM Dose=1uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1
AE-34-SK19_0.01uM Dose=0.01uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4
AE-34-SK19_0.1uM Dose=0.1uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4
AE-34-SK19_10uM Dose=10uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4
AE-34-SK19_1uM Dose=1uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4
AE-36-GL26_0.01uM Dose=0.01uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide
AE-36-GL26_0.1uM Dose=0.1uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide
AE-36-GL26_10uM Dose=10uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide
AE-36-GL26_1uM Dose=1uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide
AE-36-JB67_0.01uM Dose=0.01uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG
AE-36-JB67_0.1uM Dose=0.1uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG
AE-36-JB67_10uM Dose=10uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG
AE-36-JB67_1uM Dose=1uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG
AE-36-TF52_0.01uM Dose=0.01uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN
AE-36-TF52_0.1uM Dose=0.1uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN
AE-36-TF52_10uM Dose=10uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN
AE-36-TF52_1uM Dose=1uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN
AE-37-KS50_0.01uM Dose=0.01uM, Cgp 52432
AE-37-KS50_10uM Dose=10uM, Cgp 52432
AE-37-KS50_1uM Dose=1uM, Cgp 52432
AE-37-MC27_0.01uM Dose=0.01uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP
AE-37-MC27_0.1uM Dose=0.1uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP
AE-37-MC27_10uM Dose=10uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP
AE-37-MC27_1uM Dose=1uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP
AE-38-EW02_0.01uM Dose=0.01uM, Apoptosis Inducers;NF-kappaB (NFKB) Activation Inhibitors;5-HT3 antagonist;Apoptosis Inducers;NF-kappaB (NFKB) Activation Inhibitors;5-HT3 antagonist
AE-38-EW82_0.01uM Dose=0.01uM
AE-38-EW82_0.1uM Dose=0.1uM
AE-38-EW82_10uM Dose=10uM
AE-38-EW82_1uM Dose=1uM
AE-38-LX10_0.01uM Dose=0.01uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK
AE-38-LX10_0.1uM Dose=0.1uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK
AE-38-LX10_10uM Dose=10uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK
AE-38-LX10_1uM Dose=1uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK
AE-38-QT35_0.01uM Dose=0.01uM, ML324, KDM4E targeting KDM4E
AE-38-QT35_0.1uM Dose=0.1uM, ML324, KDM4E targeting KDM4E
AE-38-QT35_10uM Dose=10uM, ML324, KDM4E targeting KDM4E
AE-38-QT35_1uM Dose=1uM, ML324, KDM4E targeting KDM4E
AE-38-ZM08_0.01uM Dose=0.01uM
AE-38-ZM08_0.1uM Dose=0.1uM
AE-38-ZM08_10uM Dose=10uM
AE-38-ZM08_1uM Dose=1uM
AE-39-DG66_0.01uM Dose=0.01uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AE-39-DG66_0.1uM Dose=0.1uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AE-39-DG66_10uM Dose=10uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AE-39-DG66_1uM Dose=1uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AE-39-SG01_0.01uM Dose=0.01uM, Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate, P2RY12 antagonist targeting P2RY12
AE-39-SG01_0.1uM Dose=0.1uM, Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate, P2RY12 antagonist targeting P2RY12
AE-39-SG01_10uM Dose=10uM, Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate, P2RY12 antagonist targeting P2RY12
AE-39-SG01_1uM Dose=1uM, Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate, P2RY12 antagonist targeting P2RY12
AE-41-GB05_0.01uM Dose=0.01uM, Ave5638, Known Tryptase inhibitor targeting TPSB2
AE-41-GB05_0.1uM Dose=0.1uM, Ave5638, Known Tryptase inhibitor targeting TPSB2
AE-41-GB05_10uM Dose=10uM, Ave5638, Known Tryptase inhibitor targeting TPSB2
AE-41-GB05_1uM Dose=1uM, Ave5638, Known Tryptase inhibitor targeting TPSB2
AE-42-HT01_0.01uM Dose=0.01uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1
AE-42-HT01_0.1uM Dose=0.1uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1
AE-42-HT01_10uM Dose=10uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1
AE-42-HT01_1uM Dose=1uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1
AE-43-UJ94_0.01uM Dose=0.01uM
AE-43-UJ94_0.1uM Dose=0.1uM
AE-43-UJ94_10uM Dose=10uM
AE-43-UJ94_1uM Dose=1uM
AE-43-WW30_0.1uM Dose=0.1uM, Hyoscyamine, Muscarinic receptor antagonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AE-43-WW30_10uM Dose=10uM, Hyoscyamine, Muscarinic receptor antagonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AE-43-WW30_1uM Dose=1uM, Hyoscyamine, Muscarinic receptor antagonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AE-48-EW32_0.01uM Dose=0.01uM, gamma-Secretase Inhibitors
AE-48-EW32_10uM Dose=10uM, gamma-Secretase Inhibitors
AE-51-ZO26_0.01uM Dose=0.01uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9
AE-51-ZO26_0.1uM Dose=0.1uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9
AE-51-ZO26_10uM Dose=10uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9
AE-51-ZO26_1uM Dose=1uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9
AE-52-FP96_0.01uM Dose=0.01uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1
AE-52-FP96_0.1uM Dose=0.1uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1
AE-52-FP96_10uM Dose=10uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1
AE-52-FP96_1uM Dose=1uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1
AE-52-NW93_0.01uM Dose=0.01uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2
AE-52-NW93_0.1uM Dose=0.1uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2
AE-52-NW93_10uM Dose=10uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2
AE-52-NW93_1uM Dose=1uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2
AE-52-XF72_0.01uM Dose=0.01uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10
AE-52-XF72_0.1uM Dose=0.1uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10
AE-52-XF72_10uM Dose=10uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10
AE-52-XF72_1uM Dose=1uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10
AE-53-IJ74_0.01uM Dose=0.01uM, Desipramine, Norepinephrine Transporter (NET) Inhibitors;Sodium Channel Blockers targeting SLC6A2
AE-53-IJ74_0.1uM Dose=0.1uM, Desipramine, Norepinephrine Transporter (NET) Inhibitors;Sodium Channel Blockers targeting SLC6A2
AE-53-IJ74_10uM Dose=10uM, Desipramine, Norepinephrine Transporter (NET) Inhibitors;Sodium Channel Blockers targeting SLC6A2
AE-54-BN96_0.01uM Dose=0.01uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3
AE-54-BN96_0.1uM Dose=0.1uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3
AE-54-BN96_10uM Dose=10uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3
AE-54-BN96_1uM Dose=1uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3
AE-56-RB57_0.01uM Dose=0.01uM
AE-56-RB57_0.1uM Dose=0.1uM
AE-56-RB57_10uM Dose=10uM
AE-56-RB57_1uM Dose=1uM
AE-56-SL06_0.01uM Dose=0.01uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1
AE-56-SL06_0.1uM Dose=0.1uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1
AE-56-SL06_10uM Dose=10uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1
AE-56-SL06_1uM Dose=1uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1
AE-57-PS55_0.01uM Dose=0.01uM, 4-[[2-[[(1S,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide, CSF1R gene antagonist targeting CSF1R
AE-57-PS55_0.1uM Dose=0.1uM, 4-[[2-[[(1S,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide, CSF1R gene antagonist targeting CSF1R
AE-57-PS55_10uM Dose=10uM, 4-[[2-[[(1S,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide, CSF1R gene antagonist targeting CSF1R
AE-59-ZQ55_0.01uM Dose=0.01uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1
AE-59-ZQ55_0.1uM Dose=0.1uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1
AE-59-ZQ55_10uM Dose=10uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1
AE-59-ZQ55_1uM Dose=1uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1
AE-61-UO01_0.01uM Dose=0.01uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13
AE-61-UO01_0.1uM Dose=0.1uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13
AE-61-UO01_10uM Dose=10uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13
AE-61-UO01_1uM Dose=1uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13
AE-62-QI94_0.01uM Dose=0.01uM, Zankiren, Renin Inhibitors targeting REN
AE-62-QI94_0.1uM Dose=0.1uM, Zankiren, Renin Inhibitors targeting REN
AE-62-QI94_10uM Dose=10uM, Zankiren, Renin Inhibitors targeting REN
AE-63-ST43_0.01uM Dose=0.01uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A
AE-63-ST43_0.1uM Dose=0.1uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A
AE-63-ST43_10uM Dose=10uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A
AE-63-ST43_1uM Dose=1uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A
AE-64-IK64_0.01uM Dose=0.01uM
AE-64-IK64_0.1uM Dose=0.1uM
AE-64-IK64_10uM Dose=10uM
AE-64-IK64_1uM Dose=1uM
AE-64-KN26_0.01uM Dose=0.01uM
AE-64-KN26_0.1uM Dose=0.1uM
AE-64-KN26_10uM Dose=10uM
AE-64-KN26_1uM Dose=1uM
AE-65-KK96_0.01uM Dose=0.01uM, 1-(1,3-Benzodioxol-5-ylcarbonyl)piperidine, AMPA Receptor Postiive Allosteric Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4
AE-65-KK96_0.1uM Dose=0.1uM, 1-(1,3-Benzodioxol-5-ylcarbonyl)piperidine, AMPA Receptor Postiive Allosteric Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4
AE-65-KK96_1uM Dose=1uM, 1-(1,3-Benzodioxol-5-ylcarbonyl)piperidine, AMPA Receptor Postiive Allosteric Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4
AE-65-LV28_0.01uM Dose=0.01uM, Ketotifen
AE-65-LV28_0.1uM Dose=0.1uM, Ketotifen
AE-65-LV28_10uM Dose=10uM, Ketotifen
AE-66-YB82_0.01uM Dose=0.01uM, 1-N,4-N-bis[4-[[amino-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]methylidene]amino]butyl]benzene-1,4-dicarboxamide, Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A
AE-66-YB82_0.1uM Dose=0.1uM, 1-N,4-N-bis[4-[[amino-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]methylidene]amino]butyl]benzene-1,4-dicarboxamide, Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A
AE-66-YB82_10uM Dose=10uM, 1-N,4-N-bis[4-[[amino-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]methylidene]amino]butyl]benzene-1,4-dicarboxamide, Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A
AE-67-DS75_0.1uM Dose=0.1uM, (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide, SMYD2 gene inhibitor;SMYD2 inhibitor targeting SMYD2
AE-67-DS75_10uM Dose=10uM, (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide, SMYD2 gene inhibitor;SMYD2 inhibitor targeting SMYD2
AE-67-DS75_1uM Dose=1uM, (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide, SMYD2 gene inhibitor;SMYD2 inhibitor targeting SMYD2
AE-67-FF84_0.01uM Dose=0.01uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA
AE-67-FF84_0.1uM Dose=0.1uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA
AE-67-FF84_10uM Dose=10uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA
AE-67-FF84_1uM Dose=1uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA
AE-69-CH29_0.01uM Dose=0.01uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12
AE-69-CH29_0.1uM Dose=0.1uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12
AE-69-CH29_10uM Dose=10uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12
AE-69-CH29_1uM Dose=1uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12
AE-70-QB23_0.01uM Dose=0.01uM, Trifluperidol targeting CYP2D6
AE-70-QB23_0.1uM Dose=0.1uM, Trifluperidol targeting CYP2D6
AE-70-QB23_10uM Dose=10uM, Trifluperidol targeting CYP2D6
AE-70-QB23_1uM Dose=1uM, Trifluperidol targeting CYP2D6
AE-71-CB15_0.01uM Dose=0.01uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3
AE-71-CB15_0.1uM Dose=0.1uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3
AE-71-CB15_10uM Dose=10uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3
AE-71-CB15_1uM Dose=1uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3
AE-71-VB70_0.1uM Dose=0.1uM, Dipyridamole, Phosphodiesterase III Inhibitors;Adenosine Transporter Inhibitor;Phosphodiesterase V (PDE5A) Inhibitors targeting ADA, SLC29A1, SLC29A2, PDE2A, PDE5A, ENPP6
AE-71-VB70_10uM Dose=10uM, Dipyridamole, Phosphodiesterase III Inhibitors;Adenosine Transporter Inhibitor;Phosphodiesterase V (PDE5A) Inhibitors targeting ADA, SLC29A1, SLC29A2, PDE2A, PDE5A, ENPP6
AE-71-VB70_1uM Dose=1uM, Dipyridamole, Phosphodiesterase III Inhibitors;Adenosine Transporter Inhibitor;Phosphodiesterase V (PDE5A) Inhibitors targeting ADA, SLC29A1, SLC29A2, PDE2A, PDE5A, ENPP6
AE-72-UP91_0.01uM Dose=0.01uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
AE-72-UP91_0.1uM Dose=0.1uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
AE-72-UP91_10uM Dose=10uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
AE-72-UP91_1uM Dose=1uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
AE-73-KX58_0.01uM Dose=0.01uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2
AE-73-KX58_0.1uM Dose=0.1uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2
AE-73-KX58_10uM Dose=10uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2
AE-73-KX58_1uM Dose=1uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2
AE-74-SQ33_0.01uM Dose=0.01uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
AE-74-SQ33_0.1uM Dose=0.1uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
AE-74-SQ33_10uM Dose=10uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
AE-74-SQ33_1uM Dose=1uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
AE-78-XJ76_0.01uM Dose=0.01uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A
AE-78-XJ76_0.1uM Dose=0.1uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A
AE-78-XJ76_10uM Dose=10uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A
AE-78-XJ76_1uM Dose=1uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A
AE-79-LG46_0.01uM Dose=0.01uM, Gepirone
AE-79-LG46_0.1uM Dose=0.1uM, Gepirone
AE-79-LG46_10uM Dose=10uM, Gepirone
AE-79-LG46_1uM Dose=1uM, Gepirone
AE-80-WH32_0.01uM Dose=0.01uM
AE-80-WH32_0.1uM Dose=0.1uM
AE-80-WH32_10uM Dose=10uM
AE-80-WH32_1uM Dose=1uM
AE-84-YK54_0.01uM Dose=0.01uM
AE-84-YK54_0.1uM Dose=0.1uM
AE-84-YK54_1uM Dose=1uM
AE-85-KE62_0.01uM Dose=0.01uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AE-85-KE62_0.1uM Dose=0.1uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AE-85-KE62_10uM Dose=10uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AE-85-KE62_1uM Dose=1uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
AE-85-LR48_0.01uM Dose=0.01uM, SB-435495, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators targeting PLA2G7
AE-85-LR48_0.1uM Dose=0.1uM, SB-435495, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators targeting PLA2G7
AE-85-LR48_10uM Dose=10uM, SB-435495, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators targeting PLA2G7
AE-87-GP03_0.01uM Dose=0.01uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4
AE-87-GP03_0.1uM Dose=0.1uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4
AE-87-GP03_10uM Dose=10uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4
AE-87-GP03_1uM Dose=1uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4
AE-88-WQ63_0.01uM Dose=0.01uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB
AE-88-WQ63_0.1uM Dose=0.1uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB
AE-88-WQ63_10uM Dose=10uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB
AE-88-WQ63_1uM Dose=1uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB
AE-89-KX47_0.01uM Dose=0.01uM
AE-89-KX47_0.1uM Dose=0.1uM
AE-89-KX47_10uM Dose=10uM
AE-89-KX47_1uM Dose=1uM
AE-90-RS19_0.01uM Dose=0.01uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5
AE-90-RS19_0.1uM Dose=0.1uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5
AE-90-RS19_10uM Dose=10uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5
AE-90-RS19_1uM Dose=1uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5
AE-91-BF25_0.01uM Dose=0.01uM, Imetit, HRH3 agonist targeting HRH3
AE-91-BF25_0.1uM Dose=0.1uM, Imetit, HRH3 agonist targeting HRH3
AE-91-BF25_10uM Dose=10uM, Imetit, HRH3 agonist targeting HRH3
AE-91-BF25_1uM Dose=1uM, Imetit, HRH3 agonist targeting HRH3
AE-93-WW90_0.01uM Dose=0.01uM, Piclamilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4
AE-93-WW90_10uM Dose=10uM, Piclamilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4
AE-93-WW90_1uM Dose=1uM, Piclamilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4
AE-94-OX50_0.01uM Dose=0.01uM, N-(2,6-Dichloro-pyridin-4-yl)-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl}-acetamide, S1PR2 antagonist;S1PR4 antagonist targeting S1PR4
AE-94-OX50_0.1uM Dose=0.1uM, N-(2,6-Dichloro-pyridin-4-yl)-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl}-acetamide, S1PR2 antagonist;S1PR4 antagonist targeting S1PR4
AE-94-OX50_10uM Dose=10uM, N-(2,6-Dichloro-pyridin-4-yl)-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl}-acetamide, S1PR2 antagonist;S1PR4 antagonist targeting S1PR4
AE-94-ZD47_0.01uM Dose=0.01uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2
AE-94-ZD47_0.1uM Dose=0.1uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2
AE-94-ZD47_10uM Dose=10uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2
AE-94-ZD47_1uM Dose=1uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2
AE-95-HR68_0.01uM Dose=0.01uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2
AE-95-HR68_0.1uM Dose=0.1uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2
AE-95-HR68_10uM Dose=10uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2
AE-95-HR68_1uM Dose=1uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2
AE-95-KU30_0.01uM Dose=0.01uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C
AE-95-KU30_0.1uM Dose=0.1uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C
AE-95-KU30_10uM Dose=10uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C
AE-95-KU30_1uM Dose=1uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C
AE-95-UU45_10uM Dose=10uM, Terguride, Prolactin Secretion Inhibitors;5-HT2A Antagonists;5-HT2B Antagonists targeting DRD2, HTR2A, HTR2B, PRL
AE-95-UU45_1uM Dose=1uM, Terguride, Prolactin Secretion Inhibitors;5-HT2A Antagonists;5-HT2B Antagonists targeting DRD2, HTR2A, HTR2B, PRL
AE-95-ZK81_0.01uM Dose=0.01uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3
AE-95-ZK81_0.1uM Dose=0.1uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3
AE-95-ZK81_10uM Dose=10uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3
AE-95-ZK81_1uM Dose=1uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3
AE-97-TS20_0.01uM Dose=0.01uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1
AE-97-TS20_0.1uM Dose=0.1uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1
AE-97-TS20_10uM Dose=10uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1
AE-97-TS20_1uM Dose=1uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1
AF-00-QK19_0.01uM Dose=0.01uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA
AF-00-QK19_0.1uM Dose=0.1uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA
AF-00-QK19_10uM Dose=10uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA
AF-00-QK19_1uM Dose=1uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA
AF-01-FE42_0.01uM Dose=0.01uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A
AF-01-FE42_0.1uM Dose=0.1uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A
AF-01-FE42_10uM Dose=10uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A
AF-01-FE42_1uM Dose=1uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A
AF-06-AY37_0.01uM Dose=0.01uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid
AF-06-AY37_0.1uM Dose=0.1uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid
AF-06-AY37_10uM Dose=10uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid
AF-06-AY37_1uM Dose=1uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid
AF-06-ME04_0.01uM Dose=0.01uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR
AF-06-ME04_0.1uM Dose=0.1uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR
AF-06-ME04_10uM Dose=10uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR
AF-06-ME04_1uM Dose=1uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR
AF-07-LS35_0.1uM Dose=0.1uM, Somatostatin srif2B (sst4) Agonists
AF-07-LS35_10uM Dose=10uM, Somatostatin srif2B (sst4) Agonists
AF-10-BU38_0.01uM Dose=0.01uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2
AF-10-BU38_0.1uM Dose=0.1uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2
AF-10-BU38_10uM Dose=10uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2
AF-10-BU38_1uM Dose=1uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2
AF-10-QK79_0.01uM Dose=0.01uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2
AF-10-QK79_0.1uM Dose=0.1uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2
AF-10-QK79_10uM Dose=10uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2
AF-10-QK79_1uM Dose=1uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2
AF-11-IL39_0.01uM Dose=0.01uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2
AF-11-IL39_0.1uM Dose=0.1uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2
AF-11-IL39_10uM Dose=10uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2
AF-11-IL39_1uM Dose=1uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2
AF-12-IW93_0.01uM Dose=0.01uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1
AF-12-IW93_0.1uM Dose=0.1uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1
AF-12-IW93_10uM Dose=10uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1
AF-12-IW93_1uM Dose=1uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1
AF-13-LM61_0.01uM Dose=0.01uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B
AF-13-LM61_0.1uM Dose=0.1uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B
AF-13-LM61_10uM Dose=10uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B
AF-13-LM61_1uM Dose=1uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B
AF-16-GB72_0.01uM Dose=0.01uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3
AF-16-GB72_0.1uM Dose=0.1uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3
AF-16-GB72_10uM Dose=10uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3
AF-16-GB72_1uM Dose=1uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3
AF-16-IB77_0.01uM Dose=0.01uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
AF-16-IB77_0.1uM Dose=0.1uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
AF-16-IB77_10uM Dose=10uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
AF-16-IB77_1uM Dose=1uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
AF-18-FX20_0.01uM Dose=0.01uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3
AF-18-FX20_0.1uM Dose=0.1uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3
AF-18-FX20_10uM Dose=10uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3
AF-18-FX20_1uM Dose=1uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3
AF-19-KN63_0.01uM Dose=0.01uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR
AF-19-KN63_0.1uM Dose=0.1uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR
AF-19-KN63_10uM Dose=10uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR
AF-19-KN63_1uM Dose=1uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR
AF-19-OG56_0.01uM Dose=0.01uM, N-(4-((4-(Cyclopentanecarbonyl)piperazin-1-yl)sulfonyl)phenyl)acrylamide, Tissue transglutaminase inhibitor targeting TGM2
AF-19-OG56_10uM Dose=10uM, N-(4-((4-(Cyclopentanecarbonyl)piperazin-1-yl)sulfonyl)phenyl)acrylamide, Tissue transglutaminase inhibitor targeting TGM2
AF-19-OG56_1uM Dose=1uM, N-(4-((4-(Cyclopentanecarbonyl)piperazin-1-yl)sulfonyl)phenyl)acrylamide, Tissue transglutaminase inhibitor targeting TGM2
AF-20-MK39_0.01uM Dose=0.01uM, Gabapentin, Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands targeting CACNA1D, CACNA2D1, CACNA2D2, CACNA2D3
AF-20-MK39_0.1uM Dose=0.1uM, Gabapentin, Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands targeting CACNA1D, CACNA2D1, CACNA2D2, CACNA2D3
AF-20-MK39_1uM Dose=1uM, Gabapentin, Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands targeting CACNA1D, CACNA2D1, CACNA2D2, CACNA2D3
AF-23-HJ84_0.01uM Dose=0.01uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5
AF-23-HJ84_0.1uM Dose=0.1uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5
AF-23-HJ84_10uM Dose=10uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5
AF-23-HJ84_1uM Dose=1uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5
AF-23-RM26_0.01uM Dose=0.01uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR
AF-23-RM26_0.1uM Dose=0.1uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR
AF-23-RM26_10uM Dose=10uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR
AF-23-RM26_1uM Dose=1uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR
AF-25-BS76_0.01uM Dose=0.01uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4
AF-25-BS76_0.1uM Dose=0.1uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4
AF-25-BS76_10uM Dose=10uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4
AF-25-BS76_1uM Dose=1uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4
AF-28-FX20_0.01uM Dose=0.01uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2
AF-28-FX20_0.1uM Dose=0.1uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2
AF-28-FX20_10uM Dose=10uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2
AF-28-FX20_1uM Dose=1uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2
AF-30-GH67_0.01uM Dose=0.01uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4
AF-30-GH67_0.1uM Dose=0.1uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4
AF-30-GH67_10uM Dose=10uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4
AF-30-GH67_1uM Dose=1uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4
AF-31-RV78_0.01uM Dose=0.01uM, targeting NOS3, PAH, TH, TPH1
AF-31-RV78_0.1uM Dose=0.1uM, targeting NOS3, PAH, TH, TPH1
AF-31-RV78_10uM Dose=10uM, targeting NOS3, PAH, TH, TPH1
AF-31-RV78_1uM Dose=1uM, targeting NOS3, PAH, TH, TPH1
AF-33-AM86_0.01uM Dose=0.01uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
AF-33-AM86_0.1uM Dose=0.1uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
AF-33-AM86_10uM Dose=10uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
AF-33-AM86_1uM Dose=1uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
AF-33-GW65_0.01uM Dose=0.01uM, Diazoxide, potassium channel activator;K(ATP) Channel Activators targeting CA1, KCNJ11
AF-33-GW65_0.1uM Dose=0.1uM, Diazoxide, potassium channel activator;K(ATP) Channel Activators targeting CA1, KCNJ11
AF-33-GW65_10uM Dose=10uM, Diazoxide, potassium channel activator;K(ATP) Channel Activators targeting CA1, KCNJ11
AF-33-HJ54_0.01uM Dose=0.01uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2
AF-33-HJ54_0.1uM Dose=0.1uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2
AF-33-HJ54_10uM Dose=10uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2
AF-33-HJ54_1uM Dose=1uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2
AF-40-QU33_0.01uM Dose=0.01uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1
AF-40-QU33_0.1uM Dose=0.1uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1
AF-40-QU33_10uM Dose=10uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1
AF-40-QU33_1uM Dose=1uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1
AF-41-BY55_0.01uM Dose=0.01uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2
AF-41-BY55_0.1uM Dose=0.1uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2
AF-41-BY55_10uM Dose=10uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2
AF-41-BY55_1uM Dose=1uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2
AF-41-QY60_0.01uM Dose=0.01uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP
AF-41-QY60_0.1uM Dose=0.1uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP
AF-41-QY60_10uM Dose=10uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP
AF-41-QY60_1uM Dose=1uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP
AF-42-MP86_0.01uM Dose=0.01uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide
AF-42-MP86_0.1uM Dose=0.1uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide
AF-42-MP86_10uM Dose=10uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide
AF-42-MP86_1uM Dose=1uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide
AF-48-FX20_0.01uM Dose=0.01uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4
AF-48-FX20_0.1uM Dose=0.1uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4
AF-48-FX20_10uM Dose=10uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4
AF-48-FX20_1uM Dose=1uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4
AF-53-GC97_0.01uM Dose=0.01uM
AF-53-GC97_0.1uM Dose=0.1uM
AF-53-GC97_10uM Dose=10uM
AF-53-GC97_1uM Dose=1uM
AF-60-GR11_0.01uM Dose=0.01uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8
AF-60-GR11_0.1uM Dose=0.1uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8
AF-60-GR11_10uM Dose=10uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8
AF-60-GR11_1uM Dose=1uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8
AF-62-PI84_0.1uM Dose=0.1uM, Ethanone, 1-[1,1'-biphenyl]-4-yl-2-(1H-1,2,4-triazol-1-yl)-, Heme Oxygenase 1 (HO-1) Inhibitors targeting HMOX1
AF-62-PI84_10uM Dose=10uM, Ethanone, 1-[1,1'-biphenyl]-4-yl-2-(1H-1,2,4-triazol-1-yl)-, Heme Oxygenase 1 (HO-1) Inhibitors targeting HMOX1
AF-62-PI84_1uM Dose=1uM, Ethanone, 1-[1,1'-biphenyl]-4-yl-2-(1H-1,2,4-triazol-1-yl)-, Heme Oxygenase 1 (HO-1) Inhibitors targeting HMOX1
AF-64-CQ08_0.01uM Dose=0.01uM, 3,4-Dihydroxybenzoic acid, Apoptosis Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Dihydroorotate Dehydrogenase (DHODH) Inhibitors;Antioxidants targeting DHODH
AF-64-CQ08_0.1uM Dose=0.1uM, 3,4-Dihydroxybenzoic acid, Apoptosis Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Dihydroorotate Dehydrogenase (DHODH) Inhibitors;Antioxidants targeting DHODH
AF-64-CQ08_1uM Dose=1uM, 3,4-Dihydroxybenzoic acid, Apoptosis Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Dihydroorotate Dehydrogenase (DHODH) Inhibitors;Antioxidants targeting DHODH
AF-65-CU85_0.01uM Dose=0.01uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6
AF-65-CU85_0.1uM Dose=0.1uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6
AF-65-CU85_10uM Dose=10uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6
AF-65-CU85_1uM Dose=1uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6
AF-67-LZ82_0.01uM Dose=0.01uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
AF-67-LZ82_0.1uM Dose=0.1uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
AF-67-LZ82_10uM Dose=10uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
AF-67-LZ82_1uM Dose=1uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
AF-71-GL94_0.01uM Dose=0.01uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide
AF-71-GL94_0.1uM Dose=0.1uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide
AF-71-GL94_10uM Dose=10uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide
AF-71-GL94_1uM Dose=1uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide
AF-72-PP21_0.01uM Dose=0.01uM, Donepezil, Acetylcholinesterase Inhibitors targeting ACHE
AF-72-PP21_0.1uM Dose=0.1uM, Donepezil, Acetylcholinesterase Inhibitors targeting ACHE
AF-72-PP21_10uM Dose=10uM, Donepezil, Acetylcholinesterase Inhibitors targeting ACHE
AF-73-HJ84_0.01uM Dose=0.01uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7
AF-73-HJ84_0.1uM Dose=0.1uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7
AF-73-HJ84_10uM Dose=10uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7
AF-73-HJ84_1uM Dose=1uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7
AF-73-ON54_0.01uM Dose=0.01uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
AF-73-ON54_0.1uM Dose=0.1uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
AF-73-ON54_10uM Dose=10uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
AF-73-ON54_1uM Dose=1uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
AF-76-AY17_0.01uM Dose=0.01uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
AF-76-AY17_0.1uM Dose=0.1uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
AF-76-AY17_10uM Dose=10uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
AF-76-AY17_1uM Dose=1uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
AF-76-BV30_0.01uM Dose=0.01uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP
AF-76-BV30_0.1uM Dose=0.1uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP
AF-76-BV30_10uM Dose=10uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP
AF-76-BV30_1uM Dose=1uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP
AF-76-FL46_0.01uM Dose=0.01uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN
AF-76-FL46_0.1uM Dose=0.1uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN
AF-76-FL46_10uM Dose=10uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN
AF-76-FL46_1uM Dose=1uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN
AF-79-OK66_0.01uM Dose=0.01uM, Gsk583, RIPK2 inhibitor targeting RIPK2
AF-79-OK66_10uM Dose=10uM, Gsk583, RIPK2 inhibitor targeting RIPK2
AF-80-GK24_0.01uM Dose=0.01uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)]
AF-80-GK24_0.1uM Dose=0.1uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)]
AF-80-GK24_10uM Dose=10uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)]
AF-80-GK24_1uM Dose=1uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)]
AF-80-QK39_0.01uM Dose=0.01uM, Diphenidol, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands;Muscarinic M1 Receptor Ligands targeting CHRM1, CHRM3, CHRM4
AF-80-QK39_0.1uM Dose=0.1uM, Diphenidol, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands;Muscarinic M1 Receptor Ligands targeting CHRM1, CHRM3, CHRM4
AF-80-QK39_10uM Dose=10uM, Diphenidol, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands;Muscarinic M1 Receptor Ligands targeting CHRM1, CHRM3, CHRM4
AF-81-IV73_0.01uM Dose=0.01uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13
AF-81-IV73_0.1uM Dose=0.1uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13
AF-81-IV73_10uM Dose=10uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13
AF-81-IV73_1uM Dose=1uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13
AF-81-JB15_0.01uM Dose=0.01uM, Ketoconazole
AF-81-JB15_0.1uM Dose=0.1uM, Ketoconazole
AF-81-JB15_10uM Dose=10uM, Ketoconazole
AF-81-JB15_1uM Dose=1uM, Ketoconazole
AF-83-BX08_0.01uM Dose=0.01uM
AF-83-BX08_0.1uM Dose=0.1uM
AF-83-BX08_10uM Dose=10uM
AF-83-BX08_1uM Dose=1uM
AF-87-II41_0.01uM Dose=0.01uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10
AF-87-II41_0.1uM Dose=0.1uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10
AF-87-II41_10uM Dose=10uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10
AF-87-II41_1uM Dose=1uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10
AF-89-AD94_0.01uM Dose=0.01uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7
AF-89-AD94_0.1uM Dose=0.1uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7
AF-89-AD94_10uM Dose=10uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7
AF-89-AD94_1uM Dose=1uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7
AF-92-EP16_0.01uM Dose=0.01uM, (2S,4R)-N-[(2S)-1-(1,3-benzoxazol-2-yl)-1-oxobutan-2-yl]-4-[(4-bromo-2-fluorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide
AF-92-EP16_0.1uM Dose=0.1uM, (2S,4R)-N-[(2S)-1-(1,3-benzoxazol-2-yl)-1-oxobutan-2-yl]-4-[(4-bromo-2-fluorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide
AF-99-HA02_0.01uM Dose=0.01uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2
AF-99-HA02_0.1uM Dose=0.1uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2
AF-99-HA02_10uM Dose=10uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2
AF-99-HA02_1uM Dose=1uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2
AW-10-0667_0.01uM Dose=0.01uM, Clofibrate
AW-10-0667_0.1uM Dose=0.1uM, Clofibrate
AW-10-0667_10uM Dose=10uM, Clofibrate
AW-10-0667_1uM Dose=1uM, Clofibrate
AW-13-3788_0.01uM Dose=0.01uM, N,N-dimethyl-4,4-diphenylbut-3-en-1-amine, Nav1.2 (Brain Type II) Sodium Channel Blockers targeting SCN2A
AW-13-3788_0.1uM Dose=0.1uM, N,N-dimethyl-4,4-diphenylbut-3-en-1-amine, Nav1.2 (Brain Type II) Sodium Channel Blockers targeting SCN2A
AW-13-3788_1uM Dose=1uM, N,N-dimethyl-4,4-diphenylbut-3-en-1-amine, Nav1.2 (Brain Type II) Sodium Channel Blockers targeting SCN2A
AW-14-3219_0.01uM Dose=0.01uM, 8-Chloro-5-methyl-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine, Dopamine D2 Agonists;Muscarinic M1 Agonists targeting CHRM1, DRD2
AW-14-3219_0.1uM Dose=0.1uM, 8-Chloro-5-methyl-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine, Dopamine D2 Agonists;Muscarinic M1 Agonists targeting CHRM1, DRD2
AW-14-3219_10uM Dose=10uM, 8-Chloro-5-methyl-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine, Dopamine D2 Agonists;Muscarinic M1 Agonists targeting CHRM1, DRD2
AW-14-3219_1uM Dose=1uM, 8-Chloro-5-methyl-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine, Dopamine D2 Agonists;Muscarinic M1 Agonists targeting CHRM1, DRD2
AW-15-2439_0.01uM Dose=0.01uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B
AW-15-2439_0.1uM Dose=0.1uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B
AW-15-2439_10uM Dose=10uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B
AW-15-2439_1uM Dose=1uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B
AW-16-2259_0.01uM Dose=0.01uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB
AW-16-2259_0.1uM Dose=0.1uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB
AW-16-2259_10uM Dose=10uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB
AW-16-2259_1uM Dose=1uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB
BA-02-FS63_0.01uM Dose=0.01uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide
BA-02-FS63_0.1uM Dose=0.1uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide
BA-02-FS63_10uM Dose=10uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide
BA-02-FS63_1uM Dose=1uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide
BA-02-RG00_0.01uM Dose=0.01uM
BA-02-RG00_0.1uM Dose=0.1uM
BA-02-RG00_10uM Dose=10uM
BA-02-RG00_1uM Dose=1uM
BA-02-RI19_0.01uM Dose=0.01uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BA-02-RI19_0.1uM Dose=0.1uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BA-02-RI19_10uM Dose=10uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BA-02-RI19_1uM Dose=1uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BA-04-IG64_0.01uM Dose=0.01uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
BA-04-IG64_0.1uM Dose=0.1uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
BA-04-IG64_10uM Dose=10uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
BA-04-IG64_1uM Dose=1uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
BA-06-GI09_0.1uM Dose=0.1uM, 1-(3-Pyridin-3-ylisoxazol-5-YL)methanamine, Cytochrome P450 CYP2A6 Inhibitors targeting CYP2A6
BA-06-GI09_10uM Dose=10uM, 1-(3-Pyridin-3-ylisoxazol-5-YL)methanamine, Cytochrome P450 CYP2A6 Inhibitors targeting CYP2A6
BA-06-RE84_0.01uM Dose=0.01uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
BA-06-RE84_0.1uM Dose=0.1uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
BA-06-RE84_10uM Dose=10uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
BA-06-RE84_1uM Dose=1uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
BA-07-GC72_0.01uM Dose=0.01uM, Flutamide, Androgen Receptor Antagonists targeting AR, CYP1B1
BA-07-GC72_10uM Dose=10uM, Flutamide, Androgen Receptor Antagonists targeting AR, CYP1B1
BA-07-GC72_1uM Dose=1uM, Flutamide, Androgen Receptor Antagonists targeting AR, CYP1B1
BA-09-PG96_0.01uM Dose=0.01uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3
BA-09-PG96_0.1uM Dose=0.1uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3
BA-09-PG96_10uM Dose=10uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3
BA-09-PG96_1uM Dose=1uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3
BA-09-ZX42_0.01uM Dose=0.01uM, 4-(Phenylamino)benzoic acid
BA-09-ZX42_0.1uM Dose=0.1uM, 4-(Phenylamino)benzoic acid
BA-09-ZX42_10uM Dose=10uM, 4-(Phenylamino)benzoic acid
BA-09-ZX42_1uM Dose=1uM, 4-(Phenylamino)benzoic acid
BA-10-WH12_0.01uM Dose=0.01uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
BA-10-WH12_0.1uM Dose=0.1uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
BA-10-WH12_10uM Dose=10uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
BA-10-WH12_1uM Dose=1uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
BA-10-WH72_0.01uM Dose=0.01uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9
BA-10-WH72_0.1uM Dose=0.1uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9
BA-10-WH72_10uM Dose=10uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9
BA-10-WH72_1uM Dose=1uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9
BA-13-CC32_0.01uM Dose=0.01uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BA-13-CC32_0.1uM Dose=0.1uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BA-13-CC32_10uM Dose=10uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BA-13-CC32_1uM Dose=1uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BA-15-LA22_0.01uM Dose=0.01uM
BA-15-LA22_0.1uM Dose=0.1uM
BA-15-LA22_10uM Dose=10uM
BA-15-LA22_1uM Dose=1uM
BA-15-VE07_0.01uM Dose=0.01uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A
BA-15-VE07_0.1uM Dose=0.1uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A
BA-15-VE07_10uM Dose=10uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A
BA-15-VE07_1uM Dose=1uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A
BA-16-AB67_0.01uM Dose=0.01uM, Repaglinide, Insulin Secretagogues targeting ABCC8
BA-16-AB67_0.1uM Dose=0.1uM, Repaglinide, Insulin Secretagogues targeting ABCC8
BA-16-AB67_10uM Dose=10uM, Repaglinide, Insulin Secretagogues targeting ABCC8
BA-16-AB67_1uM Dose=1uM, Repaglinide, Insulin Secretagogues targeting ABCC8
BA-16-GI09_0.01uM Dose=0.01uM, Tram-34, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4
BA-16-GI09_0.1uM Dose=0.1uM, Tram-34, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4
BA-16-GI09_10uM Dose=10uM, Tram-34, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4
BA-18-SW37_0.01uM Dose=0.01uM, Ciluprevir
BA-18-SW37_0.1uM Dose=0.1uM, Ciluprevir
BA-18-SW37_10uM Dose=10uM, Ciluprevir
BA-19-VU85_0.01uM Dose=0.01uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1
BA-19-VU85_0.1uM Dose=0.1uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1
BA-19-VU85_10uM Dose=10uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1
BA-19-VU85_1uM Dose=1uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1
BA-23-MC77_0.01uM Dose=0.01uM, Oxcarbazepine, Sodium Channel Blockers targeting AQP4, SCN5A
BA-23-MC77_10uM Dose=10uM, Oxcarbazepine, Sodium Channel Blockers targeting AQP4, SCN5A
BA-23-XC02_0.01uM Dose=0.01uM, Indoramin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
BA-23-XC02_0.1uM Dose=0.1uM, Indoramin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
BA-23-XC02_10uM Dose=10uM, Indoramin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
BA-24-BX40_0.1uM Dose=0.1uM, 2-(2-Imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone targeting ATAD5
BA-24-BX40_10uM Dose=10uM, 2-(2-Imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone targeting ATAD5
BA-24-BX40_1uM Dose=1uM, 2-(2-Imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone targeting ATAD5
BA-26-GI09_0.01uM Dose=0.01uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR
BA-26-GI09_0.1uM Dose=0.1uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR
BA-26-GI09_10uM Dose=10uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR
BA-26-GI09_1uM Dose=1uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR
BA-28-JD87_0.01uM Dose=0.01uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG
BA-28-JD87_0.1uM Dose=0.1uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG
BA-28-JD87_10uM Dose=10uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG
BA-28-JD87_1uM Dose=1uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG
BA-28-XM73_0.1uM Dose=0.1uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide
BA-28-XM73_10uM Dose=10uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide
BA-28-XM73_1uM Dose=1uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide
BA-29-GH49_0.01uM Dose=0.01uM, Orforglipron targeting GLP1R
BA-29-GH49_10uM Dose=10uM, Orforglipron targeting GLP1R
BA-29-OX17_0.01uM Dose=0.01uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK
BA-29-OX17_0.1uM Dose=0.1uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK
BA-29-OX17_10uM Dose=10uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK
BA-29-OX17_1uM Dose=1uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK
BA-30-VU53_0.01uM Dose=0.01uM
BA-30-VU53_0.1uM Dose=0.1uM
BA-30-VU53_10uM Dose=10uM
BA-30-VU53_1uM Dose=1uM
BA-31-AB30_0.01uM Dose=0.01uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA
BA-31-AB30_0.1uM Dose=0.1uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA
BA-31-AB30_10uM Dose=10uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA
BA-31-AB30_1uM Dose=1uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA
BA-31-KY85_0.01uM Dose=0.01uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14
BA-31-KY85_0.1uM Dose=0.1uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14
BA-31-KY85_10uM Dose=10uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14
BA-31-KY85_1uM Dose=1uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14
BA-34-BQ43_0.01uM Dose=0.01uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB
BA-34-BQ43_0.1uM Dose=0.1uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB
BA-34-BQ43_10uM Dose=10uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB
BA-34-BQ43_1uM Dose=1uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB
BA-37-NF64_10uM Dose=10uM, Fenofibrate, APOA1 Expression Enhancers;PPARalpha Agonists targeting PPARA
BA-37-NF64_1uM Dose=1uM, Fenofibrate, APOA1 Expression Enhancers;PPARalpha Agonists targeting PPARA
BA-38-MT25_0.01uM Dose=0.01uM, (2R)-3-[4-[(E)-3-[4-[(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]prop-2-enyl]piperazin-1-yl]propane-1,2-diol
BA-38-MT25_0.1uM Dose=0.1uM, (2R)-3-[4-[(E)-3-[4-[(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]prop-2-enyl]piperazin-1-yl]propane-1,2-diol
BA-38-MT25_10uM Dose=10uM, (2R)-3-[4-[(E)-3-[4-[(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]prop-2-enyl]piperazin-1-yl]propane-1,2-diol
BA-38-XM43_0.01uM Dose=0.01uM, Paxilline targeting KCNMA1, KCNMB1
BA-38-XM43_10uM Dose=10uM, Paxilline targeting KCNMA1, KCNMB1
BA-38-XM43_1uM Dose=1uM, Paxilline targeting KCNMA1, KCNMB1
BA-39-HG26_0.01uM Dose=0.01uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2
BA-39-HG26_0.1uM Dose=0.1uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2
BA-39-HG26_10uM Dose=10uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2
BA-39-HG26_1uM Dose=1uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2
BA-39-LQ60_0.01uM Dose=0.01uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one)
BA-39-LQ60_0.1uM Dose=0.1uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one)
BA-39-LQ60_10uM Dose=10uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one)
BA-39-LQ60_1uM Dose=1uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one)
BA-39-OX47_0.01uM Dose=0.01uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide
BA-39-OX47_0.1uM Dose=0.1uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide
BA-39-OX47_10uM Dose=10uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide
BA-39-OX47_1uM Dose=1uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide
BA-40-IU73_0.01uM Dose=0.01uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR
BA-40-IU73_0.1uM Dose=0.1uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR
BA-40-IU73_10uM Dose=10uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR
BA-40-IU73_1uM Dose=1uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR
BA-40-KU28_0.01uM Dose=0.01uM
BA-40-KU28_0.1uM Dose=0.1uM
BA-40-KU28_10uM Dose=10uM
BA-40-KU28_1uM Dose=1uM
BA-41-QF30_0.01uM Dose=0.01uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide
BA-41-QF30_0.1uM Dose=0.1uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide
BA-41-QF30_10uM Dose=10uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide
BA-41-QF30_1uM Dose=1uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide
BA-41-VY30_0.01uM Dose=0.01uM, 2-methyl-5-HT targeting HTR1F
BA-41-VY30_0.1uM Dose=0.1uM, 2-methyl-5-HT targeting HTR1F
BA-41-VY30_10uM Dose=10uM, 2-methyl-5-HT targeting HTR1F
BA-44-SG89_0.01uM Dose=0.01uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD
BA-44-SG89_0.1uM Dose=0.1uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD
BA-44-SG89_10uM Dose=10uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD
BA-44-SG89_1uM Dose=1uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD
BA-44-WG29_0.01uM Dose=0.01uM, Oxprenolol, beta-Adrenoceptor Antagonists targeting ADRB1, ADRB2
BA-44-WG29_0.1uM Dose=0.1uM, Oxprenolol, beta-Adrenoceptor Antagonists targeting ADRB1, ADRB2
BA-44-WG29_10uM Dose=10uM, Oxprenolol, beta-Adrenoceptor Antagonists targeting ADRB1, ADRB2
BA-46-AB67_0.01uM Dose=0.01uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2
BA-46-AB67_0.1uM Dose=0.1uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2
BA-46-AB67_10uM Dose=10uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2
BA-46-AB67_1uM Dose=1uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2
BA-46-QO78_0.01uM Dose=0.01uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA
BA-46-QO78_0.1uM Dose=0.1uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA
BA-46-QO78_10uM Dose=10uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA
BA-46-QO78_1uM Dose=1uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA
BA-46-RB17_0.01uM Dose=0.01uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3
BA-46-RB17_0.1uM Dose=0.1uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3
BA-46-RB17_10uM Dose=10uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3
BA-46-RB17_1uM Dose=1uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3
BA-46-YF32_0.01uM Dose=0.01uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2
BA-46-YF32_0.1uM Dose=0.1uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2
BA-46-YF32_10uM Dose=10uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2
BA-46-YF32_1uM Dose=1uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2
BA-50-HH67_0.01uM Dose=0.01uM, Tomatidine
BA-50-HH67_0.1uM Dose=0.1uM, Tomatidine
BA-50-HH67_10uM Dose=10uM, Tomatidine
BA-51-DL54_0.01uM Dose=0.01uM, 6-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole, TRPA1 antagonist targeting TRPA1
BA-51-DL54_0.1uM Dose=0.1uM, 6-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole, TRPA1 antagonist targeting TRPA1
BA-51-DL54_10uM Dose=10uM, 6-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole, TRPA1 antagonist targeting TRPA1
BA-52-FW03_0.01uM Dose=0.01uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3
BA-52-FW03_0.1uM Dose=0.1uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3
BA-52-FW03_10uM Dose=10uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3
BA-52-FW03_1uM Dose=1uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3
BA-53-FM66_0.01uM Dose=0.01uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN
BA-53-FM66_0.1uM Dose=0.1uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN
BA-53-FM66_10uM Dose=10uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN
BA-53-FM66_1uM Dose=1uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN
BA-55-OU30_0.01uM Dose=0.01uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B
BA-55-OU30_0.1uM Dose=0.1uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B
BA-55-OU30_10uM Dose=10uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B
BA-55-OU30_1uM Dose=1uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B
BA-56-QV45_0.01uM Dose=0.01uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1
BA-56-QV45_0.1uM Dose=0.1uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1
BA-56-QV45_10uM Dose=10uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1
BA-56-QV45_1uM Dose=1uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1
BA-59-EN38_0.01uM Dose=0.01uM
BA-59-EN38_0.1uM Dose=0.1uM
BA-59-EN38_10uM Dose=10uM
BA-59-EN38_1uM Dose=1uM
BA-59-QN98_0.01uM Dose=0.01uM, AX-024 targeting NCK1, NCK2
BA-59-QN98_0.1uM Dose=0.1uM, AX-024 targeting NCK1, NCK2
BA-59-QN98_10uM Dose=10uM, AX-024 targeting NCK1, NCK2
BA-59-QN98_1uM Dose=1uM, AX-024 targeting NCK1, NCK2
BA-60-DK24_0.01uM Dose=0.01uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D
BA-60-DK24_0.1uM Dose=0.1uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D
BA-60-DK24_10uM Dose=10uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D
BA-60-DK24_1uM Dose=1uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D
BA-60-DR11_0.01uM Dose=0.01uM, Scd1-IN-1, SCD inhibitor targeting SCD
BA-60-DR11_0.1uM Dose=0.1uM, Scd1-IN-1, SCD inhibitor targeting SCD
BA-60-DR11_10uM Dose=10uM, Scd1-IN-1, SCD inhibitor targeting SCD
BA-60-DR11_1uM Dose=1uM, Scd1-IN-1, SCD inhibitor targeting SCD
BA-60-RH02_0.01uM Dose=0.01uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1
BA-60-RH02_0.1uM Dose=0.1uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1
BA-60-RH02_10uM Dose=10uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1
BA-60-RH02_1uM Dose=1uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1
BA-64-PX65_0.01uM Dose=0.01uM, Carnosine
BA-64-PX65_0.1uM Dose=0.1uM, Carnosine
BA-64-PX65_10uM Dose=10uM, Carnosine
BA-64-PX65_1uM Dose=1uM, Carnosine
BA-65-YU05_0.01uM Dose=0.01uM, 7-(tert-Butyl)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine, GABA(A) BZ Site Receptor Antagonists;GABA(A) BZ Site Receptor Agonists targeting GABRA2, GABRA3
BA-65-YU05_1uM Dose=1uM, 7-(tert-Butyl)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine, GABA(A) BZ Site Receptor Antagonists;GABA(A) BZ Site Receptor Agonists targeting GABRA2, GABRA3
BA-65-YU25_0.1uM Dose=0.1uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2
BA-65-YU25_10uM Dose=10uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2
BA-65-YU25_1uM Dose=1uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2
BA-66-BL56_0.01uM Dose=0.01uM, 1-(3-Hydroxy-5-(thiophen-2-yl)phenyl)-3-(naphthalen-2-yl)urea, frizzled-4 anatagonist targeting FZD4
BA-66-BL56_10uM Dose=10uM, 1-(3-Hydroxy-5-(thiophen-2-yl)phenyl)-3-(naphthalen-2-yl)urea, frizzled-4 anatagonist targeting FZD4
BA-66-BL56_1uM Dose=1uM, 1-(3-Hydroxy-5-(thiophen-2-yl)phenyl)-3-(naphthalen-2-yl)urea, frizzled-4 anatagonist targeting FZD4
BA-68-FJ41_0.01uM Dose=0.01uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
BA-68-FJ41_0.1uM Dose=0.1uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
BA-68-FJ41_10uM Dose=10uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
BA-68-FJ41_1uM Dose=1uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
BA-69-DU95_0.01uM Dose=0.01uM, Doconexent, PPARalpha Agonists targeting PPARA
BA-69-DU95_0.1uM Dose=0.1uM, Doconexent, PPARalpha Agonists targeting PPARA
BA-69-DU95_10uM Dose=10uM, Doconexent, PPARalpha Agonists targeting PPARA
BA-69-DU95_1uM Dose=1uM, Doconexent, PPARalpha Agonists targeting PPARA
BA-69-TQ80_0.01uM Dose=0.01uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A
BA-69-TQ80_0.1uM Dose=0.1uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A
BA-69-TQ80_10uM Dose=10uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A
BA-69-TQ80_1uM Dose=1uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A
BA-70-LV41_0.1uM Dose=0.1uM, Rosmarinic acid, Angiogenesis Inhibitors;4-aminobutyrate transaminase inhibitor;Antioxidants targeting ABAT
BA-70-LV41_1uM Dose=1uM, Rosmarinic acid, Angiogenesis Inhibitors;4-aminobutyrate transaminase inhibitor;Antioxidants targeting ABAT
BA-71-BE32_0.01uM Dose=0.01uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1
BA-71-BE32_0.1uM Dose=0.1uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1
BA-71-BE32_10uM Dose=10uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1
BA-71-BE32_1uM Dose=1uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1
BA-72-YP01_0.01uM Dose=0.01uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1
BA-72-YP01_0.1uM Dose=0.1uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1
BA-72-YP01_10uM Dose=10uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1
BA-72-YP01_1uM Dose=1uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1
BA-73-MC77_0.01uM Dose=0.01uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1
BA-73-MC77_0.1uM Dose=0.1uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1
BA-73-MC77_10uM Dose=10uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1
BA-73-MC77_1uM Dose=1uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1
BA-74-BQ33_0.01uM Dose=0.01uM, Cevoglitazar, PPARgamma Agonists;PPARalpha Agonists targeting PPARA, PPARG
BA-74-BQ33_0.1uM Dose=0.1uM, Cevoglitazar, PPARgamma Agonists;PPARalpha Agonists targeting PPARA, PPARG
BA-74-BQ33_10uM Dose=10uM, Cevoglitazar, PPARgamma Agonists;PPARalpha Agonists targeting PPARA, PPARG
BA-74-EG74_0.01uM Dose=0.01uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD
BA-74-EG74_0.1uM Dose=0.1uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD
BA-74-EG74_10uM Dose=10uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD
BA-74-EG74_1uM Dose=1uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD
BA-74-WG29_0.01uM Dose=0.01uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2
BA-74-WG29_0.1uM Dose=0.1uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2
BA-74-WG29_10uM Dose=10uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2
BA-74-WG29_1uM Dose=1uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2
BA-75-MA47_0.1uM Dose=0.1uM, Selurampanel, AMPA Antagonists targeting GRIA1
BA-75-MA47_10uM Dose=10uM, Selurampanel, AMPA Antagonists targeting GRIA1
BA-75-VA57_0.01uM Dose=0.01uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2
BA-75-VA57_0.1uM Dose=0.1uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2
BA-75-VA57_10uM Dose=10uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2
BA-75-VA57_1uM Dose=1uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2
BA-77-IP18_0.01uM Dose=0.01uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2
BA-77-IP18_0.1uM Dose=0.1uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2
BA-77-IP18_10uM Dose=10uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2
BA-77-IP18_1uM Dose=1uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2
BA-77-NI61_0.01uM Dose=0.01uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine
BA-77-NI61_0.1uM Dose=0.1uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine
BA-77-NI61_10uM Dose=10uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine
BA-77-NI61_1uM Dose=1uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine
BA-77-US35_0.01uM Dose=0.01uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139
BA-77-US35_0.1uM Dose=0.1uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139
BA-77-US35_10uM Dose=10uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139
BA-77-US35_1uM Dose=1uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139
BA-79-ZR48_0.01uM Dose=0.01uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5
BA-79-ZR48_0.1uM Dose=0.1uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5
BA-79-ZR48_10uM Dose=10uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5
BA-79-ZR48_1uM Dose=1uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5
BA-84-TD72_0.01uM Dose=0.01uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR
BA-84-TD72_0.1uM Dose=0.1uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR
BA-84-TD72_10uM Dose=10uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR
BA-84-TD72_1uM Dose=1uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR
BA-84-WN26_0.01uM Dose=0.01uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3
BA-84-WN26_0.1uM Dose=0.1uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3
BA-84-WN26_10uM Dose=10uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3
BA-84-WN26_1uM Dose=1uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3
BA-85-ZA57_0.01uM Dose=0.01uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA
BA-85-ZA57_0.1uM Dose=0.1uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA
BA-85-ZA57_10uM Dose=10uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA
BA-85-ZA57_1uM Dose=1uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA
BA-86-AL61_0.1uM Dose=0.1uM, Dasatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Src Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting ABL1, ABL2, BTK, FYN, LCK, MAPK12, SRC, YES1
BA-86-AL61_10uM Dose=10uM, Dasatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Src Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting ABL1, ABL2, BTK, FYN, LCK, MAPK12, SRC, YES1
BA-86-AL61_1uM Dose=1uM, Dasatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Src Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting ABL1, ABL2, BTK, FYN, LCK, MAPK12, SRC, YES1
BA-86-YY52_0.01uM Dose=0.01uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C
BA-86-YY52_0.1uM Dose=0.1uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C
BA-86-YY52_1uM Dose=1uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C
BA-87-NF64_0.01uM Dose=0.01uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D
BA-87-NF64_0.1uM Dose=0.1uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D
BA-87-NF64_10uM Dose=10uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D
BA-87-NF64_1uM Dose=1uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D
BA-88-HT15_0.01uM Dose=0.01uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4
BA-88-HT15_0.1uM Dose=0.1uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4
BA-88-HT15_10uM Dose=10uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4
BA-88-HT15_1uM Dose=1uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4
BA-89-SR63_0.01uM Dose=0.01uM, Pexidartinib, CSF1R inhibitor targeting CSF1R
BA-89-SR63_0.1uM Dose=0.1uM, Pexidartinib, CSF1R inhibitor targeting CSF1R
BA-89-SR63_10uM Dose=10uM, Pexidartinib, CSF1R inhibitor targeting CSF1R
BA-89-SR63_1uM Dose=1uM, Pexidartinib, CSF1R inhibitor targeting CSF1R
BA-90-AA10_0.01uM Dose=0.01uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
BA-90-AA10_0.1uM Dose=0.1uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
BA-90-AA10_10uM Dose=10uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
BA-90-AA10_1uM Dose=1uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
BA-92-CZ75_0.01uM Dose=0.01uM
BA-92-CZ75_0.1uM Dose=0.1uM
BA-92-CZ75_10uM Dose=10uM
BA-92-CZ75_1uM Dose=1uM
BA-92-YC70_0.01uM Dose=0.01uM, Temozolomide
BA-92-YC70_0.1uM Dose=0.1uM, Temozolomide
BA-92-YC70_10uM Dose=10uM, Temozolomide
BA-92-YC70_1uM Dose=1uM, Temozolomide
BA-94-PX65_0.01uM Dose=0.01uM, Olanzapine, Dopamine D2 Antagonists;5-HT2A Inverse Agonist;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD2, HTR2A
BA-94-PX65_10uM Dose=10uM, Olanzapine, Dopamine D2 Antagonists;5-HT2A Inverse Agonist;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD2, HTR2A
BA-95-YU85_0.01uM Dose=0.01uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR
BA-95-YU85_0.1uM Dose=0.1uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR
BA-95-YU85_10uM Dose=10uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR
BA-95-YU85_1uM Dose=1uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR
BA-96-YB32_0.01uM Dose=0.01uM
BA-96-YB32_0.1uM Dose=0.1uM
BA-96-YB32_10uM Dose=10uM
BA-96-YB32_1uM Dose=1uM
BA-97-CI76_0.01uM Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate
BA-97-CI76_0.1uM Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate
BA-97-CI76_10uM Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate
BA-97-CI76_1uM Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate
BA-98-JJ31_0.01uM Dose=0.01uM, Quinine
BA-98-JJ31_0.1uM Dose=0.1uM, Quinine
BA-98-JJ31_10uM Dose=10uM, Quinine
BA-98-JJ31_1uM Dose=1uM, Quinine
BB-00-UK69_0.01uM Dose=0.01uM, Metyrapone, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting CYP11B1, HSD11B1, NR3C2
BB-00-UK69_0.1uM Dose=0.1uM, Metyrapone, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting CYP11B1, HSD11B1, NR3C2
BB-00-UK69_10uM Dose=10uM, Metyrapone, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting CYP11B1, HSD11B1, NR3C2
BB-00-UK69_1uM Dose=1uM, Metyrapone, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting CYP11B1, HSD11B1, NR3C2
BB-01-IO76_0.01uM Dose=0.01uM, Aspartic Acid
BB-01-IO76_0.1uM Dose=0.1uM, Aspartic Acid
BB-01-IO76_10uM Dose=10uM, Aspartic Acid
BB-01-IO76_1uM Dose=1uM, Aspartic Acid
BB-03-FT18_10uM Dose=10uM, Tmp269 targeting HDAC9, HDAC4, HDAC5, HDAC7
BB-04-KA05_0.01uM Dose=0.01uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5
BB-04-KA05_0.1uM Dose=0.1uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5
BB-04-KA05_10uM Dose=10uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5
BB-04-KA05_1uM Dose=1uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5
BB-04-TN61_0.01uM Dose=0.01uM, Cloperastine
BB-04-TN61_0.1uM Dose=0.1uM, Cloperastine
BB-04-TN61_10uM Dose=10uM, Cloperastine
BB-04-TN61_1uM Dose=1uM, Cloperastine
BB-05-NK66_0.01uM Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate
BB-05-NK66_0.1uM Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate
BB-05-NK66_10uM Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate
BB-05-NK66_1uM Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate
BB-08-WM33_0.01uM Dose=0.01uM, AM 281, CNR1 antagonist targeting CNR1
BB-08-WM33_0.1uM Dose=0.1uM, AM 281, CNR1 antagonist targeting CNR1
BB-08-WM33_10uM Dose=10uM, AM 281, CNR1 antagonist targeting CNR1
BB-08-WM33_1uM Dose=1uM, AM 281, CNR1 antagonist targeting CNR1
BB-09-GD09_0.1uM Dose=0.1uM, Sunitinib targeting PTK2B, RET, FGFR3P1
BB-09-GD09_10uM Dose=10uM, Sunitinib targeting PTK2B, RET, FGFR3P1
BB-09-GD09_1uM Dose=1uM, Sunitinib targeting PTK2B, RET, FGFR3P1
BB-10-PR06_0.01uM Dose=0.01uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300
BB-10-PR06_0.1uM Dose=0.1uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300
BB-10-PR06_10uM Dose=10uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300
BB-10-PR06_1uM Dose=1uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300
BB-11-JI42_0.01uM Dose=0.01uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
BB-11-JI42_0.1uM Dose=0.1uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
BB-11-JI42_10uM Dose=10uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
BB-11-JI42_1uM Dose=1uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
BB-11-XO81_0.01uM Dose=0.01uM, 7-Hydroxy-3-(4-Methoxyphenyl)-3,4-Dihydro-2h-1,3-Benzoxazin-2-One, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
BB-11-XO81_0.1uM Dose=0.1uM, 7-Hydroxy-3-(4-Methoxyphenyl)-3,4-Dihydro-2h-1,3-Benzoxazin-2-One, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
BB-11-XO81_10uM Dose=10uM, 7-Hydroxy-3-(4-Methoxyphenyl)-3,4-Dihydro-2h-1,3-Benzoxazin-2-One, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
BB-14-KA05_0.01uM Dose=0.01uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
BB-14-KA05_0.1uM Dose=0.1uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
BB-14-KA05_10uM Dose=10uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
BB-14-KA05_1uM Dose=1uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3
BB-16-BE49_0.01uM Dose=0.01uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2
BB-16-BE49_0.1uM Dose=0.1uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2
BB-16-BE49_10uM Dose=10uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2
BB-16-BE49_1uM Dose=1uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2
BB-17-GC12_0.01uM Dose=0.01uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2
BB-17-GC12_0.1uM Dose=0.1uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2
BB-17-GC12_10uM Dose=10uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2
BB-17-GC12_1uM Dose=1uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2
BB-18-OM53_0.01uM Dose=0.01uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BB-18-OM53_0.1uM Dose=0.1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BB-18-OM53_1uM Dose=1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BB-19-ZK81_0.01uM Dose=0.01uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH
BB-19-ZK81_0.1uM Dose=0.1uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH
BB-19-ZK81_10uM Dose=10uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH
BB-19-ZK81_1uM Dose=1uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH
BB-20-UU03_0.01uM Dose=0.01uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1
BB-20-UU03_0.1uM Dose=0.1uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1
BB-20-UU03_10uM Dose=10uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1
BB-20-UU03_1uM Dose=1uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1
BB-21-KE77_0.01uM Dose=0.01uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1
BB-21-KE77_0.1uM Dose=0.1uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1
BB-21-KE77_10uM Dose=10uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1
BB-21-KE77_1uM Dose=1uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1
BB-21-XL84_0.01uM Dose=0.01uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA
BB-21-XL84_0.1uM Dose=0.1uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA
BB-21-XL84_10uM Dose=10uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA
BB-21-XL84_1uM Dose=1uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA
BB-23-AJ69_10uM Dose=10uM
BB-23-PM31_0.1uM Dose=0.1uM, 4-(1-Methylpiperidin-4-yl)oxy-5-propan-2-yl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS
BB-23-PM31_10uM Dose=10uM, 4-(1-Methylpiperidin-4-yl)oxy-5-propan-2-yl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS
BB-23-PM31_1uM Dose=1uM, 4-(1-Methylpiperidin-4-yl)oxy-5-propan-2-yl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS
BB-25-NU80_0.01uM Dose=0.01uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1
BB-25-NU80_0.1uM Dose=0.1uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1
BB-25-NU80_10uM Dose=10uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1
BB-25-NU80_1uM Dose=1uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1
BB-26-JS03_0.01uM Dose=0.01uM
BB-26-JS03_10uM Dose=10uM
BB-26-JS03_1uM Dose=1uM
BB-27-MC77_0.01uM Dose=0.01uM
BB-27-MC77_0.1uM Dose=0.1uM
BB-27-MC77_10uM Dose=10uM
BB-27-MC77_1uM Dose=1uM
BB-28-CT35_0.01uM Dose=0.01uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ
BB-28-CT35_0.1uM Dose=0.1uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ
BB-28-CT35_10uM Dose=10uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ
BB-28-CT35_1uM Dose=1uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ
BB-28-MC54_0.01uM Dose=0.01uM, GPBAR1 agonist targeting GPBAR1
BB-28-MC54_0.1uM Dose=0.1uM, GPBAR1 agonist targeting GPBAR1
BB-28-MC54_10uM Dose=10uM, GPBAR1 agonist targeting GPBAR1
BB-28-MC54_1uM Dose=1uM, GPBAR1 agonist targeting GPBAR1
BB-29-VD14_0.01uM Dose=0.01uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3
BB-29-VD14_0.1uM Dose=0.1uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3
BB-29-VD14_10uM Dose=10uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3
BB-29-VD14_1uM Dose=1uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3
BB-31-EB45_0.01uM Dose=0.01uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1
BB-31-EB45_0.1uM Dose=0.1uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1
BB-31-EB45_10uM Dose=10uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1
BB-32-IZ10_0.01uM Dose=0.01uM
BB-32-IZ10_0.1uM Dose=0.1uM
BB-32-IZ10_10uM Dose=10uM
BB-32-IZ10_1uM Dose=1uM
BB-33-HC27_0.01uM Dose=0.01uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS
BB-33-HC27_0.1uM Dose=0.1uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS
BB-33-HC27_10uM Dose=10uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS
BB-33-HC27_1uM Dose=1uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS
BB-36-JL06_0.01uM Dose=0.01uM, N-[5-(6-Chloro-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
BB-36-JL06_0.1uM Dose=0.1uM, N-[5-(6-Chloro-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
BB-36-JL06_10uM Dose=10uM, N-[5-(6-Chloro-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
BB-36-LB57_0.01uM Dose=0.01uM
BB-36-LB57_0.1uM Dose=0.1uM
BB-36-LB57_10uM Dose=10uM
BB-36-LB57_1uM Dose=1uM
BB-37-LS05_0.01uM Dose=0.01uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
BB-37-LS05_0.1uM Dose=0.1uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
BB-37-LS05_10uM Dose=10uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
BB-37-LS05_1uM Dose=1uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
BB-39-DQ95_0.01uM Dose=0.01uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7
BB-39-DQ95_0.1uM Dose=0.1uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7
BB-39-DQ95_10uM Dose=10uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7
BB-39-DQ95_1uM Dose=1uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7
BB-39-YQ35_0.01uM Dose=0.01uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A
BB-39-YQ35_0.1uM Dose=0.1uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A
BB-39-YQ35_10uM Dose=10uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A
BB-39-YQ35_1uM Dose=1uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A
BB-40-DA70_0.1uM Dose=0.1uM, (3R)-3-[6-(2,5-difluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane targeting CHRNA7
BB-40-DA70_1uM Dose=1uM, (3R)-3-[6-(2,5-difluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane targeting CHRNA7
BB-40-KK84_0.01uM Dose=0.01uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2
BB-40-KK84_0.1uM Dose=0.1uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2
BB-40-KK84_10uM Dose=10uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2
BB-40-KK84_1uM Dose=1uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2
BB-41-XE67_0.01uM Dose=0.01uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7
BB-41-XE67_0.1uM Dose=0.1uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7
BB-41-XE67_10uM Dose=10uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7
BB-41-XE67_1uM Dose=1uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7
BB-42-FF52_0.01uM Dose=0.01uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ
BB-42-FF52_0.1uM Dose=0.1uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ
BB-42-FF52_10uM Dose=10uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ
BB-42-FF52_1uM Dose=1uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ
BB-43-YQ76_0.01uM Dose=0.01uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E
BB-43-YQ76_0.1uM Dose=0.1uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E
BB-43-YQ76_10uM Dose=10uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E
BB-43-YQ76_1uM Dose=1uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E
BB-44-CQ48_10uM Dose=10uM, Resveratrol, Antioxidant;Anti-inflammatory targeting NQO2, TTR
BB-44-SX65_0.01uM Dose=0.01uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9
BB-44-SX65_0.1uM Dose=0.1uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9
BB-44-SX65_10uM Dose=10uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9
BB-44-SX65_1uM Dose=1uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9
BB-45-NH69_0.01uM Dose=0.01uM, Mosapride, 5-HT4 Agonists targeting HTR4
BB-45-NH69_0.1uM Dose=0.1uM, Mosapride, 5-HT4 Agonists targeting HTR4
BB-45-NH69_10uM Dose=10uM, Mosapride, 5-HT4 Agonists targeting HTR4
BB-45-NH69_1uM Dose=1uM, Mosapride, 5-HT4 Agonists targeting HTR4
BB-47-YI31_0.01uM Dose=0.01uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
BB-47-YI31_0.1uM Dose=0.1uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
BB-47-YI31_10uM Dose=10uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
BB-47-YI31_1uM Dose=1uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
BB-48-VW67_0.01uM Dose=0.01uM, 7-(2-cyclohexylethyl)-6-[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxymethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS
BB-48-VW67_0.1uM Dose=0.1uM, 7-(2-cyclohexylethyl)-6-[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxymethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS
BB-48-VW67_10uM Dose=10uM, 7-(2-cyclohexylethyl)-6-[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxymethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS
BB-49-OQ60_0.01uM Dose=0.01uM, Doramapimod, Inhibitors of Signal Transduction Pathways;SAPK2 (p38beta) Inhibitors;p38 MAPK Inhibitors targeting MAPK14, MAPK11, MAPK13, MAPK12
BB-49-OQ60_10uM Dose=10uM, Doramapimod, Inhibitors of Signal Transduction Pathways;SAPK2 (p38beta) Inhibitors;p38 MAPK Inhibitors targeting MAPK14, MAPK11, MAPK13, MAPK12
BB-49-OQ60_1uM Dose=1uM, Doramapimod, Inhibitors of Signal Transduction Pathways;SAPK2 (p38beta) Inhibitors;p38 MAPK Inhibitors targeting MAPK14, MAPK11, MAPK13, MAPK12
BB-50-CR51_0.01uM Dose=0.01uM, 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one, KIT (C-KIT) Inhibitors targeting KIT
BB-50-CR51_10uM Dose=10uM, 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one, KIT (C-KIT) Inhibitors targeting KIT
BB-50-CR51_1uM Dose=1uM, 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one, KIT (C-KIT) Inhibitors targeting KIT
BB-51-DP49_0.01uM Dose=0.01uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9
BB-51-DP49_0.1uM Dose=0.1uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9
BB-51-DP49_10uM Dose=10uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9
BB-51-DP49_1uM Dose=1uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9
BB-51-ML99_0.01uM Dose=0.01uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53
BB-51-ML99_0.1uM Dose=0.1uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53
BB-51-ML99_10uM Dose=10uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53
BB-51-ML99_1uM Dose=1uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53
BB-52-LF37_0.01uM Dose=0.01uM, Saxagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BB-52-LF37_0.1uM Dose=0.1uM, Saxagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BB-52-LF37_10uM Dose=10uM, Saxagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BB-52-LF37_1uM Dose=1uM, Saxagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BB-52-UP66_0.01uM Dose=0.01uM, Bopindolol, beta1-Adrenoceptor Antagonists targeting ADRB1
BB-52-UP66_10uM Dose=10uM, Bopindolol, beta1-Adrenoceptor Antagonists targeting ADRB1
BB-52-UP66_1uM Dose=1uM, Bopindolol, beta1-Adrenoceptor Antagonists targeting ADRB1
BB-53-SW55_0.01uM Dose=0.01uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
BB-53-SW55_10uM Dose=10uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
BB-53-SW55_1uM Dose=1uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
BB-55-JH29_0.01uM Dose=0.01uM
BB-55-JH29_0.1uM Dose=0.1uM
BB-55-JH29_10uM Dose=10uM
BB-55-JH29_1uM Dose=1uM
BB-56-DB67_0.01uM Dose=0.01uM, AG 490, Jak2 Inhibitors;Antiinflammatory Drugs;STAT-3 Inhibitors;Jak3 Inhibitors targeting JAK2, JAK3, STAT3
BB-56-DB67_0.1uM Dose=0.1uM, AG 490, Jak2 Inhibitors;Antiinflammatory Drugs;STAT-3 Inhibitors;Jak3 Inhibitors targeting JAK2, JAK3, STAT3
BB-56-DB67_10uM Dose=10uM, AG 490, Jak2 Inhibitors;Antiinflammatory Drugs;STAT-3 Inhibitors;Jak3 Inhibitors targeting JAK2, JAK3, STAT3
BB-56-DB67_1uM Dose=1uM, AG 490, Jak2 Inhibitors;Antiinflammatory Drugs;STAT-3 Inhibitors;Jak3 Inhibitors targeting JAK2, JAK3, STAT3
BB-57-AZ77_0.01uM Dose=0.01uM
BB-57-AZ77_0.1uM Dose=0.1uM
BB-57-AZ77_10uM Dose=10uM
BB-57-AZ77_1uM Dose=1uM
BB-57-NT83_0.01uM Dose=0.01uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2
BB-57-NT83_0.1uM Dose=0.1uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2
BB-57-NT83_10uM Dose=10uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2
BB-57-NT83_1uM Dose=1uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2
BB-58-LW82_0.01uM Dose=0.01uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
BB-58-LW82_0.1uM Dose=0.1uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
BB-58-LW82_10uM Dose=10uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
BB-58-LW82_1uM Dose=1uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
BB-62-MS83_0.01uM Dose=0.01uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK
BB-62-MS83_0.1uM Dose=0.1uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK
BB-62-MS83_10uM Dose=10uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK
BB-62-MS83_1uM Dose=1uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK
BB-62-SZ35_0.01uM Dose=0.01uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7
BB-62-SZ35_0.1uM Dose=0.1uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7
BB-62-SZ35_10uM Dose=10uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7
BB-62-SZ35_1uM Dose=1uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7
BB-63-AW70_0.01uM Dose=0.01uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3
BB-63-AW70_0.1uM Dose=0.1uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3
BB-63-AW70_10uM Dose=10uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3
BB-63-AW70_1uM Dose=1uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3
BB-64-EE60_0.01uM Dose=0.01uM, US10112926, Example 7, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
BB-64-EE60_0.1uM Dose=0.1uM, US10112926, Example 7, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
BB-64-EE60_10uM Dose=10uM, US10112926, Example 7, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
BB-64-EE60_1uM Dose=1uM, US10112926, Example 7, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
BB-65-JH59_10uM Dose=10uM, 2,9-Diazaspiro[5.5]undecan-1-one, 2-(1H-indol-3-ylMethyl)-9-(4-Methoxy-2-pyriMidinyl)-
BB-65-JH59_1uM Dose=1uM, 2,9-Diazaspiro[5.5]undecan-1-one, 2-(1H-indol-3-ylMethyl)-9-(4-Methoxy-2-pyriMidinyl)-
BB-65-SY95_0.01uM Dose=0.01uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2
BB-65-SY95_0.1uM Dose=0.1uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2
BB-65-SY95_10uM Dose=10uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2
BB-65-SY95_1uM Dose=1uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2
BB-69-WN73_0.01uM Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BB-69-WN73_0.1uM Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BB-69-WN73_10uM Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BB-69-WN73_1uM Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BB-69-YQ35_0.01uM Dose=0.01uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1
BB-69-YQ35_0.1uM Dose=0.1uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1
BB-69-YQ35_10uM Dose=10uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1
BB-69-YQ35_1uM Dose=1uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1
BB-72-TP61_0.01uM Dose=0.01uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide
BB-72-TP61_0.1uM Dose=0.1uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide
BB-72-TP61_10uM Dose=10uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide
BB-72-TP61_1uM Dose=1uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide
BB-73-OX38_0.01uM Dose=0.01uM, R-1663, Known FactorXa inhibitor targeting F10
BB-73-OX38_0.1uM Dose=0.1uM, R-1663, Known FactorXa inhibitor targeting F10
BB-73-OX38_10uM Dose=10uM, R-1663, Known FactorXa inhibitor targeting F10
BB-73-OX38_1uM Dose=1uM, R-1663, Known FactorXa inhibitor targeting F10
BB-73-ZW70_0.01uM Dose=0.01uM
BB-73-ZW70_0.1uM Dose=0.1uM
BB-73-ZW70_10uM Dose=10uM
BB-73-ZW70_1uM Dose=1uM
BB-74-RX30_0.01uM Dose=0.01uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2
BB-74-RX30_0.1uM Dose=0.1uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2
BB-74-RX30_10uM Dose=10uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2
BB-74-RX30_1uM Dose=1uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2
BB-75-JK26_0.01uM Dose=0.01uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3
BB-75-JK26_0.1uM Dose=0.1uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3
BB-75-JK26_10uM Dose=10uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3
BB-75-JK26_1uM Dose=1uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3
BB-75-UH54_0.01uM Dose=0.01uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2
BB-75-UH54_0.1uM Dose=0.1uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2
BB-75-UH54_10uM Dose=10uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2
BB-75-UH54_1uM Dose=1uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2
BB-75-XU05_0.01uM Dose=0.01uM, Scopoletin, LDL Antioxidants;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nicotinic Receptor Agonists;Acetylcholinesterase Inhibitors targeting ACHE, NOS2
BB-75-XU05_0.1uM Dose=0.1uM, Scopoletin, LDL Antioxidants;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nicotinic Receptor Agonists;Acetylcholinesterase Inhibitors targeting ACHE, NOS2
BB-75-XU05_10uM Dose=10uM, Scopoletin, LDL Antioxidants;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nicotinic Receptor Agonists;Acetylcholinesterase Inhibitors targeting ACHE, NOS2
BB-75-YK01_0.01uM Dose=0.01uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one
BB-75-YK01_0.1uM Dose=0.1uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one
BB-75-YK01_10uM Dose=10uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one
BB-75-YK01_1uM Dose=1uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one
BB-77-IG67_0.01uM Dose=0.01uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea
BB-77-IG67_0.1uM Dose=0.1uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea
BB-77-IG67_10uM Dose=10uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea
BB-77-IG67_1uM Dose=1uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea
BB-77-QQ71_0.01uM Dose=0.01uM, Ricolinostat, HDAC6 targeting HDAC6
BB-77-QQ71_0.1uM Dose=0.1uM, Ricolinostat, HDAC6 targeting HDAC6
BB-77-QQ71_10uM Dose=10uM, Ricolinostat, HDAC6 targeting HDAC6
BB-77-QQ71_1uM Dose=1uM, Ricolinostat, HDAC6 targeting HDAC6
BB-78-LT85_0.01uM Dose=0.01uM
BB-78-LT85_0.1uM Dose=0.1uM
BB-78-LT85_10uM Dose=10uM
BB-78-LT85_1uM Dose=1uM
BB-79-AG41_0.01uM Dose=0.01uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB
BB-79-AG41_0.1uM Dose=0.1uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB
BB-79-AG41_10uM Dose=10uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB
BB-79-AG41_1uM Dose=1uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB
BB-79-GA42_0.01uM Dose=0.01uM, Pratol
BB-79-GA42_0.1uM Dose=0.1uM, Pratol
BB-79-GA42_10uM Dose=10uM, Pratol
BB-79-GA42_1uM Dose=1uM, Pratol
BB-80-NH42_0.01uM Dose=0.01uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2
BB-80-NH42_0.1uM Dose=0.1uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2
BB-80-NH42_10uM Dose=10uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2
BB-80-NH42_1uM Dose=1uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2
BB-82-TP51_0.01uM Dose=0.01uM, Tegobuvir
BB-82-TP51_0.1uM Dose=0.1uM, Tegobuvir
BB-82-TP51_10uM Dose=10uM, Tegobuvir
BB-82-TP51_1uM Dose=1uM, Tegobuvir
BB-83-OX58_0.01uM Dose=0.01uM
BB-83-OX58_0.1uM Dose=0.1uM
BB-83-OX58_10uM Dose=10uM
BB-83-OX58_1uM Dose=1uM
BB-83-ZM06_0.01uM Dose=0.01uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3
BB-83-ZM06_0.1uM Dose=0.1uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3
BB-83-ZM06_10uM Dose=10uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3
BB-83-ZM06_1uM Dose=1uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3
BB-84-DG64_0.01uM Dose=0.01uM
BB-84-DG64_0.1uM Dose=0.1uM
BB-84-DG64_10uM Dose=10uM
BB-84-DG64_1uM Dose=1uM
BB-85-NU70_0.01uM Dose=0.01uM, Sotrastaurin, Protein Kinase PKC beta Inhibitors;Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC theta Inhibitors targeting PRKCA, PRKCB, PRKCD, PRKCE, PRKCQ
BB-85-NU70_10uM Dose=10uM, Sotrastaurin, Protein Kinase PKC beta Inhibitors;Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC theta Inhibitors targeting PRKCA, PRKCB, PRKCD, PRKCE, PRKCQ
BB-85-NU70_1uM Dose=1uM, Sotrastaurin, Protein Kinase PKC beta Inhibitors;Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC theta Inhibitors targeting PRKCA, PRKCB, PRKCD, PRKCE, PRKCQ
BB-86-BE19_0.01uM Dose=0.01uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG
BB-86-BE19_0.1uM Dose=0.1uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG
BB-86-BE19_10uM Dose=10uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG
BB-86-BE19_1uM Dose=1uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG
BB-86-BE39_0.01uM Dose=0.01uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
BB-86-BE39_0.1uM Dose=0.1uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
BB-86-BE39_10uM Dose=10uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
BB-86-BE39_1uM Dose=1uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
BB-86-MY27_0.01uM Dose=0.01uM, Fpl 64176, Calcium channel stimulator L-type;L-Type Calcium Channel Activators targeting CACNA1C, CACNA1D, CACNA1F, CACNA1S
BB-86-MY27_0.1uM Dose=0.1uM, Fpl 64176, Calcium channel stimulator L-type;L-Type Calcium Channel Activators targeting CACNA1C, CACNA1D, CACNA1F, CACNA1S
BB-86-MY27_10uM Dose=10uM, Fpl 64176, Calcium channel stimulator L-type;L-Type Calcium Channel Activators targeting CACNA1C, CACNA1D, CACNA1F, CACNA1S
BB-86-UL91_0.01uM Dose=0.01uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4
BB-86-UL91_0.1uM Dose=0.1uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4
BB-86-UL91_10uM Dose=10uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4
BB-86-UL91_1uM Dose=1uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4
BB-87-SF89_0.01uM Dose=0.01uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5
BB-87-SF89_0.1uM Dose=0.1uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5
BB-87-SF89_10uM Dose=10uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5
BB-87-SF89_1uM Dose=1uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5
BB-87-YF54_0.01uM Dose=0.01uM, 2-[(6-Methylpyridin-2-yl)carbamoyl]-4-(trifluoromethyl)benzoic acid
BB-87-YF54_0.1uM Dose=0.1uM, 2-[(6-Methylpyridin-2-yl)carbamoyl]-4-(trifluoromethyl)benzoic acid
BB-87-YF54_10uM Dose=10uM, 2-[(6-Methylpyridin-2-yl)carbamoyl]-4-(trifluoromethyl)benzoic acid
BB-87-YF54_1uM Dose=1uM, 2-[(6-Methylpyridin-2-yl)carbamoyl]-4-(trifluoromethyl)benzoic acid
BB-89-GD49_0.01uM Dose=0.01uM, phosphodiesterase PDE5A Inhibitors targeting PDE6A, PDE6G, PDE6H, PDE5A
BB-89-GD49_0.1uM Dose=0.1uM, phosphodiesterase PDE5A Inhibitors targeting PDE6A, PDE6G, PDE6H, PDE5A
BB-89-GD49_10uM Dose=10uM, phosphodiesterase PDE5A Inhibitors targeting PDE6A, PDE6G, PDE6H, PDE5A
BB-89-GD49_1uM Dose=1uM, phosphodiesterase PDE5A Inhibitors targeting PDE6A, PDE6G, PDE6H, PDE5A
BB-89-HE42_0.01uM Dose=0.01uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1
BB-89-HE42_0.1uM Dose=0.1uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1
BB-89-HE42_10uM Dose=10uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1
BB-89-HE42_1uM Dose=1uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1
BB-93-VT73_0.01uM Dose=0.01uM, 2-Benzyl-3-mercaptopropanoic acid targeting CPA1
BB-93-VT73_0.1uM Dose=0.1uM, 2-Benzyl-3-mercaptopropanoic acid targeting CPA1
BB-93-VT73_1uM Dose=1uM, 2-Benzyl-3-mercaptopropanoic acid targeting CPA1
BB-94-HN41_0.01uM Dose=0.01uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1
BB-94-HN41_0.1uM Dose=0.1uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1
BB-94-HN41_10uM Dose=10uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1
BB-94-HN41_1uM Dose=1uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1
BB-99-UN48_0.01uM Dose=0.01uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole
BB-99-UN48_0.1uM Dose=0.1uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole
BB-99-UN48_10uM Dose=10uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole
BB-99-UN48_1uM Dose=1uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole
BC-00-YH62_0.01uM Dose=0.01uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
BC-00-YH62_0.1uM Dose=0.1uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
BC-00-YH62_10uM Dose=10uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
BC-00-YH62_1uM Dose=1uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
BC-01-JL64_0.01uM Dose=0.01uM, Calcimycin
BC-01-JL64_0.1uM Dose=0.1uM, Calcimycin
BC-01-JL64_10uM Dose=10uM, Calcimycin
BC-01-JL64_1uM Dose=1uM, Calcimycin
BC-01-VL44_0.01uM Dose=0.01uM, Lipoic acid, Pyruvate Dehydrogenase Activators targeting DLAT, PDHA1, PDHA2, PDHB
BC-01-VL44_0.1uM Dose=0.1uM, Lipoic acid, Pyruvate Dehydrogenase Activators targeting DLAT, PDHA1, PDHA2, PDHB
BC-01-VL44_10uM Dose=10uM, Lipoic acid, Pyruvate Dehydrogenase Activators targeting DLAT, PDHA1, PDHA2, PDHB
BC-01-VL44_1uM Dose=1uM, Lipoic acid, Pyruvate Dehydrogenase Activators targeting DLAT, PDHA1, PDHA2, PDHB
BC-01-WO51_0.1uM Dose=0.1uM, 2-[[(2S)-2-aminopropanoyl]amino]ethyl N-[4-(3-chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]carbamate
BC-01-WO51_10uM Dose=10uM, 2-[[(2S)-2-aminopropanoyl]amino]ethyl N-[4-(3-chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]carbamate
BC-02-SI44_0.01uM Dose=0.01uM, Importazole, Importin beta inhibitor targeting KPNB1
BC-02-SI44_0.1uM Dose=0.1uM, Importazole, Importin beta inhibitor targeting KPNB1
BC-02-SI44_10uM Dose=10uM, Importazole, Importin beta inhibitor targeting KPNB1
BC-02-SI44_1uM Dose=1uM, Importazole, Importin beta inhibitor targeting KPNB1
BC-02-WF67_0.01uM Dose=0.01uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2
BC-02-WF67_0.1uM Dose=0.1uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2
BC-02-WF67_10uM Dose=10uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2
BC-02-WF67_1uM Dose=1uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2
BC-03-OQ01_0.01uM Dose=0.01uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM
BC-03-OQ01_0.1uM Dose=0.1uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM
BC-03-OQ01_10uM Dose=10uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM
BC-03-OQ01_1uM Dose=1uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM
BC-06-CP81_0.01uM Dose=0.01uM, Amitriptyline, 5-HT Reuptake Inhibitors;Nav1.4 (SkM1) Sodium Channel Blockers;Norepinephrine Reuptake Inhibitors targeting SCN4A
BC-06-CP81_10uM Dose=10uM, Amitriptyline, 5-HT Reuptake Inhibitors;Nav1.4 (SkM1) Sodium Channel Blockers;Norepinephrine Reuptake Inhibitors targeting SCN4A
BC-06-IL96_0.01uM Dose=0.01uM
BC-06-IL96_0.1uM Dose=0.1uM
BC-06-IL96_10uM Dose=10uM
BC-06-IL96_1uM Dose=1uM
BC-06-OP01_0.01uM Dose=0.01uM, Ubo-Qic
BC-06-OP01_0.1uM Dose=0.1uM, Ubo-Qic
BC-06-OP01_10uM Dose=10uM, Ubo-Qic
BC-06-OP01_1uM Dose=1uM, Ubo-Qic
BC-07-FZ32_0.01uM Dose=0.01uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2
BC-07-FZ32_0.1uM Dose=0.1uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2
BC-07-FZ32_10uM Dose=10uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2
BC-07-FZ32_1uM Dose=1uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2
BC-08-RC39_0.01uM Dose=0.01uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3
BC-08-RC39_0.1uM Dose=0.1uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3
BC-08-RC39_10uM Dose=10uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3
BC-08-RC39_1uM Dose=1uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3
BC-09-JG96_0.01uM Dose=0.01uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
BC-09-JG96_0.1uM Dose=0.1uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
BC-09-JG96_10uM Dose=10uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
BC-09-JG96_1uM Dose=1uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
BC-09-XN48_0.01uM Dose=0.01uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A
BC-09-XN48_0.1uM Dose=0.1uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A
BC-09-XN48_10uM Dose=10uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A
BC-09-XN48_1uM Dose=1uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A
BC-09-XQ45_0.01uM Dose=0.01uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2
BC-09-XQ45_10uM Dose=10uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2
BC-09-XQ45_1uM Dose=1uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2
BC-10-OR76_0.01uM Dose=0.01uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate
BC-10-OR76_0.1uM Dose=0.1uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate
BC-10-OR76_10uM Dose=10uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate
BC-10-OR76_1uM Dose=1uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate
BC-10-SB73_0.01uM Dose=0.01uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14
BC-10-SB73_0.1uM Dose=0.1uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14
BC-10-SB73_10uM Dose=10uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14
BC-10-SB73_1uM Dose=1uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14
BC-11-LL59_0.01uM Dose=0.01uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3
BC-11-LL59_0.1uM Dose=0.1uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3
BC-11-LL59_10uM Dose=10uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3
BC-11-LL59_1uM Dose=1uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3
BC-12-VG35_0.01uM Dose=0.01uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK
BC-12-VG35_0.1uM Dose=0.1uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK
BC-12-VG35_10uM Dose=10uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK
BC-12-VG35_1uM Dose=1uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK
BC-13-GC37_0.01uM Dose=0.01uM, N-{[(3s,4s)-4-Benzylpyrrolidin-3-Yl]methyl}-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, Renin Inhibitors targeting REN
BC-13-GC37_0.1uM Dose=0.1uM, N-{[(3s,4s)-4-Benzylpyrrolidin-3-Yl]methyl}-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, Renin Inhibitors targeting REN
BC-13-OQ01_0.01uM Dose=0.01uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
BC-13-OQ01_0.1uM Dose=0.1uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
BC-13-OQ01_10uM Dose=10uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
BC-13-OQ01_1uM Dose=1uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
BC-14-CG34_0.01uM Dose=0.01uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide
BC-14-CG34_0.1uM Dose=0.1uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide
BC-14-CG34_10uM Dose=10uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide
BC-14-CG34_1uM Dose=1uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide
BC-15-BY15_0.01uM Dose=0.01uM
BC-15-BY15_0.1uM Dose=0.1uM
BC-15-BY15_10uM Dose=10uM
BC-15-BY15_1uM Dose=1uM
BC-15-EL49_0.01uM Dose=0.01uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B
BC-15-EL49_0.1uM Dose=0.1uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B
BC-15-EL49_10uM Dose=10uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B
BC-15-EL49_1uM Dose=1uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B
BC-15-MR23_0.01uM Dose=0.01uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT
BC-15-MR23_0.1uM Dose=0.1uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT
BC-15-MR23_10uM Dose=10uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT
BC-15-MR23_1uM Dose=1uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT
BC-19-GQ25_0.1uM Dose=0.1uM, Aripiprazole, Dopamine D2 Receptor Partial Agonists;ADRA1B gene inhibitor;HTR2A gene inhibitor;5-HT1A Receptor Partial Agonists targeting ADRA1B, DRD2, HTR1A, HTR2A, SRC
BC-19-GQ25_10uM Dose=10uM, Aripiprazole, Dopamine D2 Receptor Partial Agonists;ADRA1B gene inhibitor;HTR2A gene inhibitor;5-HT1A Receptor Partial Agonists targeting ADRA1B, DRD2, HTR1A, HTR2A, SRC
BC-19-GQ25_1uM Dose=1uM, Aripiprazole, Dopamine D2 Receptor Partial Agonists;ADRA1B gene inhibitor;HTR2A gene inhibitor;5-HT1A Receptor Partial Agonists targeting ADRA1B, DRD2, HTR1A, HTR2A, SRC
BC-20-WA90_0.01uM Dose=0.01uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4
BC-20-WA90_0.1uM Dose=0.1uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4
BC-20-WA90_10uM Dose=10uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4
BC-20-WA90_1uM Dose=1uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4
BC-21-EB65_0.01uM Dose=0.01uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6
BC-21-EB65_0.1uM Dose=0.1uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6
BC-21-EB65_10uM Dose=10uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6
BC-21-EB65_1uM Dose=1uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6
BC-22-DS93_0.01uM Dose=0.01uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA
BC-22-DS93_0.1uM Dose=0.1uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA
BC-22-DS93_10uM Dose=10uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA
BC-22-DS93_1uM Dose=1uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA
BC-22-LS63_0.01uM Dose=0.01uM
BC-22-LS63_10uM Dose=10uM
BC-22-LS63_1uM Dose=1uM
BC-22-OI74_0.01uM Dose=0.01uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH
BC-22-OI74_0.1uM Dose=0.1uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH
BC-22-OI74_10uM Dose=10uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH
BC-22-OI74_1uM Dose=1uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH
BC-22-RZ85_0.01uM Dose=0.01uM, n,n-Bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1h-imidazole-5-methanamine, C5a Antagonists targeting C5AR1
BC-22-RZ85_10uM Dose=10uM, n,n-Bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1h-imidazole-5-methanamine, C5a Antagonists targeting C5AR1
BC-25-VR48_0.01uM Dose=0.01uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB
BC-25-VR48_0.1uM Dose=0.1uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB
BC-25-VR48_10uM Dose=10uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB
BC-25-VR48_1uM Dose=1uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB
BC-26-LE04_0.01uM Dose=0.01uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4
BC-26-LE04_0.1uM Dose=0.1uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4
BC-26-LE04_10uM Dose=10uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4
BC-26-LE04_1uM Dose=1uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4
BC-28-NG89_0.01uM Dose=0.01uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists
BC-28-NG89_0.1uM Dose=0.1uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists
BC-28-NG89_10uM Dose=10uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists
BC-28-NG89_1uM Dose=1uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists
BC-30-IU38_0.1uM Dose=0.1uM, N-(6-chloro-9h-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide, Apoptosis Inducers;IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKG
BC-30-IU38_10uM Dose=10uM, N-(6-chloro-9h-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide, Apoptosis Inducers;IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKG
BC-30-IU38_1uM Dose=1uM, N-(6-chloro-9h-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide, Apoptosis Inducers;IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKG
BC-31-JL64_0.1uM Dose=0.1uM, Deferiprone
BC-31-JL64_10uM Dose=10uM, Deferiprone
BC-31-JL64_1uM Dose=1uM, Deferiprone
BC-32-DI69_0.01uM Dose=0.01uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1
BC-32-DI69_0.1uM Dose=0.1uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1
BC-32-DI69_10uM Dose=10uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1
BC-32-DI69_1uM Dose=1uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1
BC-33-BM51_0.01uM Dose=0.01uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7
BC-33-BM51_0.1uM Dose=0.1uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7
BC-33-BM51_10uM Dose=10uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7
BC-33-BM51_1uM Dose=1uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7
BC-34-IH52_0.01uM Dose=0.01uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4
BC-34-IH52_0.1uM Dose=0.1uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4
BC-34-IH52_10uM Dose=10uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4
BC-34-IH52_1uM Dose=1uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4
BC-36-PL31_0.01uM Dose=0.01uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
BC-36-PL31_0.1uM Dose=0.1uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
BC-36-PL31_10uM Dose=10uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
BC-37-HI51_0.01uM Dose=0.01uM, Adenosine antagonist-1, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3
BC-37-HI51_10uM Dose=10uM, Adenosine antagonist-1, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3
BC-37-HI51_1uM Dose=1uM, Adenosine antagonist-1, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3
BC-38-UW37_0.01uM Dose=0.01uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH
BC-38-UW37_0.1uM Dose=0.1uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH
BC-38-UW37_10uM Dose=10uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH
BC-38-UW37_1uM Dose=1uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH
BC-39-JG96_0.01uM Dose=0.01uM, Gemfibrozil, PPARalpha Agonists targeting PPARA
BC-39-JG96_0.1uM Dose=0.1uM, Gemfibrozil, PPARalpha Agonists targeting PPARA
BC-39-JG96_10uM Dose=10uM, Gemfibrozil, PPARalpha Agonists targeting PPARA
BC-39-JG96_1uM Dose=1uM, Gemfibrozil, PPARalpha Agonists targeting PPARA
BC-40-TU13_0.01uM Dose=0.01uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C
BC-40-TU13_0.1uM Dose=0.1uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C
BC-40-TU13_10uM Dose=10uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C
BC-40-TU13_1uM Dose=1uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C
BC-43-HJ69_0.01uM Dose=0.01uM, Phenelzine, MAO Inhibitors targeting MAOA
BC-43-HJ69_0.1uM Dose=0.1uM, Phenelzine, MAO Inhibitors targeting MAOA
BC-43-HJ69_10uM Dose=10uM, Phenelzine, MAO Inhibitors targeting MAOA
BC-43-HJ69_1uM Dose=1uM, Phenelzine, MAO Inhibitors targeting MAOA
BC-43-JW95_0.01uM Dose=0.01uM, Phenylalanine
BC-43-JW95_0.1uM Dose=0.1uM, Phenylalanine
BC-43-JW95_10uM Dose=10uM, Phenylalanine
BC-43-JW95_1uM Dose=1uM, Phenylalanine
BC-43-PD20_0.01uM Dose=0.01uM, GPR52 agonist-1, GPR52 agonist targeting GPR52
BC-43-PD20_0.1uM Dose=0.1uM, GPR52 agonist-1, GPR52 agonist targeting GPR52
BC-43-PD20_10uM Dose=10uM, GPR52 agonist-1, GPR52 agonist targeting GPR52
BC-43-PD20_1uM Dose=1uM, GPR52 agonist-1, GPR52 agonist targeting GPR52
BC-45-VY95_0.01uM Dose=0.01uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B
BC-45-VY95_0.1uM Dose=0.1uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B
BC-45-VY95_10uM Dose=10uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B
BC-45-VY95_1uM Dose=1uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B
BC-48-WT15_0.01uM Dose=0.01uM, Thymidine Phosphorylase Inhibitors targeting TYMP
BC-48-WT15_0.1uM Dose=0.1uM, Thymidine Phosphorylase Inhibitors targeting TYMP
BC-48-WT15_10uM Dose=10uM, Thymidine Phosphorylase Inhibitors targeting TYMP
BC-48-WT15_1uM Dose=1uM, Thymidine Phosphorylase Inhibitors targeting TYMP
BC-50-TK39_0.01uM Dose=0.01uM, Vpc23019, Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg8 (S1P5) Receptor Partial Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Antagonists targeting S1PR1, S1PR3, S1PR4, S1PR5
BC-50-TK39_0.1uM Dose=0.1uM, Vpc23019, Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg8 (S1P5) Receptor Partial Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Antagonists targeting S1PR1, S1PR3, S1PR4, S1PR5
BC-50-TK39_10uM Dose=10uM, Vpc23019, Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg8 (S1P5) Receptor Partial Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Antagonists targeting S1PR1, S1PR3, S1PR4, S1PR5
BC-51-ME52_0.01uM Dose=0.01uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1
BC-51-ME52_0.1uM Dose=0.1uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1
BC-51-ME52_10uM Dose=10uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1
BC-51-ME52_1uM Dose=1uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1
BC-52-NW28_0.01uM Dose=0.01uM, Icmt-IN-1, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT
BC-52-NW28_0.1uM Dose=0.1uM, Icmt-IN-1, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT
BC-52-NW28_1uM Dose=1uM, Icmt-IN-1, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT
BC-52-WF67_0.01uM Dose=0.01uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR
BC-52-WF67_0.1uM Dose=0.1uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR
BC-52-WF67_10uM Dose=10uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR
BC-52-WF67_1uM Dose=1uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR
BC-53-HT63_0.01uM Dose=0.01uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5
BC-53-HT63_0.1uM Dose=0.1uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5
BC-53-HT63_10uM Dose=10uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5
BC-53-HT63_1uM Dose=1uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5
BC-54-ON71_0.01uM Dose=0.01uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5
BC-54-ON71_0.1uM Dose=0.1uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5
BC-54-ON71_10uM Dose=10uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5
BC-54-ON71_1uM Dose=1uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5
BC-55-CK01_0.1uM Dose=0.1uM, 3-(Benzofuran-2-yl)-1-azabicyclo[2.2.2]oct-2-ene, Muscarinic M1 Agonists targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BC-55-CK01_10uM Dose=10uM, 3-(Benzofuran-2-yl)-1-azabicyclo[2.2.2]oct-2-ene, Muscarinic M1 Agonists targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BC-56-BB82_0.01uM Dose=0.01uM, N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide, LIM kinase-1 inhibitor;LIM kinase-2 inhibitor targeting LIMK1, LIMK2
BC-56-BB82_10uM Dose=10uM, N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide, LIM kinase-1 inhibitor;LIM kinase-2 inhibitor targeting LIMK1, LIMK2
BC-56-BB82_1uM Dose=1uM, N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide, LIM kinase-1 inhibitor;LIM kinase-2 inhibitor targeting LIMK1, LIMK2
BC-56-CP81_0.01uM Dose=0.01uM, Adefovir Dipivoxil
BC-56-CP81_0.1uM Dose=0.1uM, Adefovir Dipivoxil
BC-56-CP81_10uM Dose=10uM, Adefovir Dipivoxil
BC-56-CP81_1uM Dose=1uM, Adefovir Dipivoxil
BC-56-WO88_0.01uM Dose=0.01uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5
BC-56-WO88_0.1uM Dose=0.1uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5
BC-56-WO88_10uM Dose=10uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5
BC-56-WO88_1uM Dose=1uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5
BC-57-KZ72_0.01uM Dose=0.01uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1
BC-57-KZ72_0.1uM Dose=0.1uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1
BC-57-KZ72_10uM Dose=10uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1
BC-57-KZ72_1uM Dose=1uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1
BC-60-TS99_0.01uM Dose=0.01uM, 1-[4-[4-[1-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists targeting LPAR1
BC-60-TS99_10uM Dose=10uM, 1-[4-[4-[1-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists targeting LPAR1
BC-61-BE07_0.01uM Dose=0.01uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1
BC-61-BE07_0.1uM Dose=0.1uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1
BC-61-BE07_10uM Dose=10uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1
BC-61-BE07_1uM Dose=1uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1
BC-61-ZY95_0.01uM Dose=0.01uM
BC-61-ZY95_0.1uM Dose=0.1uM
BC-61-ZY95_10uM Dose=10uM
BC-61-ZY95_1uM Dose=1uM
BC-62-RZ55_0.01uM Dose=0.01uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4
BC-62-RZ55_0.1uM Dose=0.1uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4
BC-62-RZ55_10uM Dose=10uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4
BC-62-RZ55_1uM Dose=1uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4
BC-63-DM76_0.01uM Dose=0.01uM, Cgs 22745
BC-63-DM76_0.1uM Dose=0.1uM, Cgs 22745
BC-63-DM76_10uM Dose=10uM, Cgs 22745
BC-63-DM76_1uM Dose=1uM, Cgs 22745
BC-65-QR83_0.01uM Dose=0.01uM, Pregnanolone, GABA(A) Receptor Modulators targeting GABRA1, GABRB2
BC-65-QR83_0.1uM Dose=0.1uM, Pregnanolone, GABA(A) Receptor Modulators targeting GABRA1, GABRB2
BC-65-QR83_1uM Dose=1uM, Pregnanolone, GABA(A) Receptor Modulators targeting GABRA1, GABRB2
BC-69-CQ95_0.1uM Dose=0.1uM
BC-69-CQ95_1uM Dose=1uM
BC-70-BH47_0.01uM Dose=0.01uM, Treprostinil, Prostacyclin Analogs targeting PTGIR
BC-70-BH47_0.1uM Dose=0.1uM, Treprostinil, Prostacyclin Analogs targeting PTGIR
BC-70-BH47_10uM Dose=10uM, Treprostinil, Prostacyclin Analogs targeting PTGIR
BC-72-DZ30_0.01uM Dose=0.01uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1
BC-72-DZ30_0.1uM Dose=0.1uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1
BC-72-DZ30_10uM Dose=10uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1
BC-72-DZ30_1uM Dose=1uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1
BC-74-QN56_0.01uM Dose=0.01uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A
BC-74-QN56_0.1uM Dose=0.1uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A
BC-74-QN56_10uM Dose=10uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A
BC-74-QN56_1uM Dose=1uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A
BC-75-CK91_0.01uM Dose=0.01uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK
BC-75-CK91_0.1uM Dose=0.1uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK
BC-75-CK91_10uM Dose=10uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK
BC-75-CK91_1uM Dose=1uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK
BC-75-FA82_0.01uM Dose=0.01uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1
BC-75-FA82_0.1uM Dose=0.1uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1
BC-75-FA82_10uM Dose=10uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1
BC-75-FA82_1uM Dose=1uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1
BC-76-HY47_0.01uM Dose=0.01uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1
BC-76-HY47_0.1uM Dose=0.1uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1
BC-76-HY47_10uM Dose=10uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1
BC-76-HY47_1uM Dose=1uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1
BC-78-NC89_0.01uM Dose=0.01uM, [(1R,3R)-1-methyl-1-(3-phenylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BC-78-NC89_0.1uM Dose=0.1uM, [(1R,3R)-1-methyl-1-(3-phenylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BC-78-NC89_1uM Dose=1uM, [(1R,3R)-1-methyl-1-(3-phenylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
BC-80-FK74_0.01uM Dose=0.01uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1
BC-80-FK74_0.1uM Dose=0.1uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1
BC-80-FK74_10uM Dose=10uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1
BC-80-FK74_1uM Dose=1uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1
BC-81-LO06_0.01uM Dose=0.01uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde
BC-81-LO06_0.1uM Dose=0.1uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde
BC-81-LO06_10uM Dose=10uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde
BC-81-LO06_1uM Dose=1uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde
BC-82-PP66_0.01uM Dose=0.01uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A
BC-82-PP66_0.1uM Dose=0.1uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A
BC-82-PP66_10uM Dose=10uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A
BC-82-PP66_1uM Dose=1uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A
BC-84-BQ58_0.01uM Dose=0.01uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1
BC-84-BQ58_0.1uM Dose=0.1uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1
BC-84-BQ58_10uM Dose=10uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1
BC-84-BQ58_1uM Dose=1uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1
BC-85-QR33_0.01uM Dose=0.01uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF
BC-85-QR33_0.1uM Dose=0.1uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF
BC-85-QR33_10uM Dose=10uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF
BC-85-QR33_1uM Dose=1uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF
BC-86-PL11_0.01uM Dose=0.01uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF
BC-86-PL11_0.1uM Dose=0.1uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF
BC-86-PL11_10uM Dose=10uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF
BC-86-PL11_1uM Dose=1uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF
BC-87-PJ84_10uM Dose=10uM, Urapidil, alpha1-Adrenoceptor Antagonists targeting ADRA1B
BC-87-PJ84_1uM Dose=1uM, Urapidil, alpha1-Adrenoceptor Antagonists targeting ADRA1B
BC-87-ZP43_0.01uM Dose=0.01uM, alpha-Cyano-4-hydroxycinnamic acid, Monocarboxylate Transporter 1 (MCT1) Inhibitors targeting SLC16A1
BC-87-ZP43_0.1uM Dose=0.1uM, alpha-Cyano-4-hydroxycinnamic acid, Monocarboxylate Transporter 1 (MCT1) Inhibitors targeting SLC16A1
BC-87-ZP43_10uM Dose=10uM, alpha-Cyano-4-hydroxycinnamic acid, Monocarboxylate Transporter 1 (MCT1) Inhibitors targeting SLC16A1
BC-87-ZP43_1uM Dose=1uM, alpha-Cyano-4-hydroxycinnamic acid, Monocarboxylate Transporter 1 (MCT1) Inhibitors targeting SLC16A1
BC-88-KT45_0.01uM Dose=0.01uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2
BC-88-KT45_0.1uM Dose=0.1uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2
BC-88-KT45_10uM Dose=10uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2
BC-88-KT45_1uM Dose=1uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2
BC-91-YI62_0.01uM Dose=0.01uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3
BC-91-YI62_0.1uM Dose=0.1uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3
BC-91-YI62_10uM Dose=10uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3
BC-91-YI62_1uM Dose=1uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3
BC-94-GN01_0.01uM Dose=0.01uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1
BC-94-GN01_0.1uM Dose=0.1uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1
BC-94-GN01_10uM Dose=10uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1
BC-94-GN01_1uM Dose=1uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1
BC-94-PR16_10uM Dose=10uM, 5-[({3-[(3,4-Dichlorobenzyl)sulfanyl]thiophen-2-Yl}carbonyl)sulfamoyl]-2-Methoxybenzoic Acid targeting PTPRG
BC-95-MO06_0.01uM Dose=0.01uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D
BC-95-MO06_0.1uM Dose=0.1uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D
BC-95-MO06_10uM Dose=10uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D
BC-95-MO06_1uM Dose=1uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D
BC-97-SZ42_0.01uM Dose=0.01uM, (R)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine, Known Gamma secretase modulator targeting PSEN2
BC-97-SZ42_10uM Dose=10uM, (R)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine, Known Gamma secretase modulator targeting PSEN2
BC-97-SZ42_1uM Dose=1uM, (R)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine, Known Gamma secretase modulator targeting PSEN2
BD-01-HE32_0.01uM Dose=0.01uM
BD-01-HE32_1uM Dose=1uM
BD-01-RI07_0.01uM Dose=0.01uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC
BD-01-RI07_0.1uM Dose=0.1uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC
BD-01-RI07_10uM Dose=10uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC
BD-01-RI07_1uM Dose=1uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC
BD-02-US28_0.01uM Dose=0.01uM, Nvp-qav-680, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting PTGDR2
BD-02-US28_0.1uM Dose=0.1uM, Nvp-qav-680, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting PTGDR2
BD-02-US28_10uM Dose=10uM, Nvp-qav-680, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting PTGDR2
BD-04-IN11_0.01uM Dose=0.01uM, 3-Bromo-9-phenyl-5,7-dihydro-10-oxa-5,8-diaza-benzo[a]azulen-6-one, P2X4 Receptor Antagonists targeting P2RX4
BD-04-IN11_10uM Dose=10uM, 3-Bromo-9-phenyl-5,7-dihydro-10-oxa-5,8-diaza-benzo[a]azulen-6-one, P2X4 Receptor Antagonists targeting P2RX4
BD-04-NG34_0.01uM Dose=0.01uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2
BD-04-NG34_0.1uM Dose=0.1uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2
BD-04-NG34_10uM Dose=10uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2
BD-04-NG34_1uM Dose=1uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2
BD-06-VI74_0.1uM Dose=0.1uM, Bezafibrate, PPARgamma Agonists;PPARalpha Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;PPARdelta Agonists;HSD11B1 Expression Inhibitors targeting HSD11B1, PPARA, PPARD, PPARG
BD-06-VI74_10uM Dose=10uM, Bezafibrate, PPARgamma Agonists;PPARalpha Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;PPARdelta Agonists;HSD11B1 Expression Inhibitors targeting HSD11B1, PPARA, PPARD, PPARG
BD-07-IW65_0.01uM Dose=0.01uM
BD-07-IW65_0.1uM Dose=0.1uM
BD-07-IW65_10uM Dose=10uM
BD-07-IW65_1uM Dose=1uM
BD-10-ZH17_0.1uM Dose=0.1uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR
BD-10-ZH17_10uM Dose=10uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR
BD-10-ZH17_1uM Dose=1uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR
BD-11-DV28_10uM Dose=10uM
BD-12-CM09_0.01uM Dose=0.01uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3
BD-12-CM09_0.1uM Dose=0.1uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3
BD-12-CM09_10uM Dose=10uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3
BD-12-CM09_1uM Dose=1uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3
BD-15-VR68_0.01uM Dose=0.01uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1
BD-15-VR68_0.1uM Dose=0.1uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1
BD-15-VR68_10uM Dose=10uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1
BD-15-VR68_1uM Dose=1uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1
BD-17-LT43_0.01uM Dose=0.01uM, 3-((6-((5-Chloropyridin-2-yl)amino)pyrimidin-4-yl)amino)-4-(ethylsulfonyl)-N-methylbenzenesulfonamide, Tnni3 kinase inhibitor targeting TNNI3K
BD-17-LT43_0.1uM Dose=0.1uM, 3-((6-((5-Chloropyridin-2-yl)amino)pyrimidin-4-yl)amino)-4-(ethylsulfonyl)-N-methylbenzenesulfonamide, Tnni3 kinase inhibitor targeting TNNI3K
BD-17-LT43_10uM Dose=10uM, 3-((6-((5-Chloropyridin-2-yl)amino)pyrimidin-4-yl)amino)-4-(ethylsulfonyl)-N-methylbenzenesulfonamide, Tnni3 kinase inhibitor targeting TNNI3K
BD-18-FM58_0.01uM Dose=0.01uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
BD-18-FM58_0.1uM Dose=0.1uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
BD-18-FM58_10uM Dose=10uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
BD-18-FM58_1uM Dose=1uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
BD-18-MM33_0.01uM Dose=0.01uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
BD-18-MM33_0.1uM Dose=0.1uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
BD-18-MM33_10uM Dose=10uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
BD-18-MM33_1uM Dose=1uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
BD-18-XC74_0.01uM Dose=0.01uM, Nitrendipine, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
BD-18-XC74_10uM Dose=10uM, Nitrendipine, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
BD-18-XC74_1uM Dose=1uM, Nitrendipine, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S
BD-19-MD69_0.01uM Dose=0.01uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4
BD-19-MD69_0.1uM Dose=0.1uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4
BD-19-MD69_10uM Dose=10uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4
BD-19-MD69_1uM Dose=1uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4
BD-22-KS33_0.01uM Dose=0.01uM, Aptazapine, ADRA2A antagonist targeting ADRA2A
BD-22-KS33_0.1uM Dose=0.1uM, Aptazapine, ADRA2A antagonist targeting ADRA2A
BD-22-KS33_10uM Dose=10uM, Aptazapine, ADRA2A antagonist targeting ADRA2A
BD-22-KS33_1uM Dose=1uM, Aptazapine, ADRA2A antagonist targeting ADRA2A
BD-23-MT28_0.01uM Dose=0.01uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR
BD-23-MT28_0.1uM Dose=0.1uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR
BD-23-MT28_10uM Dose=10uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR
BD-23-MT28_1uM Dose=1uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR
BD-25-SA37_0.01uM Dose=0.01uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
BD-25-SA37_0.1uM Dose=0.1uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
BD-25-SA37_10uM Dose=10uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
BD-25-SA37_1uM Dose=1uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
BD-26-EO58_0.01uM Dose=0.01uM, Norharman, Indoleamine 2,3-dioxygenase Inhibitors;MAO-B Inhibitors targeting IDO1, MAOB
BD-26-EO58_0.1uM Dose=0.1uM, Norharman, Indoleamine 2,3-dioxygenase Inhibitors;MAO-B Inhibitors targeting IDO1, MAOB
BD-26-EO58_1uM Dose=1uM, Norharman, Indoleamine 2,3-dioxygenase Inhibitors;MAO-B Inhibitors targeting IDO1, MAOB
BD-27-CC87_0.01uM Dose=0.01uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13
BD-27-CC87_0.1uM Dose=0.1uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13
BD-27-CC87_10uM Dose=10uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13
BD-27-CC87_1uM Dose=1uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13
BD-29-IQ20_0.01uM Dose=0.01uM, Tyrphostin AG 555, CDK2 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK2
BD-29-IQ20_0.1uM Dose=0.1uM, Tyrphostin AG 555, CDK2 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK2
BD-29-IQ20_10uM Dose=10uM, Tyrphostin AG 555, CDK2 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK2
BD-29-IQ20_1uM Dose=1uM, Tyrphostin AG 555, CDK2 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK2
BD-31-AE17_0.01uM Dose=0.01uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1
BD-31-AE17_0.1uM Dose=0.1uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1
BD-31-AE17_10uM Dose=10uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1
BD-31-AE17_1uM Dose=1uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1
BD-32-GI59_0.01uM Dose=0.01uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D
BD-32-GI59_0.1uM Dose=0.1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D
BD-32-GI59_10uM Dose=10uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D
BD-32-GI59_1uM Dose=1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D
BD-33-HT38_0.01uM Dose=0.01uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1
BD-33-HT38_0.1uM Dose=0.1uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1
BD-33-HT38_10uM Dose=10uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1
BD-33-HT38_1uM Dose=1uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1
BD-34-PN26_0.01uM Dose=0.01uM
BD-34-PN26_0.1uM Dose=0.1uM
BD-34-PN26_10uM Dose=10uM
BD-34-PN26_1uM Dose=1uM
BD-36-VB52_0.01uM Dose=0.01uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1
BD-36-VB52_0.1uM Dose=0.1uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1
BD-36-VB52_10uM Dose=10uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1
BD-36-VB52_1uM Dose=1uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1
BD-38-GC64_0.01uM Dose=0.01uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5
BD-38-GC64_0.1uM Dose=0.1uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5
BD-38-GC64_10uM Dose=10uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5
BD-38-QC39_0.01uM Dose=0.01uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7
BD-38-QC39_0.1uM Dose=0.1uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7
BD-38-QC39_10uM Dose=10uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7
BD-38-QC39_1uM Dose=1uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7
BD-39-KG21_0.01uM Dose=0.01uM, Selegiline, MAO-B Inhibitors targeting MAOB
BD-39-KG21_0.1uM Dose=0.1uM, Selegiline, MAO-B Inhibitors targeting MAOB
BD-39-KG21_10uM Dose=10uM, Selegiline, MAO-B Inhibitors targeting MAOB
BD-39-KG21_1uM Dose=1uM, Selegiline, MAO-B Inhibitors targeting MAOB
BD-40-EK64_0.01uM Dose=0.01uM, Terbuficin, LDL Antioxidants targeting ABCA1
BD-40-EK64_10uM Dose=10uM, Terbuficin, LDL Antioxidants targeting ABCA1
BD-40-EK64_1uM Dose=1uM, Terbuficin, LDL Antioxidants targeting ABCA1
BD-41-DB55_0.01uM Dose=0.01uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3
BD-41-DB55_0.1uM Dose=0.1uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3
BD-41-DB55_10uM Dose=10uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3
BD-41-DB55_1uM Dose=1uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3
BD-41-DI77_0.01uM Dose=0.01uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A
BD-41-DI77_0.1uM Dose=0.1uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A
BD-41-DI77_10uM Dose=10uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A
BD-41-DI77_1uM Dose=1uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A
BD-44-FH87_0.01uM Dose=0.01uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1
BD-44-FH87_0.1uM Dose=0.1uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1
BD-44-FH87_10uM Dose=10uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1
BD-44-FH87_1uM Dose=1uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1
BD-45-EU45_0.01uM Dose=0.01uM, 3-fluoro-4-[(5S)-7-[(4-fluorophenyl)methyl]-6-oxo-5-propyl-8H-imidazo[1,5-a]pyrazin-5-yl]benzonitrile
BD-45-EU45_0.1uM Dose=0.1uM, 3-fluoro-4-[(5S)-7-[(4-fluorophenyl)methyl]-6-oxo-5-propyl-8H-imidazo[1,5-a]pyrazin-5-yl]benzonitrile
BD-45-EU45_10uM Dose=10uM, 3-fluoro-4-[(5S)-7-[(4-fluorophenyl)methyl]-6-oxo-5-propyl-8H-imidazo[1,5-a]pyrazin-5-yl]benzonitrile
BD-45-WH14_0.01uM Dose=0.01uM, HC067047, TRPV4 gene inhibitor targeting TRPV4
BD-45-WH14_0.1uM Dose=0.1uM, HC067047, TRPV4 gene inhibitor targeting TRPV4
BD-45-WH14_10uM Dose=10uM, HC067047, TRPV4 gene inhibitor targeting TRPV4
BD-45-WH14_1uM Dose=1uM, HC067047, TRPV4 gene inhibitor targeting TRPV4
BD-46-RY02_0.01uM Dose=0.01uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1
BD-46-RY02_0.1uM Dose=0.1uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1
BD-46-RY02_10uM Dose=10uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1
BD-46-RY02_1uM Dose=1uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1
BD-47-DS20_0.01uM Dose=0.01uM, Cgs 22652, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1
BD-47-DS20_0.1uM Dose=0.1uM, Cgs 22652, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1
BD-47-DS20_1uM Dose=1uM, Cgs 22652, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1
BD-47-NP88_0.01uM Dose=0.01uM, A-967079, TRPA1 Antagonists targeting TRPA1
BD-47-NP88_0.1uM Dose=0.1uM, A-967079, TRPA1 Antagonists targeting TRPA1
BD-47-NP88_10uM Dose=10uM, A-967079, TRPA1 Antagonists targeting TRPA1
BD-47-NP88_1uM Dose=1uM, A-967079, TRPA1 Antagonists targeting TRPA1
BD-48-JW52_0.01uM Dose=0.01uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR
BD-48-JW52_0.1uM Dose=0.1uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR
BD-48-JW52_10uM Dose=10uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR
BD-48-JW52_1uM Dose=1uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR
BD-48-ZT65_0.01uM Dose=0.01uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide
BD-48-ZT65_0.1uM Dose=0.1uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide
BD-48-ZT65_10uM Dose=10uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide
BD-48-ZT65_1uM Dose=1uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide
BD-49-MD69_0.01uM Dose=0.01uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2
BD-49-MD69_0.1uM Dose=0.1uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2
BD-49-MD69_10uM Dose=10uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2
BD-49-MD69_1uM Dose=1uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2
BD-50-HU68_0.01uM Dose=0.01uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2
BD-50-HU68_0.1uM Dose=0.1uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2
BD-50-HU68_10uM Dose=10uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2
BD-50-HU68_1uM Dose=1uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2
BD-51-DB15_0.01uM Dose=0.01uM, 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid
BD-51-DB15_0.1uM Dose=0.1uM, 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid
BD-51-DB15_10uM Dose=10uM, 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid
BD-51-DB15_1uM Dose=1uM, 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid
BD-58-PT20_0.01uM Dose=0.01uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2
BD-58-PT20_0.1uM Dose=0.1uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2
BD-58-PT20_10uM Dose=10uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2
BD-58-PT20_1uM Dose=1uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2
BD-58-PW57_10uM Dose=10uM, Carbonyl Cyanide m-Chlorophenyl Hydrazone
BD-58-PW57_1uM Dose=1uM, Carbonyl Cyanide m-Chlorophenyl Hydrazone
BD-59-MG06_0.01uM Dose=0.01uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8
BD-59-MG06_0.1uM Dose=0.1uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8
BD-59-MG06_10uM Dose=10uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8
BD-59-MG06_1uM Dose=1uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8
BD-59-TG01_0.1uM Dose=0.1uM, 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
BD-59-TG01_10uM Dose=10uM, 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
BD-59-TG01_1uM Dose=1uM, 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
BD-60-DR81_0.01uM Dose=0.01uM, KDM5A inhibitor targeting KDM5A
BD-60-DR81_0.1uM Dose=0.1uM, KDM5A inhibitor targeting KDM5A
BD-60-DR81_10uM Dose=10uM, KDM5A inhibitor targeting KDM5A
BD-60-DR81_1uM Dose=1uM, KDM5A inhibitor targeting KDM5A
BD-60-XA25_0.01uM Dose=0.01uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine
BD-60-XA25_0.1uM Dose=0.1uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine
BD-60-XA25_10uM Dose=10uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine
BD-60-ZK54_0.01uM Dose=0.01uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
BD-60-ZK54_0.1uM Dose=0.1uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
BD-60-ZK54_10uM Dose=10uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
BD-60-ZK54_1uM Dose=1uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
BD-61-OO16_0.01uM Dose=0.01uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
BD-61-OO16_0.1uM Dose=0.1uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
BD-61-OO16_10uM Dose=10uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
BD-61-OO16_1uM Dose=1uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
BD-62-ZF67_0.01uM Dose=0.01uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1
BD-62-ZF67_0.1uM Dose=0.1uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1
BD-62-ZF67_10uM Dose=10uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1
BD-62-ZF67_1uM Dose=1uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1
BD-63-JC77_0.01uM Dose=0.01uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester
BD-63-JC77_0.1uM Dose=0.1uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester
BD-63-JC77_10uM Dose=10uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester
BD-63-JC77_1uM Dose=1uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester
BD-63-KJ69_0.01uM Dose=0.01uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR
BD-63-KJ69_0.1uM Dose=0.1uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR
BD-63-KJ69_10uM Dose=10uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR
BD-63-KJ69_1uM Dose=1uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR
BD-65-VV48_0.01uM Dose=0.01uM, Mesalamine, PPAR Gamma Inhibitor;Non-Steroidal Antiinflammatory Drugs targeting PPARG
BD-65-VV48_10uM Dose=10uM, Mesalamine, PPAR Gamma Inhibitor;Non-Steroidal Antiinflammatory Drugs targeting PPARG
BD-65-VV48_1uM Dose=1uM, Mesalamine, PPAR Gamma Inhibitor;Non-Steroidal Antiinflammatory Drugs targeting PPARG
BD-66-QO48_0.01uM Dose=0.01uM, 2-[[1-Cyclopentyl-5-[1-(Oxetan-3-Yl)piperidin-4-Yl]pyrazol-3-Yl]amino]pyridine-4-Carbonitrile, DLK Inhibitor targeting MAP3K12
BD-66-QO48_0.1uM Dose=0.1uM, 2-[[1-Cyclopentyl-5-[1-(Oxetan-3-Yl)piperidin-4-Yl]pyrazol-3-Yl]amino]pyridine-4-Carbonitrile, DLK Inhibitor targeting MAP3K12
BD-66-QO48_10uM Dose=10uM, 2-[[1-Cyclopentyl-5-[1-(Oxetan-3-Yl)piperidin-4-Yl]pyrazol-3-Yl]amino]pyridine-4-Carbonitrile, DLK Inhibitor targeting MAP3K12
BD-66-TZ80_0.01uM Dose=0.01uM, Bicalutamide, Androgen Receptor Antagonists targeting AR, CYP27A1
BD-66-TZ80_0.1uM Dose=0.1uM, Bicalutamide, Androgen Receptor Antagonists targeting AR, CYP27A1
BD-66-TZ80_1uM Dose=1uM, Bicalutamide, Androgen Receptor Antagonists targeting AR, CYP27A1
BD-68-PM33_0.01uM Dose=0.01uM, Crt 0066101, protein kinase d inhibitor targeting PKD1
BD-68-PM33_0.1uM Dose=0.1uM, Crt 0066101, protein kinase d inhibitor targeting PKD1
BD-68-PM33_10uM Dose=10uM, Crt 0066101, protein kinase d inhibitor targeting PKD1
BD-68-PM33_1uM Dose=1uM, Crt 0066101, protein kinase d inhibitor targeting PKD1
BD-68-ZT55_0.01uM Dose=0.01uM, Triclosan
BD-68-ZT55_0.1uM Dose=0.1uM, Triclosan
BD-68-ZT55_10uM Dose=10uM, Triclosan
BD-68-ZT55_1uM Dose=1uM, Triclosan
BD-69-GX17_0.01uM Dose=0.01uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6
BD-69-GX17_0.1uM Dose=0.1uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6
BD-69-GX17_10uM Dose=10uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6
BD-69-GX17_1uM Dose=1uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6
BD-69-XG81_0.01uM Dose=0.01uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1
BD-69-XG81_0.1uM Dose=0.1uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1
BD-69-XG81_10uM Dose=10uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1
BD-69-XG81_1uM Dose=1uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1
BD-69-YD09_0.01uM Dose=0.01uM, FK-1706, Neurotrophic Agents targeting FKBP1A, FKBP4
BD-69-YD09_0.1uM Dose=0.1uM, FK-1706, Neurotrophic Agents targeting FKBP1A, FKBP4
BD-69-YD09_10uM Dose=10uM, FK-1706, Neurotrophic Agents targeting FKBP1A, FKBP4
BD-70-EK54_0.01uM Dose=0.01uM
BD-70-EK54_0.1uM Dose=0.1uM
BD-70-EK54_10uM Dose=10uM
BD-70-EK54_1uM Dose=1uM
BD-70-PH02_0.01uM Dose=0.01uM
BD-70-PH02_0.1uM Dose=0.1uM
BD-70-PH02_10uM Dose=10uM
BD-70-PH02_1uM Dose=1uM
BD-73-TX58_0.01uM Dose=0.01uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8
BD-73-TX58_0.1uM Dose=0.1uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8
BD-73-TX58_10uM Dose=10uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8
BD-73-TX58_1uM Dose=1uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8
BD-74-LH52_0.01uM Dose=0.01uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL
BD-74-LH52_0.1uM Dose=0.1uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL
BD-74-LH52_10uM Dose=10uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL
BD-74-LH52_1uM Dose=1uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL
BD-78-MJ16_0.01uM Dose=0.01uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3
BD-78-MJ16_0.1uM Dose=0.1uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3
BD-78-MJ16_10uM Dose=10uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3
BD-78-MJ16_1uM Dose=1uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3
BD-80-SK69_0.01uM Dose=0.01uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7
BD-80-SK69_0.1uM Dose=0.1uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7
BD-80-SK69_10uM Dose=10uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7
BD-80-SK69_1uM Dose=1uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7
BD-81-FB30_0.01uM Dose=0.01uM
BD-81-FB30_0.1uM Dose=0.1uM
BD-81-FB30_10uM Dose=10uM
BD-81-FB30_1uM Dose=1uM
BD-81-LB65_0.01uM Dose=0.01uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1
BD-81-LB65_0.1uM Dose=0.1uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1
BD-81-LB65_10uM Dose=10uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1
BD-81-LB65_1uM Dose=1uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1
BD-82-NF37_0.1uM Dose=0.1uM
BD-82-NF37_10uM Dose=10uM
BD-82-NF37_1uM Dose=1uM
BD-83-QC82_0.01uM Dose=0.01uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
BD-83-QC82_0.1uM Dose=0.1uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
BD-83-QC82_10uM Dose=10uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
BD-83-QC82_1uM Dose=1uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
BD-83-UC82_0.01uM Dose=0.01uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2
BD-83-UC82_0.1uM Dose=0.1uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2
BD-83-UC82_10uM Dose=10uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2
BD-83-UC82_1uM Dose=1uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2
BD-84-ZR31_0.01uM Dose=0.01uM, (1S,2S,5S,8R,9S,10S,11R,15S)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one targeting NLRP3
BD-84-ZR31_0.1uM Dose=0.1uM, (1S,2S,5S,8R,9S,10S,11R,15S)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one targeting NLRP3
BD-84-ZR31_10uM Dose=10uM, (1S,2S,5S,8R,9S,10S,11R,15S)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one targeting NLRP3
BD-85-AU55_10uM Dose=10uM, N-[1-[4-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]phenyl]cyclopropyl]acetamide
BD-85-GY20_0.01uM Dose=0.01uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3
BD-85-GY20_0.1uM Dose=0.1uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3
BD-85-GY20_10uM Dose=10uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3
BD-85-GY20_1uM Dose=1uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3
BD-85-IA32_0.01uM Dose=0.01uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BD-85-IA32_0.1uM Dose=0.1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BD-85-IA32_10uM Dose=10uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BD-85-IA32_1uM Dose=1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BD-85-OV63_0.01uM Dose=0.01uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR
BD-85-OV63_0.1uM Dose=0.1uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR
BD-85-OV63_10uM Dose=10uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR
BD-85-OV63_1uM Dose=1uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR
BD-85-VR28_0.01uM Dose=0.01uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol
BD-85-VR28_0.1uM Dose=0.1uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol
BD-85-VR28_10uM Dose=10uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol
BD-85-VR28_1uM Dose=1uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol
BD-90-DK64_0.01uM Dose=0.01uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1
BD-90-DK64_0.1uM Dose=0.1uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1
BD-90-DK64_10uM Dose=10uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1
BD-90-DK64_1uM Dose=1uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1
BD-90-SE75_0.1uM Dose=0.1uM, Rilmenidine, Imidazoline I1 Receptor Agonists targeting NISCH
BD-90-SE75_10uM Dose=10uM, Rilmenidine, Imidazoline I1 Receptor Agonists targeting NISCH
BD-90-SE75_1uM Dose=1uM, Rilmenidine, Imidazoline I1 Receptor Agonists targeting NISCH
BD-93-AM31_0.01uM Dose=0.01uM, Veliparib targeting PARP1, PARP2
BD-93-AM31_0.1uM Dose=0.1uM, Veliparib targeting PARP1, PARP2
BD-93-AM31_10uM Dose=10uM, Veliparib targeting PARP1, PARP2
BD-93-AM31_1uM Dose=1uM, Veliparib targeting PARP1, PARP2
BD-94-KU93_0.01uM Dose=0.01uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA
BD-94-KU93_0.1uM Dose=0.1uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA
BD-94-KU93_10uM Dose=10uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA
BD-94-KU93_1uM Dose=1uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA
BD-96-HO33_0.01uM Dose=0.01uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1
BD-96-HO33_0.1uM Dose=0.1uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1
BD-96-HO33_10uM Dose=10uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1
BD-96-HO33_1uM Dose=1uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1
BD-97-PP33_0.01uM Dose=0.01uM, Sonlicromanol
BD-97-PP33_0.1uM Dose=0.1uM, Sonlicromanol
BD-97-PP33_10uM Dose=10uM, Sonlicromanol
BD-97-PP33_1uM Dose=1uM, Sonlicromanol
BD-98-TG79_0.01uM Dose=0.01uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9
BD-98-TG79_0.1uM Dose=0.1uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9
BD-98-TG79_10uM Dose=10uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9
BD-98-TG79_1uM Dose=1uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9
BD-98-XW77_0.01uM Dose=0.01uM
BD-98-XW77_0.1uM Dose=0.1uM
BD-98-XW77_10uM Dose=10uM
BD-98-XW77_1uM Dose=1uM
BD-99-DU20_0.01uM Dose=0.01uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1
BD-99-DU20_0.1uM Dose=0.1uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1
BD-99-DU20_10uM Dose=10uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1
BD-99-DU20_1uM Dose=1uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1
BE-03-XC62_0.01uM Dose=0.01uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2
BE-03-XC62_0.1uM Dose=0.1uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2
BE-03-XC62_10uM Dose=10uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2
BE-03-XC62_1uM Dose=1uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2
BE-04-AN21_0.01uM Dose=0.01uM, Mdm2 p53-binding protein inhibitor targeting MDM2
BE-04-AN21_0.1uM Dose=0.1uM, Mdm2 p53-binding protein inhibitor targeting MDM2
BE-04-AN21_10uM Dose=10uM, Mdm2 p53-binding protein inhibitor targeting MDM2
BE-04-AN21_1uM Dose=1uM, Mdm2 p53-binding protein inhibitor targeting MDM2
BE-05-KR03_0.01uM Dose=0.01uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK
BE-05-KR03_0.1uM Dose=0.1uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK
BE-05-KR03_10uM Dose=10uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK
BE-05-KR03_1uM Dose=1uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK
BE-07-BZ97_0.01uM Dose=0.01uM, 2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide targeting GHSR
BE-07-BZ97_0.1uM Dose=0.1uM, 2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide targeting GHSR
BE-07-BZ97_1uM Dose=1uM, 2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide targeting GHSR
BE-07-IS45_0.01uM Dose=0.01uM, Antalarmin, CRHR1 antagonist targeting CRHR1
BE-07-IS45_0.1uM Dose=0.1uM, Antalarmin, CRHR1 antagonist targeting CRHR1
BE-07-IS45_10uM Dose=10uM, Antalarmin, CRHR1 antagonist targeting CRHR1
BE-07-IS45_1uM Dose=1uM, Antalarmin, CRHR1 antagonist targeting CRHR1
BE-07-NI91_0.01uM Dose=0.01uM, Isradipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNB2, CACNA1H, CACNA2D2
BE-07-NI91_10uM Dose=10uM, Isradipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNB2, CACNA1H, CACNA2D2
BE-07-NI91_1uM Dose=1uM, Isradipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNB2, CACNA1H, CACNA2D2
BE-07-XF09_0.01uM Dose=0.01uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2
BE-07-XF09_0.1uM Dose=0.1uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2
BE-07-XF09_10uM Dose=10uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2
BE-07-XF09_1uM Dose=1uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2
BE-07-XI66_0.01uM Dose=0.01uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BE-07-XI66_0.1uM Dose=0.1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BE-07-XI66_10uM Dose=10uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BE-07-XI66_1uM Dose=1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3
BE-09-HN23_0.01uM Dose=0.01uM, Sligrl-NH2, F2RL1 agonist targeting F2RL1
BE-09-HN23_0.1uM Dose=0.1uM, Sligrl-NH2, F2RL1 agonist targeting F2RL1
BE-09-HN23_10uM Dose=10uM, Sligrl-NH2, F2RL1 agonist targeting F2RL1
BE-10-NK39_0.1uM Dose=0.1uM, Nbi-30775, CRF1 Antagonists targeting CRHR1
BE-10-NK39_10uM Dose=10uM, Nbi-30775, CRF1 Antagonists targeting CRHR1
BE-10-NK39_1uM Dose=1uM, Nbi-30775, CRF1 Antagonists targeting CRHR1
BE-13-XC52_0.01uM Dose=0.01uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1
BE-13-XC52_0.1uM Dose=0.1uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1
BE-13-XC52_10uM Dose=10uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1
BE-13-XC52_1uM Dose=1uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1
BE-15-IE57_0.01uM Dose=0.01uM, 2-(Butane-1-sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno(2,3-b)pyridin-3-amine, Prostaglandin-degrading enzyme 15-PGDH inhibitor;inhibitor of the prostaglandin-degrading enzyme 15-PGDH targeting HPGD
BE-15-IE57_1uM Dose=1uM, 2-(Butane-1-sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno(2,3-b)pyridin-3-amine, Prostaglandin-degrading enzyme 15-PGDH inhibitor;inhibitor of the prostaglandin-degrading enzyme 15-PGDH targeting HPGD
BE-16-UV45_0.01uM Dose=0.01uM
BE-16-UV45_0.1uM Dose=0.1uM
BE-16-UV45_10uM Dose=10uM
BE-16-UV45_1uM Dose=1uM
BE-16-VM54_0.01uM Dose=0.01uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC
BE-16-VM54_0.1uM Dose=0.1uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC
BE-16-VM54_10uM Dose=10uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC
BE-16-VM54_1uM Dose=1uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC
BE-17-CS60_0.01uM Dose=0.01uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
BE-17-CS60_0.1uM Dose=0.1uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
BE-17-CS60_10uM Dose=10uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
BE-17-CS60_1uM Dose=1uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1
BE-18-EM88_0.01uM Dose=0.01uM, Nimesulide, Cyclooxygenase-2 Inhibitors targeting PTGS2, SC5D
BE-18-EM88_0.1uM Dose=0.1uM, Nimesulide, Cyclooxygenase-2 Inhibitors targeting PTGS2, SC5D
BE-18-EM88_10uM Dose=10uM, Nimesulide, Cyclooxygenase-2 Inhibitors targeting PTGS2, SC5D
BE-18-EM88_1uM Dose=1uM, Nimesulide, Cyclooxygenase-2 Inhibitors targeting PTGS2, SC5D
BE-24-LQ28_0.01uM Dose=0.01uM
BE-24-LQ28_0.1uM Dose=0.1uM
BE-24-LQ28_10uM Dose=10uM
BE-24-LQ28_1uM Dose=1uM
BE-25-UR78_0.01uM Dose=0.01uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB
BE-25-UR78_0.1uM Dose=0.1uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB
BE-25-UR78_10uM Dose=10uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB
BE-25-UR78_1uM Dose=1uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB
BE-27-RQ61_0.01uM Dose=0.01uM
BE-27-RQ61_0.1uM Dose=0.1uM
BE-27-RQ61_10uM Dose=10uM
BE-27-RQ61_1uM Dose=1uM
BE-27-XF09_0.01uM Dose=0.01uM, (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione, bacterial DNA Primase Inhibitors;tat Inhibitors targeting PRIM1
BE-27-XF09_10uM Dose=10uM, (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione, bacterial DNA Primase Inhibitors;tat Inhibitors targeting PRIM1
BE-27-XF09_1uM Dose=1uM, (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione, bacterial DNA Primase Inhibitors;tat Inhibitors targeting PRIM1
BE-28-QT65_0.01uM Dose=0.01uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2
BE-28-QT65_0.1uM Dose=0.1uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2
BE-28-QT65_10uM Dose=10uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2
BE-28-QT65_1uM Dose=1uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2
BE-28-WW67_0.01uM Dose=0.01uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
BE-28-WW67_0.1uM Dose=0.1uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
BE-28-WW67_10uM Dose=10uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
BE-28-WW67_1uM Dose=1uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
BE-29-DG26_0.01uM Dose=0.01uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C
BE-29-DG26_0.1uM Dose=0.1uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C
BE-29-DG26_10uM Dose=10uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C
BE-29-DG26_1uM Dose=1uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C
BE-29-HA72_0.01uM Dose=0.01uM, Ifosfamide
BE-29-HA72_0.1uM Dose=0.1uM, Ifosfamide
BE-29-HA72_1uM Dose=1uM, Ifosfamide
BE-31-XV38_0.01uM Dose=0.01uM, Camptothecin, topoisomerase I targeting TOP1
BE-31-XV38_0.1uM Dose=0.1uM, Camptothecin, topoisomerase I targeting TOP1
BE-31-XV38_10uM Dose=10uM, Camptothecin, topoisomerase I targeting TOP1
BE-31-XV38_1uM Dose=1uM, Camptothecin, topoisomerase I targeting TOP1
BE-33-IM71_0.01uM Dose=0.01uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
BE-33-IM71_0.1uM Dose=0.1uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
BE-33-IM71_10uM Dose=10uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
BE-33-IM71_1uM Dose=1uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
BE-34-JO19_0.01uM Dose=0.01uM, EIF2B4 modulator;Inhibits UPR, reactives translation targeting EIF2B4
BE-34-JO19_10uM Dose=10uM, EIF2B4 modulator;Inhibits UPR, reactives translation targeting EIF2B4
BE-36-FY37_0.01uM Dose=0.01uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2
BE-36-FY37_0.1uM Dose=0.1uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2
BE-36-FY37_10uM Dose=10uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2
BE-36-FY37_1uM Dose=1uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2
BE-36-XE09_0.01uM Dose=0.01uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine
BE-36-XE09_0.1uM Dose=0.1uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine
BE-36-XE09_10uM Dose=10uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine
BE-36-XE09_1uM Dose=1uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine
BE-37-IC77_0.01uM Dose=0.01uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1
BE-37-IC77_0.1uM Dose=0.1uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1
BE-37-IC77_10uM Dose=10uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1
BE-37-IC77_1uM Dose=1uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1
BE-37-ZF44_0.01uM Dose=0.01uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S
BE-37-ZF44_0.1uM Dose=0.1uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S
BE-37-ZF44_10uM Dose=10uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S
BE-37-ZF44_1uM Dose=1uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S
BE-38-UW72_0.01uM Dose=0.01uM
BE-38-UW72_0.1uM Dose=0.1uM
BE-38-UW72_10uM Dose=10uM
BE-38-UW72_1uM Dose=1uM
BE-41-AV63_0.01uM Dose=0.01uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4
BE-41-AV63_0.1uM Dose=0.1uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4
BE-41-AV63_10uM Dose=10uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4
BE-41-AV63_1uM Dose=1uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4
BE-41-UE67_0.01uM Dose=0.01uM, Piericidin A, Electron transport chain inhibitor;NADH oxidase inhibitors targeting NDUFAB1, NDUFS1, NDUFV1
BE-41-UE67_0.1uM Dose=0.1uM, Piericidin A, Electron transport chain inhibitor;NADH oxidase inhibitors targeting NDUFAB1, NDUFS1, NDUFV1
BE-41-UE67_10uM Dose=10uM, Piericidin A, Electron transport chain inhibitor;NADH oxidase inhibitors targeting NDUFAB1, NDUFS1, NDUFV1
BE-41-UE67_1uM Dose=1uM, Piericidin A, Electron transport chain inhibitor;NADH oxidase inhibitors targeting NDUFAB1, NDUFS1, NDUFV1
BE-42-IC00_0.01uM Dose=0.01uM, Zygosporin A, actin polymerization targeting ACTA1
BE-42-IC00_0.1uM Dose=0.1uM, Zygosporin A, actin polymerization targeting ACTA1
BE-42-IC00_10uM Dose=10uM, Zygosporin A, actin polymerization targeting ACTA1
BE-42-IC00_1uM Dose=1uM, Zygosporin A, actin polymerization targeting ACTA1
BE-42-WI29_0.01uM Dose=0.01uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ
BE-42-WI29_0.1uM Dose=0.1uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ
BE-42-WI29_10uM Dose=10uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ
BE-42-WI29_1uM Dose=1uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ
BE-45-UU35_0.01uM Dose=0.01uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA
BE-45-UU35_0.1uM Dose=0.1uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA
BE-45-UU35_10uM Dose=10uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA
BE-45-UU35_1uM Dose=1uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA
BE-45-VH04_0.01uM Dose=0.01uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate
BE-45-VH04_0.1uM Dose=0.1uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate
BE-45-VH04_10uM Dose=10uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate
BE-45-VH04_1uM Dose=1uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate
BE-45-XA42_0.01uM Dose=0.01uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1
BE-45-XA42_0.1uM Dose=0.1uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1
BE-45-XA42_10uM Dose=10uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1
BE-45-XA42_1uM Dose=1uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1
BE-46-FY47_0.01uM Dose=0.01uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A
BE-46-FY47_0.1uM Dose=0.1uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A
BE-46-FY47_10uM Dose=10uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A
BE-46-FY47_1uM Dose=1uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A
BE-47-IP08_0.01uM Dose=0.01uM, Acifran, GPR109A agonist targeting HCAR2
BE-47-IP08_0.1uM Dose=0.1uM, Acifran, GPR109A agonist targeting HCAR2
BE-47-IP08_10uM Dose=10uM, Acifran, GPR109A agonist targeting HCAR2
BE-47-IP08_1uM Dose=1uM, Acifran, GPR109A agonist targeting HCAR2
BE-48-IT75_0.01uM Dose=0.01uM
BE-48-IT75_0.1uM Dose=0.1uM
BE-48-IT75_10uM Dose=10uM
BE-48-IT75_1uM Dose=1uM
BE-48-TM93_0.01uM Dose=0.01uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R
BE-48-TM93_0.1uM Dose=0.1uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R
BE-48-TM93_10uM Dose=10uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R
BE-48-TM93_1uM Dose=1uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R
BE-49-AQ65_0.01uM Dose=0.01uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D
BE-49-AQ65_0.1uM Dose=0.1uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D
BE-49-AQ65_10uM Dose=10uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D
BE-49-AQ65_1uM Dose=1uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D
BE-49-XN43_0.01uM Dose=0.01uM
BE-49-XN43_0.1uM Dose=0.1uM
BE-49-XN43_10uM Dose=10uM
BE-49-XN43_1uM Dose=1uM
BE-50-RK99_0.01uM Dose=0.01uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine
BE-50-RK99_0.1uM Dose=0.1uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine
BE-50-RK99_10uM Dose=10uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine
BE-50-RK99_1uM Dose=1uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine
BE-51-FL19_0.01uM Dose=0.01uM
BE-51-FL19_0.1uM Dose=0.1uM
BE-51-FL19_10uM Dose=10uM
BE-51-FL19_1uM Dose=1uM
BE-51-JY70_0.01uM Dose=0.01uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK
BE-51-JY70_0.1uM Dose=0.1uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK
BE-51-JY70_10uM Dose=10uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK
BE-51-JY70_1uM Dose=1uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK
BE-54-BG59_10uM Dose=10uM, Sgc0946, Dot1L inhibitor targeting DOT1L
BE-57-VZ17_0.01uM Dose=0.01uM
BE-57-VZ17_0.1uM Dose=0.1uM
BE-57-VZ17_10uM Dose=10uM
BE-57-VZ17_1uM Dose=1uM
BE-58-FC64_0.01uM Dose=0.01uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D
BE-58-FC64_0.1uM Dose=0.1uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D
BE-58-FC64_10uM Dose=10uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D
BE-58-FC64_1uM Dose=1uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D
BE-59-WG31_0.01uM Dose=0.01uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1
BE-59-WG31_0.1uM Dose=0.1uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1
BE-59-WG31_10uM Dose=10uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1
BE-59-WG31_1uM Dose=1uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1
BE-61-CB85_0.01uM Dose=0.01uM
BE-61-CB85_0.1uM Dose=0.1uM
BE-61-CB85_10uM Dose=10uM
BE-61-CB85_1uM Dose=1uM
BE-61-OB65_0.01uM Dose=0.01uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR
BE-61-OB65_0.1uM Dose=0.1uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR
BE-61-OB65_10uM Dose=10uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR
BE-61-OB65_1uM Dose=1uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR
BE-64-ZN31_0.01uM Dose=0.01uM, Enzalutamide, Androgen Receptor Antagonists targeting AR
BE-64-ZN31_0.1uM Dose=0.1uM, Enzalutamide, Androgen Receptor Antagonists targeting AR
BE-64-ZN31_10uM Dose=10uM, Enzalutamide, Androgen Receptor Antagonists targeting AR
BE-64-ZN31_1uM Dose=1uM, Enzalutamide, Androgen Receptor Antagonists targeting AR
BE-65-HV88_0.01uM Dose=0.01uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B
BE-65-HV88_0.1uM Dose=0.1uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B
BE-65-HV88_10uM Dose=10uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B
BE-65-HV88_1uM Dose=1uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B
BE-66-GV20_0.01uM Dose=0.01uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F
BE-66-GV20_0.1uM Dose=0.1uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F
BE-66-GV20_10uM Dose=10uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F
BE-66-GV20_1uM Dose=1uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F
BE-66-UB12_0.01uM Dose=0.01uM
BE-66-UB12_0.1uM Dose=0.1uM
BE-66-UB12_10uM Dose=10uM
BE-66-UB12_1uM Dose=1uM
BE-67-QZ92_0.01uM Dose=0.01uM, Hydrochlorothiazide, SLC12A3 gene inhibitor targeting CA1, CA4, SLC12A3, CA5B
BE-67-QZ92_0.1uM Dose=0.1uM, Hydrochlorothiazide, SLC12A3 gene inhibitor targeting CA1, CA4, SLC12A3, CA5B
BE-67-QZ92_10uM Dose=10uM, Hydrochlorothiazide, SLC12A3 gene inhibitor targeting CA1, CA4, SLC12A3, CA5B
BE-68-LK29_0.01uM Dose=0.01uM, Valproic Acid, GABAergic Transmission Enhancers;Histone Deacetylase 1 (HDAC1) Inhibitors targeting ABAT, ACADSB, HDAC1, SCN1A, HDAC9
BE-68-LK29_0.1uM Dose=0.1uM, Valproic Acid, GABAergic Transmission Enhancers;Histone Deacetylase 1 (HDAC1) Inhibitors targeting ABAT, ACADSB, HDAC1, SCN1A, HDAC9
BE-68-LK29_10uM Dose=10uM, Valproic Acid, GABAergic Transmission Enhancers;Histone Deacetylase 1 (HDAC1) Inhibitors targeting ABAT, ACADSB, HDAC1, SCN1A, HDAC9
BE-68-PM13_10uM Dose=10uM, (2R)-3-cyclopentyl-N-(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)-2-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}propanamide, Glucokinase Activators targeting GCK
BE-69-RD44_0.01uM Dose=0.01uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1
BE-69-RD44_0.1uM Dose=0.1uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1
BE-69-RD44_10uM Dose=10uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1
BE-69-RD44_1uM Dose=1uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1
BE-70-CU78_0.01uM Dose=0.01uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A
BE-70-CU78_0.1uM Dose=0.1uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A
BE-70-CU78_10uM Dose=10uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A
BE-70-CU78_1uM Dose=1uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A
BE-70-YH17_0.01uM Dose=0.01uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG
BE-70-YH17_0.1uM Dose=0.1uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG
BE-70-YH17_10uM Dose=10uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG
BE-70-YH17_1uM Dose=1uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG
BE-71-AV63_0.01uM Dose=0.01uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3
BE-71-AV63_0.1uM Dose=0.1uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3
BE-71-AV63_10uM Dose=10uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3
BE-71-AV63_1uM Dose=1uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3
BE-72-EW73_10uM Dose=10uM, Roscovitine, CDK inhibitors targeting CDK2, CDK5R1, CCNA1, CCNB2, CCNE2, CCNB3
BE-73-EJ14_0.01uM Dose=0.01uM
BE-73-EJ14_0.1uM Dose=0.1uM
BE-73-EJ14_10uM Dose=10uM
BE-73-EJ14_1uM Dose=1uM
BE-73-IJ64_0.01uM Dose=0.01uM, (1-methylcyclopropyl) 4-[[5-[2-oxo-4-[(3S)-pyrrolidin-3-yl]sulfonylpiperazin-1-yl]pyrazin-2-yl]oxymethyl]piperidine-1-carboxylate
BE-73-IJ64_0.1uM Dose=0.1uM, (1-methylcyclopropyl) 4-[[5-[2-oxo-4-[(3S)-pyrrolidin-3-yl]sulfonylpiperazin-1-yl]pyrazin-2-yl]oxymethyl]piperidine-1-carboxylate
BE-73-IJ64_10uM Dose=10uM, (1-methylcyclopropyl) 4-[[5-[2-oxo-4-[(3S)-pyrrolidin-3-yl]sulfonylpiperazin-1-yl]pyrazin-2-yl]oxymethyl]piperidine-1-carboxylate
BE-73-IJ64_1uM Dose=1uM, (1-methylcyclopropyl) 4-[[5-[2-oxo-4-[(3S)-pyrrolidin-3-yl]sulfonylpiperazin-1-yl]pyrazin-2-yl]oxymethyl]piperidine-1-carboxylate
BE-73-KD75_0.01uM Dose=0.01uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1
BE-73-KD75_0.1uM Dose=0.1uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1
BE-73-KD75_10uM Dose=10uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1
BE-73-KD75_1uM Dose=1uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1
BE-74-SX40_0.01uM Dose=0.01uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3
BE-74-SX40_0.1uM Dose=0.1uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3
BE-74-SX40_10uM Dose=10uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3
BE-74-SX40_1uM Dose=1uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3
BE-76-XL76_0.01uM Dose=0.01uM, (1-Carbamoyl-3-{[(1R,3S,5R)-3-(3-chloro-2-fluoro-benzylcarbamoyl)-2-aza-bicyclo[3.1.0]hexane-2-carbonyl]-amino}-1H-indol-5-yloxy)-acetic acid, Complement Factor D (CFD) Inhibitor targeting CFD
BE-76-XL76_0.1uM Dose=0.1uM, (1-Carbamoyl-3-{[(1R,3S,5R)-3-(3-chloro-2-fluoro-benzylcarbamoyl)-2-aza-bicyclo[3.1.0]hexane-2-carbonyl]-amino}-1H-indol-5-yloxy)-acetic acid, Complement Factor D (CFD) Inhibitor targeting CFD
BE-76-XL76_1uM Dose=1uM, (1-Carbamoyl-3-{[(1R,3S,5R)-3-(3-chloro-2-fluoro-benzylcarbamoyl)-2-aza-bicyclo[3.1.0]hexane-2-carbonyl]-amino}-1H-indol-5-yloxy)-acetic acid, Complement Factor D (CFD) Inhibitor targeting CFD
BE-77-XF69_0.01uM Dose=0.01uM
BE-77-XF69_0.1uM Dose=0.1uM
BE-77-XF69_10uM Dose=10uM
BE-77-XF69_1uM Dose=1uM
BE-79-PQ70_0.01uM Dose=0.01uM, 1-[3-Amino-6-(3,4,5-Trimethoxyphenyl)pyrazin-2-Yl]piperidine-4-Carboxylic Acid, NEK2 gene inhibitor targeting NEK2
BE-79-PQ70_10uM Dose=10uM, 1-[3-Amino-6-(3,4,5-Trimethoxyphenyl)pyrazin-2-Yl]piperidine-4-Carboxylic Acid, NEK2 gene inhibitor targeting NEK2
BE-79-PQ70_1uM Dose=1uM, 1-[3-Amino-6-(3,4,5-Trimethoxyphenyl)pyrazin-2-Yl]piperidine-4-Carboxylic Acid, NEK2 gene inhibitor targeting NEK2
BE-79-QU25_0.01uM Dose=0.01uM, Emetine, Translation inhibitor targeting RPS14, RPS20
BE-79-QU25_0.1uM Dose=0.1uM, Emetine, Translation inhibitor targeting RPS14, RPS20
BE-79-QU25_10uM Dose=10uM, Emetine, Translation inhibitor targeting RPS14, RPS20
BE-79-QU25_1uM Dose=1uM, Emetine, Translation inhibitor targeting RPS14, RPS20
BE-81-QL64_0.01uM Dose=0.01uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR
BE-81-QL64_0.1uM Dose=0.1uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR
BE-81-QL64_10uM Dose=10uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR
BE-81-QL64_1uM Dose=1uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR
BE-82-MI84_0.01uM Dose=0.01uM, Pamidronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS
BE-82-MI84_0.1uM Dose=0.1uM, Pamidronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS
BE-82-MI84_10uM Dose=10uM, Pamidronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS
BE-82-TS38_0.01uM Dose=0.01uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO
BE-82-TS38_0.1uM Dose=0.1uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO
BE-82-TS38_10uM Dose=10uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO
BE-82-TS38_1uM Dose=1uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO
BE-85-CH49_0.01uM Dose=0.01uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2
BE-85-CH49_0.1uM Dose=0.1uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2
BE-85-CH49_10uM Dose=10uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2
BE-85-CH49_1uM Dose=1uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2
BE-86-FY67_0.01uM Dose=0.01uM, Enoxolone, 11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors;17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, HSD11B2, HSD17B3
BE-86-FY67_0.1uM Dose=0.1uM, Enoxolone, 11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors;17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, HSD11B2, HSD17B3
BE-86-FY67_10uM Dose=10uM, Enoxolone, 11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors;17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, HSD11B2, HSD17B3
BE-87-TM66_0.01uM Dose=0.01uM, [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-yl][7-fluoro-1-(2-methoxyethyl)-4-trifluoromethoxy-1H-indol-3-yl]methanone, Known Tryptase inhibitor targeting TPSB2
BE-87-TM66_10uM Dose=10uM, [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-yl][7-fluoro-1-(2-methoxyethyl)-4-trifluoromethoxy-1H-indol-3-yl]methanone, Known Tryptase inhibitor targeting TPSB2
BE-89-DG86_0.01uM Dose=0.01uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide
BE-89-DG86_0.1uM Dose=0.1uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide
BE-89-DG86_10uM Dose=10uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide
BE-89-DG86_1uM Dose=1uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide
BE-90-IY33_0.01uM Dose=0.01uM, Vamifeport, Ferroportin inhibitor targeting SLC40A1
BE-90-IY33_0.1uM Dose=0.1uM, Vamifeport, Ferroportin inhibitor targeting SLC40A1
BE-90-IY33_10uM Dose=10uM, Vamifeport, Ferroportin inhibitor targeting SLC40A1
BE-90-YK54_0.01uM Dose=0.01uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
BE-90-YK54_0.1uM Dose=0.1uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
BE-90-YK54_10uM Dose=10uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
BE-90-YK54_1uM Dose=1uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1
BE-92-TW08_0.01uM Dose=0.01uM, 4-[(1E)-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylhydrazin-1-ylidene}methyl]-2-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile, ABCA1 Expression Inhibitors;Cholesterol Absorption Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;HMGCS2 Expression Enhancers targeting ABCA1, NPC1L1
BE-92-TW08_10uM Dose=10uM, 4-[(1E)-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylhydrazin-1-ylidene}methyl]-2-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile, ABCA1 Expression Inhibitors;Cholesterol Absorption Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;HMGCS2 Expression Enhancers targeting ABCA1, NPC1L1
BE-92-TW08_1uM Dose=1uM, 4-[(1E)-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylhydrazin-1-ylidene}methyl]-2-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile, ABCA1 Expression Inhibitors;Cholesterol Absorption Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;HMGCS2 Expression Enhancers targeting ABCA1, NPC1L1
BE-95-OR23_0.01uM Dose=0.01uM, (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists;Angiogenesis Inhibitors;Apoptosis Inducers;Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists targeting CXCR1, CXCR2
BE-95-OR23_10uM Dose=10uM, (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists;Angiogenesis Inhibitors;Apoptosis Inducers;Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists targeting CXCR1, CXCR2
BE-95-OR23_1uM Dose=1uM, (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists;Angiogenesis Inhibitors;Apoptosis Inducers;Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists targeting CXCR1, CXCR2
BF-00-PE90_0.01uM Dose=0.01uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2
BF-00-PE90_0.1uM Dose=0.1uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2
BF-00-PE90_10uM Dose=10uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2
BF-02-AC35_0.01uM Dose=0.01uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea
BF-02-AC35_0.1uM Dose=0.1uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea
BF-02-AC35_10uM Dose=10uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea
BF-02-AC35_1uM Dose=1uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea
BF-02-AC95_0.01uM Dose=0.01uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP
BF-02-AC95_0.1uM Dose=0.1uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP
BF-02-AC95_10uM Dose=10uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP
BF-02-AC95_1uM Dose=1uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP
BF-02-QT56_0.01uM Dose=0.01uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS
BF-02-QT56_0.1uM Dose=0.1uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS
BF-02-QT56_10uM Dose=10uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS
BF-02-QT56_1uM Dose=1uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS
BF-03-RM76_0.01uM Dose=0.01uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2
BF-03-RM76_0.1uM Dose=0.1uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2
BF-03-RM76_10uM Dose=10uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2
BF-03-RM76_1uM Dose=1uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2
BF-04-NQ13_0.01uM Dose=0.01uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester
BF-04-NQ13_0.1uM Dose=0.1uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester
BF-04-NQ13_10uM Dose=10uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester
BF-04-NQ13_1uM Dose=1uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester
BF-05-EV13_0.01uM Dose=0.01uM, Calpain Inhibitor III, Calpain Inhibitors targeting CAPN1
BF-05-EV13_0.1uM Dose=0.1uM, Calpain Inhibitor III, Calpain Inhibitors targeting CAPN1
BF-05-EV13_1uM Dose=1uM, Calpain Inhibitor III, Calpain Inhibitors targeting CAPN1
BF-08-RW47_0.01uM Dose=0.01uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D
BF-08-RW47_0.1uM Dose=0.1uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D
BF-08-RW47_10uM Dose=10uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D
BF-08-RW47_1uM Dose=1uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D
BF-10-IO69_0.01uM Dose=0.01uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3
BF-10-IO69_0.1uM Dose=0.1uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3
BF-10-IO69_10uM Dose=10uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3
BF-10-IO69_1uM Dose=1uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3
BF-12-AC65_0.01uM Dose=0.01uM, ACAT Inhibitors
BF-12-AC65_1uM Dose=1uM, ACAT Inhibitors
BF-13-HM71_0.01uM Dose=0.01uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK
BF-13-HM71_0.1uM Dose=0.1uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK
BF-13-HM71_10uM Dose=10uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK
BF-13-HM71_1uM Dose=1uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK
BF-18-MJ41_0.01uM Dose=0.01uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1
BF-18-MJ41_0.1uM Dose=0.1uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1
BF-18-MJ41_10uM Dose=10uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1
BF-18-MJ41_1uM Dose=1uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1
BF-19-KU00_0.01uM Dose=0.01uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS
BF-19-KU00_10uM Dose=10uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS
BF-19-KU00_1uM Dose=1uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS
BF-22-EP86_0.01uM Dose=0.01uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
BF-22-EP86_0.1uM Dose=0.1uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
BF-22-EP86_10uM Dose=10uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
BF-22-EP86_1uM Dose=1uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA
BF-24-JN36_0.01uM Dose=0.01uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2
BF-24-JN36_0.1uM Dose=0.1uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2
BF-24-JN36_10uM Dose=10uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2
BF-24-JN36_1uM Dose=1uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2
BF-26-MB27_0.01uM Dose=0.01uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG
BF-26-MB27_0.1uM Dose=0.1uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG
BF-26-MB27_10uM Dose=10uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG
BF-26-MB27_1uM Dose=1uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG
BF-27-HP68_0.01uM Dose=0.01uM, Argyrin A, Apoptosis Inducers;Proteasome Inhibitors;GFM1 inhibitor targeting GFM1
BF-27-HP68_0.1uM Dose=0.1uM, Argyrin A, Apoptosis Inducers;Proteasome Inhibitors;GFM1 inhibitor targeting GFM1
BF-27-HP68_10uM Dose=10uM, Argyrin A, Apoptosis Inducers;Proteasome Inhibitors;GFM1 inhibitor targeting GFM1
BF-27-HP68_1uM Dose=1uM, Argyrin A, Apoptosis Inducers;Proteasome Inhibitors;GFM1 inhibitor targeting GFM1
BF-29-LU75_0.01uM Dose=0.01uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB
BF-29-LU75_0.1uM Dose=0.1uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB
BF-29-LU75_10uM Dose=10uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB
BF-29-LU75_1uM Dose=1uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB
BF-31-BY55_0.01uM Dose=0.01uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
BF-31-BY55_0.1uM Dose=0.1uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
BF-31-BY55_10uM Dose=10uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
BF-31-BY55_1uM Dose=1uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
BF-32-CI54_0.01uM Dose=0.01uM
BF-32-CI54_0.1uM Dose=0.1uM
BF-32-CI54_10uM Dose=10uM
BF-32-CI54_1uM Dose=1uM
BF-34-DG44_0.01uM Dose=0.01uM, CID 6509858
BF-34-DG44_0.1uM Dose=0.1uM, CID 6509858
BF-34-DG44_10uM Dose=10uM, CID 6509858
BF-41-MV83_0.01uM Dose=0.01uM, Edaravone
BF-41-MV83_0.1uM Dose=0.1uM, Edaravone
BF-41-MV83_10uM Dose=10uM, Edaravone
BF-44-HD37_0.01uM Dose=0.01uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB
BF-44-HD37_0.1uM Dose=0.1uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB
BF-44-HD37_10uM Dose=10uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB
BF-44-HD37_1uM Dose=1uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB
BF-44-RX10_0.01uM Dose=0.01uM, N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1
BF-44-RX10_0.1uM Dose=0.1uM, N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1
BF-44-RX10_10uM Dose=10uM, N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1
BF-44-RX10_1uM Dose=1uM, N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1
BF-49-IA57_0.01uM Dose=0.01uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2
BF-49-IA57_0.1uM Dose=0.1uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2
BF-49-IA57_10uM Dose=10uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2
BF-49-IA57_1uM Dose=1uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2
BF-49-KQ10_0.01uM Dose=0.01uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA
BF-49-KQ10_0.1uM Dose=0.1uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA
BF-49-KQ10_10uM Dose=10uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA
BF-49-KQ10_1uM Dose=1uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA
BF-49-QA17_10uM Dose=10uM, Vaf347
BF-49-QA17_1uM Dose=1uM, Vaf347
BF-51-OI57_0.01uM Dose=0.01uM, Tolazamide
BF-51-OI57_0.1uM Dose=0.1uM, Tolazamide
BF-51-OI57_1uM Dose=1uM, Tolazamide
BF-52-HF07_0.01uM Dose=0.01uM, APOA1 Expression Enhancers;BRD2/3/4/T BET familiy inhibitor;BRD4 inhibitor targeting BRD4
BF-52-HF07_0.1uM Dose=0.1uM, APOA1 Expression Enhancers;BRD2/3/4/T BET familiy inhibitor;BRD4 inhibitor targeting BRD4
BF-52-HF07_10uM Dose=10uM, APOA1 Expression Enhancers;BRD2/3/4/T BET familiy inhibitor;BRD4 inhibitor targeting BRD4
BF-53-AT13_0.01uM Dose=0.01uM, 8-chloro-N-(4-(methylcarbamoyl)pyridin-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide, scd inhibitor targeting SCD
BF-53-AT13_0.1uM Dose=0.1uM, 8-chloro-N-(4-(methylcarbamoyl)pyridin-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide, scd inhibitor targeting SCD
BF-53-AT13_10uM Dose=10uM, 8-chloro-N-(4-(methylcarbamoyl)pyridin-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide, scd inhibitor targeting SCD
BF-53-AT13_1uM Dose=1uM, 8-chloro-N-(4-(methylcarbamoyl)pyridin-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide, scd inhibitor targeting SCD
BF-54-GX35_0.01uM Dose=0.01uM
BF-54-GX35_0.1uM Dose=0.1uM
BF-54-GX35_10uM Dose=10uM
BF-54-GX35_1uM Dose=1uM
BF-55-JR43_0.1uM Dose=0.1uM, (3R)-1-[[3-[[(1S)-1-(4-chloro-3-methylphenyl)-2,2,2-trifluoroethyl]amino]-2,6-dimethylphenyl]methyl]pyrrolidine-3-carboxylic acid, S1PR1 antagonist targeting S1PR1
BF-55-JR43_1uM Dose=1uM, (3R)-1-[[3-[[(1S)-1-(4-chloro-3-methylphenyl)-2,2,2-trifluoroethyl]amino]-2,6-dimethylphenyl]methyl]pyrrolidine-3-carboxylic acid, S1PR1 antagonist targeting S1PR1
BF-57-II91_0.01uM Dose=0.01uM, (E)-3-[4-(3,5-Diisopropyl-2-propoxy-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid, Retinoid RXRalpha Antagonists targeting RXRA
BF-57-II91_0.1uM Dose=0.1uM, (E)-3-[4-(3,5-Diisopropyl-2-propoxy-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid, Retinoid RXRalpha Antagonists targeting RXRA
BF-57-II91_1uM Dose=1uM, (E)-3-[4-(3,5-Diisopropyl-2-propoxy-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid, Retinoid RXRalpha Antagonists targeting RXRA
BF-59-OR93_0.01uM Dose=0.01uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB
BF-59-OR93_0.1uM Dose=0.1uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB
BF-59-OR93_10uM Dose=10uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB
BF-59-OR93_1uM Dose=1uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB
BF-61-BY15_0.1uM Dose=0.1uM, 5-[6-[[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole targeting CHRNA7
BF-61-BY15_10uM Dose=10uM, 5-[6-[[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole targeting CHRNA7
BF-61-BY15_1uM Dose=1uM, 5-[6-[[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole targeting CHRNA7
BF-61-IO76_0.01uM Dose=0.01uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB
BF-61-IO76_0.1uM Dose=0.1uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB
BF-61-IO76_10uM Dose=10uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB
BF-61-IO76_1uM Dose=1uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB
BF-63-DQ96_0.01uM Dose=0.01uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL
BF-63-DQ96_0.1uM Dose=0.1uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL
BF-63-DQ96_10uM Dose=10uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL
BF-63-DQ96_1uM Dose=1uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL
BF-63-NG22_0.1uM Dose=0.1uM, Tankyrase 2 (TNKS2) Inhibitors;Tankyrase 1 (TNKS1) Inhibitors targeting TNKS, TNKS2
BF-63-NG22_10uM Dose=10uM, Tankyrase 2 (TNKS2) Inhibitors;Tankyrase 1 (TNKS1) Inhibitors targeting TNKS, TNKS2
BF-63-NG22_1uM Dose=1uM, Tankyrase 2 (TNKS2) Inhibitors;Tankyrase 1 (TNKS1) Inhibitors targeting TNKS, TNKS2
BF-69-DN58_0.01uM Dose=0.01uM
BF-69-DN58_0.1uM Dose=0.1uM
BF-69-DN58_10uM Dose=10uM
BF-69-DN58_1uM Dose=1uM
BF-69-DX62_0.01uM Dose=0.01uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5
BF-69-DX62_0.1uM Dose=0.1uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5
BF-69-DX62_10uM Dose=10uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5
BF-69-DX62_1uM Dose=1uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5
BF-72-LI04_0.01uM Dose=0.01uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BF-72-LI04_0.1uM Dose=0.1uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BF-72-LI04_10uM Dose=10uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BF-72-LI04_1uM Dose=1uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
BF-76-AO03_0.01uM Dose=0.01uM, ML SA1
BF-76-AO03_0.1uM Dose=0.1uM, ML SA1
BF-76-AO03_10uM Dose=10uM, ML SA1
BF-77-FT23_0.01uM Dose=0.01uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2
BF-77-FT23_0.1uM Dose=0.1uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2
BF-77-FT23_10uM Dose=10uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2
BF-77-FT23_1uM Dose=1uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2
BF-79-GG96_0.01uM Dose=0.01uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4
BF-79-GG96_0.1uM Dose=0.1uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4
BF-79-GG96_10uM Dose=10uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4
BF-79-GG96_1uM Dose=1uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4
BF-81-KO31_0.01uM Dose=0.01uM, (S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2
BF-81-KO31_0.1uM Dose=0.1uM, (S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2
BF-81-LL19_0.01uM Dose=0.01uM, Known ACE inhibitor
BF-81-LL19_10uM Dose=10uM, Known ACE inhibitor
BF-81-LL19_1uM Dose=1uM, Known ACE inhibitor
BF-89-QD24_0.01uM Dose=0.01uM
BF-89-QD24_0.1uM Dose=0.1uM
BF-89-QD24_10uM Dose=10uM
BF-89-QD24_1uM Dose=1uM
BF-94-CQ58_0.01uM Dose=0.01uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
BF-94-CQ58_0.1uM Dose=0.1uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
BF-94-CQ58_10uM Dose=10uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
BF-94-CQ58_1uM Dose=1uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
BF-94-GX05_0.01uM Dose=0.01uM
BF-94-GX05_0.1uM Dose=0.1uM
BF-94-GX05_10uM Dose=10uM
BF-94-GX05_1uM Dose=1uM
BF-94-NX85_0.01uM Dose=0.01uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3
BF-94-NX85_0.1uM Dose=0.1uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3
BF-94-NX85_10uM Dose=10uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3
BF-94-NX85_1uM Dose=1uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3
BF-95-KA82_0.01uM Dose=0.01uM, SOAT-1 inhibitor
BF-95-KA82_0.1uM Dose=0.1uM, SOAT-1 inhibitor
BF-95-KA82_10uM Dose=10uM, SOAT-1 inhibitor
BF-95-KA82_1uM Dose=1uM, SOAT-1 inhibitor
BF-96-PY22_0.01uM Dose=0.01uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide
BF-96-PY22_0.1uM Dose=0.1uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide
BF-96-PY22_10uM Dose=10uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide
BF-96-PY22_1uM Dose=1uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide
BF-97-LS55_0.01uM Dose=0.01uM, Peptide Deformylase (PDF) Inhibitors targeting PDF
BF-97-LS55_0.1uM Dose=0.1uM, Peptide Deformylase (PDF) Inhibitors targeting PDF
BF-97-LS55_10uM Dose=10uM, Peptide Deformylase (PDF) Inhibitors targeting PDF
BF-97-LS55_1uM Dose=1uM, Peptide Deformylase (PDF) Inhibitors targeting PDF
CA-00-AR16_0.01uM Dose=0.01uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10
CA-00-AR16_0.1uM Dose=0.1uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10
CA-00-AR16_10uM Dose=10uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10
CA-00-AR16_1uM Dose=1uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10
CA-06-FY97_0.01uM Dose=0.01uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119
CA-06-FY97_0.1uM Dose=0.1uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119
CA-06-FY97_10uM Dose=10uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119
CA-06-FY97_1uM Dose=1uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119
CA-07-KS70_0.01uM Dose=0.01uM, 5-(3-Chlorophenyl)-N-(2-(pyridin-2-yl)ethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, Pim-1 Kinase Inhibitors targeting PIM1
CA-07-KS70_10uM Dose=10uM, 5-(3-Chlorophenyl)-N-(2-(pyridin-2-yl)ethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, Pim-1 Kinase Inhibitors targeting PIM1
CA-07-KS70_1uM Dose=1uM, 5-(3-Chlorophenyl)-N-(2-(pyridin-2-yl)ethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, Pim-1 Kinase Inhibitors targeting PIM1
CA-08-ON66_0.01uM Dose=0.01uM, 3-Cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, Autotaxin inhibitor targeting ENPP2
CA-08-ON66_0.1uM Dose=0.1uM, 3-Cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, Autotaxin inhibitor targeting ENPP2
CA-08-ON66_10uM Dose=10uM, 3-Cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, Autotaxin inhibitor targeting ENPP2
CA-08-ON66_1uM Dose=1uM, 3-Cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, Autotaxin inhibitor targeting ENPP2
CA-10-RU23_0.01uM Dose=0.01uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2
CA-10-RU23_0.1uM Dose=0.1uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2
CA-10-RU23_10uM Dose=10uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2
CA-10-RU23_1uM Dose=1uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2
CA-11-KY95_0.01uM Dose=0.01uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7
CA-11-KY95_0.1uM Dose=0.1uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7
CA-11-KY95_10uM Dose=10uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7
CA-11-KY95_1uM Dose=1uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7
CA-16-ZL71_0.01uM Dose=0.01uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b
CA-16-ZL71_0.1uM Dose=0.1uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b
CA-16-ZL71_10uM Dose=10uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b
CA-16-ZL71_1uM Dose=1uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b
CA-17-QL18_0.01uM Dose=0.01uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2
CA-17-QL18_0.1uM Dose=0.1uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2
CA-17-QL18_10uM Dose=10uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2
CA-17-QL18_1uM Dose=1uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2
CA-17-XB39_0.01uM Dose=0.01uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3
CA-17-XB39_0.1uM Dose=0.1uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3
CA-17-XB39_10uM Dose=10uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3
CA-17-XB39_1uM Dose=1uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3
CA-23-BW20_0.01uM Dose=0.01uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2
CA-23-BW20_0.1uM Dose=0.1uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2
CA-23-BW20_10uM Dose=10uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2
CA-23-BW20_1uM Dose=1uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2
CA-23-CC52_0.01uM Dose=0.01uM, Gsk417651A, TRPC6 Antagonists;TRPC3 Antagonists targeting TRPC3, TRPC6
CA-23-CC52_0.1uM Dose=0.1uM, Gsk417651A, TRPC6 Antagonists;TRPC3 Antagonists targeting TRPC3, TRPC6
CA-23-CC52_1uM Dose=1uM, Gsk417651A, TRPC6 Antagonists;TRPC3 Antagonists targeting TRPC3, TRPC6
CA-25-LR28_0.01uM Dose=0.01uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
CA-25-LR28_0.1uM Dose=0.1uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
CA-25-LR28_10uM Dose=10uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
CA-25-LR28_1uM Dose=1uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
CA-26-BI29_0.01uM Dose=0.01uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR
CA-26-BI29_0.1uM Dose=0.1uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR
CA-26-BI29_10uM Dose=10uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR
CA-26-BI29_1uM Dose=1uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR
CA-26-UY62_0.01uM Dose=0.01uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
CA-26-UY62_0.1uM Dose=0.1uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
CA-26-UY62_10uM Dose=10uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
CA-26-UY62_1uM Dose=1uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
CA-31-EL19_0.01uM Dose=0.01uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM
CA-31-EL19_0.1uM Dose=0.1uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM
CA-31-EL19_10uM Dose=10uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM
CA-31-EL19_1uM Dose=1uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM
CA-31-EV03_0.01uM Dose=0.01uM
CA-31-EV03_0.1uM Dose=0.1uM
CA-31-EV03_10uM Dose=10uM
CA-31-EV03_1uM Dose=1uM
CA-32-XV05_0.1uM Dose=0.1uM, Alrestatin, Aldose Reductase Inhibitors targeting AKR1B1
CA-32-XV05_1uM Dose=1uM, Alrestatin, Aldose Reductase Inhibitors targeting AKR1B1
CA-37-NI01_0.01uM Dose=0.01uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2
CA-37-NI01_0.1uM Dose=0.1uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2
CA-37-NI01_10uM Dose=10uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2
CA-37-NI01_1uM Dose=1uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2
CA-38-JF31_0.01uM Dose=0.01uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8
CA-38-JF31_0.1uM Dose=0.1uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8
CA-38-JF31_10uM Dose=10uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8
CA-38-JF31_1uM Dose=1uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8
CA-39-ZJ18_0.01uM Dose=0.01uM, Aspirin, Non-Steroidal Antiinflammatory Drugs;Nitric Oxide Donors;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TP53 Expression Enhancers targeting PTGS1, PTGS2, TP53
CA-39-ZJ18_0.1uM Dose=0.1uM, Aspirin, Non-Steroidal Antiinflammatory Drugs;Nitric Oxide Donors;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TP53 Expression Enhancers targeting PTGS1, PTGS2, TP53
CA-39-ZJ18_10uM Dose=10uM, Aspirin, Non-Steroidal Antiinflammatory Drugs;Nitric Oxide Donors;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TP53 Expression Enhancers targeting PTGS1, PTGS2, TP53
CA-39-ZJ18_1uM Dose=1uM, Aspirin, Non-Steroidal Antiinflammatory Drugs;Nitric Oxide Donors;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TP53 Expression Enhancers targeting PTGS1, PTGS2, TP53
CA-42-YI34_0.01uM Dose=0.01uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK
CA-42-YI34_0.1uM Dose=0.1uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK
CA-42-YI34_10uM Dose=10uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK
CA-42-YI34_1uM Dose=1uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK
CA-43-WF29_0.01uM Dose=0.01uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD
CA-43-WF29_0.1uM Dose=0.1uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD
CA-43-WF29_10uM Dose=10uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD
CA-43-WF29_1uM Dose=1uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD
CA-43-YM01_0.01uM Dose=0.01uM, 2-(4-Naphthalen-1-ylsulfonylpiperazin-1-yl)quinazolin-4-amine, NPY5R antagonist targeting NPY5R
CA-43-YM01_10uM Dose=10uM, 2-(4-Naphthalen-1-ylsulfonylpiperazin-1-yl)quinazolin-4-amine, NPY5R antagonist targeting NPY5R
CA-43-YM01_1uM Dose=1uM, 2-(4-Naphthalen-1-ylsulfonylpiperazin-1-yl)quinazolin-4-amine, NPY5R antagonist targeting NPY5R
CA-44-LT45_0.01uM Dose=0.01uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13
CA-44-LT45_0.1uM Dose=0.1uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13
CA-44-LT45_10uM Dose=10uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13
CA-44-LT45_1uM Dose=1uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13
CA-44-WJ06_0.01uM Dose=0.01uM, Tnp-470, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2
CA-44-WJ06_0.1uM Dose=0.1uM, Tnp-470, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2
CA-44-WJ06_10uM Dose=10uM, Tnp-470, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2
CA-44-WJ06_1uM Dose=1uM, Tnp-470, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2
CA-48-CT20_0.01uM Dose=0.01uM
CA-48-CT20_0.1uM Dose=0.1uM
CA-48-CT20_10uM Dose=10uM
CA-48-CT20_1uM Dose=1uM
CA-48-JF51_0.01uM Dose=0.01uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3
CA-48-JF51_0.1uM Dose=0.1uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3
CA-48-JF51_10uM Dose=10uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3
CA-48-JF51_1uM Dose=1uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3
CA-48-SW47_0.01uM Dose=0.01uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
CA-48-SW47_0.1uM Dose=0.1uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
CA-48-SW47_10uM Dose=10uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
CA-48-SW47_1uM Dose=1uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
CA-50-SD02_0.1uM Dose=0.1uM, Propentofylline, Adenosine Reuptake Inhibitors targeting SLC29A1, SLC29A2, SLC29A3, SLC29A4
CA-50-SD02_10uM Dose=10uM, Propentofylline, Adenosine Reuptake Inhibitors targeting SLC29A1, SLC29A2, SLC29A3, SLC29A4
CA-53-TT18_0.01uM Dose=0.01uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A
CA-53-TT18_0.1uM Dose=0.1uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A
CA-53-TT18_10uM Dose=10uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A
CA-53-TT18_1uM Dose=1uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A
CA-54-WJ96_0.01uM Dose=0.01uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B
CA-54-WJ96_0.1uM Dose=0.1uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B
CA-54-WJ96_10uM Dose=10uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B
CA-54-WJ96_1uM Dose=1uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B
CA-56-GE89_0.01uM Dose=0.01uM, 7-Deaza-2'-C-ethynyladenosine
CA-56-GE89_0.1uM Dose=0.1uM, 7-Deaza-2'-C-ethynyladenosine
CA-56-GE89_10uM Dose=10uM, 7-Deaza-2'-C-ethynyladenosine
CA-56-GE89_1uM Dose=1uM, 7-Deaza-2'-C-ethynyladenosine
CA-56-VE74_0.01uM Dose=0.01uM, Ciprofloxacin
CA-56-VE74_0.1uM Dose=0.1uM, Ciprofloxacin
CA-56-VE74_10uM Dose=10uM, Ciprofloxacin
CA-56-VE74_1uM Dose=1uM, Ciprofloxacin
CA-57-TC62_0.01uM Dose=0.01uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1
CA-57-TC62_0.1uM Dose=0.1uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1
CA-57-TC62_10uM Dose=10uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1
CA-57-TC62_1uM Dose=1uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1
CA-60-LK14_0.01uM Dose=0.01uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate
CA-60-LK14_0.1uM Dose=0.1uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate
CA-60-LK14_10uM Dose=10uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate
CA-60-LK14_1uM Dose=1uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate
CA-60-RU13_0.01uM Dose=0.01uM
CA-60-RU13_0.1uM Dose=0.1uM
CA-60-RU13_10uM Dose=10uM
CA-60-RU13_1uM Dose=1uM
CA-61-VV83_0.01uM Dose=0.01uM
CA-61-VV83_0.1uM Dose=0.1uM
CA-61-VV83_10uM Dose=10uM
CA-61-VV83_1uM Dose=1uM
CA-63-LW25_0.01uM Dose=0.01uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
CA-63-LW25_0.1uM Dose=0.1uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
CA-63-LW25_10uM Dose=10uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
CA-63-LW25_1uM Dose=1uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
CA-64-LT35_0.01uM Dose=0.01uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR
CA-64-LT35_0.1uM Dose=0.1uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR
CA-64-LT35_10uM Dose=10uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR
CA-64-LT35_1uM Dose=1uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR
CA-65-MK91_0.01uM Dose=0.01uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H
CA-65-MK91_0.1uM Dose=0.1uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H
CA-65-MK91_10uM Dose=10uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H
CA-65-MK91_1uM Dose=1uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H
CA-66-FY97_0.01uM Dose=0.01uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide
CA-66-FY97_0.1uM Dose=0.1uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide
CA-66-FY97_10uM Dose=10uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide
CA-66-FY97_1uM Dose=1uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide
CA-66-GI09_0.01uM Dose=0.01uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR
CA-66-GI09_0.1uM Dose=0.1uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR
CA-66-GI09_10uM Dose=10uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR
CA-66-GI09_1uM Dose=1uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR
CA-66-YB17_0.01uM Dose=0.01uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A
CA-66-YB17_0.1uM Dose=0.1uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A
CA-66-YB17_10uM Dose=10uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A
CA-66-YB17_1uM Dose=1uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A
CA-67-IB54_0.01uM Dose=0.01uM, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT
CA-67-IB54_10uM Dose=10uM, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT
CA-67-IB54_1uM Dose=1uM, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT
CA-67-XI76_0.01uM Dose=0.01uM, Racepinefrine, (S)-
CA-67-XI76_0.1uM Dose=0.1uM, Racepinefrine, (S)-
CA-67-XI76_10uM Dose=10uM, Racepinefrine, (S)-
CA-67-XI76_1uM Dose=1uM, Racepinefrine, (S)-
CA-68-KG29_0.01uM Dose=0.01uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1
CA-68-KG29_0.1uM Dose=0.1uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1
CA-68-KG29_10uM Dose=10uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1
CA-68-KG29_1uM Dose=1uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1
CA-68-SW47_0.01uM Dose=0.01uM, Sib-1893, mgluR5 Antagonists targeting GRM5
CA-68-SW47_0.1uM Dose=0.1uM, Sib-1893, mgluR5 Antagonists targeting GRM5
CA-68-SW47_10uM Dose=10uM, Sib-1893, mgluR5 Antagonists targeting GRM5
CA-68-TC79_0.01uM Dose=0.01uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A
CA-68-TC79_0.1uM Dose=0.1uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A
CA-68-TC79_10uM Dose=10uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A
CA-68-TC79_1uM Dose=1uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A
CA-70-EK39_0.01uM Dose=0.01uM, 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1
CA-70-EK39_0.1uM Dose=0.1uM, 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1
CA-70-EK39_10uM Dose=10uM, 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1
CA-70-EK39_1uM Dose=1uM, 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1
CA-72-JV60_0.01uM Dose=0.01uM, Benzamidine targeting PLG
CA-72-JV60_0.1uM Dose=0.1uM, Benzamidine targeting PLG
CA-72-JV60_10uM Dose=10uM, Benzamidine targeting PLG
CA-72-JV60_1uM Dose=1uM, Benzamidine targeting PLG
CA-72-UL91_0.01uM Dose=0.01uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
CA-72-UL91_0.1uM Dose=0.1uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
CA-72-UL91_10uM Dose=10uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
CA-72-UL91_1uM Dose=1uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
CA-73-BW50_0.01uM Dose=0.01uM, TG101209, Jak2 Inhibitors;Apoptosis Inducers targeting JAK2
CA-73-BW50_0.1uM Dose=0.1uM, TG101209, Jak2 Inhibitors;Apoptosis Inducers targeting JAK2
CA-73-BW50_10uM Dose=10uM, TG101209, Jak2 Inhibitors;Apoptosis Inducers targeting JAK2
CA-73-TP18_0.01uM Dose=0.01uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15
CA-73-TP18_10uM Dose=10uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15
CA-73-TP18_1uM Dose=1uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15
CA-75-HA22_0.01uM Dose=0.01uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2
CA-75-HA22_0.1uM Dose=0.1uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2
CA-75-HA22_10uM Dose=10uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2
CA-75-HA22_1uM Dose=1uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2
CA-84-IJ41_0.01uM Dose=0.01uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CA-84-IJ41_0.1uM Dose=0.1uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CA-84-IJ41_10uM Dose=10uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CA-84-IJ41_1uM Dose=1uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CA-88-FC74_0.01uM Dose=0.01uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4
CA-88-FC74_10uM Dose=10uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4
CA-88-FC74_1uM Dose=1uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4
CA-90-RU33_0.01uM Dose=0.01uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4
CA-90-RU33_0.1uM Dose=0.1uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4
CA-90-RU33_10uM Dose=10uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4
CA-90-RU33_1uM Dose=1uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4
CA-90-TK74_0.1uM Dose=0.1uM, Binds to hemoglobin, increases oxygen affinity thereby reducing sickling of cells
CA-90-TK74_1uM Dose=1uM, Binds to hemoglobin, increases oxygen affinity thereby reducing sickling of cells
CA-96-KH56_0.01uM Dose=0.01uM, (5R)-3-methyl-5-phenyl-5H-[1,3]thiazolo[2,3-b]quinazoline
CA-96-KH56_0.1uM Dose=0.1uM, (5R)-3-methyl-5-phenyl-5H-[1,3]thiazolo[2,3-b]quinazoline
CA-96-KH56_1uM Dose=1uM, (5R)-3-methyl-5-phenyl-5H-[1,3]thiazolo[2,3-b]quinazoline
CA-96-UO48_0.01uM Dose=0.01uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
CA-96-UO48_0.1uM Dose=0.1uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
CA-96-UO48_10uM Dose=10uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
CA-96-UO48_1uM Dose=1uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
CA-98-SW47_0.01uM Dose=0.01uM, Cilostazol, Phosphodiesterase III Inhibitors targeting PDE2A
CA-98-SW47_0.1uM Dose=0.1uM, Cilostazol, Phosphodiesterase III Inhibitors targeting PDE2A
CA-98-SW47_10uM Dose=10uM, Cilostazol, Phosphodiesterase III Inhibitors targeting PDE2A
CB-00-BH77_0.01uM Dose=0.01uM, 9-benzyl-8-oxo-2-pyridin-3-yl-7H-purine-6-carboxamide
CB-00-BH77_0.1uM Dose=0.1uM, 9-benzyl-8-oxo-2-pyridin-3-yl-7H-purine-6-carboxamide
CB-00-BH77_10uM Dose=10uM, 9-benzyl-8-oxo-2-pyridin-3-yl-7H-purine-6-carboxamide
CB-00-BH77_1uM Dose=1uM, 9-benzyl-8-oxo-2-pyridin-3-yl-7H-purine-6-carboxamide
CB-01-MR53_0.01uM Dose=0.01uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4
CB-01-MR53_0.1uM Dose=0.1uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4
CB-01-MR53_10uM Dose=10uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4
CB-01-MR53_1uM Dose=1uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4
CB-02-XL81_0.01uM Dose=0.01uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2
CB-02-XL81_0.1uM Dose=0.1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2
CB-02-XL81_10uM Dose=10uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2
CB-02-XL81_1uM Dose=1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2
CB-03-EP53_0.01uM Dose=0.01uM, 1-(2-Chlorophenyl)biguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CB-03-EP53_10uM Dose=10uM, 1-(2-Chlorophenyl)biguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CB-05-AU50_0.01uM Dose=0.01uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1
CB-05-AU50_0.1uM Dose=0.1uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1
CB-05-AU50_10uM Dose=10uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1
CB-05-AU50_1uM Dose=1uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1
CB-05-UD24_0.01uM Dose=0.01uM, (3R)-3-amino-1-hydroxypyrrolidin-2-one, NMDA Glycine B Receptor Partial Agonists targeting GRIN1
CB-05-UD24_10uM Dose=10uM, (3R)-3-amino-1-hydroxypyrrolidin-2-one, NMDA Glycine B Receptor Partial Agonists targeting GRIN1
CB-06-FE89_0.01uM Dose=0.01uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)-
CB-06-FE89_0.1uM Dose=0.1uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)-
CB-06-FE89_10uM Dose=10uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)-
CB-06-FE89_1uM Dose=1uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)-
CB-07-WI76_0.01uM Dose=0.01uM, Pidotimod
CB-07-WI76_0.1uM Dose=0.1uM, Pidotimod
CB-07-WI76_1uM Dose=1uM, Pidotimod
CB-10-UX80_0.01uM Dose=0.01uM
CB-10-UX80_0.1uM Dose=0.1uM
CB-10-UX80_1uM Dose=1uM
CB-10-YX20_0.01uM Dose=0.01uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1
CB-10-YX20_0.1uM Dose=0.1uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1
CB-10-YX20_10uM Dose=10uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1
CB-10-YX20_1uM Dose=1uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1
CB-11-GB40_0.01uM Dose=0.01uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4
CB-11-GB40_0.1uM Dose=0.1uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4
CB-11-GB40_10uM Dose=10uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4
CB-11-GB40_1uM Dose=1uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4
CB-12-BV05_0.01uM Dose=0.01uM
CB-12-BV05_0.1uM Dose=0.1uM
CB-12-BV05_10uM Dose=10uM
CB-12-BV05_1uM Dose=1uM
CB-12-HC20_0.01uM Dose=0.01uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55
CB-12-HC20_0.1uM Dose=0.1uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55
CB-12-HC20_10uM Dose=10uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55
CB-12-HC20_1uM Dose=1uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55
CB-13-OP88_0.01uM Dose=0.01uM, Benzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
CB-13-OP88_0.1uM Dose=0.1uM, Benzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
CB-13-OP88_1uM Dose=1uM, Benzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
CB-13-WC72_0.01uM Dose=0.01uM
CB-13-WC72_0.1uM Dose=0.1uM
CB-13-WC72_10uM Dose=10uM
CB-13-WC72_1uM Dose=1uM
CB-13-ZM26_0.01uM Dose=0.01uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA
CB-13-ZM26_0.1uM Dose=0.1uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA
CB-13-ZM26_10uM Dose=10uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA
CB-13-ZM26_1uM Dose=1uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA
CB-13-ZM96_0.01uM Dose=0.01uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
CB-13-ZM96_0.1uM Dose=0.1uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
CB-13-ZM96_10uM Dose=10uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
CB-13-ZM96_1uM Dose=1uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
CB-15-RU50_0.01uM Dose=0.01uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid
CB-15-RU50_0.1uM Dose=0.1uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid
CB-15-RU50_10uM Dose=10uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid
CB-15-RU50_1uM Dose=1uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid
CB-16-JO93_0.01uM Dose=0.01uM
CB-16-JO93_0.1uM Dose=0.1uM
CB-16-JO93_10uM Dose=10uM
CB-16-JO93_1uM Dose=1uM
CB-16-SY72_0.01uM Dose=0.01uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1
CB-16-SY72_0.1uM Dose=0.1uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1
CB-16-SY72_10uM Dose=10uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1
CB-16-SY72_1uM Dose=1uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1
CB-20-ND22_0.01uM Dose=0.01uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
CB-20-ND22_0.1uM Dose=0.1uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
CB-20-ND22_10uM Dose=10uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
CB-20-ND22_1uM Dose=1uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
CB-24-AT90_0.01uM Dose=0.01uM, Monensin
CB-24-AT90_0.1uM Dose=0.1uM, Monensin
CB-24-AT90_10uM Dose=10uM, Monensin
CB-24-AT90_1uM Dose=1uM, Monensin
CB-24-FA25_0.01uM Dose=0.01uM, Spiperone
CB-24-FA25_0.1uM Dose=0.1uM, Spiperone
CB-24-FA25_10uM Dose=10uM, Spiperone
CB-24-FA25_1uM Dose=1uM, Spiperone
CB-25-VR83_0.01uM Dose=0.01uM
CB-25-VR83_0.1uM Dose=0.1uM
CB-25-VR83_10uM Dose=10uM
CB-25-VR83_1uM Dose=1uM
CB-29-AX17_10uM Dose=10uM, (2R,3S,5R)-5-[[4,6-difluoro-5-(4-phenylphenyl)-1H-benzimidazol-2-yl]oxy]-2-(hydroxymethyl)oxan-3-ol
CB-29-AX17_1uM Dose=1uM, (2R,3S,5R)-5-[[4,6-difluoro-5-(4-phenylphenyl)-1H-benzimidazol-2-yl]oxy]-2-(hydroxymethyl)oxan-3-ol
CB-29-KG96_0.01uM Dose=0.01uM
CB-29-KG96_0.1uM Dose=0.1uM
CB-29-KG96_10uM Dose=10uM
CB-29-KG96_1uM Dose=1uM
CB-30-KN11_0.1uM Dose=0.1uM, Sardomozide, SAMDC inhibitor targeting AMD1
CB-30-KN11_10uM Dose=10uM, Sardomozide, SAMDC inhibitor targeting AMD1
CB-30-KN11_1uM Dose=1uM, Sardomozide, SAMDC inhibitor targeting AMD1
CB-31-UO16_0.01uM Dose=0.01uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1
CB-31-UO16_0.1uM Dose=0.1uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1
CB-31-UO16_10uM Dose=10uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1
CB-31-UO16_1uM Dose=1uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1
CB-32-EI69_0.01uM Dose=0.01uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1
CB-32-EI69_0.1uM Dose=0.1uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1
CB-32-EI69_10uM Dose=10uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1
CB-32-EI69_1uM Dose=1uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1
CB-36-QH71_0.01uM Dose=0.01uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid
CB-36-QH71_0.1uM Dose=0.1uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid
CB-36-QH71_10uM Dose=10uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid
CB-36-QH71_1uM Dose=1uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid
CB-36-TO28_0.01uM Dose=0.01uM, [(9Z,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
CB-36-TO28_0.1uM Dose=0.1uM, [(9Z,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
CB-36-TO28_10uM Dose=10uM, [(9Z,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
CB-36-TO28_1uM Dose=1uM, [(9Z,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
CB-37-NM86_0.01uM Dose=0.01uM, (4-Hydroxypiperidin-1-yl)(5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophen-2-yl)methanone, Novel and Selective Monoamine Oxidase B Inhibitors targeting MAOB
CB-37-NM86_10uM Dose=10uM, (4-Hydroxypiperidin-1-yl)(5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophen-2-yl)methanone, Novel and Selective Monoamine Oxidase B Inhibitors targeting MAOB
CB-37-NM86_1uM Dose=1uM, (4-Hydroxypiperidin-1-yl)(5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophen-2-yl)methanone, Novel and Selective Monoamine Oxidase B Inhibitors targeting MAOB
CB-38-AW77_0.01uM Dose=0.01uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1
CB-38-AW77_0.1uM Dose=0.1uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1
CB-38-AW77_10uM Dose=10uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1
CB-38-AW77_1uM Dose=1uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1
CB-40-DA30_0.01uM Dose=0.01uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5
CB-40-DA30_0.1uM Dose=0.1uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5
CB-40-DA30_10uM Dose=10uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5
CB-40-DA30_1uM Dose=1uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5
CB-42-EI79_0.01uM Dose=0.01uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1
CB-42-EI79_0.1uM Dose=0.1uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1
CB-42-EI79_10uM Dose=10uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1
CB-42-EI79_1uM Dose=1uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1
CB-44-FA25_0.01uM Dose=0.01uM, N-Tosyl-L-phenylalanyl chloromethyl ketone
CB-44-FA25_0.1uM Dose=0.1uM, N-Tosyl-L-phenylalanyl chloromethyl ketone
CB-44-FA25_10uM Dose=10uM, N-Tosyl-L-phenylalanyl chloromethyl ketone
CB-44-FA25_1uM Dose=1uM, N-Tosyl-L-phenylalanyl chloromethyl ketone
CB-44-RT90_0.01uM Dose=0.01uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2
CB-44-RT90_0.1uM Dose=0.1uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2
CB-44-RT90_10uM Dose=10uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2
CB-44-RT90_1uM Dose=1uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2
CB-45-VH79_0.01uM Dose=0.01uM
CB-45-VH79_0.1uM Dose=0.1uM
CB-45-VH79_10uM Dose=10uM
CB-45-VH79_1uM Dose=1uM
CB-46-FO63_0.01uM Dose=0.01uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8
CB-46-FO63_0.1uM Dose=0.1uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8
CB-46-FO63_10uM Dose=10uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8
CB-46-FO63_1uM Dose=1uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8
CB-47-SB29_0.1uM Dose=0.1uM, Opc-21268, Vasopressin (AVP) V1a Antagonists targeting AVPR1A
CB-47-SB29_10uM Dose=10uM, Opc-21268, Vasopressin (AVP) V1a Antagonists targeting AVPR1A
CB-47-SB29_1uM Dose=1uM, Opc-21268, Vasopressin (AVP) V1a Antagonists targeting AVPR1A
CB-48-WM43_0.01uM Dose=0.01uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E
CB-48-WM43_0.1uM Dose=0.1uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E
CB-48-WM43_10uM Dose=10uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E
CB-48-WM43_1uM Dose=1uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E
CB-49-OG36_0.01uM Dose=0.01uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1
CB-49-OG36_0.1uM Dose=0.1uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1
CB-49-OG36_10uM Dose=10uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1
CB-49-OG36_1uM Dose=1uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1
CB-52-IL46_0.01uM Dose=0.01uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate
CB-52-IL46_0.1uM Dose=0.1uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate
CB-52-IL46_10uM Dose=10uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate
CB-52-IL46_1uM Dose=1uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate
CB-55-AK76_0.01uM Dose=0.01uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4
CB-55-AK76_0.1uM Dose=0.1uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4
CB-55-AK76_10uM Dose=10uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4
CB-55-AK76_1uM Dose=1uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4
CB-55-GX92_0.01uM Dose=0.01uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2
CB-55-GX92_0.1uM Dose=0.1uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2
CB-55-GX92_10uM Dose=10uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2
CB-55-GX92_1uM Dose=1uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2
CB-59-FD39_0.01uM Dose=0.01uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1
CB-59-FD39_0.1uM Dose=0.1uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1
CB-59-FD39_10uM Dose=10uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1
CB-59-FD39_1uM Dose=1uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1
CB-59-ZX97_0.01uM Dose=0.01uM
CB-59-ZX97_0.1uM Dose=0.1uM
CB-59-ZX97_10uM Dose=10uM
CB-59-ZX97_1uM Dose=1uM
CB-62-TB77_0.01uM Dose=0.01uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2
CB-62-TB77_0.1uM Dose=0.1uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2
CB-62-TB77_10uM Dose=10uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2
CB-62-TB77_1uM Dose=1uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2
CB-68-GZ09_0.01uM Dose=0.01uM, SB-204741, HTR2B antagonist targeting HTR2B
CB-68-GZ09_0.1uM Dose=0.1uM, SB-204741, HTR2B antagonist targeting HTR2B
CB-68-GZ09_10uM Dose=10uM, SB-204741, HTR2B antagonist targeting HTR2B
CB-68-GZ09_1uM Dose=1uM, SB-204741, HTR2B antagonist targeting HTR2B
CB-68-HM58_0.01uM Dose=0.01uM
CB-68-HM58_0.1uM Dose=0.1uM
CB-68-HM58_10uM Dose=10uM
CB-68-HM58_1uM Dose=1uM
CB-68-SP90_0.01uM Dose=0.01uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
CB-68-SP90_0.1uM Dose=0.1uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
CB-68-SP90_10uM Dose=10uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
CB-68-SP90_1uM Dose=1uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
CB-69-DJ58_0.01uM Dose=0.01uM, Midafotel, NMDA Antagonists targeting GRIN1
CB-69-DJ58_0.1uM Dose=0.1uM, Midafotel, NMDA Antagonists targeting GRIN1
CB-69-DJ58_10uM Dose=10uM, Midafotel, NMDA Antagonists targeting GRIN1
CB-69-DJ58_1uM Dose=1uM, Midafotel, NMDA Antagonists targeting GRIN1
CB-69-KJ83_0.01uM Dose=0.01uM
CB-69-KJ83_0.1uM Dose=0.1uM
CB-69-KJ83_1uM Dose=1uM
CB-72-CP81_0.01uM Dose=0.01uM
CB-72-CP81_0.1uM Dose=0.1uM
CB-72-CP81_10uM Dose=10uM
CB-72-CP81_1uM Dose=1uM
CB-73-HZ47_0.01uM Dose=0.01uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS
CB-73-HZ47_0.1uM Dose=0.1uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS
CB-73-HZ47_10uM Dose=10uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS
CB-73-HZ47_1uM Dose=1uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS
CB-73-MJ69_0.01uM Dose=0.01uM, AC1LA18U, HIF prolyl hydroxylase-1 inhibitor targeting P4HA1, P4HB, P4HA2, EGLN1, P4HA3
CB-73-MJ69_0.1uM Dose=0.1uM, AC1LA18U, HIF prolyl hydroxylase-1 inhibitor targeting P4HA1, P4HB, P4HA2, EGLN1, P4HA3
CB-73-MJ69_10uM Dose=10uM, AC1LA18U, HIF prolyl hydroxylase-1 inhibitor targeting P4HA1, P4HB, P4HA2, EGLN1, P4HA3
CB-73-ZP43_1uM Dose=1uM, 5-tert-butyl-N-[(2S)-1-(cyanomethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpyrazole-3-carboxamide, cathepsin L (CTSL1) inhibitor targeting CTSL
CB-75-PH34_0.01uM Dose=0.01uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A
CB-75-PH34_0.1uM Dose=0.1uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A
CB-75-PH34_10uM Dose=10uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A
CB-75-PH34_1uM Dose=1uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A
CB-77-KL88_0.01uM Dose=0.01uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B
CB-77-KL88_0.1uM Dose=0.1uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B
CB-77-KL88_10uM Dose=10uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B
CB-77-KL88_1uM Dose=1uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B
CB-80-CK24_0.01uM Dose=0.01uM, F1174-1718
CB-80-CK24_0.1uM Dose=0.1uM, F1174-1718
CB-80-CK24_10uM Dose=10uM, F1174-1718
CB-80-CK24_1uM Dose=1uM, F1174-1718
CB-82-BV25_0.01uM Dose=0.01uM, [4-(2-Acetylamino-2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-benzyl]-phosphonic acid, Grb2 SH2 Domain Inhibitors targeting GRB2, PTK2B, PTK2, PTK6, PTK7
CB-82-BV25_0.1uM Dose=0.1uM, [4-(2-Acetylamino-2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-benzyl]-phosphonic acid, Grb2 SH2 Domain Inhibitors targeting GRB2, PTK2B, PTK2, PTK6, PTK7
CB-82-BV25_10uM Dose=10uM, [4-(2-Acetylamino-2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-benzyl]-phosphonic acid, Grb2 SH2 Domain Inhibitors targeting GRB2, PTK2B, PTK2, PTK6, PTK7
CB-82-PL01_0.1uM Dose=0.1uM, N-(4-((6-(Cyclobutylamino)-9H-purin-2-yl)amino)phenyl)-N-methylacetamide, Syk Kinase Inhibitors targeting SYK
CB-82-PL01_10uM Dose=10uM, N-(4-((6-(Cyclobutylamino)-9H-purin-2-yl)amino)phenyl)-N-methylacetamide, Syk Kinase Inhibitors targeting SYK
CB-82-PL01_1uM Dose=1uM, N-(4-((6-(Cyclobutylamino)-9H-purin-2-yl)amino)phenyl)-N-methylacetamide, Syk Kinase Inhibitors targeting SYK
CB-83-LF14_0.01uM Dose=0.01uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
CB-83-LF14_0.1uM Dose=0.1uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
CB-83-LF14_10uM Dose=10uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
CB-83-LF14_1uM Dose=1uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
CB-83-SC82_0.01uM Dose=0.01uM
CB-83-SC82_0.1uM Dose=0.1uM
CB-83-SC82_10uM Dose=10uM
CB-83-SC82_1uM Dose=1uM
CB-83-ZW70_0.01uM Dose=0.01uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5
CB-83-ZW70_0.1uM Dose=0.1uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5
CB-83-ZW70_10uM Dose=10uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5
CB-83-ZW70_1uM Dose=1uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5
CB-84-FA85_0.01uM Dose=0.01uM
CB-84-FA85_0.1uM Dose=0.1uM
CB-84-FA85_10uM Dose=10uM
CB-84-FA85_1uM Dose=1uM
CB-86-ME74_0.01uM Dose=0.01uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3
CB-86-ME74_0.1uM Dose=0.1uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3
CB-86-ME74_10uM Dose=10uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3
CB-86-ME74_1uM Dose=1uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3
CB-87-GT98_0.01uM Dose=0.01uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL
CB-87-GT98_0.1uM Dose=0.1uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL
CB-87-GT98_10uM Dose=10uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL
CB-87-GT98_1uM Dose=1uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL
CB-87-RB49_0.01uM Dose=0.01uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5
CB-87-RB49_0.1uM Dose=0.1uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5
CB-87-RB49_10uM Dose=10uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5
CB-87-RB49_1uM Dose=1uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5
CB-88-LG34_0.01uM Dose=0.01uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1
CB-88-LG34_0.1uM Dose=0.1uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1
CB-88-LG34_10uM Dose=10uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1
CB-88-LG34_1uM Dose=1uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1
CB-88-OC19_0.01uM Dose=0.01uM, Prenalterol, beta-Adrenoceptor Agonists targeting ADRB1
CB-88-OC19_0.1uM Dose=0.1uM, Prenalterol, beta-Adrenoceptor Agonists targeting ADRB1
CB-88-OC19_1uM Dose=1uM, Prenalterol, beta-Adrenoceptor Agonists targeting ADRB1
CB-92-FS28_0.01uM Dose=0.01uM
CB-92-FS28_0.1uM Dose=0.1uM
CB-92-FS28_10uM Dose=10uM
CB-92-FS28_1uM Dose=1uM
CB-92-VC05_0.01uM Dose=0.01uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R
CB-92-VC05_0.1uM Dose=0.1uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R
CB-92-VC05_10uM Dose=10uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R
CB-92-VC05_1uM Dose=1uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R
CB-93-YZ07_0.01uM Dose=0.01uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
CB-93-YZ07_0.1uM Dose=0.1uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
CB-93-YZ07_10uM Dose=10uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
CB-93-YZ07_1uM Dose=1uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
CB-97-LV32_0.01uM Dose=0.01uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1
CB-97-LV32_0.1uM Dose=0.1uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1
CB-97-LV32_10uM Dose=10uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1
CB-97-LV32_1uM Dose=1uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1
CB-99-NG16_0.01uM Dose=0.01uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD
CB-99-NG16_0.1uM Dose=0.1uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD
CB-99-NG16_10uM Dose=10uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD
CB-99-NG16_1uM Dose=1uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD
CB-99-OG76_0.01uM Dose=0.01uM
CB-99-OG76_0.1uM Dose=0.1uM
CB-99-OG76_10uM Dose=10uM
CB-99-OG76_1uM Dose=1uM
CC-00-ZO24_0.01uM Dose=0.01uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R
CC-00-ZO24_0.1uM Dose=0.1uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R
CC-00-ZO24_10uM Dose=10uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R
CC-00-ZO24_1uM Dose=1uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R
CC-01-ER18_0.01uM Dose=0.01uM, Pirodomast
CC-01-ER18_0.1uM Dose=0.1uM, Pirodomast
CC-01-ER18_10uM Dose=10uM, Pirodomast
CC-01-ER18_1uM Dose=1uM, Pirodomast
CC-01-PR23_0.01uM Dose=0.01uM, Saredutant, Tachykinin NK2 Antagonists targeting TACR2
CC-01-PR23_0.1uM Dose=0.1uM, Saredutant, Tachykinin NK2 Antagonists targeting TACR2
CC-01-PR23_10uM Dose=10uM, Saredutant, Tachykinin NK2 Antagonists targeting TACR2
CC-03-PW00_0.01uM Dose=0.01uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH
CC-03-PW00_0.1uM Dose=0.1uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH
CC-03-PW00_10uM Dose=10uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH
CC-03-PW00_1uM Dose=1uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH
CC-04-FJ21_10uM Dose=10uM, ML315, CLK4 inhibitor targeting CLK4
CC-04-WK34_0.01uM Dose=0.01uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1
CC-04-WK34_0.1uM Dose=0.1uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1
CC-04-WK34_10uM Dose=10uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1
CC-04-WK34_1uM Dose=1uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1
CC-04-YT10_0.01uM Dose=0.01uM
CC-04-YT10_0.1uM Dose=0.1uM
CC-04-YT10_10uM Dose=10uM
CC-04-YT10_1uM Dose=1uM
CC-05-MK46_0.01uM Dose=0.01uM, (RS)-4-Carboxy-3-hydroxyphenylglycine
CC-05-MK46_0.1uM Dose=0.1uM, (RS)-4-Carboxy-3-hydroxyphenylglycine
CC-05-MK46_10uM Dose=10uM, (RS)-4-Carboxy-3-hydroxyphenylglycine
CC-05-MK46_1uM Dose=1uM, (RS)-4-Carboxy-3-hydroxyphenylglycine
CC-06-WH01_0.01uM Dose=0.01uM
CC-06-WH01_0.1uM Dose=0.1uM
CC-06-WH01_10uM Dose=10uM
CC-06-WH01_1uM Dose=1uM
CC-07-DV77_0.01uM Dose=0.01uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A
CC-07-DV77_0.1uM Dose=0.1uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A
CC-07-DV77_10uM Dose=10uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A
CC-07-DV77_1uM Dose=1uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A
CC-07-LB64_0.01uM Dose=0.01uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one
CC-07-LB64_0.1uM Dose=0.1uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one
CC-07-LB64_10uM Dose=10uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one
CC-07-LB64_1uM Dose=1uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one
CC-08-JZ09_0.01uM Dose=0.01uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4
CC-08-JZ09_0.1uM Dose=0.1uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4
CC-08-JZ09_10uM Dose=10uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4
CC-08-JZ09_1uM Dose=1uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4
CC-09-YG11_0.01uM Dose=0.01uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2
CC-09-YG11_0.1uM Dose=0.1uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2
CC-09-YG11_10uM Dose=10uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2
CC-09-YG11_1uM Dose=1uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2
CC-14-WK34_0.01uM Dose=0.01uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2
CC-14-WK34_0.1uM Dose=0.1uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2
CC-14-WK34_10uM Dose=10uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2
CC-14-WK34_1uM Dose=1uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2
CC-15-HU70_0.01uM Dose=0.01uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12
CC-15-HU70_0.1uM Dose=0.1uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12
CC-15-HU70_10uM Dose=10uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12
CC-15-HU70_1uM Dose=1uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12
CC-15-MK46_0.01uM Dose=0.01uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2
CC-15-MK46_0.1uM Dose=0.1uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2
CC-15-MK46_10uM Dose=10uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2
CC-15-MK46_1uM Dose=1uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2
CC-15-TX17_0.01uM Dose=0.01uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10
CC-15-TX17_0.1uM Dose=0.1uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10
CC-15-TX17_10uM Dose=10uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10
CC-15-TX17_1uM Dose=1uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10
CC-16-ZE49_0.01uM Dose=0.01uM, Linopirdine, Acetylcholine Release Enhancers targeting KCNQ1
CC-16-ZE49_0.1uM Dose=0.1uM, Linopirdine, Acetylcholine Release Enhancers targeting KCNQ1
CC-16-ZE49_1uM Dose=1uM, Linopirdine, Acetylcholine Release Enhancers targeting KCNQ1
CC-17-HI11_0.01uM Dose=0.01uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
CC-17-HI11_0.1uM Dose=0.1uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
CC-17-HI11_10uM Dose=10uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
CC-17-HI11_1uM Dose=1uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
CC-17-JL38_0.01uM Dose=0.01uM, Ilk-IN-1 targeting ILK
CC-17-JL38_0.1uM Dose=0.1uM, Ilk-IN-1 targeting ILK
CC-17-JL38_10uM Dose=10uM, Ilk-IN-1 targeting ILK
CC-17-JL38_1uM Dose=1uM, Ilk-IN-1 targeting ILK
CC-18-YW57_0.01uM Dose=0.01uM
CC-18-YW57_0.1uM Dose=0.1uM
CC-18-YW57_10uM Dose=10uM
CC-18-YW57_1uM Dose=1uM
CC-20-FN31_0.01uM Dose=0.01uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1
CC-20-FN31_0.1uM Dose=0.1uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1
CC-20-FN31_10uM Dose=10uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1
CC-20-FN31_1uM Dose=1uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1
CC-20-ZO24_0.01uM Dose=0.01uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2
CC-20-ZO24_0.1uM Dose=0.1uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2
CC-20-ZO24_10uM Dose=10uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2
CC-20-ZO24_1uM Dose=1uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2
CC-21-IE22_0.01uM Dose=0.01uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1
CC-21-IE22_0.1uM Dose=0.1uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1
CC-21-IE22_10uM Dose=10uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1
CC-21-IE22_1uM Dose=1uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1
CC-25-QN53_0.01uM Dose=0.01uM, Medetomidine, ADRA2A agonist;ADRA2B agonist;alpha2-Adrenoceptor Agonists;Extracellular-regulated kinase (ERK) Activators;ADRA2C agonist targeting ADRA2B, ADRA2C, MAPK13
CC-25-QN53_0.1uM Dose=0.1uM, Medetomidine, ADRA2A agonist;ADRA2B agonist;alpha2-Adrenoceptor Agonists;Extracellular-regulated kinase (ERK) Activators;ADRA2C agonist targeting ADRA2B, ADRA2C, MAPK13
CC-25-QN53_10uM Dose=10uM, Medetomidine, ADRA2A agonist;ADRA2B agonist;alpha2-Adrenoceptor Agonists;Extracellular-regulated kinase (ERK) Activators;ADRA2C agonist targeting ADRA2B, ADRA2C, MAPK13
CC-25-QN53_1uM Dose=1uM, Medetomidine, ADRA2A agonist;ADRA2B agonist;alpha2-Adrenoceptor Agonists;Extracellular-regulated kinase (ERK) Activators;ADRA2C agonist targeting ADRA2B, ADRA2C, MAPK13
CC-29-RG66_0.01uM Dose=0.01uM
CC-29-RG66_0.1uM Dose=0.1uM
CC-29-RG66_10uM Dose=10uM
CC-29-RG66_1uM Dose=1uM
CC-30-TN36_0.1uM Dose=0.1uM, Benalfocin, alpha2-Adrenoceptor Antagonists targeting ADRA1B
CC-30-TN36_10uM Dose=10uM, Benalfocin, alpha2-Adrenoceptor Antagonists targeting ADRA1B
CC-30-TN36_1uM Dose=1uM, Benalfocin, alpha2-Adrenoceptor Antagonists targeting ADRA1B
CC-31-VS31_0.01uM Dose=0.01uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1
CC-31-VS31_0.1uM Dose=0.1uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1
CC-31-VS31_10uM Dose=10uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1
CC-31-VS31_1uM Dose=1uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1
CC-37-QW80_0.01uM Dose=0.01uM
CC-37-QW80_0.1uM Dose=0.1uM
CC-37-QW80_10uM Dose=10uM
CC-37-QW80_1uM Dose=1uM
CC-41-SI77_0.01uM Dose=0.01uM, 5-(2-chloro-4-cyclopropylphenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-4-methyl-1,2-oxazole-3-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1
CC-41-SI77_10uM Dose=10uM, 5-(2-chloro-4-cyclopropylphenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-4-methyl-1,2-oxazole-3-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1
CC-42-ZV45_0.01uM Dose=0.01uM, (S)-2-amino-5-phosphonopentanoic acid
CC-42-ZV45_0.1uM Dose=0.1uM, (S)-2-amino-5-phosphonopentanoic acid
CC-42-ZV45_10uM Dose=10uM, (S)-2-amino-5-phosphonopentanoic acid
CC-42-ZV45_1uM Dose=1uM, (S)-2-amino-5-phosphonopentanoic acid
CC-44-MG29_0.01uM Dose=0.01uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
CC-44-MG29_0.1uM Dose=0.1uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
CC-44-MG29_10uM Dose=10uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
CC-44-MG29_1uM Dose=1uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
CC-46-CE74_0.01uM Dose=0.01uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4
CC-46-CE74_0.1uM Dose=0.1uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4
CC-46-CE74_10uM Dose=10uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4
CC-46-CE74_1uM Dose=1uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4
CC-47-VS90_0.01uM Dose=0.01uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB
CC-47-VS90_0.1uM Dose=0.1uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB
CC-47-VS90_10uM Dose=10uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB
CC-47-VS90_1uM Dose=1uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB
CC-48-OM48_0.01uM Dose=0.01uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2
CC-48-OM48_0.1uM Dose=0.1uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2
CC-48-OM48_10uM Dose=10uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2
CC-48-OM48_1uM Dose=1uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2
CC-48-ZJ56_10uM Dose=10uM
CC-49-CQ25_0.01uM Dose=0.01uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
CC-49-CQ25_0.1uM Dose=0.1uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
CC-49-CQ25_10uM Dose=10uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
CC-49-CQ25_1uM Dose=1uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
CC-50-FK24_0.01uM Dose=0.01uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2
CC-50-FK24_0.1uM Dose=0.1uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2
CC-50-FK24_10uM Dose=10uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2
CC-50-FK24_1uM Dose=1uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2
CC-51-KS26_0.01uM Dose=0.01uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B
CC-51-KS26_0.1uM Dose=0.1uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B
CC-51-KS26_10uM Dose=10uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B
CC-51-KS26_1uM Dose=1uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B
CC-55-CD84_0.01uM Dose=0.01uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB
CC-55-CD84_0.1uM Dose=0.1uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB
CC-55-CD84_10uM Dose=10uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB
CC-55-CD84_1uM Dose=1uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB
CC-56-MO03_0.01uM Dose=0.01uM, 4-(1H-indol-3-yl)pyrimidin-2-amine
CC-56-MO03_0.1uM Dose=0.1uM, 4-(1H-indol-3-yl)pyrimidin-2-amine
CC-56-MO03_10uM Dose=10uM, 4-(1H-indol-3-yl)pyrimidin-2-amine
CC-56-MO03_1uM Dose=1uM, 4-(1H-indol-3-yl)pyrimidin-2-amine
CC-58-DF11_0.01uM Dose=0.01uM, Xanomeline, Muscarinic M1 receptor agonist;Cholinergic Muscarinic 1-4 agonist;Muscarinic M4 receptor agonist;Muscarinic M5 receptor agonist targeting CHRM1, CHRM4, CHRM5
CC-58-DF11_0.1uM Dose=0.1uM, Xanomeline, Muscarinic M1 receptor agonist;Cholinergic Muscarinic 1-4 agonist;Muscarinic M4 receptor agonist;Muscarinic M5 receptor agonist targeting CHRM1, CHRM4, CHRM5
CC-58-DF11_10uM Dose=10uM, Xanomeline, Muscarinic M1 receptor agonist;Cholinergic Muscarinic 1-4 agonist;Muscarinic M4 receptor agonist;Muscarinic M5 receptor agonist targeting CHRM1, CHRM4, CHRM5
CC-58-JZ09_0.01uM Dose=0.01uM, LCK and PI3K dual inhibitor, also targets mTOR
CC-58-JZ09_10uM Dose=10uM, LCK and PI3K dual inhibitor, also targets mTOR
CC-58-RP30_0.01uM Dose=0.01uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP
CC-58-RP30_0.1uM Dose=0.1uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP
CC-58-RP30_10uM Dose=10uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP
CC-58-RP30_1uM Dose=1uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP
CC-61-HH09_0.01uM Dose=0.01uM, 6-Chrysenamine targeting HPRT1
CC-61-HH09_10uM Dose=10uM, 6-Chrysenamine targeting HPRT1
CC-61-HH09_1uM Dose=1uM, 6-Chrysenamine targeting HPRT1
CC-61-KS26_0.01uM Dose=0.01uM, PK 11195, Pregnane X Receptor (PXR) Agonists;Peripheral Benzodiazepine Receptor (PBR) Antagonists;Constitutive Androstane Receptor (CAR) Antagonists targeting TSPO, NR1I2, NR1I3
CC-61-KS26_10uM Dose=10uM, PK 11195, Pregnane X Receptor (PXR) Agonists;Peripheral Benzodiazepine Receptor (PBR) Antagonists;Constitutive Androstane Receptor (CAR) Antagonists targeting TSPO, NR1I2, NR1I3
CC-62-XM29_0.01uM Dose=0.01uM, Skf-81297, DRD1 agonist targeting DRD1
CC-62-XM29_0.1uM Dose=0.1uM, Skf-81297, DRD1 agonist targeting DRD1
CC-62-XM29_10uM Dose=10uM, Skf-81297, DRD1 agonist targeting DRD1
CC-62-XM29_1uM Dose=1uM, Skf-81297, DRD1 agonist targeting DRD1
CC-67-LI41_0.01uM Dose=0.01uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
CC-67-LI41_0.1uM Dose=0.1uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
CC-67-LI41_10uM Dose=10uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
CC-67-LI41_1uM Dose=1uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
CC-68-YZ44_0.01uM Dose=0.01uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CC-68-YZ44_0.1uM Dose=0.1uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CC-68-YZ44_10uM Dose=10uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CC-68-YZ44_1uM Dose=1uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CC-70-BD07_0.01uM Dose=0.01uM, Voriconazole Impurity 7
CC-70-BD07_0.1uM Dose=0.1uM, Voriconazole Impurity 7
CC-70-BD07_10uM Dose=10uM, Voriconazole Impurity 7
CC-70-BD07_1uM Dose=1uM, Voriconazole Impurity 7
CC-72-ZV25_0.01uM Dose=0.01uM, N-(1,2-diphenylethyl)-4,5-dihydrothiazol-2-amine, alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA2A, ADRA2B
CC-72-ZV25_0.1uM Dose=0.1uM, N-(1,2-diphenylethyl)-4,5-dihydrothiazol-2-amine, alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA2A, ADRA2B
CC-72-ZV25_1uM Dose=1uM, N-(1,2-diphenylethyl)-4,5-dihydrothiazol-2-amine, alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA2A, ADRA2B
CC-84-JQ48_0.01uM Dose=0.01uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2
CC-84-JQ48_0.1uM Dose=0.1uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2
CC-84-JQ48_10uM Dose=10uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2
CC-84-JQ48_1uM Dose=1uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2
CC-84-QJ26_0.01uM Dose=0.01uM, Fluoxetine, Serotonin Transporter (SERT) Inhibitors;Sodium Channel Blockers targeting SLC6A4
CC-84-QJ26_0.1uM Dose=0.1uM, Fluoxetine, Serotonin Transporter (SERT) Inhibitors;Sodium Channel Blockers targeting SLC6A4
CC-84-QJ26_10uM Dose=10uM, Fluoxetine, Serotonin Transporter (SERT) Inhibitors;Sodium Channel Blockers targeting SLC6A4
CC-85-AY05_0.01uM Dose=0.01uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB
CC-85-AY05_0.1uM Dose=0.1uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB
CC-85-AY05_10uM Dose=10uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB
CC-85-AY05_1uM Dose=1uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB
CC-85-XK71_0.01uM Dose=0.01uM, GW 4064, Farnesoid X Receptor (FXR) Agonists targeting NR1H4
CC-85-XK71_0.1uM Dose=0.1uM, GW 4064, Farnesoid X Receptor (FXR) Agonists targeting NR1H4
CC-85-XK71_1uM Dose=1uM, GW 4064, Farnesoid X Receptor (FXR) Agonists targeting NR1H4
CC-86-IO63_0.01uM Dose=0.01uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6
CC-86-IO63_0.1uM Dose=0.1uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6
CC-86-IO63_10uM Dose=10uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6
CC-86-IO63_1uM Dose=1uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6
CC-88-JZ09_0.01uM Dose=0.01uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide
CC-88-JZ09_0.1uM Dose=0.1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide
CC-88-JZ09_10uM Dose=10uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide
CC-88-JZ09_1uM Dose=1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide
CC-90-EX35_0.01uM Dose=0.01uM
CC-90-EX35_0.1uM Dose=0.1uM
CC-90-EX35_10uM Dose=10uM
CC-90-EX35_1uM Dose=1uM
CC-90-FE70_0.01uM Dose=0.01uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12
CC-90-FE70_0.1uM Dose=0.1uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12
CC-90-FE70_10uM Dose=10uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12
CC-90-FE70_1uM Dose=1uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12
CC-90-NK44_0.01uM Dose=0.01uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A
CC-90-NK44_0.1uM Dose=0.1uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A
CC-90-NK44_10uM Dose=10uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A
CC-90-NK44_1uM Dose=1uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A
CC-91-RO81_0.01uM Dose=0.01uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3
CC-91-RO81_0.1uM Dose=0.1uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3
CC-91-RO81_10uM Dose=10uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3
CC-91-RO81_1uM Dose=1uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3
CC-91-VE57_0.01uM Dose=0.01uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4
CC-91-VE57_0.1uM Dose=0.1uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4
CC-91-VE57_10uM Dose=10uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4
CC-91-VE57_1uM Dose=1uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4
CC-93-RP38_0.01uM Dose=0.01uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
CC-93-RP38_0.1uM Dose=0.1uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
CC-93-RP38_10uM Dose=10uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
CC-93-RP38_1uM Dose=1uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
CC-98-YC44_0.01uM Dose=0.01uM, N-(4,4-Diphenyl-3-butenyl)nipecotic acid, GAT-1 Inhibitors targeting SLC6A1, SLC6A12
CC-98-YC44_0.1uM Dose=0.1uM, N-(4,4-Diphenyl-3-butenyl)nipecotic acid, GAT-1 Inhibitors targeting SLC6A1, SLC6A12
CC-98-YC44_10uM Dose=10uM, N-(4,4-Diphenyl-3-butenyl)nipecotic acid, GAT-1 Inhibitors targeting SLC6A1, SLC6A12
CD-01-ZO61_10uM Dose=10uM, Fatty Acid Amide Hydrolase (FAAH) Inhibitors
CD-01-ZO61_1uM Dose=1uM, Fatty Acid Amide Hydrolase (FAAH) Inhibitors
CD-03-QC42_0.01uM Dose=0.01uM, 3-Aminopropyl(methyl)phosphinic acid, GABA(B) Agonists;GABBR1 agonist targeting GABBR1, GABBR2
CD-03-QC42_10uM Dose=10uM, 3-Aminopropyl(methyl)phosphinic acid, GABA(B) Agonists;GABBR1 agonist targeting GABBR1, GABBR2
CD-03-QC42_1uM Dose=1uM, 3-Aminopropyl(methyl)phosphinic acid, GABA(B) Agonists;GABBR1 agonist targeting GABBR1, GABBR2
CD-05-PU90_0.01uM Dose=0.01uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3
CD-05-PU90_0.1uM Dose=0.1uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3
CD-05-PU90_10uM Dose=10uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3
CD-05-PU90_1uM Dose=1uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3
CD-07-GB34_0.01uM Dose=0.01uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F
CD-07-GB34_0.1uM Dose=0.1uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F
CD-07-GB34_10uM Dose=10uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F
CD-07-GB34_1uM Dose=1uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F
CD-08-MF16_0.01uM Dose=0.01uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1
CD-08-MF16_0.1uM Dose=0.1uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1
CD-08-MF16_10uM Dose=10uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1
CD-08-MF16_1uM Dose=1uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1
CD-10-LX95_0.01uM Dose=0.01uM, (E)-[5-(2-diethylcarbamoyl-1-methyl-vinyl)-2-(2,6-difluorobenzyloxy)-phenyl]-acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2
CD-10-LX95_10uM Dose=10uM, (E)-[5-(2-diethylcarbamoyl-1-methyl-vinyl)-2-(2,6-difluorobenzyloxy)-phenyl]-acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2
CD-10-LX95_1uM Dose=1uM, (E)-[5-(2-diethylcarbamoyl-1-methyl-vinyl)-2-(2,6-difluorobenzyloxy)-phenyl]-acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2
CD-12-NI84_0.01uM Dose=0.01uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2
CD-12-NI84_0.1uM Dose=0.1uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2
CD-12-NI84_10uM Dose=10uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2
CD-12-NI84_1uM Dose=1uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2
CD-13-QZ32_0.01uM Dose=0.01uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CD-13-QZ32_0.1uM Dose=0.1uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CD-13-QZ32_10uM Dose=10uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CD-13-QZ32_1uM Dose=1uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CD-16-KY17_0.01uM Dose=0.01uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4
CD-16-KY17_0.1uM Dose=0.1uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4
CD-16-KY17_10uM Dose=10uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4
CD-16-KY17_1uM Dose=1uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4
CD-18-KC24_0.1uM Dose=0.1uM, Finasteride, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
CD-18-KC24_10uM Dose=10uM, Finasteride, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
CD-18-RM48_0.01uM Dose=0.01uM, Rabeprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
CD-18-RM48_0.1uM Dose=0.1uM, Rabeprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
CD-18-RM48_10uM Dose=10uM, Rabeprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
CD-18-RM48_1uM Dose=1uM, Rabeprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
CD-20-GE75_0.01uM Dose=0.01uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL
CD-20-GE75_0.1uM Dose=0.1uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL
CD-20-GE75_10uM Dose=10uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL
CD-20-GE75_1uM Dose=1uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL
CD-20-MH57_0.01uM Dose=0.01uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3
CD-20-MH57_0.1uM Dose=0.1uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3
CD-20-MH57_10uM Dose=10uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3
CD-20-MH57_1uM Dose=1uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3
CD-21-MI27_0.01uM Dose=0.01uM, Deoxyuridine
CD-21-MI27_0.1uM Dose=0.1uM, Deoxyuridine
CD-21-MI27_10uM Dose=10uM, Deoxyuridine
CD-21-MI27_1uM Dose=1uM, Deoxyuridine
CD-25-PY50_10uM Dose=10uM, Lumacaftor, Specific stabilization of CFTR MSD1, specifically TMD1. targeting CFTR
CD-26-MB82_0.01uM Dose=0.01uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A
CD-26-MB82_0.1uM Dose=0.1uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A
CD-26-MB82_10uM Dose=10uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A
CD-26-MB82_1uM Dose=1uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A
CD-29-EG36_0.1uM Dose=0.1uM, Sparfosic Acid, Aspartate Carbamoyltransferase Inhibitors;Antimetabolites targeting CAD
CD-29-EG36_1uM Dose=1uM, Sparfosic Acid, Aspartate Carbamoyltransferase Inhibitors;Antimetabolites targeting CAD
CD-30-AD57_0.01uM Dose=0.01uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1
CD-30-AD57_0.1uM Dose=0.1uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1
CD-30-AD57_10uM Dose=10uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1
CD-30-AD57_1uM Dose=1uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1
CD-30-JO39_10uM Dose=10uM, [2-chloro-3-(trifluoromethyl)phenyl]-[1-(5-fluoropyrimidin-2-yl)-6,7-dihydro-4H-triazolo[4,5-c]pyridin-5-yl]methanone, P2RX7 antagonist targeting P2RX7
CD-35-BD44_0.01uM Dose=0.01uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide
CD-35-BD44_0.1uM Dose=0.1uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide
CD-35-BD44_10uM Dose=10uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide
CD-35-BD44_1uM Dose=1uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide
CD-41-RE87_0.01uM Dose=0.01uM, (1R,2R)-2-[[6-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxy-1,3-benzothiazol-2-yl]amino]cyclohexan-1-ol, Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors targeting CSF1R
CD-41-RE87_0.1uM Dose=0.1uM, (1R,2R)-2-[[6-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxy-1,3-benzothiazol-2-yl]amino]cyclohexan-1-ol, Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors targeting CSF1R
CD-41-RE87_10uM Dose=10uM, (1R,2R)-2-[[6-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxy-1,3-benzothiazol-2-yl]amino]cyclohexan-1-ol, Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors targeting CSF1R
CD-44-XT40_0.01uM Dose=0.01uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2
CD-44-XT40_0.1uM Dose=0.1uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2
CD-44-XT40_10uM Dose=10uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2
CD-44-XT40_1uM Dose=1uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2
CD-47-BV87_0.01uM Dose=0.01uM, Atomoxetine, Norepinephrine Transporter (NET) Inhibitors targeting SLC6A2
CD-47-BV87_0.1uM Dose=0.1uM, Atomoxetine, Norepinephrine Transporter (NET) Inhibitors targeting SLC6A2
CD-47-BV87_10uM Dose=10uM, Atomoxetine, Norepinephrine Transporter (NET) Inhibitors targeting SLC6A2
CD-47-YL43_0.01uM Dose=0.01uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B
CD-47-YL43_0.1uM Dose=0.1uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B
CD-47-YL43_10uM Dose=10uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B
CD-47-YL43_1uM Dose=1uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B
CD-49-HJ53_0.01uM Dose=0.01uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13
CD-49-HJ53_0.1uM Dose=0.1uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13
CD-49-HJ53_10uM Dose=10uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13
CD-49-HJ53_1uM Dose=1uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13
CD-54-FJ31_0.01uM Dose=0.01uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT
CD-54-FJ31_0.1uM Dose=0.1uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT
CD-54-FJ31_10uM Dose=10uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT
CD-54-FJ31_1uM Dose=1uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT
CD-55-ZN88_0.01uM Dose=0.01uM, cyclo(Arg-Gly-Asp-D-Phe-Val), Integrin binder;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5
CD-55-ZN88_10uM Dose=10uM, cyclo(Arg-Gly-Asp-D-Phe-Val), Integrin binder;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5
CD-55-ZN88_1uM Dose=1uM, cyclo(Arg-Gly-Asp-D-Phe-Val), Integrin binder;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5
CD-59-MG26_0.01uM Dose=0.01uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK
CD-59-MG26_0.1uM Dose=0.1uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK
CD-59-MG26_10uM Dose=10uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK
CD-59-MG26_1uM Dose=1uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK
CD-59-PT17_0.01uM Dose=0.01uM, FK-739 free acid, Angiotensin Receptor Antagonists targeting AGTR1
CD-59-PT17_10uM Dose=10uM, FK-739 free acid, Angiotensin Receptor Antagonists targeting AGTR1
CD-59-PT17_1uM Dose=1uM, FK-739 free acid, Angiotensin Receptor Antagonists targeting AGTR1
CD-62-GL56_0.01uM Dose=0.01uM, Fenesin
CD-62-GL56_0.1uM Dose=0.1uM, Fenesin
CD-62-GL56_10uM Dose=10uM, Fenesin
CD-62-GL56_1uM Dose=1uM, Fenesin
CD-63-FZ67_0.01uM Dose=0.01uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB
CD-63-FZ67_0.1uM Dose=0.1uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB
CD-63-FZ67_10uM Dose=10uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB
CD-63-FZ67_1uM Dose=1uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB
CD-70-GD72_0.01uM Dose=0.01uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1
CD-70-GD72_0.1uM Dose=0.1uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1
CD-70-GD72_10uM Dose=10uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1
CD-70-GD72_1uM Dose=1uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1
CD-75-QY45_0.01uM Dose=0.01uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A
CD-75-QY45_0.1uM Dose=0.1uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A
CD-75-QY45_10uM Dose=10uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A
CD-75-QY45_1uM Dose=1uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A
CD-77-YB29_0.1uM Dose=0.1uM, NMDA Glycine-Site Antagonists
CD-77-YB29_10uM Dose=10uM, NMDA Glycine-Site Antagonists
CD-77-YB29_1uM Dose=1uM, NMDA Glycine-Site Antagonists
CD-80-ZD47_0.01uM Dose=0.01uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT
CD-80-ZD47_0.1uM Dose=0.1uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT
CD-80-ZD47_10uM Dose=10uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT
CD-80-ZD47_1uM Dose=1uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT
CD-84-BU23_0.01uM Dose=0.01uM, Oseltamivir
CD-84-BU23_0.1uM Dose=0.1uM, Oseltamivir
CD-84-BU23_10uM Dose=10uM, Oseltamivir
CD-84-BU23_1uM Dose=1uM, Oseltamivir
CD-84-ET75_0.1uM Dose=0.1uM
CD-84-ET75_10uM Dose=10uM
CD-84-FJ21_0.01uM Dose=0.01uM, Dpn 205-734
CD-84-FJ21_0.1uM Dose=0.1uM, Dpn 205-734
CD-84-FJ21_10uM Dose=10uM, Dpn 205-734
CD-84-FJ21_1uM Dose=1uM, Dpn 205-734
CD-88-UF56_0.01uM Dose=0.01uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CD-88-UF56_0.1uM Dose=0.1uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CD-88-UF56_10uM Dose=10uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CD-88-UF56_1uM Dose=1uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CD-89-CG91_0.01uM Dose=0.01uM
CD-89-CG91_0.1uM Dose=0.1uM
CD-89-CG91_10uM Dose=10uM
CD-89-CG91_1uM Dose=1uM
CD-90-SN76_0.01uM Dose=0.01uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1
CD-90-SN76_0.1uM Dose=0.1uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1
CD-90-SN76_1uM Dose=1uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1
CD-91-BY60_0.01uM Dose=0.01uM, N'-(5-chlorobenzofuran-2-carbonyl)-2-(trifluoromethyl)benzenesulfonohydrazide, Branched amino acid aminotransferase 1 inhibitor targeting BCAT1
CD-91-BY60_0.1uM Dose=0.1uM, N'-(5-chlorobenzofuran-2-carbonyl)-2-(trifluoromethyl)benzenesulfonohydrazide, Branched amino acid aminotransferase 1 inhibitor targeting BCAT1
CD-91-BY60_1uM Dose=1uM, N'-(5-chlorobenzofuran-2-carbonyl)-2-(trifluoromethyl)benzenesulfonohydrazide, Branched amino acid aminotransferase 1 inhibitor targeting BCAT1
CD-91-MI27_0.01uM Dose=0.01uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7
CD-91-MI27_0.1uM Dose=0.1uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7
CD-91-MI27_10uM Dose=10uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7
CD-91-MI27_1uM Dose=1uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7
CD-96-HO43_0.01uM Dose=0.01uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ
CD-96-HO43_0.1uM Dose=0.1uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ
CD-96-HO43_10uM Dose=10uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ
CD-96-HO43_1uM Dose=1uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ
CD-97-ZV62_0.01uM Dose=0.01uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B
CD-97-ZV62_0.1uM Dose=0.1uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B
CD-97-ZV62_10uM Dose=10uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B
CD-97-ZV62_1uM Dose=1uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B
CE-00-EK89_0.01uM Dose=0.01uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide
CE-00-EK89_0.1uM Dose=0.1uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide
CE-00-EK89_10uM Dose=10uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide
CE-00-EK89_1uM Dose=1uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide
CE-02-FZ80_0.01uM Dose=0.01uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1
CE-02-FZ80_0.1uM Dose=0.1uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1
CE-02-FZ80_10uM Dose=10uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1
CE-02-FZ80_1uM Dose=1uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1
CE-03-PW65_0.1uM Dose=0.1uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8
CE-03-PW65_10uM Dose=10uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8
CE-03-PW65_1uM Dose=1uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8
CE-03-YQ91_0.01uM Dose=0.01uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine
CE-03-YQ91_0.1uM Dose=0.1uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine
CE-03-YQ91_10uM Dose=10uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine
CE-03-YQ91_1uM Dose=1uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine
CE-04-HT15_0.01uM Dose=0.01uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1
CE-04-HT15_0.1uM Dose=0.1uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1
CE-04-HT15_10uM Dose=10uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1
CE-04-HT15_1uM Dose=1uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1
CE-04-OJ56_0.01uM Dose=0.01uM, 2-(2-Aminoethyl)pyridine
CE-04-OJ56_0.1uM Dose=0.1uM, 2-(2-Aminoethyl)pyridine
CE-04-OJ56_10uM Dose=10uM, 2-(2-Aminoethyl)pyridine
CE-04-OJ56_1uM Dose=1uM, 2-(2-Aminoethyl)pyridine
CE-04-PX35_0.01uM Dose=0.01uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1
CE-04-PX35_0.1uM Dose=0.1uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1
CE-04-PX35_10uM Dose=10uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1
CE-04-PX35_1uM Dose=1uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1
CE-09-HG76_0.01uM Dose=0.01uM, Triprolidine, HRH1 antagonist targeting HRH1
CE-09-HG76_0.1uM Dose=0.1uM, Triprolidine, HRH1 antagonist targeting HRH1
CE-09-HG76_10uM Dose=10uM, Triprolidine, HRH1 antagonist targeting HRH1
CE-09-HG76_1uM Dose=1uM, Triprolidine, HRH1 antagonist targeting HRH1
CE-09-ZT22_0.01uM Dose=0.01uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2
CE-09-ZT22_0.1uM Dose=0.1uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2
CE-09-ZT22_10uM Dose=10uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2
CE-09-ZT22_1uM Dose=1uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2
CE-10-WA05_0.01uM Dose=0.01uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide
CE-10-WA05_0.1uM Dose=0.1uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide
CE-10-WA05_10uM Dose=10uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide
CE-10-WA05_1uM Dose=1uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide
CE-14-SQ43_0.01uM Dose=0.01uM, 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole, Dopamine D4 Agonists targeting DRD4
CE-14-SQ43_10uM Dose=10uM, 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole, Dopamine D4 Agonists targeting DRD4
CE-15-DU45_0.01uM Dose=0.01uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3
CE-15-DU45_0.1uM Dose=0.1uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3
CE-15-DU45_10uM Dose=10uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3
CE-15-DU45_1uM Dose=1uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3
CE-15-YU05_0.01uM Dose=0.01uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1
CE-15-YU05_0.1uM Dose=0.1uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1
CE-15-YU05_10uM Dose=10uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1
CE-15-YU05_1uM Dose=1uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1
CE-17-FI51_0.01uM Dose=0.01uM, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester, CETP inhibitor targeting CETP
CE-17-FI51_10uM Dose=10uM, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester, CETP inhibitor targeting CETP
CE-17-FI51_1uM Dose=1uM, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester, CETP inhibitor targeting CETP
CE-18-AP15_0.01uM Dose=0.01uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CE-18-AP15_0.1uM Dose=0.1uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CE-18-AP15_10uM Dose=10uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CE-18-AP15_1uM Dose=1uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CE-18-AP85_0.01uM Dose=0.01uM
CE-18-AP85_0.1uM Dose=0.1uM
CE-18-AP85_10uM Dose=10uM
CE-18-AP85_1uM Dose=1uM
CE-18-CG29_0.01uM Dose=0.01uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1
CE-18-CG29_0.1uM Dose=0.1uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1
CE-18-CG29_10uM Dose=10uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1
CE-18-CG29_1uM Dose=1uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1
CE-18-ZM38_0.01uM Dose=0.01uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ
CE-18-ZM38_0.1uM Dose=0.1uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ
CE-18-ZM38_10uM Dose=10uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ
CE-18-ZM38_1uM Dose=1uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ
CE-19-PD79_0.01uM Dose=0.01uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4
CE-19-PD79_0.1uM Dose=0.1uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4
CE-19-PD79_10uM Dose=10uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4
CE-19-PD79_1uM Dose=1uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4
CE-20-VA70_0.01uM Dose=0.01uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6
CE-20-VA70_0.1uM Dose=0.1uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6
CE-20-VA70_10uM Dose=10uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6
CE-20-VA70_1uM Dose=1uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6
CE-21-AY10_0.1uM Dose=0.1uM, 1-Piperidinesulfonamide, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Carbonic anhydrase inhibitor targeting CA1, CA2, NAMPT
CE-21-AY10_1uM Dose=1uM, 1-Piperidinesulfonamide, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Carbonic anhydrase inhibitor targeting CA1, CA2, NAMPT
CE-21-UO81_0.01uM Dose=0.01uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
CE-21-UO81_0.1uM Dose=0.1uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
CE-21-UO81_10uM Dose=10uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
CE-21-UO81_1uM Dose=1uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2
CE-23-HP88_0.01uM Dose=0.01uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CE-23-HP88_0.1uM Dose=0.1uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CE-23-HP88_10uM Dose=10uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CE-23-HP88_1uM Dose=1uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CE-24-LQ98_0.01uM Dose=0.01uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide
CE-24-LQ98_0.1uM Dose=0.1uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide
CE-24-LQ98_10uM Dose=10uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide
CE-24-LQ98_1uM Dose=1uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide
CE-25-VD54_0.01uM Dose=0.01uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A
CE-25-VD54_0.1uM Dose=0.1uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A
CE-25-VD54_10uM Dose=10uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A
CE-25-VD54_1uM Dose=1uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A
CE-35-LA42_0.01uM Dose=0.01uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide
CE-35-LA42_0.1uM Dose=0.1uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide
CE-35-LA42_10uM Dose=10uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide
CE-35-LA42_1uM Dose=1uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide
CE-36-HY42_0.01uM Dose=0.01uM
CE-36-HY42_0.1uM Dose=0.1uM
CE-36-HY42_10uM Dose=10uM
CE-36-HY42_1uM Dose=1uM
CE-36-KR60_0.01uM Dose=0.01uM, Hydroxychloroquine
CE-36-KR60_0.1uM Dose=0.1uM, Hydroxychloroquine
CE-36-KR60_10uM Dose=10uM, Hydroxychloroquine
CE-36-KR60_1uM Dose=1uM, Hydroxychloroquine
CE-36-UR55_0.1uM Dose=0.1uM, 2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, Thromboxane Synthase Inhibitors targeting TBXAS1
CE-36-UR55_10uM Dose=10uM, 2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, Thromboxane Synthase Inhibitors targeting TBXAS1
CE-36-UR55_1uM Dose=1uM, 2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, Thromboxane Synthase Inhibitors targeting TBXAS1
CE-37-MS25_0.01uM Dose=0.01uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2
CE-37-MS25_0.1uM Dose=0.1uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2
CE-37-MS25_10uM Dose=10uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2
CE-37-MS25_1uM Dose=1uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2
CE-37-XI06_0.01uM Dose=0.01uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5
CE-37-XI06_0.1uM Dose=0.1uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5
CE-37-XI06_10uM Dose=10uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5
CE-37-XI06_1uM Dose=1uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5
CE-38-KX20_0.01uM Dose=0.01uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK
CE-38-KX20_0.1uM Dose=0.1uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK
CE-38-KX20_10uM Dose=10uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK
CE-38-KX20_1uM Dose=1uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK
CE-39-DG56_0.01uM Dose=0.01uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1
CE-39-DG56_0.1uM Dose=0.1uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1
CE-39-DG56_10uM Dose=10uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1
CE-39-DG56_1uM Dose=1uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1
CE-40-VU73_0.01uM Dose=0.01uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1
CE-40-VU73_0.1uM Dose=0.1uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1
CE-40-VU73_10uM Dose=10uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1
CE-40-VU73_1uM Dose=1uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1
CE-42-GB12_0.01uM Dose=0.01uM
CE-42-GB12_0.1uM Dose=0.1uM
CE-42-GB12_10uM Dose=10uM
CE-42-GB12_1uM Dose=1uM
CE-44-KU68_0.1uM Dose=0.1uM, Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Inhibitors of Signal Transduction Pathways
CE-44-KU68_1uM Dose=1uM, Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Inhibitors of Signal Transduction Pathways
CE-45-AD14_0.01uM Dose=0.01uM, Omigapil, Apoptosis Inhibitors;Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitors targeting GAPDH
CE-45-AD14_0.1uM Dose=0.1uM, Omigapil, Apoptosis Inhibitors;Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitors targeting GAPDH
CE-45-AD14_1uM Dose=1uM, Omigapil, Apoptosis Inhibitors;Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitors targeting GAPDH
CE-48-TP40_0.01uM Dose=0.01uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B
CE-48-TP40_0.1uM Dose=0.1uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B
CE-48-TP40_10uM Dose=10uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B
CE-48-TP40_1uM Dose=1uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B
CE-52-SB42_10uM Dose=10uM, 1-Aminobenzotriazole, Cytochrome P450 Inhibitors targeting CYP2W1
CE-52-SB42_1uM Dose=1uM, 1-Aminobenzotriazole, Cytochrome P450 Inhibitors targeting CYP2W1
CE-52-XV55_0.01uM Dose=0.01uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A
CE-52-XV55_0.1uM Dose=0.1uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A
CE-52-XV55_10uM Dose=10uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A
CE-52-XV55_1uM Dose=1uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A
CE-57-KI16_0.01uM Dose=0.01uM, CID 134691740, SPPL2A Inhibitor targeting SPPL2A
CE-57-KI16_0.1uM Dose=0.1uM, CID 134691740, SPPL2A Inhibitor targeting SPPL2A
CE-57-KI16_10uM Dose=10uM, CID 134691740, SPPL2A Inhibitor targeting SPPL2A
CE-58-XJ66_0.01uM Dose=0.01uM, Unoprostone Isopropyl
CE-58-XJ66_0.1uM Dose=0.1uM, Unoprostone Isopropyl
CE-58-XJ66_10uM Dose=10uM, Unoprostone Isopropyl
CE-58-XJ66_1uM Dose=1uM, Unoprostone Isopropyl
CE-66-GR30_0.01uM Dose=0.01uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2
CE-66-GR30_0.1uM Dose=0.1uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2
CE-66-GR30_10uM Dose=10uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2
CE-66-GR30_1uM Dose=1uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2
CE-68-CC69_0.01uM Dose=0.01uM
CE-68-CC69_0.1uM Dose=0.1uM
CE-68-CC69_10uM Dose=10uM
CE-68-CC69_1uM Dose=1uM
CE-69-FD64_0.01uM Dose=0.01uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1
CE-69-FD64_0.1uM Dose=0.1uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1
CE-69-FD64_10uM Dose=10uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1
CE-69-FD64_1uM Dose=1uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1
CE-69-HJ13_0.01uM Dose=0.01uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K
CE-69-HJ13_0.1uM Dose=0.1uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K
CE-69-HJ13_10uM Dose=10uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K
CE-69-HJ13_1uM Dose=1uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K
CE-69-VJ68_0.01uM Dose=0.01uM, Gallic Acid, PPARgamma Agonists;Apoptosis Inducers;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants targeting APP, PPARG
CE-69-VJ68_0.1uM Dose=0.1uM, Gallic Acid, PPARgamma Agonists;Apoptosis Inducers;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants targeting APP, PPARG
CE-69-VJ68_10uM Dose=10uM, Gallic Acid, PPARgamma Agonists;Apoptosis Inducers;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants targeting APP, PPARG
CE-70-KX45_0.01uM Dose=0.01uM, Bq-123, Endothelin ETA Receptor Antagonists targeting EDNRA
CE-70-KX45_0.1uM Dose=0.1uM, Bq-123, Endothelin ETA Receptor Antagonists targeting EDNRA
CE-70-KX45_1uM Dose=1uM, Bq-123, Endothelin ETA Receptor Antagonists targeting EDNRA
CE-70-RN96_0.01uM Dose=0.01uM, Phlorizin, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A1, SLC5A2
CE-70-RN96_0.1uM Dose=0.1uM, Phlorizin, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A1, SLC5A2
CE-70-RN96_1uM Dose=1uM, Phlorizin, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A1, SLC5A2
CE-72-GF32_0.01uM Dose=0.01uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR
CE-72-GF32_0.1uM Dose=0.1uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR
CE-72-GF32_10uM Dose=10uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR
CE-72-GF32_1uM Dose=1uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR
CE-72-SF92_0.01uM Dose=0.01uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6
CE-72-SF92_0.1uM Dose=0.1uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6
CE-72-SF92_10uM Dose=10uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6
CE-72-SF92_1uM Dose=1uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6
CE-73-JW90_0.01uM Dose=0.01uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2
CE-73-JW90_0.1uM Dose=0.1uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2
CE-73-JW90_10uM Dose=10uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2
CE-73-JW90_1uM Dose=1uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2
CE-73-XC72_0.01uM Dose=0.01uM, Type 1 deiodinase inhibitor;Thyroid peroxidase inhibitor targeting TPO, DIO1
CE-73-XC72_0.1uM Dose=0.1uM, Type 1 deiodinase inhibitor;Thyroid peroxidase inhibitor targeting TPO, DIO1
CE-73-XC72_10uM Dose=10uM, Type 1 deiodinase inhibitor;Thyroid peroxidase inhibitor targeting TPO, DIO1
CE-74-KU68_0.01uM Dose=0.01uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10
CE-74-KU68_0.1uM Dose=0.1uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10
CE-74-KU68_10uM Dose=10uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10
CE-74-KU68_1uM Dose=1uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10
CE-77-JB44_0.01uM Dose=0.01uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1
CE-77-JB44_0.1uM Dose=0.1uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1
CE-77-JB44_10uM Dose=10uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1
CE-77-JB44_1uM Dose=1uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1
CE-85-KN13_0.01uM Dose=0.01uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide
CE-85-KN13_0.1uM Dose=0.1uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide
CE-85-KN13_10uM Dose=10uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide
CE-85-KN13_1uM Dose=1uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide
CE-88-RJ81_0.01uM Dose=0.01uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide
CE-88-RJ81_0.1uM Dose=0.1uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide
CE-88-RJ81_10uM Dose=10uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide
CE-88-RJ81_1uM Dose=1uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide
CE-95-YX02_0.01uM Dose=0.01uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3
CE-95-YX02_0.1uM Dose=0.1uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3
CE-95-YX02_10uM Dose=10uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3
CE-95-YX02_1uM Dose=1uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3
CE-96-CZ90_0.01uM Dose=0.01uM
CE-96-CZ90_10uM Dose=10uM
CE-96-CZ90_1uM Dose=1uM
CE-96-GH46_0.01uM Dose=0.01uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CE-96-GH46_0.1uM Dose=0.1uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CE-96-GH46_10uM Dose=10uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CE-96-GH46_1uM Dose=1uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
CE-96-JE44_0.01uM Dose=0.01uM, A438079, P2X7 Receptor Antagonists targeting P2RX7
CE-96-JE44_0.1uM Dose=0.1uM, A438079, P2X7 Receptor Antagonists targeting P2RX7
CE-96-JE44_10uM Dose=10uM, A438079, P2X7 Receptor Antagonists targeting P2RX7
CE-99-NH84_0.1uM Dose=0.1uM, C3AR1 antagonist
CF-01-BY15_0.01uM Dose=0.01uM
CF-01-BY15_10uM Dose=10uM
CF-01-BY15_1uM Dose=1uM
CF-01-IO46_0.1uM Dose=0.1uM, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, Potassium Channel Blockers;Soluble Guanylyl Cyclase (sGC) Inhibitors targeting GUCY1A2, GUCY1A1, GUCY1B1
CF-01-IO46_10uM Dose=10uM, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, Potassium Channel Blockers;Soluble Guanylyl Cyclase (sGC) Inhibitors targeting GUCY1A2, GUCY1A1, GUCY1B1
CF-02-MS93_0.01uM Dose=0.01uM, Agi-6780, Isocitrate Dehydrogenase (NADP+) (IDPm, IDH2) (Arg140Gln Mutant) Inhibitors targeting IDH2
CF-02-MS93_0.1uM Dose=0.1uM, Agi-6780, Isocitrate Dehydrogenase (NADP+) (IDPm, IDH2) (Arg140Gln Mutant) Inhibitors targeting IDH2
CF-02-MS93_1uM Dose=1uM, Agi-6780, Isocitrate Dehydrogenase (NADP+) (IDPm, IDH2) (Arg140Gln Mutant) Inhibitors targeting IDH2
CF-03-QN99_0.01uM Dose=0.01uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8
CF-03-QN99_0.1uM Dose=0.1uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8
CF-03-QN99_10uM Dose=10uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8
CF-03-QN99_1uM Dose=1uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8
CF-15-FD69_0.01uM Dose=0.01uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12
CF-15-FD69_0.1uM Dose=0.1uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12
CF-15-FD69_10uM Dose=10uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12
CF-15-FD69_1uM Dose=1uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12
CF-15-GU15_0.01uM Dose=0.01uM
CF-15-GU15_0.1uM Dose=0.1uM
CF-15-GU15_1uM Dose=1uM
CF-17-PV42_0.1uM Dose=0.1uM, Dsp 4, Adrenergic Neuron Blockers targeting SLC22A3, SLC22A2
CF-17-PV42_10uM Dose=10uM, Dsp 4, Adrenergic Neuron Blockers targeting SLC22A3, SLC22A2
CF-22-IS33_0.01uM Dose=0.01uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL
CF-22-IS33_0.1uM Dose=0.1uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL
CF-22-IS33_10uM Dose=10uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL
CF-22-IS33_1uM Dose=1uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL
CF-22-OS28_0.01uM Dose=0.01uM, [2-(5-Ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS
CF-22-OS28_0.1uM Dose=0.1uM, [2-(5-Ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS
CF-22-OS28_10uM Dose=10uM, [2-(5-Ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS
CF-22-OS28_1uM Dose=1uM, [2-(5-Ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS
CF-24-KQ98_0.01uM Dose=0.01uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1
CF-24-KQ98_0.1uM Dose=0.1uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1
CF-24-KQ98_10uM Dose=10uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1
CF-24-KQ98_1uM Dose=1uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1
CF-24-PH37_0.01uM Dose=0.01uM, ethyl 2-(1H-imidazol-4-yl)acetate, IL-10 Production Enhancers targeting IL10
CF-24-PH37_0.1uM Dose=0.1uM, ethyl 2-(1H-imidazol-4-yl)acetate, IL-10 Production Enhancers targeting IL10
CF-24-PH37_10uM Dose=10uM, ethyl 2-(1H-imidazol-4-yl)acetate, IL-10 Production Enhancers targeting IL10
CF-26-ME34_10uM Dose=10uM, N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide, 15-Lipoxygenase Inhibitors targeting ALOX15, ALOX15B
CF-26-ME34_1uM Dose=1uM, N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide, 15-Lipoxygenase Inhibitors targeting ALOX15, ALOX15B
CF-31-GE67_0.01uM Dose=0.01uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1
CF-31-GE67_0.1uM Dose=0.1uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1
CF-31-GE67_10uM Dose=10uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1
CF-31-GE67_1uM Dose=1uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1
CF-32-LB77_0.01uM Dose=0.01uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2
CF-32-LB77_0.1uM Dose=0.1uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2
CF-32-LB77_10uM Dose=10uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2
CF-32-LB77_1uM Dose=1uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2
CF-35-NN63_0.1uM Dose=0.1uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO
CF-35-NN63_10uM Dose=10uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO
CF-35-NN63_1uM Dose=1uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO
CF-42-OS28_0.01uM Dose=0.01uM, Paclitaxel, Microtubule stabilizer targeting TUBB1
CF-42-OS28_0.1uM Dose=0.1uM, Paclitaxel, Microtubule stabilizer targeting TUBB1
CF-42-OS28_10uM Dose=10uM, Paclitaxel, Microtubule stabilizer targeting TUBB1
CF-42-OS28_1uM Dose=1uM, Paclitaxel, Microtubule stabilizer targeting TUBB1
CF-44-NQ13_0.01uM Dose=0.01uM
CF-44-NQ13_0.1uM Dose=0.1uM
CF-44-NQ13_10uM Dose=10uM
CF-44-NQ13_1uM Dose=1uM
CF-46-PR45_0.01uM Dose=0.01uM, Aldo keto reductase 1C1 inhibitor
CF-46-PR45_0.1uM Dose=0.1uM, Aldo keto reductase 1C1 inhibitor
CF-46-PR45_1uM Dose=1uM, Aldo keto reductase 1C1 inhibitor
CF-48-QD87_0.01uM Dose=0.01uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2
CF-48-QD87_0.1uM Dose=0.1uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2
CF-48-QD87_10uM Dose=10uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2
CF-48-QD87_1uM Dose=1uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2
CF-50-MN16_0.01uM Dose=0.01uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1
CF-50-MN16_0.1uM Dose=0.1uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1
CF-50-MN16_10uM Dose=10uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1
CF-50-MN16_1uM Dose=1uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1
CF-50-QK79_0.01uM Dose=0.01uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2
CF-50-QK79_0.1uM Dose=0.1uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2
CF-50-QK79_10uM Dose=10uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2
CF-50-QK79_1uM Dose=1uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2
CF-53-GP28_0.01uM Dose=0.01uM, Retinol, 1 Epidermal transglutaminase inhibitor targeting TGM1
CF-53-GP28_10uM Dose=10uM, Retinol, 1 Epidermal transglutaminase inhibitor targeting TGM1
CF-53-HM41_0.01uM Dose=0.01uM, GRM6 agonist;GRM4 agonist;GRM7 agonist;GRM8 agonist targeting GRM4, GRM6, GRM7, GRM8
CF-53-HM41_10uM Dose=10uM, GRM6 agonist;GRM4 agonist;GRM7 agonist;GRM8 agonist targeting GRM4, GRM6, GRM7, GRM8
CF-53-HM41_1uM Dose=1uM, GRM6 agonist;GRM4 agonist;GRM7 agonist;GRM8 agonist targeting GRM4, GRM6, GRM7, GRM8
CF-55-OA12_0.01uM Dose=0.01uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2
CF-55-OA12_0.1uM Dose=0.1uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2
CF-55-OA12_10uM Dose=10uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2
CF-55-OA12_1uM Dose=1uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2
CF-56-LO98_0.01uM Dose=0.01uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1
CF-56-LO98_0.1uM Dose=0.1uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1
CF-56-LO98_10uM Dose=10uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1
CF-56-LO98_1uM Dose=1uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1
CF-57-GW25_0.1uM Dose=0.1uM, Perphenazine, Dopamine Receptor Antagonists targeting DRD2
CF-57-GW25_10uM Dose=10uM, Perphenazine, Dopamine Receptor Antagonists targeting DRD2
CF-61-EH59_0.01uM Dose=0.01uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2
CF-61-EH59_0.1uM Dose=0.1uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2
CF-61-EH59_10uM Dose=10uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2
CF-61-EH59_1uM Dose=1uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2
CF-61-OL44_0.01uM Dose=0.01uM, N-(3-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide, Phosphodiesterase PDE11A Inhibitors targeting PDE11A
CF-61-OL44_10uM Dose=10uM, N-(3-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide, Phosphodiesterase PDE11A Inhibitors targeting PDE11A
CF-61-OL44_1uM Dose=1uM, N-(3-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide, Phosphodiesterase PDE11A Inhibitors targeting PDE11A
CF-65-GU65_0.01uM Dose=0.01uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1
CF-65-GU65_0.1uM Dose=0.1uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1
CF-65-GU65_10uM Dose=10uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1
CF-65-GU65_1uM Dose=1uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1
CF-68-DM58_0.01uM Dose=0.01uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR
CF-68-DM58_0.1uM Dose=0.1uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR
CF-68-DM58_10uM Dose=10uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR
CF-68-DM58_1uM Dose=1uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR
CF-79-FU20_0.01uM Dose=0.01uM, Muscimol, GABA A receptor agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
CF-79-FU20_0.1uM Dose=0.1uM, Muscimol, GABA A receptor agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
CF-79-FU20_10uM Dose=10uM, Muscimol, GABA A receptor agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
CF-79-FU20_1uM Dose=1uM, Muscimol, GABA A receptor agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6
CF-81-DS26_0.01uM Dose=0.01uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C
CF-81-DS26_0.1uM Dose=0.1uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C
CF-81-DS26_10uM Dose=10uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C
CF-81-DS26_1uM Dose=1uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C
CF-82-AS63_0.01uM Dose=0.01uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
CF-82-AS63_0.1uM Dose=0.1uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
CF-82-AS63_10uM Dose=10uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
CF-82-AS63_1uM Dose=1uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
CF-82-FS38_0.01uM Dose=0.01uM
CF-82-FS38_0.1uM Dose=0.1uM
CF-82-FS38_10uM Dose=10uM
CF-82-FS38_1uM Dose=1uM
CF-82-LL11_0.01uM Dose=0.01uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5
CF-82-LL11_0.1uM Dose=0.1uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5
CF-82-LL11_10uM Dose=10uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5
CF-82-LL11_1uM Dose=1uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5
CF-83-HM41_0.01uM Dose=0.01uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA
CF-83-HM41_0.1uM Dose=0.1uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA
CF-83-HM41_10uM Dose=10uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA
CF-83-HM41_1uM Dose=1uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA
CF-83-PM81_0.01uM Dose=0.01uM
CF-83-PM81_0.1uM Dose=0.1uM
CF-83-PM81_10uM Dose=10uM
CF-83-PM81_1uM Dose=1uM
CF-87-AS90_0.01uM Dose=0.01uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2
CF-87-AS90_0.1uM Dose=0.1uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2
CF-87-AS90_10uM Dose=10uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2
CF-87-AS90_1uM Dose=1uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2
CF-90-DA50_0.01uM Dose=0.01uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1
CF-90-DA50_0.1uM Dose=0.1uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1
CF-90-DA50_10uM Dose=10uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1
CF-90-DA50_1uM Dose=1uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1
CF-91-JY05_0.01uM Dose=0.01uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CF-91-JY05_0.1uM Dose=0.1uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CF-91-JY05_10uM Dose=10uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CF-91-JY05_1uM Dose=1uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
CF-92-QS83_0.01uM Dose=0.01uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3
CF-92-QS83_0.1uM Dose=0.1uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3
CF-92-QS83_10uM Dose=10uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3
CF-92-QS83_1uM Dose=1uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3
CF-97-AV07_0.01uM Dose=0.01uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4
CF-97-AV07_0.1uM Dose=0.1uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4
CF-97-AV07_10uM Dose=10uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4
CF-97-AV07_1uM Dose=1uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4
CF-97-KZ12_0.01uM Dose=0.01uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4
CF-97-KZ12_0.1uM Dose=0.1uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4
CF-97-KZ12_10uM Dose=10uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4
CF-97-KZ12_1uM Dose=1uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4
CF-98-GZ19_0.01uM Dose=0.01uM, 2-Phenyl-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1
CF-98-GZ19_0.1uM Dose=0.1uM, 2-Phenyl-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1
CF-98-KM73_0.01uM Dose=0.01uM, Senicapoc, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4
CF-98-KM73_10uM Dose=10uM, Senicapoc, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4
CF-98-KM73_1uM Dose=1uM, Senicapoc, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4
DA-01-GV68_0.01uM Dose=0.01uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15
DA-01-GV68_0.1uM Dose=0.1uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15
DA-01-GV68_10uM Dose=10uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15
DA-01-GV68_1uM Dose=1uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15
DA-05-NN93_0.01uM Dose=0.01uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3
DA-05-NN93_0.1uM Dose=0.1uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3
DA-05-NN93_10uM Dose=10uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3
DA-05-NN93_1uM Dose=1uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3
DA-07-LL18_0.01uM Dose=0.01uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine
DA-07-LL18_0.1uM Dose=0.1uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine
DA-07-LL18_10uM Dose=10uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine
DA-07-LL18_1uM Dose=1uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine
DA-08-XJ96_0.01uM Dose=0.01uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1
DA-08-XJ96_0.1uM Dose=0.1uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1
DA-08-XJ96_10uM Dose=10uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1
DA-08-XJ96_1uM Dose=1uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1
DA-09-XJ53_0.01uM Dose=0.01uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7
DA-09-XJ53_0.1uM Dose=0.1uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7
DA-09-XJ53_10uM Dose=10uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7
DA-09-XJ53_1uM Dose=1uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7
DA-10-GX45_0.01uM Dose=0.01uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
DA-10-GX45_0.1uM Dose=0.1uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
DA-10-GX45_10uM Dose=10uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
DA-10-GX45_1uM Dose=1uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8
DA-10-HD17_0.01uM Dose=0.01uM, N-Phthalylglycine
DA-10-HD17_0.1uM Dose=0.1uM, N-Phthalylglycine
DA-10-HD17_10uM Dose=10uM, N-Phthalylglycine
DA-10-HD17_1uM Dose=1uM, N-Phthalylglycine
DA-10-VU83_0.01uM Dose=0.01uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2
DA-10-VU83_0.1uM Dose=0.1uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2
DA-10-VU83_10uM Dose=10uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2
DA-10-VU83_1uM Dose=1uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2
DA-10-ZX00_0.01uM Dose=0.01uM, 5-chloro-N-[(1S,3S)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]furan-2-carboxamide, mgluR5 Antagonists targeting GRM5
DA-10-ZX00_0.1uM Dose=0.1uM, 5-chloro-N-[(1S,3S)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]furan-2-carboxamide, mgluR5 Antagonists targeting GRM5
DA-10-ZX00_10uM Dose=10uM, 5-chloro-N-[(1S,3S)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]furan-2-carboxamide, mgluR5 Antagonists targeting GRM5
DA-10-ZX00_1uM Dose=1uM, 5-chloro-N-[(1S,3S)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]furan-2-carboxamide, mgluR5 Antagonists targeting GRM5
DA-11-GV88_0.01uM Dose=0.01uM, PD 128042, ACAT Inhibitors targeting SOAT1
DA-11-GV88_0.1uM Dose=0.1uM, PD 128042, ACAT Inhibitors targeting SOAT1
DA-11-GV88_10uM Dose=10uM, PD 128042, ACAT Inhibitors targeting SOAT1
DA-11-GV88_1uM Dose=1uM, PD 128042, ACAT Inhibitors targeting SOAT1
DA-15-PU65_0.01uM Dose=0.01uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E
DA-15-PU65_0.1uM Dose=0.1uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E
DA-15-PU65_10uM Dose=10uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E
DA-15-PU65_1uM Dose=1uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E
DA-17-XI26_0.01uM Dose=0.01uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2
DA-17-XI26_0.1uM Dose=0.1uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2
DA-17-XI26_10uM Dose=10uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2
DA-17-XI26_1uM Dose=1uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2
DA-17-YW85_0.01uM Dose=0.01uM, Tgba01AD
DA-17-YW85_0.1uM Dose=0.1uM, Tgba01AD
DA-17-YW85_10uM Dose=10uM, Tgba01AD
DA-17-YW85_1uM Dose=1uM, Tgba01AD
DA-18-QP05_0.01uM Dose=0.01uM
DA-18-QP05_0.1uM Dose=0.1uM
DA-18-QP05_10uM Dose=10uM
DA-18-QP05_1uM Dose=1uM
DA-19-AJ18_0.01uM Dose=0.01uM, Dicumarol, Anticoagulant;Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors;NADPH Quinone Oxidoreductase 1 (NQO1) Inhibitors targeting NQO1, VKORC1
DA-19-AJ18_0.1uM Dose=0.1uM, Dicumarol, Anticoagulant;Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors;NADPH Quinone Oxidoreductase 1 (NQO1) Inhibitors targeting NQO1, VKORC1
DA-19-AJ18_10uM Dose=10uM, Dicumarol, Anticoagulant;Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors;NADPH Quinone Oxidoreductase 1 (NQO1) Inhibitors targeting NQO1, VKORC1
DA-19-JA87_0.01uM Dose=0.01uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1
DA-19-JA87_0.1uM Dose=0.1uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1
DA-19-JA87_10uM Dose=10uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1
DA-19-JA87_1uM Dose=1uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1
DA-20-OX15_0.01uM Dose=0.01uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9
DA-20-OX15_0.1uM Dose=0.1uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9
DA-20-OX15_10uM Dose=10uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9
DA-20-OX15_1uM Dose=1uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9
DA-20-VR86_0.01uM Dose=0.01uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN
DA-20-VR86_0.1uM Dose=0.1uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN
DA-20-VR86_10uM Dose=10uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN
DA-20-VR86_1uM Dose=1uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN
DA-21-GV88_0.01uM Dose=0.01uM, 4-{2-[(7-Amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol, Adenosine A2A Antagonists;Adenosine A2B Antagonists targeting ADORA2A, ADORA2B
DA-21-GV88_0.1uM Dose=0.1uM, 4-{2-[(7-Amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol, Adenosine A2A Antagonists;Adenosine A2B Antagonists targeting ADORA2A, ADORA2B
DA-21-GV88_10uM Dose=10uM, 4-{2-[(7-Amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol, Adenosine A2A Antagonists;Adenosine A2B Antagonists targeting ADORA2A, ADORA2B
DA-21-GV88_1uM Dose=1uM, 4-{2-[(7-Amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol, Adenosine A2A Antagonists;Adenosine A2B Antagonists targeting ADORA2A, ADORA2B
DA-23-IF64_0.01uM Dose=0.01uM, Lufironil, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
DA-23-IF64_0.1uM Dose=0.1uM, Lufironil, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
DA-23-IF64_10uM Dose=10uM, Lufironil, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
DA-23-TZ42_0.01uM Dose=0.01uM
DA-23-TZ42_0.1uM Dose=0.1uM
DA-23-TZ42_10uM Dose=10uM
DA-23-TZ42_1uM Dose=1uM
DA-27-BW20_0.01uM Dose=0.01uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2
DA-27-BW20_0.1uM Dose=0.1uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2
DA-27-BW20_10uM Dose=10uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2
DA-27-BW20_1uM Dose=1uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2
DA-27-BW40_0.01uM Dose=0.01uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4
DA-27-BW40_0.1uM Dose=0.1uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4
DA-27-BW40_10uM Dose=10uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4
DA-27-BW40_1uM Dose=1uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4
DA-28-TM43_0.1uM Dose=0.1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2
DA-28-TM43_10uM Dose=10uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2
DA-28-TM43_1uM Dose=1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2
DA-29-ZD04_0.1uM Dose=0.1uM, Losartan, AGTR1 gene inhibitor targeting AGTR1
DA-29-ZD04_10uM Dose=10uM, Losartan, AGTR1 gene inhibitor targeting AGTR1
DA-29-ZD04_1uM Dose=1uM, Losartan, AGTR1 gene inhibitor targeting AGTR1
DA-30-HN81_0.1uM Dose=0.1uM, Peripheral Benzodiazepine Receptor (PBR) Ligands
DA-32-QL71_0.01uM Dose=0.01uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3
DA-32-QL71_0.1uM Dose=0.1uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3
DA-32-QL71_10uM Dose=10uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3
DA-32-QL71_1uM Dose=1uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3
DA-33-BM26_0.01uM Dose=0.01uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9
DA-33-BM26_0.1uM Dose=0.1uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9
DA-33-BM26_10uM Dose=10uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9
DA-33-BM26_1uM Dose=1uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9
DA-33-CW45_0.01uM Dose=0.01uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2
DA-33-CW45_0.1uM Dose=0.1uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2
DA-33-CW45_10uM Dose=10uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2
DA-33-CW45_1uM Dose=1uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2
DA-33-CX68_0.01uM Dose=0.01uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B
DA-33-CX68_0.1uM Dose=0.1uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B
DA-33-CX68_10uM Dose=10uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B
DA-33-CX68_1uM Dose=1uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B
DA-33-IZ67_0.01uM Dose=0.01uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1
DA-33-IZ67_0.1uM Dose=0.1uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1
DA-33-IZ67_10uM Dose=10uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1
DA-33-IZ67_1uM Dose=1uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1
DA-33-NF79_0.01uM Dose=0.01uM, Brofaromine, MAO-A Inhibitors targeting MAOA
DA-33-NF79_0.1uM Dose=0.1uM, Brofaromine, MAO-A Inhibitors targeting MAOA
DA-33-NF79_10uM Dose=10uM, Brofaromine, MAO-A Inhibitors targeting MAOA
DA-33-NF79_1uM Dose=1uM, Brofaromine, MAO-A Inhibitors targeting MAOA
DA-35-DU85_0.01uM Dose=0.01uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8
DA-35-DU85_0.1uM Dose=0.1uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8
DA-35-DU85_10uM Dose=10uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8
DA-35-DU85_1uM Dose=1uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8
DA-35-ZK21_0.01uM Dose=0.01uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3
DA-35-ZK21_0.1uM Dose=0.1uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3
DA-35-ZK21_10uM Dose=10uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3
DA-35-ZK21_1uM Dose=1uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3
DA-39-AJ98_0.01uM Dose=0.01uM, Metylperon, DRD2 antagonist targeting DRD2
DA-39-AJ98_0.1uM Dose=0.1uM, Metylperon, DRD2 antagonist targeting DRD2
DA-39-AJ98_10uM Dose=10uM, Metylperon, DRD2 antagonist targeting DRD2
DA-39-AJ98_1uM Dose=1uM, Metylperon, DRD2 antagonist targeting DRD2
DA-40-HO94_0.01uM Dose=0.01uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR
DA-40-HO94_0.1uM Dose=0.1uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR
DA-40-HO94_10uM Dose=10uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR
DA-40-HO94_1uM Dose=1uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR
DA-42-BI19_0.01uM Dose=0.01uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB
DA-42-BI19_0.1uM Dose=0.1uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB
DA-42-BI19_10uM Dose=10uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB
DA-42-BI19_1uM Dose=1uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB
DA-45-PU65_0.01uM Dose=0.01uM, Torsemide, Drugs Acting on Potassium Channels targeting SLC12A1, SLC12A2
DA-45-PU65_0.1uM Dose=0.1uM, Torsemide, Drugs Acting on Potassium Channels targeting SLC12A1, SLC12A2
DA-46-KH36_0.01uM Dose=0.01uM, 1,2,3,4-Tetrahydroisoquinoline
DA-46-KH36_0.1uM Dose=0.1uM, 1,2,3,4-Tetrahydroisoquinoline
DA-46-KH36_10uM Dose=10uM, 1,2,3,4-Tetrahydroisoquinoline
DA-46-KH36_1uM Dose=1uM, 1,2,3,4-Tetrahydroisoquinoline
DA-48-IP75_0.01uM Dose=0.01uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG
DA-48-IP75_0.1uM Dose=0.1uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG
DA-48-IP75_10uM Dose=10uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG
DA-48-IP75_1uM Dose=1uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG
DA-48-NC44_0.01uM Dose=0.01uM
DA-48-NC44_0.1uM Dose=0.1uM
DA-48-NC44_10uM Dose=10uM
DA-48-NC44_1uM Dose=1uM
DA-49-ZD74_0.01uM Dose=0.01uM, Latanoprost, Prostaglandin F agonists targeting PTGFR
DA-49-ZD74_0.1uM Dose=0.1uM, Latanoprost, Prostaglandin F agonists targeting PTGFR
DA-49-ZD74_10uM Dose=10uM, Latanoprost, Prostaglandin F agonists targeting PTGFR
DA-49-ZD74_1uM Dose=1uM, Latanoprost, Prostaglandin F agonists targeting PTGFR
DA-54-NN76_0.01uM Dose=0.01uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1
DA-54-NN76_0.1uM Dose=0.1uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1
DA-54-NN76_10uM Dose=10uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1
DA-54-NN76_1uM Dose=1uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1
DA-56-CH26_0.1uM Dose=0.1uM, N-(1-(3-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2
DA-56-CH26_10uM Dose=10uM, N-(1-(3-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2
DA-56-CH26_1uM Dose=1uM, N-(1-(3-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2
DA-58-LZ09_0.01uM Dose=0.01uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13
DA-58-LZ09_0.1uM Dose=0.1uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13
DA-58-LZ09_10uM Dose=10uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13
DA-58-LZ09_1uM Dose=1uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13
DA-59-ZD74_0.01uM Dose=0.01uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB
DA-59-ZD74_0.1uM Dose=0.1uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB
DA-59-ZD74_10uM Dose=10uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB
DA-59-ZD74_1uM Dose=1uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB
DA-60-KU38_0.01uM Dose=0.01uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide
DA-60-KU38_0.1uM Dose=0.1uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide
DA-60-KU38_10uM Dose=10uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide
DA-60-KU38_1uM Dose=1uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide
DA-62-QB27_0.01uM Dose=0.01uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
DA-62-QB27_0.1uM Dose=0.1uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
DA-62-QB27_10uM Dose=10uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
DA-62-QB27_1uM Dose=1uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
DA-62-XV25_0.01uM Dose=0.01uM, (4S,5R)-4-[5-(1H-indol-5-yl)pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane, Nicotinic alpha7 Agonists targeting CHRNA7
DA-62-XV25_0.1uM Dose=0.1uM, (4S,5R)-4-[5-(1H-indol-5-yl)pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane, Nicotinic alpha7 Agonists targeting CHRNA7
DA-62-XV25_10uM Dose=10uM, (4S,5R)-4-[5-(1H-indol-5-yl)pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane, Nicotinic alpha7 Agonists targeting CHRNA7
DA-63-NP63_0.01uM Dose=0.01uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID
DA-63-NP63_0.1uM Dose=0.1uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID
DA-63-NP63_10uM Dose=10uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID
DA-63-NP63_1uM Dose=1uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID
DA-66-OE69_0.01uM Dose=0.01uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1
DA-66-OE69_0.1uM Dose=0.1uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1
DA-66-OE69_10uM Dose=10uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1
DA-66-OE69_1uM Dose=1uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1
DA-67-HS65_0.01uM Dose=0.01uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2
DA-67-HS65_0.1uM Dose=0.1uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2
DA-67-HS65_10uM Dose=10uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2
DA-67-HS65_1uM Dose=1uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2
DA-69-UN88_0.01uM Dose=0.01uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1
DA-69-UN88_0.1uM Dose=0.1uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1
DA-69-UN88_10uM Dose=10uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1
DA-69-UN88_1uM Dose=1uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1
DA-75-KD59_0.01uM Dose=0.01uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17
DA-75-KD59_0.1uM Dose=0.1uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17
DA-75-KD59_10uM Dose=10uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17
DA-75-KD59_1uM Dose=1uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17
DA-75-NX57_0.01uM Dose=0.01uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-acetylamino-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1
DA-75-NX57_1uM Dose=1uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-acetylamino-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1
DA-76-NE84_0.01uM Dose=0.01uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET
DA-76-NE84_0.1uM Dose=0.1uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET
DA-76-NE84_10uM Dose=10uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET
DA-76-NE84_1uM Dose=1uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET
DA-77-II31_0.01uM Dose=0.01uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7
DA-77-II31_0.1uM Dose=0.1uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7
DA-77-II31_10uM Dose=10uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7
DA-77-II31_1uM Dose=1uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7
DA-78-WW87_0.01uM Dose=0.01uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
DA-78-WW87_0.1uM Dose=0.1uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
DA-78-WW87_10uM Dose=10uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
DA-78-WW87_1uM Dose=1uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
DA-79-ZD74_0.01uM Dose=0.01uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH
DA-79-ZD74_0.1uM Dose=0.1uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH
DA-79-ZD74_10uM Dose=10uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH
DA-79-ZD74_1uM Dose=1uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH
DA-80-IV36_0.01uM Dose=0.01uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2
DA-80-IV36_0.1uM Dose=0.1uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2
DA-80-IV36_10uM Dose=10uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2
DA-80-IV36_1uM Dose=1uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2
DA-80-IY83_0.01uM Dose=0.01uM, Doxazosin, alpha1-Adrenoceptor Antagonists;Apoptosis Inducers targeting ADRA1D, ADRA1B, ADRA1A
DA-80-IY83_0.1uM Dose=0.1uM, Doxazosin, alpha1-Adrenoceptor Antagonists;Apoptosis Inducers targeting ADRA1D, ADRA1B, ADRA1A
DA-80-IY83_10uM Dose=10uM, Doxazosin, alpha1-Adrenoceptor Antagonists;Apoptosis Inducers targeting ADRA1D, ADRA1B, ADRA1A
DA-80-IY83_1uM Dose=1uM, Doxazosin, alpha1-Adrenoceptor Antagonists;Apoptosis Inducers targeting ADRA1D, ADRA1B, ADRA1A
DA-81-VY50_0.1uM Dose=0.1uM, 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropoxy-pyridin-3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG
DA-81-VY50_10uM Dose=10uM, 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropoxy-pyridin-3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG
DA-81-VY50_1uM Dose=1uM, 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropoxy-pyridin-3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG
DA-83-IZ87_0.01uM Dose=0.01uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2
DA-83-IZ87_0.1uM Dose=0.1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2
DA-83-IZ87_10uM Dose=10uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2
DA-83-IZ87_1uM Dose=1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2
DA-83-VJ09_0.01uM Dose=0.01uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4
DA-83-VJ09_0.1uM Dose=0.1uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4
DA-83-VJ09_10uM Dose=10uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4
DA-83-VJ09_1uM Dose=1uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4
DA-85-SU90_0.01uM Dose=0.01uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1
DA-85-SU90_0.1uM Dose=0.1uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1
DA-85-SU90_10uM Dose=10uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1
DA-85-SU90_1uM Dose=1uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1
DA-86-GO43_0.01uM Dose=0.01uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B
DA-86-GO43_0.1uM Dose=0.1uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B
DA-86-GO43_10uM Dose=10uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B
DA-86-GO43_1uM Dose=1uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B
DA-87-JB14_0.1uM Dose=0.1uM, Protoporphyrinogen oxidase inhibitor
DA-87-JB14_10uM Dose=10uM, Protoporphyrinogen oxidase inhibitor
DA-88-JF21_0.01uM Dose=0.01uM, FG-9041 targeting GRIA4
DA-88-JF21_0.1uM Dose=0.1uM, FG-9041 targeting GRIA4
DA-88-JF21_10uM Dose=10uM, FG-9041 targeting GRIA4
DA-88-JF21_1uM Dose=1uM, FG-9041 targeting GRIA4
DA-91-NR73_0.01uM Dose=0.01uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester
DA-91-NR73_0.1uM Dose=0.1uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester
DA-91-NR73_10uM Dose=10uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester
DA-91-NR73_1uM Dose=1uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester
DA-91-RR73_0.01uM Dose=0.01uM, Drugs Acting on 5-Hydroxytryptamine Receptors
DA-91-RR73_0.1uM Dose=0.1uM, Drugs Acting on 5-Hydroxytryptamine Receptors
DA-91-RR73_10uM Dose=10uM, Drugs Acting on 5-Hydroxytryptamine Receptors
DA-91-RR73_1uM Dose=1uM, Drugs Acting on 5-Hydroxytryptamine Receptors
DA-97-MT18_10uM Dose=10uM
DB-00-QN66_0.01uM Dose=0.01uM
DB-00-QN66_0.1uM Dose=0.1uM
DB-00-QN66_10uM Dose=10uM
DB-00-QN66_1uM Dose=1uM
DB-01-BR68_0.01uM Dose=0.01uM, Guaifenesin
DB-01-BR68_0.1uM Dose=0.1uM, Guaifenesin
DB-01-BR68_10uM Dose=10uM, Guaifenesin
DB-01-BR68_1uM Dose=1uM, Guaifenesin
DB-05-UK61_0.01uM Dose=0.01uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1
DB-05-UK61_10uM Dose=10uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1
DB-05-UK61_1uM Dose=1uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1
DB-06-HE04_0.1uM Dose=0.1uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF
DB-06-HE04_10uM Dose=10uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF
DB-06-HE04_1uM Dose=1uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF
DB-07-WB29_0.01uM Dose=0.01uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK
DB-07-WB29_0.1uM Dose=0.1uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK
DB-07-WB29_10uM Dose=10uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK
DB-07-WB29_1uM Dose=1uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK
DB-11-SS01_0.01uM Dose=0.01uM, Thal-sns-032 targeting CDK9
DB-11-SS01_0.1uM Dose=0.1uM, Thal-sns-032 targeting CDK9
DB-11-SS01_10uM Dose=10uM, Thal-sns-032 targeting CDK9
DB-18-IF31_0.01uM Dose=0.01uM, (4bS,7R,8aR)-4b-benzyl-7-hydroxy-7-(prop-1-ynyl)-N-(pyridin-4-ylmethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide, Glucocorticoid Receptor (GR) Modulators targeting NR3C1
DB-18-IF31_0.1uM Dose=0.1uM, (4bS,7R,8aR)-4b-benzyl-7-hydroxy-7-(prop-1-ynyl)-N-(pyridin-4-ylmethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide, Glucocorticoid Receptor (GR) Modulators targeting NR3C1
DB-18-IF31_10uM Dose=10uM, (4bS,7R,8aR)-4b-benzyl-7-hydroxy-7-(prop-1-ynyl)-N-(pyridin-4-ylmethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide, Glucocorticoid Receptor (GR) Modulators targeting NR3C1
DB-18-IF31_1uM Dose=1uM, (4bS,7R,8aR)-4b-benzyl-7-hydroxy-7-(prop-1-ynyl)-N-(pyridin-4-ylmethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide, Glucocorticoid Receptor (GR) Modulators targeting NR3C1
DB-18-UF01_0.01uM Dose=0.01uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4
DB-18-UF01_0.1uM Dose=0.1uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4
DB-18-UF01_10uM Dose=10uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4
DB-18-UF01_1uM Dose=1uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4
DB-20-QK39_0.01uM Dose=0.01uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1
DB-20-QK39_0.1uM Dose=0.1uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1
DB-20-QK39_10uM Dose=10uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1
DB-20-QK39_1uM Dose=1uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1
DB-21-FY25_0.01uM Dose=0.01uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
DB-21-FY25_0.1uM Dose=0.1uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
DB-21-FY25_10uM Dose=10uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
DB-21-FY25_1uM Dose=1uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
DB-21-FY75_0.01uM Dose=0.01uM, CID 67042933, CDK9 inhibitor targeting CDK9
DB-21-FY75_0.1uM Dose=0.1uM, CID 67042933, CDK9 inhibitor targeting CDK9
DB-21-FY75_10uM Dose=10uM, CID 67042933, CDK9 inhibitor targeting CDK9
DB-21-FY75_1uM Dose=1uM, CID 67042933, CDK9 inhibitor targeting CDK9
DB-24-CQ08_0.01uM Dose=0.01uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol
DB-24-CQ08_0.1uM Dose=0.1uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol
DB-24-CQ08_10uM Dose=10uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol
DB-24-CQ08_1uM Dose=1uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol
DB-28-SP20_0.1uM Dose=0.1uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4
DB-28-SP20_10uM Dose=10uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4
DB-28-SP20_1uM Dose=1uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4
DB-28-ZJ81_0.01uM Dose=0.01uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9
DB-28-ZJ81_0.1uM Dose=0.1uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9
DB-28-ZJ81_10uM Dose=10uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9
DB-28-ZJ81_1uM Dose=1uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9
DB-29-HQ45_0.01uM Dose=0.01uM
DB-29-HQ45_0.1uM Dose=0.1uM
DB-29-HQ45_10uM Dose=10uM
DB-29-HQ45_1uM Dose=1uM
DB-32-FS68_0.01uM Dose=0.01uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4
DB-32-FS68_0.1uM Dose=0.1uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4
DB-32-FS68_10uM Dose=10uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4
DB-32-FS68_1uM Dose=1uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4
DB-33-HZ87_0.01uM Dose=0.01uM, Vgx-1027, Cytokine Modulators targeting TLR4
DB-33-HZ87_10uM Dose=10uM, Vgx-1027, Cytokine Modulators targeting TLR4
DB-33-HZ87_1uM Dose=1uM, Vgx-1027, Cytokine Modulators targeting TLR4
DB-33-TM61_0.01uM Dose=0.01uM, Profenamine, NMDA Antagonists;Butyrylcholinesterase Inhibitors targeting BCHE
DB-33-TM61_10uM Dose=10uM, Profenamine, NMDA Antagonists;Butyrylcholinesterase Inhibitors targeting BCHE
DB-33-TM61_1uM Dose=1uM, Profenamine, NMDA Antagonists;Butyrylcholinesterase Inhibitors targeting BCHE
DB-34-KT45_0.01uM Dose=0.01uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF
DB-34-KT45_0.1uM Dose=0.1uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF
DB-34-KT45_10uM Dose=10uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF
DB-34-KT45_1uM Dose=1uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF
DB-34-QA60_0.01uM Dose=0.01uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB
DB-34-QA60_0.1uM Dose=0.1uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB
DB-34-QA60_10uM Dose=10uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB
DB-34-QA60_1uM Dose=1uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB
DB-36-TR95_0.01uM Dose=0.01uM, Ramatroban, PTGDR antagonist;Prostanoid TP Antagonists;CCL2 Expression Inhibitors;CRTH2 Receptor Antagonists;GPR44 antagonist targeting PTGDR, CCL2, TBXA2R, PTGDR2
DB-36-TR95_0.1uM Dose=0.1uM, Ramatroban, PTGDR antagonist;Prostanoid TP Antagonists;CCL2 Expression Inhibitors;CRTH2 Receptor Antagonists;GPR44 antagonist targeting PTGDR, CCL2, TBXA2R, PTGDR2
DB-36-TR95_10uM Dose=10uM, Ramatroban, PTGDR antagonist;Prostanoid TP Antagonists;CCL2 Expression Inhibitors;CRTH2 Receptor Antagonists;GPR44 antagonist targeting PTGDR, CCL2, TBXA2R, PTGDR2
DB-40-GN91_0.01uM Dose=0.01uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DB-40-GN91_0.1uM Dose=0.1uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DB-40-GN91_10uM Dose=10uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DB-40-GN91_1uM Dose=1uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DB-40-HA40_0.01uM Dose=0.01uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
DB-40-HA40_0.1uM Dose=0.1uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
DB-40-HA40_10uM Dose=10uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
DB-40-HA40_1uM Dose=1uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
DB-41-IH69_0.01uM Dose=0.01uM
DB-41-IH69_0.1uM Dose=0.1uM
DB-41-IH69_10uM Dose=10uM
DB-41-IH69_1uM Dose=1uM
DB-41-OE47_0.01uM Dose=0.01uM
DB-41-OE47_10uM Dose=10uM
DB-41-OE47_1uM Dose=1uM
DB-41-SH04_0.01uM Dose=0.01uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3
DB-41-SH04_0.1uM Dose=0.1uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3
DB-41-SH04_10uM Dose=10uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3
DB-41-SH04_1uM Dose=1uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3
DB-42-FS68_0.01uM Dose=0.01uM, Valspodar
DB-42-FS68_0.1uM Dose=0.1uM, Valspodar
DB-42-FS68_10uM Dose=10uM, Valspodar
DB-42-FS68_1uM Dose=1uM, Valspodar
DB-42-PI54_0.01uM Dose=0.01uM
DB-42-PI54_0.1uM Dose=0.1uM
DB-42-PI54_10uM Dose=10uM
DB-42-PI54_1uM Dose=1uM
DB-45-EH09_0.1uM Dose=0.1uM, [[5-Cyano-2-prop-2-ynylsulfanyl-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amino]thiourea, LSD1 inhibitor targeting KDM1A
DB-45-EH09_10uM Dose=10uM, [[5-Cyano-2-prop-2-ynylsulfanyl-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amino]thiourea, LSD1 inhibitor targeting KDM1A
DB-45-EH09_1uM Dose=1uM, [[5-Cyano-2-prop-2-ynylsulfanyl-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amino]thiourea, LSD1 inhibitor targeting KDM1A
DB-47-EV77_0.01uM Dose=0.01uM, Rofecoxib targeting SC5D
DB-47-EV77_0.1uM Dose=0.1uM, Rofecoxib targeting SC5D
DB-47-EV77_10uM Dose=10uM, Rofecoxib targeting SC5D
DB-47-QB24_1uM Dose=1uM, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands
DB-51-UO66_0.01uM Dose=0.01uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2
DB-51-UO66_0.1uM Dose=0.1uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2
DB-51-UO66_10uM Dose=10uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2
DB-51-UO66_1uM Dose=1uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2
DB-54-GQ68_0.01uM Dose=0.01uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK
DB-54-GQ68_0.1uM Dose=0.1uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK
DB-54-GQ68_10uM Dose=10uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK
DB-54-GQ68_1uM Dose=1uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK
DB-54-ZQ73_0.01uM Dose=0.01uM
DB-54-ZQ73_0.1uM Dose=0.1uM
DB-54-ZQ73_10uM Dose=10uM
DB-54-ZQ73_1uM Dose=1uM
DB-55-UX87_0.01uM Dose=0.01uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2
DB-55-UX87_0.1uM Dose=0.1uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2
DB-55-UX87_10uM Dose=10uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2
DB-55-UX87_1uM Dose=1uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2
DB-56-XL71_0.01uM Dose=0.01uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB
DB-56-XL71_0.1uM Dose=0.1uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB
DB-56-XL71_10uM Dose=10uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB
DB-56-XL71_1uM Dose=1uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB
DB-58-ZC04_0.01uM Dose=0.01uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2
DB-58-ZC04_0.1uM Dose=0.1uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2
DB-58-ZC04_10uM Dose=10uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2
DB-58-ZC04_1uM Dose=1uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2
DB-62-ES23_0.01uM Dose=0.01uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile
DB-62-ES23_0.1uM Dose=0.1uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile
DB-62-ES23_10uM Dose=10uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile
DB-62-ES23_1uM Dose=1uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile
DB-63-TM61_0.01uM Dose=0.01uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1
DB-63-TM61_0.1uM Dose=0.1uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1
DB-63-TM61_10uM Dose=10uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1
DB-63-TM61_1uM Dose=1uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1
DB-67-IP73_0.01uM Dose=0.01uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5
DB-67-IP73_0.1uM Dose=0.1uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5
DB-67-IP73_10uM Dose=10uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5
DB-68-AC34_0.01uM Dose=0.01uM, (3R)-N-[2-(4-cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]piperidine-3-carboxamide, GPBAR1 agonist targeting GPBAR1
DB-68-AC34_0.1uM Dose=0.1uM, (3R)-N-[2-(4-cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]piperidine-3-carboxamide, GPBAR1 agonist targeting GPBAR1
DB-68-AC34_1uM Dose=1uM, (3R)-N-[2-(4-cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]piperidine-3-carboxamide, GPBAR1 agonist targeting GPBAR1
DB-69-JG66_0.01uM Dose=0.01uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide
DB-69-JG66_0.1uM Dose=0.1uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide
DB-69-JG66_10uM Dose=10uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide
DB-69-JG66_1uM Dose=1uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide
DB-73-BC12_0.01uM Dose=0.01uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4
DB-73-BC12_0.1uM Dose=0.1uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4
DB-73-BC12_10uM Dose=10uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4
DB-73-BC12_1uM Dose=1uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4
DB-73-KP48_0.01uM Dose=0.01uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN
DB-73-KP48_0.1uM Dose=0.1uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN
DB-73-KP48_10uM Dose=10uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN
DB-73-KP48_1uM Dose=1uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN
DB-74-HJ91_0.01uM Dose=0.01uM, Dazoxiben, Thromboxane Synthase Inhibitors targeting TBXAS1
DB-74-HJ91_0.1uM Dose=0.1uM, Dazoxiben, Thromboxane Synthase Inhibitors targeting TBXAS1
DB-74-HJ91_10uM Dose=10uM, Dazoxiben, Thromboxane Synthase Inhibitors targeting TBXAS1
DB-77-AV67_0.01uM Dose=0.01uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate
DB-77-AV67_0.1uM Dose=0.1uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate
DB-77-AV67_10uM Dose=10uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate
DB-77-AV67_1uM Dose=1uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate
DB-78-NM13_0.01uM Dose=0.01uM, Telenzepine, CHRM1 antagonist targeting CHRM1
DB-78-NM13_0.1uM Dose=0.1uM, Telenzepine, CHRM1 antagonist targeting CHRM1
DB-78-NM13_10uM Dose=10uM, Telenzepine, CHRM1 antagonist targeting CHRM1
DB-78-NM13_1uM Dose=1uM, Telenzepine, CHRM1 antagonist targeting CHRM1
DB-80-CD47_0.01uM Dose=0.01uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT
DB-80-CD47_0.1uM Dose=0.1uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT
DB-80-CD47_10uM Dose=10uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT
DB-80-CD47_1uM Dose=1uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT
DB-80-QN16_0.01uM Dose=0.01uM, Valpromide
DB-80-QN16_0.1uM Dose=0.1uM, Valpromide
DB-80-QN16_10uM Dose=10uM, Valpromide
DB-80-QN16_1uM Dose=1uM, Valpromide
DB-82-PI34_0.01uM Dose=0.01uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4
DB-82-PI34_0.1uM Dose=0.1uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4
DB-82-PI34_10uM Dose=10uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4
DB-82-PI34_1uM Dose=1uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4
DB-83-LM41_0.01uM Dose=0.01uM, N-(5-cyclopropyl-1,2-oxazol-3-yl)-5-(6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
DB-83-LM41_0.1uM Dose=0.1uM, N-(5-cyclopropyl-1,2-oxazol-3-yl)-5-(6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
DB-83-LM41_10uM Dose=10uM, N-(5-cyclopropyl-1,2-oxazol-3-yl)-5-(6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
DB-83-LM41_1uM Dose=1uM, N-(5-cyclopropyl-1,2-oxazol-3-yl)-5-(6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
DB-84-EQ63_0.01uM Dose=0.01uM, Oleoyl Ethanolamide, K(V)4.3 Channel Blockers;Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists targeting KCND3, GPR55, GPR119
DB-84-EQ63_0.1uM Dose=0.1uM, Oleoyl Ethanolamide, K(V)4.3 Channel Blockers;Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists targeting KCND3, GPR55, GPR119
DB-84-EQ63_10uM Dose=10uM, Oleoyl Ethanolamide, K(V)4.3 Channel Blockers;Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists targeting KCND3, GPR55, GPR119
DB-84-EQ63_1uM Dose=1uM, Oleoyl Ethanolamide, K(V)4.3 Channel Blockers;Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists targeting KCND3, GPR55, GPR119
DB-86-XL71_0.01uM Dose=0.01uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2
DB-86-XL71_0.1uM Dose=0.1uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2
DB-86-XL71_10uM Dose=10uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2
DB-86-XL71_1uM Dose=1uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2
DB-87-WL13_0.01uM Dose=0.01uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2
DB-87-WL13_0.1uM Dose=0.1uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2
DB-87-WL13_10uM Dose=10uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2
DB-87-WL13_1uM Dose=1uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2
DB-88-VW47_0.01uM Dose=0.01uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3
DB-88-VW47_0.1uM Dose=0.1uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3
DB-88-VW47_10uM Dose=10uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3
DB-88-VW47_1uM Dose=1uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3
DB-89-DT62_1uM Dose=1uM
DB-89-PT22_0.01uM Dose=0.01uM, 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione, Muscarinic Agonists targeting CHRM1
DB-89-PT22_0.1uM Dose=0.1uM, 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione, Muscarinic Agonists targeting CHRM1
DB-89-PT22_10uM Dose=10uM, 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione, Muscarinic Agonists targeting CHRM1
DB-89-PT22_1uM Dose=1uM, 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione, Muscarinic Agonists targeting CHRM1
DB-92-FB02_0.01uM Dose=0.01uM, 6-[[4-(2,4-Dimethoxyphenyl)piperazin-1-yl]methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK
DB-92-FB02_10uM Dose=10uM, 6-[[4-(2,4-Dimethoxyphenyl)piperazin-1-yl]methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK
DB-92-FB02_1uM Dose=1uM, 6-[[4-(2,4-Dimethoxyphenyl)piperazin-1-yl]methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK
DB-93-SW55_0.01uM Dose=0.01uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN
DB-93-SW55_0.1uM Dose=0.1uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN
DB-93-SW55_10uM Dose=10uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN
DB-93-SW55_1uM Dose=1uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN
DB-98-LQ88_0.01uM Dose=0.01uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF
DB-98-LQ88_0.1uM Dose=0.1uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF
DB-98-LQ88_10uM Dose=10uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF
DB-98-LQ88_1uM Dose=1uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF
DC-01-WE57_0.01uM Dose=0.01uM
DC-01-WE57_0.1uM Dose=0.1uM
DC-01-WE57_10uM Dose=10uM
DC-01-WE57_1uM Dose=1uM
DC-02-OP01_0.01uM Dose=0.01uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5
DC-02-OP01_0.1uM Dose=0.1uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5
DC-02-OP01_10uM Dose=10uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5
DC-02-OP01_1uM Dose=1uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5
DC-04-FQ48_0.01uM Dose=0.01uM, (S)-4-(3-(1-(5,7-Difluoroquinolin-6-yl)ethyl)imidazo[1,2-b]pyridazin-6-yl)piperazin-2-one, c-Met) Inhibitors;HGFR (MET targeting MET
DC-04-FQ48_0.1uM Dose=0.1uM, (S)-4-(3-(1-(5,7-Difluoroquinolin-6-yl)ethyl)imidazo[1,2-b]pyridazin-6-yl)piperazin-2-one, c-Met) Inhibitors;HGFR (MET targeting MET
DC-04-FQ48_10uM Dose=10uM, (S)-4-(3-(1-(5,7-Difluoroquinolin-6-yl)ethyl)imidazo[1,2-b]pyridazin-6-yl)piperazin-2-one, c-Met) Inhibitors;HGFR (MET targeting MET
DC-04-FQ48_1uM Dose=1uM, (S)-4-(3-(1-(5,7-Difluoroquinolin-6-yl)ethyl)imidazo[1,2-b]pyridazin-6-yl)piperazin-2-one, c-Met) Inhibitors;HGFR (MET targeting MET
DC-05-LU10_0.01uM Dose=0.01uM, (S)-3-{[1-(2-Fluoro-Phenyl)-5-Hydroxy-1h-Pyrazole-3-Carbonyl]-Amino}-3-O-Tolyl-Propionic Acid targeting CTSA
DC-05-LU10_0.1uM Dose=0.1uM, (S)-3-{[1-(2-Fluoro-Phenyl)-5-Hydroxy-1h-Pyrazole-3-Carbonyl]-Amino}-3-O-Tolyl-Propionic Acid targeting CTSA
DC-05-LU10_10uM Dose=10uM, (S)-3-{[1-(2-Fluoro-Phenyl)-5-Hydroxy-1h-Pyrazole-3-Carbonyl]-Amino}-3-O-Tolyl-Propionic Acid targeting CTSA
DC-08-CM08_0.01uM Dose=0.01uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2
DC-08-CM08_0.1uM Dose=0.1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2
DC-08-CM08_10uM Dose=10uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2
DC-08-CM08_1uM Dose=1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2
DC-08-KP05_0.01uM Dose=0.01uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4
DC-08-KP05_0.1uM Dose=0.1uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4
DC-08-KP05_10uM Dose=10uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4
DC-08-KP05_1uM Dose=1uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4
DC-11-AR68_0.01uM Dose=0.01uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB
DC-11-AR68_0.1uM Dose=0.1uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB
DC-11-AR68_10uM Dose=10uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB
DC-11-AR68_1uM Dose=1uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB
DC-13-RZ62_0.01uM Dose=0.01uM, Ubidecarenone
DC-13-RZ62_0.1uM Dose=0.1uM, Ubidecarenone
DC-13-RZ62_10uM Dose=10uM, Ubidecarenone
DC-13-RZ62_1uM Dose=1uM, Ubidecarenone
DC-17-EL33_0.01uM Dose=0.01uM, 10-Methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline, Glucocorticoid Receptor (GR) Modulators targeting NR3C1
DC-17-EL33_0.1uM Dose=0.1uM, 10-Methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline, Glucocorticoid Receptor (GR) Modulators targeting NR3C1
DC-17-EL33_10uM Dose=10uM, 10-Methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline, Glucocorticoid Receptor (GR) Modulators targeting NR3C1
DC-17-ZB19_0.01uM Dose=0.01uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13
DC-17-ZB19_0.1uM Dose=0.1uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13
DC-17-ZB19_10uM Dose=10uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13
DC-17-ZB19_1uM Dose=1uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13
DC-22-HS83_0.01uM Dose=0.01uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
DC-22-HS83_0.1uM Dose=0.1uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
DC-22-HS83_10uM Dose=10uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
DC-22-HS83_1uM Dose=1uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
DC-22-OP01_0.01uM Dose=0.01uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4
DC-22-OP01_0.1uM Dose=0.1uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4
DC-22-OP01_10uM Dose=10uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4
DC-22-OP01_1uM Dose=1uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4
DC-23-UM36_0.01uM Dose=0.01uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD
DC-23-UM36_0.1uM Dose=0.1uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD
DC-23-UM36_10uM Dose=10uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD
DC-23-UM36_1uM Dose=1uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD
DC-28-NF06_0.01uM Dose=0.01uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A
DC-28-NF06_0.1uM Dose=0.1uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A
DC-28-NF06_10uM Dose=10uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A
DC-28-NF06_1uM Dose=1uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A
DC-31-WP64_0.01uM Dose=0.01uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide
DC-31-WP64_0.1uM Dose=0.1uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide
DC-31-WP64_10uM Dose=10uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide
DC-31-WP64_1uM Dose=1uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide
DC-39-CT52_0.01uM Dose=0.01uM
DC-39-CT52_0.1uM Dose=0.1uM
DC-39-CT52_10uM Dose=10uM
DC-39-CT52_1uM Dose=1uM
DC-43-KF54_0.01uM Dose=0.01uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1
DC-43-KF54_0.1uM Dose=0.1uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1
DC-43-KF54_10uM Dose=10uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1
DC-43-KF54_1uM Dose=1uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1
DC-45-WU45_0.01uM Dose=0.01uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2
DC-45-WU45_0.1uM Dose=0.1uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2
DC-45-WU45_10uM Dose=10uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2
DC-45-WU45_1uM Dose=1uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2
DC-47-KV62_0.01uM Dose=0.01uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1
DC-47-KV62_0.1uM Dose=0.1uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1
DC-47-KV62_10uM Dose=10uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1
DC-47-KV62_1uM Dose=1uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1
DC-49-EJ23_0.01uM Dose=0.01uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6
DC-49-EJ23_0.1uM Dose=0.1uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6
DC-49-EJ23_10uM Dose=10uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6
DC-49-EJ23_1uM Dose=1uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6
DC-50-QD52_0.01uM Dose=0.01uM, Cts-1027, MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors;MMP-12 (Macrophage Elastase) Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
DC-50-QD52_0.1uM Dose=0.1uM, Cts-1027, MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors;MMP-12 (Macrophage Elastase) Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
DC-50-QD52_10uM Dose=10uM, Cts-1027, MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors;MMP-12 (Macrophage Elastase) Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
DC-50-QD52_1uM Dose=1uM, Cts-1027, MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors;MMP-12 (Macrophage Elastase) Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
DC-51-WE27_0.01uM Dose=0.01uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9
DC-51-WE27_0.1uM Dose=0.1uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9
DC-51-WE27_10uM Dose=10uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9
DC-51-WE27_1uM Dose=1uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9
DC-59-NQ20_0.01uM Dose=0.01uM, Vx-702, P38a kinase inhibitor targeting MAPK14
DC-59-NQ20_0.1uM Dose=0.1uM, Vx-702, P38a kinase inhibitor targeting MAPK14
DC-59-NQ20_10uM Dose=10uM, Vx-702, P38a kinase inhibitor targeting MAPK14
DC-59-NQ20_1uM Dose=1uM, Vx-702, P38a kinase inhibitor targeting MAPK14
DC-61-QV78_0.01uM Dose=0.01uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2
DC-61-QV78_0.1uM Dose=0.1uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2
DC-61-QV78_10uM Dose=10uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2
DC-61-QV78_1uM Dose=1uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2
DC-63-KC77_0.01uM Dose=0.01uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13
DC-63-KC77_0.1uM Dose=0.1uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13
DC-63-KC77_10uM Dose=10uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13
DC-63-KC77_1uM Dose=1uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13
DC-70-EK34_0.01uM Dose=0.01uM, BF-844, CLRN stabilizer targeting CLRN1
DC-70-EK34_0.1uM Dose=0.1uM, BF-844, CLRN stabilizer targeting CLRN1
DC-70-EK34_10uM Dose=10uM, BF-844, CLRN stabilizer targeting CLRN1
DC-70-EK34_1uM Dose=1uM, BF-844, CLRN stabilizer targeting CLRN1
DC-72-IB32_0.01uM Dose=0.01uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A
DC-72-IB32_0.1uM Dose=0.1uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A
DC-72-IB32_10uM Dose=10uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A
DC-72-IB32_1uM Dose=1uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A
DC-78-CM38_0.01uM Dose=0.01uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1
DC-78-CM38_0.1uM Dose=0.1uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1
DC-78-CM38_10uM Dose=10uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1
DC-78-CM38_1uM Dose=1uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1
DC-81-PH69_0.01uM Dose=0.01uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1
DC-81-PH69_0.1uM Dose=0.1uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1
DC-81-PH69_10uM Dose=10uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1
DC-81-PH69_1uM Dose=1uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1
DC-82-AV25_0.01uM Dose=0.01uM, 3-[[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-[(3,4-dichlorophenyl)methyl]amino]-N-[(3R)-2-oxoazepan-3-yl]propanamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR1
DC-82-AV25_0.1uM Dose=0.1uM, 3-[[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-[(3,4-dichlorophenyl)methyl]amino]-N-[(3R)-2-oxoazepan-3-yl]propanamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR1
DC-82-AV25_10uM Dose=10uM, 3-[[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-[(3,4-dichlorophenyl)methyl]amino]-N-[(3R)-2-oxoazepan-3-yl]propanamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR1
DC-82-AV25_1uM Dose=1uM, 3-[[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-[(3,4-dichlorophenyl)methyl]amino]-N-[(3R)-2-oxoazepan-3-yl]propanamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR1
DC-84-CJ21_0.01uM Dose=0.01uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3
DC-84-CJ21_0.1uM Dose=0.1uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3
DC-84-CJ21_10uM Dose=10uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3
DC-84-CJ21_1uM Dose=1uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3
DC-84-GJ21_0.01uM Dose=0.01uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK
DC-84-GJ21_10uM Dose=10uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK
DC-84-GJ21_1uM Dose=1uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK
DC-87-HI21_0.01uM Dose=0.01uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9
DC-87-HI21_0.1uM Dose=0.1uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9
DC-87-HI21_10uM Dose=10uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9
DC-87-HI21_1uM Dose=1uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9
DC-91-ME12_0.01uM Dose=0.01uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6
DC-91-ME12_0.1uM Dose=0.1uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6
DC-91-ME12_10uM Dose=10uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6
DC-91-ME12_1uM Dose=1uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6
DC-93-NP78_0.01uM Dose=0.01uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN
DC-93-NP78_0.1uM Dose=0.1uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN
DC-93-NP78_10uM Dose=10uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN
DC-93-NP78_1uM Dose=1uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN
DC-93-RZ62_0.01uM Dose=0.01uM
DC-93-RZ62_0.1uM Dose=0.1uM
DC-93-RZ62_10uM Dose=10uM
DC-93-RZ62_1uM Dose=1uM
DC-93-WC67_0.01uM Dose=0.01uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2
DC-93-WC67_0.1uM Dose=0.1uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2
DC-93-WC67_10uM Dose=10uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2
DC-93-WC67_1uM Dose=1uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2
DC-96-HY67_0.01uM Dose=0.01uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1
DC-96-HY67_0.1uM Dose=0.1uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1
DC-96-HY67_10uM Dose=10uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1
DC-96-HY67_1uM Dose=1uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1
DC-97-ZB69_0.01uM Dose=0.01uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
DC-97-ZB69_0.1uM Dose=0.1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
DC-97-ZB69_1uM Dose=1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
DC-98-CP35_0.01uM Dose=0.01uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1
DC-98-CP35_0.1uM Dose=0.1uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1
DC-98-CP35_10uM Dose=10uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1
DC-98-CP35_1uM Dose=1uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1
DC-98-HC94_0.01uM Dose=0.01uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4
DC-98-HC94_0.1uM Dose=0.1uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4
DC-98-HC94_10uM Dose=10uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4
DC-98-HC94_1uM Dose=1uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4
DC-98-RF46_0.01uM Dose=0.01uM, 4-[8-(3-Cyano-phenyl)-[1,7]naphthyridin-6-yl]-cyclohexanecarboxylic acid
DC-98-RF46_0.1uM Dose=0.1uM, 4-[8-(3-Cyano-phenyl)-[1,7]naphthyridin-6-yl]-cyclohexanecarboxylic acid
DC-98-RF46_10uM Dose=10uM, 4-[8-(3-Cyano-phenyl)-[1,7]naphthyridin-6-yl]-cyclohexanecarboxylic acid
DC-99-NQ50_0.01uM Dose=0.01uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
DC-99-NQ50_0.1uM Dose=0.1uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
DC-99-NQ50_10uM Dose=10uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
DC-99-NQ50_1uM Dose=1uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
DD-01-VE87_0.01uM Dose=0.01uM
DD-01-VE87_0.1uM Dose=0.1uM
DD-01-VE87_10uM Dose=10uM
DD-01-VE87_1uM Dose=1uM
DD-08-BT45_0.01uM Dose=0.01uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH
DD-08-BT45_0.1uM Dose=0.1uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH
DD-08-BT45_10uM Dose=10uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH
DD-08-BT45_1uM Dose=1uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH
DD-08-NW42_0.01uM Dose=0.01uM, Ras/Rac Transformation Blocker, SCH 51344, NUDT1 inhibitor;Ras/Rac transformation blocker targeting NUDT1
DD-08-NW42_10uM Dose=10uM, Ras/Rac Transformation Blocker, SCH 51344, NUDT1 inhibitor;Ras/Rac transformation blocker targeting NUDT1
DD-08-NW42_1uM Dose=1uM, Ras/Rac Transformation Blocker, SCH 51344, NUDT1 inhibitor;Ras/Rac transformation blocker targeting NUDT1
DD-10-NA60_0.01uM Dose=0.01uM
DD-10-NA60_0.1uM Dose=0.1uM
DD-10-NA60_10uM Dose=10uM
DD-10-NA60_1uM Dose=1uM
DD-12-RF07_0.01uM Dose=0.01uM, Ivacaftor, CFTR Channel Activators targeting CFTR
DD-12-RF07_0.1uM Dose=0.1uM, Ivacaftor, CFTR Channel Activators targeting CFTR
DD-12-RF07_10uM Dose=10uM, Ivacaftor, CFTR Channel Activators targeting CFTR
DD-12-RF07_1uM Dose=1uM, Ivacaftor, CFTR Channel Activators targeting CFTR
DD-15-VH74_0.01uM Dose=0.01uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1
DD-15-VH74_0.1uM Dose=0.1uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1
DD-15-VH74_10uM Dose=10uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1
DD-15-VH74_1uM Dose=1uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1
DD-16-GL76_0.01uM Dose=0.01uM, Memantine, NMDA Antagonists targeting GRIN2A, GRIN2B
DD-16-GL76_0.1uM Dose=0.1uM, Memantine, NMDA Antagonists targeting GRIN2A, GRIN2B
DD-16-GL76_1uM Dose=1uM, Memantine, NMDA Antagonists targeting GRIN2A, GRIN2B
DD-16-RV85_0.01uM Dose=0.01uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1
DD-16-RV85_0.1uM Dose=0.1uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1
DD-16-RV85_10uM Dose=10uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1
DD-16-RV85_1uM Dose=1uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1
DD-17-HS50_0.1uM Dose=0.1uM, N-[(2-fluoro-6-methoxyphenyl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED
DD-17-HS50_10uM Dose=10uM, N-[(2-fluoro-6-methoxyphenyl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED
DD-17-HS50_1uM Dose=1uM, N-[(2-fluoro-6-methoxyphenyl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED
DD-23-QZ62_0.01uM Dose=0.01uM, Carbonic Anhydrase Type VII Inhibitors
DD-23-QZ62_10uM Dose=10uM, Carbonic Anhydrase Type VII Inhibitors
DD-23-ZC57_0.01uM Dose=0.01uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12
DD-23-ZC57_0.1uM Dose=0.1uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12
DD-23-ZC57_10uM Dose=10uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12
DD-23-ZC57_1uM Dose=1uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12
DD-24-TT70_0.01uM Dose=0.01uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4
DD-24-TT70_0.1uM Dose=0.1uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4
DD-24-TT70_10uM Dose=10uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4
DD-24-TT70_1uM Dose=1uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4
DD-26-RY82_0.01uM Dose=0.01uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR
DD-26-RY82_0.1uM Dose=0.1uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR
DD-26-RY82_10uM Dose=10uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR
DD-26-RY82_1uM Dose=1uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR
DD-26-VR55_10uM Dose=10uM, 6-[[2-(3-Methoxyanilino)pyrimidin-4-yl]amino]-2,3-dihydro-1,4-benzodioxine-5-sulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ALK, ZAP70
DD-26-VR55_1uM Dose=1uM, 6-[[2-(3-Methoxyanilino)pyrimidin-4-yl]amino]-2,3-dihydro-1,4-benzodioxine-5-sulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ALK, ZAP70
DD-28-MZ39_0.01uM Dose=0.01uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO
DD-28-MZ39_0.1uM Dose=0.1uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO
DD-28-MZ39_10uM Dose=10uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO
DD-28-MZ39_1uM Dose=1uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO
DD-30-NA60_0.01uM Dose=0.01uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide
DD-30-NA60_0.1uM Dose=0.1uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide
DD-30-NA60_10uM Dose=10uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide
DD-30-NA60_1uM Dose=1uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide
DD-30-SX80_0.01uM Dose=0.01uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2
DD-30-SX80_0.1uM Dose=0.1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2
DD-30-SX80_10uM Dose=10uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2
DD-30-SX80_1uM Dose=1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2
DD-31-LY65_0.01uM Dose=0.01uM, Menatetrenone
DD-31-LY65_0.1uM Dose=0.1uM, Menatetrenone
DD-31-LY65_10uM Dose=10uM, Menatetrenone
DD-31-LY65_1uM Dose=1uM, Menatetrenone
DD-33-XP23_0.01uM Dose=0.01uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
DD-33-XP23_0.1uM Dose=0.1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
DD-33-XP23_10uM Dose=10uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
DD-33-XP23_1uM Dose=1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
DD-34-AN51_0.01uM Dose=0.01uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH
DD-34-AN51_0.1uM Dose=0.1uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH
DD-34-AN51_10uM Dose=10uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH
DD-34-AN51_1uM Dose=1uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH
DD-34-TT70_0.01uM Dose=0.01uM, 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
DD-34-TT70_0.1uM Dose=0.1uM, 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
DD-34-TT70_1uM Dose=1uM, 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
DD-36-YH76_0.01uM Dose=0.01uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10
DD-36-YH76_0.1uM Dose=0.1uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10
DD-36-YH76_10uM Dose=10uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10
DD-36-YH76_1uM Dose=1uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10
DD-38-BM78_0.01uM Dose=0.01uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2
DD-38-BM78_0.1uM Dose=0.1uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2
DD-38-BM78_10uM Dose=10uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2
DD-38-BM78_1uM Dose=1uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2
DD-38-MZ39_0.01uM Dose=0.01uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine
DD-38-MZ39_0.1uM Dose=0.1uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine
DD-38-MZ39_10uM Dose=10uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine
DD-38-MZ39_1uM Dose=1uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine
DD-41-AE67_0.01uM Dose=0.01uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3
DD-41-AE67_0.1uM Dose=0.1uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3
DD-41-AE67_10uM Dose=10uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3
DD-41-AE67_1uM Dose=1uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3
DD-42-DB72_0.01uM Dose=0.01uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1
DD-42-DB72_0.1uM Dose=0.1uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1
DD-42-DB72_10uM Dose=10uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1
DD-42-DB72_1uM Dose=1uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1
DD-42-PC65_0.01uM Dose=0.01uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5
DD-42-PC65_0.1uM Dose=0.1uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5
DD-42-PC65_10uM Dose=10uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5
DD-42-PC65_1uM Dose=1uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5
DD-43-WW40_0.01uM Dose=0.01uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8
DD-43-WW40_0.1uM Dose=0.1uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8
DD-43-WW40_10uM Dose=10uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8
DD-43-WW40_1uM Dose=1uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8
DD-44-OX00_0.01uM Dose=0.01uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide
DD-44-OX00_0.1uM Dose=0.1uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide
DD-44-OX00_10uM Dose=10uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide
DD-44-OX00_1uM Dose=1uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide
DD-47-GB64_0.01uM Dose=0.01uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5
DD-47-GB64_0.1uM Dose=0.1uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5
DD-47-GB64_10uM Dose=10uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5
DD-47-GB64_1uM Dose=1uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5
DD-48-MZ39_0.01uM Dose=0.01uM, 3-[(3,4-Dichlorobenzyl)sulfanyl]-2-thiophenecarboxylic acid
DD-48-MZ39_0.1uM Dose=0.1uM, 3-[(3,4-Dichlorobenzyl)sulfanyl]-2-thiophenecarboxylic acid
DD-48-MZ39_10uM Dose=10uM, 3-[(3,4-Dichlorobenzyl)sulfanyl]-2-thiophenecarboxylic acid
DD-49-YG96_0.01uM Dose=0.01uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
DD-49-YG96_0.1uM Dose=0.1uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
DD-49-YG96_10uM Dose=10uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
DD-49-YG96_1uM Dose=1uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2
DD-54-MA35_0.01uM Dose=0.01uM, N-(5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, PDGFR kinase inhibitor targeting PDGFRA, PDGFRB
DD-54-MA35_10uM Dose=10uM, N-(5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, PDGFR kinase inhibitor targeting PDGFRA, PDGFRB
DD-54-MA35_1uM Dose=1uM, N-(5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, PDGFR kinase inhibitor targeting PDGFRA, PDGFRB
DD-55-AU25_0.01uM Dose=0.01uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1
DD-55-AU25_0.1uM Dose=0.1uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1
DD-55-AU25_10uM Dose=10uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1
DD-55-AU25_1uM Dose=1uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1
DD-55-SD64_0.01uM Dose=0.01uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C
DD-55-SD64_0.1uM Dose=0.1uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C
DD-55-SD64_10uM Dose=10uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C
DD-55-SD64_1uM Dose=1uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C
DD-58-HC29_0.01uM Dose=0.01uM
DD-58-HC29_0.1uM Dose=0.1uM
DD-58-HC29_10uM Dose=10uM
DD-58-HC29_1uM Dose=1uM
DD-61-DY35_0.01uM Dose=0.01uM
DD-61-DY35_0.1uM Dose=0.1uM
DD-61-DY35_10uM Dose=10uM
DD-61-DY35_1uM Dose=1uM
DD-64-ET45_0.01uM Dose=0.01uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2
DD-64-ET45_0.1uM Dose=0.1uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2
DD-64-ET45_10uM Dose=10uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2
DD-64-ET45_1uM Dose=1uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2
DD-65-SA37_0.01uM Dose=0.01uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4
DD-65-SA37_0.1uM Dose=0.1uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4
DD-65-SA37_10uM Dose=10uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4
DD-65-SA37_1uM Dose=1uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4
DD-66-VY52_0.01uM Dose=0.01uM, SB 218795, Tachykinin NK3 Antagonists targeting TACR3
DD-66-VY52_0.1uM Dose=0.1uM, SB 218795, Tachykinin NK3 Antagonists targeting TACR3
DD-66-VY52_1uM Dose=1uM, SB 218795, Tachykinin NK3 Antagonists targeting TACR3
DD-67-EC82_0.1uM Dose=0.1uM, Quetiapine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
DD-67-EC82_10uM Dose=10uM, Quetiapine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
DD-67-EC82_1uM Dose=1uM, Quetiapine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
DD-68-ZP95_0.01uM Dose=0.01uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A
DD-68-ZP95_0.1uM Dose=0.1uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A
DD-68-ZP95_10uM Dose=10uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A
DD-68-ZP95_1uM Dose=1uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A
DD-71-LY65_0.01uM Dose=0.01uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR
DD-71-LY65_0.1uM Dose=0.1uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR
DD-71-LY65_10uM Dose=10uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR
DD-71-LY65_1uM Dose=1uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR
DD-73-IP88_0.01uM Dose=0.01uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2
DD-73-IP88_0.1uM Dose=0.1uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2
DD-73-IP88_10uM Dose=10uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2
DD-73-IP88_1uM Dose=1uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2
DD-74-PJ26_0.01uM Dose=0.01uM, Amn082, mgluR7 Agonists targeting GRM7
DD-74-PJ26_0.1uM Dose=0.1uM, Amn082, mgluR7 Agonists targeting GRM7
DD-74-PJ26_10uM Dose=10uM, Amn082, mgluR7 Agonists targeting GRM7
DD-74-PJ26_1uM Dose=1uM, Amn082, mgluR7 Agonists targeting GRM7
DD-75-HY40_0.01uM Dose=0.01uM, Celastrol
DD-75-HY40_0.1uM Dose=0.1uM, Celastrol
DD-75-HY40_10uM Dose=10uM, Celastrol
DD-75-HY40_1uM Dose=1uM, Celastrol
DD-77-GV27_0.01uM Dose=0.01uM, Fluspirilene, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F
DD-77-GV27_10uM Dose=10uM, Fluspirilene, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F
DD-77-GV27_1uM Dose=1uM, Fluspirilene, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F
DD-77-OI11_0.01uM Dose=0.01uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2
DD-77-OI11_0.1uM Dose=0.1uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2
DD-77-OI11_10uM Dose=10uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2
DD-77-OI11_1uM Dose=1uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2
DD-82-GV50_0.01uM Dose=0.01uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DD-82-GV50_0.1uM Dose=0.1uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DD-82-GV50_10uM Dose=10uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DD-82-GV50_1uM Dose=1uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DD-82-HB82_0.1uM Dose=0.1uM, Prodipine targeting CYP2D6
DD-82-HB82_10uM Dose=10uM, Prodipine targeting CYP2D6
DD-82-HB82_1uM Dose=1uM, Prodipine targeting CYP2D6
DD-85-AN28_0.01uM Dose=0.01uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B
DD-85-AN28_0.1uM Dose=0.1uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B
DD-85-AN28_10uM Dose=10uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B
DD-85-AN28_1uM Dose=1uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B
DD-85-KU00_0.01uM Dose=0.01uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1
DD-85-KU00_0.1uM Dose=0.1uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1
DD-85-KU00_10uM Dose=10uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1
DD-85-KU00_1uM Dose=1uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1
DD-85-WO51_0.01uM Dose=0.01uM
DD-85-WO51_0.1uM Dose=0.1uM
DD-85-WO51_10uM Dose=10uM
DD-85-WO51_1uM Dose=1uM
DD-89-HG56_0.01uM Dose=0.01uM, eIF4A3-IN-1 targeting EIF4A3
DD-89-HG56_10uM Dose=10uM, eIF4A3-IN-1 targeting EIF4A3
DD-89-MJ03_0.01uM Dose=0.01uM, Peptide Deformylase (PDF) Inhibitors targeting PDF
DD-89-MJ03_10uM Dose=10uM, Peptide Deformylase (PDF) Inhibitors targeting PDF
DD-89-MJ03_1uM Dose=1uM, Peptide Deformylase (PDF) Inhibitors targeting PDF
DD-89-WQ95_0.01uM Dose=0.01uM
DD-89-WQ95_0.1uM Dose=0.1uM
DD-89-WQ95_10uM Dose=10uM
DD-89-WQ95_1uM Dose=1uM
DD-91-OY40_0.01uM Dose=0.01uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB
DD-91-OY40_0.1uM Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB
DD-91-OY40_10uM Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB
DD-91-OY40_1uM Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB
DD-93-NF74_0.01uM Dose=0.01uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide
DD-93-NF74_0.1uM Dose=0.1uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide
DD-93-NF74_10uM Dose=10uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide
DD-93-NF74_1uM Dose=1uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide
DD-95-TY80_0.01uM Dose=0.01uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2
DD-95-TY80_0.1uM Dose=0.1uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2
DD-95-TY80_10uM Dose=10uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2
DD-95-TY80_1uM Dose=1uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2
DD-96-DE39_0.01uM Dose=0.01uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide
DD-96-DE39_0.1uM Dose=0.1uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide
DD-96-DE39_10uM Dose=10uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide
DD-96-DE39_1uM Dose=1uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide
DD-96-VY72_0.01uM Dose=0.01uM
DD-96-VY72_0.1uM Dose=0.1uM
DD-96-VY72_10uM Dose=10uM
DD-96-VY72_1uM Dose=1uM
DD-99-WQ55_0.01uM Dose=0.01uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)-
DD-99-WQ55_0.1uM Dose=0.1uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)-
DD-99-WQ55_10uM Dose=10uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)-
DD-99-WQ55_1uM Dose=1uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)-
DE-00-JU18_0.01uM Dose=0.01uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2
DE-00-JU18_0.1uM Dose=0.1uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2
DE-00-JU18_10uM Dose=10uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2
DE-00-JU18_1uM Dose=1uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2
DE-01-HO61_0.01uM Dose=0.01uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR
DE-01-HO61_0.1uM Dose=0.1uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR
DE-01-HO61_10uM Dose=10uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR
DE-01-HO61_1uM Dose=1uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR
DE-02-BL66_0.01uM Dose=0.01uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7
DE-02-BL66_0.1uM Dose=0.1uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7
DE-02-BL66_10uM Dose=10uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7
DE-02-BL66_1uM Dose=1uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7
DE-03-BW70_0.01uM Dose=0.01uM, 1-(6-Fluoro-2-methyl-3,4-dihydroquinolin-1(2h)-yl)-2-(isoquinolin-5-yloxy)ethanone, Bile Acid Responsive TGR5 Receptors (GPBAR1, AXOR 109, GPCR19) Agonists targeting GPBAR1
DE-03-BW70_10uM Dose=10uM, 1-(6-Fluoro-2-methyl-3,4-dihydroquinolin-1(2h)-yl)-2-(isoquinolin-5-yloxy)ethanone, Bile Acid Responsive TGR5 Receptors (GPBAR1, AXOR 109, GPCR19) Agonists targeting GPBAR1
DE-03-BW70_1uM Dose=1uM, 1-(6-Fluoro-2-methyl-3,4-dihydroquinolin-1(2h)-yl)-2-(isoquinolin-5-yloxy)ethanone, Bile Acid Responsive TGR5 Receptors (GPBAR1, AXOR 109, GPCR19) Agonists targeting GPBAR1
DE-03-NP53_0.01uM Dose=0.01uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate
DE-03-NP53_0.1uM Dose=0.1uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate
DE-03-NP53_10uM Dose=10uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate
DE-03-NP53_1uM Dose=1uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate
DE-05-NX87_0.01uM Dose=0.01uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT
DE-05-NX87_0.1uM Dose=0.1uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT
DE-05-NX87_10uM Dose=10uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT
DE-05-NX87_1uM Dose=1uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT
DE-09-HJ53_0.01uM Dose=0.01uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DE-09-HJ53_0.1uM Dose=0.1uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DE-09-HJ53_10uM Dose=10uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DE-09-HJ53_1uM Dose=1uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DE-10-AU63_0.01uM Dose=0.01uM, Pentostatin, Antimetabolites;Adenosine Deaminase Inhibitors targeting ADA, ADAR
DE-10-AU63_0.1uM Dose=0.1uM, Pentostatin, Antimetabolites;Adenosine Deaminase Inhibitors targeting ADA, ADAR
DE-10-AU63_1uM Dose=1uM, Pentostatin, Antimetabolites;Adenosine Deaminase Inhibitors targeting ADA, ADAR
DE-11-PO61_0.01uM Dose=0.01uM, (S)-N-(8-((2-Amino-4-methylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)cyclopropanecarboxamide, AP2-Associated Protein Kinase 1 (AAK1) Inhibitors targeting AAK1
DE-11-PO61_0.1uM Dose=0.1uM, (S)-N-(8-((2-Amino-4-methylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)cyclopropanecarboxamide, AP2-Associated Protein Kinase 1 (AAK1) Inhibitors targeting AAK1
DE-11-PO61_10uM Dose=10uM, (S)-N-(8-((2-Amino-4-methylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)cyclopropanecarboxamide, AP2-Associated Protein Kinase 1 (AAK1) Inhibitors targeting AAK1
DE-14-EG14_0.01uM Dose=0.01uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide
DE-14-EG14_0.1uM Dose=0.1uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide
DE-14-EG14_10uM Dose=10uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide
DE-14-EG14_1uM Dose=1uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide
DE-15-GD59_0.01uM Dose=0.01uM
DE-15-GD59_0.1uM Dose=0.1uM
DE-15-GD59_10uM Dose=10uM
DE-15-GD59_1uM Dose=1uM
DE-17-IZ77_0.01uM Dose=0.01uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B
DE-17-IZ77_0.1uM Dose=0.1uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B
DE-17-IZ77_10uM Dose=10uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B
DE-17-IZ77_1uM Dose=1uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B
DE-18-BC44_0.01uM Dose=0.01uM
DE-18-BC44_0.1uM Dose=0.1uM
DE-18-BC44_10uM Dose=10uM
DE-18-BC44_1uM Dose=1uM
DE-20-VX20_0.01uM Dose=0.01uM
DE-20-VX20_0.1uM Dose=0.1uM
DE-20-VX20_10uM Dose=10uM
DE-20-VX20_1uM Dose=1uM
DE-22-JV30_0.01uM Dose=0.01uM, Isotretinoin, Retinoid RAR Agonists targeting RARA, RARB, RARG
DE-22-JV30_10uM Dose=10uM, Isotretinoin, Retinoid RAR Agonists targeting RARA, RARB, RARG
DE-23-IF54_0.1uM Dose=0.1uM, (3R)-1,1-bis(ethoxymethyl)-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole, Somatostatin srif1C (sst3) Antagonists targeting SSTR3
DE-23-IF54_1uM Dose=1uM, (3R)-1,1-bis(ethoxymethyl)-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole, Somatostatin srif1C (sst3) Antagonists targeting SSTR3
DE-24-AX80_0.01uM Dose=0.01uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8
DE-24-AX80_0.1uM Dose=0.1uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8
DE-24-AX80_10uM Dose=10uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8
DE-24-AX80_1uM Dose=1uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8
DE-27-WV67_0.01uM Dose=0.01uM
DE-27-WV67_0.1uM Dose=0.1uM
DE-27-WV67_10uM Dose=10uM
DE-27-WV67_1uM Dose=1uM
DE-27-WV87_0.01uM Dose=0.01uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2
DE-27-WV87_0.1uM Dose=0.1uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2
DE-27-WV87_10uM Dose=10uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2
DE-28-BW67_0.01uM Dose=0.01uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide
DE-28-BW67_0.1uM Dose=0.1uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide
DE-28-BW67_10uM Dose=10uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide
DE-28-BW67_1uM Dose=1uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide
DE-28-XP50_0.01uM Dose=0.01uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B
DE-28-XP50_0.1uM Dose=0.1uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B
DE-28-XP50_10uM Dose=10uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B
DE-28-XP50_1uM Dose=1uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B
DE-28-ZP75_0.01uM Dose=0.01uM, Deserpidine
DE-28-ZP75_0.1uM Dose=0.1uM, Deserpidine
DE-28-ZP75_10uM Dose=10uM, Deserpidine
DE-28-ZP75_1uM Dose=1uM, Deserpidine
DE-29-MT22_0.01uM Dose=0.01uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1
DE-29-MT22_0.1uM Dose=0.1uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1
DE-29-MT22_10uM Dose=10uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1
DE-29-MT22_1uM Dose=1uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1
DE-30-EA70_0.01uM Dose=0.01uM, Tiplasinin, Plasminogen Activator Inhibitor (PAI-1) Inhibitors targeting SERPINE1
DE-30-EA70_0.1uM Dose=0.1uM, Tiplasinin, Plasminogen Activator Inhibitor (PAI-1) Inhibitors targeting SERPINE1
DE-30-EA70_1uM Dose=1uM, Tiplasinin, Plasminogen Activator Inhibitor (PAI-1) Inhibitors targeting SERPINE1
DE-30-UR76_0.01uM Dose=0.01uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA
DE-30-UR76_0.1uM Dose=0.1uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA
DE-30-UR76_10uM Dose=10uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA
DE-30-UR76_1uM Dose=1uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA
DE-34-DT75_0.1uM Dose=0.1uM, NG5DD6UA5D, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers;Caspase 8 Activators;Caspase 3 Activators;Angiogenesis Inhibitors;Caspase 9 Activators targeting BIRC2, XIAP
DE-34-DT75_10uM Dose=10uM, NG5DD6UA5D, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers;Caspase 8 Activators;Caspase 3 Activators;Angiogenesis Inhibitors;Caspase 9 Activators targeting BIRC2, XIAP
DE-34-DT75_1uM Dose=1uM, NG5DD6UA5D, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers;Caspase 8 Activators;Caspase 3 Activators;Angiogenesis Inhibitors;Caspase 9 Activators targeting BIRC2, XIAP
DE-37-JV37_0.01uM Dose=0.01uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2
DE-37-JV37_0.1uM Dose=0.1uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2
DE-37-JV37_10uM Dose=10uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2
DE-37-JV37_1uM Dose=1uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2
DE-40-RX20_0.01uM Dose=0.01uM, Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)-
DE-40-RX20_0.1uM Dose=0.1uM, Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)-
DE-40-RX20_10uM Dose=10uM, Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)-
DE-40-RX20_1uM Dose=1uM, Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)-
DE-42-QB97_0.01uM Dose=0.01uM, N-Acetylserotonin
DE-42-QB97_0.1uM Dose=0.1uM, N-Acetylserotonin
DE-42-QB97_10uM Dose=10uM, N-Acetylserotonin
DE-42-QB97_1uM Dose=1uM, N-Acetylserotonin
DE-46-NH51_0.01uM Dose=0.01uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one
DE-46-NH51_0.1uM Dose=0.1uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one
DE-46-NH51_10uM Dose=10uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one
DE-46-NH51_1uM Dose=1uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one
DE-48-FF01_0.01uM Dose=0.01uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK
DE-48-FF01_0.1uM Dose=0.1uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK
DE-48-FF01_10uM Dose=10uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK
DE-48-FF01_1uM Dose=1uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK
DE-48-HZ49_0.01uM Dose=0.01uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2
DE-48-HZ49_0.1uM Dose=0.1uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2
DE-48-HZ49_10uM Dose=10uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2
DE-48-HZ49_1uM Dose=1uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2
DE-48-PP80_0.01uM Dose=0.01uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR
DE-48-PP80_0.1uM Dose=0.1uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR
DE-48-PP80_10uM Dose=10uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR
DE-48-PP80_1uM Dose=1uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR
DE-52-BS63_0.01uM Dose=0.01uM, PAK1 gene inhibitor targeting PAK1
DE-52-BS63_0.1uM Dose=0.1uM, PAK1 gene inhibitor targeting PAK1
DE-52-BS63_10uM Dose=10uM, PAK1 gene inhibitor targeting PAK1
DE-52-BS63_1uM Dose=1uM, PAK1 gene inhibitor targeting PAK1
DE-57-JI61_0.01uM Dose=0.01uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2
DE-57-JI61_0.1uM Dose=0.1uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2
DE-57-JI61_10uM Dose=10uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2
DE-57-JI61_1uM Dose=1uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2
DE-57-XI06_0.01uM Dose=0.01uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2
DE-57-XI06_0.1uM Dose=0.1uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2
DE-57-XI06_10uM Dose=10uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2
DE-57-XI06_1uM Dose=1uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2
DE-58-OW37_0.01uM Dose=0.01uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L
DE-58-OW37_0.1uM Dose=0.1uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L
DE-58-OW37_10uM Dose=10uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L
DE-58-OW37_1uM Dose=1uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L
DE-59-HQ30_0.01uM Dose=0.01uM, (2S,4R)-1-N-(1-carbamoylindol-3-yl)-4-fluoro-2-N-[2-fluoro-3-(trifluoromethoxy)phenyl]pyrrolidine-1,2-dicarboxamide, Complement Factor D (CFD) Inhibitor targeting CFD
DE-59-HQ30_0.1uM Dose=0.1uM, (2S,4R)-1-N-(1-carbamoylindol-3-yl)-4-fluoro-2-N-[2-fluoro-3-(trifluoromethoxy)phenyl]pyrrolidine-1,2-dicarboxamide, Complement Factor D (CFD) Inhibitor targeting CFD
DE-59-HQ30_10uM Dose=10uM, (2S,4R)-1-N-(1-carbamoylindol-3-yl)-4-fluoro-2-N-[2-fluoro-3-(trifluoromethoxy)phenyl]pyrrolidine-1,2-dicarboxamide, Complement Factor D (CFD) Inhibitor targeting CFD
DE-59-OT87_0.01uM Dose=0.01uM, N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide, Chemokine CXCR3 Antagonists targeting CXCR3
DE-59-OT87_0.1uM Dose=0.1uM, N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide, Chemokine CXCR3 Antagonists targeting CXCR3
DE-59-OT87_1uM Dose=1uM, N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide, Chemokine CXCR3 Antagonists targeting CXCR3
DE-60-SD92_0.01uM Dose=0.01uM, Lamotrigine
DE-60-SD92_0.1uM Dose=0.1uM, Lamotrigine
DE-60-SD92_10uM Dose=10uM, Lamotrigine
DE-60-SD92_1uM Dose=1uM, Lamotrigine
DE-62-FI29_0.01uM Dose=0.01uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4
DE-62-FI29_0.1uM Dose=0.1uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4
DE-62-FI29_10uM Dose=10uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4
DE-62-FI29_1uM Dose=1uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4
DE-62-MB57_0.01uM Dose=0.01uM, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors
DE-65-KO26_0.01uM Dose=0.01uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG
DE-65-KO26_0.1uM Dose=0.1uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG
DE-65-KO26_10uM Dose=10uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG
DE-65-KO26_1uM Dose=1uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG
DE-65-KO66_0.01uM Dose=0.01uM
DE-65-KO66_0.1uM Dose=0.1uM
DE-65-KO66_10uM Dose=10uM
DE-65-KO66_1uM Dose=1uM
DE-69-QQ25_0.01uM Dose=0.01uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X
DE-69-QQ25_0.1uM Dose=0.1uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X
DE-69-QQ25_10uM Dose=10uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X
DE-69-QQ25_1uM Dose=1uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X
DE-73-EF24_0.01uM Dose=0.01uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R
DE-73-EF24_0.1uM Dose=0.1uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R
DE-73-EF24_10uM Dose=10uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R
DE-73-JX23_0.01uM Dose=0.01uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1
DE-73-JX23_0.1uM Dose=0.1uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1
DE-73-JX23_10uM Dose=10uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1
DE-73-JX23_1uM Dose=1uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1
DE-79-FD94_0.01uM Dose=0.01uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB
DE-79-FD94_0.1uM Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB
DE-79-FD94_10uM Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB
DE-79-FD94_1uM Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB
DE-80-BU08_0.01uM Dose=0.01uM, DC_AC50, ATOX1 inhibitor targeting ATOX1
DE-80-BU08_0.1uM Dose=0.1uM, DC_AC50, ATOX1 inhibitor targeting ATOX1
DE-80-BU08_10uM Dose=10uM, DC_AC50, ATOX1 inhibitor targeting ATOX1
DE-80-BU08_1uM Dose=1uM, DC_AC50, ATOX1 inhibitor targeting ATOX1
DE-81-OY65_10uM Dose=10uM, Erlotinib, EGFR (HER1 or erbB1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting EGFR
DE-81-OY65_1uM Dose=1uM, Erlotinib, EGFR (HER1 or erbB1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting EGFR
DE-81-PO11_0.01uM Dose=0.01uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300
DE-81-PO11_0.1uM Dose=0.1uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300
DE-81-PO11_10uM Dose=10uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300
DE-81-PO11_1uM Dose=1uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300
DE-81-UE07_0.01uM Dose=0.01uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A
DE-81-UE07_0.1uM Dose=0.1uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A
DE-81-UE07_10uM Dose=10uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A
DE-81-UE07_1uM Dose=1uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A
DE-82-SC55_0.01uM Dose=0.01uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP
DE-82-SC55_0.1uM Dose=0.1uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP
DE-82-SC55_10uM Dose=10uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP
DE-82-SC55_1uM Dose=1uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP
DE-85-DO61_0.01uM Dose=0.01uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2
DE-85-DO61_0.1uM Dose=0.1uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2
DE-85-DO61_10uM Dose=10uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2
DE-85-FR73_0.01uM Dose=0.01uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3
DE-85-FR73_0.1uM Dose=0.1uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3
DE-85-FR73_10uM Dose=10uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3
DE-85-FR73_1uM Dose=1uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3
DE-85-LX22_0.01uM Dose=0.01uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DE-85-LX22_0.1uM Dose=0.1uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DE-85-LX22_10uM Dose=10uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DE-85-LX22_1uM Dose=1uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DE-86-XV75_0.01uM Dose=0.01uM, Griseofulvin, Keratin 12 modulator targeting KRT12
DE-86-XV75_0.1uM Dose=0.1uM, Griseofulvin, Keratin 12 modulator targeting KRT12
DE-86-XV75_10uM Dose=10uM, Griseofulvin, Keratin 12 modulator targeting KRT12
DE-86-XV75_1uM Dose=1uM, Griseofulvin, Keratin 12 modulator targeting KRT12
DE-90-RU43_0.01uM Dose=0.01uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP
DE-90-RU43_0.1uM Dose=0.1uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP
DE-90-RU43_10uM Dose=10uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP
DE-90-RU43_1uM Dose=1uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP
DE-91-FH69_0.01uM Dose=0.01uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
DE-91-FH69_0.1uM Dose=0.1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
DE-91-FH69_10uM Dose=10uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
DE-91-FH69_1uM Dose=1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
DE-93-IC37_0.01uM Dose=0.01uM, Protein Tyrosine Phosphatase PTP-1C Inhibitors;Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1, PTPN6, PTPN11
DE-93-IC37_0.1uM Dose=0.1uM, Protein Tyrosine Phosphatase PTP-1C Inhibitors;Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1, PTPN6, PTPN11
DE-93-IC37_1uM Dose=1uM, Protein Tyrosine Phosphatase PTP-1C Inhibitors;Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1, PTPN6, PTPN11
DE-97-IV02_0.1uM Dose=0.1uM, 2-amino-4-(2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl)-N-ethylthieno(2,3-d)pyrimidine-6-carboxamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1, HSP90B1
DE-97-IV02_10uM Dose=10uM, 2-amino-4-(2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl)-N-ethylthieno(2,3-d)pyrimidine-6-carboxamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1, HSP90B1
DE-97-IV02_1uM Dose=1uM, 2-amino-4-(2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl)-N-ethylthieno(2,3-d)pyrimidine-6-carboxamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1, HSP90B1
DE-98-FC24_0.01uM Dose=0.01uM
DE-98-FC24_0.1uM Dose=0.1uM
DE-98-FC24_10uM Dose=10uM
DE-98-FC24_1uM Dose=1uM
DE-99-OT37_0.01uM Dose=0.01uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5
DE-99-OT37_0.1uM Dose=0.1uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5
DE-99-OT37_10uM Dose=10uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5
DE-99-OT37_1uM Dose=1uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5
DF-00-BU08_0.01uM Dose=0.01uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4
DF-00-BU08_0.1uM Dose=0.1uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4
DF-00-BU08_10uM Dose=10uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4
DF-00-BU08_1uM Dose=1uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4
DF-00-BX35_0.01uM Dose=0.01uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1
DF-00-BX35_0.1uM Dose=0.1uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1
DF-00-BX35_10uM Dose=10uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1
DF-00-BX35_1uM Dose=1uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1
DF-00-DK69_0.01uM Dose=0.01uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1
DF-00-DK69_0.1uM Dose=0.1uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1
DF-00-DK69_10uM Dose=10uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1
DF-00-DK69_1uM Dose=1uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1
DF-00-NA25_0.01uM Dose=0.01uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES
DF-00-NA25_10uM Dose=10uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES
DF-00-NA25_1uM Dose=1uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES
DF-03-OP38_0.01uM Dose=0.01uM
DF-03-OP38_10uM Dose=10uM
DF-03-OP38_1uM Dose=1uM
DF-11-IL69_0.01uM Dose=0.01uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS
DF-11-IL69_0.1uM Dose=0.1uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS
DF-11-IL69_10uM Dose=10uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS
DF-11-IL69_1uM Dose=1uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS
DF-13-OP48_0.01uM Dose=0.01uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol
DF-13-OP48_0.1uM Dose=0.1uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol
DF-13-OP48_10uM Dose=10uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol
DF-13-OP48_1uM Dose=1uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol
DF-26-EY87_0.01uM Dose=0.01uM
DF-26-EY87_0.1uM Dose=0.1uM
DF-26-EY87_10uM Dose=10uM
DF-26-EY87_1uM Dose=1uM
DF-32-EL16_0.01uM Dose=0.01uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1
DF-32-EL16_0.1uM Dose=0.1uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1
DF-32-EL16_10uM Dose=10uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1
DF-32-EL16_1uM Dose=1uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1
DF-32-MM89_10uM Dose=10uM, Dihydropyrimidine Dehydrogenase Inhibitors targeting DPYD
DF-32-MM89_1uM Dose=1uM, Dihydropyrimidine Dehydrogenase Inhibitors targeting DPYD
DF-37-AV77_0.01uM Dose=0.01uM, Chlorthalidone, Carbonic Anhydrase Type VII Inhibitors targeting CA1, CA4, CA5A, CA7, CA12, CA5B
DF-37-AV77_10uM Dose=10uM, Chlorthalidone, Carbonic Anhydrase Type VII Inhibitors targeting CA1, CA4, CA5A, CA7, CA12, CA5B
DF-37-AV77_1uM Dose=1uM, Chlorthalidone, Carbonic Anhydrase Type VII Inhibitors targeting CA1, CA4, CA5A, CA7, CA12, CA5B
DF-40-CD57_0.01uM Dose=0.01uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1
DF-40-CD57_0.1uM Dose=0.1uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1
DF-40-CD57_10uM Dose=10uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1
DF-40-CD57_1uM Dose=1uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1
DF-41-HL79_0.01uM Dose=0.01uM, D-Methionine
DF-41-HL79_0.1uM Dose=0.1uM, D-Methionine
DF-41-HL79_10uM Dose=10uM, D-Methionine
DF-45-GA42_0.01uM Dose=0.01uM, SB 224289, HTR1B antagonist targeting HTR1B
DF-45-GA42_0.1uM Dose=0.1uM, SB 224289, HTR1B antagonist targeting HTR1B
DF-45-GA42_10uM Dose=10uM, SB 224289, HTR1B antagonist targeting HTR1B
DF-45-GA42_1uM Dose=1uM, SB 224289, HTR1B antagonist targeting HTR1B
DF-46-QE34_0.01uM Dose=0.01uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1
DF-46-QE34_0.1uM Dose=0.1uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1
DF-46-QE34_10uM Dose=10uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1
DF-46-QE34_1uM Dose=1uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1
DF-53-QT23_0.01uM Dose=0.01uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9
DF-53-QT23_0.1uM Dose=0.1uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9
DF-53-QT23_10uM Dose=10uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9
DF-53-QT23_1uM Dose=1uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9
DF-56-GR45_0.01uM Dose=0.01uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM
DF-56-GR45_0.1uM Dose=0.1uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM
DF-56-GR45_10uM Dose=10uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM
DF-56-GR45_1uM Dose=1uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM
DF-57-BL63_0.01uM Dose=0.01uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1
DF-57-BL63_0.1uM Dose=0.1uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1
DF-57-BL63_10uM Dose=10uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1
DF-57-BL63_1uM Dose=1uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1
DF-57-FI46_0.01uM Dose=0.01uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1
DF-57-FI46_0.1uM Dose=0.1uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1
DF-57-FI46_10uM Dose=10uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1
DF-57-FI46_1uM Dose=1uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1
DF-70-CD57_0.01uM Dose=0.01uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2
DF-70-CD57_0.1uM Dose=0.1uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2
DF-70-CD57_10uM Dose=10uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2
DF-70-CD57_1uM Dose=1uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2
DF-74-MG39_0.01uM Dose=0.01uM, N-(2-Methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide targeting HDAC9, HDAC4, HDAC5, HDAC7
DF-74-MG39_10uM Dose=10uM, N-(2-Methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide targeting HDAC9, HDAC4, HDAC5, HDAC7
DF-74-MG39_1uM Dose=1uM, N-(2-Methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide targeting HDAC9, HDAC4, HDAC5, HDAC7
DF-75-JD89_0.01uM Dose=0.01uM, (2S)-N-(4-ethylpyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DF-75-JD89_0.1uM Dose=0.1uM, (2S)-N-(4-ethylpyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DF-75-JD89_10uM Dose=10uM, (2S)-N-(4-ethylpyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DF-75-JD89_1uM Dose=1uM, (2S)-N-(4-ethylpyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF
DF-75-MR73_0.01uM Dose=0.01uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4
DF-75-MR73_0.1uM Dose=0.1uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4
DF-75-MR73_10uM Dose=10uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4
DF-75-OU25_0.1uM Dose=0.1uM, Dot1L-IN-4
DF-75-OU25_10uM Dose=10uM, Dot1L-IN-4
DF-75-OU25_1uM Dose=1uM, Dot1L-IN-4
DF-80-BU28_0.01uM Dose=0.01uM, Nvs-crf38, CRF1 Antagonists;CRF-1 receptor antagonist targeting CRHR1
DF-80-BU28_0.1uM Dose=0.1uM, Nvs-crf38, CRF1 Antagonists;CRF-1 receptor antagonist targeting CRHR1
DF-80-BU28_1uM Dose=1uM, Nvs-crf38, CRF1 Antagonists;CRF-1 receptor antagonist targeting CRHR1
DF-80-HY53_0.1uM Dose=0.1uM, Baicalein
DF-80-HY53_10uM Dose=10uM, Baicalein
DF-84-RT50_0.01uM Dose=0.01uM
DF-84-RT50_0.1uM Dose=0.1uM
DF-84-RT50_10uM Dose=10uM
DF-84-RT50_1uM Dose=1uM
DF-85-QA87_0.01uM Dose=0.01uM, Htfmt, HRH1 agonist targeting HRH1
DF-85-QA87_0.1uM Dose=0.1uM, Htfmt, HRH1 agonist targeting HRH1
DF-85-QA87_10uM Dose=10uM, Htfmt, HRH1 agonist targeting HRH1
DF-85-QA87_1uM Dose=1uM, Htfmt, HRH1 agonist targeting HRH1
DF-92-CF17_0.01uM Dose=0.01uM, Carbonyl cyanide p-trifluoromethoxyphenylhydrazone
DF-92-CF17_10uM Dose=10uM, Carbonyl cyanide p-trifluoromethoxyphenylhydrazone
DF-92-CF17_1uM Dose=1uM, Carbonyl cyanide p-trifluoromethoxyphenylhydrazone
DF-93-BT88_0.01uM Dose=0.01uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C
DF-93-BT88_10uM Dose=10uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C
DF-93-BT88_1uM Dose=1uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C
DF-95-CY55_0.01uM Dose=0.01uM
DF-95-CY55_0.1uM Dose=0.1uM
DF-95-CY55_10uM Dose=10uM
DF-95-CY55_1uM Dose=1uM
EA-00-QR36_0.01uM Dose=0.01uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A
EA-00-QR36_0.1uM Dose=0.1uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A
EA-00-QR36_10uM Dose=10uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A
EA-00-QR36_1uM Dose=1uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A
EA-00-RN06_0.01uM Dose=0.01uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
EA-00-RN06_0.1uM Dose=0.1uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
EA-00-RN06_10uM Dose=10uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
EA-00-RN06_1uM Dose=1uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
EA-02-ZO63_0.01uM Dose=0.01uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3
EA-02-ZO63_0.1uM Dose=0.1uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3
EA-02-ZO63_10uM Dose=10uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3
EA-02-ZO63_1uM Dose=1uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3
EA-06-CH36_0.01uM Dose=0.01uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
EA-06-CH36_0.1uM Dose=0.1uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
EA-06-CH36_10uM Dose=10uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
EA-06-CH36_1uM Dose=1uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
EA-07-RB34_0.01uM Dose=0.01uM
EA-07-RB34_0.1uM Dose=0.1uM
EA-07-RB34_10uM Dose=10uM
EA-07-RB34_1uM Dose=1uM
EA-09-HM95_0.01uM Dose=0.01uM
EA-09-HM95_0.1uM Dose=0.1uM
EA-09-HM95_10uM Dose=10uM
EA-09-HM95_1uM Dose=1uM
EA-12-SS08_0.01uM Dose=0.01uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8
EA-12-SS08_0.1uM Dose=0.1uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8
EA-12-SS08_10uM Dose=10uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8
EA-12-SS08_1uM Dose=1uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8
EA-17-BY69_0.01uM Dose=0.01uM
EA-17-BY69_0.1uM Dose=0.1uM
EA-17-BY69_10uM Dose=10uM
EA-17-BY69_1uM Dose=1uM
EA-18-FP00_0.01uM Dose=0.01uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E
EA-18-FP00_0.1uM Dose=0.1uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E
EA-18-FP00_10uM Dose=10uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E
EA-18-FP00_1uM Dose=1uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E
EA-22-SB72_0.01uM Dose=0.01uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R
EA-22-SB72_0.1uM Dose=0.1uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R
EA-22-SB72_10uM Dose=10uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R
EA-22-SB72_1uM Dose=1uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R
EA-25-VD74_0.01uM Dose=0.01uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP
EA-25-VD74_0.1uM Dose=0.1uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP
EA-25-VD74_10uM Dose=10uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP
EA-25-VD74_1uM Dose=1uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP
EA-30-DG14_0.01uM Dose=0.01uM, Lanepitant, Growth Hormone Secretagogues;Tachykinin NK1 Antagonists targeting GH1, TACR1
EA-30-DG14_10uM Dose=10uM, Lanepitant, Growth Hormone Secretagogues;Tachykinin NK1 Antagonists targeting GH1, TACR1
EA-30-ZX90_0.01uM Dose=0.01uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
EA-30-ZX90_0.1uM Dose=0.1uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
EA-30-ZX90_10uM Dose=10uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
EA-30-ZX90_1uM Dose=1uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
EA-32-CY22_0.01uM Dose=0.01uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2
EA-32-CY22_0.1uM Dose=0.1uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2
EA-32-CY22_10uM Dose=10uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2
EA-32-CY22_1uM Dose=1uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2
EA-33-QC97_0.01uM Dose=0.01uM
EA-33-QC97_0.1uM Dose=0.1uM
EA-33-QC97_10uM Dose=10uM
EA-33-QC97_1uM Dose=1uM
EA-39-WW34_0.01uM Dose=0.01uM, 5-Phosphono-D-norvaline, NMDA Antagonists targeting GRIN1
EA-39-WW34_10uM Dose=10uM, 5-Phosphono-D-norvaline, NMDA Antagonists targeting GRIN1
EA-39-YN88_0.01uM Dose=0.01uM
EA-39-YN88_0.1uM Dose=0.1uM
EA-39-YN88_10uM Dose=10uM
EA-39-YN88_1uM Dose=1uM
EA-40-GQ08_0.01uM Dose=0.01uM, N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine, Endothelin ETB Receptor Antagonists targeting EDNRB
EA-40-GQ08_10uM Dose=10uM, N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine, Endothelin ETB Receptor Antagonists targeting EDNRB
EA-40-GQ08_1uM Dose=1uM, N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine, Endothelin ETB Receptor Antagonists targeting EDNRB
EA-40-KQ08_0.01uM Dose=0.01uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9
EA-40-KQ08_0.1uM Dose=0.1uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9
EA-40-KQ08_10uM Dose=10uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9
EA-40-KQ08_1uM Dose=1uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9
EA-41-GV68_0.01uM Dose=0.01uM, Firibastat, Known aminopeptidase A inhibitor targeting ENPEP
EA-41-GV68_0.1uM Dose=0.1uM, Firibastat, Known aminopeptidase A inhibitor targeting ENPEP
EA-41-GV68_10uM Dose=10uM, Firibastat, Known aminopeptidase A inhibitor targeting ENPEP
EA-41-GV68_1uM Dose=1uM, Firibastat, Known aminopeptidase A inhibitor targeting ENPEP
EA-43-FS10_0.01uM Dose=0.01uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one
EA-43-FS10_0.1uM Dose=0.1uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one
EA-43-FS10_10uM Dose=10uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one
EA-43-FS10_1uM Dose=1uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one
EA-43-XP68_0.01uM Dose=0.01uM, 3-[[4-[(2R)-1-[(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-3-cyclopentyl-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid
EA-43-XP68_0.1uM Dose=0.1uM, 3-[[4-[(2R)-1-[(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-3-cyclopentyl-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid
EA-43-XP68_10uM Dose=10uM, 3-[[4-[(2R)-1-[(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-3-cyclopentyl-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid
EA-50-GQ38_0.01uM Dose=0.01uM, Gentisic Acid
EA-50-GQ38_10uM Dose=10uM, Gentisic Acid
EA-60-LN91_0.01uM Dose=0.01uM, N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide, BRPF1 inhibitor;BRPF1 inhbitor targeting BRPF1
EA-60-LN91_0.1uM Dose=0.1uM, N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide, BRPF1 inhibitor;BRPF1 inhbitor targeting BRPF1
EA-60-LN91_10uM Dose=10uM, N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide, BRPF1 inhibitor;BRPF1 inhbitor targeting BRPF1
EA-61-RR63_0.01uM Dose=0.01uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
EA-61-RR63_0.1uM Dose=0.1uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
EA-61-RR63_10uM Dose=10uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
EA-61-RR63_1uM Dose=1uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
EA-62-MI89_0.01uM Dose=0.01uM, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, Apoptosis Inducers;Wnt Signaling Inhibitors;CREBBP - beta-catenin interaction inhibitor targeting CREBBP, CTNNB1
EA-62-MI89_0.1uM Dose=0.1uM, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, Apoptosis Inducers;Wnt Signaling Inhibitors;CREBBP - beta-catenin interaction inhibitor targeting CREBBP, CTNNB1
EA-62-MI89_10uM Dose=10uM, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, Apoptosis Inducers;Wnt Signaling Inhibitors;CREBBP - beta-catenin interaction inhibitor targeting CREBBP, CTNNB1
EA-67-CO00_0.01uM Dose=0.01uM, Flupirtine, Voltage-Gated K(V) 7 (KCNQ) Channel Activators targeting KCNQ2, KCNQ3, KCNQ4
EA-67-CO00_0.1uM Dose=0.1uM, Flupirtine, Voltage-Gated K(V) 7 (KCNQ) Channel Activators targeting KCNQ2, KCNQ3, KCNQ4
EA-67-CO00_1uM Dose=1uM, Flupirtine, Voltage-Gated K(V) 7 (KCNQ) Channel Activators targeting KCNQ2, KCNQ3, KCNQ4
EA-67-FY34_0.01uM Dose=0.01uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA
EA-67-FY34_0.1uM Dose=0.1uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA
EA-67-FY34_10uM Dose=10uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA
EA-67-FY34_1uM Dose=1uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA
EA-67-SE76_0.01uM Dose=0.01uM
EA-67-SE76_0.1uM Dose=0.1uM
EA-67-SE76_10uM Dose=10uM
EA-67-SE76_1uM Dose=1uM
EA-69-VJ68_0.01uM Dose=0.01uM
EA-69-VJ68_0.1uM Dose=0.1uM
EA-69-VJ68_10uM Dose=10uM
EA-69-VJ68_1uM Dose=1uM
EA-73-MI41_0.01uM Dose=0.01uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B
EA-73-MI41_0.1uM Dose=0.1uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B
EA-73-MI41_10uM Dose=10uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B
EA-73-MI41_1uM Dose=1uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B
EA-73-UC67_0.01uM Dose=0.01uM
EA-73-UC67_0.1uM Dose=0.1uM
EA-73-UC67_10uM Dose=10uM
EA-73-UC67_1uM Dose=1uM
EA-73-WI86_0.01uM Dose=0.01uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1
EA-73-WI86_0.1uM Dose=0.1uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1
EA-73-WI86_10uM Dose=10uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1
EA-73-WI86_1uM Dose=1uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1
EA-81-CR68_0.01uM Dose=0.01uM
EA-81-CR68_0.1uM Dose=0.1uM
EA-81-CR68_10uM Dose=10uM
EA-81-CR68_1uM Dose=1uM
EA-84-SC49_10uM Dose=10uM, (3-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone, CDK inhibitor targeting CDK2, CDK4, CCNA1
EA-84-SC49_1uM Dose=1uM, (3-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone, CDK inhibitor targeting CDK2, CDK4, CCNA1
EA-86-QK08_0.01uM Dose=0.01uM, N-{{3-{3-[4-Acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)-phenoxy]-propoxy}-4-bromo-6-methyl-phenyl}}-oxamic acid, Non-Steroidal Antiinflammatory Drugs;Phospholipase A2 (PLA2) Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Leukotriene Antagonists targeting PTAFR, PLA2G10
EA-86-QK08_0.1uM Dose=0.1uM, N-{{3-{3-[4-Acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)-phenoxy]-propoxy}-4-bromo-6-methyl-phenyl}}-oxamic acid, Non-Steroidal Antiinflammatory Drugs;Phospholipase A2 (PLA2) Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Leukotriene Antagonists targeting PTAFR, PLA2G10
EA-86-QK08_10uM Dose=10uM, N-{{3-{3-[4-Acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)-phenoxy]-propoxy}-4-bromo-6-methyl-phenyl}}-oxamic acid, Non-Steroidal Antiinflammatory Drugs;Phospholipase A2 (PLA2) Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Leukotriene Antagonists targeting PTAFR, PLA2G10
EA-86-YK48_0.01uM Dose=0.01uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1
EA-86-YK48_0.1uM Dose=0.1uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1
EA-86-YK48_10uM Dose=10uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1
EA-86-YK48_1uM Dose=1uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1
EA-90-PK44_0.01uM Dose=0.01uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
EA-90-PK44_0.1uM Dose=0.1uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
EA-90-PK44_10uM Dose=10uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
EA-90-PK44_1uM Dose=1uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
EA-92-CV45_0.01uM Dose=0.01uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A
EA-92-CV45_0.1uM Dose=0.1uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A
EA-92-CV45_10uM Dose=10uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A
EA-92-CV45_1uM Dose=1uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A
EA-93-KT88_0.01uM Dose=0.01uM
EA-93-KT88_0.1uM Dose=0.1uM
EA-93-KT88_10uM Dose=10uM
EA-93-KT88_1uM Dose=1uM
EA-95-OQ30_0.01uM Dose=0.01uM, Azinphos-methyl
EA-95-OQ30_0.1uM Dose=0.1uM, Azinphos-methyl
EA-95-OQ30_10uM Dose=10uM, Azinphos-methyl
EA-95-OQ30_1uM Dose=1uM, Azinphos-methyl
EA-95-YN88_0.1uM Dose=0.1uM, rel-(3R,4S)-3-((4-Chlorophenyl)sulfonyl)-4-(isobutylamino)tetrahydrothiophene 1,1-dioxide targeting PGK1
EA-95-YN88_10uM Dose=10uM, rel-(3R,4S)-3-((4-Chlorophenyl)sulfonyl)-4-(isobutylamino)tetrahydrothiophene 1,1-dioxide targeting PGK1
EA-95-YN88_1uM Dose=1uM, rel-(3R,4S)-3-((4-Chlorophenyl)sulfonyl)-4-(isobutylamino)tetrahydrothiophene 1,1-dioxide targeting PGK1
EA-95-YQ95_0.01uM Dose=0.01uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6
EA-95-YQ95_0.1uM Dose=0.1uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6
EA-95-YQ95_10uM Dose=10uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6
EA-95-YQ95_1uM Dose=1uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6
EA-96-QK68_0.01uM Dose=0.01uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
EA-96-QK68_0.1uM Dose=0.1uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
EA-96-QK68_10uM Dose=10uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
EA-96-QK68_1uM Dose=1uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
EA-98-NW07_0.01uM Dose=0.01uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3
EA-98-NW07_0.1uM Dose=0.1uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3
EA-98-NW07_10uM Dose=10uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3
EA-98-NW07_1uM Dose=1uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3
EB-00-JQ48_0.01uM Dose=0.01uM, Tandamine, Drugs Acting on Adrenergic Transmission;norepinephrine reuptake inhibitor targeting SLC6A2
EB-00-JQ48_0.1uM Dose=0.1uM, Tandamine, Drugs Acting on Adrenergic Transmission;norepinephrine reuptake inhibitor targeting SLC6A2
EB-00-JQ48_1uM Dose=1uM, Tandamine, Drugs Acting on Adrenergic Transmission;norepinephrine reuptake inhibitor targeting SLC6A2
EB-07-JB09_0.01uM Dose=0.01uM
EB-07-JB09_0.1uM Dose=0.1uM
EB-07-JB09_10uM Dose=10uM
EB-07-JB09_1uM Dose=1uM
EB-08-WP80_0.01uM Dose=0.01uM
EB-08-WP80_0.1uM Dose=0.1uM
EB-08-WP80_10uM Dose=10uM
EB-08-WP80_1uM Dose=1uM
EB-09-GW59_0.01uM Dose=0.01uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B
EB-09-GW59_0.1uM Dose=0.1uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B
EB-09-GW59_10uM Dose=10uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B
EB-09-GW59_1uM Dose=1uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B
EB-09-JJ93_0.01uM Dose=0.01uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A
EB-09-JJ93_0.1uM Dose=0.1uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A
EB-09-JJ93_10uM Dose=10uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A
EB-09-JJ93_1uM Dose=1uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A
EB-09-LQ45_0.01uM Dose=0.01uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2
EB-09-LQ45_0.1uM Dose=0.1uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2
EB-09-LQ45_10uM Dose=10uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2
EB-09-LQ45_1uM Dose=1uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2
EB-09-OC36_0.01uM Dose=0.01uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
EB-09-OC36_0.1uM Dose=0.1uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
EB-09-OC36_10uM Dose=10uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
EB-09-OC36_1uM Dose=1uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
EB-11-MR93_0.01uM Dose=0.01uM, 7beta,25-Dihydroxycholesterol
EB-11-MR93_0.1uM Dose=0.1uM, 7beta,25-Dihydroxycholesterol
EB-11-MR93_10uM Dose=10uM, 7beta,25-Dihydroxycholesterol
EB-11-MR93_1uM Dose=1uM, 7beta,25-Dihydroxycholesterol
EB-18-PP65_0.01uM Dose=0.01uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK
EB-18-PP65_0.1uM Dose=0.1uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK
EB-18-PP65_10uM Dose=10uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK
EB-18-PP65_1uM Dose=1uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK
EB-19-SM10_0.01uM Dose=0.01uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8
EB-19-SM10_0.1uM Dose=0.1uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8
EB-19-SM10_10uM Dose=10uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8
EB-19-SM10_1uM Dose=1uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8
EB-28-HP05_0.01uM Dose=0.01uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
EB-28-HP05_0.1uM Dose=0.1uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
EB-28-HP05_10uM Dose=10uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
EB-28-HP05_1uM Dose=1uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
EB-28-ZJ41_0.01uM Dose=0.01uM, Cidofovir
EB-28-ZJ41_0.1uM Dose=0.1uM, Cidofovir
EB-28-ZJ41_10uM Dose=10uM, Cidofovir
EB-28-ZJ41_1uM Dose=1uM, Cidofovir
EB-30-VD02_0.01uM Dose=0.01uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2
EB-30-VD02_0.1uM Dose=0.1uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2
EB-30-VD02_10uM Dose=10uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2
EB-30-VD02_1uM Dose=1uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2
EB-33-ZP53_0.01uM Dose=0.01uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA
EB-33-ZP53_0.1uM Dose=0.1uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA
EB-33-ZP53_10uM Dose=10uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA
EB-33-ZP53_1uM Dose=1uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA
EB-34-KW22_0.01uM Dose=0.01uM, Mifobate, PPARgamma Antagonists targeting PPARG
EB-34-KW22_0.1uM Dose=0.1uM, Mifobate, PPARgamma Antagonists targeting PPARG
EB-34-KW22_10uM Dose=10uM, Mifobate, PPARgamma Antagonists targeting PPARG
EB-34-KW22_1uM Dose=1uM, Mifobate, PPARgamma Antagonists targeting PPARG
EB-44-GM58_0.01uM Dose=0.01uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B
EB-44-GM58_0.1uM Dose=0.1uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B
EB-44-GM58_10uM Dose=10uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B
EB-44-GM58_1uM Dose=1uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B
EB-44-OW82_0.01uM Dose=0.01uM, Pitrazepin, Glycine Receptor Antagonists;GABA(A) Receptor Antagonists targeting GABRA1, GLRA1
EB-44-OW82_0.1uM Dose=0.1uM, Pitrazepin, Glycine Receptor Antagonists;GABA(A) Receptor Antagonists targeting GABRA1, GLRA1
EB-44-OW82_10uM Dose=10uM, Pitrazepin, Glycine Receptor Antagonists;GABA(A) Receptor Antagonists targeting GABRA1, GLRA1
EB-44-OW82_1uM Dose=1uM, Pitrazepin, Glycine Receptor Antagonists;GABA(A) Receptor Antagonists targeting GABRA1, GLRA1
EB-47-BB89_0.01uM Dose=0.01uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3
EB-47-BB89_0.1uM Dose=0.1uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3
EB-47-BB89_10uM Dose=10uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3
EB-47-BB89_1uM Dose=1uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3
EB-52-HZ20_0.01uM Dose=0.01uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1
EB-52-HZ20_0.1uM Dose=0.1uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1
EB-52-HZ20_10uM Dose=10uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1
EB-52-HZ20_1uM Dose=1uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1
EB-55-VD69_0.01uM Dose=0.01uM, (1S,2S,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide
EB-55-VD69_10uM Dose=10uM, (1S,2S,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide
EB-55-VD69_1uM Dose=1uM, (1S,2S,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide
EB-56-HU77_0.01uM Dose=0.01uM, (4-Morpholin-4-yl-1,2,5-thiadiazol-3-yl) N-cyclooctyl-N-methylcarbamate, ABHD6 Inhibitor targeting ABHD6
EB-56-HU77_0.1uM Dose=0.1uM, (4-Morpholin-4-yl-1,2,5-thiadiazol-3-yl) N-cyclooctyl-N-methylcarbamate, ABHD6 Inhibitor targeting ABHD6
EB-56-HU77_10uM Dose=10uM, (4-Morpholin-4-yl-1,2,5-thiadiazol-3-yl) N-cyclooctyl-N-methylcarbamate, ABHD6 Inhibitor targeting ABHD6
EB-56-HU77_1uM Dose=1uM, (4-Morpholin-4-yl-1,2,5-thiadiazol-3-yl) N-cyclooctyl-N-methylcarbamate, ABHD6 Inhibitor targeting ABHD6
EB-61-FU05_0.01uM Dose=0.01uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A
EB-61-FU05_0.1uM Dose=0.1uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A
EB-61-FU05_10uM Dose=10uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A
EB-61-FU05_1uM Dose=1uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A
EB-66-IH06_0.01uM Dose=0.01uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2
EB-66-IH06_0.1uM Dose=0.1uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2
EB-66-IH06_10uM Dose=10uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2
EB-66-IH06_1uM Dose=1uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2
EB-66-TU32_10uM Dose=10uM, CID 9940118 targeting GRB2
EB-66-TU32_1uM Dose=1uM, CID 9940118 targeting GRB2
EB-67-WB79_0.01uM Dose=0.01uM
EB-67-WB79_0.1uM Dose=0.1uM
EB-67-WB79_10uM Dose=10uM
EB-67-WB79_1uM Dose=1uM
EB-70-JQ38_0.01uM Dose=0.01uM, Z-Phe-DL-Ala-fluoromethylketone
EB-70-JQ38_0.1uM Dose=0.1uM, Z-Phe-DL-Ala-fluoromethylketone
EB-70-JQ38_10uM Dose=10uM, Z-Phe-DL-Ala-fluoromethylketone
EB-70-JQ38_1uM Dose=1uM, Z-Phe-DL-Ala-fluoromethylketone
EB-72-SO78_0.01uM Dose=0.01uM, N,N-dimethyl-1-(3-pyridin-3-yl-1H-inden-2-yl)methanamine, 5-HT Reuptake Inhibitors;mu-Opioid Receptor Ligands;Norepinephrine Reuptake Inhibitors targeting OPRM1, SLC6A2, SLC6A4
EB-72-SO78_10uM Dose=10uM, N,N-dimethyl-1-(3-pyridin-3-yl-1H-inden-2-yl)methanamine, 5-HT Reuptake Inhibitors;mu-Opioid Receptor Ligands;Norepinephrine Reuptake Inhibitors targeting OPRM1, SLC6A2, SLC6A4
EB-82-HZ30_0.1uM Dose=0.1uM
EB-82-HZ30_10uM Dose=10uM
EB-82-HZ30_1uM Dose=1uM
EB-82-QI99_0.01uM Dose=0.01uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4
EB-82-QI99_0.1uM Dose=0.1uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4
EB-82-QI99_10uM Dose=10uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4
EB-82-QI99_1uM Dose=1uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4
EB-83-IM06_0.01uM Dose=0.01uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE
EB-83-IM06_0.1uM Dose=0.1uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE
EB-83-IM06_10uM Dose=10uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE
EB-83-IM06_1uM Dose=1uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE
EB-85-DG91_0.01uM Dose=0.01uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3
EB-85-DG91_0.1uM Dose=0.1uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3
EB-85-DG91_10uM Dose=10uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3
EB-85-DG91_1uM Dose=1uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3
EB-85-JN83_0.01uM Dose=0.01uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide
EB-85-JN83_0.1uM Dose=0.1uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide
EB-85-JN83_10uM Dose=10uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide
EB-85-JN83_1uM Dose=1uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide
EB-89-KM10_0.01uM Dose=0.01uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5
EB-89-KM10_0.1uM Dose=0.1uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5
EB-89-KM10_10uM Dose=10uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5
EB-89-KM10_1uM Dose=1uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5
EB-90-BR21_0.01uM Dose=0.01uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9
EB-90-BR21_0.1uM Dose=0.1uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9
EB-90-BR21_10uM Dose=10uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9
EB-90-BR21_1uM Dose=1uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9
EB-92-TL51_0.01uM Dose=0.01uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide
EB-92-TL51_0.1uM Dose=0.1uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide
EB-92-TL51_10uM Dose=10uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide
EB-92-TL51_1uM Dose=1uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide
EB-97-AV17_0.01uM Dose=0.01uM, Diphenylamine-2,2'-dicarboxylic acid
EB-97-AV17_0.1uM Dose=0.1uM, Diphenylamine-2,2'-dicarboxylic acid
EB-97-AV17_10uM Dose=10uM, Diphenylamine-2,2'-dicarboxylic acid
EB-97-AV17_1uM Dose=1uM, Diphenylamine-2,2'-dicarboxylic acid
EB-98-LS52_0.01uM Dose=0.01uM, (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium, Muscarinic receptor agonist targeting CHRM1, CHRM4, CHRM5, CHRM2, CHRM3
EB-98-LS52_0.1uM Dose=0.1uM, (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium, Muscarinic receptor agonist targeting CHRM1, CHRM4, CHRM5, CHRM2, CHRM3
EB-98-LS52_10uM Dose=10uM, (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium, Muscarinic receptor agonist targeting CHRM1, CHRM4, CHRM5, CHRM2, CHRM3
EB-98-OI08_0.01uM Dose=0.01uM
EB-98-OI08_0.1uM Dose=0.1uM
EB-98-OI08_10uM Dose=10uM
EB-98-OI08_1uM Dose=1uM
EC-00-KR26_0.01uM Dose=0.01uM, Dexibuprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
EC-00-KR26_0.1uM Dose=0.1uM, Dexibuprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
EC-00-KR26_1uM Dose=1uM, Dexibuprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
EC-01-PH79_0.01uM Dose=0.01uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE
EC-01-PH79_0.1uM Dose=0.1uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE
EC-01-PH79_10uM Dose=10uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE
EC-01-PH79_1uM Dose=1uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE
EC-07-AO30_0.01uM Dose=0.01uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A
EC-07-AO30_0.1uM Dose=0.1uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A
EC-07-AO30_10uM Dose=10uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A
EC-07-AO30_1uM Dose=1uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A
EC-07-OP38_0.01uM Dose=0.01uM, 2-(4-Chlorophenyl)-5-(4-methylpiperazin-1-yl)-4-(4-phenylphenoxy)pyridazin-3-one, Protein-Lysine 6-Oxidase Inhibitors targeting LOX
EC-07-OP38_0.1uM Dose=0.1uM, 2-(4-Chlorophenyl)-5-(4-methylpiperazin-1-yl)-4-(4-phenylphenoxy)pyridazin-3-one, Protein-Lysine 6-Oxidase Inhibitors targeting LOX
EC-07-OP38_10uM Dose=10uM, 2-(4-Chlorophenyl)-5-(4-methylpiperazin-1-yl)-4-(4-phenylphenoxy)pyridazin-3-one, Protein-Lysine 6-Oxidase Inhibitors targeting LOX
EC-07-ZB49_0.01uM Dose=0.01uM, ML-9 free base
EC-07-ZB49_0.1uM Dose=0.1uM, ML-9 free base
EC-07-ZB49_10uM Dose=10uM, ML-9 free base
EC-07-ZB49_1uM Dose=1uM, ML-9 free base
EC-08-AP40_0.01uM Dose=0.01uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP
EC-08-AP40_0.1uM Dose=0.1uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP
EC-08-AP40_10uM Dose=10uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP
EC-08-AP40_1uM Dose=1uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP
EC-08-KS82_0.01uM Dose=0.01uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C
EC-08-KS82_0.1uM Dose=0.1uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C
EC-08-KS82_10uM Dose=10uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C
EC-08-KS82_1uM Dose=1uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C
EC-09-DC91_0.01uM Dose=0.01uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT
EC-09-DC91_0.1uM Dose=0.1uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT
EC-09-DC91_10uM Dose=10uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT
EC-09-DC91_1uM Dose=1uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT
EC-12-AY12_0.01uM Dose=0.01uM, Lisofylline
EC-12-AY12_0.1uM Dose=0.1uM, Lisofylline
EC-12-AY12_10uM Dose=10uM, Lisofylline
EC-12-AY12_1uM Dose=1uM, Lisofylline
EC-14-UM93_0.01uM Dose=0.01uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
EC-14-UM93_0.1uM Dose=0.1uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
EC-14-UM93_10uM Dose=10uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
EC-14-UM93_1uM Dose=1uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
EC-17-MF19_0.01uM Dose=0.01uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1
EC-17-MF19_0.1uM Dose=0.1uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1
EC-17-MF19_10uM Dose=10uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1
EC-17-MF19_1uM Dose=1uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1
EC-17-VB09_0.01uM Dose=0.01uM, Pyridazine, 4,6-diphenyl-3-(4-(2-pyrimidinyl)-1-piperazinyl)-
EC-17-VB09_10uM Dose=10uM, Pyridazine, 4,6-diphenyl-3-(4-(2-pyrimidinyl)-1-piperazinyl)-
EC-17-VB09_1uM Dose=1uM, Pyridazine, 4,6-diphenyl-3-(4-(2-pyrimidinyl)-1-piperazinyl)-
EC-18-TF61_0.01uM Dose=0.01uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1
EC-18-TF61_0.1uM Dose=0.1uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1
EC-18-TF61_10uM Dose=10uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1
EC-18-TF61_1uM Dose=1uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1
EC-22-ZY92_0.01uM Dose=0.01uM
EC-22-ZY92_0.1uM Dose=0.1uM
EC-22-ZY92_10uM Dose=10uM
EC-22-ZY92_1uM Dose=1uM
EC-26-KB37_0.1uM Dose=0.1uM, Isopregnanolone, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;GABA(A) Receptor Antagonists targeting HSD11B1
EC-26-KB37_10uM Dose=10uM, Isopregnanolone, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;GABA(A) Receptor Antagonists targeting HSD11B1
EC-31-MR88_0.01uM Dose=0.01uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14
EC-31-MR88_0.1uM Dose=0.1uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14
EC-31-MR88_10uM Dose=10uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14
EC-31-MR88_1uM Dose=1uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14
EC-34-FT85_0.01uM Dose=0.01uM, Nibr-0213 targeting S1PR1
EC-34-FT85_0.1uM Dose=0.1uM, Nibr-0213 targeting S1PR1
EC-34-FT85_10uM Dose=10uM, Nibr-0213 targeting S1PR1
EC-34-FT85_1uM Dose=1uM, Nibr-0213 targeting S1PR1
EC-37-MB09_0.01uM Dose=0.01uM, MK6-83, Mucolipin agonist targeting MCOLN1
EC-37-MB09_0.1uM Dose=0.1uM, MK6-83, Mucolipin agonist targeting MCOLN1
EC-37-MB09_10uM Dose=10uM, MK6-83, Mucolipin agonist targeting MCOLN1
EC-37-MB09_1uM Dose=1uM, MK6-83, Mucolipin agonist targeting MCOLN1
EC-40-DQ58_0.01uM Dose=0.01uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4
EC-40-DQ58_0.1uM Dose=0.1uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4
EC-40-DQ58_10uM Dose=10uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4
EC-40-DQ58_1uM Dose=1uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4
EC-41-PH99_0.01uM Dose=0.01uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide
EC-41-PH99_0.1uM Dose=0.1uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide
EC-41-PH99_10uM Dose=10uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide
EC-41-PH99_1uM Dose=1uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide
EC-42-DO33_0.01uM Dose=0.01uM, 1-Propyl-2,3,4,4a,10,10a-hexahydro-1H-9-oxa-1-aza-phenanthren-6-ol, Dopamine Autoreceptor Agonists;Prolactin Secretion Inhibitors targeting PRL
EC-42-DO33_10uM Dose=10uM, 1-Propyl-2,3,4,4a,10,10a-hexahydro-1H-9-oxa-1-aza-phenanthren-6-ol, Dopamine Autoreceptor Agonists;Prolactin Secretion Inhibitors targeting PRL
EC-42-WE14_0.01uM Dose=0.01uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2
EC-42-WE14_0.1uM Dose=0.1uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2
EC-42-WE14_10uM Dose=10uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2
EC-42-WE14_1uM Dose=1uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2
EC-47-EO60_0.01uM Dose=0.01uM, 2-[4-(Morpholin-4-ylsulfonyl)phenyl]benzo[c]azolidine-1,3-dione, Phosphodiesterase IV Inhibitors;Phosphodiesterase V (PDE5A) Inhibitors;TNF-alpha Production Inhibitors targeting PDE5A, PDE2A
EC-47-EO60_10uM Dose=10uM, 2-[4-(Morpholin-4-ylsulfonyl)phenyl]benzo[c]azolidine-1,3-dione, Phosphodiesterase IV Inhibitors;Phosphodiesterase V (PDE5A) Inhibitors;TNF-alpha Production Inhibitors targeting PDE5A, PDE2A
EC-47-EO60_1uM Dose=1uM, 2-[4-(Morpholin-4-ylsulfonyl)phenyl]benzo[c]azolidine-1,3-dione, Phosphodiesterase IV Inhibitors;Phosphodiesterase V (PDE5A) Inhibitors;TNF-alpha Production Inhibitors targeting PDE5A, PDE2A
EC-49-OQ85_0.01uM Dose=0.01uM
EC-49-OQ85_0.1uM Dose=0.1uM
EC-49-OQ85_10uM Dose=10uM
EC-49-OQ85_1uM Dose=1uM
EC-50-TX10_0.01uM Dose=0.01uM, [7-(Aminomethyl)-6-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
EC-50-TX10_10uM Dose=10uM, [7-(Aminomethyl)-6-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
EC-55-XG31_0.01uM Dose=0.01uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2
EC-55-XG31_0.1uM Dose=0.1uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2
EC-55-XG31_10uM Dose=10uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2
EC-55-XG31_1uM Dose=1uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2
EC-56-YK73_0.01uM Dose=0.01uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2
EC-56-YK73_0.1uM Dose=0.1uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2
EC-56-YK73_10uM Dose=10uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2
EC-56-YK73_1uM Dose=1uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2
EC-60-CX20_0.01uM Dose=0.01uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A
EC-60-CX20_0.1uM Dose=0.1uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A
EC-60-CX20_10uM Dose=10uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A
EC-60-CX20_1uM Dose=1uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A
EC-60-IX15_0.01uM Dose=0.01uM, 3',4',7-Trihydroxyisoflavone, Tyrosinase Inhibitors;Melanin Inhibitors;Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF, TYR
EC-60-IX15_10uM Dose=10uM, 3',4',7-Trihydroxyisoflavone, Tyrosinase Inhibitors;Melanin Inhibitors;Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF, TYR
EC-62-HO43_0.01uM Dose=0.01uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1
EC-62-HO43_0.1uM Dose=0.1uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1
EC-62-HO43_10uM Dose=10uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1
EC-62-HO43_1uM Dose=1uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1
EC-62-NP61_0.01uM Dose=0.01uM, 4'-(3,6,9,12-Tetraoxapentadec-14-yn-1-yloxy)-[1,1'-biphenyl]-4-yl sulfurofluoridate, CRABP2 inhibitor targeting CRABP2
EC-62-NP61_0.1uM Dose=0.1uM, 4'-(3,6,9,12-Tetraoxapentadec-14-yn-1-yloxy)-[1,1'-biphenyl]-4-yl sulfurofluoridate, CRABP2 inhibitor targeting CRABP2
EC-62-NP61_10uM Dose=10uM, 4'-(3,6,9,12-Tetraoxapentadec-14-yn-1-yloxy)-[1,1'-biphenyl]-4-yl sulfurofluoridate, CRABP2 inhibitor targeting CRABP2
EC-62-OE64_0.01uM Dose=0.01uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
EC-62-OE64_0.1uM Dose=0.1uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
EC-62-OE64_10uM Dose=10uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
EC-62-OE64_1uM Dose=1uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
EC-67-PV87_0.01uM Dose=0.01uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA
EC-67-PV87_0.1uM Dose=0.1uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA
EC-67-PV87_10uM Dose=10uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA
EC-67-PV87_1uM Dose=1uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA
EC-70-XX20_0.01uM Dose=0.01uM, [5-(7-Chloro-1-propyl-1H-benzoimidazol-2-yl)-pyrimidin-2-yl]-(6-methyl-pyridin-3-yl)-amine, mgluR5 Antagonists targeting GRM5
EC-70-XX20_0.1uM Dose=0.1uM, [5-(7-Chloro-1-propyl-1H-benzoimidazol-2-yl)-pyrimidin-2-yl]-(6-methyl-pyridin-3-yl)-amine, mgluR5 Antagonists targeting GRM5
EC-70-XX20_10uM Dose=10uM, [5-(7-Chloro-1-propyl-1H-benzoimidazol-2-yl)-pyrimidin-2-yl]-(6-methyl-pyridin-3-yl)-amine, mgluR5 Antagonists targeting GRM5
EC-71-PH39_0.01uM Dose=0.01uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1
EC-71-PH39_0.1uM Dose=0.1uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1
EC-71-PH39_10uM Dose=10uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1
EC-71-PH39_1uM Dose=1uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1
EC-72-RE74_0.01uM Dose=0.01uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L
EC-72-RE74_0.1uM Dose=0.1uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L
EC-72-RE74_10uM Dose=10uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L
EC-72-RE74_1uM Dose=1uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L
EC-81-BA87_0.01uM Dose=0.01uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3
EC-81-BA87_0.1uM Dose=0.1uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3
EC-81-BA87_10uM Dose=10uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3
EC-81-BA87_1uM Dose=1uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3
EC-82-LV30_0.01uM Dose=0.01uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B
EC-82-LV30_0.1uM Dose=0.1uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B
EC-82-LV30_10uM Dose=10uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B
EC-82-LV30_1uM Dose=1uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B
EC-84-CC24_0.1uM Dose=0.1uM, Lfm-A13, Inhibitors of Signal Transduction Pathways;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
EC-84-CC24_10uM Dose=10uM, Lfm-A13, Inhibitors of Signal Transduction Pathways;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
EC-85-CG61_0.01uM Dose=0.01uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB
EC-85-CG61_0.1uM Dose=0.1uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB
EC-85-CG61_10uM Dose=10uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB
EC-85-CG61_1uM Dose=1uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB
EC-86-EK93_0.01uM Dose=0.01uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4
EC-86-EK93_0.1uM Dose=0.1uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4
EC-86-EK93_10uM Dose=10uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4
EC-86-EK93_1uM Dose=1uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4
EC-87-ZB49_0.01uM Dose=0.01uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1
EC-87-ZB49_0.1uM Dose=0.1uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1
EC-87-ZB49_10uM Dose=10uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1
EC-87-ZB49_1uM Dose=1uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1
EC-87-ZE76_0.01uM Dose=0.01uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10
EC-87-ZE76_0.1uM Dose=0.1uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10
EC-87-ZE76_10uM Dose=10uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10
EC-87-ZE76_1uM Dose=1uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10
EC-89-AJ93_0.01uM Dose=0.01uM, Valinomycin
EC-89-AJ93_0.1uM Dose=0.1uM, Valinomycin
EC-89-AJ93_10uM Dose=10uM, Valinomycin
EC-89-AJ93_1uM Dose=1uM, Valinomycin
EC-90-QX75_0.01uM Dose=0.01uM, N-[5-cyano-4-[(2S)-2-methoxypropoxy]pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, FGFR4 gene inhibitor targeting FGFR4
EC-90-QX75_10uM Dose=10uM, N-[5-cyano-4-[(2S)-2-methoxypropoxy]pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, FGFR4 gene inhibitor targeting FGFR4
EC-90-QX75_1uM Dose=1uM, N-[5-cyano-4-[(2S)-2-methoxypropoxy]pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, FGFR4 gene inhibitor targeting FGFR4
EC-95-BQ25_0.01uM Dose=0.01uM, 2-(5-Oxo-5,11-dihydro-10-thia-dibenzo[a,d]cyclohepten-7-yl)-propionic acid, DNA Polymerase Inhibitors;ATPase Inhibitors targeting REV3L
EC-95-BQ25_0.1uM Dose=0.1uM, 2-(5-Oxo-5,11-dihydro-10-thia-dibenzo[a,d]cyclohepten-7-yl)-propionic acid, DNA Polymerase Inhibitors;ATPase Inhibitors targeting REV3L
EC-95-BQ25_10uM Dose=10uM, 2-(5-Oxo-5,11-dihydro-10-thia-dibenzo[a,d]cyclohepten-7-yl)-propionic acid, DNA Polymerase Inhibitors;ATPase Inhibitors targeting REV3L
EC-96-KI84_0.01uM Dose=0.01uM
EC-96-KI84_0.1uM Dose=0.1uM
EC-96-KI84_10uM Dose=10uM
EC-96-KI84_1uM Dose=1uM
EC-96-OH91_0.01uM Dose=0.01uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4
EC-96-OH91_0.1uM Dose=0.1uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4
EC-96-OH91_10uM Dose=10uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4
EC-96-OH91_1uM Dose=1uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4
EC-98-KI28_0.01uM Dose=0.01uM, CID 196804
EC-98-KI28_0.1uM Dose=0.1uM, CID 196804
EC-98-KI28_10uM Dose=10uM, CID 196804
EC-98-KI28_1uM Dose=1uM, CID 196804
EC-98-YS67_0.01uM Dose=0.01uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A
EC-98-YS67_0.1uM Dose=0.1uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A
EC-98-YS67_10uM Dose=10uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A
EC-98-YS67_1uM Dose=1uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A
ED-00-OH22_0.01uM Dose=0.01uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT
ED-00-OH22_0.1uM Dose=0.1uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT
ED-00-OH22_10uM Dose=10uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT
ED-00-OH22_1uM Dose=1uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT
ED-02-CL76_0.1uM Dose=0.1uM, Purine Antagonists;Immunosuppressive targeting HPRT1, IMPDH1, IMPDH2, PPAT
ED-02-CL76_10uM Dose=10uM, Purine Antagonists;Immunosuppressive targeting HPRT1, IMPDH1, IMPDH2, PPAT
ED-02-CL76_1uM Dose=1uM, Purine Antagonists;Immunosuppressive targeting HPRT1, IMPDH1, IMPDH2, PPAT
ED-03-IP48_0.01uM Dose=0.01uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1
ED-03-IP48_0.1uM Dose=0.1uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1
ED-03-IP48_10uM Dose=10uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1
ED-03-IP48_1uM Dose=1uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1
ED-05-KX67_0.01uM Dose=0.01uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC
ED-05-KX67_0.1uM Dose=0.1uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC
ED-05-KX67_10uM Dose=10uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC
ED-05-KX67_1uM Dose=1uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC
ED-05-LQ40_0.01uM Dose=0.01uM, N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine
ED-05-LQ40_10uM Dose=10uM, N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine
ED-05-LQ40_1uM Dose=1uM, N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine
ED-10-ED67_0.01uM Dose=0.01uM, Dcebio
ED-10-ED67_0.1uM Dose=0.1uM, Dcebio
ED-10-ED67_10uM Dose=10uM, Dcebio
ED-10-ED67_1uM Dose=1uM, Dcebio
ED-11-BL19_0.01uM Dose=0.01uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A
ED-11-BL19_0.1uM Dose=0.1uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A
ED-11-BL19_10uM Dose=10uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A
ED-11-BL19_1uM Dose=1uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A
ED-11-KK36_0.01uM Dose=0.01uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1
ED-11-KK36_0.1uM Dose=0.1uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1
ED-11-KK36_10uM Dose=10uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1
ED-11-KK36_1uM Dose=1uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1
ED-12-PB22_0.01uM Dose=0.01uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT
ED-12-PB22_0.1uM Dose=0.1uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT
ED-12-PB22_10uM Dose=10uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT
ED-12-PB22_1uM Dose=1uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT
ED-14-GQ53_0.01uM Dose=0.01uM, 2-(4-Methylphenoxy)benzoic acid
ED-14-GQ53_0.1uM Dose=0.1uM, 2-(4-Methylphenoxy)benzoic acid
ED-14-GQ53_10uM Dose=10uM, 2-(4-Methylphenoxy)benzoic acid
ED-14-GQ53_1uM Dose=1uM, 2-(4-Methylphenoxy)benzoic acid
ED-15-OX47_0.01uM Dose=0.01uM, Dimaprit, HRH2 agonist targeting HRH2
ED-15-OX47_0.1uM Dose=0.1uM, Dimaprit, HRH2 agonist targeting HRH2
ED-15-OX47_10uM Dose=10uM, Dimaprit, HRH2 agonist targeting HRH2
ED-15-OX47_1uM Dose=1uM, Dimaprit, HRH2 agonist targeting HRH2
ED-22-QV85_0.01uM Dose=0.01uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3
ED-22-QV85_0.1uM Dose=0.1uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3
ED-22-QV85_10uM Dose=10uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3
ED-22-QV85_1uM Dose=1uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3
ED-25-BD54_0.01uM Dose=0.01uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
ED-25-BD54_0.1uM Dose=0.1uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
ED-25-BD54_10uM Dose=10uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
ED-25-BD54_1uM Dose=1uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2
ED-26-RU42_0.01uM Dose=0.01uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1
ED-26-RU42_0.1uM Dose=0.1uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1
ED-26-RU42_10uM Dose=10uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1
ED-26-RU42_1uM Dose=1uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1
ED-27-OE11_0.01uM Dose=0.01uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1
ED-27-OE11_0.1uM Dose=0.1uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1
ED-27-OE11_10uM Dose=10uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1
ED-27-OE11_1uM Dose=1uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1
ED-28-RW52_0.01uM Dose=0.01uM, 8-(2-Fluorophenyl)-5-(furan-2-ylmethylamino)-[1,2,4]triazolo[4,3-a]pyridine-6-carbonitrile, EED gene inhibitor;PRC2/EED targeting EED
ED-28-RW52_1uM Dose=1uM, 8-(2-Fluorophenyl)-5-(furan-2-ylmethylamino)-[1,2,4]triazolo[4,3-a]pyridine-6-carbonitrile, EED gene inhibitor;PRC2/EED targeting EED
ED-31-AA47_0.01uM Dose=0.01uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2
ED-31-AA47_0.1uM Dose=0.1uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2
ED-31-AA47_10uM Dose=10uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2
ED-31-AA47_1uM Dose=1uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2
ED-32-JY57_0.01uM Dose=0.01uM, N-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2-methylaniline, α2-Adrenoceptors targeting ADRA2A
ED-32-JY57_0.1uM Dose=0.1uM, N-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2-methylaniline, α2-Adrenoceptors targeting ADRA2A
ED-32-JY57_10uM Dose=10uM, N-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2-methylaniline, α2-Adrenoceptors targeting ADRA2A
ED-32-JY57_1uM Dose=1uM, N-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2-methylaniline, α2-Adrenoceptors targeting ADRA2A
ED-32-VE54_0.01uM Dose=0.01uM, Thiosalicylic Acid
ED-32-VE54_0.1uM Dose=0.1uM, Thiosalicylic Acid
ED-32-VE54_10uM Dose=10uM, Thiosalicylic Acid
ED-32-VE54_1uM Dose=1uM, Thiosalicylic Acid
ED-33-YZ72_0.01uM Dose=0.01uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300
ED-33-YZ72_0.1uM Dose=0.1uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300
ED-33-YZ72_10uM Dose=10uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300
ED-33-YZ72_1uM Dose=1uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300
ED-35-EX82_0.01uM Dose=0.01uM, N-[4-chloro-3-(5-phenyl-1H-imidazol-2-yl)phenyl]-2-[(2R)-2-methylmorpholin-4-yl]-1,6-naphthyridin-5-amine, Smoothened Antagonist targeting SMO
ED-35-EX82_0.1uM Dose=0.1uM, N-[4-chloro-3-(5-phenyl-1H-imidazol-2-yl)phenyl]-2-[(2R)-2-methylmorpholin-4-yl]-1,6-naphthyridin-5-amine, Smoothened Antagonist targeting SMO
ED-35-EX82_10uM Dose=10uM, N-[4-chloro-3-(5-phenyl-1H-imidazol-2-yl)phenyl]-2-[(2R)-2-methylmorpholin-4-yl]-1,6-naphthyridin-5-amine, Smoothened Antagonist targeting SMO
ED-35-ZX52_0.01uM Dose=0.01uM, Bergenin, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1
ED-35-ZX52_10uM Dose=10uM, Bergenin, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1
ED-39-VX22_0.01uM Dose=0.01uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1
ED-39-VX22_0.1uM Dose=0.1uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1
ED-39-VX22_10uM Dose=10uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1
ED-39-VX22_1uM Dose=1uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1
ED-43-XF39_0.01uM Dose=0.01uM, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine, Adenylate Cyclase Inhibitors targeting ADCY5
ED-43-XF39_10uM Dose=10uM, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine, Adenylate Cyclase Inhibitors targeting ADCY5
ED-43-XF39_1uM Dose=1uM, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine, Adenylate Cyclase Inhibitors targeting ADCY5
ED-62-DB62_0.01uM Dose=0.01uM
ED-62-DB62_0.1uM Dose=0.1uM
ED-62-DB62_10uM Dose=10uM
ED-62-DB62_1uM Dose=1uM
ED-62-GS43_0.01uM Dose=0.01uM, APLNR agonist targeting APLNR
ED-62-GS43_0.1uM Dose=0.1uM, APLNR agonist targeting APLNR
ED-62-GS43_10uM Dose=10uM, APLNR agonist targeting APLNR
ED-62-GS43_1uM Dose=1uM, APLNR agonist targeting APLNR
ED-71-GA72_0.01uM Dose=0.01uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1
ED-71-GA72_0.1uM Dose=0.1uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1
ED-71-GA72_10uM Dose=10uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1
ED-71-GA72_1uM Dose=1uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1
ED-79-EW79_0.01uM Dose=0.01uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5
ED-79-EW79_0.1uM Dose=0.1uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5
ED-79-EW79_10uM Dose=10uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5
ED-79-EW79_1uM Dose=1uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5
ED-80-NA90_0.01uM Dose=0.01uM, 1-(4-Nitrophenyl)-4-piperidinol, CDK Inhibitors targeting CCND2, CCND3
ED-80-NA90_0.1uM Dose=0.1uM, 1-(4-Nitrophenyl)-4-piperidinol, CDK Inhibitors targeting CCND2, CCND3
ED-80-NA90_10uM Dose=10uM, 1-(4-Nitrophenyl)-4-piperidinol, CDK Inhibitors targeting CCND2, CCND3
ED-80-NA90_1uM Dose=1uM, 1-(4-Nitrophenyl)-4-piperidinol, CDK Inhibitors targeting CCND2, CCND3
ED-81-ZH14_0.01uM Dose=0.01uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK
ED-81-ZH14_0.1uM Dose=0.1uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK
ED-81-ZH14_10uM Dose=10uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK
ED-81-ZH14_1uM Dose=1uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK
ED-83-GF49_0.01uM Dose=0.01uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide
ED-83-GF49_0.1uM Dose=0.1uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide
ED-83-GF49_10uM Dose=10uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide
ED-83-GF49_1uM Dose=1uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide
ED-84-WW97_0.01uM Dose=0.01uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5
ED-84-WW97_0.1uM Dose=0.1uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5
ED-84-WW97_10uM Dose=10uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5
ED-84-WW97_1uM Dose=1uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5
ED-87-UE76_0.01uM Dose=0.01uM, CP-122721, Neurokinin 1 receptor antagonist;Tachykinin NK1 Antagonists targeting CYP2D6
ED-87-UE76_0.1uM Dose=0.1uM, CP-122721, Neurokinin 1 receptor antagonist;Tachykinin NK1 Antagonists targeting CYP2D6
ED-87-UE76_10uM Dose=10uM, CP-122721, Neurokinin 1 receptor antagonist;Tachykinin NK1 Antagonists targeting CYP2D6
ED-90-AH37_0.01uM Dose=0.01uM
ED-90-AH37_10uM Dose=10uM
ED-90-AH37_1uM Dose=1uM
ED-91-LA02_0.01uM Dose=0.01uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B
ED-91-LA02_0.1uM Dose=0.1uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B
ED-91-LA02_10uM Dose=10uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B
ED-91-LA02_1uM Dose=1uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B
ED-91-LY45_0.01uM Dose=0.01uM, Tideglusib, GSK3B gene inhibitor targeting GSK3B
ED-91-LY45_10uM Dose=10uM, Tideglusib, GSK3B gene inhibitor targeting GSK3B
ED-91-LY45_1uM Dose=1uM, Tideglusib, GSK3B gene inhibitor targeting GSK3B
ED-92-AL11_0.01uM Dose=0.01uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1
ED-92-AL11_0.1uM Dose=0.1uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1
ED-92-AL11_10uM Dose=10uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1
ED-92-AL11_1uM Dose=1uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1
ED-93-KF69_0.01uM Dose=0.01uM, 3-(2-Aminoethyl)adamantan-1-ol
ED-93-KF69_0.1uM Dose=0.1uM, 3-(2-Aminoethyl)adamantan-1-ol
ED-93-KF69_10uM Dose=10uM, 3-(2-Aminoethyl)adamantan-1-ol
ED-93-KF69_1uM Dose=1uM, 3-(2-Aminoethyl)adamantan-1-ol
ED-98-UI13_0.01uM Dose=0.01uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E
ED-98-UI13_0.1uM Dose=0.1uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E
ED-98-UI13_10uM Dose=10uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E
ED-99-XG61_0.01uM Dose=0.01uM, Kartogenin, Chondrogenesis activator targeting FLNA
ED-99-XG61_0.1uM Dose=0.1uM, Kartogenin, Chondrogenesis activator targeting FLNA
ED-99-XG61_10uM Dose=10uM, Kartogenin, Chondrogenesis activator targeting FLNA
ED-99-XG61_1uM Dose=1uM, Kartogenin, Chondrogenesis activator targeting FLNA
EE-01-DO31_0.01uM Dose=0.01uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8
EE-01-DO31_0.1uM Dose=0.1uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8
EE-01-DO31_10uM Dose=10uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8
EE-01-DO31_1uM Dose=1uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8
EE-01-FB85_0.01uM Dose=0.01uM, Indolactam V, PKC agonist targeting PRKCA
EE-01-FB85_0.1uM Dose=0.1uM, Indolactam V, PKC agonist targeting PRKCA
EE-01-FB85_10uM Dose=10uM, Indolactam V, PKC agonist targeting PRKCA
EE-01-FB85_1uM Dose=1uM, Indolactam V, PKC agonist targeting PRKCA
EE-02-BO83_0.01uM Dose=0.01uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B
EE-02-BO83_0.1uM Dose=0.1uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B
EE-02-BO83_10uM Dose=10uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B
EE-02-BO83_1uM Dose=1uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B
EE-03-SG02_0.01uM Dose=0.01uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide
EE-03-SG02_0.1uM Dose=0.1uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide
EE-03-SG02_10uM Dose=10uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide
EE-03-SG02_1uM Dose=1uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide
EE-04-QG34_0.01uM Dose=0.01uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1
EE-04-QG34_0.1uM Dose=0.1uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1
EE-04-QG34_10uM Dose=10uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1
EE-04-QG34_1uM Dose=1uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1
EE-08-FF71_0.01uM Dose=0.01uM, Levofloxacin
EE-08-FF71_0.1uM Dose=0.1uM, Levofloxacin
EE-08-FF71_10uM Dose=10uM, Levofloxacin
EE-08-SZ54_0.01uM Dose=0.01uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3
EE-08-SZ54_0.1uM Dose=0.1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3
EE-08-SZ54_10uM Dose=10uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3
EE-08-SZ54_1uM Dose=1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3
EE-13-PS05_0.01uM Dose=0.01uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P
EE-13-PS05_0.1uM Dose=0.1uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P
EE-13-PS05_10uM Dose=10uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P
EE-13-PS05_1uM Dose=1uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P
EE-16-RH01_0.01uM Dose=0.01uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3
EE-16-RH01_0.1uM Dose=0.1uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3
EE-16-RH01_10uM Dose=10uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3
EE-16-RH01_1uM Dose=1uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3
EE-18-HW72_0.01uM Dose=0.01uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2
EE-18-HW72_0.1uM Dose=0.1uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2
EE-18-HW72_10uM Dose=10uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2
EE-18-HW72_1uM Dose=1uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2
EE-23-MF14_0.01uM Dose=0.01uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid
EE-23-MF14_0.1uM Dose=0.1uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid
EE-23-MF14_10uM Dose=10uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid
EE-23-MF14_1uM Dose=1uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid
EE-26-UK38_0.01uM Dose=0.01uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A
EE-26-UK38_0.1uM Dose=0.1uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A
EE-26-UK38_10uM Dose=10uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A
EE-26-UK38_1uM Dose=1uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A
EE-32-EY37_0.01uM Dose=0.01uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2
EE-32-EY37_0.1uM Dose=0.1uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2
EE-32-EY37_10uM Dose=10uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2
EE-32-EY37_1uM Dose=1uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2
EE-35-XA42_0.01uM Dose=0.01uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide
EE-35-XA42_0.1uM Dose=0.1uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide
EE-35-XA42_10uM Dose=10uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide
EE-35-XA42_1uM Dose=1uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide
EE-45-VG61_0.01uM Dose=0.01uM, (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, EDNRB gene inhibitor targeting EDNRB
EE-45-VG61_0.1uM Dose=0.1uM, (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, EDNRB gene inhibitor targeting EDNRB
EE-45-VG61_10uM Dose=10uM, (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, EDNRB gene inhibitor targeting EDNRB
EE-45-VG61_1uM Dose=1uM, (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, EDNRB gene inhibitor targeting EDNRB
EE-45-YQ15_0.01uM Dose=0.01uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7
EE-45-YQ15_0.1uM Dose=0.1uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7
EE-45-YQ15_10uM Dose=10uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7
EE-47-TB79_0.01uM Dose=0.01uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-[2-(4-methoxyphenyl)ethyl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein 7 Inhibitors targeting KLK7
EE-47-TB79_0.1uM Dose=0.1uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-[2-(4-methoxyphenyl)ethyl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein 7 Inhibitors targeting KLK7
EE-47-TB79_10uM Dose=10uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-[2-(4-methoxyphenyl)ethyl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein 7 Inhibitors targeting KLK7
EE-49-CD29_0.01uM Dose=0.01uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1
EE-49-CD29_0.1uM Dose=0.1uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1
EE-49-CD29_10uM Dose=10uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1
EE-49-CD29_1uM Dose=1uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1
EE-57-RZ27_0.01uM Dose=0.01uM, Naproxen, Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
EE-57-RZ27_10uM Dose=10uM, Naproxen, Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
EE-57-RZ27_1uM Dose=1uM, Naproxen, Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
EE-59-HC06_0.01uM Dose=0.01uM, 1,2,3,4-Tetrahydroisoquinoline-2-sulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type XIV Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA14
EE-59-HC06_0.1uM Dose=0.1uM, 1,2,3,4-Tetrahydroisoquinoline-2-sulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type XIV Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA14
EE-59-HC06_10uM Dose=10uM, 1,2,3,4-Tetrahydroisoquinoline-2-sulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type XIV Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA14
EE-60-CG74_0.01uM Dose=0.01uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT
EE-60-CG74_0.1uM Dose=0.1uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT
EE-60-CG74_10uM Dose=10uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT
EE-60-CG74_1uM Dose=1uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT
EE-61-NU30_0.01uM Dose=0.01uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7
EE-61-NU30_0.1uM Dose=0.1uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7
EE-61-NU30_10uM Dose=10uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7
EE-61-NU30_1uM Dose=1uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7
EE-62-XB72_0.01uM Dose=0.01uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1
EE-62-XB72_0.1uM Dose=0.1uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1
EE-62-XB72_10uM Dose=10uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1
EE-62-XB72_1uM Dose=1uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1
EE-64-WM03_0.01uM Dose=0.01uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1
EE-64-WM03_0.1uM Dose=0.1uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1
EE-64-WM03_10uM Dose=10uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1
EE-64-WM03_1uM Dose=1uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1
EE-66-CK83_0.01uM Dose=0.01uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH
EE-66-CK83_0.1uM Dose=0.1uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH
EE-66-CK83_10uM Dose=10uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH
EE-66-CK83_1uM Dose=1uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH
EE-66-OE89_0.01uM Dose=0.01uM, Tirofiban, Integrin binder;Integrin alpha-2/beta-3 antagonist targeting ITGA2B, ITGB3
EE-66-OE89_0.1uM Dose=0.1uM, Tirofiban, Integrin binder;Integrin alpha-2/beta-3 antagonist targeting ITGA2B, ITGB3
EE-66-OE89_10uM Dose=10uM, Tirofiban, Integrin binder;Integrin alpha-2/beta-3 antagonist targeting ITGA2B, ITGB3
EE-66-OE89_1uM Dose=1uM, Tirofiban, Integrin binder;Integrin alpha-2/beta-3 antagonist targeting ITGA2B, ITGB3
EE-77-XO60_0.01uM Dose=0.01uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol
EE-77-XO60_0.1uM Dose=0.1uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol
EE-77-XO60_10uM Dose=10uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol
EE-77-XO60_1uM Dose=1uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol
EE-78-ES92_0.01uM Dose=0.01uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A
EE-78-ES92_0.1uM Dose=0.1uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A
EE-78-ES92_10uM Dose=10uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A
EE-78-ES92_1uM Dose=1uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A
EE-83-RW10_0.01uM Dose=0.01uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1
EE-83-RW10_0.1uM Dose=0.1uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1
EE-83-RW10_10uM Dose=10uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1
EE-83-RW10_1uM Dose=1uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1
EE-83-WF69_0.01uM Dose=0.01uM, Nvp-dpp728, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
EE-83-WF69_0.1uM Dose=0.1uM, Nvp-dpp728, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
EE-83-WF69_1uM Dose=1uM, Nvp-dpp728, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
EE-85-SK26_0.01uM Dose=0.01uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
EE-85-SK26_0.1uM Dose=0.1uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
EE-85-SK26_10uM Dose=10uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
EE-85-SK26_1uM Dose=1uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
EE-98-PF86_0.01uM Dose=0.01uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2
EE-98-PF86_0.1uM Dose=0.1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2
EE-98-PF86_10uM Dose=10uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2
EE-98-PF86_1uM Dose=1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2
EE-99-ZM45_0.01uM Dose=0.01uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H
EE-99-ZM45_0.1uM Dose=0.1uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H
EE-99-ZM45_10uM Dose=10uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H
EE-99-ZM45_1uM Dose=1uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H
EF-01-LB20_0.01uM Dose=0.01uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A
EF-01-LB20_0.1uM Dose=0.1uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A
EF-01-LB20_10uM Dose=10uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A
EF-01-LB20_1uM Dose=1uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A
EF-14-GN61_0.01uM Dose=0.01uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9
EF-14-GN61_0.1uM Dose=0.1uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9
EF-14-GN61_10uM Dose=10uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9
EF-14-GN61_1uM Dose=1uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9
EF-16-GV25_0.1uM Dose=0.1uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1
EF-16-GV25_10uM Dose=10uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1
EF-16-GV25_1uM Dose=1uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1
EF-19-KJ63_0.01uM Dose=0.01uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A
EF-19-KJ63_0.1uM Dose=0.1uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A
EF-19-KJ63_10uM Dose=10uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A
EF-19-KJ63_1uM Dose=1uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A
EF-20-MG69_0.01uM Dose=0.01uM, 7,8-Dihydroxyflavone, TRKB Activators targeting NTRK2
EF-20-MG69_10uM Dose=10uM, 7,8-Dihydroxyflavone, TRKB Activators targeting NTRK2
EF-20-MG69_1uM Dose=1uM, 7,8-Dihydroxyflavone, TRKB Activators targeting NTRK2
EF-22-PB37_0.01uM Dose=0.01uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A
EF-22-PB37_0.1uM Dose=0.1uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A
EF-22-PB37_10uM Dose=10uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A
EF-22-PB37_1uM Dose=1uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A
EF-30-GD67_0.1uM Dose=0.1uM, N-(1-Benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine, EGLN1 gene inhibitor;EGLN1 inhibitor targeting EGLN1, EGLN2
EF-30-GD67_10uM Dose=10uM, N-(1-Benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine, EGLN1 gene inhibitor;EGLN1 inhibitor targeting EGLN1, EGLN2
EF-30-GD67_1uM Dose=1uM, N-(1-Benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine, EGLN1 gene inhibitor;EGLN1 inhibitor targeting EGLN1, EGLN2
EF-33-IW50_0.01uM Dose=0.01uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2
EF-33-IW50_0.1uM Dose=0.1uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2
EF-33-IW50_10uM Dose=10uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2
EF-33-IW50_1uM Dose=1uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2
EF-33-QP63_0.01uM Dose=0.01uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2
EF-33-QP63_0.1uM Dose=0.1uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2
EF-33-QP63_10uM Dose=10uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2
EF-33-QP63_1uM Dose=1uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2
EF-43-OP88_0.01uM Dose=0.01uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD
EF-43-OP88_0.1uM Dose=0.1uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD
EF-43-OP88_10uM Dose=10uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD
EF-43-OP88_1uM Dose=1uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD
EF-46-LK88_0.01uM Dose=0.01uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate
EF-46-LK88_0.1uM Dose=0.1uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate
EF-46-LK88_10uM Dose=10uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate
EF-46-LK88_1uM Dose=1uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate
EF-52-ML96_0.01uM Dose=0.01uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2
EF-52-ML96_0.1uM Dose=0.1uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2
EF-52-ML96_10uM Dose=10uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2
EF-52-ML96_1uM Dose=1uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2
EF-61-NY75_0.01uM Dose=0.01uM, US9580437, Example 229, PRC2/EED targeting EED
EF-61-NY75_0.1uM Dose=0.1uM, US9580437, Example 229, PRC2/EED targeting EED
EF-61-NY75_10uM Dose=10uM, US9580437, Example 229, PRC2/EED targeting EED
EF-61-NY75_1uM Dose=1uM, US9580437, Example 229, PRC2/EED targeting EED
EF-62-IO23_0.01uM Dose=0.01uM
EF-62-IO23_0.1uM Dose=0.1uM
EF-62-IO23_10uM Dose=10uM
EF-62-IO23_1uM Dose=1uM
EF-64-HJ41_0.1uM Dose=0.1uM, LY 255283, LTB4R2 antagonist targeting LTB4R2
EF-64-HJ41_10uM Dose=10uM, LY 255283, LTB4R2 antagonist targeting LTB4R2
EF-64-HJ41_1uM Dose=1uM, LY 255283, LTB4R2 antagonist targeting LTB4R2
EF-73-IP33_0.01uM Dose=0.01uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4
EF-73-IP33_0.1uM Dose=0.1uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4
EF-73-IP33_10uM Dose=10uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4
EF-73-IP33_1uM Dose=1uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4
EF-74-KW12_0.01uM Dose=0.01uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3
EF-74-KW12_0.1uM Dose=0.1uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3
EF-74-KW12_10uM Dose=10uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3
EF-74-KW12_1uM Dose=1uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3
EF-75-CQ05_0.01uM Dose=0.01uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5
EF-75-CQ05_0.1uM Dose=0.1uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5
EF-75-CQ05_10uM Dose=10uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5
EF-75-CQ05_1uM Dose=1uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5
EF-75-JG46_0.01uM Dose=0.01uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F
EF-75-JG46_0.1uM Dose=0.1uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F
EF-75-JG46_10uM Dose=10uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F
EF-75-JG46_1uM Dose=1uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F
EF-80-OD07_0.01uM Dose=0.01uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
EF-80-OD07_0.1uM Dose=0.1uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
EF-80-OD07_10uM Dose=10uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
EF-80-OD07_1uM Dose=1uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
EF-82-OV15_0.01uM Dose=0.01uM
EF-82-OV15_0.1uM Dose=0.1uM
EF-82-OV15_10uM Dose=10uM
EF-82-OV15_1uM Dose=1uM
EF-83-OP68_0.1uM Dose=0.1uM, StemRegenin 1, Aryl hydrocarbon receptor antagonist;Stem cell expansion targeting AHR
EF-83-OP68_10uM Dose=10uM, StemRegenin 1, Aryl hydrocarbon receptor antagonist;Stem cell expansion targeting AHR
EF-83-OP68_1uM Dose=1uM, StemRegenin 1, Aryl hydrocarbon receptor antagonist;Stem cell expansion targeting AHR
EF-84-QW37_0.01uM Dose=0.01uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR
EF-84-QW37_0.1uM Dose=0.1uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR
EF-84-QW37_10uM Dose=10uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR
EF-84-QW37_1uM Dose=1uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR
EF-85-DA07_0.01uM Dose=0.01uM
EF-85-DA07_0.1uM Dose=0.1uM
EF-85-DA07_10uM Dose=10uM
EF-85-DA07_1uM Dose=1uM
EF-89-OM00_0.01uM Dose=0.01uM, Paraquat
EF-89-OM00_0.1uM Dose=0.1uM, Paraquat
EF-89-OM00_10uM Dose=10uM, Paraquat
EF-89-OM00_1uM Dose=1uM, Paraquat
EF-92-OO68_0.01uM Dose=0.01uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3
EF-92-OO68_0.1uM Dose=0.1uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3
EF-92-OO68_10uM Dose=10uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3
EF-92-OO68_1uM Dose=1uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3
EF-99-HJ48_0.01uM Dose=0.01uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7
EF-99-HJ48_0.1uM Dose=0.1uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7
EF-99-HJ48_10uM Dose=10uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7
EF-99-HJ48_1uM Dose=1uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7
FA-02-RV60_0.01uM Dose=0.01uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1
FA-02-RV60_0.1uM Dose=0.1uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1
FA-02-RV60_10uM Dose=10uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1
FA-02-RV60_1uM Dose=1uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1
FA-03-CZ62_0.1uM Dose=0.1uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1
FA-03-CZ62_10uM Dose=10uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1
FA-03-CZ62_1uM Dose=1uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1
FA-06-GA39_0.01uM Dose=0.01uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR
FA-06-GA39_0.1uM Dose=0.1uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR
FA-06-GA39_10uM Dose=10uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR
FA-06-GA39_1uM Dose=1uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR
FA-10-DN36_0.01uM Dose=0.01uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B
FA-10-DN36_0.1uM Dose=0.1uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B
FA-10-DN36_10uM Dose=10uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B
FA-10-DN36_1uM Dose=1uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B
FA-10-KQ78_0.01uM Dose=0.01uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A
FA-10-KQ78_0.1uM Dose=0.1uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A
FA-10-KQ78_10uM Dose=10uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A
FA-10-KQ78_1uM Dose=1uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A
FA-10-SN61_0.01uM Dose=0.01uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN
FA-10-SN61_0.1uM Dose=0.1uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN
FA-10-SN61_10uM Dose=10uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN
FA-10-SN61_1uM Dose=1uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN
FA-12-QB17_0.01uM Dose=0.01uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2
FA-12-QB17_0.1uM Dose=0.1uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2
FA-12-QB17_10uM Dose=10uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2
FA-12-QB17_1uM Dose=1uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2
FA-14-WC79_0.01uM Dose=0.01uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B
FA-14-WC79_0.1uM Dose=0.1uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B
FA-14-WC79_10uM Dose=10uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B
FA-14-WC79_1uM Dose=1uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B
FA-16-HR75_0.01uM Dose=0.01uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2
FA-16-HR75_0.1uM Dose=0.1uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2
FA-16-HR75_10uM Dose=10uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2
FA-16-HR75_1uM Dose=1uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2
FA-16-KA99_0.01uM Dose=0.01uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea
FA-16-KA99_0.1uM Dose=0.1uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea
FA-16-KA99_10uM Dose=10uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea
FA-16-KA99_1uM Dose=1uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea
FA-17-JZ87_0.01uM Dose=0.01uM, Valdecoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
FA-17-JZ87_0.1uM Dose=0.1uM, Valdecoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
FA-20-GU88_0.01uM Dose=0.01uM, N-(4-Cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-acetamide, Adenosine A2B Antagonists targeting ADORA2B
FA-20-GU88_0.1uM Dose=0.1uM, N-(4-Cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-acetamide, Adenosine A2B Antagonists targeting ADORA2B
FA-20-GU88_1uM Dose=1uM, N-(4-Cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-acetamide, Adenosine A2B Antagonists targeting ADORA2B
FA-23-LP18_0.01uM Dose=0.01uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B
FA-23-LP18_0.1uM Dose=0.1uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B
FA-23-LP18_10uM Dose=10uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B
FA-23-LP18_1uM Dose=1uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B
FA-28-MT45_0.1uM Dose=0.1uM, Cloprostenol, PTGFR agonist targeting PTGFR
FA-28-MT45_1uM Dose=1uM, Cloprostenol, PTGFR agonist targeting PTGFR
FA-30-KQ38_0.1uM Dose=0.1uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB
FA-30-KQ38_10uM Dose=10uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB
FA-30-KQ38_1uM Dose=1uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB
FA-31-XR78_0.01uM Dose=0.01uM
FA-31-XR78_0.1uM Dose=0.1uM
FA-31-XR78_10uM Dose=10uM
FA-31-XR78_1uM Dose=1uM
FA-36-VA24_0.01uM Dose=0.01uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea
FA-36-VA24_0.1uM Dose=0.1uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea
FA-36-VA24_10uM Dose=10uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea
FA-36-VA24_1uM Dose=1uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea
FA-39-KG56_0.01uM Dose=0.01uM, (3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetic acid ethyl ester
FA-39-KG56_0.1uM Dose=0.1uM, (3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetic acid ethyl ester
FA-39-KG56_10uM Dose=10uM, (3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetic acid ethyl ester
FA-39-KG56_1uM Dose=1uM, (3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetic acid ethyl ester
FA-39-ZT32_0.01uM Dose=0.01uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6
FA-39-ZT32_0.1uM Dose=0.1uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6
FA-39-ZT32_10uM Dose=10uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6
FA-39-ZT32_1uM Dose=1uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6
FA-43-TP28_0.1uM Dose=0.1uM, Doxapram targeting KCNK3, KCNK9
FA-43-TP28_10uM Dose=10uM, Doxapram targeting KCNK3, KCNK9
FA-43-TP28_1uM Dose=1uM, Doxapram targeting KCNK3, KCNK9
FA-43-XS35_0.01uM Dose=0.01uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6
FA-43-XS35_0.1uM Dose=0.1uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6
FA-43-XS35_10uM Dose=10uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6
FA-43-XS35_1uM Dose=1uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6
FA-45-PN48_0.01uM Dose=0.01uM
FA-45-PN48_10uM Dose=10uM
FA-45-PN48_1uM Dose=1uM
FA-45-XX32_0.01uM Dose=0.01uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1
FA-45-XX32_0.1uM Dose=0.1uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1
FA-45-XX32_10uM Dose=10uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1
FA-45-XX32_1uM Dose=1uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1
FA-47-IB34_0.01uM Dose=0.01uM
FA-47-IB34_0.1uM Dose=0.1uM
FA-47-IB34_10uM Dose=10uM
FA-47-IB34_1uM Dose=1uM
FA-47-JB44_0.01uM Dose=0.01uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183
FA-47-JB44_0.1uM Dose=0.1uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183
FA-47-JB44_10uM Dose=10uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183
FA-47-JB44_1uM Dose=1uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183
FA-48-FF91_0.1uM Dose=0.1uM, 8-Hydroxyquinoline-4-carboxylic acid
FA-48-FF91_10uM Dose=10uM, 8-Hydroxyquinoline-4-carboxylic acid
FA-52-OO58_0.01uM Dose=0.01uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9
FA-52-OO58_0.1uM Dose=0.1uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9
FA-52-OO58_10uM Dose=10uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9
FA-52-OO58_1uM Dose=1uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9
FA-56-WH26_0.01uM Dose=0.01uM, Venglustat targeting UGCG
FA-56-WH26_0.1uM Dose=0.1uM, Venglustat targeting UGCG
FA-56-WH26_10uM Dose=10uM, Venglustat targeting UGCG
FA-56-WH26_1uM Dose=1uM, Venglustat targeting UGCG
FA-57-CO50_0.01uM Dose=0.01uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D
FA-57-CO50_0.1uM Dose=0.1uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D
FA-57-CO50_10uM Dose=10uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D
FA-57-CO50_1uM Dose=1uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D
FA-57-OP23_0.01uM Dose=0.01uM
FA-57-OP23_0.1uM Dose=0.1uM
FA-57-OP23_10uM Dose=10uM
FA-57-OP23_1uM Dose=1uM
FA-62-JE09_0.01uM Dose=0.01uM
FA-62-JE09_0.1uM Dose=0.1uM
FA-62-JE09_10uM Dose=10uM
FA-62-JE09_1uM Dose=1uM
FA-63-WI26_0.01uM Dose=0.01uM
FA-63-WI26_0.1uM Dose=0.1uM
FA-63-WI26_10uM Dose=10uM
FA-63-WI26_1uM Dose=1uM
FA-65-UA27_0.01uM Dose=0.01uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3
FA-65-UA27_0.1uM Dose=0.1uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3
FA-65-UA27_10uM Dose=10uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3
FA-65-UA27_1uM Dose=1uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3
FA-66-LB92_0.01uM Dose=0.01uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR
FA-66-LB92_0.1uM Dose=0.1uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR
FA-66-LB92_10uM Dose=10uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR
FA-66-LB92_1uM Dose=1uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR
FA-67-MV22_0.01uM Dose=0.01uM, 4-((3,5-Dichloro-N-(4-fluorobenzyl)-2-hydroxyphenylsulfonamido)methyl)-N-(3,5-dichlorobenzyl)-N-(4-fluorobenzyl)benzamide, Bcl-2 Inhibitors;Apoptosis Inducers;Mcl-1 Inhibitors targeting BCL2, MCL1
FA-67-MV22_0.1uM Dose=0.1uM, 4-((3,5-Dichloro-N-(4-fluorobenzyl)-2-hydroxyphenylsulfonamido)methyl)-N-(3,5-dichlorobenzyl)-N-(4-fluorobenzyl)benzamide, Bcl-2 Inhibitors;Apoptosis Inducers;Mcl-1 Inhibitors targeting BCL2, MCL1
FA-67-MV22_10uM Dose=10uM, 4-((3,5-Dichloro-N-(4-fluorobenzyl)-2-hydroxyphenylsulfonamido)methyl)-N-(3,5-dichlorobenzyl)-N-(4-fluorobenzyl)benzamide, Bcl-2 Inhibitors;Apoptosis Inducers;Mcl-1 Inhibitors targeting BCL2, MCL1
FA-70-ZG69_0.01uM Dose=0.01uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3
FA-70-ZG69_0.1uM Dose=0.1uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3
FA-70-ZG69_10uM Dose=10uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3
FA-70-ZG69_1uM Dose=1uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3
FA-71-QH69_0.01uM Dose=0.01uM, (E)-3-(2-(1H-Tetrazol-5-YL)vinyl)-6-fluoro-1H-indole, Immunosuppressant;Tryptophan 2,3 dioxygenase inhibitor targeting TDO2
FA-71-QH69_10uM Dose=10uM, (E)-3-(2-(1H-Tetrazol-5-YL)vinyl)-6-fluoro-1H-indole, Immunosuppressant;Tryptophan 2,3 dioxygenase inhibitor targeting TDO2
FA-71-UB40_0.01uM Dose=0.01uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid
FA-71-UB40_0.1uM Dose=0.1uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid
FA-71-UB40_10uM Dose=10uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid
FA-71-UB40_1uM Dose=1uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid
FA-72-JL16_0.01uM Dose=0.01uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2
FA-72-JL16_0.1uM Dose=0.1uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2
FA-72-JL16_10uM Dose=10uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2
FA-72-JL16_1uM Dose=1uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2
FA-73-WF99_0.01uM Dose=0.01uM, 9-Benzyl-5-[(furan-2-ylmethyl)amino]-7,8,9,10-tetrahydro[1,2,4]triazolo[3,4-a][2,7]naphthyridine-6-carbonitrile, PRC2/EED;EED targeting EED
FA-73-WF99_10uM Dose=10uM, 9-Benzyl-5-[(furan-2-ylmethyl)amino]-7,8,9,10-tetrahydro[1,2,4]triazolo[3,4-a][2,7]naphthyridine-6-carbonitrile, PRC2/EED;EED targeting EED
FA-73-WF99_1uM Dose=1uM, 9-Benzyl-5-[(furan-2-ylmethyl)amino]-7,8,9,10-tetrahydro[1,2,4]triazolo[3,4-a][2,7]naphthyridine-6-carbonitrile, PRC2/EED;EED targeting EED
FA-77-LS25_0.01uM Dose=0.01uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2
FA-77-LS25_0.1uM Dose=0.1uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2
FA-77-LS25_10uM Dose=10uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2
FA-77-LS25_1uM Dose=1uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2
FA-77-YL98_0.01uM Dose=0.01uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11
FA-77-YL98_0.1uM Dose=0.1uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11
FA-77-YL98_10uM Dose=10uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11
FA-77-YL98_1uM Dose=1uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11
FA-79-WC91_0.01uM Dose=0.01uM, 3-[2-(4,7-Diazaspiro[2.5]octan-7-yl)quinazolin-4-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCA, PRKCQ
FA-79-WC91_0.1uM Dose=0.1uM, 3-[2-(4,7-Diazaspiro[2.5]octan-7-yl)quinazolin-4-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCA, PRKCQ
FA-79-WC91_10uM Dose=10uM, 3-[2-(4,7-Diazaspiro[2.5]octan-7-yl)quinazolin-4-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCA, PRKCQ
FA-80-DR66_0.01uM Dose=0.01uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB
FA-80-DR66_0.1uM Dose=0.1uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB
FA-80-DR66_10uM Dose=10uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB
FA-80-DR66_1uM Dose=1uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB
FA-88-II68_0.01uM Dose=0.01uM
FA-88-II68_0.1uM Dose=0.1uM
FA-88-II68_10uM Dose=10uM
FA-88-II68_1uM Dose=1uM
FA-88-PW92_0.01uM Dose=0.01uM
FA-88-PW92_10uM Dose=10uM
FA-88-PW92_1uM Dose=1uM
FA-89-PW29_0.01uM Dose=0.01uM, P505-15 targeting SYK
FA-89-PW29_0.1uM Dose=0.1uM, P505-15 targeting SYK
FA-89-PW29_10uM Dose=10uM, P505-15 targeting SYK
FA-89-PW29_1uM Dose=1uM, P505-15 targeting SYK
FA-90-DR66_0.01uM Dose=0.01uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B
FA-90-DR66_0.1uM Dose=0.1uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B
FA-90-DR66_10uM Dose=10uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B
FA-90-DR66_1uM Dose=1uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B
FA-91-OA82_0.01uM Dose=0.01uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7
FA-91-OA82_0.1uM Dose=0.1uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7
FA-91-OA82_10uM Dose=10uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7
FA-91-OA82_1uM Dose=1uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7
FA-92-JL46_0.01uM Dose=0.01uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2
FA-92-JL46_0.1uM Dose=0.1uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2
FA-92-JL46_10uM Dose=10uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2
FA-92-JL46_1uM Dose=1uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2
FA-94-QJ71_0.01uM Dose=0.01uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1
FA-94-QJ71_0.1uM Dose=0.1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1
FA-94-QJ71_10uM Dose=10uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1
FA-94-QJ71_1uM Dose=1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1
FA-95-HA77_0.01uM Dose=0.01uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2
FA-95-HA77_0.1uM Dose=0.1uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2
FA-95-HA77_10uM Dose=10uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2
FA-95-HA77_1uM Dose=1uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2
FB-02-OL41_0.01uM Dose=0.01uM, Mgat2-IN-2, MOGAT2 inhibitor targeting MOGAT2
FB-02-OL41_0.1uM Dose=0.1uM, Mgat2-IN-2, MOGAT2 inhibitor targeting MOGAT2
FB-02-OL41_10uM Dose=10uM, Mgat2-IN-2, MOGAT2 inhibitor targeting MOGAT2
FB-02-OL41_1uM Dose=1uM, Mgat2-IN-2, MOGAT2 inhibitor targeting MOGAT2
FB-06-IU47_0.01uM Dose=0.01uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10
FB-06-IU47_0.1uM Dose=0.1uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10
FB-06-IU47_10uM Dose=10uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10
FB-12-UL66_0.01uM Dose=0.01uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2
FB-12-UL66_0.1uM Dose=0.1uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2
FB-12-UL66_10uM Dose=10uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2
FB-12-UL66_1uM Dose=1uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2
FB-13-ES60_0.01uM Dose=0.01uM, IL-12 Production Inhibitors;Phosphodiesterase IV Inhibitors;TNF-alpha Production Inhibitors;IL-1beta Production Inhibitors
FB-16-FK53_0.1uM Dose=0.1uM, Phosphodiesterase IV Inhibitors;TNF-alpha Production Inhibitors
FB-19-ZG81_0.01uM Dose=0.01uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY
FB-19-ZG81_0.1uM Dose=0.1uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY
FB-19-ZG81_10uM Dose=10uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY
FB-19-ZG81_1uM Dose=1uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY
FB-20-YQ23_0.01uM Dose=0.01uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R
FB-20-YQ23_0.1uM Dose=0.1uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R
FB-20-YQ23_10uM Dose=10uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R
FB-20-YQ23_1uM Dose=1uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R
FB-24-UT80_0.01uM Dose=0.01uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2
FB-24-UT80_0.1uM Dose=0.1uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2
FB-24-UT80_10uM Dose=10uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2
FB-24-UT80_1uM Dose=1uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2
FB-29-KC76_0.01uM Dose=0.01uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5
FB-29-KC76_0.1uM Dose=0.1uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5
FB-29-KC76_10uM Dose=10uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5
FB-29-KC76_1uM Dose=1uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5
FB-30-CD67_0.01uM Dose=0.01uM
FB-30-CD67_0.1uM Dose=0.1uM
FB-30-CD67_10uM Dose=10uM
FB-31-TA57_0.01uM Dose=0.01uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7
FB-31-TA57_0.1uM Dose=0.1uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7
FB-31-TA57_10uM Dose=10uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7
FB-31-TA57_1uM Dose=1uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7
FB-32-PY27_0.01uM Dose=0.01uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4
FB-32-PY27_0.1uM Dose=0.1uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4
FB-32-PY27_10uM Dose=10uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4
FB-32-PY27_1uM Dose=1uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4
FB-32-TL51_0.01uM Dose=0.01uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4
FB-32-TL51_0.1uM Dose=0.1uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4
FB-32-TL51_10uM Dose=10uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4
FB-32-TL51_1uM Dose=1uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4
FB-33-LI31_0.01uM Dose=0.01uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile
FB-33-LI31_0.1uM Dose=0.1uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile
FB-33-LI31_10uM Dose=10uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile
FB-33-LI31_1uM Dose=1uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile
FB-39-CW59_0.01uM Dose=0.01uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
FB-39-CW59_0.1uM Dose=0.1uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
FB-39-CW59_10uM Dose=10uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
FB-39-CW59_1uM Dose=1uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2
FB-39-VW14_0.01uM Dose=0.01uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1
FB-39-VW14_0.1uM Dose=0.1uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1
FB-39-VW14_10uM Dose=10uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1
FB-39-VW14_1uM Dose=1uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1
FB-42-IV40_0.01uM Dose=0.01uM, 3,4-diMethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)thiazol-2-yl)benzenesulfonaMide
FB-42-IV40_0.1uM Dose=0.1uM, 3,4-diMethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)thiazol-2-yl)benzenesulfonaMide
FB-42-IV40_10uM Dose=10uM, 3,4-diMethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)thiazol-2-yl)benzenesulfonaMide
FB-42-IV40_1uM Dose=1uM, 3,4-diMethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)thiazol-2-yl)benzenesulfonaMide
FB-43-LF24_0.01uM Dose=0.01uM
FB-43-LF24_0.1uM Dose=0.1uM
FB-43-LF24_10uM Dose=10uM
FB-43-LF24_1uM Dose=1uM
FB-49-NW04_0.01uM Dose=0.01uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3
FB-49-NW04_0.1uM Dose=0.1uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3
FB-49-NW04_10uM Dose=10uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3
FB-49-NW04_1uM Dose=1uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3
FB-51-DL49_0.01uM Dose=0.01uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4
FB-51-DL49_0.1uM Dose=0.1uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4
FB-51-DL49_10uM Dose=10uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4
FB-51-DL49_1uM Dose=1uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4
FB-52-MO63_0.01uM Dose=0.01uM, Mes-D-Abu(4-piperidyl)-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14
FB-52-MO63_0.1uM Dose=0.1uM, Mes-D-Abu(4-piperidyl)-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14
FB-52-MO63_10uM Dose=10uM, Mes-D-Abu(4-piperidyl)-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14
FB-52-MO63_1uM Dose=1uM, Mes-D-Abu(4-piperidyl)-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14
FB-56-IR20_0.01uM Dose=0.01uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2
FB-56-IR20_0.1uM Dose=0.1uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2
FB-56-IR20_10uM Dose=10uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2
FB-56-IR20_1uM Dose=1uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2
FB-56-SR65_0.01uM Dose=0.01uM, Arginine
FB-56-SR65_0.1uM Dose=0.1uM, Arginine
FB-56-SR65_10uM Dose=10uM, Arginine
FB-56-SR65_1uM Dose=1uM, Arginine
FB-60-JQ38_0.01uM Dose=0.01uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1
FB-60-JQ38_0.1uM Dose=0.1uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1
FB-60-JQ38_10uM Dose=10uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1
FB-60-JQ38_1uM Dose=1uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1
FB-62-GL41_0.01uM Dose=0.01uM, 3-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]benzoic acid, Nurr1 Receptor Activators targeting NR4A2
FB-62-GL41_0.1uM Dose=0.1uM, 3-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]benzoic acid, Nurr1 Receptor Activators targeting NR4A2
FB-62-GL41_10uM Dose=10uM, 3-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]benzoic acid, Nurr1 Receptor Activators targeting NR4A2
FB-62-JY52_0.01uM Dose=0.01uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO
FB-62-JY52_0.1uM Dose=0.1uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO
FB-62-JY52_10uM Dose=10uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO
FB-62-JY52_1uM Dose=1uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO
FB-62-KB87_0.01uM Dose=0.01uM
FB-62-KB87_0.1uM Dose=0.1uM
FB-62-KB87_10uM Dose=10uM
FB-62-KB87_1uM Dose=1uM
FB-66-UU47_0.01uM Dose=0.01uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1
FB-66-UU47_0.1uM Dose=0.1uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1
FB-66-UU47_10uM Dose=10uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1
FB-66-UU47_1uM Dose=1uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1
FB-67-OY39_0.01uM Dose=0.01uM, Galnon, GALR2 agonist targeting GALR2
FB-67-OY39_0.1uM Dose=0.1uM, Galnon, GALR2 agonist targeting GALR2
FB-67-OY39_10uM Dose=10uM, Galnon, GALR2 agonist targeting GALR2
FB-67-OY39_1uM Dose=1uM, Galnon, GALR2 agonist targeting GALR2
FB-67-PL18_0.01uM Dose=0.01uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
FB-67-PL18_0.1uM Dose=0.1uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
FB-67-PL18_10uM Dose=10uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
FB-67-PL18_1uM Dose=1uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3
FB-68-SI43_0.01uM Dose=0.01uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide
FB-68-SI43_0.1uM Dose=0.1uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide
FB-68-SI43_10uM Dose=10uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide
FB-68-SI43_1uM Dose=1uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide
FB-75-YG01_0.01uM Dose=0.01uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF
FB-75-YG01_0.1uM Dose=0.1uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF
FB-75-YG01_10uM Dose=10uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF
FB-75-YG01_1uM Dose=1uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF
FB-84-TJ61_0.1uM Dose=0.1uM, Rizatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D
FB-84-TJ61_10uM Dose=10uM, Rizatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D
FB-84-TJ61_1uM Dose=1uM, Rizatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D
FB-85-ND09_0.01uM Dose=0.01uM
FB-85-ND09_0.1uM Dose=0.1uM
FB-85-ND09_10uM Dose=10uM
FB-85-ND09_1uM Dose=1uM
FB-86-FA19_0.01uM Dose=0.01uM
FB-86-FA19_0.1uM Dose=0.1uM
FB-86-FA19_1uM Dose=1uM
FB-86-IO73_0.01uM Dose=0.01uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20
FB-86-IO73_0.1uM Dose=0.1uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20
FB-86-IO73_10uM Dose=10uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20
FB-86-IO73_1uM Dose=1uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20
FB-88-FZ09_0.01uM Dose=0.01uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1
FB-88-FZ09_0.1uM Dose=0.1uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1
FB-88-FZ09_10uM Dose=10uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1
FB-88-FZ09_1uM Dose=1uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1
FB-91-BU05_0.01uM Dose=0.01uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
FB-91-BU05_0.1uM Dose=0.1uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
FB-91-BU05_10uM Dose=10uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
FB-91-BU05_1uM Dose=1uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
FB-94-TJ61_0.01uM Dose=0.01uM
FB-94-TJ61_0.1uM Dose=0.1uM
FB-94-TJ61_10uM Dose=10uM
FB-94-TJ61_1uM Dose=1uM
FB-95-JD99_0.01uM Dose=0.01uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B
FB-95-JD99_0.1uM Dose=0.1uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B
FB-95-JD99_10uM Dose=10uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B
FB-95-JD99_1uM Dose=1uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B
FB-97-DI91_0.01uM Dose=0.01uM, 4-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-1H-indole
FB-97-DI91_0.1uM Dose=0.1uM, 4-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-1H-indole
FB-97-DI91_1uM Dose=1uM, 4-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-1H-indole
FB-98-HM88_0.1uM Dose=0.1uM, N-(1-morpholin-4-ylpropan-2-yl)-6-(8-pyridin-4-ylimidazo[4,5-c][1,7]naphthyridin-1-yl)quinolin-2-amine, Cot kinase inhibitor targeting MAP3K8, FLT3
FB-98-HM88_10uM Dose=10uM, N-(1-morpholin-4-ylpropan-2-yl)-6-(8-pyridin-4-ylimidazo[4,5-c][1,7]naphthyridin-1-yl)quinolin-2-amine, Cot kinase inhibitor targeting MAP3K8, FLT3
FB-99-SM50_0.01uM Dose=0.01uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile
FB-99-SM50_0.1uM Dose=0.1uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile
FB-99-SM50_10uM Dose=10uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile
FB-99-SM50_1uM Dose=1uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile
FC-03-PM86_0.01uM Dose=0.01uM, Oxytocin, OXTR agonist targeting OXTR
FC-03-PM86_0.1uM Dose=0.1uM, Oxytocin, OXTR agonist targeting OXTR
FC-03-PM86_10uM Dose=10uM, Oxytocin, OXTR agonist targeting OXTR
FC-03-PM86_1uM Dose=1uM, Oxytocin, OXTR agonist targeting OXTR
FC-05-ID99_0.01uM Dose=0.01uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET
FC-05-ID99_0.1uM Dose=0.1uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET
FC-05-ID99_10uM Dose=10uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET
FC-05-ID99_1uM Dose=1uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET
FC-05-LX47_0.01uM Dose=0.01uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4
FC-05-LX47_0.1uM Dose=0.1uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4
FC-05-LX47_10uM Dose=10uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4
FC-05-LX47_1uM Dose=1uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4
FC-08-PZ84_0.01uM Dose=0.01uM, 5-{3-[(Furan-2-carbonyl)-amino]-benzoylamino}-2-hydroxy-benzoic acid, SIRT6 inhibitor targeting SIRT6
FC-08-PZ84_10uM Dose=10uM, 5-{3-[(Furan-2-carbonyl)-amino]-benzoylamino}-2-hydroxy-benzoic acid, SIRT6 inhibitor targeting SIRT6
FC-08-PZ84_1uM Dose=1uM, 5-{3-[(Furan-2-carbonyl)-amino]-benzoylamino}-2-hydroxy-benzoic acid, SIRT6 inhibitor targeting SIRT6
FC-11-WH14_0.01uM Dose=0.01uM, Pivanex, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors targeting HDAC3
FC-11-WH14_10uM Dose=10uM, Pivanex, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors targeting HDAC3
FC-11-WH14_1uM Dose=1uM, Pivanex, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors targeting HDAC3
FC-11-YA62_0.1uM Dose=0.1uM, Candesartan Cilexetil, Angiotensin AT1 Antagonists targeting AGTR1
FC-13-UF39_0.01uM Dose=0.01uM
FC-13-UF39_0.1uM Dose=0.1uM
FC-13-UF39_10uM Dose=10uM
FC-13-UF39_1uM Dose=1uM
FC-13-VS25_0.01uM Dose=0.01uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4
FC-13-VS25_0.1uM Dose=0.1uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4
FC-13-VS25_10uM Dose=10uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4
FC-13-VS25_1uM Dose=1uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4
FC-15-XG61_0.01uM Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
FC-15-XG61_0.1uM Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
FC-15-XG61_10uM Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
FC-15-XG61_1uM Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3
FC-19-RM40_0.01uM Dose=0.01uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR
FC-19-RM40_0.1uM Dose=0.1uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR
FC-19-RM40_10uM Dose=10uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR
FC-19-RM40_1uM Dose=1uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR
FC-20-EQ58_0.01uM Dose=0.01uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10
FC-20-EQ58_0.1uM Dose=0.1uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10
FC-20-EQ58_10uM Dose=10uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10
FC-20-EQ58_1uM Dose=1uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10
FC-22-VC55_0.01uM Dose=0.01uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR
FC-22-VC55_0.1uM Dose=0.1uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR
FC-22-VC55_10uM Dose=10uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR
FC-22-VC55_1uM Dose=1uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR
FC-22-ZV65_0.01uM Dose=0.01uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2
FC-22-ZV65_0.1uM Dose=0.1uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2
FC-22-ZV65_10uM Dose=10uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2
FC-22-ZV65_1uM Dose=1uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2
FC-31-HE22_0.01uM Dose=0.01uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1
FC-31-HE22_10uM Dose=10uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1
FC-31-HE22_1uM Dose=1uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1
FC-35-BX82_0.01uM Dose=0.01uM, Cyclosporin V
FC-35-BX82_0.1uM Dose=0.1uM, Cyclosporin V
FC-35-BX82_10uM Dose=10uM, Cyclosporin V
FC-35-BX82_1uM Dose=1uM, Cyclosporin V
FC-36-SU62_0.01uM Dose=0.01uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
FC-36-SU62_0.1uM Dose=0.1uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
FC-36-SU62_10uM Dose=10uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
FC-36-SU62_1uM Dose=1uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
FC-40-QD52_0.01uM Dose=0.01uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1
FC-40-QD52_0.1uM Dose=0.1uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1
FC-40-QD52_10uM Dose=10uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1
FC-40-QD52_1uM Dose=1uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1
FC-52-RL51_0.1uM Dose=0.1uM, [1-[(2-Chlorophenyl)methyl]-3-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-5-(trifluoromethoxy)indol-2-yl]methanol, PAR4 antagonist targeting F2RL3
FC-52-RL51_10uM Dose=10uM, [1-[(2-Chlorophenyl)methyl]-3-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-5-(trifluoromethoxy)indol-2-yl]methanol, PAR4 antagonist targeting F2RL3
FC-52-RL51_1uM Dose=1uM, [1-[(2-Chlorophenyl)methyl]-3-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-5-(trifluoromethoxy)indol-2-yl]methanol, PAR4 antagonist targeting F2RL3
FC-55-IG96_0.01uM Dose=0.01uM, 3-(2-Methoxybenzylamino)-2-phenylpiperidine, Tachykinin NK1 Antagonists targeting CYP2D6
FC-55-IG96_0.1uM Dose=0.1uM, 3-(2-Methoxybenzylamino)-2-phenylpiperidine, Tachykinin NK1 Antagonists targeting CYP2D6
FC-55-IG96_10uM Dose=10uM, 3-(2-Methoxybenzylamino)-2-phenylpiperidine, Tachykinin NK1 Antagonists targeting CYP2D6
FC-56-ZH16_0.01uM Dose=0.01uM, 8-Hydroxy-5-quinolinecarboxylic acid, broad-spectrum inhibitor of 2OG oxygenases targeting KDM2A
FC-56-ZH16_0.1uM Dose=0.1uM, 8-Hydroxy-5-quinolinecarboxylic acid, broad-spectrum inhibitor of 2OG oxygenases targeting KDM2A
FC-56-ZH16_10uM Dose=10uM, 8-Hydroxy-5-quinolinecarboxylic acid, broad-spectrum inhibitor of 2OG oxygenases targeting KDM2A
FC-56-ZH16_1uM Dose=1uM, 8-Hydroxy-5-quinolinecarboxylic acid, broad-spectrum inhibitor of 2OG oxygenases targeting KDM2A
FC-58-KP35_0.01uM Dose=0.01uM, AM-966, LPAR1 antagonist targeting LPAR1
FC-58-KP35_0.1uM Dose=0.1uM, AM-966, LPAR1 antagonist targeting LPAR1
FC-58-KP35_10uM Dose=10uM, AM-966, LPAR1 antagonist targeting LPAR1
FC-58-KP35_1uM Dose=1uM, AM-966, LPAR1 antagonist targeting LPAR1
FC-58-QS77_0.01uM Dose=0.01uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4
FC-58-QS77_0.1uM Dose=0.1uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4
FC-58-QS77_10uM Dose=10uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4
FC-58-QS77_1uM Dose=1uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4
FC-61-BK21_0.01uM Dose=0.01uM, Cinnamaldehyde, Aldose Reductase Inhibitors;TRPA1 Agonists targeting AKR1B1, TRPA1
FC-61-BK21_10uM Dose=10uM, Cinnamaldehyde, Aldose Reductase Inhibitors;TRPA1 Agonists targeting AKR1B1, TRPA1
FC-61-BK21_1uM Dose=1uM, Cinnamaldehyde, Aldose Reductase Inhibitors;TRPA1 Agonists targeting AKR1B1, TRPA1
FC-62-AI14_0.01uM Dose=0.01uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ
FC-62-AI14_0.1uM Dose=0.1uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ
FC-62-AI14_10uM Dose=10uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ
FC-62-AI14_1uM Dose=1uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ
FC-64-QJ96_0.01uM Dose=0.01uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
FC-64-QJ96_0.1uM Dose=0.1uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
FC-64-QJ96_1uM Dose=1uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
FC-67-SZ42_0.01uM Dose=0.01uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1
FC-67-SZ42_0.1uM Dose=0.1uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1
FC-67-SZ42_10uM Dose=10uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1
FC-67-SZ42_1uM Dose=1uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1
FC-68-LJ11_0.01uM Dose=0.01uM
FC-68-LJ11_0.1uM Dose=0.1uM
FC-68-LJ11_10uM Dose=10uM
FC-68-LJ11_1uM Dose=1uM
FC-71-PK06_10uM Dose=10uM, 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1A, CACNA1B, CACNA1C, CACNA1S
FC-71-PK06_1uM Dose=1uM, 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1A, CACNA1B, CACNA1C, CACNA1S
FC-82-WB67_0.01uM Dose=0.01uM, Lycopene
FC-82-WB67_0.1uM Dose=0.1uM, Lycopene
FC-82-WB67_10uM Dose=10uM, Lycopene
FC-82-WB67_1uM Dose=1uM, Lycopene
FC-85-OX77_0.01uM Dose=0.01uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide
FC-85-OX77_0.1uM Dose=0.1uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide
FC-85-OX77_10uM Dose=10uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide
FC-85-OX77_1uM Dose=1uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide
FC-88-AJ86_0.01uM Dose=0.01uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one
FC-88-AJ86_0.1uM Dose=0.1uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one
FC-88-AJ86_10uM Dose=10uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one
FC-88-AJ86_1uM Dose=1uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one
FC-96-WR45_0.01uM Dose=0.01uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H
FC-96-WR45_0.1uM Dose=0.1uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H
FC-96-WR45_10uM Dose=10uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H
FC-96-WR45_1uM Dose=1uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H
FC-97-EO10_0.01uM Dose=0.01uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide
FC-97-EO10_0.1uM Dose=0.1uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide
FC-97-EO10_10uM Dose=10uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide
FC-97-EO10_1uM Dose=1uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide
FC-98-AJ86_0.01uM Dose=0.01uM, Trimebutine
FC-98-AJ86_0.1uM Dose=0.1uM, Trimebutine
FC-98-AJ86_10uM Dose=10uM, Trimebutine
FD-00-QG34_0.01uM Dose=0.01uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E
FD-00-QG34_0.1uM Dose=0.1uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E
FD-00-QG34_10uM Dose=10uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E
FD-00-QG34_1uM Dose=1uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E
FD-05-QX72_0.01uM Dose=0.01uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11
FD-05-QX72_0.1uM Dose=0.1uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11
FD-05-QX72_10uM Dose=10uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11
FD-05-QX72_1uM Dose=1uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11
FD-06-CV80_0.01uM Dose=0.01uM, (2R)-2-[(9,10-dioxoanthracene-2-carbonyl)amino]-3-phenylpropanoic acid targeting XDH
FD-06-CV80_0.1uM Dose=0.1uM, (2R)-2-[(9,10-dioxoanthracene-2-carbonyl)amino]-3-phenylpropanoic acid targeting XDH
FD-06-CV80_10uM Dose=10uM, (2R)-2-[(9,10-dioxoanthracene-2-carbonyl)amino]-3-phenylpropanoic acid targeting XDH
FD-06-CV80_1uM Dose=1uM, (2R)-2-[(9,10-dioxoanthracene-2-carbonyl)amino]-3-phenylpropanoic acid targeting XDH
FD-09-BQ45_0.01uM Dose=0.01uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2
FD-09-BQ45_0.1uM Dose=0.1uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2
FD-09-BQ45_10uM Dose=10uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2
FD-09-BQ45_1uM Dose=1uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2
FD-13-TF49_0.01uM Dose=0.01uM
FD-13-TF49_0.1uM Dose=0.1uM
FD-13-TF49_10uM Dose=10uM
FD-13-TF49_1uM Dose=1uM
FD-15-HD09_0.01uM Dose=0.01uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU
FD-15-HD09_0.1uM Dose=0.1uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU
FD-15-HD09_10uM Dose=10uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU
FD-15-HD09_1uM Dose=1uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU
FD-19-TD14_0.01uM Dose=0.01uM
FD-19-TD14_0.1uM Dose=0.1uM
FD-19-TD14_10uM Dose=10uM
FD-19-TD14_1uM Dose=1uM
FD-20-DQ38_0.01uM Dose=0.01uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
FD-20-DQ38_0.1uM Dose=0.1uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
FD-20-DQ38_10uM Dose=10uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
FD-20-DQ38_1uM Dose=1uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
FD-20-OG99_0.01uM Dose=0.01uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1
FD-20-OG99_0.1uM Dose=0.1uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1
FD-20-OG99_10uM Dose=10uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1
FD-20-OG99_1uM Dose=1uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1
FD-25-KX07_0.01uM Dose=0.01uM
FD-25-KX07_0.1uM Dose=0.1uM
FD-25-KX07_10uM Dose=10uM
FD-25-KX07_1uM Dose=1uM
FD-28-EZ19_0.01uM Dose=0.01uM, Selexipag, Prostanoid IP Agonists targeting PTGIR
FD-28-EZ19_1uM Dose=1uM, Selexipag, Prostanoid IP Agonists targeting PTGIR
FD-29-MM50_0.01uM Dose=0.01uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP
FD-29-MM50_0.1uM Dose=0.1uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP
FD-29-MM50_10uM Dose=10uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP
FD-29-MM50_1uM Dose=1uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP
FD-35-PQ00_0.01uM Dose=0.01uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2
FD-35-PQ00_0.1uM Dose=0.1uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2
FD-35-PQ00_10uM Dose=10uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2
FD-35-PQ00_1uM Dose=1uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2
FD-37-GE41_0.01uM Dose=0.01uM, Torcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP
FD-37-GE41_10uM Dose=10uM, Torcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP
FD-37-GE41_1uM Dose=1uM, Torcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP
FD-43-EF54_0.01uM Dose=0.01uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1
FD-43-EF54_0.1uM Dose=0.1uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1
FD-43-EF54_10uM Dose=10uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1
FD-43-EF54_1uM Dose=1uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1
FD-44-AD67_0.1uM Dose=0.1uM, 3-(2,3-Difluoro-4-methoxyphenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine targeting GRM7, GRM8
FD-44-AD67_10uM Dose=10uM, 3-(2,3-Difluoro-4-methoxyphenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine targeting GRM7, GRM8
FD-46-HV00_0.01uM Dose=0.01uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
FD-46-HV00_0.1uM Dose=0.1uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
FD-46-HV00_10uM Dose=10uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
FD-46-HV00_1uM Dose=1uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
FD-48-HZ39_0.01uM Dose=0.01uM
FD-48-HZ39_0.1uM Dose=0.1uM
FD-48-HZ39_10uM Dose=10uM
FD-48-HZ39_1uM Dose=1uM
FD-48-ZP65_10uM Dose=10uM, 5-Fluoro-2-phenyl-1,2-benzothiazol-3-one, PMI Inhibitor targeting MPI
FD-48-ZP65_1uM Dose=1uM, 5-Fluoro-2-phenyl-1,2-benzothiazol-3-one, PMI Inhibitor targeting MPI
FD-49-XC21_0.01uM Dose=0.01uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2
FD-49-XC21_0.1uM Dose=0.1uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2
FD-49-XC21_10uM Dose=10uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2
FD-49-XC21_1uM Dose=1uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2
FD-55-XG26_0.01uM Dose=0.01uM
FD-55-XG26_0.1uM Dose=0.1uM
FD-55-XG26_10uM Dose=10uM
FD-55-XG26_1uM Dose=1uM
FD-59-TC81_0.1uM Dose=0.1uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4
FD-59-TC81_10uM Dose=10uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4
FD-59-TC81_1uM Dose=1uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4
FD-62-ZB67_0.01uM Dose=0.01uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR
FD-62-ZB67_0.1uM Dose=0.1uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR
FD-62-ZB67_10uM Dose=10uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR
FD-62-ZB67_1uM Dose=1uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR
FD-63-JF34_0.01uM Dose=0.01uM
FD-63-JF34_0.1uM Dose=0.1uM
FD-63-JF34_10uM Dose=10uM
FD-63-JF34_1uM Dose=1uM
FD-65-VN78_0.1uM Dose=0.1uM, N-(3-Methylbenzyl)-1H-benzo[d][1,2,3]triazole-1-carboxamide, Endothelial Lipase (EL) Inhibitors targeting LIPG
FD-65-VN78_1uM Dose=1uM, N-(3-Methylbenzyl)-1H-benzo[d][1,2,3]triazole-1-carboxamide, Endothelial Lipase (EL) Inhibitors targeting LIPG
FD-67-GI76_0.01uM Dose=0.01uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2
FD-67-GI76_0.1uM Dose=0.1uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2
FD-67-GI76_10uM Dose=10uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2
FD-67-GI76_1uM Dose=1uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2
FD-69-CC31_0.01uM Dose=0.01uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1
FD-69-CC31_0.1uM Dose=0.1uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1
FD-69-CC31_10uM Dose=10uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1
FD-69-CC31_1uM Dose=1uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1
FD-72-CE19_0.01uM Dose=0.01uM, Zaldaride, Calmodulin Antagonists targeting CALM1
FD-72-CE19_0.1uM Dose=0.1uM, Zaldaride, Calmodulin Antagonists targeting CALM1
FD-72-CE19_10uM Dose=10uM, Zaldaride, Calmodulin Antagonists targeting CALM1
FD-72-CE19_1uM Dose=1uM, Zaldaride, Calmodulin Antagonists targeting CALM1
FD-74-LD52_0.01uM Dose=0.01uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB
FD-74-LD52_0.1uM Dose=0.1uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB
FD-74-LD52_10uM Dose=10uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB
FD-74-LD52_1uM Dose=1uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB
FD-74-XT10_0.01uM Dose=0.01uM
FD-74-XT10_0.1uM Dose=0.1uM
FD-74-XT10_10uM Dose=10uM
FD-74-XT10_1uM Dose=1uM
FD-75-PQ00_0.01uM Dose=0.01uM, methyl 3-(4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-yl)imidazole-4-carboxylate
FD-75-PQ00_0.1uM Dose=0.1uM, methyl 3-(4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-yl)imidazole-4-carboxylate
FD-75-PQ00_10uM Dose=10uM, methyl 3-(4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-yl)imidazole-4-carboxylate
FD-75-PQ00_1uM Dose=1uM, methyl 3-(4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-yl)imidazole-4-carboxylate
FD-77-DL33_0.01uM Dose=0.01uM, Imidapril
FD-77-DL33_0.1uM Dose=0.1uM, Imidapril
FD-77-DL33_10uM Dose=10uM, Imidapril
FD-77-DL33_1uM Dose=1uM, Imidapril
FD-77-ZV22_0.01uM Dose=0.01uM, n-(2-(1h-Indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9h-purin-6-amine, Aryl hydrocarbon receptor antagonist targeting AHR
FD-77-ZV22_10uM Dose=10uM, n-(2-(1h-Indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9h-purin-6-amine, Aryl hydrocarbon receptor antagonist targeting AHR
FD-77-ZV22_1uM Dose=1uM, n-(2-(1h-Indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9h-purin-6-amine, Aryl hydrocarbon receptor antagonist targeting AHR
FD-79-KT27_0.01uM Dose=0.01uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1
FD-79-KT27_0.1uM Dose=0.1uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1
FD-79-KT27_10uM Dose=10uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1
FD-79-KT27_1uM Dose=1uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1
FD-79-TC61_0.01uM Dose=0.01uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70
FD-79-TC61_0.1uM Dose=0.1uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70
FD-79-TC61_10uM Dose=10uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70
FD-79-TC61_1uM Dose=1uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70
FD-80-EG54_0.01uM Dose=0.01uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14
FD-80-EG54_0.1uM Dose=0.1uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14
FD-80-EG54_10uM Dose=10uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14
FD-80-EG54_1uM Dose=1uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14
FD-81-SU40_0.01uM Dose=0.01uM, Methoxyamine
FD-81-SU40_0.1uM Dose=0.1uM, Methoxyamine
FD-81-SU40_10uM Dose=10uM, Methoxyamine
FD-81-SU40_1uM Dose=1uM, Methoxyamine
FD-85-SX37_0.01uM Dose=0.01uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2
FD-85-SX37_0.1uM Dose=0.1uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2
FD-85-SX37_10uM Dose=10uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2
FD-85-SX37_1uM Dose=1uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2
FD-86-NE74_0.01uM Dose=0.01uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300
FD-86-NE74_0.1uM Dose=0.1uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300
FD-86-NE74_10uM Dose=10uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300
FD-86-NE74_1uM Dose=1uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300
FD-88-CF51_0.01uM Dose=0.01uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4
FD-88-CF51_0.1uM Dose=0.1uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4
FD-88-CF51_10uM Dose=10uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4
FD-91-OK66_0.01uM Dose=0.01uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2
FD-91-OK66_0.1uM Dose=0.1uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2
FD-91-OK66_10uM Dose=10uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2
FD-91-OK66_1uM Dose=1uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2
FE-03-MI11_0.01uM Dose=0.01uM, 1-[(4-fluorophenyl)sulfonyl]-1H-benzimidazole
FE-03-MI11_0.1uM Dose=0.1uM, 1-[(4-fluorophenyl)sulfonyl]-1H-benzimidazole
FE-03-MI11_10uM Dose=10uM, 1-[(4-fluorophenyl)sulfonyl]-1H-benzimidazole
FE-03-MI11_1uM Dose=1uM, 1-[(4-fluorophenyl)sulfonyl]-1H-benzimidazole
FE-06-GR60_0.01uM Dose=0.01uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1
FE-06-GR60_0.1uM Dose=0.1uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1
FE-06-GR60_10uM Dose=10uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1
FE-06-GR60_1uM Dose=1uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1
FE-09-JD34_0.01uM Dose=0.01uM, Dot1L-IN-5
FE-09-JD34_0.1uM Dose=0.1uM, Dot1L-IN-5
FE-09-JD34_10uM Dose=10uM, Dot1L-IN-5
FE-09-JD34_1uM Dose=1uM, Dot1L-IN-5
FE-10-KQ78_0.01uM Dose=0.01uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1
FE-10-KQ78_0.1uM Dose=0.1uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1
FE-10-KQ78_10uM Dose=10uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1
FE-10-KQ78_1uM Dose=1uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1
FE-12-TO68_0.01uM Dose=0.01uM
FE-12-TO68_0.1uM Dose=0.1uM
FE-12-TO68_10uM Dose=10uM
FE-12-TO68_1uM Dose=1uM
FE-16-UK58_0.01uM Dose=0.01uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2
FE-16-UK58_0.1uM Dose=0.1uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2
FE-16-UK58_10uM Dose=10uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2
FE-16-UK58_1uM Dose=1uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2
FE-18-SS57_0.01uM Dose=0.01uM, CID 6993119, Calpain Inhibitors targeting CAPN1
FE-18-SS57_0.1uM Dose=0.1uM, CID 6993119, Calpain Inhibitors targeting CAPN1
FE-18-SS57_1uM Dose=1uM, CID 6993119, Calpain Inhibitors targeting CAPN1
FE-19-OW54_0.01uM Dose=0.01uM, Fenofibric Acid
FE-19-OW54_0.1uM Dose=0.1uM, Fenofibric Acid
FE-19-OW54_10uM Dose=10uM, Fenofibric Acid
FE-19-OW54_1uM Dose=1uM, Fenofibric Acid
FE-19-SC91_0.01uM Dose=0.01uM, 1-Benzenesulfonyl-5-(4-methylpiperazin-1-yl-methyl)-1H-indole, 5-HT6 Receptor Ligands targeting HTR6
FE-19-SC91_0.1uM Dose=0.1uM, 1-Benzenesulfonyl-5-(4-methylpiperazin-1-yl-methyl)-1H-indole, 5-HT6 Receptor Ligands targeting HTR6
FE-19-SC91_1uM Dose=1uM, 1-Benzenesulfonyl-5-(4-methylpiperazin-1-yl-methyl)-1H-indole, 5-HT6 Receptor Ligands targeting HTR6
FE-21-KA32_0.01uM Dose=0.01uM, Brl 55834
FE-21-KA32_0.1uM Dose=0.1uM, Brl 55834
FE-21-KA32_1uM Dose=1uM, Brl 55834
FE-21-KA82_0.01uM Dose=0.01uM, (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5
FE-21-KA82_0.1uM Dose=0.1uM, (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5
FE-21-KA82_10uM Dose=10uM, (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5
FE-22-JV50_0.01uM Dose=0.01uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD
FE-22-JV50_0.1uM Dose=0.1uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD
FE-22-JV50_10uM Dose=10uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD
FE-22-JV50_1uM Dose=1uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD
FE-23-WP33_0.01uM Dose=0.01uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1
FE-23-WP33_0.1uM Dose=0.1uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1
FE-23-WP33_10uM Dose=10uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1
FE-23-WP33_1uM Dose=1uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1
FE-25-GD89_0.01uM Dose=0.01uM
FE-25-GD89_0.1uM Dose=0.1uM
FE-25-GD89_10uM Dose=10uM
FE-25-GD89_1uM Dose=1uM
FE-26-GO83_0.1uM Dose=0.1uM, methyl 2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoate
FE-26-GO83_10uM Dose=10uM, methyl 2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoate
FE-26-GO83_1uM Dose=1uM, methyl 2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoate
FE-27-XB49_0.1uM Dose=0.1uM, Telcagepant, CGRP antagonist;Calcitonin gene peptide ligand inhibitor targeting CALCA, CALCB, CALCRL, RAMP1, CRCP
FE-27-XB49_10uM Dose=10uM, Telcagepant, CGRP antagonist;Calcitonin gene peptide ligand inhibitor targeting CALCA, CALCB, CALCRL, RAMP1, CRCP
FE-27-XB49_1uM Dose=1uM, Telcagepant, CGRP antagonist;Calcitonin gene peptide ligand inhibitor targeting CALCA, CALCB, CALCRL, RAMP1, CRCP
FE-29-HC66_0.01uM Dose=0.01uM, Pkf-242-484, MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP3, MMP9, MMP13, ADAM17
FE-29-HC66_0.1uM Dose=0.1uM, Pkf-242-484, MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP3, MMP9, MMP13, ADAM17
FE-29-HC66_10uM Dose=10uM, Pkf-242-484, MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP3, MMP9, MMP13, ADAM17
FE-29-HC66_1uM Dose=1uM, Pkf-242-484, MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP3, MMP9, MMP13, ADAM17
FE-29-XM40_0.01uM Dose=0.01uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2
FE-29-XM40_0.1uM Dose=0.1uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2
FE-29-XM40_10uM Dose=10uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2
FE-29-XM40_1uM Dose=1uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2
FE-31-JU80_0.01uM Dose=0.01uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid
FE-31-JU80_0.1uM Dose=0.1uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid
FE-31-JU80_10uM Dose=10uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid
FE-31-JU80_1uM Dose=1uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid
FE-36-JU27_0.01uM Dose=0.01uM, 4-ethyl-3-(3-methoxypropoxy)-N-[[(3S,4S)-4-[[methyl-(2-phenylacetyl)amino]methyl]pyrrolidin-3-yl]methyl]-N-propan-2-ylbenzamide, Renin Inhibitors targeting REN
FE-36-JU27_10uM Dose=10uM, 4-ethyl-3-(3-methoxypropoxy)-N-[[(3S,4S)-4-[[methyl-(2-phenylacetyl)amino]methyl]pyrrolidin-3-yl]methyl]-N-propan-2-ylbenzamide, Renin Inhibitors targeting REN
FE-36-JU27_1uM Dose=1uM, 4-ethyl-3-(3-methoxypropoxy)-N-[[(3S,4S)-4-[[methyl-(2-phenylacetyl)amino]methyl]pyrrolidin-3-yl]methyl]-N-propan-2-ylbenzamide, Renin Inhibitors targeting REN
FE-36-XA09_0.01uM Dose=0.01uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3
FE-36-XA09_0.1uM Dose=0.1uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3
FE-36-XA09_10uM Dose=10uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3
FE-36-XA09_1uM Dose=1uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3
FE-37-OL13_0.01uM Dose=0.01uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA
FE-37-OL13_0.1uM Dose=0.1uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA
FE-37-OL13_10uM Dose=10uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA
FE-37-OL13_1uM Dose=1uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA
FE-37-OS90_0.01uM Dose=0.01uM, 6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, Pyruvate kinase 2 stimulator targeting PKM
FE-37-OS90_0.1uM Dose=0.1uM, 6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, Pyruvate kinase 2 stimulator targeting PKM
FE-37-OS90_10uM Dose=10uM, 6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, Pyruvate kinase 2 stimulator targeting PKM
FE-37-OS90_1uM Dose=1uM, 6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, Pyruvate kinase 2 stimulator targeting PKM
FE-39-LJ73_0.01uM Dose=0.01uM
FE-39-LJ73_0.1uM Dose=0.1uM
FE-39-LJ73_1uM Dose=1uM
FE-48-QP65_0.01uM Dose=0.01uM, Iralukast, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Antagonists targeting CYSLTR1
FE-48-QP65_10uM Dose=10uM, Iralukast, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Antagonists targeting CYSLTR1
FE-49-VJ28_0.01uM Dose=0.01uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A
FE-49-VJ28_0.1uM Dose=0.1uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A
FE-49-VJ28_10uM Dose=10uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A
FE-49-VJ28_1uM Dose=1uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A
FE-49-ZJ78_0.01uM Dose=0.01uM
FE-49-ZJ78_0.1uM Dose=0.1uM
FE-49-ZJ78_10uM Dose=10uM
FE-49-ZJ78_1uM Dose=1uM
FE-56-PV35_0.01uM Dose=0.01uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B
FE-56-PV35_0.1uM Dose=0.1uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B
FE-56-PV35_10uM Dose=10uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B
FE-56-PV35_1uM Dose=1uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B
FE-58-ES32_0.01uM Dose=0.01uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine
FE-58-ES32_0.1uM Dose=0.1uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine
FE-58-ES32_10uM Dose=10uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine
FE-58-ES32_1uM Dose=1uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine
FE-59-BC81_0.01uM Dose=0.01uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR
FE-59-BC81_0.1uM Dose=0.1uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR
FE-59-BC81_10uM Dose=10uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR
FE-59-BC81_1uM Dose=1uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR
FE-61-DL94_0.01uM Dose=0.01uM
FE-61-DL94_0.1uM Dose=0.1uM
FE-61-DL94_10uM Dose=10uM
FE-61-DL94_1uM Dose=1uM
FE-64-KC49_0.01uM Dose=0.01uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1
FE-64-KC49_0.1uM Dose=0.1uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1
FE-64-KC49_10uM Dose=10uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1
FE-64-KC49_1uM Dose=1uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1
FE-67-IO55_0.01uM Dose=0.01uM, 3-[3-(4,7-Diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione targeting PRKCQ
FE-68-DZ79_0.01uM Dose=0.01uM, N-benzylaminosulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2
FE-68-DZ79_0.1uM Dose=0.1uM, N-benzylaminosulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2
FE-68-DZ79_1uM Dose=1uM, N-benzylaminosulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2
FE-69-HJ93_0.01uM Dose=0.01uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42
FE-69-HJ93_0.1uM Dose=0.1uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42
FE-69-HJ93_10uM Dose=10uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42
FE-69-HJ93_1uM Dose=1uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42
FE-72-KZ75_0.01uM Dose=0.01uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3
FE-72-KZ75_0.1uM Dose=0.1uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3
FE-72-KZ75_10uM Dose=10uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3
FE-72-KZ75_1uM Dose=1uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3
FE-73-PS05_0.01uM Dose=0.01uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1
FE-73-PS05_0.1uM Dose=0.1uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1
FE-73-PS05_10uM Dose=10uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1
FE-73-PS05_1uM Dose=1uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1
FE-75-VG41_0.01uM Dose=0.01uM, Muscarinic M3 Antagonists targeting CHRM3
FE-75-VG41_0.1uM Dose=0.1uM, Muscarinic M3 Antagonists targeting CHRM3
FE-75-VG41_10uM Dose=10uM, Muscarinic M3 Antagonists targeting CHRM3
FE-75-VG41_1uM Dose=1uM, Muscarinic M3 Antagonists targeting CHRM3
FE-76-CA29_0.01uM Dose=0.01uM, Gnf-2, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2
FE-76-CA29_0.1uM Dose=0.1uM, Gnf-2, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2
FE-76-CA29_10uM Dose=10uM, Gnf-2, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2
FE-76-CA29_1uM Dose=1uM, Gnf-2, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2
FE-82-JV20_0.01uM Dose=0.01uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2
FE-82-JV20_0.1uM Dose=0.1uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2
FE-82-JV20_10uM Dose=10uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2
FE-82-JV20_1uM Dose=1uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2
FE-82-MY37_0.01uM Dose=0.01uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid
FE-82-MY37_0.1uM Dose=0.1uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid
FE-82-MY37_10uM Dose=10uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid
FE-82-MY37_1uM Dose=1uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid
FE-82-WB22_0.01uM Dose=0.01uM, MRT67307 HCl targeting ULK1
FE-82-WB22_0.1uM Dose=0.1uM, MRT67307 HCl targeting ULK1
FE-82-WB22_10uM Dose=10uM, MRT67307 HCl targeting ULK1
FE-82-WB22_1uM Dose=1uM, MRT67307 HCl targeting ULK1
FE-92-ZL16_0.01uM Dose=0.01uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2
FE-92-ZL16_0.1uM Dose=0.1uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2
FE-92-ZL16_10uM Dose=10uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2
FE-92-ZL16_1uM Dose=1uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2
FE-94-NQ13_0.01uM Dose=0.01uM, Tirasemtiv targeting TNNI2, TNNT3
FE-94-NQ13_0.1uM Dose=0.1uM, Tirasemtiv targeting TNNI2, TNNT3
FE-94-NQ13_1uM Dose=1uM, Tirasemtiv targeting TNNI2, TNNT3
FE-94-WT30_0.01uM Dose=0.01uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2
FE-94-WT30_0.1uM Dose=0.1uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2
FE-94-WT30_10uM Dose=10uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2
FE-94-WT30_1uM Dose=1uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2
FE-95-PU35_0.01uM Dose=0.01uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine
FE-95-PU35_0.1uM Dose=0.1uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine
FE-95-PU35_10uM Dose=10uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine
FE-95-PU35_1uM Dose=1uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine
FE-99-RJ28_0.01uM Dose=0.01uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1
FE-99-RJ28_0.1uM Dose=0.1uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1
FE-99-RJ28_10uM Dose=10uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1
FE-99-RJ28_1uM Dose=1uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1
FF-01-OH44_0.01uM Dose=0.01uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38
FF-01-OH44_0.1uM Dose=0.1uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38
FF-01-OH44_10uM Dose=10uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38
FF-01-OH44_1uM Dose=1uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38
FF-06-MA64_0.01uM Dose=0.01uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1
FF-06-MA64_0.1uM Dose=0.1uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1
FF-06-MA64_10uM Dose=10uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1
FF-06-MA64_1uM Dose=1uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1
FF-06-MO73_0.01uM Dose=0.01uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3
FF-06-MO73_0.1uM Dose=0.1uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3
FF-06-MO73_10uM Dose=10uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3
FF-06-MO73_1uM Dose=1uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3
FF-07-FL63_0.01uM Dose=0.01uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12
FF-07-FL63_0.1uM Dose=0.1uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12
FF-07-FL63_10uM Dose=10uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12
FF-07-FL63_1uM Dose=1uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12
FF-08-DP35_0.01uM Dose=0.01uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2
FF-08-DP35_0.1uM Dose=0.1uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2
FF-08-DP35_10uM Dose=10uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2
FF-08-DP35_1uM Dose=1uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2
FF-10-JX55_0.01uM Dose=0.01uM
FF-10-JX55_0.1uM Dose=0.1uM
FF-10-JX55_10uM Dose=10uM
FF-10-JX55_1uM Dose=1uM
FF-14-JG89_0.01uM Dose=0.01uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2
FF-14-JG89_0.1uM Dose=0.1uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2
FF-14-JG89_10uM Dose=10uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2
FF-14-JG89_1uM Dose=1uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2
FF-22-NB12_0.01uM Dose=0.01uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR
FF-22-NB12_0.1uM Dose=0.1uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR
FF-22-NB12_10uM Dose=10uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR
FF-22-NB12_1uM Dose=1uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR
FF-28-ES17_0.01uM Dose=0.01uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one
FF-28-ES17_0.1uM Dose=0.1uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one
FF-28-ES17_10uM Dose=10uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one
FF-28-ES17_1uM Dose=1uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one
FF-31-BR08_0.01uM Dose=0.01uM, 4-(4-Chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole, Histone N-Acetyltransferase (HAT) Inhibitors targeting KAT2A, HAT1
FF-31-BR08_0.1uM Dose=0.1uM, 4-(4-Chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole, Histone N-Acetyltransferase (HAT) Inhibitors targeting KAT2A, HAT1
FF-31-BR08_10uM Dose=10uM, 4-(4-Chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole, Histone N-Acetyltransferase (HAT) Inhibitors targeting KAT2A, HAT1
FF-31-BR08_1uM Dose=1uM, 4-(4-Chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole, Histone N-Acetyltransferase (HAT) Inhibitors targeting KAT2A, HAT1
FF-32-LL81_0.01uM Dose=0.01uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1
FF-32-LL81_0.1uM Dose=0.1uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1
FF-32-LL81_10uM Dose=10uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1
FF-34-KW62_0.01uM Dose=0.01uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
FF-34-KW62_0.1uM Dose=0.1uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
FF-34-KW62_10uM Dose=10uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
FF-34-KW62_1uM Dose=1uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
FF-35-JG06_0.01uM Dose=0.01uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1
FF-35-JG06_0.1uM Dose=0.1uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1
FF-35-JG06_10uM Dose=10uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1
FF-35-JG06_1uM Dose=1uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1
FF-46-CU92_0.01uM Dose=0.01uM
FF-46-CU92_0.1uM Dose=0.1uM
FF-46-CU92_10uM Dose=10uM
FF-46-CU92_1uM Dose=1uM
FF-46-IE04_0.01uM Dose=0.01uM, 4-nitrophenyl 4-[bis(2H-1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate, Monoglyceride lipase inhibitor;Monoacylglycerol Lipase Inhibitors targeting MGLL
FF-46-IE04_10uM Dose=10uM, 4-nitrophenyl 4-[bis(2H-1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate, Monoglyceride lipase inhibitor;Monoacylglycerol Lipase Inhibitors targeting MGLL
FF-46-IE04_1uM Dose=1uM, 4-nitrophenyl 4-[bis(2H-1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate, Monoglyceride lipase inhibitor;Monoacylglycerol Lipase Inhibitors targeting MGLL
FF-46-OR35_0.01uM Dose=0.01uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5
FF-46-OR35_0.1uM Dose=0.1uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5
FF-46-OR35_10uM Dose=10uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5
FF-46-OR35_1uM Dose=1uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5
FF-54-JC89_0.01uM Dose=0.01uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine
FF-54-JC89_0.1uM Dose=0.1uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine
FF-54-JC89_10uM Dose=10uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine
FF-54-JC89_1uM Dose=1uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine
FF-55-AD09_0.01uM Dose=0.01uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183
FF-55-AD09_0.1uM Dose=0.1uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183
FF-55-AD09_10uM Dose=10uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183
FF-55-AD09_1uM Dose=1uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183
FF-59-KC06_0.01uM Dose=0.01uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B
FF-59-KC06_0.1uM Dose=0.1uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B
FF-59-KC06_10uM Dose=10uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B
FF-59-KC06_1uM Dose=1uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B
FF-60-FQ28_0.01uM Dose=0.01uM
FF-60-FQ28_0.1uM Dose=0.1uM
FF-60-FQ28_1uM Dose=1uM
FF-61-BU95_0.1uM Dose=0.1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB
FF-61-BU95_10uM Dose=10uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB
FF-61-BU95_1uM Dose=1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB
FF-61-PA27_0.01uM Dose=0.01uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD
FF-61-PA27_0.1uM Dose=0.1uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD
FF-61-PA27_10uM Dose=10uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD
FF-61-PA27_1uM Dose=1uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD
FF-76-LK08_0.01uM Dose=0.01uM
FF-76-LK08_0.1uM Dose=0.1uM
FF-76-LK08_10uM Dose=10uM
FF-76-LK08_1uM Dose=1uM
FF-86-NH56_0.01uM Dose=0.01uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
FF-86-NH56_0.1uM Dose=0.1uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
FF-86-NH56_10uM Dose=10uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
FF-86-NH56_1uM Dose=1uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
FF-89-KK36_0.01uM Dose=0.01uM, rac-tert-Butyl (R,E)-3-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamido)-3-(5-(4-((methoxycarbonyl)amino)phenyl)-6-oxo-1,6-dihydropyridazin-3-yl)propanoate, Known FactorXI inhibitor targeting F11
FF-89-KK36_0.1uM Dose=0.1uM, rac-tert-Butyl (R,E)-3-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamido)-3-(5-(4-((methoxycarbonyl)amino)phenyl)-6-oxo-1,6-dihydropyridazin-3-yl)propanoate, Known FactorXI inhibitor targeting F11
FF-89-KK36_10uM Dose=10uM, rac-tert-Butyl (R,E)-3-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamido)-3-(5-(4-((methoxycarbonyl)amino)phenyl)-6-oxo-1,6-dihydropyridazin-3-yl)propanoate, Known FactorXI inhibitor targeting F11
FF-89-KK36_1uM Dose=1uM, rac-tert-Butyl (R,E)-3-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamido)-3-(5-(4-((methoxycarbonyl)amino)phenyl)-6-oxo-1,6-dihydropyridazin-3-yl)propanoate, Known FactorXI inhibitor targeting F11
FF-90-JK74_0.01uM Dose=0.01uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A
FF-90-JK74_0.1uM Dose=0.1uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A
FF-90-JK74_10uM Dose=10uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A
FF-90-JK74_1uM Dose=1uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A
FF-96-HL81_0.01uM Dose=0.01uM
FF-96-HL81_0.1uM Dose=0.1uM
FF-96-HL81_10uM Dose=10uM
FF-96-HL81_1uM Dose=1uM
GA-01-EO66_0.1uM Dose=0.1uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1
GA-01-EO66_10uM Dose=10uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1
GA-01-EO66_1uM Dose=1uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1
GA-04-JM33_0.01uM Dose=0.01uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4
GA-04-JM33_0.1uM Dose=0.1uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4
GA-04-JM33_10uM Dose=10uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4
GA-04-JM33_1uM Dose=1uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4
GA-04-SF76_0.01uM Dose=0.01uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2
GA-04-SF76_0.1uM Dose=0.1uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2
GA-04-SF76_10uM Dose=10uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2
GA-04-SF76_1uM Dose=1uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2
GA-06-UU42_0.01uM Dose=0.01uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4
GA-06-UU42_0.1uM Dose=0.1uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4
GA-06-UU42_10uM Dose=10uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4
GA-06-UU42_1uM Dose=1uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4
GA-07-NB64_0.01uM Dose=0.01uM, (1,1-Dimethylpiperidin-1-ium-4-yl) octadecyl hydrogen phosphate, Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1
GA-07-NB64_0.1uM Dose=0.1uM, (1,1-Dimethylpiperidin-1-ium-4-yl) octadecyl hydrogen phosphate, Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1
GA-07-NB64_1uM Dose=1uM, (1,1-Dimethylpiperidin-1-ium-4-yl) octadecyl hydrogen phosphate, Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1
GA-09-TM90_0.01uM Dose=0.01uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK
GA-09-TM90_0.1uM Dose=0.1uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK
GA-09-TM90_10uM Dose=10uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK
GA-09-TM90_1uM Dose=1uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK
GA-10-WX15_0.01uM Dose=0.01uM
GA-10-WX15_0.1uM Dose=0.1uM
GA-10-WX15_10uM Dose=10uM
GA-10-WX15_1uM Dose=1uM
GA-13-WB79_0.01uM Dose=0.01uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide
GA-13-WB79_0.1uM Dose=0.1uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide
GA-13-WB79_10uM Dose=10uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide
GA-13-WB79_1uM Dose=1uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide
GA-16-IU17_0.01uM Dose=0.01uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1
GA-16-IU17_0.1uM Dose=0.1uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1
GA-16-IU17_10uM Dose=10uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1
GA-16-IU17_1uM Dose=1uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1
GA-18-KF56_0.01uM Dose=0.01uM
GA-18-KF56_0.1uM Dose=0.1uM
GA-18-KF56_10uM Dose=10uM
GA-18-KF56_1uM Dose=1uM
GA-18-PV59_0.01uM Dose=0.01uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17
GA-18-PV59_0.1uM Dose=0.1uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17
GA-18-PV59_10uM Dose=10uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17
GA-18-PV59_1uM Dose=1uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17
GA-23-VF89_0.01uM Dose=0.01uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine
GA-23-VF89_0.1uM Dose=0.1uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine
GA-23-VF89_10uM Dose=10uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine
GA-23-VF89_1uM Dose=1uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine
GA-27-MH98_0.01uM Dose=0.01uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3
GA-27-MH98_0.1uM Dose=0.1uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3
GA-27-MH98_10uM Dose=10uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3
GA-27-MH98_1uM Dose=1uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3
GA-28-SS67_0.01uM Dose=0.01uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH
GA-28-SS67_0.1uM Dose=0.1uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH
GA-28-SS67_10uM Dose=10uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH
GA-28-SS67_1uM Dose=1uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH
GA-30-HJ41_0.01uM Dose=0.01uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1
GA-30-HJ41_0.1uM Dose=0.1uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1
GA-30-HJ41_10uM Dose=10uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1
GA-30-HJ41_1uM Dose=1uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1
GA-32-TO88_0.01uM Dose=0.01uM, 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9
GA-32-TO88_0.1uM Dose=0.1uM, 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9
GA-32-TO88_1uM Dose=1uM, 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9
GA-41-JD09_0.01uM Dose=0.01uM, 4-[(2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carbonyl]benzonitrile, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
GA-41-JD09_0.1uM Dose=0.1uM, 4-[(2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carbonyl]benzonitrile, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
GA-41-JD09_10uM Dose=10uM, 4-[(2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carbonyl]benzonitrile, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
GA-41-JD09_1uM Dose=1uM, 4-[(2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carbonyl]benzonitrile, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
GA-43-FL03_0.01uM Dose=0.01uM, Aliskiren, Renin Inhibitors targeting REN
GA-43-FL03_0.1uM Dose=0.1uM, Aliskiren, Renin Inhibitors targeting REN
GA-43-FL03_10uM Dose=10uM, Aliskiren, Renin Inhibitors targeting REN
GA-43-FL03_1uM Dose=1uM, Aliskiren, Renin Inhibitors targeting REN
GA-47-CH23_0.1uM Dose=0.1uM, N-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]propanamide, EGFR (HER1;erbB1) Inhibitors targeting EGFR
GA-47-CH23_10uM Dose=10uM, N-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]propanamide, EGFR (HER1;erbB1) Inhibitors targeting EGFR
GA-47-CH23_1uM Dose=1uM, N-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]propanamide, EGFR (HER1;erbB1) Inhibitors targeting EGFR
GA-47-MH68_0.01uM Dose=0.01uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1
GA-47-MH68_0.1uM Dose=0.1uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1
GA-47-MH68_10uM Dose=10uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1
GA-47-MH68_1uM Dose=1uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1
GA-48-JB51_0.01uM Dose=0.01uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B
GA-48-JB51_0.1uM Dose=0.1uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B
GA-48-JB51_10uM Dose=10uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B
GA-48-JB51_1uM Dose=1uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B
GA-48-QI68_0.01uM Dose=0.01uM
GA-48-QI68_0.1uM Dose=0.1uM
GA-48-QI68_10uM Dose=10uM
GA-48-QI68_1uM Dose=1uM
GA-49-SZ11_0.01uM Dose=0.01uM, (2S)-2-amino-2-cyclohexyl-1-(pyrrolidin-1-yl)ethan-1-one, Dipeptidyl Peptidase VIII (DPP8) Inhibitors;Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors;Dipeptidyl Peptidase IV (CD26| DPP-IV| DP-IV) Inhibitors targeting DPP8
GA-49-SZ11_0.1uM Dose=0.1uM, (2S)-2-amino-2-cyclohexyl-1-(pyrrolidin-1-yl)ethan-1-one, Dipeptidyl Peptidase VIII (DPP8) Inhibitors;Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors;Dipeptidyl Peptidase IV (CD26| DPP-IV| DP-IV) Inhibitors targeting DPP8
GA-49-SZ11_10uM Dose=10uM, (2S)-2-amino-2-cyclohexyl-1-(pyrrolidin-1-yl)ethan-1-one, Dipeptidyl Peptidase VIII (DPP8) Inhibitors;Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors;Dipeptidyl Peptidase IV (CD26| DPP-IV| DP-IV) Inhibitors targeting DPP8
GA-51-DD14_0.01uM Dose=0.01uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine
GA-51-DD14_0.1uM Dose=0.1uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine
GA-51-DD14_10uM Dose=10uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine
GA-51-DD14_1uM Dose=1uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine
GA-53-SC22_0.01uM Dose=0.01uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB
GA-53-SC22_0.1uM Dose=0.1uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB
GA-53-SC22_10uM Dose=10uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB
GA-53-SC22_1uM Dose=1uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB
GA-56-IU17_0.01uM Dose=0.01uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4
GA-56-IU17_0.1uM Dose=0.1uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4
GA-56-IU17_10uM Dose=10uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4
GA-56-IU17_1uM Dose=1uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4
GA-59-RW04_0.01uM Dose=0.01uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP
GA-59-RW04_0.1uM Dose=0.1uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP
GA-59-RW04_10uM Dose=10uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP
GA-59-RW04_1uM Dose=1uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP
GA-61-GX82_0.01uM Dose=0.01uM, Abeorphine
GA-61-GX82_0.1uM Dose=0.1uM, Abeorphine
GA-61-GX82_10uM Dose=10uM, Abeorphine
GA-61-GX82_1uM Dose=1uM, Abeorphine
GA-66-IX54_0.01uM Dose=0.01uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT
GA-66-IX54_0.1uM Dose=0.1uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT
GA-66-IX54_10uM Dose=10uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT
GA-66-IX54_1uM Dose=1uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT
GA-66-XX49_0.01uM Dose=0.01uM
GA-66-XX49_0.1uM Dose=0.1uM
GA-66-XX49_10uM Dose=10uM
GA-66-XX49_1uM Dose=1uM
GA-68-KC29_0.01uM Dose=0.01uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6
GA-68-KC29_0.1uM Dose=0.1uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6
GA-68-KC29_10uM Dose=10uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6
GA-68-KC29_1uM Dose=1uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6
GA-68-SS47_0.01uM Dose=0.01uM, ERK1 Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;MKK4 Inhibitors
GA-68-SS47_0.1uM Dose=0.1uM, ERK1 Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;MKK4 Inhibitors
GA-68-SS47_10uM Dose=10uM, ERK1 Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;MKK4 Inhibitors
GA-77-FY14_0.01uM Dose=0.01uM
GA-77-FY14_0.1uM Dose=0.1uM
GA-77-FY14_10uM Dose=10uM
GA-77-FY14_1uM Dose=1uM
GA-77-MH38_0.01uM Dose=0.01uM
GA-77-MH38_0.1uM Dose=0.1uM
GA-77-MH38_10uM Dose=10uM
GA-77-MH38_1uM Dose=1uM
GA-79-DW49_0.01uM Dose=0.01uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG
GA-79-DW49_0.1uM Dose=0.1uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG
GA-79-DW49_10uM Dose=10uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG
GA-79-DW49_1uM Dose=1uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG
GA-79-ZF28_0.01uM Dose=0.01uM, 5-{[(4-Methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2, CA4
GA-79-ZF28_10uM Dose=10uM, 5-{[(4-Methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2, CA4
GA-79-ZF28_1uM Dose=1uM, 5-{[(4-Methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2, CA4
GA-81-DL34_0.01uM Dose=0.01uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7
GA-81-DL34_0.1uM Dose=0.1uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7
GA-81-DL34_10uM Dose=10uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7
GA-81-DL34_1uM Dose=1uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7
GA-85-SJ43_0.01uM Dose=0.01uM, DRD1 antagonist
GA-85-SJ43_0.1uM Dose=0.1uM, DRD1 antagonist
GA-85-SJ43_10uM Dose=10uM, DRD1 antagonist
GA-87-BR97_0.01uM Dose=0.01uM
GA-87-BR97_0.1uM Dose=0.1uM
GA-87-BR97_10uM Dose=10uM
GA-87-BR97_1uM Dose=1uM
GA-88-CF36_0.01uM Dose=0.01uM, Brusatol
GA-88-CF36_0.1uM Dose=0.1uM, Brusatol
GA-88-CF36_10uM Dose=10uM, Brusatol
GA-88-CF36_1uM Dose=1uM, Brusatol
GA-88-PV69_0.01uM Dose=0.01uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1
GA-88-PV69_0.1uM Dose=0.1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1
GA-88-PV69_10uM Dose=10uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1
GA-88-PV69_1uM Dose=1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1
GA-89-ZT62_0.01uM Dose=0.01uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS
GA-89-ZT62_0.1uM Dose=0.1uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS
GA-89-ZT62_10uM Dose=10uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS
GA-89-ZT62_1uM Dose=1uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS
GA-94-KZ19_0.01uM Dose=0.01uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2
GA-94-KZ19_0.1uM Dose=0.1uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2
GA-94-KZ19_1uM Dose=1uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2
GA-94-MC54_0.01uM Dose=0.01uM, 6-(1,4-Diazepan-1-yl)-5-(3,3-dichloroprop-2-enyl)-3-(isoquinolin-1-ylmethyl)-4-oxopyrrolo[3,2-d]pyrimidine-7-carbonitrile, Autophagy agonist targeting DPP4
GA-94-MC54_10uM Dose=10uM, 6-(1,4-Diazepan-1-yl)-5-(3,3-dichloroprop-2-enyl)-3-(isoquinolin-1-ylmethyl)-4-oxopyrrolo[3,2-d]pyrimidine-7-carbonitrile, Autophagy agonist targeting DPP4
GA-94-MC54_1uM Dose=1uM, 6-(1,4-Diazepan-1-yl)-5-(3,3-dichloroprop-2-enyl)-3-(isoquinolin-1-ylmethyl)-4-oxopyrrolo[3,2-d]pyrimidine-7-carbonitrile, Autophagy agonist targeting DPP4
GA-97-UL18_0.01uM Dose=0.01uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3
GA-97-UL18_0.1uM Dose=0.1uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3
GA-97-UL18_10uM Dose=10uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3
GA-97-UL18_1uM Dose=1uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3
GB-01-UN23_0.01uM Dose=0.01uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol
GB-01-UN23_0.1uM Dose=0.1uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol
GB-01-UN23_10uM Dose=10uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol
GB-01-UN23_1uM Dose=1uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol
GB-05-QT17_10uM Dose=10uM, 4-Nitro-N-(4-sulfamoylphenyl)benzene-1-sulfonamide, Carbonic anhydrase inhibitor targeting CA1
GB-06-BA49_0.01uM Dose=0.01uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1
GB-06-BA49_0.1uM Dose=0.1uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1
GB-06-BA49_10uM Dose=10uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1
GB-06-BA49_1uM Dose=1uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1
GB-10-QG19_0.01uM Dose=0.01uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
GB-10-QG19_0.1uM Dose=0.1uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
GB-10-QG19_10uM Dose=10uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
GB-10-QG19_1uM Dose=1uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
GB-11-PX47_0.01uM Dose=0.01uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3
GB-11-PX47_0.1uM Dose=0.1uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3
GB-11-PX47_10uM Dose=10uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3
GB-11-TA37_0.01uM Dose=0.01uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7
GB-11-TA37_0.1uM Dose=0.1uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7
GB-11-TA37_10uM Dose=10uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7
GB-11-TA37_1uM Dose=1uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7
GB-14-AJ76_0.01uM Dose=0.01uM
GB-14-AJ76_0.1uM Dose=0.1uM
GB-14-AJ76_10uM Dose=10uM
GB-14-AJ76_1uM Dose=1uM
GB-16-NN30_0.01uM Dose=0.01uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2
GB-16-NN30_0.1uM Dose=0.1uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2
GB-16-NN30_10uM Dose=10uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2
GB-16-NN30_1uM Dose=1uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2
GB-16-SU72_0.01uM Dose=0.01uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1
GB-16-SU72_0.1uM Dose=0.1uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1
GB-16-SU72_10uM Dose=10uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1
GB-16-SU72_1uM Dose=1uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1
GB-19-AP57_0.01uM Dose=0.01uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol
GB-19-AP57_0.1uM Dose=0.1uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol
GB-19-AP57_10uM Dose=10uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol
GB-19-AP57_1uM Dose=1uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol
GB-21-FN58_0.01uM Dose=0.01uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK
GB-21-FN58_0.1uM Dose=0.1uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK
GB-21-FN58_10uM Dose=10uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK
GB-21-FN58_1uM Dose=1uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK
GB-27-AY54_0.01uM Dose=0.01uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2
GB-27-AY54_0.1uM Dose=0.1uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2
GB-27-AY54_10uM Dose=10uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2
GB-27-AY54_1uM Dose=1uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2
GB-31-HY20_0.01uM Dose=0.01uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2
GB-31-HY20_0.1uM Dose=0.1uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2
GB-31-HY20_10uM Dose=10uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2
GB-31-HY20_1uM Dose=1uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2
GB-33-FW25_0.01uM Dose=0.01uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT
GB-33-FW25_0.1uM Dose=0.1uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT
GB-33-FW25_10uM Dose=10uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT
GB-33-FW25_1uM Dose=1uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT
GB-33-SS25_0.01uM Dose=0.01uM, 5-Hydroxyflavone targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
GB-33-SS25_0.1uM Dose=0.1uM, 5-Hydroxyflavone targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
GB-33-SS25_1uM Dose=1uM, 5-Hydroxyflavone targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13
GB-35-DG61_0.01uM Dose=0.01uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2
GB-35-DG61_0.1uM Dose=0.1uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2
GB-35-DG61_10uM Dose=10uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2
GB-35-DG61_1uM Dose=1uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2
GB-37-WI36_0.01uM Dose=0.01uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
GB-37-WI36_0.1uM Dose=0.1uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
GB-37-WI36_10uM Dose=10uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
GB-37-WI36_1uM Dose=1uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
GB-39-OF03_0.01uM Dose=0.01uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2
GB-39-OF03_0.1uM Dose=0.1uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2
GB-39-OF03_10uM Dose=10uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2
GB-39-OF03_1uM Dose=1uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2
GB-45-CJ58_0.01uM Dose=0.01uM, 7-Chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 5-HT2C Agonists targeting HTR2C
GB-45-CJ58_0.1uM Dose=0.1uM, 7-Chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 5-HT2C Agonists targeting HTR2C
GB-45-CJ58_10uM Dose=10uM, 7-Chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 5-HT2C Agonists targeting HTR2C
GB-45-YG91_0.01uM Dose=0.01uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2
GB-45-YG91_0.1uM Dose=0.1uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2
GB-45-YG91_10uM Dose=10uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2
GB-45-YG91_1uM Dose=1uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2
GB-46-CK08_0.01uM Dose=0.01uM
GB-46-CK08_0.1uM Dose=0.1uM
GB-46-CK08_10uM Dose=10uM
GB-46-CK08_1uM Dose=1uM
GB-48-YF11_0.01uM Dose=0.01uM, Nicaraven, Lipid Peroxidation Inhibitors;PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
GB-48-YF11_0.1uM Dose=0.1uM, Nicaraven, Lipid Peroxidation Inhibitors;PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
GB-48-YF11_10uM Dose=10uM, Nicaraven, Lipid Peroxidation Inhibitors;PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
GB-48-YF11_1uM Dose=1uM, Nicaraven, Lipid Peroxidation Inhibitors;PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
GB-50-PK29_0.01uM Dose=0.01uM, Azapropazone, Xanthine Oxidase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting XDH
GB-50-PK29_10uM Dose=10uM, Azapropazone, Xanthine Oxidase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting XDH
GB-51-MD79_0.01uM Dose=0.01uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG
GB-51-MD79_0.1uM Dose=0.1uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG
GB-51-MD79_10uM Dose=10uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG
GB-51-MD79_1uM Dose=1uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG
GB-56-TN25_0.01uM Dose=0.01uM
GB-56-TN25_0.1uM Dose=0.1uM
GB-56-TN25_10uM Dose=10uM
GB-56-TN25_1uM Dose=1uM
GB-57-XV52_0.01uM Dose=0.01uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1
GB-57-XV52_0.1uM Dose=0.1uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1
GB-57-XV52_10uM Dose=10uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1
GB-57-XV52_1uM Dose=1uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1
GB-62-IH36_0.01uM Dose=0.01uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B
GB-62-IH36_0.1uM Dose=0.1uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B
GB-62-IH36_10uM Dose=10uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B
GB-62-IH36_1uM Dose=1uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B
GB-64-HC34_0.01uM Dose=0.01uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1
GB-64-HC34_0.1uM Dose=0.1uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1
GB-64-HC34_10uM Dose=10uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1
GB-64-HC34_1uM Dose=1uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1
GB-69-YC71_0.01uM Dose=0.01uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3
GB-69-YC71_0.1uM Dose=0.1uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3
GB-69-YC71_10uM Dose=10uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3
GB-69-YC71_1uM Dose=1uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3
GB-72-BR65_0.01uM Dose=0.01uM, Opc 14117
GB-72-BR65_0.1uM Dose=0.1uM, Opc 14117
GB-72-BR65_10uM Dose=10uM, Opc 14117
GB-72-BR65_1uM Dose=1uM, Opc 14117
GB-73-QS80_0.01uM Dose=0.01uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
GB-73-QS80_0.1uM Dose=0.1uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
GB-73-QS80_10uM Dose=10uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
GB-73-QS80_1uM Dose=1uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10
GB-76-TN05_0.01uM Dose=0.01uM, SB 258719, 5-HT7 Antagonists targeting HTR7
GB-76-TN05_10uM Dose=10uM, SB 258719, 5-HT7 Antagonists targeting HTR7
GB-81-GK41_0.01uM Dose=0.01uM, QX-314, BLMH gene inhibitor targeting BLM
GB-81-GK41_0.1uM Dose=0.1uM, QX-314, BLMH gene inhibitor targeting BLM
GB-81-GK41_10uM Dose=10uM, QX-314, BLMH gene inhibitor targeting BLM
GB-81-GK41_1uM Dose=1uM, QX-314, BLMH gene inhibitor targeting BLM
GB-81-UN03_0.01uM Dose=0.01uM, 4-Quinolinamine, 2-(2-thienyl)-
GB-81-UN03_0.1uM Dose=0.1uM, 4-Quinolinamine, 2-(2-thienyl)-
GB-81-UN03_10uM Dose=10uM, 4-Quinolinamine, 2-(2-thienyl)-
GB-81-UN03_1uM Dose=1uM, 4-Quinolinamine, 2-(2-thienyl)-
GB-84-KP45_0.01uM Dose=0.01uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8
GB-84-KP45_0.1uM Dose=0.1uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8
GB-84-KP45_10uM Dose=10uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8
GB-84-KP45_1uM Dose=1uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8
GB-86-PE04_0.01uM Dose=0.01uM, N-(tert-Butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine, GLP-1 Receptor Agonists;positive allosteric modulator of GLP1R targeting GLP1R
GB-86-PE04_0.1uM Dose=0.1uM, N-(tert-Butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine, GLP-1 Receptor Agonists;positive allosteric modulator of GLP1R targeting GLP1R
GB-86-PE04_10uM Dose=10uM, N-(tert-Butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine, GLP-1 Receptor Agonists;positive allosteric modulator of GLP1R targeting GLP1R
GB-88-ZP20_0.1uM Dose=0.1uM, Gemilukast, Dual CysLT1 and CysLT2 antagonist targeting CYSLTR1, CYSLTR2
GB-88-ZP20_10uM Dose=10uM, Gemilukast, Dual CysLT1 and CysLT2 antagonist targeting CYSLTR1, CYSLTR2
GB-90-UG49_0.01uM Dose=0.01uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B
GB-90-UG49_0.1uM Dose=0.1uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B
GB-90-UG49_10uM Dose=10uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B
GB-90-UG49_1uM Dose=1uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B
GB-90-VQ08_0.1uM Dose=0.1uM, PH 797804, P38a inhibitor targeting MAPK14
GB-90-VQ08_10uM Dose=10uM, PH 797804, P38a inhibitor targeting MAPK14
GB-90-VQ08_1uM Dose=1uM, PH 797804, P38a inhibitor targeting MAPK14
GB-92-JY12_0.01uM Dose=0.01uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3
GB-92-JY12_0.1uM Dose=0.1uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3
GB-92-JY12_10uM Dose=10uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3
GB-92-JY12_1uM Dose=1uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3
GB-92-MH66_0.01uM Dose=0.01uM, Ureidosuccinic acid
GB-92-MH66_0.1uM Dose=0.1uM, Ureidosuccinic acid
GB-92-MH66_10uM Dose=10uM, Ureidosuccinic acid
GB-92-MH66_1uM Dose=1uM, Ureidosuccinic acid
GB-93-CC27_0.01uM Dose=0.01uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6
GB-93-CC27_0.1uM Dose=0.1uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6
GB-93-CC27_10uM Dose=10uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6
GB-93-CC27_1uM Dose=1uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6
GB-94-XG34_0.01uM Dose=0.01uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN
GB-94-XG34_0.1uM Dose=0.1uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN
GB-94-XG34_10uM Dose=10uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN
GB-94-XG34_1uM Dose=1uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN
GB-96-WX99_0.01uM Dose=0.01uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1
GB-96-WX99_0.1uM Dose=0.1uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1
GB-96-WX99_10uM Dose=10uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1
GB-96-WX99_1uM Dose=1uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1
GB-98-IZ84_0.01uM Dose=0.01uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5
GB-98-IZ84_0.1uM Dose=0.1uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5
GB-98-IZ84_10uM Dose=10uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5
GB-98-IZ84_1uM Dose=1uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5
GC-02-TV70_0.01uM Dose=0.01uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP
GC-02-TV70_0.1uM Dose=0.1uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP
GC-02-TV70_10uM Dose=10uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP
GC-02-TV70_1uM Dose=1uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP
GC-03-VV12_0.01uM Dose=0.01uM, Vanillin
GC-03-VV12_0.1uM Dose=0.1uM, Vanillin
GC-03-VV12_1uM Dose=1uM, Vanillin
GC-04-UF36_0.01uM Dose=0.01uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1
GC-04-UF36_0.1uM Dose=0.1uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1
GC-04-UF36_10uM Dose=10uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1
GC-04-UF36_1uM Dose=1uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1
GC-06-BU42_0.01uM Dose=0.01uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD
GC-06-BU42_0.1uM Dose=0.1uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD
GC-06-BU42_10uM Dose=10uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD
GC-06-BU42_1uM Dose=1uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD
GC-07-KH68_0.01uM Dose=0.01uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GC-07-KH68_0.1uM Dose=0.1uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GC-07-KH68_10uM Dose=10uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GC-07-KH68_1uM Dose=1uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GC-07-UO80_0.01uM Dose=0.01uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68
GC-07-UO80_0.1uM Dose=0.1uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68
GC-07-UO80_10uM Dose=10uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68
GC-07-UO80_1uM Dose=1uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68
GC-08-VP20_0.01uM Dose=0.01uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2
GC-08-VP20_0.1uM Dose=0.1uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2
GC-08-VP20_10uM Dose=10uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2
GC-08-VP20_1uM Dose=1uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2
GC-09-EG26_0.01uM Dose=0.01uM, Carcinine, HRH3 antagonist targeting HRH3
GC-09-EG26_0.1uM Dose=0.1uM, Carcinine, HRH3 antagonist targeting HRH3
GC-09-EG26_10uM Dose=10uM, Carcinine, HRH3 antagonist targeting HRH3
GC-09-EG26_1uM Dose=1uM, Carcinine, HRH3 antagonist targeting HRH3
GC-09-XF08_0.01uM Dose=0.01uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1
GC-09-XF08_0.1uM Dose=0.1uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1
GC-09-XF08_10uM Dose=10uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1
GC-09-XF08_1uM Dose=1uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1
GC-11-YA32_0.01uM Dose=0.01uM
GC-11-YA32_0.1uM Dose=0.1uM
GC-11-YA32_10uM Dose=10uM
GC-11-YA32_1uM Dose=1uM
GC-15-JX22_0.01uM Dose=0.01uM
GC-15-JX22_0.1uM Dose=0.1uM
GC-15-JX22_10uM Dose=10uM
GC-15-JX22_1uM Dose=1uM
GC-21-AN18_0.01uM Dose=0.01uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1
GC-21-AN18_0.1uM Dose=0.1uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1
GC-21-AN18_10uM Dose=10uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1
GC-21-AN18_1uM Dose=1uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1
GC-21-IX32_0.01uM Dose=0.01uM, Boc-Met-Leu-Phe-OH, FPR1 antagonist targeting FPR1
GC-21-IX32_0.1uM Dose=0.1uM, Boc-Met-Leu-Phe-OH, FPR1 antagonist targeting FPR1
GC-21-IX32_10uM Dose=10uM, Boc-Met-Leu-Phe-OH, FPR1 antagonist targeting FPR1
GC-21-IX32_1uM Dose=1uM, Boc-Met-Leu-Phe-OH, FPR1 antagonist targeting FPR1
GC-28-YS77_0.01uM Dose=0.01uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
GC-28-YS77_0.1uM Dose=0.1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
GC-28-YS77_10uM Dose=10uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
GC-28-YS77_1uM Dose=1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
GC-29-JC76_0.01uM Dose=0.01uM, 1-[4-(4-Benzhydryl-piperazin-1-yl)-3-cyano-phenyl]-3-(3,5-dimethyl-isoxazol-4-yl)-urea, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
GC-29-JC76_0.1uM Dose=0.1uM, 1-[4-(4-Benzhydryl-piperazin-1-yl)-3-cyano-phenyl]-3-(3,5-dimethyl-isoxazol-4-yl)-urea, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
GC-29-JC76_10uM Dose=10uM, 1-[4-(4-Benzhydryl-piperazin-1-yl)-3-cyano-phenyl]-3-(3,5-dimethyl-isoxazol-4-yl)-urea, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
GC-32-SH41_0.01uM Dose=0.01uM, MMP3 inhibitor 2
GC-32-SH41_10uM Dose=10uM, MMP3 inhibitor 2
GC-32-SH41_1uM Dose=1uM, MMP3 inhibitor 2
GC-35-PT27_1uM Dose=1uM, MMP-9 (Gelatinase B) Inhibitors
GC-40-VJ01_0.01uM Dose=0.01uM, Pterocarpanquinone
GC-40-VJ01_0.1uM Dose=0.1uM, Pterocarpanquinone
GC-40-VJ01_10uM Dose=10uM, Pterocarpanquinone
GC-40-VJ01_1uM Dose=1uM, Pterocarpanquinone
GC-42-LL86_0.01uM Dose=0.01uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE
GC-42-LL86_0.1uM Dose=0.1uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE
GC-42-LL86_10uM Dose=10uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE
GC-42-LL86_1uM Dose=1uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE
GC-42-SY57_0.01uM Dose=0.01uM, (S)-3-(4-Hydroxy-phenyl)-N-methyl-2-[3-(5-thioxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-ureido]-propionamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
GC-42-SY57_10uM Dose=10uM, (S)-3-(4-Hydroxy-phenyl)-N-methyl-2-[3-(5-thioxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-ureido]-propionamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
GC-42-SY57_1uM Dose=1uM, (S)-3-(4-Hydroxy-phenyl)-N-methyl-2-[3-(5-thioxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-ureido]-propionamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
GC-46-AX49_0.01uM Dose=0.01uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13
GC-46-AX49_0.1uM Dose=0.1uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13
GC-46-AX49_10uM Dose=10uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13
GC-46-AX49_1uM Dose=1uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13
GC-46-CA74_0.01uM Dose=0.01uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R
GC-46-CA74_10uM Dose=10uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R
GC-46-CA74_1uM Dose=1uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R
GC-49-HD44_0.1uM Dose=0.1uM, Unc0642, EHMT1/2 targeting EHMT2, EHMT1
GC-49-HD44_10uM Dose=10uM, Unc0642, EHMT1/2 targeting EHMT2, EHMT1
GC-49-HD44_1uM Dose=1uM, Unc0642, EHMT1/2 targeting EHMT2, EHMT1
GC-54-IZ89_0.01uM Dose=0.01uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1
GC-54-IZ89_0.1uM Dose=0.1uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1
GC-54-IZ89_10uM Dose=10uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1
GC-54-IZ89_1uM Dose=1uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1
GC-57-HV87_0.01uM Dose=0.01uM
GC-57-HV87_0.1uM Dose=0.1uM
GC-57-HV87_10uM Dose=10uM
GC-57-HV87_1uM Dose=1uM
GC-60-XQ43_0.1uM Dose=0.1uM, Insulin Receptor Antagonists;IGF-1R Inhibitors targeting IGF1R, INSR
GC-60-XQ43_10uM Dose=10uM, Insulin Receptor Antagonists;IGF-1R Inhibitors targeting IGF1R, INSR
GC-60-XQ43_1uM Dose=1uM, Insulin Receptor Antagonists;IGF-1R Inhibitors targeting IGF1R, INSR
GC-61-BD64_0.01uM Dose=0.01uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B
GC-61-BD64_0.1uM Dose=0.1uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B
GC-61-BD64_10uM Dose=10uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B
GC-61-BD64_1uM Dose=1uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B
GC-67-AH43_0.01uM Dose=0.01uM, Biomed 101, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
GC-67-AH43_0.1uM Dose=0.1uM, Biomed 101, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
GC-67-AH43_1uM Dose=1uM, Biomed 101, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
GC-69-JF03_0.01uM Dose=0.01uM
GC-69-JF03_0.1uM Dose=0.1uM
GC-69-JF03_10uM Dose=10uM
GC-69-JF03_1uM Dose=1uM
GC-72-GY67_0.01uM Dose=0.01uM
GC-72-GY67_0.1uM Dose=0.1uM
GC-72-GY67_10uM Dose=10uM
GC-72-GY67_1uM Dose=1uM
GC-73-YI26_0.01uM Dose=0.01uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2
GC-73-YI26_0.1uM Dose=0.1uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2
GC-73-YI26_10uM Dose=10uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2
GC-73-YI26_1uM Dose=1uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2
GC-74-QF56_0.01uM Dose=0.01uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl
GC-74-QF56_0.1uM Dose=0.1uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl
GC-74-QF56_10uM Dose=10uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl
GC-74-QF56_1uM Dose=1uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl
GC-81-IA52_0.01uM Dose=0.01uM, 2-(2-hydroxy-(1,1'-biphenyl)-3-yl)-1H-1,3-benzodiazole-5-carboximidamide, Urokinase (u-PA) Inhibitors;Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting F2, PLAT, PLAU, F10, PLG
GC-81-IA52_10uM Dose=10uM, 2-(2-hydroxy-(1,1'-biphenyl)-3-yl)-1H-1,3-benzodiazole-5-carboximidamide, Urokinase (u-PA) Inhibitors;Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting F2, PLAT, PLAU, F10, PLG
GC-81-IA52_1uM Dose=1uM, 2-(2-hydroxy-(1,1'-biphenyl)-3-yl)-1H-1,3-benzodiazole-5-carboximidamide, Urokinase (u-PA) Inhibitors;Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting F2, PLAT, PLAU, F10, PLG
GC-82-RV65_0.01uM Dose=0.01uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B
GC-82-RV65_0.1uM Dose=0.1uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B
GC-82-RV65_10uM Dose=10uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B
GC-82-RV65_1uM Dose=1uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B
GC-83-NL88_0.01uM Dose=0.01uM, SC-58125, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
GC-83-NL88_10uM Dose=10uM, SC-58125, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
GC-83-NL88_1uM Dose=1uM, SC-58125, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
GC-86-TD91_0.01uM Dose=0.01uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10
GC-86-TD91_0.1uM Dose=0.1uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10
GC-86-TD91_10uM Dose=10uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10
GC-86-TD91_1uM Dose=1uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10
GC-90-GG29_0.01uM Dose=0.01uM, KDM1A (LSD1) inhibitor targeting KDM1A
GC-90-GG29_0.1uM Dose=0.1uM, KDM1A (LSD1) inhibitor targeting KDM1A
GC-90-GG29_10uM Dose=10uM, KDM1A (LSD1) inhibitor targeting KDM1A
GC-90-GG29_1uM Dose=1uM, KDM1A (LSD1) inhibitor targeting KDM1A
GD-07-HO70_0.01uM Dose=0.01uM
GD-07-HO70_0.1uM Dose=0.1uM
GD-07-HO70_10uM Dose=10uM
GD-07-HO70_1uM Dose=1uM
GD-07-UH23_0.01uM Dose=0.01uM, 2-[[2-(4-Propan-2-ylphenoxy)acetyl]amino]benzoic acid, HM74A) Receptor Agonists;GPR109A;Nicotinic Acid (Niacin targeting HCAR2
GD-07-UH23_0.1uM Dose=0.1uM, 2-[[2-(4-Propan-2-ylphenoxy)acetyl]amino]benzoic acid, HM74A) Receptor Agonists;GPR109A;Nicotinic Acid (Niacin targeting HCAR2
GD-07-UH23_10uM Dose=10uM, 2-[[2-(4-Propan-2-ylphenoxy)acetyl]amino]benzoic acid, HM74A) Receptor Agonists;GPR109A;Nicotinic Acid (Niacin targeting HCAR2
GD-07-XY44_0.01uM Dose=0.01uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide
GD-07-XY44_0.1uM Dose=0.1uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide
GD-07-XY44_10uM Dose=10uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide
GD-07-XY44_1uM Dose=1uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide
GD-08-JL45_0.01uM Dose=0.01uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid
GD-08-JL45_0.1uM Dose=0.1uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid
GD-08-JL45_10uM Dose=10uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid
GD-08-JL45_1uM Dose=1uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid
GD-09-QJ83_0.01uM Dose=0.01uM, Lotamilast, PDE4 inhibitor for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D
GD-09-QJ83_10uM Dose=10uM, Lotamilast, PDE4 inhibitor for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D
GD-09-QJ83_1uM Dose=1uM, Lotamilast, PDE4 inhibitor for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D
GD-11-LR18_0.1uM Dose=0.1uM, acyl protein thioesterase 1 inhibitor
GD-17-GR17_0.01uM Dose=0.01uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
GD-17-GR17_0.1uM Dose=0.1uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
GD-17-GR17_1uM Dose=1uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
GD-23-GS20_0.01uM Dose=0.01uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2
GD-23-GS20_0.1uM Dose=0.1uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2
GD-23-GS20_10uM Dose=10uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2
GD-23-GS20_1uM Dose=1uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2
GD-27-UE16_0.01uM Dose=0.01uM, GPR41 agonist-1, GPR41 agonist targeting FFAR3
GD-27-UE16_0.1uM Dose=0.1uM, GPR41 agonist-1, GPR41 agonist targeting FFAR3
GD-27-UE16_10uM Dose=10uM, GPR41 agonist-1, GPR41 agonist targeting FFAR3
GD-33-XB49_0.01uM Dose=0.01uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
GD-33-XB49_0.1uM Dose=0.1uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
GD-33-XB49_10uM Dose=10uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
GD-33-XB49_1uM Dose=1uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
GD-39-YG36_0.01uM Dose=0.01uM, CID 137636547
GD-39-YG36_0.1uM Dose=0.1uM, CID 137636547
GD-39-YG36_10uM Dose=10uM, CID 137636547
GD-39-YG36_1uM Dose=1uM, CID 137636547
GD-41-HR28_0.01uM Dose=0.01uM
GD-41-HR28_0.1uM Dose=0.1uM
GD-41-HR28_10uM Dose=10uM
GD-41-HR28_1uM Dose=1uM
GD-43-TP28_0.01uM Dose=0.01uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2
GD-43-TP28_0.1uM Dose=0.1uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2
GD-43-TP28_10uM Dose=10uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2
GD-43-TP28_1uM Dose=1uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2
GD-46-BU97_0.01uM Dose=0.01uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide
GD-46-BU97_0.1uM Dose=0.1uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide
GD-46-BU97_10uM Dose=10uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide
GD-46-BU97_1uM Dose=1uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide
GD-46-OD81_0.01uM Dose=0.01uM, U 41792
GD-46-OD81_0.1uM Dose=0.1uM, U 41792
GD-46-OD81_10uM Dose=10uM, U 41792
GD-46-OD81_1uM Dose=1uM, U 41792
GD-48-HM23_10uM Dose=10uM, Selonsertib, MAP3K5 inhibitor targeting MAP3K5
GD-51-SU60_0.01uM Dose=0.01uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H
GD-51-SU60_0.1uM Dose=0.1uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H
GD-51-SU60_10uM Dose=10uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H
GD-51-SU60_1uM Dose=1uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H
GD-56-YA39_0.01uM Dose=0.01uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1
GD-56-YA39_0.1uM Dose=0.1uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1
GD-56-YA39_10uM Dose=10uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1
GD-56-YA39_1uM Dose=1uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1
GD-59-OG21_0.01uM Dose=0.01uM, Stavudine
GD-59-OG21_0.1uM Dose=0.1uM, Stavudine
GD-59-OG21_10uM Dose=10uM, Stavudine
GD-59-OG21_1uM Dose=1uM, Stavudine
GD-59-QF63_0.01uM Dose=0.01uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR
GD-59-QF63_0.1uM Dose=0.1uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR
GD-59-QF63_10uM Dose=10uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR
GD-59-QF63_1uM Dose=1uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR
GD-63-XB79_0.01uM Dose=0.01uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
GD-63-XB79_0.1uM Dose=0.1uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
GD-63-XB79_10uM Dose=10uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
GD-63-XB79_1uM Dose=1uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
GD-66-LN30_0.01uM Dose=0.01uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A
GD-66-LN30_0.1uM Dose=0.1uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A
GD-66-LN30_10uM Dose=10uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A
GD-66-LN30_1uM Dose=1uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A
GD-66-XE49_0.01uM Dose=0.01uM
GD-66-XE49_0.1uM Dose=0.1uM
GD-66-XE49_10uM Dose=10uM
GD-66-XE49_1uM Dose=1uM
GD-69-GP37_0.01uM Dose=0.01uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
GD-69-GP37_0.1uM Dose=0.1uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
GD-69-GP37_10uM Dose=10uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
GD-69-GP37_1uM Dose=1uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1
GD-69-KC91_0.01uM Dose=0.01uM, Bleomycin
GD-69-KC91_0.1uM Dose=0.1uM, Bleomycin
GD-69-KC91_10uM Dose=10uM, Bleomycin
GD-69-KC91_1uM Dose=1uM, Bleomycin
GD-70-NJ06_0.01uM Dose=0.01uM, (2S)-2-[[2-(furan-2-ylmethyl)-1-[(1R,2R)-2-methylcyclohexyl]benzimidazole-5-carbonyl]amino]-4-methylpentanoic acid, Apelin receptor agonist targeting APLNR
GD-70-NJ06_0.1uM Dose=0.1uM, (2S)-2-[[2-(furan-2-ylmethyl)-1-[(1R,2R)-2-methylcyclohexyl]benzimidazole-5-carbonyl]amino]-4-methylpentanoic acid, Apelin receptor agonist targeting APLNR
GD-70-NJ06_10uM Dose=10uM, (2S)-2-[[2-(furan-2-ylmethyl)-1-[(1R,2R)-2-methylcyclohexyl]benzimidazole-5-carbonyl]amino]-4-methylpentanoic acid, Apelin receptor agonist targeting APLNR
GD-70-NJ06_1uM Dose=1uM, (2S)-2-[[2-(furan-2-ylmethyl)-1-[(1R,2R)-2-methylcyclohexyl]benzimidazole-5-carbonyl]amino]-4-methylpentanoic acid, Apelin receptor agonist targeting APLNR
GD-71-OU80_0.01uM Dose=0.01uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
GD-71-OU80_0.1uM Dose=0.1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
GD-71-OU80_10uM Dose=10uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
GD-71-OU80_1uM Dose=1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
GD-72-XO18_0.01uM Dose=0.01uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2
GD-72-XO18_0.1uM Dose=0.1uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2
GD-72-XO18_10uM Dose=10uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2
GD-72-XO18_1uM Dose=1uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2
GD-73-ZF64_0.01uM Dose=0.01uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9
GD-73-ZF64_0.1uM Dose=0.1uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9
GD-73-ZF64_10uM Dose=10uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9
GD-73-ZF64_1uM Dose=1uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9
GD-79-JJ38_0.01uM Dose=0.01uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5
GD-79-JJ38_0.1uM Dose=0.1uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5
GD-79-JJ38_10uM Dose=10uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5
GD-79-JJ38_1uM Dose=1uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5
GD-79-TW34_0.1uM Dose=0.1uM, N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide, SIRT1;Histone Deacetylase SIRT1 Activators targeting SIRT1
GD-79-TW34_10uM Dose=10uM, N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide, SIRT1;Histone Deacetylase SIRT1 Activators targeting SIRT1
GD-79-TW34_1uM Dose=1uM, N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide, SIRT1;Histone Deacetylase SIRT1 Activators targeting SIRT1
GD-82-CS38_0.01uM Dose=0.01uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2
GD-82-CS38_0.1uM Dose=0.1uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2
GD-82-CS38_10uM Dose=10uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2
GD-82-CS38_1uM Dose=1uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2
GD-85-ST07_0.01uM Dose=0.01uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))-
GD-85-ST07_0.1uM Dose=0.1uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))-
GD-85-ST07_10uM Dose=10uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))-
GD-85-ST07_1uM Dose=1uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))-
GD-90-RA90_0.01uM Dose=0.01uM, SIS3 free base targeting SMAD3
GD-90-RA90_0.1uM Dose=0.1uM, SIS3 free base targeting SMAD3
GD-90-RA90_10uM Dose=10uM, SIS3 free base targeting SMAD3
GD-90-RA90_1uM Dose=1uM, SIS3 free base targeting SMAD3
GD-96-AK08_0.01uM Dose=0.01uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
GD-96-AK08_0.1uM Dose=0.1uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
GD-96-AK08_10uM Dose=10uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
GD-96-AK08_1uM Dose=1uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
GD-98-WZ24_0.01uM Dose=0.01uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35
GD-98-WZ24_0.1uM Dose=0.1uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35
GD-98-WZ24_10uM Dose=10uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35
GD-98-WZ24_1uM Dose=1uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35
GE-01-QX17_0.01uM Dose=0.01uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2
GE-01-QX17_0.1uM Dose=0.1uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2
GE-01-QX17_10uM Dose=10uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2
GE-01-QX17_1uM Dose=1uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2
GE-06-JX14_0.01uM Dose=0.01uM, (4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-Acetamido-3-(4-nitrophenyl)propanoyl]amino]-10-(4-aminobutyl)-N-[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, SSTR2 antagonist targeting SSTR2
GE-06-JX14_0.1uM Dose=0.1uM, (4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-Acetamido-3-(4-nitrophenyl)propanoyl]amino]-10-(4-aminobutyl)-N-[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, SSTR2 antagonist targeting SSTR2
GE-06-JX14_10uM Dose=10uM, (4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-Acetamido-3-(4-nitrophenyl)propanoyl]amino]-10-(4-aminobutyl)-N-[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, SSTR2 antagonist targeting SSTR2
GE-06-JX14_1uM Dose=1uM, (4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-Acetamido-3-(4-nitrophenyl)propanoyl]amino]-10-(4-aminobutyl)-N-[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, SSTR2 antagonist targeting SSTR2
GE-11-ZR43_0.01uM Dose=0.01uM
GE-11-ZR43_10uM Dose=10uM
GE-13-TV02_0.01uM Dose=0.01uM, 4-Phenylbutylamine, Semicarbazide-Sensitive Amine Oxidase (SSAO| VAP-1) Inhibitors targeting AOC3
GE-13-TV02_0.1uM Dose=0.1uM, 4-Phenylbutylamine, Semicarbazide-Sensitive Amine Oxidase (SSAO| VAP-1) Inhibitors targeting AOC3
GE-13-TV02_10uM Dose=10uM, 4-Phenylbutylamine, Semicarbazide-Sensitive Amine Oxidase (SSAO| VAP-1) Inhibitors targeting AOC3
GE-13-TV02_1uM Dose=1uM, 4-Phenylbutylamine, Semicarbazide-Sensitive Amine Oxidase (SSAO| VAP-1) Inhibitors targeting AOC3
GE-14-EF51_0.01uM Dose=0.01uM, LL-Z1272.Episilon. targeting FNTB
GE-14-EF51_0.1uM Dose=0.1uM, LL-Z1272.Episilon. targeting FNTB
GE-14-EF51_10uM Dose=10uM, LL-Z1272.Episilon. targeting FNTB
GE-14-EF51_1uM Dose=1uM, LL-Z1272.Episilon. targeting FNTB
GE-17-FE71_0.01uM Dose=0.01uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR
GE-17-FE71_0.1uM Dose=0.1uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR
GE-17-FE71_10uM Dose=10uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR
GE-17-FE71_1uM Dose=1uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR
GE-17-WR07_0.01uM Dose=0.01uM, N-(5-(5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)pentanoyl)-2,4-dimethoxyphenyl)-4-(trifluoromethyl)benzenesulfonamide, HTR2C antagonist;5-HT2C Antagonists targeting HTR2C
GE-17-WR07_10uM Dose=10uM, N-(5-(5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)pentanoyl)-2,4-dimethoxyphenyl)-4-(trifluoromethyl)benzenesulfonamide, HTR2C antagonist;5-HT2C Antagonists targeting HTR2C
GE-17-WR07_1uM Dose=1uM, N-(5-(5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)pentanoyl)-2,4-dimethoxyphenyl)-4-(trifluoromethyl)benzenesulfonamide, HTR2C antagonist;5-HT2C Antagonists targeting HTR2C
GE-22-ME44_0.01uM Dose=0.01uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2
GE-22-ME44_0.1uM Dose=0.1uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2
GE-22-ME44_10uM Dose=10uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2
GE-22-ME44_1uM Dose=1uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2
GE-25-DQ65_0.01uM Dose=0.01uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2
GE-25-DQ65_0.1uM Dose=0.1uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2
GE-25-DQ65_10uM Dose=10uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2
GE-25-DQ65_1uM Dose=1uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2
GE-25-YQ75_0.01uM Dose=0.01uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2
GE-25-YQ75_0.1uM Dose=0.1uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2
GE-25-YQ75_10uM Dose=10uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2
GE-25-YQ75_1uM Dose=1uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2
GE-26-BO33_0.01uM Dose=0.01uM, USP7/USP47 inhibitor targeting USP7
GE-26-BO33_0.1uM Dose=0.1uM, USP7/USP47 inhibitor targeting USP7
GE-26-BO33_10uM Dose=10uM, USP7/USP47 inhibitor targeting USP7
GE-26-BO33_1uM Dose=1uM, USP7/USP47 inhibitor targeting USP7
GE-28-EL65_0.01uM Dose=0.01uM, 3-O-Methyldopa, DL-
GE-28-EL65_0.1uM Dose=0.1uM, 3-O-Methyldopa, DL-
GE-28-EL65_10uM Dose=10uM, 3-O-Methyldopa, DL-
GE-28-EL65_1uM Dose=1uM, 3-O-Methyldopa, DL-
GE-29-BW04_0.01uM Dose=0.01uM, Evenamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers targeting SCN3A, SCN9A, SCN10A
GE-29-BW04_0.1uM Dose=0.1uM, Evenamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers targeting SCN3A, SCN9A, SCN10A
GE-29-BW04_10uM Dose=10uM, Evenamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers targeting SCN3A, SCN9A, SCN10A
GE-29-BW54_0.01uM Dose=0.01uM, 6-[[acetyl(methyl)amino]methyl]-N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, ATP competitive inhibitor targeting FGFR4
GE-29-BW54_0.1uM Dose=0.1uM, 6-[[acetyl(methyl)amino]methyl]-N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, ATP competitive inhibitor targeting FGFR4
GE-29-BW54_10uM Dose=10uM, 6-[[acetyl(methyl)amino]methyl]-N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, ATP competitive inhibitor targeting FGFR4
GE-29-BW54_1uM Dose=1uM, 6-[[acetyl(methyl)amino]methyl]-N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, ATP competitive inhibitor targeting FGFR4
GE-29-ZM45_0.01uM Dose=0.01uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK
GE-29-ZM45_0.1uM Dose=0.1uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK
GE-29-ZM45_10uM Dose=10uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK
GE-29-ZM45_1uM Dose=1uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK
GE-32-JR10_0.01uM Dose=0.01uM, 3-Phenylpropylamine
GE-32-JR10_0.1uM Dose=0.1uM, 3-Phenylpropylamine
GE-32-JR10_10uM Dose=10uM, 3-Phenylpropylamine
GE-32-JR10_1uM Dose=1uM, 3-Phenylpropylamine
GE-34-TW62_0.01uM Dose=0.01uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF
GE-34-TW62_0.1uM Dose=0.1uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF
GE-34-TW62_10uM Dose=10uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF
GE-34-TW62_1uM Dose=1uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF
GE-40-GQ38_0.01uM Dose=0.01uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE
GE-40-GQ38_0.1uM Dose=0.1uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE
GE-40-GQ38_10uM Dose=10uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE
GE-40-GQ38_1uM Dose=1uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE
GE-40-VJ66_0.01uM Dose=0.01uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2
GE-40-VJ66_0.1uM Dose=0.1uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2
GE-40-VJ66_10uM Dose=10uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2
GE-40-VJ66_1uM Dose=1uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2
GE-44-AZ94_0.01uM Dose=0.01uM, 4-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-benzoic acid
GE-44-AZ94_0.1uM Dose=0.1uM, 4-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-benzoic acid
GE-44-AZ94_1uM Dose=1uM, 4-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-benzoic acid
GE-47-OO30_0.01uM Dose=0.01uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3
GE-47-OO30_0.1uM Dose=0.1uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3
GE-47-OO30_10uM Dose=10uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3
GE-47-OO30_1uM Dose=1uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3
GE-53-SM76_0.01uM Dose=0.01uM
GE-53-SM76_0.1uM Dose=0.1uM
GE-53-SM76_10uM Dose=10uM
GE-53-SM76_1uM Dose=1uM
GE-54-IF41_0.01uM Dose=0.01uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3
GE-54-IF41_0.1uM Dose=0.1uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3
GE-54-IF41_10uM Dose=10uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3
GE-54-IF41_1uM Dose=1uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3
GE-58-RW27_0.01uM Dose=0.01uM, Fomepizole
GE-58-RW27_0.1uM Dose=0.1uM, Fomepizole
GE-58-RW27_10uM Dose=10uM, Fomepizole
GE-58-RW27_1uM Dose=1uM, Fomepizole
GE-63-WI86_0.01uM Dose=0.01uM, Nesbuvir
GE-63-WI86_0.1uM Dose=0.1uM, Nesbuvir
GE-63-WI86_10uM Dose=10uM, Nesbuvir
GE-63-WI86_1uM Dose=1uM, Nesbuvir
GE-68-FZ64_0.01uM Dose=0.01uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA
GE-68-FZ64_0.1uM Dose=0.1uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA
GE-68-FZ64_10uM Dose=10uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA
GE-72-PR35_0.01uM Dose=0.01uM
GE-72-PR35_0.1uM Dose=0.1uM
GE-72-PR35_10uM Dose=10uM
GE-72-PR35_1uM Dose=1uM
GE-74-KC09_0.01uM Dose=0.01uM, Sdz isq 844, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors;Nucleoside-Diphosphate Kinase Inhibitors targeting PDE2A, NME1, NME2
GE-74-KC09_0.1uM Dose=0.1uM, Sdz isq 844, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors;Nucleoside-Diphosphate Kinase Inhibitors targeting PDE2A, NME1, NME2
GE-74-KC09_10uM Dose=10uM, Sdz isq 844, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors;Nucleoside-Diphosphate Kinase Inhibitors targeting PDE2A, NME1, NME2
GE-74-KC09_1uM Dose=1uM, Sdz isq 844, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors;Nucleoside-Diphosphate Kinase Inhibitors targeting PDE2A, NME1, NME2
GE-77-CO40_0.1uM Dose=0.1uM, CHRM2 agonist;CHRM3 agonist;CHRM4 agonist;CHRM5 agonist
GE-77-CO40_10uM Dose=10uM, CHRM2 agonist;CHRM3 agonist;CHRM4 agonist;CHRM5 agonist
GE-77-CO40_1uM Dose=1uM, CHRM2 agonist;CHRM3 agonist;CHRM4 agonist;CHRM5 agonist
GE-77-FY84_0.01uM Dose=0.01uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate
GE-77-FY84_0.1uM Dose=0.1uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate
GE-77-FY84_10uM Dose=10uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate
GE-77-FY84_1uM Dose=1uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate
GE-77-IH08_0.01uM Dose=0.01uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine
GE-77-IH08_0.1uM Dose=0.1uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine
GE-77-IH08_10uM Dose=10uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine
GE-77-IH08_1uM Dose=1uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine
GE-84-SM43_0.01uM Dose=0.01uM, 2-[8-(2-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]acetic acid methyl ester, OPRL1 agonist targeting OPRL1
GE-84-SM43_0.1uM Dose=0.1uM, 2-[8-(2-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]acetic acid methyl ester, OPRL1 agonist targeting OPRL1
GE-84-SM43_10uM Dose=10uM, 2-[8-(2-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]acetic acid methyl ester, OPRL1 agonist targeting OPRL1
GE-84-SM43_1uM Dose=1uM, 2-[8-(2-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]acetic acid methyl ester, OPRL1 agonist targeting OPRL1
GE-84-VZ24_0.01uM Dose=0.01uM, 8-[5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chroman-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one, Phospholipase A2 (PLA2) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PLA2G10
GE-84-VZ24_0.1uM Dose=0.1uM, 8-[5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chroman-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one, Phospholipase A2 (PLA2) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PLA2G10
GE-84-VZ24_1uM Dose=1uM, 8-[5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chroman-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one, Phospholipase A2 (PLA2) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PLA2G10
GE-97-UL88_0.01uM Dose=0.01uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide
GE-97-UL88_0.1uM Dose=0.1uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide
GE-97-UL88_10uM Dose=10uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide
GE-97-UL88_1uM Dose=1uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide
GE-98-ZI68_0.01uM Dose=0.01uM
GE-98-ZI68_0.1uM Dose=0.1uM
GE-98-ZI68_10uM Dose=10uM
GE-98-ZI68_1uM Dose=1uM
GF-02-ER50_0.01uM Dose=0.01uM, Ethane-1,2-diyl dicarbamimidothioate
GF-02-ER50_0.1uM Dose=0.1uM, Ethane-1,2-diyl dicarbamimidothioate
GF-02-ER50_10uM Dose=10uM, Ethane-1,2-diyl dicarbamimidothioate
GF-02-ER50_1uM Dose=1uM, Ethane-1,2-diyl dicarbamimidothioate
GF-03-HI41_0.01uM Dose=0.01uM, RS 39604, HTR4 antagonist targeting HTR4
GF-03-HI41_0.1uM Dose=0.1uM, RS 39604, HTR4 antagonist targeting HTR4
GF-03-HI41_10uM Dose=10uM, RS 39604, HTR4 antagonist targeting HTR4
GF-03-HI41_1uM Dose=1uM, RS 39604, HTR4 antagonist targeting HTR4
GF-05-GQ05_0.01uM Dose=0.01uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1
GF-05-GQ05_0.1uM Dose=0.1uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1
GF-05-GQ05_10uM Dose=10uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1
GF-05-GQ05_1uM Dose=1uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1
GF-14-RF56_0.01uM Dose=0.01uM
GF-14-RF56_10uM Dose=10uM
GF-14-RF56_1uM Dose=1uM
GF-15-LT47_0.01uM Dose=0.01uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3
GF-15-LT47_0.1uM Dose=0.1uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3
GF-15-LT47_10uM Dose=10uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3
GF-15-LT47_1uM Dose=1uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3
GF-16-AN80_0.01uM Dose=0.01uM, 8-(3,5-Dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine, inhibitor of Grp94 targeting HSP90B1
GF-16-AN80_0.1uM Dose=0.1uM, 8-(3,5-Dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine, inhibitor of Grp94 targeting HSP90B1
GF-16-AN80_10uM Dose=10uM, 8-(3,5-Dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine, inhibitor of Grp94 targeting HSP90B1
GF-16-RR50_0.01uM Dose=0.01uM, Gsk484, PAD4 (Protein-arginine deiminase type-4) substrate competitive reversible inhibitor targeting PADI4
GF-16-RR50_0.1uM Dose=0.1uM, Gsk484, PAD4 (Protein-arginine deiminase type-4) substrate competitive reversible inhibitor targeting PADI4
GF-16-RR50_10uM Dose=10uM, Gsk484, PAD4 (Protein-arginine deiminase type-4) substrate competitive reversible inhibitor targeting PADI4
GF-19-NZ91_0.01uM Dose=0.01uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
GF-19-NZ91_0.1uM Dose=0.1uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
GF-19-NZ91_10uM Dose=10uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
GF-19-NZ91_1uM Dose=1uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME
GF-19-OF53_0.01uM Dose=0.01uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5
GF-19-OF53_0.1uM Dose=0.1uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5
GF-19-OF53_10uM Dose=10uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5
GF-19-OF53_1uM Dose=1uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5
GF-32-FY02_0.01uM Dose=0.01uM
GF-32-FY02_0.1uM Dose=0.1uM
GF-32-FY02_10uM Dose=10uM
GF-32-FY02_1uM Dose=1uM
GF-35-IT27_0.01uM Dose=0.01uM
GF-35-IT27_0.1uM Dose=0.1uM
GF-35-IT27_10uM Dose=10uM
GF-35-IT27_1uM Dose=1uM
GF-37-MB64_0.01uM Dose=0.01uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA
GF-37-MB64_0.1uM Dose=0.1uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA
GF-37-MB64_10uM Dose=10uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA
GF-37-MB64_1uM Dose=1uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA
GF-46-FA29_0.01uM Dose=0.01uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2
GF-46-FA29_0.1uM Dose=0.1uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2
GF-46-FA29_10uM Dose=10uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2
GF-46-FA29_1uM Dose=1uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2
GF-46-LK68_0.01uM Dose=0.01uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2
GF-46-LK68_0.1uM Dose=0.1uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2
GF-46-LK68_10uM Dose=10uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2
GF-46-LK68_1uM Dose=1uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2
GF-53-OL28_0.01uM Dose=0.01uM, Factor VII-IN-1, Coagulation Factor VIIa Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F7
GF-53-OL28_0.1uM Dose=0.1uM, Factor VII-IN-1, Coagulation Factor VIIa Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F7
GF-53-OL28_10uM Dose=10uM, Factor VII-IN-1, Coagulation Factor VIIa Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F7
GF-53-OL28_1uM Dose=1uM, Factor VII-IN-1, Coagulation Factor VIIa Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F7
GF-57-LR72_0.01uM Dose=0.01uM, Napsagatran, Known Thrombin inhibitor targeting F2
GF-57-LR72_0.1uM Dose=0.1uM, Napsagatran, Known Thrombin inhibitor targeting F2
GF-57-LR72_10uM Dose=10uM, Napsagatran, Known Thrombin inhibitor targeting F2
GF-57-LR72_1uM Dose=1uM, Napsagatran, Known Thrombin inhibitor targeting F2
GF-57-MY04_0.01uM Dose=0.01uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB
GF-57-MY04_0.1uM Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB
GF-57-MY04_10uM Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB
GF-57-MY04_1uM Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB
GF-58-OL90_0.01uM Dose=0.01uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2
GF-58-OL90_0.1uM Dose=0.1uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2
GF-58-OL90_10uM Dose=10uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2
GF-58-OL90_1uM Dose=1uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2
GF-67-HH28_0.01uM Dose=0.01uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2
GF-67-HH28_0.1uM Dose=0.1uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2
GF-67-HH28_10uM Dose=10uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2
GF-67-HH28_1uM Dose=1uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2
GF-72-OO48_0.01uM Dose=0.01uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
GF-72-OO48_0.1uM Dose=0.1uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
GF-72-OO48_10uM Dose=10uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
GF-72-OO48_1uM Dose=1uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
GF-73-HI61_0.01uM Dose=0.01uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
GF-73-HI61_0.1uM Dose=0.1uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
GF-73-HI61_10uM Dose=10uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
GF-73-HI61_1uM Dose=1uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
GF-81-MU70_0.01uM Dose=0.01uM, Betahistine, Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists targeting HRH1, HRH3
GF-81-MU70_0.1uM Dose=0.1uM, Betahistine, Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists targeting HRH1, HRH3
GF-81-MU70_1uM Dose=1uM, Betahistine, Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists targeting HRH1, HRH3
GF-84-NF76_0.01uM Dose=0.01uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1
GF-84-NF76_0.1uM Dose=0.1uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1
GF-84-NF76_10uM Dose=10uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1
GF-84-NF76_1uM Dose=1uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1
GF-90-DG49_0.01uM Dose=0.01uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11
GF-90-DG49_0.1uM Dose=0.1uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11
GF-90-DG49_10uM Dose=10uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11
GF-90-DG49_1uM Dose=1uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11
GF-92-IR00_0.01uM Dose=0.01uM, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1
GF-92-IR00_0.1uM Dose=0.1uM, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1
GF-92-IR00_10uM Dose=10uM, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1
GF-93-DV47_0.01uM Dose=0.01uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1
GF-93-DV47_0.1uM Dose=0.1uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1
GF-93-DV47_10uM Dose=10uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1
GF-93-DV47_1uM Dose=1uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1
GF-98-RS57_0.1uM Dose=0.1uM, Cilastatin, Dehydropeptidase I Inhibitors targeting DPEP1
GF-98-RS57_10uM Dose=10uM, Cilastatin, Dehydropeptidase I Inhibitors targeting DPEP1
GF-98-RS57_1uM Dose=1uM, Cilastatin, Dehydropeptidase I Inhibitors targeting DPEP1
HA-03-TL98_0.01uM Dose=0.01uM, Ornithine Decarboxylase Inhibitors;Antimetabolites targeting ODC1
HA-03-TL98_10uM Dose=10uM, Ornithine Decarboxylase Inhibitors;Antimetabolites targeting ODC1
HA-03-TL98_1uM Dose=1uM, Ornithine Decarboxylase Inhibitors;Antimetabolites targeting ODC1
HA-08-IL05_0.01uM Dose=0.01uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
HA-08-IL05_10uM Dose=10uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
HA-08-IL05_1uM Dose=1uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
HA-10-LJ21_0.01uM Dose=0.01uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88
HA-10-LJ21_0.1uM Dose=0.1uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88
HA-10-LJ21_10uM Dose=10uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88
HA-10-LJ21_1uM Dose=1uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88
HA-17-MS45_0.01uM Dose=0.01uM, Sb 225002, CXCR2 antagonist targeting CXCR2
HA-17-MS45_0.1uM Dose=0.1uM, Sb 225002, CXCR2 antagonist targeting CXCR2
HA-17-MS45_10uM Dose=10uM, Sb 225002, CXCR2 antagonist targeting CXCR2
HA-17-MS45_1uM Dose=1uM, Sb 225002, CXCR2 antagonist targeting CXCR2
HA-21-ND29_0.01uM Dose=0.01uM
HA-21-ND29_0.1uM Dose=0.1uM
HA-21-ND29_10uM Dose=10uM
HA-21-ND29_1uM Dose=1uM
HA-22-CY42_0.01uM Dose=0.01uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD
HA-22-CY42_0.1uM Dose=0.1uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD
HA-22-CY42_10uM Dose=10uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD
HA-22-CY42_1uM Dose=1uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD
HA-22-YE24_0.01uM Dose=0.01uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR
HA-22-YE24_0.1uM Dose=0.1uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR
HA-22-YE24_10uM Dose=10uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR
HA-22-YE24_1uM Dose=1uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR
HA-27-FV67_0.01uM Dose=0.01uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4
HA-27-FV67_0.1uM Dose=0.1uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4
HA-27-FV67_10uM Dose=10uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4
HA-27-FV67_1uM Dose=1uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4
HA-29-PM90_0.01uM Dose=0.01uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR
HA-29-PM90_0.1uM Dose=0.1uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR
HA-29-PM90_10uM Dose=10uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR
HA-29-PM90_1uM Dose=1uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR
HA-29-ZM35_0.01uM Dose=0.01uM
HA-29-ZM35_0.1uM Dose=0.1uM
HA-29-ZM35_10uM Dose=10uM
HA-29-ZM35_1uM Dose=1uM
HA-30-KD77_0.01uM Dose=0.01uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2
HA-30-KD77_0.1uM Dose=0.1uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2
HA-30-KD77_10uM Dose=10uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2
HA-30-KD77_1uM Dose=1uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2
HA-32-YH61_0.01uM Dose=0.01uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP
HA-32-YH61_0.1uM Dose=0.1uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP
HA-32-YH61_10uM Dose=10uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP
HA-32-YH61_1uM Dose=1uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP
HA-33-ZI46_0.01uM Dose=0.01uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
HA-33-ZI46_10uM Dose=10uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
HA-33-ZI46_1uM Dose=1uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
HA-36-JX64_0.01uM Dose=0.01uM, 4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzo[4,5]-cyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid
HA-36-JX64_0.1uM Dose=0.1uM, 4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzo[4,5]-cyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid
HA-36-JX64_1uM Dose=1uM, 4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzo[4,5]-cyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid
HA-36-VD41_0.01uM Dose=0.01uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9
HA-36-VD41_0.1uM Dose=0.1uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9
HA-36-VD41_10uM Dose=10uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9
HA-36-VD41_1uM Dose=1uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9
HA-38-ML65_0.01uM Dose=0.01uM
HA-38-ML65_0.1uM Dose=0.1uM
HA-38-ML65_10uM Dose=10uM
HA-38-ML65_1uM Dose=1uM
HA-40-OT25_0.01uM Dose=0.01uM, 11-Deoxy-PGE1 targeting PTGER2
HA-40-OT25_10uM Dose=10uM, 11-Deoxy-PGE1 targeting PTGER2
HA-42-TE64_0.01uM Dose=0.01uM, Herbacetin, ODC1 gene inhibitor targeting ODC1
HA-42-TE64_0.1uM Dose=0.1uM, Herbacetin, ODC1 gene inhibitor targeting ODC1
HA-42-TE64_10uM Dose=10uM, Herbacetin, ODC1 gene inhibitor targeting ODC1
HA-42-TE64_1uM Dose=1uM, Herbacetin, ODC1 gene inhibitor targeting ODC1
HA-48-LV39_0.01uM Dose=0.01uM, Allocryptopine
HA-48-LV39_0.1uM Dose=0.1uM, Allocryptopine
HA-48-LV39_10uM Dose=10uM, Allocryptopine
HA-48-LV39_1uM Dose=1uM, Allocryptopine
HA-50-AT10_0.01uM Dose=0.01uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2
HA-50-AT10_0.1uM Dose=0.1uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2
HA-50-AT10_10uM Dose=10uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2
HA-50-AT10_1uM Dose=1uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2
HA-51-DA67_0.01uM Dose=0.01uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR
HA-51-DA67_0.1uM Dose=0.1uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR
HA-51-DA67_10uM Dose=10uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR
HA-51-DA67_1uM Dose=1uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR
HA-53-FL63_0.01uM Dose=0.01uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB
HA-53-FL63_0.1uM Dose=0.1uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB
HA-53-FL63_10uM Dose=10uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB
HA-57-XH23_0.01uM Dose=0.01uM
HA-57-XH23_0.1uM Dose=0.1uM
HA-57-XH23_10uM Dose=10uM
HA-57-XH23_1uM Dose=1uM
HA-64-OZ89_0.01uM Dose=0.01uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
HA-64-OZ89_0.1uM Dose=0.1uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
HA-64-OZ89_10uM Dose=10uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
HA-64-OZ89_1uM Dose=1uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
HA-72-NR60_0.01uM Dose=0.01uM
HA-72-NR60_0.1uM Dose=0.1uM
HA-72-NR60_10uM Dose=10uM
HA-72-NR60_1uM Dose=1uM
HA-75-LT22_0.01uM Dose=0.01uM, Rg-4733, Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors targeting PSEN1
HA-75-LT22_0.1uM Dose=0.1uM, Rg-4733, Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors targeting PSEN1
HA-75-LT22_10uM Dose=10uM, Rg-4733, Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors targeting PSEN1
HA-75-LT22_1uM Dose=1uM, Rg-4733, Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors targeting PSEN1
HA-81-VN33_0.01uM Dose=0.01uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4
HA-81-VN33_0.1uM Dose=0.1uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4
HA-81-VN33_10uM Dose=10uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4
HA-81-VN33_1uM Dose=1uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4
HA-82-OO58_0.01uM Dose=0.01uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB
HA-82-OO58_0.1uM Dose=0.1uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB
HA-82-OO58_10uM Dose=10uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB
HA-82-OO58_1uM Dose=1uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB
HA-82-XO48_0.01uM Dose=0.01uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK
HA-82-XO48_10uM Dose=10uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK
HA-82-XO48_1uM Dose=1uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK
HA-83-HZ77_0.01uM Dose=0.01uM, Cytisinicline, Nicotinic alpha4beta2 Partial Agonists targeting CHRNA1, CHRNA3, CHRNA4, CHRNB1, CHRNB2, CHRNB4, CHRND, CHRNG
HA-83-HZ77_0.1uM Dose=0.1uM, Cytisinicline, Nicotinic alpha4beta2 Partial Agonists targeting CHRNA1, CHRNA3, CHRNA4, CHRNB1, CHRNB2, CHRNB4, CHRND, CHRNG
HA-83-HZ77_10uM Dose=10uM, Cytisinicline, Nicotinic alpha4beta2 Partial Agonists targeting CHRNA1, CHRNA3, CHRNA4, CHRNB1, CHRNB2, CHRNB4, CHRND, CHRNG
HA-83-HZ77_1uM Dose=1uM, Cytisinicline, Nicotinic alpha4beta2 Partial Agonists targeting CHRNA1, CHRNA3, CHRNA4, CHRNB1, CHRNB2, CHRNB4, CHRND, CHRNG
HA-83-MI31_0.01uM Dose=0.01uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2
HA-83-MI31_0.1uM Dose=0.1uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2
HA-83-MI31_10uM Dose=10uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2
HA-83-MI31_1uM Dose=1uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2
HA-88-EI28_0.01uM Dose=0.01uM
HA-88-EI28_0.1uM Dose=0.1uM
HA-88-EI28_10uM Dose=10uM
HA-88-EI28_1uM Dose=1uM
HA-88-JB21_0.1uM Dose=0.1uM, 1,5-Dihydroxyisoquinoline, PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
HA-88-JB21_10uM Dose=10uM, 1,5-Dihydroxyisoquinoline, PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
HA-99-PM50_0.01uM Dose=0.01uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide
HA-99-PM50_0.1uM Dose=0.1uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide
HA-99-PM50_10uM Dose=10uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide
HA-99-PM50_1uM Dose=1uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide
HA-99-UT82_0.01uM Dose=0.01uM
HA-99-UT82_0.1uM Dose=0.1uM
HA-99-UT82_10uM Dose=10uM
HA-99-UT82_1uM Dose=1uM
HB-01-ZU75_0.01uM Dose=0.01uM
HB-01-ZU75_0.1uM Dose=0.1uM
HB-01-ZU75_10uM Dose=10uM
HB-01-ZU75_1uM Dose=1uM
HB-03-JZ32_0.01uM Dose=0.01uM, 4-{[{[Amino(imino)methyl]amino}(imino)methyl]amino}-2-chloro-1-methylbenzene, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
HB-03-JZ32_10uM Dose=10uM, 4-{[{[Amino(imino)methyl]amino}(imino)methyl]amino}-2-chloro-1-methylbenzene, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
HB-06-WU12_0.01uM Dose=0.01uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1
HB-06-WU12_0.1uM Dose=0.1uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1
HB-06-WU12_10uM Dose=10uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1
HB-06-WU12_1uM Dose=1uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1
HB-09-NP07_0.01uM Dose=0.01uM, 4-(Cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK inhibitors targeting CCND2, CCND3
HB-09-NP07_0.1uM Dose=0.1uM, 4-(Cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK inhibitors targeting CCND2, CCND3
HB-09-OC16_0.01uM Dose=0.01uM
HB-09-OC16_0.1uM Dose=0.1uM
HB-09-OC16_10uM Dose=10uM
HB-09-OC16_1uM Dose=1uM
HB-09-RP77_0.01uM Dose=0.01uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D
HB-09-RP77_0.1uM Dose=0.1uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D
HB-09-RP77_10uM Dose=10uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D
HB-09-RP77_1uM Dose=1uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D
HB-13-XB94_0.01uM Dose=0.01uM, Basimglurant, MGLUR5 NAM targeting GRM5
HB-13-XB94_0.1uM Dose=0.1uM, Basimglurant, MGLUR5 NAM targeting GRM5
HB-13-XB94_10uM Dose=10uM, Basimglurant, MGLUR5 NAM targeting GRM5
HB-13-XB94_1uM Dose=1uM, Basimglurant, MGLUR5 NAM targeting GRM5
HB-16-NO83_0.01uM Dose=0.01uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S
HB-16-NO83_0.1uM Dose=0.1uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S
HB-16-NO83_10uM Dose=10uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S
HB-16-NO83_1uM Dose=1uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S
HB-19-DP22_0.01uM Dose=0.01uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1
HB-19-DP22_0.1uM Dose=0.1uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1
HB-19-DP22_10uM Dose=10uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1
HB-19-DP22_1uM Dose=1uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1
HB-19-OF33_0.01uM Dose=0.01uM, N-[5-Chloro-2-[(1E)-3-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-3-oxo-1-propen-1-YL]phenyl]-acetamide, Chemokine CCR1 Antagonists targeting CCR1
HB-19-OF33_0.1uM Dose=0.1uM, N-[5-Chloro-2-[(1E)-3-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-3-oxo-1-propen-1-YL]phenyl]-acetamide, Chemokine CCR1 Antagonists targeting CCR1
HB-19-OF33_1uM Dose=1uM, N-[5-Chloro-2-[(1E)-3-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-3-oxo-1-propen-1-YL]phenyl]-acetamide, Chemokine CCR1 Antagonists targeting CCR1
HB-24-AP80_0.01uM Dose=0.01uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine
HB-24-AP80_0.1uM Dose=0.1uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine
HB-24-AP80_10uM Dose=10uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine
HB-24-AP80_1uM Dose=1uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine
HB-24-GP45_0.01uM Dose=0.01uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D
HB-24-GP45_0.1uM Dose=0.1uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D
HB-24-GP45_10uM Dose=10uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D
HB-24-GP45_1uM Dose=1uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D
HB-29-DM15_0.01uM Dose=0.01uM, 4-(4-Guanidinobenzoyloxy)phenylacetate
HB-29-DM15_0.1uM Dose=0.1uM, 4-(4-Guanidinobenzoyloxy)phenylacetate
HB-29-DM15_10uM Dose=10uM, 4-(4-Guanidinobenzoyloxy)phenylacetate
HB-29-DM15_1uM Dose=1uM, 4-(4-Guanidinobenzoyloxy)phenylacetate
HB-36-FN80_0.01uM Dose=0.01uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
HB-36-FN80_0.1uM Dose=0.1uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
HB-36-FN80_10uM Dose=10uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
HB-36-FN80_1uM Dose=1uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
HB-43-TI61_0.01uM Dose=0.01uM, Travoprost, Prostanoid FP Agonists targeting PTGFR
HB-43-TI61_0.1uM Dose=0.1uM, Travoprost, Prostanoid FP Agonists targeting PTGFR
HB-43-TI61_10uM Dose=10uM, Travoprost, Prostanoid FP Agonists targeting PTGFR
HB-43-TI61_1uM Dose=1uM, Travoprost, Prostanoid FP Agonists targeting PTGFR
HB-45-XQ45_0.01uM Dose=0.01uM, Apoptosis Inducers;Mcl-1 Inhibitors
HB-45-XQ45_0.1uM Dose=0.1uM, Apoptosis Inducers;Mcl-1 Inhibitors
HB-45-XQ45_10uM Dose=10uM, Apoptosis Inducers;Mcl-1 Inhibitors
HB-45-XQ45_1uM Dose=1uM, Apoptosis Inducers;Mcl-1 Inhibitors
HB-49-VZ71_0.01uM Dose=0.01uM, Krn-633, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK4, MAPK6, MAPK7, MAPK12, MAPK15
HB-49-VZ71_0.1uM Dose=0.1uM, Krn-633, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK4, MAPK6, MAPK7, MAPK12, MAPK15
HB-49-VZ71_10uM Dose=10uM, Krn-633, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK4, MAPK6, MAPK7, MAPK12, MAPK15
HB-51-FH64_0.01uM Dose=0.01uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3
HB-51-FH64_0.1uM Dose=0.1uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3
HB-51-FH64_10uM Dose=10uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3
HB-51-FH64_1uM Dose=1uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3
HB-54-ZC59_0.01uM Dose=0.01uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2
HB-54-ZC59_0.1uM Dose=0.1uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2
HB-54-ZC59_10uM Dose=10uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2
HB-54-ZC59_1uM Dose=1uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2
HB-55-NJ83_0.01uM Dose=0.01uM, 2-(1-(3-cyano-4-fluorophenylsulfonyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid, CRTH2 Receptor Antagonists targeting PTGDR2
HB-55-NJ83_0.1uM Dose=0.1uM, 2-(1-(3-cyano-4-fluorophenylsulfonyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid, CRTH2 Receptor Antagonists targeting PTGDR2
HB-55-NJ83_10uM Dose=10uM, 2-(1-(3-cyano-4-fluorophenylsulfonyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid, CRTH2 Receptor Antagonists targeting PTGDR2
HB-69-CT62_0.01uM Dose=0.01uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
HB-69-CT62_0.1uM Dose=0.1uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
HB-69-CT62_10uM Dose=10uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
HB-69-CT62_1uM Dose=1uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
HB-72-BR75_0.01uM Dose=0.01uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3
HB-72-BR75_0.1uM Dose=0.1uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3
HB-72-BR75_10uM Dose=10uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3
HB-72-BR75_1uM Dose=1uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3
HB-75-KT12_0.01uM Dose=0.01uM
HB-75-KT12_0.1uM Dose=0.1uM
HB-75-KT12_10uM Dose=10uM
HB-75-KT12_1uM Dose=1uM
HB-77-UY14_0.01uM Dose=0.01uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B
HB-77-UY14_0.1uM Dose=0.1uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B
HB-77-UY14_10uM Dose=10uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B
HB-77-UY14_1uM Dose=1uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B
HB-79-CT92_0.01uM Dose=0.01uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2
HB-79-CT92_0.1uM Dose=0.1uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2
HB-79-CT92_10uM Dose=10uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2
HB-79-CT92_1uM Dose=1uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2
HB-79-CZ36_0.01uM Dose=0.01uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2
HB-79-CZ36_10uM Dose=10uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2
HB-79-CZ36_1uM Dose=1uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2
HB-87-YY34_0.01uM Dose=0.01uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9
HB-87-YY34_0.1uM Dose=0.1uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9
HB-87-YY34_10uM Dose=10uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9
HB-87-YY34_1uM Dose=1uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9
HB-90-QG69_0.01uM Dose=0.01uM, Rucaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors;DNA Repair Inhibitors targeting PARP1, PARP2
HB-90-QG69_0.1uM Dose=0.1uM, Rucaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors;DNA Repair Inhibitors targeting PARP1, PARP2
HB-90-QG69_10uM Dose=10uM, Rucaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors;DNA Repair Inhibitors targeting PARP1, PARP2
HB-92-PE54_0.01uM Dose=0.01uM
HB-92-PE54_0.1uM Dose=0.1uM
HB-92-PE54_10uM Dose=10uM
HB-92-PE54_1uM Dose=1uM
HB-92-XE24_0.01uM Dose=0.01uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1
HB-92-XE24_0.1uM Dose=0.1uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1
HB-92-XE24_10uM Dose=10uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1
HB-92-XE24_1uM Dose=1uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1
HB-95-ZG66_0.01uM Dose=0.01uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR
HB-95-ZG66_0.1uM Dose=0.1uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR
HB-95-ZG66_10uM Dose=10uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR
HB-95-ZG66_1uM Dose=1uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR
HB-96-QD61_0.01uM Dose=0.01uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4
HB-96-QD61_0.1uM Dose=0.1uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4
HB-96-QD61_10uM Dose=10uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4
HB-96-QD61_1uM Dose=1uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4
HB-98-OB36_0.01uM Dose=0.01uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH
HB-98-OB36_0.1uM Dose=0.1uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH
HB-98-OB36_10uM Dose=10uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH
HB-98-OB36_1uM Dose=1uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH
HC-01-CN33_0.01uM Dose=0.01uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile
HC-01-CN33_0.1uM Dose=0.1uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile
HC-01-CN33_10uM Dose=10uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile
HC-01-CN33_1uM Dose=1uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile
HC-01-FD24_0.01uM Dose=0.01uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol
HC-01-FD24_0.1uM Dose=0.1uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol
HC-01-FD24_10uM Dose=10uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol
HC-01-FD24_1uM Dose=1uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol
HC-04-ZM18_0.01uM Dose=0.01uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS
HC-04-ZM18_0.1uM Dose=0.1uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS
HC-04-ZM18_10uM Dose=10uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS
HC-04-ZM18_1uM Dose=1uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS
HC-06-EN50_0.01uM Dose=0.01uM
HC-06-EN50_0.1uM Dose=0.1uM
HC-06-EN50_10uM Dose=10uM
HC-06-EN50_1uM Dose=1uM
HC-09-KP12_10uM Dose=10uM, Cl-316243 Free diacid, ADRB3 agonist;beta3-Adrenoceptor Agonists targeting ADRB3
HC-09-KP12_1uM Dose=1uM, Cl-316243 Free diacid, ADRB3 agonist;beta3-Adrenoceptor Agonists targeting ADRB3
HC-10-FJ51_0.01uM Dose=0.01uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]-2,4,5-trimethylbenzene-1-sulfonamide
HC-10-FJ51_0.1uM Dose=0.1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]-2,4,5-trimethylbenzene-1-sulfonamide
HC-10-FJ51_10uM Dose=10uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]-2,4,5-trimethylbenzene-1-sulfonamide
HC-10-FJ51_1uM Dose=1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]-2,4,5-trimethylbenzene-1-sulfonamide
HC-11-RK51_0.01uM Dose=0.01uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A
HC-11-RK51_0.1uM Dose=0.1uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A
HC-11-RK51_10uM Dose=10uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A
HC-11-RK51_1uM Dose=1uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A
HC-14-FM48_0.01uM Dose=0.01uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET
HC-14-FM48_0.1uM Dose=0.1uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET
HC-14-FM48_10uM Dose=10uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET
HC-14-FM48_1uM Dose=1uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET
HC-15-LT47_0.01uM Dose=0.01uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid
HC-15-LT47_0.1uM Dose=0.1uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid
HC-15-LT47_10uM Dose=10uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid
HC-15-LT47_1uM Dose=1uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid
HC-16-SU62_0.1uM Dose=0.1uM, Belnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
HC-16-SU62_10uM Dose=10uM, Belnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
HC-16-SU62_1uM Dose=1uM, Belnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1
HC-16-VX59_0.01uM Dose=0.01uM, 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone, IL-5 Production Inhibitors;Mediator Release Inhibitors targeting IL5
HC-16-VX59_0.1uM Dose=0.1uM, 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone, IL-5 Production Inhibitors;Mediator Release Inhibitors targeting IL5
HC-16-VX59_10uM Dose=10uM, 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone, IL-5 Production Inhibitors;Mediator Release Inhibitors targeting IL5
HC-16-VX59_1uM Dose=1uM, 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone, IL-5 Production Inhibitors;Mediator Release Inhibitors targeting IL5
HC-18-NB46_0.01uM Dose=0.01uM, N-Acetyl-6-methoxytryptamine
HC-18-NB46_0.1uM Dose=0.1uM, N-Acetyl-6-methoxytryptamine
HC-18-NB46_10uM Dose=10uM, N-Acetyl-6-methoxytryptamine
HC-18-NB46_1uM Dose=1uM, N-Acetyl-6-methoxytryptamine
HC-19-UZ81_0.01uM Dose=0.01uM, Galgravin
HC-19-UZ81_0.1uM Dose=0.1uM, Galgravin
HC-19-UZ81_10uM Dose=10uM, Galgravin
HC-19-UZ81_1uM Dose=1uM, Galgravin
HC-20-JJ81_0.01uM Dose=0.01uM, 1-[[6-(2-Hydroxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
HC-20-JJ81_10uM Dose=10uM, 1-[[6-(2-Hydroxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
HC-24-QF06_0.01uM Dose=0.01uM, N(1),N(11)-Diethylnorspermine, Ornithine Decarboxylase Inhibitors;Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1, ODC1
HC-24-QF06_0.1uM Dose=0.1uM, N(1),N(11)-Diethylnorspermine, Ornithine Decarboxylase Inhibitors;Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1, ODC1
HC-24-QF06_10uM Dose=10uM, N(1),N(11)-Diethylnorspermine, Ornithine Decarboxylase Inhibitors;Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1, ODC1
HC-24-QF06_1uM Dose=1uM, N(1),N(11)-Diethylnorspermine, Ornithine Decarboxylase Inhibitors;Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1, ODC1
HC-26-PX74_0.01uM Dose=0.01uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid
HC-26-PX74_0.1uM Dose=0.1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid
HC-26-PX74_1uM Dose=1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid
HC-38-KI38_0.01uM Dose=0.01uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP
HC-38-KI38_0.1uM Dose=0.1uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP
HC-38-KI38_10uM Dose=10uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP
HC-38-KI38_1uM Dose=1uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP
HC-40-TX80_0.01uM Dose=0.01uM, N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide, Cathepsin S Inhibitors targeting CTSS
HC-40-TX80_10uM Dose=10uM, N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide, Cathepsin S Inhibitors targeting CTSS
HC-43-CV47_0.01uM Dose=0.01uM, Bergapten
HC-43-CV47_0.1uM Dose=0.1uM, Bergapten
HC-43-CV47_10uM Dose=10uM, Bergapten
HC-43-CV47_1uM Dose=1uM, Bergapten
HC-48-BS22_0.01uM Dose=0.01uM
HC-48-BS22_0.1uM Dose=0.1uM
HC-48-BS22_10uM Dose=10uM
HC-48-BS22_1uM Dose=1uM
HC-49-RF93_0.01uM Dose=0.01uM
HC-49-RF93_0.1uM Dose=0.1uM
HC-49-RF93_10uM Dose=10uM
HC-49-RF93_1uM Dose=1uM
HC-63-SV27_0.01uM Dose=0.01uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
HC-63-SV27_0.1uM Dose=0.1uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
HC-63-SV27_10uM Dose=10uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
HC-63-SV27_1uM Dose=1uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
HC-69-UG51_0.01uM Dose=0.01uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR
HC-69-UG51_0.1uM Dose=0.1uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR
HC-69-UG51_10uM Dose=10uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR
HC-69-UG51_1uM Dose=1uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR
HC-74-FM38_0.01uM Dose=0.01uM
HC-74-FM38_0.1uM Dose=0.1uM
HC-74-FM38_10uM Dose=10uM
HC-74-FM38_1uM Dose=1uM
HC-74-HM63_0.01uM Dose=0.01uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3
HC-74-HM63_0.1uM Dose=0.1uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3
HC-74-HM63_10uM Dose=10uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3
HC-74-HM63_1uM Dose=1uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3
HC-76-HU27_0.01uM Dose=0.01uM
HC-76-HU27_0.1uM Dose=0.1uM
HC-76-HU27_10uM Dose=10uM
HC-76-HU27_1uM Dose=1uM
HC-76-PX74_0.01uM Dose=0.01uM
HC-76-PX74_0.1uM Dose=0.1uM
HC-76-PX74_10uM Dose=10uM
HC-76-PX74_1uM Dose=1uM
HC-76-SY22_0.01uM Dose=0.01uM, Sulprostone
HC-76-SY22_0.1uM Dose=0.1uM, Sulprostone
HC-76-SY22_10uM Dose=10uM, Sulprostone
HC-76-SY22_1uM Dose=1uM, Sulprostone
HC-83-TS50_0.01uM Dose=0.01uM, RORgammat-IN-9a, RORC gamma t inhibitor targeting RORC
HC-83-TS50_0.1uM Dose=0.1uM, RORgammat-IN-9a, RORC gamma t inhibitor targeting RORC
HC-83-TS50_10uM Dose=10uM, RORgammat-IN-9a, RORC gamma t inhibitor targeting RORC
HC-83-TS50_1uM Dose=1uM, RORgammat-IN-9a, RORC gamma t inhibitor targeting RORC
HC-86-IA49_0.01uM Dose=0.01uM
HC-86-IA49_0.1uM Dose=0.1uM
HC-86-IA49_10uM Dose=10uM
HC-86-IA49_1uM Dose=1uM
HC-89-WQ85_0.01uM Dose=0.01uM, Siramesine targeting TMEM97
HC-89-WQ85_10uM Dose=10uM, Siramesine targeting TMEM97
HC-92-HE59_0.1uM Dose=0.1uM
HC-92-HE59_10uM Dose=10uM
HC-92-HE59_1uM Dose=1uM
HC-94-AQ98_0.01uM Dose=0.01uM, Roxadustat, hypoxia-inducible factor prolyl hydroxylase inhibitor targeting EGLN1, EGLN2, EGLN3
HC-94-AQ98_0.1uM Dose=0.1uM, Roxadustat, hypoxia-inducible factor prolyl hydroxylase inhibitor targeting EGLN1, EGLN2, EGLN3
HC-94-AQ98_10uM Dose=10uM, Roxadustat, hypoxia-inducible factor prolyl hydroxylase inhibitor targeting EGLN1, EGLN2, EGLN3
HC-94-AQ98_1uM Dose=1uM, Roxadustat, hypoxia-inducible factor prolyl hydroxylase inhibitor targeting EGLN1, EGLN2, EGLN3
HC-95-WQ65_0.01uM Dose=0.01uM, Monomethyl Fumarate
HC-95-WQ65_0.1uM Dose=0.1uM, Monomethyl Fumarate
HC-95-WQ65_10uM Dose=10uM, Monomethyl Fumarate
HC-95-WQ65_1uM Dose=1uM, Monomethyl Fumarate
HC-96-WV85_0.01uM Dose=0.01uM, Asn04421891, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17
HC-96-WV85_10uM Dose=10uM, Asn04421891, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17
HC-96-WV85_1uM Dose=1uM, Asn04421891, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17
HC-97-AH03_0.01uM Dose=0.01uM, (S)-3-(3,4-Dimethoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid, Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists;Integrin binder targeting ITGA4, ITGB1
HC-97-AH03_0.1uM Dose=0.1uM, (S)-3-(3,4-Dimethoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid, Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists;Integrin binder targeting ITGA4, ITGB1
HC-97-AH03_1uM Dose=1uM, (S)-3-(3,4-Dimethoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid, Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists;Integrin binder targeting ITGA4, ITGB1
HC-97-OH18_0.01uM Dose=0.01uM, 1,3,5-Triazine, 2-isopropylamino-4,6-di(phenylamino)-, KCNH voltage-gated potassium channel-3 inhibitor targeting KCNH3
HC-97-OH18_0.1uM Dose=0.1uM, 1,3,5-Triazine, 2-isopropylamino-4,6-di(phenylamino)-, KCNH voltage-gated potassium channel-3 inhibitor targeting KCNH3
HC-97-OH18_10uM Dose=10uM, 1,3,5-Triazine, 2-isopropylamino-4,6-di(phenylamino)-, KCNH voltage-gated potassium channel-3 inhibitor targeting KCNH3
HC-97-OH18_1uM Dose=1uM, 1,3,5-Triazine, 2-isopropylamino-4,6-di(phenylamino)-, KCNH voltage-gated potassium channel-3 inhibitor targeting KCNH3
HD-00-AG74_0.01uM Dose=0.01uM
HD-00-AG74_0.1uM Dose=0.1uM
HD-00-AG74_10uM Dose=10uM
HD-00-AG74_1uM Dose=1uM
HD-03-XB39_0.01uM Dose=0.01uM, N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1
HD-03-XB39_0.1uM Dose=0.1uM, N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1
HD-03-XB39_10uM Dose=10uM, N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1
HD-03-XB39_1uM Dose=1uM, N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1
HD-08-BP45_0.01uM Dose=0.01uM, Ticlopidine, P2Y12 (P2T) Antagonists targeting P2RY12
HD-08-BP45_0.1uM Dose=0.1uM, Ticlopidine, P2Y12 (P2T) Antagonists targeting P2RY12
HD-08-BP45_10uM Dose=10uM, Ticlopidine, P2Y12 (P2T) Antagonists targeting P2RY12
HD-08-BP45_1uM Dose=1uM, Ticlopidine, P2Y12 (P2T) Antagonists targeting P2RY12
HD-09-QF83_0.01uM Dose=0.01uM, 6-chloro-N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-2-carboxamide, mgluR5 Antagonists targeting GRM5
HD-09-QF83_0.1uM Dose=0.1uM, 6-chloro-N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-2-carboxamide, mgluR5 Antagonists targeting GRM5
HD-09-QF83_10uM Dose=10uM, 6-chloro-N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-2-carboxamide, mgluR5 Antagonists targeting GRM5
HD-09-QF83_1uM Dose=1uM, 6-chloro-N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-2-carboxamide, mgluR5 Antagonists targeting GRM5
HD-16-HN20_0.01uM Dose=0.01uM
HD-16-HN20_0.1uM Dose=0.1uM
HD-16-HN20_10uM Dose=10uM
HD-16-HN20_1uM Dose=1uM
HD-18-YL30_0.01uM Dose=0.01uM, Nitroxoline, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Antibiotic;Angiogenesis Inhibitors;Chelator targeting METAP2, SIRT2, SIRT1
HD-18-YL30_0.1uM Dose=0.1uM, Nitroxoline, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Antibiotic;Angiogenesis Inhibitors;Chelator targeting METAP2, SIRT2, SIRT1
HD-18-YL30_10uM Dose=10uM, Nitroxoline, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Antibiotic;Angiogenesis Inhibitors;Chelator targeting METAP2, SIRT2, SIRT1
HD-18-YL30_1uM Dose=1uM, Nitroxoline, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Antibiotic;Angiogenesis Inhibitors;Chelator targeting METAP2, SIRT2, SIRT1
HD-19-IW09_10uM Dose=10uM
HD-19-IW09_1uM Dose=1uM
HD-22-GO73_0.01uM Dose=0.01uM, (S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide, Orexin Receptor Antagonists targeting HCRTR1, HCRTR2
HD-22-GO73_0.1uM Dose=0.1uM, (S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide, Orexin Receptor Antagonists targeting HCRTR1, HCRTR2
HD-22-GO73_10uM Dose=10uM, (S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide, Orexin Receptor Antagonists targeting HCRTR1, HCRTR2
HD-22-GO73_1uM Dose=1uM, (S)-N-((1-(5-(4-Fluorophenyl)-2-methylthiazole-4-carbonyl)piperidin-2-yl)methyl)benzofuran-4-carboxamide, Orexin Receptor Antagonists targeting HCRTR1, HCRTR2
HD-22-KR30_0.01uM Dose=0.01uM, K(V)1.5 Channel Blockers;K(V)1.3 Channel Blockers targeting KCNA3, KCNA5
HD-22-KR30_0.1uM Dose=0.1uM, K(V)1.5 Channel Blockers;K(V)1.3 Channel Blockers targeting KCNA3, KCNA5
HD-22-KR30_10uM Dose=10uM, K(V)1.5 Channel Blockers;K(V)1.3 Channel Blockers targeting KCNA3, KCNA5
HD-22-KR30_1uM Dose=1uM, K(V)1.5 Channel Blockers;K(V)1.3 Channel Blockers targeting KCNA3, KCNA5
HD-26-KX74_0.01uM Dose=0.01uM
HD-26-KX74_0.1uM Dose=0.1uM
HD-26-KX74_10uM Dose=10uM
HD-26-KX74_1uM Dose=1uM
HD-27-CV87_0.01uM Dose=0.01uM, Jte 013, S1PR2 antagonist;Lysophospholipid edg5 (S1P2) Receptor Antagonists targeting S1PR2
HD-27-CV87_10uM Dose=10uM, Jte 013, S1PR2 antagonist;Lysophospholipid edg5 (S1P2) Receptor Antagonists targeting S1PR2
HD-27-CV87_1uM Dose=1uM, Jte 013, S1PR2 antagonist;Lysophospholipid edg5 (S1P2) Receptor Antagonists targeting S1PR2
HD-28-QL60_0.1uM Dose=0.1uM, (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine, Na+/H+ Exchanger type 3 (NHE-3) Inhibitors targeting SLC9A3
HD-28-QL60_10uM Dose=10uM, (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine, Na+/H+ Exchanger type 3 (NHE-3) Inhibitors targeting SLC9A3
HD-28-QL60_1uM Dose=1uM, (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine, Na+/H+ Exchanger type 3 (NHE-3) Inhibitors targeting SLC9A3
HD-29-LW24_0.01uM Dose=0.01uM, Mocetinostat, Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;HDAC1/2 targeting HDAC1, HDAC2, HDAC3
HD-29-LW24_0.1uM Dose=0.1uM, Mocetinostat, Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;HDAC1/2 targeting HDAC1, HDAC2, HDAC3
HD-29-LW24_10uM Dose=10uM, Mocetinostat, Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;HDAC1/2 targeting HDAC1, HDAC2, HDAC3
HD-29-LW24_1uM Dose=1uM, Mocetinostat, Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;HDAC1/2 targeting HDAC1, HDAC2, HDAC3
HD-29-PZ41_0.01uM Dose=0.01uM, 6-hydroxy-2-(pyridin-4-ylcarbonyl)pyridazin-3(2H)-one
HD-29-PZ41_0.1uM Dose=0.1uM, 6-hydroxy-2-(pyridin-4-ylcarbonyl)pyridazin-3(2H)-one
HD-29-PZ41_10uM Dose=10uM, 6-hydroxy-2-(pyridin-4-ylcarbonyl)pyridazin-3(2H)-one
HD-29-PZ41_1uM Dose=1uM, 6-hydroxy-2-(pyridin-4-ylcarbonyl)pyridazin-3(2H)-one
HD-33-CS00_0.01uM Dose=0.01uM, IWR-1-endo, Wnt Signaling Inhibitors targeting TNKS2
HD-33-CS00_10uM Dose=10uM, IWR-1-endo, Wnt Signaling Inhibitors targeting TNKS2
HD-33-CS00_1uM Dose=1uM, IWR-1-endo, Wnt Signaling Inhibitors targeting TNKS2
HD-35-ZQ35_0.01uM Dose=0.01uM, 5-{[(1E)-5-fluoro-2,3-dihydro-1H-inden-1-ylidene]methyl}pyrimidine, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
HD-35-ZQ35_0.1uM Dose=0.1uM, 5-{[(1E)-5-fluoro-2,3-dihydro-1H-inden-1-ylidene]methyl}pyrimidine, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
HD-35-ZQ35_10uM Dose=10uM, 5-{[(1E)-5-fluoro-2,3-dihydro-1H-inden-1-ylidene]methyl}pyrimidine, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2
HD-36-DK23_0.01uM Dose=0.01uM, N-[1-[[5-[(4-acetylpiperazin-1-yl)methyl]-4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-4-fluorobenzamide
HD-36-DK23_0.1uM Dose=0.1uM, N-[1-[[5-[(4-acetylpiperazin-1-yl)methyl]-4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-4-fluorobenzamide
HD-36-DK23_10uM Dose=10uM, N-[1-[[5-[(4-acetylpiperazin-1-yl)methyl]-4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-4-fluorobenzamide
HD-36-DK23_1uM Dose=1uM, N-[1-[[5-[(4-acetylpiperazin-1-yl)methyl]-4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-4-fluorobenzamide
HD-40-AK39_0.01uM Dose=0.01uM, Eliglustat targeting UGCG
HD-40-AK39_0.1uM Dose=0.1uM, Eliglustat targeting UGCG
HD-40-AK39_10uM Dose=10uM, Eliglustat targeting UGCG
HD-40-AK39_1uM Dose=1uM, Eliglustat targeting UGCG
HD-41-DX72_0.01uM Dose=0.01uM, (R)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, Cholinergics targeting CHRM1
HD-41-DX72_0.1uM Dose=0.1uM, (R)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, Cholinergics targeting CHRM1
HD-41-DX72_10uM Dose=10uM, (R)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, Cholinergics targeting CHRM1
HD-41-DX72_1uM Dose=1uM, (R)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, Cholinergics targeting CHRM1
HD-44-WW47_0.01uM Dose=0.01uM, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
HD-44-WW47_10uM Dose=10uM, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
HD-44-WW47_1uM Dose=1uM, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
HD-47-RR92_0.01uM Dose=0.01uM, Sipatrigine, Nav1.2 (Brain Type II) Sodium Channel Blockers;Glutamate Release Inhibitors;N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B, SCN2A
HD-47-RR92_0.1uM Dose=0.1uM, Sipatrigine, Nav1.2 (Brain Type II) Sodium Channel Blockers;Glutamate Release Inhibitors;N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B, SCN2A
HD-47-RR92_10uM Dose=10uM, Sipatrigine, Nav1.2 (Brain Type II) Sodium Channel Blockers;Glutamate Release Inhibitors;N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B, SCN2A
HD-47-RR92_1uM Dose=1uM, Sipatrigine, Nav1.2 (Brain Type II) Sodium Channel Blockers;Glutamate Release Inhibitors;N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B, SCN2A
HD-51-KD29_0.01uM Dose=0.01uM, 5-bromo-2-N-[4-[3-(propan-2-ylamino)propylamino]phenyl]-4-N-pyridin-2-ylpyrimidine-2,4-diamine, Cyclin-Dependent Kinase Inhibitors targeting CDK4, CDKL5, CDK6
HD-51-KD29_0.1uM Dose=0.1uM, 5-bromo-2-N-[4-[3-(propan-2-ylamino)propylamino]phenyl]-4-N-pyridin-2-ylpyrimidine-2,4-diamine, Cyclin-Dependent Kinase Inhibitors targeting CDK4, CDKL5, CDK6
HD-51-KD29_10uM Dose=10uM, 5-bromo-2-N-[4-[3-(propan-2-ylamino)propylamino]phenyl]-4-N-pyridin-2-ylpyrimidine-2,4-diamine, Cyclin-Dependent Kinase Inhibitors targeting CDK4, CDKL5, CDK6
HD-51-KD29_1uM Dose=1uM, 5-bromo-2-N-[4-[3-(propan-2-ylamino)propylamino]phenyl]-4-N-pyridin-2-ylpyrimidine-2,4-diamine, Cyclin-Dependent Kinase Inhibitors targeting CDK4, CDKL5, CDK6
HD-62-KE69_0.01uM Dose=0.01uM, Roflumilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4, PDE2A
HD-62-KE69_0.1uM Dose=0.1uM, Roflumilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4, PDE2A
HD-62-KE69_10uM Dose=10uM, Roflumilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4, PDE2A
HD-62-KE69_1uM Dose=1uM, Roflumilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4, PDE2A
HD-68-CB31_0.01uM Dose=0.01uM, N-Methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide targeting CYP2D6
HD-68-CB31_0.1uM Dose=0.1uM, N-Methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide targeting CYP2D6
HD-68-CB31_10uM Dose=10uM, N-Methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide targeting CYP2D6
HD-68-CB31_1uM Dose=1uM, N-Methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide targeting CYP2D6
HD-85-AJ28_0.01uM Dose=0.01uM, Nelivaptan, DNA-Directed RNA Polymerase Inhibitors targeting AVPR1B
HD-85-AJ28_0.1uM Dose=0.1uM, Nelivaptan, DNA-Directed RNA Polymerase Inhibitors targeting AVPR1B
HD-85-AJ28_10uM Dose=10uM, Nelivaptan, DNA-Directed RNA Polymerase Inhibitors targeting AVPR1B
HD-85-AJ28_1uM Dose=1uM, Nelivaptan, DNA-Directed RNA Polymerase Inhibitors targeting AVPR1B
HD-86-DD86_0.01uM Dose=0.01uM, 7-(4-fluorobenzyloxy)-3-hydroxymethyl-2-methyl-1-[(1S,2S)-2-methylcyclopropylmethyl]pyrrolo[2,3-d]pyridazine, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
HD-86-DD86_0.1uM Dose=0.1uM, 7-(4-fluorobenzyloxy)-3-hydroxymethyl-2-methyl-1-[(1S,2S)-2-methylcyclopropylmethyl]pyrrolo[2,3-d]pyridazine, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
HD-86-DD86_10uM Dose=10uM, 7-(4-fluorobenzyloxy)-3-hydroxymethyl-2-methyl-1-[(1S,2S)-2-methylcyclopropylmethyl]pyrrolo[2,3-d]pyridazine, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
HD-89-HC56_0.1uM Dose=0.1uM, eIF4A3-IN-2 targeting EIF4A3
HD-89-HC56_10uM Dose=10uM, eIF4A3-IN-2 targeting EIF4A3
HD-89-HC56_1uM Dose=1uM, eIF4A3-IN-2 targeting EIF4A3
HD-90-HQ28_0.01uM Dose=0.01uM, 2-[[(3R)-pyrrolidin-3-yl]methylamino]-9-[[2-(trifluoromethoxy)phenyl]methyl]-7H-purin-8-one, PKC theta inhibitor targeting PRKCQ
HD-90-HQ28_0.1uM Dose=0.1uM, 2-[[(3R)-pyrrolidin-3-yl]methylamino]-9-[[2-(trifluoromethoxy)phenyl]methyl]-7H-purin-8-one, PKC theta inhibitor targeting PRKCQ
HD-90-HQ28_10uM Dose=10uM, 2-[[(3R)-pyrrolidin-3-yl]methylamino]-9-[[2-(trifluoromethoxy)phenyl]methyl]-7H-purin-8-one, PKC theta inhibitor targeting PRKCQ
HD-90-HQ28_1uM Dose=1uM, 2-[[(3R)-pyrrolidin-3-yl]methylamino]-9-[[2-(trifluoromethoxy)phenyl]methyl]-7H-purin-8-one, PKC theta inhibitor targeting PRKCQ
HD-91-YX62_0.01uM Dose=0.01uM, 6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile
HD-91-YX62_0.1uM Dose=0.1uM, 6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile
HD-91-YX62_10uM Dose=10uM, 6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile
HD-91-YX62_1uM Dose=1uM, 6-(5-Bromo-2-hydroxyphenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile
HD-96-GX64_0.01uM Dose=0.01uM, Methyl 4-[(3,6-dichloro-2-methoxybenzoyl)amino]benzoate targeting TAS1R1
HD-96-GX64_0.1uM Dose=0.1uM, Methyl 4-[(3,6-dichloro-2-methoxybenzoyl)amino]benzoate targeting TAS1R1
HD-96-GX64_10uM Dose=10uM, Methyl 4-[(3,6-dichloro-2-methoxybenzoyl)amino]benzoate targeting TAS1R1
HD-96-GX64_1uM Dose=1uM, Methyl 4-[(3,6-dichloro-2-methoxybenzoyl)amino]benzoate targeting TAS1R1
HD-99-BT62_0.01uM Dose=0.01uM, RO5166017, Trace amine-associated receptor-1 agonist targeting TAAR1
HD-99-BT62_0.1uM Dose=0.1uM, RO5166017, Trace amine-associated receptor-1 agonist targeting TAAR1
HD-99-BT62_10uM Dose=10uM, RO5166017, Trace amine-associated receptor-1 agonist targeting TAAR1
HD-99-BT62_1uM Dose=1uM, RO5166017, Trace amine-associated receptor-1 agonist targeting TAAR1
HE-01-ND39_0.01uM Dose=0.01uM, 2-{[1-(2-Mercapto-4-methyl-pentanoylamino)-cyclopentanecarbonyl]-amino}-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
HE-01-ND39_0.1uM Dose=0.1uM, 2-{[1-(2-Mercapto-4-methyl-pentanoylamino)-cyclopentanecarbonyl]-amino}-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
HE-01-ND39_10uM Dose=10uM, 2-{[1-(2-Mercapto-4-methyl-pentanoylamino)-cyclopentanecarbonyl]-amino}-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
HE-01-ND39_1uM Dose=1uM, 2-{[1-(2-Mercapto-4-methyl-pentanoylamino)-cyclopentanecarbonyl]-amino}-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2
HE-09-WC21_0.01uM Dose=0.01uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
HE-09-WC21_0.1uM Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
HE-09-WC21_10uM Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
HE-09-WC21_1uM Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
HE-10-QN66_0.01uM Dose=0.01uM, Cytoxazone
HE-10-QN66_0.1uM Dose=0.1uM, Cytoxazone
HE-10-QN66_10uM Dose=10uM, Cytoxazone
HE-10-QN66_1uM Dose=1uM, Cytoxazone
HE-11-PK61_0.01uM Dose=0.01uM, 8-Hydroxy-2-phenyl-4H-1-benzothiopyran-4-one-1,1-dioxide, Binds HSPA8 preveting it from binding to OCT4 which facilitates OCT4 binding to DNA targeting HSPA8
HE-11-PK61_0.1uM Dose=0.1uM, 8-Hydroxy-2-phenyl-4H-1-benzothiopyran-4-one-1,1-dioxide, Binds HSPA8 preveting it from binding to OCT4 which facilitates OCT4 binding to DNA targeting HSPA8
HE-11-PK61_10uM Dose=10uM, 8-Hydroxy-2-phenyl-4H-1-benzothiopyran-4-one-1,1-dioxide, Binds HSPA8 preveting it from binding to OCT4 which facilitates OCT4 binding to DNA targeting HSPA8
HE-11-PK61_1uM Dose=1uM, 8-Hydroxy-2-phenyl-4H-1-benzothiopyran-4-one-1,1-dioxide, Binds HSPA8 preveting it from binding to OCT4 which facilitates OCT4 binding to DNA targeting HSPA8
HE-14-AT80_0.01uM Dose=0.01uM, Filgotinib targeting JAK1, JAK2, JAK3, TYK2
HE-14-AT80_0.1uM Dose=0.1uM, Filgotinib targeting JAK1, JAK2, JAK3, TYK2
HE-14-AT80_10uM Dose=10uM, Filgotinib targeting JAK1, JAK2, JAK3, TYK2
HE-14-AT80_1uM Dose=1uM, Filgotinib targeting JAK1, JAK2, JAK3, TYK2
HE-15-UQ55_0.01uM Dose=0.01uM
HE-15-UQ55_0.1uM Dose=0.1uM
HE-15-UQ55_10uM Dose=10uM
HE-15-UQ55_1uM Dose=1uM
HE-16-PO98_0.01uM Dose=0.01uM, Azd-5153, inhibitor of BRD4 targeting BRD4
HE-16-PO98_0.1uM Dose=0.1uM, Azd-5153, inhibitor of BRD4 targeting BRD4
HE-16-PO98_10uM Dose=10uM, Azd-5153, inhibitor of BRD4 targeting BRD4
HE-16-PO98_1uM Dose=1uM, Azd-5153, inhibitor of BRD4 targeting BRD4
HE-17-FY34_0.01uM Dose=0.01uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
HE-17-FY34_0.1uM Dose=0.1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
HE-17-FY34_10uM Dose=10uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
HE-17-FY34_1uM Dose=1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
HE-18-HV99_0.01uM Dose=0.01uM
HE-18-HV99_0.1uM Dose=0.1uM
HE-18-HV99_10uM Dose=10uM
HE-18-HV99_1uM Dose=1uM
HE-22-JR80_0.1uM Dose=0.1uM, Telbivudine
HE-22-JR80_10uM Dose=10uM, Telbivudine
HE-27-FR27_0.01uM Dose=0.01uM, 5-(3-Bromophenyl)-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one, Rho C GTPase Inhibitors targeting RHOC
HE-27-FR27_0.1uM Dose=0.1uM, 5-(3-Bromophenyl)-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one, Rho C GTPase Inhibitors targeting RHOC
HE-27-FR27_10uM Dose=10uM, 5-(3-Bromophenyl)-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one, Rho C GTPase Inhibitors targeting RHOC
HE-27-FR27_1uM Dose=1uM, 5-(3-Bromophenyl)-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one, Rho C GTPase Inhibitors targeting RHOC
HE-29-OW54_0.01uM Dose=0.01uM, Camicinal, Motilin Receptor Agonists targeting MLNR
HE-29-OW54_0.1uM Dose=0.1uM, Camicinal, Motilin Receptor Agonists targeting MLNR
HE-29-OW54_10uM Dose=10uM, Camicinal, Motilin Receptor Agonists targeting MLNR
HE-29-OW54_1uM Dose=1uM, Camicinal, Motilin Receptor Agonists targeting MLNR
HE-29-ZP52_0.01uM Dose=0.01uM, (R)-1-{2-methyl-2-[3-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-propionyl}-pyrrolidine-2-carboxylic acid
HE-29-ZP52_0.1uM Dose=0.1uM, (R)-1-{2-methyl-2-[3-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-propionyl}-pyrrolidine-2-carboxylic acid
HE-29-ZP52_10uM Dose=10uM, (R)-1-{2-methyl-2-[3-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-propionyl}-pyrrolidine-2-carboxylic acid
HE-34-NJ16_0.01uM Dose=0.01uM, N-Desmethyl trifluoperazine, Apoptosis Inducers;Serotonin Antagonists;Caspase 8 Activators;Caspase 3 Activators;Caspase 9 Activators targeting CASP3, CASP8, CASP9
HE-34-NJ16_0.1uM Dose=0.1uM, N-Desmethyl trifluoperazine, Apoptosis Inducers;Serotonin Antagonists;Caspase 8 Activators;Caspase 3 Activators;Caspase 9 Activators targeting CASP3, CASP8, CASP9
HE-34-NJ16_10uM Dose=10uM, N-Desmethyl trifluoperazine, Apoptosis Inducers;Serotonin Antagonists;Caspase 8 Activators;Caspase 3 Activators;Caspase 9 Activators targeting CASP3, CASP8, CASP9
HE-34-NJ16_1uM Dose=1uM, N-Desmethyl trifluoperazine, Apoptosis Inducers;Serotonin Antagonists;Caspase 8 Activators;Caspase 3 Activators;Caspase 9 Activators targeting CASP3, CASP8, CASP9
HE-34-ZC14_0.01uM Dose=0.01uM
HE-34-ZC14_0.1uM Dose=0.1uM
HE-34-ZC14_10uM Dose=10uM
HE-34-ZC14_1uM Dose=1uM
HE-43-BS90_0.01uM Dose=0.01uM, benzyl 4-(6-carbamoyl-8-oxo-2-pyridin-3-yl-7H-purin-9-yl)piperidine-1-carboxylate, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
HE-43-BS90_0.1uM Dose=0.1uM, benzyl 4-(6-carbamoyl-8-oxo-2-pyridin-3-yl-7H-purin-9-yl)piperidine-1-carboxylate, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
HE-43-BS90_10uM Dose=10uM, benzyl 4-(6-carbamoyl-8-oxo-2-pyridin-3-yl-7H-purin-9-yl)piperidine-1-carboxylate, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
HE-43-BS90_1uM Dose=1uM, benzyl 4-(6-carbamoyl-8-oxo-2-pyridin-3-yl-7H-purin-9-yl)piperidine-1-carboxylate, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR
HE-55-AG11_0.01uM Dose=0.01uM, 2,6-Difluoro-4-[4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]phenol, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3
HE-55-AG11_0.1uM Dose=0.1uM, 2,6-Difluoro-4-[4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]phenol, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3
HE-55-AG11_10uM Dose=10uM, 2,6-Difluoro-4-[4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]phenol, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3
HE-55-AG11_1uM Dose=1uM, 2,6-Difluoro-4-[4-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]phenol, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3
HE-55-NT77_0.01uM Dose=0.01uM, 1-[(4aR,10aR)-6-methoxy-4-methyl-2,3,4a,5,10,10a-hexahydrobenzo[g][1,4]benzoxazin-9-yl]propan-1-one, 5-HT1D Agonists targeting HTR1D
HE-55-NT77_10uM Dose=10uM, 1-[(4aR,10aR)-6-methoxy-4-methyl-2,3,4a,5,10,10a-hexahydrobenzo[g][1,4]benzoxazin-9-yl]propan-1-one, 5-HT1D Agonists targeting HTR1D
HE-55-NT77_1uM Dose=1uM, 1-[(4aR,10aR)-6-methoxy-4-methyl-2,3,4a,5,10,10a-hexahydrobenzo[g][1,4]benzoxazin-9-yl]propan-1-one, 5-HT1D Agonists targeting HTR1D
HE-55-QD94_0.01uM Dose=0.01uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-phenoxyacetamide
HE-55-QD94_0.1uM Dose=0.1uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-phenoxyacetamide
HE-55-QD94_10uM Dose=10uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-phenoxyacetamide
HE-55-QD94_1uM Dose=1uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-phenoxyacetamide
HE-59-VP02_0.01uM Dose=0.01uM, (5R)-7-(3,5-dichlorophenyl)-5-methyl-3-piperazin-1-ylsulfonyl-5-[(4-pyrimidin-5-ylphenyl)methyl]imidazo[1,2-a]imidazol-6-one, Integrin alphaLbeta2 (LFA-1) Antagonists targeting ITGAL, ITGB2
HE-59-VP02_0.1uM Dose=0.1uM, (5R)-7-(3,5-dichlorophenyl)-5-methyl-3-piperazin-1-ylsulfonyl-5-[(4-pyrimidin-5-ylphenyl)methyl]imidazo[1,2-a]imidazol-6-one, Integrin alphaLbeta2 (LFA-1) Antagonists targeting ITGAL, ITGB2
HE-59-VP02_10uM Dose=10uM, (5R)-7-(3,5-dichlorophenyl)-5-methyl-3-piperazin-1-ylsulfonyl-5-[(4-pyrimidin-5-ylphenyl)methyl]imidazo[1,2-a]imidazol-6-one, Integrin alphaLbeta2 (LFA-1) Antagonists targeting ITGAL, ITGB2
HE-59-VP02_1uM Dose=1uM, (5R)-7-(3,5-dichlorophenyl)-5-methyl-3-piperazin-1-ylsulfonyl-5-[(4-pyrimidin-5-ylphenyl)methyl]imidazo[1,2-a]imidazol-6-one, Integrin alphaLbeta2 (LFA-1) Antagonists targeting ITGAL, ITGB2
HE-64-VW17_0.01uM Dose=0.01uM
HE-64-VW17_0.1uM Dose=0.1uM
HE-64-VW17_1uM Dose=1uM
HE-68-XL70_0.01uM Dose=0.01uM, 1,2,5-Thiadiazolidin-3-one, 5-[4-(cyclohexylmethyl)-2-fluoro-6-hydroxyphenyl]-, 1,1-dioxide, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1
HE-68-XL70_0.1uM Dose=0.1uM, 1,2,5-Thiadiazolidin-3-one, 5-[4-(cyclohexylmethyl)-2-fluoro-6-hydroxyphenyl]-, 1,1-dioxide, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1
HE-68-XL70_10uM Dose=10uM, 1,2,5-Thiadiazolidin-3-one, 5-[4-(cyclohexylmethyl)-2-fluoro-6-hydroxyphenyl]-, 1,1-dioxide, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1
HE-68-XL70_1uM Dose=1uM, 1,2,5-Thiadiazolidin-3-one, 5-[4-(cyclohexylmethyl)-2-fluoro-6-hydroxyphenyl]-, 1,1-dioxide, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1
HE-80-BQ08_0.01uM Dose=0.01uM, 6-(3-Aminopropyl)-8-hydroxy-3-nitroindeno[1,2-c]isoquinoline-5,11-dione, Dual Top1, TDP1 inhibitors targeting TOP1, TDP1
HE-80-BQ08_0.1uM Dose=0.1uM, 6-(3-Aminopropyl)-8-hydroxy-3-nitroindeno[1,2-c]isoquinoline-5,11-dione, Dual Top1, TDP1 inhibitors targeting TOP1, TDP1
HE-80-BQ08_10uM Dose=10uM, 6-(3-Aminopropyl)-8-hydroxy-3-nitroindeno[1,2-c]isoquinoline-5,11-dione, Dual Top1, TDP1 inhibitors targeting TOP1, TDP1
HE-80-BQ08_1uM Dose=1uM, 6-(3-Aminopropyl)-8-hydroxy-3-nitroindeno[1,2-c]isoquinoline-5,11-dione, Dual Top1, TDP1 inhibitors targeting TOP1, TDP1
HE-84-RW47_0.01uM Dose=0.01uM, Cytosporone B, NR4A1 gene stimulator targeting NR4A1
HE-84-RW47_0.1uM Dose=0.1uM, Cytosporone B, NR4A1 gene stimulator targeting NR4A1
HE-84-RW47_10uM Dose=10uM, Cytosporone B, NR4A1 gene stimulator targeting NR4A1
HE-84-RW47_1uM Dose=1uM, Cytosporone B, NR4A1 gene stimulator targeting NR4A1
HE-84-SC79_0.01uM Dose=0.01uM
HE-84-SC79_0.1uM Dose=0.1uM
HE-84-SC79_10uM Dose=10uM
HE-84-SC79_1uM Dose=1uM
HE-94-WM93_0.01uM Dose=0.01uM, Resolvin E1, Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Ligands;Leukotriene BLT1 Receptor Ligands targeting CMKLR1, LTB4R
HE-94-WM93_0.1uM Dose=0.1uM, Resolvin E1, Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Ligands;Leukotriene BLT1 Receptor Ligands targeting CMKLR1, LTB4R
HE-94-WM93_1uM Dose=1uM, Resolvin E1, Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Ligands;Leukotriene BLT1 Receptor Ligands targeting CMKLR1, LTB4R
HE-95-KK46_0.01uM Dose=0.01uM, (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate, P2X7 Receptor Antagonists;Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Calmodulin Antagonists targeting CALM1, P2RX7, CAMK2A
HE-95-KK46_0.1uM Dose=0.1uM, (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate, P2X7 Receptor Antagonists;Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Calmodulin Antagonists targeting CALM1, P2RX7, CAMK2A
HE-95-KK46_10uM Dose=10uM, (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate, P2X7 Receptor Antagonists;Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Calmodulin Antagonists targeting CALM1, P2RX7, CAMK2A
HE-95-KK46_1uM Dose=1uM, (S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate, P2X7 Receptor Antagonists;Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Calmodulin Antagonists targeting CALM1, P2RX7, CAMK2A
HE-99-KP87_0.01uM Dose=0.01uM, {4-[4-(4-Isopropoxyphenyl)-5-(4-trifluoromethoxyphenyl)thiazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARD
HE-99-KP87_0.1uM Dose=0.1uM, {4-[4-(4-Isopropoxyphenyl)-5-(4-trifluoromethoxyphenyl)thiazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARD
HE-99-KP87_10uM Dose=10uM, {4-[4-(4-Isopropoxyphenyl)-5-(4-trifluoromethoxyphenyl)thiazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARD
HE-99-KP87_1uM Dose=1uM, {4-[4-(4-Isopropoxyphenyl)-5-(4-trifluoromethoxyphenyl)thiazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARD
HF-00-QG19_0.01uM Dose=0.01uM, R-Psop, Neuromedin U Receptor 2 (NMU2) Ligands targeting NMUR2
HF-00-QG19_0.1uM Dose=0.1uM, R-Psop, Neuromedin U Receptor 2 (NMU2) Ligands targeting NMUR2
HF-00-QG19_10uM Dose=10uM, R-Psop, Neuromedin U Receptor 2 (NMU2) Ligands targeting NMUR2
HF-00-QG19_1uM Dose=1uM, R-Psop, Neuromedin U Receptor 2 (NMU2) Ligands targeting NMUR2
HF-01-QN73_0.01uM Dose=0.01uM, 1-Isopropyl-1h-1,2,3-benzotriazole-5-carboxylic acid, GPR109B agonist;HM74) Receptor Agonists;GPR109B;Nicotinic Acid (Niacin targeting HCAR3
HF-01-QN73_0.1uM Dose=0.1uM, 1-Isopropyl-1h-1,2,3-benzotriazole-5-carboxylic acid, GPR109B agonist;HM74) Receptor Agonists;GPR109B;Nicotinic Acid (Niacin targeting HCAR3
HF-01-QN73_10uM Dose=10uM, 1-Isopropyl-1h-1,2,3-benzotriazole-5-carboxylic acid, GPR109B agonist;HM74) Receptor Agonists;GPR109B;Nicotinic Acid (Niacin targeting HCAR3
HF-07-ER47_0.01uM Dose=0.01uM, 1H-Indole, 3-(3-pyridinylmethyl)-
HF-07-ER47_0.1uM Dose=0.1uM, 1H-Indole, 3-(3-pyridinylmethyl)-
HF-07-ER47_10uM Dose=10uM, 1H-Indole, 3-(3-pyridinylmethyl)-
HF-07-ER47_1uM Dose=1uM, 1H-Indole, 3-(3-pyridinylmethyl)-
HF-25-LA47_0.01uM Dose=0.01uM, Cathepsin inhibitor 1, Cathepsin L Inhibitors targeting CTSL, CTSV, CTSL3P
HF-25-LA47_0.1uM Dose=0.1uM, Cathepsin inhibitor 1, Cathepsin L Inhibitors targeting CTSL, CTSV, CTSL3P
HF-25-LA47_10uM Dose=10uM, Cathepsin inhibitor 1, Cathepsin L Inhibitors targeting CTSL, CTSV, CTSL3P
HF-25-LA47_1uM Dose=1uM, Cathepsin inhibitor 1, Cathepsin L Inhibitors targeting CTSL, CTSV, CTSL3P
HF-29-JW14_0.01uM Dose=0.01uM, Latrepirdine, NMDA Antagonists;5-HT6 Antagonists targeting HTR6
HF-29-JW14_0.1uM Dose=0.1uM, Latrepirdine, NMDA Antagonists;5-HT6 Antagonists targeting HTR6
HF-29-JW14_10uM Dose=10uM, Latrepirdine, NMDA Antagonists;5-HT6 Antagonists targeting HTR6
HF-29-JW14_1uM Dose=1uM, Latrepirdine, NMDA Antagonists;5-HT6 Antagonists targeting HTR6
HF-33-KS15_0.01uM Dose=0.01uM, l-Menthol, TRPM8 (TRP-p8;CMR1) Agonists targeting TRPM8
HF-33-KS15_0.1uM Dose=0.1uM, l-Menthol, TRPM8 (TRP-p8;CMR1) Agonists targeting TRPM8
HF-33-KS15_1uM Dose=1uM, l-Menthol, TRPM8 (TRP-p8;CMR1) Agonists targeting TRPM8
HF-35-HT37_0.01uM Dose=0.01uM
HF-35-HT37_0.1uM Dose=0.1uM
HF-35-HT37_10uM Dose=10uM
HF-35-HT37_1uM Dose=1uM
HF-36-FK93_0.01uM Dose=0.01uM, (2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide, SPHK1 inhibitor targeting SPHK1
HF-36-FK93_0.1uM Dose=0.1uM, (2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide, SPHK1 inhibitor targeting SPHK1
HF-36-FK93_10uM Dose=10uM, (2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide, SPHK1 inhibitor targeting SPHK1
HF-36-FK93_1uM Dose=1uM, (2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide, SPHK1 inhibitor targeting SPHK1
HF-39-BC66_0.01uM Dose=0.01uM, 8-amino-N-cyclopropyl-2-(3-fluorophenyl)-1,7-naphthyridine-5-carboxamide, MAP4K4 inhibitor targeting MAP4K4
HF-39-BC66_0.1uM Dose=0.1uM, 8-amino-N-cyclopropyl-2-(3-fluorophenyl)-1,7-naphthyridine-5-carboxamide, MAP4K4 inhibitor targeting MAP4K4
HF-39-BC66_10uM Dose=10uM, 8-amino-N-cyclopropyl-2-(3-fluorophenyl)-1,7-naphthyridine-5-carboxamide, MAP4K4 inhibitor targeting MAP4K4
HF-51-NR28_0.01uM Dose=0.01uM, 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide, ARP2/3 Complex inhibitor targeting ACTR3, ACTR2
HF-51-NR28_0.1uM Dose=0.1uM, 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide, ARP2/3 Complex inhibitor targeting ACTR3, ACTR2
HF-51-NR28_10uM Dose=10uM, 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide, ARP2/3 Complex inhibitor targeting ACTR3, ACTR2
HF-51-NR28_1uM Dose=1uM, 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide, ARP2/3 Complex inhibitor targeting ACTR3, ACTR2
HF-57-QB74_0.01uM Dose=0.01uM, Ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate, steroidogenic factor 1 inhibitor;NR5A1 inhibitor targeting NR5A1
HF-57-QB74_0.1uM Dose=0.1uM, Ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate, steroidogenic factor 1 inhibitor;NR5A1 inhibitor targeting NR5A1
HF-57-QB74_10uM Dose=10uM, Ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate, steroidogenic factor 1 inhibitor;NR5A1 inhibitor targeting NR5A1
HF-57-QB74_1uM Dose=1uM, Ethyl 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate, steroidogenic factor 1 inhibitor;NR5A1 inhibitor targeting NR5A1
HF-66-BD96_0.01uM Dose=0.01uM
HF-66-BD96_0.1uM Dose=0.1uM
HF-66-BD96_1uM Dose=1uM
HF-67-IR57_0.01uM Dose=0.01uM
HF-67-IR57_0.1uM Dose=0.1uM
HF-67-IR57_10uM Dose=10uM
HF-67-IR57_1uM Dose=1uM
HF-68-PM58_0.01uM Dose=0.01uM
HF-68-PM58_10uM Dose=10uM
HF-73-FS05_0.01uM Dose=0.01uM, 13-(Methylamino)-23,24,25-Trioxa-17,18,19,21-Tetrazatetracyclo-Tricosa-1(3),2(10),4(11),12(14),13(18),16(19)-Hexan-15-One, NUDT1 inhibitor;NUDT1 Inhibitor targeting NUDT1
HF-73-FS05_0.1uM Dose=0.1uM, 13-(Methylamino)-23,24,25-Trioxa-17,18,19,21-Tetrazatetracyclo-Tricosa-1(3),2(10),4(11),12(14),13(18),16(19)-Hexan-15-One, NUDT1 inhibitor;NUDT1 Inhibitor targeting NUDT1
HF-73-FS05_10uM Dose=10uM, 13-(Methylamino)-23,24,25-Trioxa-17,18,19,21-Tetrazatetracyclo-Tricosa-1(3),2(10),4(11),12(14),13(18),16(19)-Hexan-15-One, NUDT1 inhibitor;NUDT1 Inhibitor targeting NUDT1
HF-76-AK33_0.01uM Dose=0.01uM, VU0409551, GRM5 positive allosteric modulator targeting GRM5
HF-76-AK33_0.1uM Dose=0.1uM, VU0409551, GRM5 positive allosteric modulator targeting GRM5
HF-76-AK33_10uM Dose=10uM, VU0409551, GRM5 positive allosteric modulator targeting GRM5
HF-76-AK33_1uM Dose=1uM, VU0409551, GRM5 positive allosteric modulator targeting GRM5
HF-79-EC41_0.01uM Dose=0.01uM, Blu-9931, FGFR4 inhibior targeting FGFR4
HF-79-EC41_0.1uM Dose=0.1uM, Blu-9931, FGFR4 inhibior targeting FGFR4
HF-79-EC41_10uM Dose=10uM, Blu-9931, FGFR4 inhibior targeting FGFR4
HF-79-EC41_1uM Dose=1uM, Blu-9931, FGFR4 inhibior targeting FGFR4
HF-82-PE14_0.01uM Dose=0.01uM
HF-82-PE14_0.1uM Dose=0.1uM
HF-82-PE14_10uM Dose=10uM
HF-82-PE14_1uM Dose=1uM
HF-91-IU60_0.01uM Dose=0.01uM, PD-166326, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, BCR, SRC, ABL2
HF-91-IU60_0.1uM Dose=0.1uM, PD-166326, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, BCR, SRC, ABL2
HF-91-IU60_10uM Dose=10uM, PD-166326, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, BCR, SRC, ABL2
HF-91-IU60_1uM Dose=1uM, PD-166326, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, BCR, SRC, ABL2
IA-00-RJ06_0.01uM Dose=0.01uM, N-(3-methylphenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
IA-00-RJ06_0.1uM Dose=0.1uM, N-(3-methylphenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
IA-00-RJ06_1uM Dose=1uM, N-(3-methylphenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
IA-03-BO30_0.01uM Dose=0.01uM, Methyl gallate, 5-Lipoxygenase Inhibitors;Cyclooxygenase-2 Inhibitors;Antioxidants targeting ALOX5, PTGS2
IA-03-BO30_0.1uM Dose=0.1uM, Methyl gallate, 5-Lipoxygenase Inhibitors;Cyclooxygenase-2 Inhibitors;Antioxidants targeting ALOX5, PTGS2
IA-03-BO30_10uM Dose=10uM, Methyl gallate, 5-Lipoxygenase Inhibitors;Cyclooxygenase-2 Inhibitors;Antioxidants targeting ALOX5, PTGS2
IA-03-BO30_1uM Dose=1uM, Methyl gallate, 5-Lipoxygenase Inhibitors;Cyclooxygenase-2 Inhibitors;Antioxidants targeting ALOX5, PTGS2
IA-08-DE38_0.01uM Dose=0.01uM
IA-08-DE38_0.1uM Dose=0.1uM
IA-08-DE38_10uM Dose=10uM
IA-10-ET40_0.01uM Dose=0.01uM, Anpirtoline, 5-HT1B Agonists targeting HTR1B
IA-10-ET40_10uM Dose=10uM, Anpirtoline, 5-HT1B Agonists targeting HTR1B
IA-10-ET40_1uM Dose=1uM, Anpirtoline, 5-HT1B Agonists targeting HTR1B
IA-13-FI66_0.01uM Dose=0.01uM, Way-213613, Excitatory amino acid transporter 2 inhibitor targeting SLC1A2
IA-13-FI66_0.1uM Dose=0.1uM, Way-213613, Excitatory amino acid transporter 2 inhibitor targeting SLC1A2
IA-13-FI66_10uM Dose=10uM, Way-213613, Excitatory amino acid transporter 2 inhibitor targeting SLC1A2
IA-13-FI66_1uM Dose=1uM, Way-213613, Excitatory amino acid transporter 2 inhibitor targeting SLC1A2
IA-14-WP20_0.01uM Dose=0.01uM, Tazarotene, Ornithine Decarboxylase Inhibitors;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists targeting ODC1, RARB, RARG
IA-14-WP20_0.1uM Dose=0.1uM, Tazarotene, Ornithine Decarboxylase Inhibitors;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists targeting ODC1, RARB, RARG
IA-14-WP20_10uM Dose=10uM, Tazarotene, Ornithine Decarboxylase Inhibitors;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists targeting ODC1, RARB, RARG
IA-14-WP20_1uM Dose=1uM, Tazarotene, Ornithine Decarboxylase Inhibitors;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists targeting ODC1, RARB, RARG
IA-19-ET52_0.01uM Dose=0.01uM, 2'-Deoxyadenosine
IA-19-ET52_0.1uM Dose=0.1uM, 2'-Deoxyadenosine
IA-19-ET52_10uM Dose=10uM, 2'-Deoxyadenosine
IA-19-ET52_1uM Dose=1uM, 2'-Deoxyadenosine
IA-23-DB04_0.01uM Dose=0.01uM, Avatrombopag, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL
IA-23-DB04_0.1uM Dose=0.1uM, Avatrombopag, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL
IA-23-DB04_10uM Dose=10uM, Avatrombopag, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL
IA-23-DB04_1uM Dose=1uM, Avatrombopag, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL
IA-27-CK10_0.01uM Dose=0.01uM, Sch 28080, Reversible H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
IA-27-CK10_0.1uM Dose=0.1uM, Sch 28080, Reversible H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
IA-27-CK10_10uM Dose=10uM, Sch 28080, Reversible H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
IA-27-CK10_1uM Dose=1uM, Sch 28080, Reversible H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B
IA-28-VB61_0.01uM Dose=0.01uM
IA-28-VB61_0.1uM Dose=0.1uM
IA-28-VB61_10uM Dose=10uM
IA-28-VB61_1uM Dose=1uM
IA-35-KC86_0.01uM Dose=0.01uM, L-lobeline free base
IA-35-KC86_0.1uM Dose=0.1uM, L-lobeline free base
IA-35-KC86_10uM Dose=10uM, L-lobeline free base
IA-35-KC86_1uM Dose=1uM, L-lobeline free base
IA-35-VT87_0.01uM Dose=0.01uM, Gka-50, Glucose Lowering Agents;Glucokinase Activators targeting GCK
IA-35-VT87_0.1uM Dose=0.1uM, Gka-50, Glucose Lowering Agents;Glucokinase Activators targeting GCK
IA-35-VT87_10uM Dose=10uM, Gka-50, Glucose Lowering Agents;Glucokinase Activators targeting GCK
IA-35-VT87_1uM Dose=1uM, Gka-50, Glucose Lowering Agents;Glucokinase Activators targeting GCK
IA-37-FR87_0.01uM Dose=0.01uM, Pexacerfont, CRF1 Antagonists targeting CRHR1
IA-37-FR87_0.1uM Dose=0.1uM, Pexacerfont, CRF1 Antagonists targeting CRHR1
IA-37-FR87_10uM Dose=10uM, Pexacerfont, CRF1 Antagonists targeting CRHR1
IA-38-XE73_0.01uM Dose=0.01uM, 1-[(Z)-2-Cyclohexyloxy-2-(2,4-dichloro-phenyl)-vinyl]-1H-[1,2,4]triazole, mgluR2 Antagonists;mgluR3 Antagonists targeting GRM2, GRM3
IA-38-XE73_0.1uM Dose=0.1uM, 1-[(Z)-2-Cyclohexyloxy-2-(2,4-dichloro-phenyl)-vinyl]-1H-[1,2,4]triazole, mgluR2 Antagonists;mgluR3 Antagonists targeting GRM2, GRM3
IA-38-XE73_10uM Dose=10uM, 1-[(Z)-2-Cyclohexyloxy-2-(2,4-dichloro-phenyl)-vinyl]-1H-[1,2,4]triazole, mgluR2 Antagonists;mgluR3 Antagonists targeting GRM2, GRM3
IA-38-XE73_1uM Dose=1uM, 1-[(Z)-2-Cyclohexyloxy-2-(2,4-dichloro-phenyl)-vinyl]-1H-[1,2,4]triazole, mgluR2 Antagonists;mgluR3 Antagonists targeting GRM2, GRM3
IA-41-GR68_0.01uM Dose=0.01uM, (3S)-3-Amino-4-sulfanylbutane-1-sulfonic acid, Glutamyl Aminopeptidase (Aminopeptidase A) Inhibitors targeting ENPEP
IA-41-GR68_0.1uM Dose=0.1uM, (3S)-3-Amino-4-sulfanylbutane-1-sulfonic acid, Glutamyl Aminopeptidase (Aminopeptidase A) Inhibitors targeting ENPEP
IA-41-GR68_10uM Dose=10uM, (3S)-3-Amino-4-sulfanylbutane-1-sulfonic acid, Glutamyl Aminopeptidase (Aminopeptidase A) Inhibitors targeting ENPEP
IA-41-GR68_1uM Dose=1uM, (3S)-3-Amino-4-sulfanylbutane-1-sulfonic acid, Glutamyl Aminopeptidase (Aminopeptidase A) Inhibitors targeting ENPEP
IA-41-VQ90_0.01uM Dose=0.01uM
IA-41-VQ90_0.1uM Dose=0.1uM
IA-41-VQ90_10uM Dose=10uM
IA-41-VQ90_1uM Dose=1uM
IA-48-KI53_0.01uM Dose=0.01uM, Vinaxanthone, semaphorin inhibitor targeting SEMA3A
IA-48-KI53_0.1uM Dose=0.1uM, Vinaxanthone, semaphorin inhibitor targeting SEMA3A
IA-48-KI53_10uM Dose=10uM, Vinaxanthone, semaphorin inhibitor targeting SEMA3A
IA-48-KI53_1uM Dose=1uM, Vinaxanthone, semaphorin inhibitor targeting SEMA3A
IA-50-ET40_0.01uM Dose=0.01uM, N-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide, dual CHRM2/CHRM4 antagonist targeting CHRM2, CHRM4
IA-50-ET40_10uM Dose=10uM, N-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide, dual CHRM2/CHRM4 antagonist targeting CHRM2, CHRM4
IA-50-ET40_1uM Dose=1uM, N-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide, dual CHRM2/CHRM4 antagonist targeting CHRM2, CHRM4
IA-65-QX27_0.01uM Dose=0.01uM, 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione, 5-HT1A Receptor Antagonists;alpha1D-Adrenoceptor Antagonists targeting ADRA1D, HTR1A
IA-65-QX27_0.1uM Dose=0.1uM, 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione, 5-HT1A Receptor Antagonists;alpha1D-Adrenoceptor Antagonists targeting ADRA1D, HTR1A
IA-65-QX27_10uM Dose=10uM, 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione, 5-HT1A Receptor Antagonists;alpha1D-Adrenoceptor Antagonists targeting ADRA1D, HTR1A
IA-65-QX27_1uM Dose=1uM, 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione, 5-HT1A Receptor Antagonists;alpha1D-Adrenoceptor Antagonists targeting ADRA1D, HTR1A
IA-67-CK10_0.01uM Dose=0.01uM, 1-Amino-4-m-anisidino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonic acid
IA-67-CK10_0.1uM Dose=0.1uM, 1-Amino-4-m-anisidino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonic acid
IA-67-CK10_10uM Dose=10uM, 1-Amino-4-m-anisidino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonic acid
IA-67-CK10_1uM Dose=1uM, 1-Amino-4-m-anisidino-9,10-dihydro-9,10-dioxoanthracene-2-sulphonic acid
IA-67-NA51_0.01uM Dose=0.01uM, 3-[2-(Pyridin-2-ylamino)-5-pyrimidin-4-yl-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists targeting ADORA2B
IA-67-NA51_10uM Dose=10uM, 3-[2-(Pyridin-2-ylamino)-5-pyrimidin-4-yl-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists targeting ADORA2B
IA-67-NA51_1uM Dose=1uM, 3-[2-(Pyridin-2-ylamino)-5-pyrimidin-4-yl-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists targeting ADORA2B
IA-75-LQ65_0.01uM Dose=0.01uM, Enasidenib, IDH2 R140Q mutant inhibitor targeting IDH2
IA-75-LQ65_0.1uM Dose=0.1uM, Enasidenib, IDH2 R140Q mutant inhibitor targeting IDH2
IA-75-LQ65_10uM Dose=10uM, Enasidenib, IDH2 R140Q mutant inhibitor targeting IDH2
IA-75-LQ65_1uM Dose=1uM, Enasidenib, IDH2 R140Q mutant inhibitor targeting IDH2
IA-76-YQ42_0.01uM Dose=0.01uM, 2-{[4-(dimethylamino)benzene](2-methylpropyl)sulfonamido}-N-hydroxyacetamide
IA-76-YQ42_0.1uM Dose=0.1uM, 2-{[4-(dimethylamino)benzene](2-methylpropyl)sulfonamido}-N-hydroxyacetamide
IA-76-YQ42_10uM Dose=10uM, 2-{[4-(dimethylamino)benzene](2-methylpropyl)sulfonamido}-N-hydroxyacetamide
IA-76-YQ42_1uM Dose=1uM, 2-{[4-(dimethylamino)benzene](2-methylpropyl)sulfonamido}-N-hydroxyacetamide
IA-76-ZU47_0.01uM Dose=0.01uM, hSMG-1 inhibitor 11e, SMG1 gene inhibitor targeting SMG1
IA-76-ZU47_0.1uM Dose=0.1uM, hSMG-1 inhibitor 11e, SMG1 gene inhibitor targeting SMG1
IA-76-ZU47_10uM Dose=10uM, hSMG-1 inhibitor 11e, SMG1 gene inhibitor targeting SMG1
IA-76-ZU47_1uM Dose=1uM, hSMG-1 inhibitor 11e, SMG1 gene inhibitor targeting SMG1
IA-77-NA41_0.01uM Dose=0.01uM, 6-(4-((diethylamino)methyl)benzyl)-7-neopentyl-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK
IA-77-NA41_10uM Dose=10uM, 6-(4-((diethylamino)methyl)benzyl)-7-neopentyl-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK
IA-77-NA41_1uM Dose=1uM, 6-(4-((diethylamino)methyl)benzyl)-7-neopentyl-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK
IA-80-OW42_0.01uM Dose=0.01uM, N-(3-Ethoxycarbonyloxirane-2-carbonyl)-isoleucyl-proline, Cathepsin B Inhibitors targeting CTSB
IA-80-OW42_0.1uM Dose=0.1uM, N-(3-Ethoxycarbonyloxirane-2-carbonyl)-isoleucyl-proline, Cathepsin B Inhibitors targeting CTSB
IA-80-OW42_10uM Dose=10uM, N-(3-Ethoxycarbonyloxirane-2-carbonyl)-isoleucyl-proline, Cathepsin B Inhibitors targeting CTSB
IA-80-OW42_1uM Dose=1uM, N-(3-Ethoxycarbonyloxirane-2-carbonyl)-isoleucyl-proline, Cathepsin B Inhibitors targeting CTSB
IA-84-ES37_0.01uM Dose=0.01uM, (6aS,10aS)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
IA-84-ES37_0.1uM Dose=0.1uM, (6aS,10aS)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
IA-84-ES37_10uM Dose=10uM, (6aS,10aS)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
IA-84-ES37_1uM Dose=1uM, (6aS,10aS)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
IA-94-MZ54_0.01uM Dose=0.01uM, BC-1215, FBXO3 gene inhibitor targeting FBXO3
IA-94-MZ54_0.1uM Dose=0.1uM, BC-1215, FBXO3 gene inhibitor targeting FBXO3
IA-94-MZ54_10uM Dose=10uM, BC-1215, FBXO3 gene inhibitor targeting FBXO3
IA-94-MZ54_1uM Dose=1uM, BC-1215, FBXO3 gene inhibitor targeting FBXO3
IA-95-KW09_0.01uM Dose=0.01uM, (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester, Leukotriene Antagonists targeting CYSLTR1
IA-95-KW09_0.1uM Dose=0.1uM, (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester, Leukotriene Antagonists targeting CYSLTR1
IA-95-KW09_10uM Dose=10uM, (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester, Leukotriene Antagonists targeting CYSLTR1
IA-95-KW09_1uM Dose=1uM, (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester, Leukotriene Antagonists targeting CYSLTR1
IA-97-VE31_0.01uM Dose=0.01uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-7-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN
IA-97-VE31_0.1uM Dose=0.1uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-7-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN
IA-97-VE31_10uM Dose=10uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-7-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN
IA-97-VE31_1uM Dose=1uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-7-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN
IB-06-YD91_0.01uM Dose=0.01uM, dual thymidylate synthase and dihydrofolate reductase inhibitors targeting DHFR, FOLR1, GART, SLC19A1, TYMS
IB-06-YD91_0.1uM Dose=0.1uM, dual thymidylate synthase and dihydrofolate reductase inhibitors targeting DHFR, FOLR1, GART, SLC19A1, TYMS
IB-06-YD91_10uM Dose=10uM, dual thymidylate synthase and dihydrofolate reductase inhibitors targeting DHFR, FOLR1, GART, SLC19A1, TYMS
IB-06-YD91_1uM Dose=1uM, dual thymidylate synthase and dihydrofolate reductase inhibitors targeting DHFR, FOLR1, GART, SLC19A1, TYMS
IB-08-VY61_0.01uM Dose=0.01uM, Rivanicline, Nicotinic alpha4beta2 Agonists;Nicotinic Receptor Agonists targeting CHRNA4, CHRNB2
IB-08-VY61_0.1uM Dose=0.1uM, Rivanicline, Nicotinic alpha4beta2 Agonists;Nicotinic Receptor Agonists targeting CHRNA4, CHRNB2
IB-08-VY61_10uM Dose=10uM, Rivanicline, Nicotinic alpha4beta2 Agonists;Nicotinic Receptor Agonists targeting CHRNA4, CHRNB2
IB-08-VY61_1uM Dose=1uM, Rivanicline, Nicotinic alpha4beta2 Agonists;Nicotinic Receptor Agonists targeting CHRNA4, CHRNB2
IB-14-XS97_0.01uM Dose=0.01uM, Pomalidomide-6-OH, E3 ligase inhibitor;CRBN neomorph targeting CRBN
IB-14-XS97_0.1uM Dose=0.1uM, Pomalidomide-6-OH, E3 ligase inhibitor;CRBN neomorph targeting CRBN
IB-14-XS97_10uM Dose=10uM, Pomalidomide-6-OH, E3 ligase inhibitor;CRBN neomorph targeting CRBN
IB-14-XS97_1uM Dose=1uM, Pomalidomide-6-OH, E3 ligase inhibitor;CRBN neomorph targeting CRBN
IB-14-YP50_0.01uM Dose=0.01uM, Sar405, VPS34 inhibitor targeting PIK3C3
IB-14-YP50_0.1uM Dose=0.1uM, Sar405, VPS34 inhibitor targeting PIK3C3
IB-14-YP50_10uM Dose=10uM, Sar405, VPS34 inhibitor targeting PIK3C3
IB-14-YP50_1uM Dose=1uM, Sar405, VPS34 inhibitor targeting PIK3C3
IB-23-AO00_0.01uM Dose=0.01uM, 6-Amino-4-[(3-methylphenyl)amino]quinazoline, Inhibitors of Signal Transduction Pathways;Tyrosine Kinase Inhibitors targeting EGFR, TIE1
IB-23-AO00_0.1uM Dose=0.1uM, 6-Amino-4-[(3-methylphenyl)amino]quinazoline, Inhibitors of Signal Transduction Pathways;Tyrosine Kinase Inhibitors targeting EGFR, TIE1
IB-23-AO00_10uM Dose=10uM, 6-Amino-4-[(3-methylphenyl)amino]quinazoline, Inhibitors of Signal Transduction Pathways;Tyrosine Kinase Inhibitors targeting EGFR, TIE1
IB-26-FG03_0.01uM Dose=0.01uM, 3-(2-amino-2-methylpropyl)-1H-indol-5-ol
IB-26-FG03_0.1uM Dose=0.1uM, 3-(2-amino-2-methylpropyl)-1H-indol-5-ol
IB-26-FG03_10uM Dose=10uM, 3-(2-amino-2-methylpropyl)-1H-indol-5-ol
IB-26-FG03_1uM Dose=1uM, 3-(2-amino-2-methylpropyl)-1H-indol-5-ol
IB-30-KN41_0.01uM Dose=0.01uM, ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate, Known Thrombin inhibitor targeting F2
IB-30-KN41_0.1uM Dose=0.1uM, ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate, Known Thrombin inhibitor targeting F2
IB-30-KN41_10uM Dose=10uM, ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate, Known Thrombin inhibitor targeting F2
IB-30-KN41_1uM Dose=1uM, ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate, Known Thrombin inhibitor targeting F2
IB-33-TE51_0.01uM Dose=0.01uM, 5-methyl-10H-indolo[3,2-b]quinolin-5-ium
IB-33-TE51_0.1uM Dose=0.1uM, 5-methyl-10H-indolo[3,2-b]quinolin-5-ium
IB-33-TE51_10uM Dose=10uM, 5-methyl-10H-indolo[3,2-b]quinolin-5-ium
IB-33-TE51_1uM Dose=1uM, 5-methyl-10H-indolo[3,2-b]quinolin-5-ium
IB-34-OS52_0.01uM Dose=0.01uM, (R)-2-Amino-3-(4-bromo-1H-indole-2-carboxamido)propanoic acid, NMDA Glycine-Site Modulators targeting GRIN1
IB-34-OS52_10uM Dose=10uM, (R)-2-Amino-3-(4-bromo-1H-indole-2-carboxamido)propanoic acid, NMDA Glycine-Site Modulators targeting GRIN1
IB-34-OS52_1uM Dose=1uM, (R)-2-Amino-3-(4-bromo-1H-indole-2-carboxamido)propanoic acid, NMDA Glycine-Site Modulators targeting GRIN1
IB-39-YI25_0.01uM Dose=0.01uM, CHRM2 antagonist;Muscarinic M2 Antagonists
IB-42-HL06_0.01uM Dose=0.01uM, N-((1R,3aS,3bS,9aR,9bS,11aR)-9a,11a-dimethyl-1-((2R)-6-methylheptan-2-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta(a)phenanthren-7-ylidene)hydroxylamine, neuroprotective;Mitochondrial VDAC channel blocker targeting VDAC1
IB-42-HL06_0.1uM Dose=0.1uM, N-((1R,3aS,3bS,9aR,9bS,11aR)-9a,11a-dimethyl-1-((2R)-6-methylheptan-2-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta(a)phenanthren-7-ylidene)hydroxylamine, neuroprotective;Mitochondrial VDAC channel blocker targeting VDAC1
IB-42-HL06_1uM Dose=1uM, N-((1R,3aS,3bS,9aR,9bS,11aR)-9a,11a-dimethyl-1-((2R)-6-methylheptan-2-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta(a)phenanthren-7-ylidene)hydroxylamine, neuroprotective;Mitochondrial VDAC channel blocker targeting VDAC1
IB-56-BR35_0.01uM Dose=0.01uM, Eptifibatide, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways targeting ITGA2B, ITGA3
IB-56-BR35_0.1uM Dose=0.1uM, Eptifibatide, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways targeting ITGA2B, ITGA3
IB-56-BR35_10uM Dose=10uM, Eptifibatide, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways targeting ITGA2B, ITGA3
IB-56-BR35_1uM Dose=1uM, Eptifibatide, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways targeting ITGA2B, ITGA3
IB-56-JN40_0.01uM Dose=0.01uM, Y-33075, Rho Kinase Inhibitors targeting ROCK1, ROCK2
IB-56-JN40_0.1uM Dose=0.1uM, Y-33075, Rho Kinase Inhibitors targeting ROCK1, ROCK2
IB-56-JN40_10uM Dose=10uM, Y-33075, Rho Kinase Inhibitors targeting ROCK1, ROCK2
IB-56-JN40_1uM Dose=1uM, Y-33075, Rho Kinase Inhibitors targeting ROCK1, ROCK2
IB-59-SI50_0.01uM Dose=0.01uM, (E)-N-hydroxy-3-[4-[[2-(5-phenylmethoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
IB-59-SI50_0.1uM Dose=0.1uM, (E)-N-hydroxy-3-[4-[[2-(5-phenylmethoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
IB-59-SI50_10uM Dose=10uM, (E)-N-hydroxy-3-[4-[[2-(5-phenylmethoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
IB-59-SI50_1uM Dose=1uM, (E)-N-hydroxy-3-[4-[[2-(5-phenylmethoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
IB-67-WH43_0.01uM Dose=0.01uM, 4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid, mgluR1 Antagonists targeting GRM1
IB-67-WH43_0.1uM Dose=0.1uM, 4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid, mgluR1 Antagonists targeting GRM1
IB-67-WH43_10uM Dose=10uM, 4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid, mgluR1 Antagonists targeting GRM1
IB-67-WH43_1uM Dose=1uM, 4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid, mgluR1 Antagonists targeting GRM1
IB-78-AY41_0.01uM Dose=0.01uM, 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Cyclooxygenase-2 Inhibitors targeting SC5D
IB-78-AY41_0.1uM Dose=0.1uM, 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Cyclooxygenase-2 Inhibitors targeting SC5D
IB-78-AY41_1uM Dose=1uM, 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Cyclooxygenase-2 Inhibitors targeting SC5D
IB-80-NT15_0.01uM Dose=0.01uM, (4R)-N-[2-(dimethylamino)ethyl]-1-[4-[(2-fluorobenzoyl)amino]benzoyl]spiro[3,5-dihydro-2H-1-benzazepine-4,3'-cyclopentene]-1'-carboxamide, Vasopressin (AVP) V1a Antagonists targeting AVPR1A
IB-80-NT15_0.1uM Dose=0.1uM, (4R)-N-[2-(dimethylamino)ethyl]-1-[4-[(2-fluorobenzoyl)amino]benzoyl]spiro[3,5-dihydro-2H-1-benzazepine-4,3'-cyclopentene]-1'-carboxamide, Vasopressin (AVP) V1a Antagonists targeting AVPR1A
IB-80-NT15_10uM Dose=10uM, (4R)-N-[2-(dimethylamino)ethyl]-1-[4-[(2-fluorobenzoyl)amino]benzoyl]spiro[3,5-dihydro-2H-1-benzazepine-4,3'-cyclopentene]-1'-carboxamide, Vasopressin (AVP) V1a Antagonists targeting AVPR1A
IB-80-NT15_1uM Dose=1uM, (4R)-N-[2-(dimethylamino)ethyl]-1-[4-[(2-fluorobenzoyl)amino]benzoyl]spiro[3,5-dihydro-2H-1-benzazepine-4,3'-cyclopentene]-1'-carboxamide, Vasopressin (AVP) V1a Antagonists targeting AVPR1A
IB-80-NT65_0.01uM Dose=0.01uM
IB-80-NT65_0.1uM Dose=0.1uM
IB-80-NT65_10uM Dose=10uM
IB-80-NT65_1uM Dose=1uM
IB-87-IU44_0.01uM Dose=0.01uM, Thymol
IB-87-IU44_0.1uM Dose=0.1uM, Thymol
IB-87-IU44_10uM Dose=10uM, Thymol
IB-87-IU44_1uM Dose=1uM, Thymol
IB-87-ZR37_0.01uM Dose=0.01uM, 6-Chloro-2-[(4-chlorophenyl)methylsulfanyl]-1-(4-ethoxyphenyl)benzimidazole, Free Fatty Acid Receptor 1 (FFAR1;GPR40) Antagonists targeting FFAR1
IB-87-ZR37_0.1uM Dose=0.1uM, 6-Chloro-2-[(4-chlorophenyl)methylsulfanyl]-1-(4-ethoxyphenyl)benzimidazole, Free Fatty Acid Receptor 1 (FFAR1;GPR40) Antagonists targeting FFAR1
IB-87-ZR37_10uM Dose=10uM, 6-Chloro-2-[(4-chlorophenyl)methylsulfanyl]-1-(4-ethoxyphenyl)benzimidazole, Free Fatty Acid Receptor 1 (FFAR1;GPR40) Antagonists targeting FFAR1
IB-87-ZR37_1uM Dose=1uM, 6-Chloro-2-[(4-chlorophenyl)methylsulfanyl]-1-(4-ethoxyphenyl)benzimidazole, Free Fatty Acid Receptor 1 (FFAR1;GPR40) Antagonists targeting FFAR1
IB-88-LO32_0.01uM Dose=0.01uM, Sch 37370, Histamine H1 Receptor Antagonists;Platelet-Activating Factor Receptor (PAFR) Antagonists;Non-Steroidal Antiinflammatory Drugs targeting HRH1, PTAFR
IB-88-LO32_0.1uM Dose=0.1uM, Sch 37370, Histamine H1 Receptor Antagonists;Platelet-Activating Factor Receptor (PAFR) Antagonists;Non-Steroidal Antiinflammatory Drugs targeting HRH1, PTAFR
IB-88-LO32_10uM Dose=10uM, Sch 37370, Histamine H1 Receptor Antagonists;Platelet-Activating Factor Receptor (PAFR) Antagonists;Non-Steroidal Antiinflammatory Drugs targeting HRH1, PTAFR
IB-88-LO32_1uM Dose=1uM, Sch 37370, Histamine H1 Receptor Antagonists;Platelet-Activating Factor Receptor (PAFR) Antagonists;Non-Steroidal Antiinflammatory Drugs targeting HRH1, PTAFR
IB-89-RS34_0.01uM Dose=0.01uM, Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2
IB-89-RS34_0.1uM Dose=0.1uM, Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2
IB-89-RS34_10uM Dose=10uM, Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2
IB-89-RS34_1uM Dose=1uM, Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2
IB-90-MD82_0.01uM Dose=0.01uM, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine
IB-90-MD82_0.1uM Dose=0.1uM, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine
IB-90-MD82_10uM Dose=10uM, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine
IB-90-MD82_1uM Dose=1uM, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine
IB-92-XA34_0.01uM Dose=0.01uM, 3-Methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine, Anxiolytics targeting GABRA1
IB-92-XA34_0.1uM Dose=0.1uM, 3-Methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine, Anxiolytics targeting GABRA1
IB-92-XA34_10uM Dose=10uM, 3-Methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine, Anxiolytics targeting GABRA1
IB-92-XA34_1uM Dose=1uM, 3-Methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine, Anxiolytics targeting GABRA1
IB-94-WM88_0.01uM Dose=0.01uM, Ethyl 4-[2-(4,6-dimethyl-3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)acetyl]piperazine-1-carboxylate, DTYMK inhibitor targeting DTYMK
IB-94-WM88_0.1uM Dose=0.1uM, Ethyl 4-[2-(4,6-dimethyl-3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)acetyl]piperazine-1-carboxylate, DTYMK inhibitor targeting DTYMK
IB-94-WM88_10uM Dose=10uM, Ethyl 4-[2-(4,6-dimethyl-3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)acetyl]piperazine-1-carboxylate, DTYMK inhibitor targeting DTYMK
IB-94-WM88_1uM Dose=1uM, Ethyl 4-[2-(4,6-dimethyl-3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)acetyl]piperazine-1-carboxylate, DTYMK inhibitor targeting DTYMK
IB-96-PK68_0.01uM Dose=0.01uM
IB-96-PK68_0.1uM Dose=0.1uM
IB-96-PK68_10uM Dose=10uM
IB-96-PK68_1uM Dose=1uM
IC-05-AW29_0.01uM Dose=0.01uM, Malotilate
IC-05-AW29_0.1uM Dose=0.1uM, Malotilate
IC-05-AW29_10uM Dose=10uM, Malotilate
IC-05-AW29_1uM Dose=1uM, Malotilate
IC-05-WD74_0.01uM Dose=0.01uM, N-[(2,6-dimethylphenyl)methyl]-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine, HRI Kinase inhibitor targeting EIF2AK1
IC-05-WD74_0.1uM Dose=0.1uM, N-[(2,6-dimethylphenyl)methyl]-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine, HRI Kinase inhibitor targeting EIF2AK1
IC-05-WD74_10uM Dose=10uM, N-[(2,6-dimethylphenyl)methyl]-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine, HRI Kinase inhibitor targeting EIF2AK1
IC-05-WD74_1uM Dose=1uM, N-[(2,6-dimethylphenyl)methyl]-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine, HRI Kinase inhibitor targeting EIF2AK1
IC-07-AK50_0.01uM Dose=0.01uM, 4-[[N-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
IC-07-AK50_0.1uM Dose=0.1uM, 4-[[N-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
IC-07-AK50_1uM Dose=1uM, 4-[[N-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
IC-07-VY79_0.01uM Dose=0.01uM, Formoterol, ADRB2 agonist targeting ADRB2
IC-07-VY79_0.1uM Dose=0.1uM, Formoterol, ADRB2 agonist targeting ADRB2
IC-07-VY79_10uM Dose=10uM, Formoterol, ADRB2 agonist targeting ADRB2
IC-07-VY79_1uM Dose=1uM, Formoterol, ADRB2 agonist targeting ADRB2
IC-08-NY46_0.01uM Dose=0.01uM, N-(3-phenoxycinnamyl)acetohydroxamic acid
IC-08-NY46_0.1uM Dose=0.1uM, N-(3-phenoxycinnamyl)acetohydroxamic acid
IC-08-NY46_10uM Dose=10uM, N-(3-phenoxycinnamyl)acetohydroxamic acid
IC-08-NY46_1uM Dose=1uM, N-(3-phenoxycinnamyl)acetohydroxamic acid
IC-15-FM25_0.01uM Dose=0.01uM, 2,4-Dioxo-6-phenylamino-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid phenylamide, SAPK1b (JNK3) Inhibitors targeting MAPK10
IC-15-FM25_10uM Dose=10uM, 2,4-Dioxo-6-phenylamino-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid phenylamide, SAPK1b (JNK3) Inhibitors targeting MAPK10
IC-15-FM25_1uM Dose=1uM, 2,4-Dioxo-6-phenylamino-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid phenylamide, SAPK1b (JNK3) Inhibitors targeting MAPK10
IC-18-TY61_0.01uM Dose=0.01uM, Silmitasertib, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B, MTOR, PIK3CD
IC-18-TY61_0.1uM Dose=0.1uM, Silmitasertib, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B, MTOR, PIK3CD
IC-18-TY61_10uM Dose=10uM, Silmitasertib, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B, MTOR, PIK3CD
IC-18-TY61_1uM Dose=1uM, Silmitasertib, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B, MTOR, PIK3CD
IC-23-YE16_0.01uM Dose=0.01uM, N-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide
IC-23-YE16_0.1uM Dose=0.1uM, N-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide
IC-23-YE16_10uM Dose=10uM, N-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide
IC-23-YE16_1uM Dose=1uM, N-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide
IC-27-TE11_0.01uM Dose=0.01uM, US9592235, Example 314, MAP4K4 inhibitor targeting MAP4K4
IC-27-TE11_0.1uM Dose=0.1uM, US9592235, Example 314, MAP4K4 inhibitor targeting MAP4K4
IC-27-TE11_10uM Dose=10uM, US9592235, Example 314, MAP4K4 inhibitor targeting MAP4K4
IC-27-TE11_1uM Dose=1uM, US9592235, Example 314, MAP4K4 inhibitor targeting MAP4K4
IC-28-HS37_0.01uM Dose=0.01uM, Nvs-cecr2-1, CECR2 inhibitor;CECR2 inhbitor targeting CECR2
IC-28-HS37_0.1uM Dose=0.1uM, Nvs-cecr2-1, CECR2 inhibitor;CECR2 inhbitor targeting CECR2
IC-28-HS37_10uM Dose=10uM, Nvs-cecr2-1, CECR2 inhibitor;CECR2 inhbitor targeting CECR2
IC-28-HS37_1uM Dose=1uM, Nvs-cecr2-1, CECR2 inhibitor;CECR2 inhbitor targeting CECR2
IC-37-QU39_0.01uM Dose=0.01uM, Emixustat, Retinoid Isomerohydrolase (RPE65) Inhibitors targeting RPE65
IC-37-QU39_10uM Dose=10uM, Emixustat, Retinoid Isomerohydrolase (RPE65) Inhibitors targeting RPE65
IC-37-QU39_1uM Dose=1uM, Emixustat, Retinoid Isomerohydrolase (RPE65) Inhibitors targeting RPE65
IC-43-CV07_0.01uM Dose=0.01uM
IC-43-CV07_0.1uM Dose=0.1uM
IC-43-CV07_10uM Dose=10uM
IC-43-CV07_1uM Dose=1uM
IC-57-ZA36_0.01uM Dose=0.01uM, Dibromsalicil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
IC-57-ZA36_0.1uM Dose=0.1uM, Dibromsalicil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
IC-57-ZA36_10uM Dose=10uM, Dibromsalicil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
IC-60-AG74_0.01uM Dose=0.01uM, Ucph-101, SLC1A3 - EAAT1/GLAST inhibitor targeting SLC1A3
IC-60-AG74_0.1uM Dose=0.1uM, Ucph-101, SLC1A3 - EAAT1/GLAST inhibitor targeting SLC1A3
IC-60-AG74_10uM Dose=10uM, Ucph-101, SLC1A3 - EAAT1/GLAST inhibitor targeting SLC1A3
IC-60-AG74_1uM Dose=1uM, Ucph-101, SLC1A3 - EAAT1/GLAST inhibitor targeting SLC1A3
IC-61-PQ10_0.01uM Dose=0.01uM, Coumate, Steryl Sulfatase Inhibitors targeting STS
IC-61-PQ10_0.1uM Dose=0.1uM, Coumate, Steryl Sulfatase Inhibitors targeting STS
IC-61-PQ10_10uM Dose=10uM, Coumate, Steryl Sulfatase Inhibitors targeting STS
IC-61-PQ10_1uM Dose=1uM, Coumate, Steryl Sulfatase Inhibitors targeting STS
IC-72-HR20_0.01uM Dose=0.01uM, 3-Hydroxykynurenine
IC-72-HR20_0.1uM Dose=0.1uM, 3-Hydroxykynurenine
IC-72-HR20_10uM Dose=10uM, 3-Hydroxykynurenine
IC-72-HR20_1uM Dose=1uM, 3-Hydroxykynurenine
IC-72-TE79_0.01uM Dose=0.01uM
IC-72-TE79_0.1uM Dose=0.1uM
IC-72-TE79_10uM Dose=10uM
IC-72-TE79_1uM Dose=1uM
IC-76-JU42_0.01uM Dose=0.01uM
IC-76-JU42_0.1uM Dose=0.1uM
IC-76-JU42_10uM Dose=10uM
IC-76-JU42_1uM Dose=1uM
IC-79-JZ26_0.01uM Dose=0.01uM, 3-Amino-5-(4-fluorophenyl)thiophene-2-carboxamide
IC-79-JZ26_0.1uM Dose=0.1uM, 3-Amino-5-(4-fluorophenyl)thiophene-2-carboxamide
IC-79-JZ26_10uM Dose=10uM, 3-Amino-5-(4-fluorophenyl)thiophene-2-carboxamide
IC-79-JZ26_1uM Dose=1uM, 3-Amino-5-(4-fluorophenyl)thiophene-2-carboxamide
IC-80-CT90_0.01uM Dose=0.01uM, N-(4-cyanophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea
IC-80-CT90_0.1uM Dose=0.1uM, N-(4-cyanophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea
IC-80-CT90_10uM Dose=10uM, N-(4-cyanophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea
IC-80-CT90_1uM Dose=1uM, N-(4-cyanophenyl)-N'-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)urea
IC-83-DE66_0.01uM Dose=0.01uM
IC-83-DE66_0.1uM Dose=0.1uM
IC-86-MA49_0.01uM Dose=0.01uM, 2-Adamantanecarbonyl-arg-phe-NH2 trifluoroacetate, Neuropeptide FF Receptor Antagonists targeting NPFFR1
IC-86-MA49_0.1uM Dose=0.1uM, 2-Adamantanecarbonyl-arg-phe-NH2 trifluoroacetate, Neuropeptide FF Receptor Antagonists targeting NPFFR1
IC-86-MA49_10uM Dose=10uM, 2-Adamantanecarbonyl-arg-phe-NH2 trifluoroacetate, Neuropeptide FF Receptor Antagonists targeting NPFFR1
IC-86-MA49_1uM Dose=1uM, 2-Adamantanecarbonyl-arg-phe-NH2 trifluoroacetate, Neuropeptide FF Receptor Antagonists targeting NPFFR1
IC-91-IX22_0.01uM Dose=0.01uM, 1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Angiogenesis Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;EphB4 Inhibitors targeting CAMK2B, EPHB4, FYN, MAPK13, CAMK2G
IC-91-IX22_0.1uM Dose=0.1uM, 1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Angiogenesis Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;EphB4 Inhibitors targeting CAMK2B, EPHB4, FYN, MAPK13, CAMK2G
IC-91-IX22_10uM Dose=10uM, 1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Angiogenesis Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;EphB4 Inhibitors targeting CAMK2B, EPHB4, FYN, MAPK13, CAMK2G
IC-91-IX22_1uM Dose=1uM, 1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Angiogenesis Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;EphB4 Inhibitors targeting CAMK2B, EPHB4, FYN, MAPK13, CAMK2G
IC-96-AX39_0.01uM Dose=0.01uM, Sivelestat, Elastase inhibitor;Leukocyte Elastase Inhibitors targeting CELA1, ELANE
IC-96-AX39_0.1uM Dose=0.1uM, Sivelestat, Elastase inhibitor;Leukocyte Elastase Inhibitors targeting CELA1, ELANE
IC-96-AX39_10uM Dose=10uM, Sivelestat, Elastase inhibitor;Leukocyte Elastase Inhibitors targeting CELA1, ELANE
IC-98-UO17_0.01uM Dose=0.01uM, D-Glutamic Acid targeting GRIA4, GRIK3, GRIK5
IC-98-UO17_0.1uM Dose=0.1uM, D-Glutamic Acid targeting GRIA4, GRIK3, GRIK5
IC-98-UO17_10uM Dose=10uM, D-Glutamic Acid targeting GRIA4, GRIK3, GRIK5
IC-98-UO17_1uM Dose=1uM, D-Glutamic Acid targeting GRIA4, GRIK3, GRIK5
IC-99-JZ46_0.01uM Dose=0.01uM, Lobeline, alpha4beta2 nicotinic acid receptor partial agonist;Dopamine Receptor Modulators targeting CHRNA4, CHRNB2, SLC18A2
IC-99-JZ46_0.1uM Dose=0.1uM, Lobeline, alpha4beta2 nicotinic acid receptor partial agonist;Dopamine Receptor Modulators targeting CHRNA4, CHRNB2, SLC18A2
IC-99-JZ46_10uM Dose=10uM, Lobeline, alpha4beta2 nicotinic acid receptor partial agonist;Dopamine Receptor Modulators targeting CHRNA4, CHRNB2, SLC18A2
IC-99-JZ46_1uM Dose=1uM, Lobeline, alpha4beta2 nicotinic acid receptor partial agonist;Dopamine Receptor Modulators targeting CHRNA4, CHRNB2, SLC18A2
ID-00-IC14_0.01uM Dose=0.01uM
ID-00-IC14_0.1uM Dose=0.1uM
ID-00-IC14_10uM Dose=10uM
ID-00-IC14_1uM Dose=1uM
ID-05-KT67_0.01uM Dose=0.01uM, Benzaldehyde, bis(phenylmethyl)hydrazone
ID-05-KT67_0.1uM Dose=0.1uM, Benzaldehyde, bis(phenylmethyl)hydrazone
ID-05-KT67_10uM Dose=10uM, Benzaldehyde, bis(phenylmethyl)hydrazone
ID-05-KT67_1uM Dose=1uM, Benzaldehyde, bis(phenylmethyl)hydrazone
ID-07-YY69_0.01uM Dose=0.01uM, 2-{[2-amino-5-cyano-6-(methylsulfanyl)pyrimidin-4-yl]sulfanyl}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3
ID-07-YY69_0.1uM Dose=0.1uM, 2-{[2-amino-5-cyano-6-(methylsulfanyl)pyrimidin-4-yl]sulfanyl}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3
ID-07-YY69_10uM Dose=10uM, 2-{[2-amino-5-cyano-6-(methylsulfanyl)pyrimidin-4-yl]sulfanyl}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3
ID-07-YY69_1uM Dose=1uM, 2-{[2-amino-5-cyano-6-(methylsulfanyl)pyrimidin-4-yl]sulfanyl}-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3
ID-12-CA39_0.1uM Dose=0.1uM, Enecadin, Nitric Oxide Synthase Inhibitors;Calcium Channel Blockers;Sodium Channel Blockers targeting SCN4A
ID-12-CA39_10uM Dose=10uM, Enecadin, Nitric Oxide Synthase Inhibitors;Calcium Channel Blockers;Sodium Channel Blockers targeting SCN4A
ID-12-CA39_1uM Dose=1uM, Enecadin, Nitric Oxide Synthase Inhibitors;Calcium Channel Blockers;Sodium Channel Blockers targeting SCN4A
ID-12-GA19_0.01uM Dose=0.01uM, Apoptosis Inducers;Polyamine Oxidase Inhibitors targeting SMOX
ID-12-GA19_0.1uM Dose=0.1uM, Apoptosis Inducers;Polyamine Oxidase Inhibitors targeting SMOX
ID-12-GA19_10uM Dose=10uM, Apoptosis Inducers;Polyamine Oxidase Inhibitors targeting SMOX
ID-12-GA19_1uM Dose=1uM, Apoptosis Inducers;Polyamine Oxidase Inhibitors targeting SMOX
ID-12-NA84_0.01uM Dose=0.01uM, 1-(2-Methoxyphenyl)-4-(3-phenylpropyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
ID-12-NA84_0.1uM Dose=0.1uM, 1-(2-Methoxyphenyl)-4-(3-phenylpropyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
ID-12-NA84_10uM Dose=10uM, 1-(2-Methoxyphenyl)-4-(3-phenylpropyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
ID-12-NA84_1uM Dose=1uM, 1-(2-Methoxyphenyl)-4-(3-phenylpropyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B
ID-13-PY29_0.01uM Dose=0.01uM, 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole, 5-HT1B Agonists;5-HT1A Receptor Agonists targeting HTR1A, HTR1B
ID-13-PY29_0.1uM Dose=0.1uM, 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole, 5-HT1B Agonists;5-HT1A Receptor Agonists targeting HTR1A, HTR1B
ID-13-PY29_10uM Dose=10uM, 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole, 5-HT1B Agonists;5-HT1A Receptor Agonists targeting HTR1A, HTR1B
ID-13-PY29_1uM Dose=1uM, 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole, 5-HT1B Agonists;5-HT1A Receptor Agonists targeting HTR1A, HTR1B
ID-17-PL23_0.01uM Dose=0.01uM, (S)-5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one targeting USP7
ID-17-PL23_0.1uM Dose=0.1uM, (S)-5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one targeting USP7
ID-17-PL23_10uM Dose=10uM, (S)-5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one targeting USP7
ID-26-HX79_0.01uM Dose=0.01uM, N-(3-Chloro-5-Fluorophenyl)-4-Nitro-2,1,3-Benzoxadiazol-5-Amine, HIF-2;HIF-2 Inhibitor targeting EPAS1
ID-26-HX79_0.1uM Dose=0.1uM, N-(3-Chloro-5-Fluorophenyl)-4-Nitro-2,1,3-Benzoxadiazol-5-Amine, HIF-2;HIF-2 Inhibitor targeting EPAS1
ID-26-HX79_10uM Dose=10uM, N-(3-Chloro-5-Fluorophenyl)-4-Nitro-2,1,3-Benzoxadiazol-5-Amine, HIF-2;HIF-2 Inhibitor targeting EPAS1
ID-26-HX79_1uM Dose=1uM, N-(3-Chloro-5-Fluorophenyl)-4-Nitro-2,1,3-Benzoxadiazol-5-Amine, HIF-2;HIF-2 Inhibitor targeting EPAS1
ID-30-NC19_0.01uM Dose=0.01uM, N-[[(2S)-1-Isopropylpyrrolidine-2-yl]methyl]-2-cyclopentyl-9-methyl-1-oxo-1,2-dihydro-9H-pyrido[3,4-b]indole-4-carboxamide, GLP-1 receptor agonist targeting GLP1R
ID-30-NC19_0.1uM Dose=0.1uM, N-[[(2S)-1-Isopropylpyrrolidine-2-yl]methyl]-2-cyclopentyl-9-methyl-1-oxo-1,2-dihydro-9H-pyrido[3,4-b]indole-4-carboxamide, GLP-1 receptor agonist targeting GLP1R
ID-30-NC19_10uM Dose=10uM, N-[[(2S)-1-Isopropylpyrrolidine-2-yl]methyl]-2-cyclopentyl-9-methyl-1-oxo-1,2-dihydro-9H-pyrido[3,4-b]indole-4-carboxamide, GLP-1 receptor agonist targeting GLP1R
ID-30-NC19_1uM Dose=1uM, N-[[(2S)-1-Isopropylpyrrolidine-2-yl]methyl]-2-cyclopentyl-9-methyl-1-oxo-1,2-dihydro-9H-pyrido[3,4-b]indole-4-carboxamide, GLP-1 receptor agonist targeting GLP1R
ID-30-ST90_0.01uM Dose=0.01uM, 3-[[2-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide
ID-30-ST90_0.1uM Dose=0.1uM, 3-[[2-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide
ID-30-ST90_10uM Dose=10uM, 3-[[2-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide
ID-30-ST90_1uM Dose=1uM, 3-[[2-[[(1R)-1-(4-fluorophenyl)ethyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide
ID-31-AD14_0.01uM Dose=0.01uM, 3-(3,4-dimethoxyphenyl)-N-(3-morpholin-4-ylpropyl)pyrazolo[1,5-a]pyrimidin-5-amine
ID-31-AD14_0.1uM Dose=0.1uM, 3-(3,4-dimethoxyphenyl)-N-(3-morpholin-4-ylpropyl)pyrazolo[1,5-a]pyrimidin-5-amine
ID-31-AD14_10uM Dose=10uM, 3-(3,4-dimethoxyphenyl)-N-(3-morpholin-4-ylpropyl)pyrazolo[1,5-a]pyrimidin-5-amine
ID-31-AD14_1uM Dose=1uM, 3-(3,4-dimethoxyphenyl)-N-(3-morpholin-4-ylpropyl)pyrazolo[1,5-a]pyrimidin-5-amine
ID-31-PA82_0.01uM Dose=0.01uM, D-Nmappd, Apoptosis Inducers;Ceramidase Inhibitors targeting ASAH1
ID-31-PA82_0.1uM Dose=0.1uM, D-Nmappd, Apoptosis Inducers;Ceramidase Inhibitors targeting ASAH1
ID-31-PA82_10uM Dose=10uM, D-Nmappd, Apoptosis Inducers;Ceramidase Inhibitors targeting ASAH1
ID-31-PA82_1uM Dose=1uM, D-Nmappd, Apoptosis Inducers;Ceramidase Inhibitors targeting ASAH1
ID-32-NA94_0.01uM Dose=0.01uM, Ggti 298, Farnesyl Transferase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting FNTA, PGGT1B
ID-32-NA94_0.1uM Dose=0.1uM, Ggti 298, Farnesyl Transferase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting FNTA, PGGT1B
ID-32-NA94_10uM Dose=10uM, Ggti 298, Farnesyl Transferase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting FNTA, PGGT1B
ID-32-NA94_1uM Dose=1uM, Ggti 298, Farnesyl Transferase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting FNTA, PGGT1B
ID-37-UU19_0.01uM Dose=0.01uM, 5-[[4-[3-(trifluoromethyl)anilino]phthalazin-1-yl]methyl]-1H-pyridin-2-one
ID-37-UU19_0.1uM Dose=0.1uM, 5-[[4-[3-(trifluoromethyl)anilino]phthalazin-1-yl]methyl]-1H-pyridin-2-one
ID-37-UU19_10uM Dose=10uM, 5-[[4-[3-(trifluoromethyl)anilino]phthalazin-1-yl]methyl]-1H-pyridin-2-one
ID-37-UU19_1uM Dose=1uM, 5-[[4-[3-(trifluoromethyl)anilino]phthalazin-1-yl]methyl]-1H-pyridin-2-one
ID-43-YL08_0.01uM Dose=0.01uM, PRL-3 inhibitor I, PTP4A3xa0inhibitor/antagonist targeting PTP4A3
ID-43-YL08_0.1uM Dose=0.1uM, PRL-3 inhibitor I, PTP4A3xa0inhibitor/antagonist targeting PTP4A3
ID-43-YL08_10uM Dose=10uM, PRL-3 inhibitor I, PTP4A3xa0inhibitor/antagonist targeting PTP4A3
ID-43-YL08_1uM Dose=1uM, PRL-3 inhibitor I, PTP4A3xa0inhibitor/antagonist targeting PTP4A3
ID-55-OJ03_0.01uM Dose=0.01uM, JNK inhibitor targeting MAPK8, MAPK9, MAPK10
ID-55-OJ03_0.1uM Dose=0.1uM, JNK inhibitor targeting MAPK8, MAPK9, MAPK10
ID-55-OJ03_10uM Dose=10uM, JNK inhibitor targeting MAPK8, MAPK9, MAPK10
ID-55-OJ03_1uM Dose=1uM, JNK inhibitor targeting MAPK8, MAPK9, MAPK10
ID-69-QF93_0.01uM Dose=0.01uM
ID-69-QF93_0.1uM Dose=0.1uM
ID-69-QF93_10uM Dose=10uM
ID-69-QF93_1uM Dose=1uM
ID-70-SM63_0.01uM Dose=0.01uM, Masoprocol, IGF-1R Phosphorylation Inhibitors;ER stress inducer;Lipoxygenase Inhibitors targeting ALOX5, ALOX15
ID-70-SM63_0.1uM Dose=0.1uM, Masoprocol, IGF-1R Phosphorylation Inhibitors;ER stress inducer;Lipoxygenase Inhibitors targeting ALOX5, ALOX15
ID-70-SM63_10uM Dose=10uM, Masoprocol, IGF-1R Phosphorylation Inhibitors;ER stress inducer;Lipoxygenase Inhibitors targeting ALOX5, ALOX15
ID-70-SM63_1uM Dose=1uM, Masoprocol, IGF-1R Phosphorylation Inhibitors;ER stress inducer;Lipoxygenase Inhibitors targeting ALOX5, ALOX15
ID-90-NM43_0.01uM Dose=0.01uM, Rx-5902, phosphorylated-p68 RNA helicase inhibitor targeting DDX5
ID-90-NM43_0.1uM Dose=0.1uM, Rx-5902, phosphorylated-p68 RNA helicase inhibitor targeting DDX5
ID-90-NM43_10uM Dose=10uM, Rx-5902, phosphorylated-p68 RNA helicase inhibitor targeting DDX5
ID-90-NM43_1uM Dose=1uM, Rx-5902, phosphorylated-p68 RNA helicase inhibitor targeting DDX5
ID-96-UX79_0.01uM Dose=0.01uM, Vaniprevir
ID-96-UX79_0.1uM Dose=0.1uM, Vaniprevir
ID-96-UX79_10uM Dose=10uM, Vaniprevir
ID-96-UX79_1uM Dose=1uM, Vaniprevir
IE-02-TR35_0.01uM Dose=0.01uM, (S)-N-(4-fluorobenzyl)-3-oxo-1,1-diphenyltetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide, NPSR1 antagonist targeting NPSR1
IE-02-TR35_0.1uM Dose=0.1uM, (S)-N-(4-fluorobenzyl)-3-oxo-1,1-diphenyltetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide, NPSR1 antagonist targeting NPSR1
IE-02-TR35_10uM Dose=10uM, (S)-N-(4-fluorobenzyl)-3-oxo-1,1-diphenyltetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide, NPSR1 antagonist targeting NPSR1
IE-02-TR35_1uM Dose=1uM, (S)-N-(4-fluorobenzyl)-3-oxo-1,1-diphenyltetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide, NPSR1 antagonist targeting NPSR1
IE-04-SI43_0.01uM Dose=0.01uM, 4-Tert-butyl-2-[[4-(pyridin-4-ylmethyl)phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Antagonists;Mineralocorticoid Receptor (MR) Antagonists;Drugs Acting on Estrogen Receptors (ER) targeting AR, NR3C2, PGR
IE-04-SI43_0.1uM Dose=0.1uM, 4-Tert-butyl-2-[[4-(pyridin-4-ylmethyl)phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Antagonists;Mineralocorticoid Receptor (MR) Antagonists;Drugs Acting on Estrogen Receptors (ER) targeting AR, NR3C2, PGR
IE-04-SI43_10uM Dose=10uM, 4-Tert-butyl-2-[[4-(pyridin-4-ylmethyl)phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Antagonists;Mineralocorticoid Receptor (MR) Antagonists;Drugs Acting on Estrogen Receptors (ER) targeting AR, NR3C2, PGR
IE-05-JN93_0.01uM Dose=0.01uM, MRGPRX2 agonist
IE-05-JN93_10uM Dose=10uM, MRGPRX2 agonist
IE-13-CP28_0.01uM Dose=0.01uM, CLK1 protein kinase inhibitor targeting CLK1, DYRK1A, DYRK2
IE-13-CP28_0.1uM Dose=0.1uM, CLK1 protein kinase inhibitor targeting CLK1, DYRK1A, DYRK2
IE-13-CP28_10uM Dose=10uM, CLK1 protein kinase inhibitor targeting CLK1, DYRK1A, DYRK2
IE-13-CP28_1uM Dose=1uM, CLK1 protein kinase inhibitor targeting CLK1, DYRK1A, DYRK2
IE-17-LV02_0.01uM Dose=0.01uM, targeting GSK3A
IE-17-LV02_0.1uM Dose=0.1uM, targeting GSK3A
IE-17-LV02_10uM Dose=10uM, targeting GSK3A
IE-19-LI00_0.01uM Dose=0.01uM, Bis-indolylmaleimide deriv. 8d, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
IE-19-LI00_0.1uM Dose=0.1uM, Bis-indolylmaleimide deriv. 8d, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
IE-19-LI00_10uM Dose=10uM, Bis-indolylmaleimide deriv. 8d, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
IE-19-LI00_1uM Dose=1uM, Bis-indolylmaleimide deriv. 8d, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
IE-28-SY71_0.01uM Dose=0.01uM, 13h-Benzo[g]indeno[1,2-b]quinoxalin-13-one
IE-28-SY71_0.1uM Dose=0.1uM, 13h-Benzo[g]indeno[1,2-b]quinoxalin-13-one
IE-28-SY71_10uM Dose=10uM, 13h-Benzo[g]indeno[1,2-b]quinoxalin-13-one
IE-28-SY71_1uM Dose=1uM, 13h-Benzo[g]indeno[1,2-b]quinoxalin-13-one
IE-30-KW32_0.01uM Dose=0.01uM, 1-(5-Chloro-2-methoxyphenyl)-3-(2-hydroxyethyl)thiourea
IE-30-KW32_0.1uM Dose=0.1uM, 1-(5-Chloro-2-methoxyphenyl)-3-(2-hydroxyethyl)thiourea
IE-30-KW32_10uM Dose=10uM, 1-(5-Chloro-2-methoxyphenyl)-3-(2-hydroxyethyl)thiourea
IE-30-KW32_1uM Dose=1uM, 1-(5-Chloro-2-methoxyphenyl)-3-(2-hydroxyethyl)thiourea
IE-34-IW27_0.01uM Dose=0.01uM, 3-((4-(Trifluoromethyl)Phenyl)Amino)Benzoic Acid, AKR1C3 inhibitor targeting AKR1C3
IE-34-IW27_0.1uM Dose=0.1uM, 3-((4-(Trifluoromethyl)Phenyl)Amino)Benzoic Acid, AKR1C3 inhibitor targeting AKR1C3
IE-34-IW27_10uM Dose=10uM, 3-((4-(Trifluoromethyl)Phenyl)Amino)Benzoic Acid, AKR1C3 inhibitor targeting AKR1C3
IE-36-BO23_0.01uM Dose=0.01uM
IE-36-BO23_0.1uM Dose=0.1uM
IE-36-BO23_10uM Dose=10uM
IE-38-FB31_0.01uM Dose=0.01uM
IE-38-FB31_0.1uM Dose=0.1uM
IE-38-FB31_10uM Dose=10uM
IE-38-FB31_1uM Dose=1uM
IE-44-DP45_0.01uM Dose=0.01uM, Butabindide, Tripeptidyl Peptidase II Inhibitors targeting TPP2
IE-44-DP45_0.1uM Dose=0.1uM, Butabindide, Tripeptidyl Peptidase II Inhibitors targeting TPP2
IE-44-DP45_10uM Dose=10uM, Butabindide, Tripeptidyl Peptidase II Inhibitors targeting TPP2
IE-44-DP45_1uM Dose=1uM, Butabindide, Tripeptidyl Peptidase II Inhibitors targeting TPP2
IE-44-GZ79_0.01uM Dose=0.01uM, 2,3,4,5-Tetra(4-pyridyl)thiophene, Hedgehog Signaling Inhibitors targeting GLI1
IE-44-GZ79_0.1uM Dose=0.1uM, 2,3,4,5-Tetra(4-pyridyl)thiophene, Hedgehog Signaling Inhibitors targeting GLI1
IE-44-GZ79_10uM Dose=10uM, 2,3,4,5-Tetra(4-pyridyl)thiophene, Hedgehog Signaling Inhibitors targeting GLI1
IE-44-GZ79_1uM Dose=1uM, 2,3,4,5-Tetra(4-pyridyl)thiophene, Hedgehog Signaling Inhibitors targeting GLI1
IE-46-OA29_0.01uM Dose=0.01uM, 6-Fluoro-3-((1E)-2-(3-pyridinyl)ethenyl)-1H-indole, Tryptophan 2,3 dioxygenase inhibitor targeting TDO2
IE-46-OA29_0.1uM Dose=0.1uM, 6-Fluoro-3-((1E)-2-(3-pyridinyl)ethenyl)-1H-indole, Tryptophan 2,3 dioxygenase inhibitor targeting TDO2
IE-46-OA29_10uM Dose=10uM, 6-Fluoro-3-((1E)-2-(3-pyridinyl)ethenyl)-1H-indole, Tryptophan 2,3 dioxygenase inhibitor targeting TDO2
IE-46-OA29_1uM Dose=1uM, 6-Fluoro-3-((1E)-2-(3-pyridinyl)ethenyl)-1H-indole, Tryptophan 2,3 dioxygenase inhibitor targeting TDO2
IE-46-VU57_0.01uM Dose=0.01uM, Locostatin, RKIP-RAF1 interaction inhibitor targeting PEBP1
IE-46-VU57_0.1uM Dose=0.1uM, Locostatin, RKIP-RAF1 interaction inhibitor targeting PEBP1
IE-46-VU57_10uM Dose=10uM, Locostatin, RKIP-RAF1 interaction inhibitor targeting PEBP1
IE-46-VU57_1uM Dose=1uM, Locostatin, RKIP-RAF1 interaction inhibitor targeting PEBP1
IE-47-KU59_0.01uM Dose=0.01uM, Icerguastat, sustains UPR targeting PPP1R15A
IE-47-KU59_0.1uM Dose=0.1uM, Icerguastat, sustains UPR targeting PPP1R15A
IE-47-KU59_10uM Dose=10uM, Icerguastat, sustains UPR targeting PPP1R15A
IE-47-KU59_1uM Dose=1uM, Icerguastat, sustains UPR targeting PPP1R15A
IE-49-AI35_0.01uM Dose=0.01uM, Sovateltide, EDNRB agonist targeting EDNRB
IE-49-AI35_0.1uM Dose=0.1uM, Sovateltide, EDNRB agonist targeting EDNRB
IE-49-AI35_10uM Dose=10uM, Sovateltide, EDNRB agonist targeting EDNRB
IE-49-AI35_1uM Dose=1uM, Sovateltide, EDNRB agonist targeting EDNRB
IE-70-HC14_0.01uM Dose=0.01uM, 5-[3-(5-aminopentyl)-5-[(7-methyl-1H-indol-3-yl)methyl]-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(3-chloro-4-hydroxyphenoxy)-N,N-dimethylbenzamide, SSTR2 agonist targeting SSTR2
IE-70-HC14_0.1uM Dose=0.1uM, 5-[3-(5-aminopentyl)-5-[(7-methyl-1H-indol-3-yl)methyl]-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(3-chloro-4-hydroxyphenoxy)-N,N-dimethylbenzamide, SSTR2 agonist targeting SSTR2
IE-70-HC14_1uM Dose=1uM, 5-[3-(5-aminopentyl)-5-[(7-methyl-1H-indol-3-yl)methyl]-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(3-chloro-4-hydroxyphenoxy)-N,N-dimethylbenzamide, SSTR2 agonist targeting SSTR2
IE-75-ZC91_0.01uM Dose=0.01uM, 7-Hydroxyflavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1
IE-75-ZC91_0.1uM Dose=0.1uM, 7-Hydroxyflavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1
IE-75-ZC91_10uM Dose=10uM, 7-Hydroxyflavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1
IE-75-ZC91_1uM Dose=1uM, 7-Hydroxyflavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1
IE-80-DC24_0.01uM Dose=0.01uM, 2-amino-3-methyl-N-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]butanamide
IE-80-DC24_0.1uM Dose=0.1uM, 2-amino-3-methyl-N-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]butanamide
IE-80-DC24_10uM Dose=10uM, 2-amino-3-methyl-N-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]butanamide
IE-80-DC24_1uM Dose=1uM, 2-amino-3-methyl-N-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]butanamide
IF-00-FW22_0.01uM Dose=0.01uM, E 5090
IF-00-FW22_0.1uM Dose=0.1uM, E 5090
IF-03-OL58_0.01uM Dose=0.01uM, Tazarotenic acid, Drugs Acting on Retinoid Receptors targeting RARB
IF-03-OL58_0.1uM Dose=0.1uM, Tazarotenic acid, Drugs Acting on Retinoid Receptors targeting RARB
IF-03-OL58_10uM Dose=10uM, Tazarotenic acid, Drugs Acting on Retinoid Receptors targeting RARB
IF-03-OL58_1uM Dose=1uM, Tazarotenic acid, Drugs Acting on Retinoid Receptors targeting RARB
IF-06-KQ42_0.01uM Dose=0.01uM, Setanaxib, NOX1, NOX4 inhibitor targeting NOX1, NOX4
IF-06-KQ42_0.1uM Dose=0.1uM, Setanaxib, NOX1, NOX4 inhibitor targeting NOX1, NOX4
IF-06-KQ42_10uM Dose=10uM, Setanaxib, NOX1, NOX4 inhibitor targeting NOX1, NOX4
IF-06-KQ42_1uM Dose=1uM, Setanaxib, NOX1, NOX4 inhibitor targeting NOX1, NOX4
IF-08-GY16_0.01uM Dose=0.01uM, (1E)-1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-1-hepten-3-one, IL-1 Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Tyrosinase Inhibitors;TNF-alpha Production Inhibitors;Antioxidants targeting NOS2, TYR
IF-08-GY16_0.1uM Dose=0.1uM, (1E)-1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-1-hepten-3-one, IL-1 Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Tyrosinase Inhibitors;TNF-alpha Production Inhibitors;Antioxidants targeting NOS2, TYR
IF-08-GY16_10uM Dose=10uM, (1E)-1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-1-hepten-3-one, IL-1 Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Tyrosinase Inhibitors;TNF-alpha Production Inhibitors;Antioxidants targeting NOS2, TYR
IF-22-EA89_0.01uM Dose=0.01uM, Gusperimus
IF-22-EA89_0.1uM Dose=0.1uM, Gusperimus
IF-22-EA89_10uM Dose=10uM, Gusperimus
IF-22-EA89_1uM Dose=1uM, Gusperimus
IF-23-HY54_0.01uM Dose=0.01uM, 4-Chlorophenyl Sulfamate, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA1
IF-23-HY54_0.1uM Dose=0.1uM, 4-Chlorophenyl Sulfamate, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA1
IF-23-HY54_10uM Dose=10uM, 4-Chlorophenyl Sulfamate, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA1
IF-23-HY54_1uM Dose=1uM, 4-Chlorophenyl Sulfamate, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA1
IF-28-AV94_0.01uM Dose=0.01uM
IF-28-AV94_0.1uM Dose=0.1uM
IF-28-AV94_10uM Dose=10uM
IF-28-AV94_1uM Dose=1uM
IF-31-BQ95_0.01uM Dose=0.01uM, Calcium-Sensing Receptor Antagonists I, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
IF-31-BQ95_0.1uM Dose=0.1uM, Calcium-Sensing Receptor Antagonists I, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
IF-31-BQ95_10uM Dose=10uM, Calcium-Sensing Receptor Antagonists I, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
IF-31-BQ95_1uM Dose=1uM, Calcium-Sensing Receptor Antagonists I, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
IF-31-RN78_0.01uM Dose=0.01uM, Levosimendan, Nitric Oxide (NO) Production Inhibitors;K(ATP) Channel Activators;Troponin C slow skeletal muscle stabilizer;Calcium sensitizer targeting KCNJ8, KCNJ11, PDE3A, TNNC1
IF-31-RN78_0.1uM Dose=0.1uM, Levosimendan, Nitric Oxide (NO) Production Inhibitors;K(ATP) Channel Activators;Troponin C slow skeletal muscle stabilizer;Calcium sensitizer targeting KCNJ8, KCNJ11, PDE3A, TNNC1
IF-31-RN78_10uM Dose=10uM, Levosimendan, Nitric Oxide (NO) Production Inhibitors;K(ATP) Channel Activators;Troponin C slow skeletal muscle stabilizer;Calcium sensitizer targeting KCNJ8, KCNJ11, PDE3A, TNNC1
IF-31-RN78_1uM Dose=1uM, Levosimendan, Nitric Oxide (NO) Production Inhibitors;K(ATP) Channel Activators;Troponin C slow skeletal muscle stabilizer;Calcium sensitizer targeting KCNJ8, KCNJ11, PDE3A, TNNC1
IF-43-EO10_0.01uM Dose=0.01uM
IF-43-EO10_0.1uM Dose=0.1uM
IF-43-EO10_10uM Dose=10uM
IF-43-EO10_1uM Dose=1uM
IF-45-JC86_0.01uM Dose=0.01uM, 1-Piperazinylpyrazine
IF-45-JC86_10uM Dose=10uM, 1-Piperazinylpyrazine
IF-45-JC86_1uM Dose=1uM, 1-Piperazinylpyrazine
IF-72-BO18_0.01uM Dose=0.01uM, CU CPT 4a, TLR3 gene inhibitor targeting TLR3
IF-72-BO18_0.1uM Dose=0.1uM, CU CPT 4a, TLR3 gene inhibitor targeting TLR3
IF-72-BO18_10uM Dose=10uM, CU CPT 4a, TLR3 gene inhibitor targeting TLR3
IF-72-BO18_1uM Dose=1uM, CU CPT 4a, TLR3 gene inhibitor targeting TLR3
IF-75-AJ33_0.01uM Dose=0.01uM, 2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester, Sodium calcium exchanger 1 inhibitor targeting SLC8A1
IF-75-AJ33_0.1uM Dose=0.1uM, 2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester, Sodium calcium exchanger 1 inhibitor targeting SLC8A1
IF-75-AJ33_10uM Dose=10uM, 2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester, Sodium calcium exchanger 1 inhibitor targeting SLC8A1
IF-75-AJ33_1uM Dose=1uM, 2-[[4-[(4-Nitrophenyl)methoxy]phenyl]methyl]-4-thiazolidinecarboxylic acid ethyl ester, Sodium calcium exchanger 1 inhibitor targeting SLC8A1
IF-78-GO12_0.01uM Dose=0.01uM, Acetaminophen, Cyclooxygenase-3 Inhibitors targeting PTGS1
IF-78-GO12_0.1uM Dose=0.1uM, Acetaminophen, Cyclooxygenase-3 Inhibitors targeting PTGS1
IF-78-GO12_10uM Dose=10uM, Acetaminophen, Cyclooxygenase-3 Inhibitors targeting PTGS1
IF-78-GO12_1uM Dose=1uM, Acetaminophen, Cyclooxygenase-3 Inhibitors targeting PTGS1
IF-81-QQ90_0.01uM Dose=0.01uM, Dmppo, Phosphodiesterase Inhibitors targeting PDE5A
IF-81-QQ90_0.1uM Dose=0.1uM, Dmppo, Phosphodiesterase Inhibitors targeting PDE5A
IF-81-QQ90_10uM Dose=10uM, Dmppo, Phosphodiesterase Inhibitors targeting PDE5A
IF-81-QQ90_1uM Dose=1uM, Dmppo, Phosphodiesterase Inhibitors targeting PDE5A
IF-83-OL68_0.01uM Dose=0.01uM, 2-(1-benzothiophen-3-yl)-N-[2-(1H-indol-3-yl)ethyl]-9-propan-2-ylpurin-6-amine
IF-83-OL68_0.1uM Dose=0.1uM, 2-(1-benzothiophen-3-yl)-N-[2-(1H-indol-3-yl)ethyl]-9-propan-2-ylpurin-6-amine
IF-83-OL68_10uM Dose=10uM, 2-(1-benzothiophen-3-yl)-N-[2-(1H-indol-3-yl)ethyl]-9-propan-2-ylpurin-6-amine
IF-83-OL68_1uM Dose=1uM, 2-(1-benzothiophen-3-yl)-N-[2-(1H-indol-3-yl)ethyl]-9-propan-2-ylpurin-6-amine
IF-86-JG83_0.01uM Dose=0.01uM, (S)-2-benzylamino-3-phenyl-1-propanol
IF-86-JG83_0.1uM Dose=0.1uM, (S)-2-benzylamino-3-phenyl-1-propanol
IF-86-JG83_10uM Dose=10uM, (S)-2-benzylamino-3-phenyl-1-propanol
IF-86-JG83_1uM Dose=1uM, (S)-2-benzylamino-3-phenyl-1-propanol
IF-86-OK88_0.1uM Dose=0.1uM, 9-(Dimethylamino)-3-(4-methoxyphenyl)-4-pyrido[1,2]thieno[3,4-d]pyrimidinone, mgluR1 Antagonists targeting GRM1
IF-86-OK88_10uM Dose=10uM, 9-(Dimethylamino)-3-(4-methoxyphenyl)-4-pyrido[1,2]thieno[3,4-d]pyrimidinone, mgluR1 Antagonists targeting GRM1
IF-86-OK88_1uM Dose=1uM, 9-(Dimethylamino)-3-(4-methoxyphenyl)-4-pyrido[1,2]thieno[3,4-d]pyrimidinone, mgluR1 Antagonists targeting GRM1
IF-87-AU84_0.01uM Dose=0.01uM
IF-87-AU84_0.1uM Dose=0.1uM
IF-87-AU84_10uM Dose=10uM
IF-87-AU84_1uM Dose=1uM
IF-92-OK68_0.01uM Dose=0.01uM, Ethyl 4-(methylamino)-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3
IF-92-OK68_0.1uM Dose=0.1uM, Ethyl 4-(methylamino)-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3
IF-92-OK68_10uM Dose=10uM, Ethyl 4-(methylamino)-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3
IF-92-OK68_1uM Dose=1uM, Ethyl 4-(methylamino)-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3
JA-01-GQ75_0.01uM Dose=0.01uM, NS 1652, Chloride Channel Blockers targeting GRIK1
JA-01-GQ75_0.1uM Dose=0.1uM, NS 1652, Chloride Channel Blockers targeting GRIK1
JA-01-GQ75_10uM Dose=10uM, NS 1652, Chloride Channel Blockers targeting GRIK1
JA-01-GQ75_1uM Dose=1uM, NS 1652, Chloride Channel Blockers targeting GRIK1
JA-02-IU07_0.01uM Dose=0.01uM, 5-Cyclooctyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, mglu5 Receptor (mgluR5) Ligands;mglu1 Receptor (mgluR1) Ligands targeting GRM1, GRM5
JA-02-IU07_0.1uM Dose=0.1uM, 5-Cyclooctyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, mglu5 Receptor (mgluR5) Ligands;mglu1 Receptor (mgluR1) Ligands targeting GRM1, GRM5
JA-02-IU07_10uM Dose=10uM, 5-Cyclooctyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, mglu5 Receptor (mgluR5) Ligands;mglu1 Receptor (mgluR1) Ligands targeting GRM1, GRM5
JA-02-IU07_1uM Dose=1uM, 5-Cyclooctyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, mglu5 Receptor (mgluR5) Ligands;mglu1 Receptor (mgluR1) Ligands targeting GRM1, GRM5
JA-12-YH01_0.1uM Dose=0.1uM, Plasma Kallikrein (KLKB1) Inhibitor
JA-12-YH01_10uM Dose=10uM, Plasma Kallikrein (KLKB1) Inhibitor
JA-17-JV87_0.01uM Dose=0.01uM, Tegafur, Cytochrome P450 CYP2A6 inhibitor targeting CYP2A6
JA-17-JV87_0.1uM Dose=0.1uM, Tegafur, Cytochrome P450 CYP2A6 inhibitor targeting CYP2A6
JA-17-JV87_10uM Dose=10uM, Tegafur, Cytochrome P450 CYP2A6 inhibitor targeting CYP2A6
JA-17-JV87_1uM Dose=1uM, Tegafur, Cytochrome P450 CYP2A6 inhibitor targeting CYP2A6
JA-20-KM58_0.01uM Dose=0.01uM, Semagacestat, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
JA-20-KM58_0.1uM Dose=0.1uM, Semagacestat, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
JA-20-KM58_10uM Dose=10uM, Semagacestat, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
JA-20-KM58_1uM Dose=1uM, Semagacestat, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B
JA-23-QE71_0.01uM Dose=0.01uM, [4-(8-chloro-5-methyl-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)piperidin-1-yl]-(1H-indol-6-yl)methanone, AVPR1A antagonist targeting AVPR1A
JA-23-QE71_0.1uM Dose=0.1uM, [4-(8-chloro-5-methyl-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)piperidin-1-yl]-(1H-indol-6-yl)methanone, AVPR1A antagonist targeting AVPR1A
JA-23-QE71_10uM Dose=10uM, [4-(8-chloro-5-methyl-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)piperidin-1-yl]-(1H-indol-6-yl)methanone, AVPR1A antagonist targeting AVPR1A
JA-23-QE71_1uM Dose=1uM, [4-(8-chloro-5-methyl-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)piperidin-1-yl]-(1H-indol-6-yl)methanone, AVPR1A antagonist targeting AVPR1A
JA-23-RY79_0.01uM Dose=0.01uM
JA-23-RY79_0.1uM Dose=0.1uM
JA-23-RY79_10uM Dose=10uM
JA-23-RY79_1uM Dose=1uM
JA-24-VW07_0.01uM Dose=0.01uM, Istradefylline, Adenosine A2A Antagonists targeting ADORA2A
JA-24-VW07_10uM Dose=10uM, Istradefylline, Adenosine A2A Antagonists targeting ADORA2A
JA-26-YQ32_0.01uM Dose=0.01uM, Bentiromide, Pancreatic trypsin inhibitor targeting HPN
JA-26-YQ32_0.1uM Dose=0.1uM, Bentiromide, Pancreatic trypsin inhibitor targeting HPN
JA-26-YQ32_10uM Dose=10uM, Bentiromide, Pancreatic trypsin inhibitor targeting HPN
JA-26-YQ32_1uM Dose=1uM, Bentiromide, Pancreatic trypsin inhibitor targeting HPN
JA-32-HE94_0.01uM Dose=0.01uM, CPP-115 free base, Covalent inhibitor of GABA aminotransferase targeting ABAT
JA-32-HE94_0.1uM Dose=0.1uM, CPP-115 free base, Covalent inhibitor of GABA aminotransferase targeting ABAT
JA-32-HE94_10uM Dose=10uM, CPP-115 free base, Covalent inhibitor of GABA aminotransferase targeting ABAT
JA-32-HE94_1uM Dose=1uM, CPP-115 free base, Covalent inhibitor of GABA aminotransferase targeting ABAT
JA-38-XE73_0.01uM Dose=0.01uM
JA-38-XE73_0.1uM Dose=0.1uM
JA-38-XE73_10uM Dose=10uM
JA-38-XE73_1uM Dose=1uM
JA-42-MU37_0.01uM Dose=0.01uM
JA-42-MU37_0.1uM Dose=0.1uM
JA-42-MU37_10uM Dose=10uM
JA-42-MU37_1uM Dose=1uM
JA-42-NH96_0.01uM Dose=0.01uM, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, lanosterol synthetase inhibitor targeting LSS
JA-42-NH96_0.1uM Dose=0.1uM, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, lanosterol synthetase inhibitor targeting LSS
JA-42-NH96_10uM Dose=10uM, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, lanosterol synthetase inhibitor targeting LSS
JA-42-NH96_1uM Dose=1uM, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, lanosterol synthetase inhibitor targeting LSS
JA-46-LK88_0.01uM Dose=0.01uM, 3-Benzoylnaphtho[1,2-b]furan-4,5-dione, Inhibitors of Signal Transduction Pathways;CDC25A Inhibitors;CDC25C Inhibitors;CDC25B Inhibitors targeting CDC25C, NOS3
JA-46-LK88_0.1uM Dose=0.1uM, 3-Benzoylnaphtho[1,2-b]furan-4,5-dione, Inhibitors of Signal Transduction Pathways;CDC25A Inhibitors;CDC25C Inhibitors;CDC25B Inhibitors targeting CDC25C, NOS3
JA-46-LK88_10uM Dose=10uM, 3-Benzoylnaphtho[1,2-b]furan-4,5-dione, Inhibitors of Signal Transduction Pathways;CDC25A Inhibitors;CDC25C Inhibitors;CDC25B Inhibitors targeting CDC25C, NOS3
JA-46-LK88_1uM Dose=1uM, 3-Benzoylnaphtho[1,2-b]furan-4,5-dione, Inhibitors of Signal Transduction Pathways;CDC25A Inhibitors;CDC25C Inhibitors;CDC25B Inhibitors targeting CDC25C, NOS3
JA-52-PL41_0.01uM Dose=0.01uM, [4-Chloro-3-(5-chloro-benzothiazol-2-yl)-phenyl]-carbamic acid prop-2-ynyl ester, Lysophosphatidic Acid-Acyltransferase beta (LPAAT-beta) Inhibitors targeting AGPAT2
JA-52-PL41_0.1uM Dose=0.1uM, [4-Chloro-3-(5-chloro-benzothiazol-2-yl)-phenyl]-carbamic acid prop-2-ynyl ester, Lysophosphatidic Acid-Acyltransferase beta (LPAAT-beta) Inhibitors targeting AGPAT2
JA-52-PL41_10uM Dose=10uM, [4-Chloro-3-(5-chloro-benzothiazol-2-yl)-phenyl]-carbamic acid prop-2-ynyl ester, Lysophosphatidic Acid-Acyltransferase beta (LPAAT-beta) Inhibitors targeting AGPAT2
JA-52-PL41_1uM Dose=1uM, [4-Chloro-3-(5-chloro-benzothiazol-2-yl)-phenyl]-carbamic acid prop-2-ynyl ester, Lysophosphatidic Acid-Acyltransferase beta (LPAAT-beta) Inhibitors targeting AGPAT2
JA-57-AV27_0.01uM Dose=0.01uM, SGC-iMLLT targeting MLLT1, MLLT3
JA-57-AV27_0.1uM Dose=0.1uM, SGC-iMLLT targeting MLLT1, MLLT3
JA-57-AV27_10uM Dose=10uM, SGC-iMLLT targeting MLLT1, MLLT3
JA-57-AV27_1uM Dose=1uM, SGC-iMLLT targeting MLLT1, MLLT3
JA-62-XU82_0.01uM Dose=0.01uM, benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-phenylethyl]carbamate, Cathepsin K Inhibitors;Cathepsin S Inhibitors;Cathepsin L Inhibitors targeting CTSK, CTSL, CTSS
JA-62-XU82_0.1uM Dose=0.1uM, benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-phenylethyl]carbamate, Cathepsin K Inhibitors;Cathepsin S Inhibitors;Cathepsin L Inhibitors targeting CTSK, CTSL, CTSS
JA-62-XU82_1uM Dose=1uM, benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-phenylethyl]carbamate, Cathepsin K Inhibitors;Cathepsin S Inhibitors;Cathepsin L Inhibitors targeting CTSK, CTSL, CTSS
JA-63-WB39_0.01uM Dose=0.01uM
JA-63-WB39_0.1uM Dose=0.1uM
JA-63-WB39_10uM Dose=10uM
JA-63-WB39_1uM Dose=1uM
JA-74-VZ14_0.01uM Dose=0.01uM, CID 25108278, PAR2 Agonists;F2RL1 agonist targeting F2RL1
JA-74-VZ14_0.1uM Dose=0.1uM, CID 25108278, PAR2 Agonists;F2RL1 agonist targeting F2RL1
JA-74-VZ14_10uM Dose=10uM, CID 25108278, PAR2 Agonists;F2RL1 agonist targeting F2RL1
JA-74-VZ14_1uM Dose=1uM, CID 25108278, PAR2 Agonists;F2RL1 agonist targeting F2RL1
JA-77-UH38_0.01uM Dose=0.01uM
JA-77-UH38_0.1uM Dose=0.1uM
JA-77-UH38_10uM Dose=10uM
JA-77-UH38_1uM Dose=1uM
JA-79-II25_0.01uM Dose=0.01uM, Jnj-10329670, Cathepsin S Inhibitors targeting CTSS
JA-79-II25_0.1uM Dose=0.1uM, Jnj-10329670, Cathepsin S Inhibitors targeting CTSS
JA-79-II25_10uM Dose=10uM, Jnj-10329670, Cathepsin S Inhibitors targeting CTSS
JA-79-II25_1uM Dose=1uM, Jnj-10329670, Cathepsin S Inhibitors targeting CTSS
JA-80-KW72_0.01uM Dose=0.01uM, 9-[(2-Methyl-1,2,4-triazol-3-yl)methoxy]-6-phenyl-4,5,7,8-tetrazatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3,5,8-tetraene targeting GABRA2, GABRA3
JA-80-KW72_0.1uM Dose=0.1uM, 9-[(2-Methyl-1,2,4-triazol-3-yl)methoxy]-6-phenyl-4,5,7,8-tetrazatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3,5,8-tetraene targeting GABRA2, GABRA3
JA-80-KW72_10uM Dose=10uM, 9-[(2-Methyl-1,2,4-triazol-3-yl)methoxy]-6-phenyl-4,5,7,8-tetrazatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3,5,8-tetraene targeting GABRA2, GABRA3
JA-80-KW72_1uM Dose=1uM, 9-[(2-Methyl-1,2,4-triazol-3-yl)methoxy]-6-phenyl-4,5,7,8-tetrazatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3,5,8-tetraene targeting GABRA2, GABRA3
JA-82-EV20_0.01uM Dose=0.01uM, Ldn-91946, Inhibitor of Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4);Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Inhibitors targeting UCHL1
JA-82-EV20_0.1uM Dose=0.1uM, Ldn-91946, Inhibitor of Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4);Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Inhibitors targeting UCHL1
JA-82-EV20_10uM Dose=10uM, Ldn-91946, Inhibitor of Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4);Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Inhibitors targeting UCHL1
JA-82-EV20_1uM Dose=1uM, Ldn-91946, Inhibitor of Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4);Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Inhibitors targeting UCHL1
JA-85-CW09_0.01uM Dose=0.01uM, 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK Inhibitors targeting CCND2, CCND3
JA-85-CW09_0.1uM Dose=0.1uM, 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK Inhibitors targeting CCND2, CCND3
JA-85-CW09_10uM Dose=10uM, 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK Inhibitors targeting CCND2, CCND3
JA-85-CW09_1uM Dose=1uM, 4-(Methylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK Inhibitors targeting CCND2, CCND3
JA-85-SW39_0.01uM Dose=0.01uM, Adavosertib, WEE1 gene inhibitor targeting WEE1, WEE2
JA-85-SW39_0.1uM Dose=0.1uM, Adavosertib, WEE1 gene inhibitor targeting WEE1, WEE2
JA-85-SW39_10uM Dose=10uM, Adavosertib, WEE1 gene inhibitor targeting WEE1, WEE2
JA-85-SW39_1uM Dose=1uM, Adavosertib, WEE1 gene inhibitor targeting WEE1, WEE2
JA-88-IO52_0.01uM Dose=0.01uM
JA-88-IO52_0.1uM Dose=0.1uM
JA-88-IO52_10uM Dose=10uM
JA-88-IO52_1uM Dose=1uM
JA-95-PQ25_0.01uM Dose=0.01uM, Tocopherol Nicotinate
JA-95-PQ25_0.1uM Dose=0.1uM, Tocopherol Nicotinate
JA-95-PQ25_10uM Dose=10uM, Tocopherol Nicotinate
JA-95-PQ25_1uM Dose=1uM, Tocopherol Nicotinate
JA-98-CL60_0.1uM Dose=0.1uM, 2-Acetamido-3-[[1,4,4a,5,6,6a,7,12,12a,12b-decahydro-4a,8,12a,12b-tetrahydroxy-3-methyl-1,7,12-trioxobenz[a]anthracene-6a-yl]thio]propionic acid, Endothelin Receptor Antagonists targeting EDNRA
JA-98-CL60_10uM Dose=10uM, 2-Acetamido-3-[[1,4,4a,5,6,6a,7,12,12a,12b-decahydro-4a,8,12a,12b-tetrahydroxy-3-methyl-1,7,12-trioxobenz[a]anthracene-6a-yl]thio]propionic acid, Endothelin Receptor Antagonists targeting EDNRA
JB-01-MH79_0.01uM Dose=0.01uM, Osu-53, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1
JB-01-MH79_0.1uM Dose=0.1uM, Osu-53, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1
JB-01-MH79_10uM Dose=10uM, Osu-53, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1
JB-08-BL30_0.01uM Dose=0.01uM, 3-{1-[3-(biphenyl-4-ylamino)-3-oxopropyl]-1H-1,2,3-triazol-4-yl}-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
JB-08-BL30_0.1uM Dose=0.1uM, 3-{1-[3-(biphenyl-4-ylamino)-3-oxopropyl]-1H-1,2,3-triazol-4-yl}-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
JB-08-BL30_1uM Dose=1uM, 3-{1-[3-(biphenyl-4-ylamino)-3-oxopropyl]-1H-1,2,3-triazol-4-yl}-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11
JB-09-SI50_0.01uM Dose=0.01uM, 3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCG
JB-09-SI50_0.1uM Dose=0.1uM, 3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCG
JB-09-SI50_10uM Dose=10uM, 3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCG
JB-09-SI50_1uM Dose=1uM, 3-(1-Benzo[b]thiophen-2-yl-1H-indol-3-yl)-4-[1-(3-dimethylamino-propyl)-1H-indazol-3-yl]-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCG
JB-14-TF61_0.01uM Dose=0.01uM, Plerixafor, HIV Attachment Inhibitors;Chelating Agents;CXCR4 antagonist;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4
JB-14-TF61_0.1uM Dose=0.1uM, Plerixafor, HIV Attachment Inhibitors;Chelating Agents;CXCR4 antagonist;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4
JB-14-TF61_10uM Dose=10uM, Plerixafor, HIV Attachment Inhibitors;Chelating Agents;CXCR4 antagonist;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4
JB-14-ZM03_0.01uM Dose=0.01uM, Idronoxil, Apoptosis Inducers;BIRC4 Expression Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;Inhibitors of Signal Transduction Pathways;Sphingosine Kinase Inhibitors targeting ENOX2, SPHK2
JB-14-ZM03_0.1uM Dose=0.1uM, Idronoxil, Apoptosis Inducers;BIRC4 Expression Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;Inhibitors of Signal Transduction Pathways;Sphingosine Kinase Inhibitors targeting ENOX2, SPHK2
JB-14-ZM03_10uM Dose=10uM, Idronoxil, Apoptosis Inducers;BIRC4 Expression Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;Inhibitors of Signal Transduction Pathways;Sphingosine Kinase Inhibitors targeting ENOX2, SPHK2
JB-14-ZM03_1uM Dose=1uM, Idronoxil, Apoptosis Inducers;BIRC4 Expression Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;Inhibitors of Signal Transduction Pathways;Sphingosine Kinase Inhibitors targeting ENOX2, SPHK2
JB-23-ZE86_0.01uM Dose=0.01uM, N-benzyl-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-amine, Lck Kinase Inhibitors targeting LCK
JB-23-ZE86_0.1uM Dose=0.1uM, N-benzyl-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-amine, Lck Kinase Inhibitors targeting LCK
JB-23-ZE86_10uM Dose=10uM, N-benzyl-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-amine, Lck Kinase Inhibitors targeting LCK
JB-23-ZE86_1uM Dose=1uM, N-benzyl-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-amine, Lck Kinase Inhibitors targeting LCK
JB-28-VO37_0.01uM Dose=0.01uM, 7-[(1R)-2-[[(1R,2R)-2-(3-ethoxyphenyl)cyclopentyl]amino]-1-hydroxyethyl]-4-hydroxy-3H-1,3-benzothiazol-2-one
JB-28-VO37_0.1uM Dose=0.1uM, 7-[(1R)-2-[[(1R,2R)-2-(3-ethoxyphenyl)cyclopentyl]amino]-1-hydroxyethyl]-4-hydroxy-3H-1,3-benzothiazol-2-one
JB-28-VO37_10uM Dose=10uM, 7-[(1R)-2-[[(1R,2R)-2-(3-ethoxyphenyl)cyclopentyl]amino]-1-hydroxyethyl]-4-hydroxy-3H-1,3-benzothiazol-2-one
JB-28-VO37_1uM Dose=1uM, 7-[(1R)-2-[[(1R,2R)-2-(3-ethoxyphenyl)cyclopentyl]amino]-1-hydroxyethyl]-4-hydroxy-3H-1,3-benzothiazol-2-one
JB-34-VI53_0.01uM Dose=0.01uM, 4-fluoro-N-(2-(4-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)benzamide, PLD1 inhibitor targeting PLD1, PLD2
JB-34-VI53_0.1uM Dose=0.1uM, 4-fluoro-N-(2-(4-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)benzamide, PLD1 inhibitor targeting PLD1, PLD2
JB-34-VI53_10uM Dose=10uM, 4-fluoro-N-(2-(4-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)benzamide, PLD1 inhibitor targeting PLD1, PLD2
JB-35-RC26_0.01uM Dose=0.01uM, Valopicitabine
JB-35-RC26_0.1uM Dose=0.1uM, Valopicitabine
JB-35-RC26_10uM Dose=10uM, Valopicitabine
JB-35-RC26_1uM Dose=1uM, Valopicitabine
JB-37-OU59_0.01uM Dose=0.01uM, GW766994, Chemokine CCR3 Antagonists targeting CXCR3
JB-37-OU59_10uM Dose=10uM, GW766994, Chemokine CCR3 Antagonists targeting CXCR3
JB-37-OU59_1uM Dose=1uM, GW766994, Chemokine CCR3 Antagonists targeting CXCR3
JB-41-UN43_0.01uM Dose=0.01uM, N-[(2S)-3-(4-aminophenyl)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxopropan-2-yl]-4-[[(2S)-1-morpholin-4-yl-3-phenylpropan-2-yl]amino]pyridine-3-sulfonamide, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2
JB-41-UN43_0.1uM Dose=0.1uM, N-[(2S)-3-(4-aminophenyl)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxopropan-2-yl]-4-[[(2S)-1-morpholin-4-yl-3-phenylpropan-2-yl]amino]pyridine-3-sulfonamide, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2
JB-41-UN43_1uM Dose=1uM, N-[(2S)-3-(4-aminophenyl)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxopropan-2-yl]-4-[[(2S)-1-morpholin-4-yl-3-phenylpropan-2-yl]amino]pyridine-3-sulfonamide, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2
JB-48-AO57_0.01uM Dose=0.01uM, [(1S,3R,7S,8S,8aR)-8-[2-[(4R,6R)-3-[[4-(2-hydroxypropan-2-yl)phenyl]methyl]-4-(2-methoxy-2-oxoethyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
JB-48-AO57_0.1uM Dose=0.1uM, [(1S,3R,7S,8S,8aR)-8-[2-[(4R,6R)-3-[[4-(2-hydroxypropan-2-yl)phenyl]methyl]-4-(2-methoxy-2-oxoethyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
JB-48-AO57_10uM Dose=10uM, [(1S,3R,7S,8S,8aR)-8-[2-[(4R,6R)-3-[[4-(2-hydroxypropan-2-yl)phenyl]methyl]-4-(2-methoxy-2-oxoethyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
JB-48-AO57_1uM Dose=1uM, [(1S,3R,7S,8S,8aR)-8-[2-[(4R,6R)-3-[[4-(2-hydroxypropan-2-yl)phenyl]methyl]-4-(2-methoxy-2-oxoethyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
JB-48-TL55_0.01uM Dose=0.01uM, Levamisole, Nicotinic Receptor Agonists targeting CHRNA3
JB-48-TL55_0.1uM Dose=0.1uM, Levamisole, Nicotinic Receptor Agonists targeting CHRNA3
JB-48-TL55_10uM Dose=10uM, Levamisole, Nicotinic Receptor Agonists targeting CHRNA3
JB-48-TL55_1uM Dose=1uM, Levamisole, Nicotinic Receptor Agonists targeting CHRNA3
JB-50-NM08_0.01uM Dose=0.01uM, 3,3-Dimethyl-7-[2-(4-propoxyphenyl)ethynyl]-2,4-dihydro-1,5-benzodioxepine, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB
JB-50-NM08_10uM Dose=10uM, 3,3-Dimethyl-7-[2-(4-propoxyphenyl)ethynyl]-2,4-dihydro-1,5-benzodioxepine, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB
JB-55-CM55_0.01uM Dose=0.01uM, 8-Chloro-6-phenylspiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7A gene inhibitor targeting PDE7A
JB-55-CM55_0.1uM Dose=0.1uM, 8-Chloro-6-phenylspiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7A gene inhibitor targeting PDE7A
JB-55-CM55_10uM Dose=10uM, 8-Chloro-6-phenylspiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7A gene inhibitor targeting PDE7A
JB-55-CM55_1uM Dose=1uM, 8-Chloro-6-phenylspiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7A gene inhibitor targeting PDE7A
JB-58-VY51_0.01uM Dose=0.01uM, Thymidine, Thymidine kinase 1 ligand;Thymidine kinase 2 ligand targeting TK1, TYMP, TK2
JB-58-VY51_0.1uM Dose=0.1uM, Thymidine, Thymidine kinase 1 ligand;Thymidine kinase 2 ligand targeting TK1, TYMP, TK2
JB-58-VY51_1uM Dose=1uM, Thymidine, Thymidine kinase 1 ligand;Thymidine kinase 2 ligand targeting TK1, TYMP, TK2
JB-60-JM38_0.01uM Dose=0.01uM, RS 67333, 5-HT4 Partial Agonists targeting HTR4
JB-60-JM38_0.1uM Dose=0.1uM, RS 67333, 5-HT4 Partial Agonists targeting HTR4
JB-60-JM38_10uM Dose=10uM, RS 67333, 5-HT4 Partial Agonists targeting HTR4
JB-60-JM38_1uM Dose=1uM, RS 67333, 5-HT4 Partial Agonists targeting HTR4
JB-61-UQ50_10uM Dose=10uM, Benzylamphetamine targeting FARS2
JB-62-SR15_0.01uM Dose=0.01uM, (2S)-3-(1H-indol-3-yl)-2-[[(3S)-1,2,3,4-tetrahydroisoquinolin-2-ium-3-carbonyl]amino]propanoate
JB-62-SR15_10uM Dose=10uM, (2S)-3-(1H-indol-3-yl)-2-[[(3S)-1,2,3,4-tetrahydroisoquinolin-2-ium-3-carbonyl]amino]propanoate
JB-63-NV02_0.01uM Dose=0.01uM, 5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
JB-63-NV02_0.1uM Dose=0.1uM, 5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
JB-63-NV02_10uM Dose=10uM, 5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
JB-63-NV02_1uM Dose=1uM, 5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
JB-65-ON98_0.01uM Dose=0.01uM
JB-65-ON98_0.1uM Dose=0.1uM
JB-65-ON98_10uM Dose=10uM
JB-65-ON98_1uM Dose=1uM
JB-72-IH66_0.01uM Dose=0.01uM, CID 49843509, Proteinase activated receptor 2 (PAR2) partial agonist targeting F2RL1
JB-72-IH66_0.1uM Dose=0.1uM, CID 49843509, Proteinase activated receptor 2 (PAR2) partial agonist targeting F2RL1
JB-72-IH66_10uM Dose=10uM, CID 49843509, Proteinase activated receptor 2 (PAR2) partial agonist targeting F2RL1
JB-72-IH66_1uM Dose=1uM, CID 49843509, Proteinase activated receptor 2 (PAR2) partial agonist targeting F2RL1
JB-74-LF71_0.01uM Dose=0.01uM, 6-(6-(Diethylamino)pyridin-3-yl)-N-(4-morpholinophenyl)-9H-purin-2-amine, Jak3 Inhibitors targeting JAK3
JB-74-LF71_0.1uM Dose=0.1uM, 6-(6-(Diethylamino)pyridin-3-yl)-N-(4-morpholinophenyl)-9H-purin-2-amine, Jak3 Inhibitors targeting JAK3
JB-74-LF71_10uM Dose=10uM, 6-(6-(Diethylamino)pyridin-3-yl)-N-(4-morpholinophenyl)-9H-purin-2-amine, Jak3 Inhibitors targeting JAK3
JB-74-LF71_1uM Dose=1uM, 6-(6-(Diethylamino)pyridin-3-yl)-N-(4-morpholinophenyl)-9H-purin-2-amine, Jak3 Inhibitors targeting JAK3
JB-74-LJ21_0.01uM Dose=0.01uM, 4-Amino-N-[(1S)-1-cyano-2-(4'-cyano[1,1'-biphenyl]-4-yl)ethyl]tetrahydro-2H-pyran-4-carboxamide, cathepsin C (DPP1) inhibitor targeting CTSC
JB-74-LJ21_10uM Dose=10uM, 4-Amino-N-[(1S)-1-cyano-2-(4'-cyano[1,1'-biphenyl]-4-yl)ethyl]tetrahydro-2H-pyran-4-carboxamide, cathepsin C (DPP1) inhibitor targeting CTSC
JB-74-LJ21_1uM Dose=1uM, 4-Amino-N-[(1S)-1-cyano-2-(4'-cyano[1,1'-biphenyl]-4-yl)ethyl]tetrahydro-2H-pyran-4-carboxamide, cathepsin C (DPP1) inhibitor targeting CTSC
JB-75-NC66_0.01uM Dose=0.01uM, 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, HSP70 co-inducer or chaperone targeting HSPA1A
JB-75-NC66_0.1uM Dose=0.1uM, 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, HSP70 co-inducer or chaperone targeting HSPA1A
JB-75-NC66_10uM Dose=10uM, 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, HSP70 co-inducer or chaperone targeting HSPA1A
JB-75-NC66_1uM Dose=1uM, 3-Pyridinecarboximidoyl chloride, N-[(2R)-2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide, HSP70 co-inducer or chaperone targeting HSPA1A
JB-76-JD86_0.01uM Dose=0.01uM, N-[(6-amino-4-methylpyridin-3-yl)methyl]-1-benzylpyrazole-4-carboxamide
JB-76-JD86_0.1uM Dose=0.1uM, N-[(6-amino-4-methylpyridin-3-yl)methyl]-1-benzylpyrazole-4-carboxamide
JB-76-JD86_10uM Dose=10uM, N-[(6-amino-4-methylpyridin-3-yl)methyl]-1-benzylpyrazole-4-carboxamide
JB-76-JD86_1uM Dose=1uM, N-[(6-amino-4-methylpyridin-3-yl)methyl]-1-benzylpyrazole-4-carboxamide
JB-81-XD04_0.1uM Dose=0.1uM, N-Benzylphenethylamine targeting FARS2
JB-81-XD04_10uM Dose=10uM, N-Benzylphenethylamine targeting FARS2
JB-81-XD04_1uM Dose=1uM, N-Benzylphenethylamine targeting FARS2
JB-82-MH86_0.01uM Dose=0.01uM, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
JB-82-MH86_0.1uM Dose=0.1uM, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
JB-82-MH86_10uM Dose=10uM, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
JB-82-MH86_1uM Dose=1uM, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1
JB-82-SK68_0.01uM Dose=0.01uM, Oxyfenthiin
JB-82-SK68_0.1uM Dose=0.1uM, Oxyfenthiin
JB-82-SK68_10uM Dose=10uM, Oxyfenthiin
JB-82-SK68_1uM Dose=1uM, Oxyfenthiin
JB-89-SI60_0.01uM Dose=0.01uM, (3s,5r)-N-{[9-(4-Methoxybutyl)-9h-Xanthen-9-Yl]methyl}-5-{[(4-Methylphenyl)sulfonyl]amino}piperidine-3-Carboxamide, Renin Inhibitors targeting REN
JB-89-SI60_0.1uM Dose=0.1uM, (3s,5r)-N-{[9-(4-Methoxybutyl)-9h-Xanthen-9-Yl]methyl}-5-{[(4-Methylphenyl)sulfonyl]amino}piperidine-3-Carboxamide, Renin Inhibitors targeting REN
JB-89-SI60_10uM Dose=10uM, (3s,5r)-N-{[9-(4-Methoxybutyl)-9h-Xanthen-9-Yl]methyl}-5-{[(4-Methylphenyl)sulfonyl]amino}piperidine-3-Carboxamide, Renin Inhibitors targeting REN
JB-89-SI60_1uM Dose=1uM, (3s,5r)-N-{[9-(4-Methoxybutyl)-9h-Xanthen-9-Yl]methyl}-5-{[(4-Methylphenyl)sulfonyl]amino}piperidine-3-Carboxamide, Renin Inhibitors targeting REN
JB-91-QG66_0.01uM Dose=0.01uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[4-fluoro-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
JB-91-QG66_10uM Dose=10uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[4-fluoro-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
JB-91-QG66_1uM Dose=1uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[4-fluoro-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR
JB-98-EB51_0.01uM Dose=0.01uM, Pochonin D, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1
JB-98-EB51_0.1uM Dose=0.1uM, Pochonin D, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1
JB-98-EB51_10uM Dose=10uM, Pochonin D, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1
JB-98-EB51_1uM Dose=1uM, Pochonin D, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1
JB-99-UC61_0.01uM Dose=0.01uM, [4-[(2S)-2-[[(2R)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
JB-99-UC61_0.1uM Dose=0.1uM, [4-[(2S)-2-[[(2R)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
JB-99-UC61_10uM Dose=10uM, [4-[(2S)-2-[[(2R)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
JB-99-UC61_1uM Dose=1uM, [4-[(2S)-2-[[(2R)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
JC-02-ZR15_0.01uM Dose=0.01uM, 1-[(4-Chloro-3-nitrophenyl)sulfonyl]-1H-indole-3-methanol, Apoptosis Inducers;BCL2 Expression Inhibitors targeting BCL2
JC-02-ZR15_0.1uM Dose=0.1uM, 1-[(4-Chloro-3-nitrophenyl)sulfonyl]-1H-indole-3-methanol, Apoptosis Inducers;BCL2 Expression Inhibitors targeting BCL2
JC-02-ZR15_10uM Dose=10uM, 1-[(4-Chloro-3-nitrophenyl)sulfonyl]-1H-indole-3-methanol, Apoptosis Inducers;BCL2 Expression Inhibitors targeting BCL2
JC-02-ZR15_1uM Dose=1uM, 1-[(4-Chloro-3-nitrophenyl)sulfonyl]-1H-indole-3-methanol, Apoptosis Inducers;BCL2 Expression Inhibitors targeting BCL2
JC-03-OI01_0.01uM Dose=0.01uM, Trapidil, Platelet activating factor receptor antagonist targeting PDGFRA
JC-03-OI01_0.1uM Dose=0.1uM, Trapidil, Platelet activating factor receptor antagonist targeting PDGFRA
JC-03-OI01_10uM Dose=10uM, Trapidil, Platelet activating factor receptor antagonist targeting PDGFRA
JC-03-OI01_1uM Dose=1uM, Trapidil, Platelet activating factor receptor antagonist targeting PDGFRA
JC-05-CC41_0.01uM Dose=0.01uM, 3-{(R)-3-[(4-Fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic acid
JC-05-CC41_0.1uM Dose=0.1uM, 3-{(R)-3-[(4-Fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic acid
JC-05-CC41_10uM Dose=10uM, 3-{(R)-3-[(4-Fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic acid
JC-05-CC41_1uM Dose=1uM, 3-{(R)-3-[(4-Fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-carbazol-9-yl}-propionic acid
JC-06-ED36_0.01uM Dose=0.01uM, CDDO-Im, PPARgamma Agonists;Apoptosis Inducers;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Nitric Oxide Production Inhibitors targeting NFE2L2, PPARG, KEAP1
JC-06-ED36_0.1uM Dose=0.1uM, CDDO-Im, PPARgamma Agonists;Apoptosis Inducers;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Nitric Oxide Production Inhibitors targeting NFE2L2, PPARG, KEAP1
JC-06-ED36_10uM Dose=10uM, CDDO-Im, PPARgamma Agonists;Apoptosis Inducers;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Nitric Oxide Production Inhibitors targeting NFE2L2, PPARG, KEAP1
JC-06-ED36_1uM Dose=1uM, CDDO-Im, PPARgamma Agonists;Apoptosis Inducers;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Nitric Oxide Production Inhibitors targeting NFE2L2, PPARG, KEAP1
JC-14-YI23_0.01uM Dose=0.01uM, Sdccgsbi-0050877.P002
JC-14-YI23_10uM Dose=10uM, Sdccgsbi-0050877.P002
JC-14-YI23_1uM Dose=1uM, Sdccgsbi-0050877.P002
JC-19-ST72_0.01uM Dose=0.01uM, US10669234, Example 126 targeting USP30
JC-19-ST72_10uM Dose=10uM, US10669234, Example 126 targeting USP30
JC-19-ST72_1uM Dose=1uM, US10669234, Example 126 targeting USP30
JC-22-WH91_0.01uM Dose=0.01uM, 1-[4-[2-(4-Chlorophenyl)propan-2-yl]phenyl]-5-methyl-1,2,4-triazole-3-carboxamide
JC-22-WH91_0.1uM Dose=0.1uM, 1-[4-[2-(4-Chlorophenyl)propan-2-yl]phenyl]-5-methyl-1,2,4-triazole-3-carboxamide
JC-22-WH91_10uM Dose=10uM, 1-[4-[2-(4-Chlorophenyl)propan-2-yl]phenyl]-5-methyl-1,2,4-triazole-3-carboxamide
JC-22-WH91_1uM Dose=1uM, 1-[4-[2-(4-Chlorophenyl)propan-2-yl]phenyl]-5-methyl-1,2,4-triazole-3-carboxamide
JC-24-MC69_0.01uM Dose=0.01uM, [4-(4-Phenylphenyl)-1-triazolyl]-(1-pyrrolidinyl)methanone, Acylaminoacyl peptidase inhibitor targeting APEH
JC-24-MC69_0.1uM Dose=0.1uM, [4-(4-Phenylphenyl)-1-triazolyl]-(1-pyrrolidinyl)methanone, Acylaminoacyl peptidase inhibitor targeting APEH
JC-24-MC69_10uM Dose=10uM, [4-(4-Phenylphenyl)-1-triazolyl]-(1-pyrrolidinyl)methanone, Acylaminoacyl peptidase inhibitor targeting APEH
JC-24-MC69_1uM Dose=1uM, [4-(4-Phenylphenyl)-1-triazolyl]-(1-pyrrolidinyl)methanone, Acylaminoacyl peptidase inhibitor targeting APEH
JC-26-DD86_0.01uM Dose=0.01uM, 1-[6-(4-Methylphenyl)-[1,3]oxazolo[4,5-b]pyridin-2-yl]-6-phenylhexan-1-one, dual diacyglycerol lipase alpha and beta reversible inhibitor targeting DAGLA, DAGLB
JC-26-DD86_0.1uM Dose=0.1uM, 1-[6-(4-Methylphenyl)-[1,3]oxazolo[4,5-b]pyridin-2-yl]-6-phenylhexan-1-one, dual diacyglycerol lipase alpha and beta reversible inhibitor targeting DAGLA, DAGLB
JC-26-DD86_1uM Dose=1uM, 1-[6-(4-Methylphenyl)-[1,3]oxazolo[4,5-b]pyridin-2-yl]-6-phenylhexan-1-one, dual diacyglycerol lipase alpha and beta reversible inhibitor targeting DAGLA, DAGLB
JC-47-KK95_0.01uM Dose=0.01uM, 4-(2-Cyano-5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid
JC-47-KK95_0.1uM Dose=0.1uM, 4-(2-Cyano-5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid
JC-47-KK95_10uM Dose=10uM, 4-(2-Cyano-5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid
JC-47-KK95_1uM Dose=1uM, 4-(2-Cyano-5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid
JC-51-JD64_0.01uM Dose=0.01uM, Spirapril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
JC-51-JD64_0.1uM Dose=0.1uM, Spirapril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
JC-51-JD64_10uM Dose=10uM, Spirapril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
JC-51-JD64_1uM Dose=1uM, Spirapril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE
JC-52-RH51_0.01uM Dose=0.01uM, 3-[4-[[4-Chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methoxy]-2-fluorophenyl]propanoic acid, GPR40 agonist targeting FFAR1
JC-52-RH51_0.1uM Dose=0.1uM, 3-[4-[[4-Chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methoxy]-2-fluorophenyl]propanoic acid, GPR40 agonist targeting FFAR1
JC-52-RH51_10uM Dose=10uM, 3-[4-[[4-Chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methoxy]-2-fluorophenyl]propanoic acid, GPR40 agonist targeting FFAR1
JC-52-RH51_1uM Dose=1uM, 3-[4-[[4-Chloro-3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methoxy]-2-fluorophenyl]propanoic acid, GPR40 agonist targeting FFAR1
JC-53-YE56_0.01uM Dose=0.01uM, Quiflapon
JC-53-YE56_0.1uM Dose=0.1uM, Quiflapon
JC-53-YE56_10uM Dose=10uM, Quiflapon
JC-57-DO70_0.1uM Dose=0.1uM, Cabergoline, Dopamine D2 Agonists;Prolactin Secretion Inhibitors targeting DRD2, HTR2B, PRL
JC-57-DO70_10uM Dose=10uM, Cabergoline, Dopamine D2 Agonists;Prolactin Secretion Inhibitors targeting DRD2, HTR2B, PRL
JC-57-DO70_1uM Dose=1uM, Cabergoline, Dopamine D2 Agonists;Prolactin Secretion Inhibitors targeting DRD2, HTR2B, PRL
JC-63-BE61_0.01uM Dose=0.01uM
JC-63-BE61_0.1uM Dose=0.1uM
JC-63-BE61_10uM Dose=10uM
JC-63-BE61_1uM Dose=1uM
JC-63-DO70_0.01uM Dose=0.01uM, Tachykinin NK1 Antagonists targeting TACR1
JC-63-DO70_0.1uM Dose=0.1uM, Tachykinin NK1 Antagonists targeting TACR1
JC-63-DO70_1uM Dose=1uM, Tachykinin NK1 Antagonists targeting TACR1
JC-64-QI43_0.01uM Dose=0.01uM, 4-Bromo-2,6-diisopropylphenol, Nav1.2 (Brain Type II) Sodium Channel Blockers;Nav1.4 (SkM1) Sodium Channel Blockers targeting SCN2A, SCN4A
JC-64-QI43_0.1uM Dose=0.1uM, 4-Bromo-2,6-diisopropylphenol, Nav1.2 (Brain Type II) Sodium Channel Blockers;Nav1.4 (SkM1) Sodium Channel Blockers targeting SCN2A, SCN4A
JC-64-QI43_10uM Dose=10uM, 4-Bromo-2,6-diisopropylphenol, Nav1.2 (Brain Type II) Sodium Channel Blockers;Nav1.4 (SkM1) Sodium Channel Blockers targeting SCN2A, SCN4A
JC-64-QI43_1uM Dose=1uM, 4-Bromo-2,6-diisopropylphenol, Nav1.2 (Brain Type II) Sodium Channel Blockers;Nav1.4 (SkM1) Sodium Channel Blockers targeting SCN2A, SCN4A
JC-67-FV32_0.01uM Dose=0.01uM, 4-[4-(2-Pyrrolidin-1-ylethyl)piperidin-1-yl]thieno[3,2-d]pyrimidine-6-carboxamide targeting SIRT2, SIRT3, SIRT1
JC-67-FV32_0.1uM Dose=0.1uM, 4-[4-(2-Pyrrolidin-1-ylethyl)piperidin-1-yl]thieno[3,2-d]pyrimidine-6-carboxamide targeting SIRT2, SIRT3, SIRT1
JC-67-FV32_10uM Dose=10uM, 4-[4-(2-Pyrrolidin-1-ylethyl)piperidin-1-yl]thieno[3,2-d]pyrimidine-6-carboxamide targeting SIRT2, SIRT3, SIRT1
JC-67-FV32_1uM Dose=1uM, 4-[4-(2-Pyrrolidin-1-ylethyl)piperidin-1-yl]thieno[3,2-d]pyrimidine-6-carboxamide targeting SIRT2, SIRT3, SIRT1
JC-75-LJ73_0.01uM Dose=0.01uM, (1S,2S)-N-((R)-2-Hydroxy-1-(4-((S)-2-methylbutoxy)phenyl)ethyl)-2-(thiophen-2-yl)cyclopropanecarboxamide, GPR88 agonist targeting GPR88
JC-75-LJ73_10uM Dose=10uM, (1S,2S)-N-((R)-2-Hydroxy-1-(4-((S)-2-methylbutoxy)phenyl)ethyl)-2-(thiophen-2-yl)cyclopropanecarboxamide, GPR88 agonist targeting GPR88
JC-76-VX29_0.01uM Dose=0.01uM, 7-Nitro-1,2,3,4-tetrahydroisoquinoline, phenylethanolamine N-methyltransferase inhibitor targeting PNMT
JC-76-VX29_0.1uM Dose=0.1uM, 7-Nitro-1,2,3,4-tetrahydroisoquinoline, phenylethanolamine N-methyltransferase inhibitor targeting PNMT
JC-76-VX29_10uM Dose=10uM, 7-Nitro-1,2,3,4-tetrahydroisoquinoline, phenylethanolamine N-methyltransferase inhibitor targeting PNMT
JC-76-VX29_1uM Dose=1uM, 7-Nitro-1,2,3,4-tetrahydroisoquinoline, phenylethanolamine N-methyltransferase inhibitor targeting PNMT
JC-86-PD41_0.01uM Dose=0.01uM, CID 58580621, angiotensin I converting enzyme 2 inhibitor targeting ACE2
JC-86-PD41_0.1uM Dose=0.1uM, CID 58580621, angiotensin I converting enzyme 2 inhibitor targeting ACE2
JC-86-PD41_1uM Dose=1uM, CID 58580621, angiotensin I converting enzyme 2 inhibitor targeting ACE2
JC-95-LT07_0.01uM Dose=0.01uM, 2-Chloro-6-fluorobenzyl (3-(2,6-dimethylphenyl)-5-methylisoxazol-4-yl)carbamate, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A
JC-95-LT07_0.1uM Dose=0.1uM, 2-Chloro-6-fluorobenzyl (3-(2,6-dimethylphenyl)-5-methylisoxazol-4-yl)carbamate, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A
JC-95-LT07_10uM Dose=10uM, 2-Chloro-6-fluorobenzyl (3-(2,6-dimethylphenyl)-5-methylisoxazol-4-yl)carbamate, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A
JC-95-LT07_1uM Dose=1uM, 2-Chloro-6-fluorobenzyl (3-(2,6-dimethylphenyl)-5-methylisoxazol-4-yl)carbamate, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A
JC-96-ID26_0.01uM Dose=0.01uM, N-((R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-3-(2-fluorophenyl)-1-oxopropan-2-yl)-4-fluoro-2-(trifluoromethyl)benzamide, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A
JC-96-ID26_0.1uM Dose=0.1uM, N-((R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-3-(2-fluorophenyl)-1-oxopropan-2-yl)-4-fluoro-2-(trifluoromethyl)benzamide, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A
JC-96-ID26_10uM Dose=10uM, N-((R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-3-(2-fluorophenyl)-1-oxopropan-2-yl)-4-fluoro-2-(trifluoromethyl)benzamide, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A
JC-96-ID26_1uM Dose=1uM, N-((R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-3-(2-fluorophenyl)-1-oxopropan-2-yl)-4-fluoro-2-(trifluoromethyl)benzamide, Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting SCN9A
JC-99-EF33_10uM Dose=10uM, 3-({[4-Methyl-5-(Pyridin-4-Yl)-4h-1,2,4-Triazol-3-Yl]methyl}amino)-N-[2-(Trifluoromethyl)benzyl]benzamide, beta adrenergic receptor kinase 1 and 2 targeting GRK2, GRK3, GRK1
JD-00-TT75_0.01uM Dose=0.01uM, 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-naphthalene-1-carboxylic Acid, Lactate dehydrogenase inhibitor targeting LDHA, LDHB
JD-00-TT75_0.1uM Dose=0.1uM, 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-naphthalene-1-carboxylic Acid, Lactate dehydrogenase inhibitor targeting LDHA, LDHB
JD-00-TT75_10uM Dose=10uM, 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-naphthalene-1-carboxylic Acid, Lactate dehydrogenase inhibitor targeting LDHA, LDHB
JD-00-TT75_1uM Dose=1uM, 7-benzyl-2,3-dihydroxy-6-methyl-4-propyl-naphthalene-1-carboxylic Acid, Lactate dehydrogenase inhibitor targeting LDHA, LDHB
JD-00-YJ41_0.01uM Dose=0.01uM, Pexmetinib, Tie-2 p38 MAPK dual inhibitor targeting TEK
JD-00-YJ41_0.1uM Dose=0.1uM, Pexmetinib, Tie-2 p38 MAPK dual inhibitor targeting TEK
JD-00-YJ41_10uM Dose=10uM, Pexmetinib, Tie-2 p38 MAPK dual inhibitor targeting TEK
JD-00-YJ41_1uM Dose=1uM, Pexmetinib, Tie-2 p38 MAPK dual inhibitor targeting TEK
JD-01-RA07_0.01uM Dose=0.01uM, N-(4,6-Dimethylpyrimidin-2-yl)-4-((2-methylbenzyl)amino)benzenesulfonamide, alpha2B-Adrenoceptor Antagonists targeting ADRA2B
JD-01-RA07_0.1uM Dose=0.1uM, N-(4,6-Dimethylpyrimidin-2-yl)-4-((2-methylbenzyl)amino)benzenesulfonamide, alpha2B-Adrenoceptor Antagonists targeting ADRA2B
JD-01-RA07_10uM Dose=10uM, N-(4,6-Dimethylpyrimidin-2-yl)-4-((2-methylbenzyl)amino)benzenesulfonamide, alpha2B-Adrenoceptor Antagonists targeting ADRA2B
JD-01-RA07_1uM Dose=1uM, N-(4,6-Dimethylpyrimidin-2-yl)-4-((2-methylbenzyl)amino)benzenesulfonamide, alpha2B-Adrenoceptor Antagonists targeting ADRA2B
JD-02-GA59_0.01uM Dose=0.01uM
JD-02-GA59_0.1uM Dose=0.1uM
JD-02-GA59_10uM Dose=10uM
JD-02-GA59_1uM Dose=1uM
JD-04-UT85_0.01uM Dose=0.01uM, Lenalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting CRBN
JD-04-UT85_0.1uM Dose=0.1uM, Lenalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting CRBN
JD-04-UT85_10uM Dose=10uM, Lenalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting CRBN
JD-04-UT85_1uM Dose=1uM, Lenalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting CRBN
JD-05-LJ73_0.01uM Dose=0.01uM, N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide
JD-05-LJ73_0.1uM Dose=0.1uM, N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide
JD-05-LJ73_10uM Dose=10uM, N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide
JD-05-LJ73_1uM Dose=1uM, N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide
JD-10-HM98_0.01uM Dose=0.01uM, 2-Phenyl-3-phosphonopropanoic acid, Glutamate Carboxypeptidase II (NAALADase;NAAG Peptidase, FOLH1, PSMA) Inhibitors targeting FOLH1
JD-10-HM98_0.1uM Dose=0.1uM, 2-Phenyl-3-phosphonopropanoic acid, Glutamate Carboxypeptidase II (NAALADase;NAAG Peptidase, FOLH1, PSMA) Inhibitors targeting FOLH1
JD-10-HM98_10uM Dose=10uM, 2-Phenyl-3-phosphonopropanoic acid, Glutamate Carboxypeptidase II (NAALADase;NAAG Peptidase, FOLH1, PSMA) Inhibitors targeting FOLH1
JD-10-HM98_1uM Dose=1uM, 2-Phenyl-3-phosphonopropanoic acid, Glutamate Carboxypeptidase II (NAALADase;NAAG Peptidase, FOLH1, PSMA) Inhibitors targeting FOLH1
JD-10-HW02_0.01uM Dose=0.01uM
JD-10-HW02_0.1uM Dose=0.1uM
JD-10-HW02_10uM Dose=10uM
JD-10-HW02_1uM Dose=1uM
JD-12-CE09_0.01uM Dose=0.01uM, Galunisertib, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1
JD-12-CE09_0.1uM Dose=0.1uM, Galunisertib, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1
JD-12-CE09_10uM Dose=10uM, Galunisertib, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1
JD-12-CE09_1uM Dose=1uM, Galunisertib, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1
JD-12-YK78_0.01uM Dose=0.01uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
JD-12-YK78_0.1uM Dose=0.1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
JD-12-YK78_10uM Dose=10uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
JD-12-YK78_1uM Dose=1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
JD-26-QG88_0.01uM Dose=0.01uM
JD-26-QG88_0.1uM Dose=0.1uM
JD-38-MY26_0.01uM Dose=0.01uM, FTY720 (R)-Phosphate, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR1, S1PR3, S1PR4
JD-38-MY26_0.1uM Dose=0.1uM, FTY720 (R)-Phosphate, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR1, S1PR3, S1PR4
JD-38-MY26_10uM Dose=10uM, FTY720 (R)-Phosphate, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR1, S1PR3, S1PR4
JD-38-MY26_1uM Dose=1uM, FTY720 (R)-Phosphate, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR1, S1PR3, S1PR4
JD-44-KF86_0.1uM Dose=0.1uM, Cinobufagin, Na+/K+-ATPase Inhibitors;Cinobufagin, SMUT;Chloride Channel Activators targeting ATAD5
JD-44-KF86_10uM Dose=10uM, Cinobufagin, Na+/K+-ATPase Inhibitors;Cinobufagin, SMUT;Chloride Channel Activators targeting ATAD5
JD-44-KF86_1uM Dose=1uM, Cinobufagin, Na+/K+-ATPase Inhibitors;Cinobufagin, SMUT;Chloride Channel Activators targeting ATAD5
JD-47-WR37_0.01uM Dose=0.01uM
JD-47-WR37_0.1uM Dose=0.1uM
JD-47-WR37_10uM Dose=10uM
JD-47-WR37_1uM Dose=1uM
JD-48-EV39_0.01uM Dose=0.01uM, Xanthenone-4-acetic acid
JD-48-EV39_0.1uM Dose=0.1uM, Xanthenone-4-acetic acid
JD-48-EV39_10uM Dose=10uM, Xanthenone-4-acetic acid
JD-48-EV39_1uM Dose=1uM, Xanthenone-4-acetic acid
JD-50-EC04_0.01uM Dose=0.01uM, 6-(4-Fluorophenyl)-5-methyl-3-[3-(4-methylpiperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-7-amine, EphB4 Inhibitors;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, EPHB4, SRC, ABL2
JD-50-EC04_0.1uM Dose=0.1uM, 6-(4-Fluorophenyl)-5-methyl-3-[3-(4-methylpiperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-7-amine, EphB4 Inhibitors;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, EPHB4, SRC, ABL2
JD-50-EC04_10uM Dose=10uM, 6-(4-Fluorophenyl)-5-methyl-3-[3-(4-methylpiperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-7-amine, EphB4 Inhibitors;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, EPHB4, SRC, ABL2
JD-50-EC04_1uM Dose=1uM, 6-(4-Fluorophenyl)-5-methyl-3-[3-(4-methylpiperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-7-amine, EphB4 Inhibitors;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, EPHB4, SRC, ABL2
JD-51-GD99_0.01uM Dose=0.01uM, 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one, MAP3K11 gene inhibitor targeting MAP3K9, MAP3K11
JD-51-GD99_0.1uM Dose=0.1uM, 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one, MAP3K11 gene inhibitor targeting MAP3K9, MAP3K11
JD-51-GD99_10uM Dose=10uM, 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one, MAP3K11 gene inhibitor targeting MAP3K9, MAP3K11
JD-51-GD99_1uM Dose=1uM, 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one, MAP3K11 gene inhibitor targeting MAP3K9, MAP3K11
JD-54-BS97_0.01uM Dose=0.01uM, 3-(4-cyanophenyl)-N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methylbenzamide, smoothened antagonist targeting SMO
JD-54-BS97_0.1uM Dose=0.1uM, 3-(4-cyanophenyl)-N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methylbenzamide, smoothened antagonist targeting SMO
JD-54-BS97_10uM Dose=10uM, 3-(4-cyanophenyl)-N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methylbenzamide, smoothened antagonist targeting SMO
JD-54-BS97_1uM Dose=1uM, 3-(4-cyanophenyl)-N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methylbenzamide, smoothened antagonist targeting SMO
JD-58-MV19_0.1uM Dose=0.1uM, mTOR Complex 2 (mTORC2) Inhibitors;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR
JD-58-MV19_10uM Dose=10uM, mTOR Complex 2 (mTORC2) Inhibitors;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR
JD-58-MV19_1uM Dose=1uM, mTOR Complex 2 (mTORC2) Inhibitors;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR
JD-61-EG41_0.01uM Dose=0.01uM, 5-chloro-N-(2-methoxyphenyl)-3-methyl-1-benzothiophene-2-sulfonamide, CDK5/p25 Inhibitors targeting CDK5
JD-61-EG41_0.1uM Dose=0.1uM, 5-chloro-N-(2-methoxyphenyl)-3-methyl-1-benzothiophene-2-sulfonamide, CDK5/p25 Inhibitors targeting CDK5
JD-61-EG41_10uM Dose=10uM, 5-chloro-N-(2-methoxyphenyl)-3-methyl-1-benzothiophene-2-sulfonamide, CDK5/p25 Inhibitors targeting CDK5
JD-61-EG41_1uM Dose=1uM, 5-chloro-N-(2-methoxyphenyl)-3-methyl-1-benzothiophene-2-sulfonamide, CDK5/p25 Inhibitors targeting CDK5
JD-62-HR05_0.01uM Dose=0.01uM, (1S,3R)-Rsl3, GPX4 covalent inhibitor targeting GPX4
JD-62-HR05_10uM Dose=10uM, (1S,3R)-Rsl3, GPX4 covalent inhibitor targeting GPX4
JD-62-HR05_1uM Dose=1uM, (1S,3R)-Rsl3, GPX4 covalent inhibitor targeting GPX4
JD-62-TK68_0.01uM Dose=0.01uM
JD-62-TK68_0.1uM Dose=0.1uM
JD-62-TK68_10uM Dose=10uM
JD-62-TK68_1uM Dose=1uM
JD-70-IC84_0.01uM Dose=0.01uM, Genipin, Free Radical Scavengers;Apoptosis Inhibitors;UCP2 inhibitor;Non-Steroidal Antiinflammatory Drugs targeting UCP2
JD-70-IC84_0.1uM Dose=0.1uM, Genipin, Free Radical Scavengers;Apoptosis Inhibitors;UCP2 inhibitor;Non-Steroidal Antiinflammatory Drugs targeting UCP2
JD-70-IC84_10uM Dose=10uM, Genipin, Free Radical Scavengers;Apoptosis Inhibitors;UCP2 inhibitor;Non-Steroidal Antiinflammatory Drugs targeting UCP2
JD-70-IC84_1uM Dose=1uM, Genipin, Free Radical Scavengers;Apoptosis Inhibitors;UCP2 inhibitor;Non-Steroidal Antiinflammatory Drugs targeting UCP2
JD-74-IP25_0.01uM Dose=0.01uM, Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors
JD-74-IP25_0.1uM Dose=0.1uM, Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors
JD-74-IP25_10uM Dose=10uM, Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors
JD-74-IP25_1uM Dose=1uM, Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors
JD-78-FE08_0.1uM Dose=0.1uM, (2S)-2-[[2,6-dichloro-4-[(3-hydroxyphenyl)methylcarbamoyl]benzoyl]amino]-3-[(3,5-dihydroxybenzoyl)amino]propanoic acid, Integrin alphaLbeta2 (LFA-1) Antagonists;Anti-ICAM-1 (CD54) Agents targeting ICAM1, ITGAL
JD-78-FE08_1uM Dose=1uM, (2S)-2-[[2,6-dichloro-4-[(3-hydroxyphenyl)methylcarbamoyl]benzoyl]amino]-3-[(3,5-dihydroxybenzoyl)amino]propanoic acid, Integrin alphaLbeta2 (LFA-1) Antagonists;Anti-ICAM-1 (CD54) Agents targeting ICAM1, ITGAL
JD-79-ZS29_0.01uM Dose=0.01uM, 1,1'-Methylenebis(2-naphthol), Antiamyloidogenic Agents targeting APP
JD-79-ZS29_0.1uM Dose=0.1uM, 1,1'-Methylenebis(2-naphthol), Antiamyloidogenic Agents targeting APP
JD-79-ZS29_10uM Dose=10uM, 1,1'-Methylenebis(2-naphthol), Antiamyloidogenic Agents targeting APP
JD-79-ZS29_1uM Dose=1uM, 1,1'-Methylenebis(2-naphthol), Antiamyloidogenic Agents targeting APP
JD-81-YX02_0.01uM Dose=0.01uM, Jnj-7706621, Aurora Kinase Inhibitors;Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting CDK1, CDK2, AURKA, CCNA1
JD-81-YX02_0.1uM Dose=0.1uM, Jnj-7706621, Aurora Kinase Inhibitors;Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting CDK1, CDK2, AURKA, CCNA1
JD-81-YX02_10uM Dose=10uM, Jnj-7706621, Aurora Kinase Inhibitors;Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting CDK1, CDK2, AURKA, CCNA1
JD-81-YX02_1uM Dose=1uM, Jnj-7706621, Aurora Kinase Inhibitors;Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting CDK1, CDK2, AURKA, CCNA1
JD-87-KA71_0.01uM Dose=0.01uM, 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethyl-quinazoline, Antimitotic Drugs targeting TUBB
JD-87-KA71_0.1uM Dose=0.1uM, 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethyl-quinazoline, Antimitotic Drugs targeting TUBB
JD-87-KA71_10uM Dose=10uM, 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethyl-quinazoline, Antimitotic Drugs targeting TUBB
JD-87-KA71_1uM Dose=1uM, 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethyl-quinazoline, Antimitotic Drugs targeting TUBB
JD-87-MR82_0.01uM Dose=0.01uM, N-[1,3-Dimethyl-6-[(2r)-2-Methylpiperazin-1-Yl]-2-Oxidanylidene-Benzimidazol-5-Yl]-2-Methoxy-Benzamide, BRPF1 inhibitor;BRPF1 inhibitors targeting BRPF1
JD-87-MR82_0.1uM Dose=0.1uM, N-[1,3-Dimethyl-6-[(2r)-2-Methylpiperazin-1-Yl]-2-Oxidanylidene-Benzimidazol-5-Yl]-2-Methoxy-Benzamide, BRPF1 inhibitor;BRPF1 inhibitors targeting BRPF1
JD-87-MR82_10uM Dose=10uM, N-[1,3-Dimethyl-6-[(2r)-2-Methylpiperazin-1-Yl]-2-Oxidanylidene-Benzimidazol-5-Yl]-2-Methoxy-Benzamide, BRPF1 inhibitor;BRPF1 inhibitors targeting BRPF1
JD-87-MR82_1uM Dose=1uM, N-[1,3-Dimethyl-6-[(2r)-2-Methylpiperazin-1-Yl]-2-Oxidanylidene-Benzimidazol-5-Yl]-2-Methoxy-Benzamide, BRPF1 inhibitor;BRPF1 inhibitors targeting BRPF1
JD-90-SN16_0.01uM Dose=0.01uM, 3-(2-Chloro-7-methoxyacridin-9-yl)sulfanylpropan-1-amine
JD-90-SN16_0.1uM Dose=0.1uM, 3-(2-Chloro-7-methoxyacridin-9-yl)sulfanylpropan-1-amine
JD-90-SN16_10uM Dose=10uM, 3-(2-Chloro-7-methoxyacridin-9-yl)sulfanylpropan-1-amine
JD-90-SN16_1uM Dose=1uM, 3-(2-Chloro-7-methoxyacridin-9-yl)sulfanylpropan-1-amine
JD-94-BC04_0.01uM Dose=0.01uM, Mangostin, Antioxidants;Fatty Acid Synthase Inhibitors;Acidic Sphingomyelinase (A-SMase) Inhibitors targeting FASN, SMPD1
JD-94-BC04_0.1uM Dose=0.1uM, Mangostin, Antioxidants;Fatty Acid Synthase Inhibitors;Acidic Sphingomyelinase (A-SMase) Inhibitors targeting FASN, SMPD1
JD-94-BC04_10uM Dose=10uM, Mangostin, Antioxidants;Fatty Acid Synthase Inhibitors;Acidic Sphingomyelinase (A-SMase) Inhibitors targeting FASN, SMPD1
JD-94-BC04_1uM Dose=1uM, Mangostin, Antioxidants;Fatty Acid Synthase Inhibitors;Acidic Sphingomyelinase (A-SMase) Inhibitors targeting FASN, SMPD1
JD-95-WC21_0.01uM Dose=0.01uM, 2-(2-hydroxyphenyl)-3-phenethylquinazolin-4(3H)-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
JD-95-WC21_0.1uM Dose=0.1uM, 2-(2-hydroxyphenyl)-3-phenethylquinazolin-4(3H)-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
JD-95-WC21_10uM Dose=10uM, 2-(2-hydroxyphenyl)-3-phenethylquinazolin-4(3H)-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
JD-95-WC21_1uM Dose=1uM, 2-(2-hydroxyphenyl)-3-phenethylquinazolin-4(3H)-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
JE-04-LS32_0.01uM Dose=0.01uM
JE-04-LS32_0.1uM Dose=0.1uM
JE-04-LS32_10uM Dose=10uM
JE-04-LS32_1uM Dose=1uM
JE-11-UD64_0.01uM Dose=0.01uM, 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-, Dopamine D3 Agonists targeting DRD3
JE-11-UD64_0.1uM Dose=0.1uM, 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-, Dopamine D3 Agonists targeting DRD3
JE-11-UD64_10uM Dose=10uM, 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-, Dopamine D3 Agonists targeting DRD3
JE-11-UD64_1uM Dose=1uM, 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-, Dopamine D3 Agonists targeting DRD3
JE-13-EV67_0.01uM Dose=0.01uM, N-(1-Cyanocyclopropyl)-2-(2-(6-phenylbenzo[d]thiazol-2-yl)acetamido)acetamide, Endothelial Lipase (EL) Inhibitors targeting LIPG
JE-13-EV67_0.1uM Dose=0.1uM, N-(1-Cyanocyclopropyl)-2-(2-(6-phenylbenzo[d]thiazol-2-yl)acetamido)acetamide, Endothelial Lipase (EL) Inhibitors targeting LIPG
JE-13-EV67_10uM Dose=10uM, N-(1-Cyanocyclopropyl)-2-(2-(6-phenylbenzo[d]thiazol-2-yl)acetamido)acetamide, Endothelial Lipase (EL) Inhibitors targeting LIPG
JE-13-EV67_1uM Dose=1uM, N-(1-Cyanocyclopropyl)-2-(2-(6-phenylbenzo[d]thiazol-2-yl)acetamido)acetamide, Endothelial Lipase (EL) Inhibitors targeting LIPG
JE-22-JR20_0.01uM Dose=0.01uM, (S)-1-(5-((2-aminopropanamido)methyl)thiophen-3-yl)-N-(2-methoxybenzyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Coactivator Associated Arginine Methyltransferase 1 (CARM1 PRMT4) Inhibitors targeting CARM1
JE-22-JR20_0.1uM Dose=0.1uM, (S)-1-(5-((2-aminopropanamido)methyl)thiophen-3-yl)-N-(2-methoxybenzyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Coactivator Associated Arginine Methyltransferase 1 (CARM1 PRMT4) Inhibitors targeting CARM1
JE-22-JR20_10uM Dose=10uM, (S)-1-(5-((2-aminopropanamido)methyl)thiophen-3-yl)-N-(2-methoxybenzyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Coactivator Associated Arginine Methyltransferase 1 (CARM1 PRMT4) Inhibitors targeting CARM1
JE-22-JR20_1uM Dose=1uM, (S)-1-(5-((2-aminopropanamido)methyl)thiophen-3-yl)-N-(2-methoxybenzyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Coactivator Associated Arginine Methyltransferase 1 (CARM1 PRMT4) Inhibitors targeting CARM1
JE-27-XK20_0.01uM Dose=0.01uM, Rifapentine, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT
JE-27-XK20_0.1uM Dose=0.1uM, Rifapentine, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT
JE-27-XK20_10uM Dose=10uM, Rifapentine, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT
JE-27-XK20_1uM Dose=1uM, Rifapentine, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT
JE-31-PK61_0.01uM Dose=0.01uM, 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, PDE9a inhibitor targeting PDE9A
JE-31-PK61_0.1uM Dose=0.1uM, 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, PDE9a inhibitor targeting PDE9A
JE-31-PK61_10uM Dose=10uM, 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, PDE9a inhibitor targeting PDE9A
JE-31-PK61_1uM Dose=1uM, 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, PDE9a inhibitor targeting PDE9A
JE-43-OY99_0.01uM Dose=0.01uM
JE-43-OY99_0.1uM Dose=0.1uM
JE-43-OY99_10uM Dose=10uM
JE-43-OY99_1uM Dose=1uM
JE-47-FU54_0.01uM Dose=0.01uM, Naringenin, Cytochrome P450 CYP3A4 Inhibitors;Apoptosis Inducers;Cell Adhesion Inhibitors;Antioxidants targeting CYP3A4
JE-47-FU54_0.1uM Dose=0.1uM, Naringenin, Cytochrome P450 CYP3A4 Inhibitors;Apoptosis Inducers;Cell Adhesion Inhibitors;Antioxidants targeting CYP3A4
JE-47-FU54_10uM Dose=10uM, Naringenin, Cytochrome P450 CYP3A4 Inhibitors;Apoptosis Inducers;Cell Adhesion Inhibitors;Antioxidants targeting CYP3A4
JE-47-FU54_1uM Dose=1uM, Naringenin, Cytochrome P450 CYP3A4 Inhibitors;Apoptosis Inducers;Cell Adhesion Inhibitors;Antioxidants targeting CYP3A4
JE-52-BH86_0.01uM Dose=0.01uM
JE-52-BH86_0.1uM Dose=0.1uM
JE-52-BH86_10uM Dose=10uM
JE-55-OJ53_0.01uM Dose=0.01uM, 2-(4-(8-Bromo-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
JE-55-OJ53_0.1uM Dose=0.1uM, 2-(4-(8-Bromo-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
JE-55-OJ53_10uM Dose=10uM, 2-(4-(8-Bromo-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
JE-55-OJ53_1uM Dose=1uM, 2-(4-(8-Bromo-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
JE-59-EI25_0.01uM Dose=0.01uM, 2-Hydroxycarbazole-3-carboxylic acid 4-chloroanilide, Carboxylesterase Inhibitors targeting CES2
JE-59-EI25_0.1uM Dose=0.1uM, 2-Hydroxycarbazole-3-carboxylic acid 4-chloroanilide, Carboxylesterase Inhibitors targeting CES2
JE-59-EI25_10uM Dose=10uM, 2-Hydroxycarbazole-3-carboxylic acid 4-chloroanilide, Carboxylesterase Inhibitors targeting CES2
JE-59-EI25_1uM Dose=1uM, 2-Hydroxycarbazole-3-carboxylic acid 4-chloroanilide, Carboxylesterase Inhibitors targeting CES2
JE-61-EQ70_0.01uM Dose=0.01uM, 6-N-(6-chloro-8-methylquinoxalin-5-yl)-4-N-(cyclopropylmethyl)-2,5-dimethyl-4-N-propylpyrimidine-4,6-diamine
JE-61-EQ70_0.1uM Dose=0.1uM, 6-N-(6-chloro-8-methylquinoxalin-5-yl)-4-N-(cyclopropylmethyl)-2,5-dimethyl-4-N-propylpyrimidine-4,6-diamine
JE-61-EQ70_10uM Dose=10uM, 6-N-(6-chloro-8-methylquinoxalin-5-yl)-4-N-(cyclopropylmethyl)-2,5-dimethyl-4-N-propylpyrimidine-4,6-diamine
JE-61-EQ70_1uM Dose=1uM, 6-N-(6-chloro-8-methylquinoxalin-5-yl)-4-N-(cyclopropylmethyl)-2,5-dimethyl-4-N-propylpyrimidine-4,6-diamine
JE-61-XN48_0.01uM Dose=0.01uM, HC-030031, TRPA1 Antagonists targeting TRPA1
JE-61-XN48_0.1uM Dose=0.1uM, HC-030031, TRPA1 Antagonists targeting TRPA1
JE-61-XN48_10uM Dose=10uM, HC-030031, TRPA1 Antagonists targeting TRPA1
JE-61-XN48_1uM Dose=1uM, HC-030031, TRPA1 Antagonists targeting TRPA1
JE-63-IE01_0.01uM Dose=0.01uM, Vercirnon, CCR9 chemokine antagonist targeting CCR9
JE-63-IE01_10uM Dose=10uM, Vercirnon, CCR9 chemokine antagonist targeting CCR9
JE-63-IE01_1uM Dose=1uM, Vercirnon, CCR9 chemokine antagonist targeting CCR9
JE-72-KV75_0.01uM Dose=0.01uM, 6-Chloro-2-(2-Fluoro-4,5-Dimethoxyphenyl)-N-(Piperidin-4-Ylmethyl)-3h-Imidazo[4,5-B]pyridin-7-Amine, JAK1 selective inhibitors targeting CDK2, JAK1, AURKB
JE-72-KV75_0.1uM Dose=0.1uM, 6-Chloro-2-(2-Fluoro-4,5-Dimethoxyphenyl)-N-(Piperidin-4-Ylmethyl)-3h-Imidazo[4,5-B]pyridin-7-Amine, JAK1 selective inhibitors targeting CDK2, JAK1, AURKB
JE-72-KV75_10uM Dose=10uM, 6-Chloro-2-(2-Fluoro-4,5-Dimethoxyphenyl)-N-(Piperidin-4-Ylmethyl)-3h-Imidazo[4,5-B]pyridin-7-Amine, JAK1 selective inhibitors targeting CDK2, JAK1, AURKB
JE-72-KV75_1uM Dose=1uM, 6-Chloro-2-(2-Fluoro-4,5-Dimethoxyphenyl)-N-(Piperidin-4-Ylmethyl)-3h-Imidazo[4,5-B]pyridin-7-Amine, JAK1 selective inhibitors targeting CDK2, JAK1, AURKB
JE-86-QG78_0.01uM Dose=0.01uM, Ibrolipim
JE-86-QG78_0.1uM Dose=0.1uM, Ibrolipim
JE-86-QG78_10uM Dose=10uM, Ibrolipim
JF-08-NB76_0.1uM Dose=0.1uM, 4-[(2E)-3-phenylprop-2-en-1-yl]-N-(4-sulfamoylphenyl)piperazine-1-carbothioamide, CTNNBIP1 gene inhibitor targeting CTNNB1, TCF4
JF-08-NB76_10uM Dose=10uM, 4-[(2E)-3-phenylprop-2-en-1-yl]-N-(4-sulfamoylphenyl)piperazine-1-carbothioamide, CTNNBIP1 gene inhibitor targeting CTNNB1, TCF4
JF-08-NB76_1uM Dose=1uM, 4-[(2E)-3-phenylprop-2-en-1-yl]-N-(4-sulfamoylphenyl)piperazine-1-carbothioamide, CTNNBIP1 gene inhibitor targeting CTNNB1, TCF4
JF-12-EH36_0.01uM Dose=0.01uM, 4-(7,7-Dimethyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-8-yl)benzonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B1, CYP11B2
JF-12-EH36_1uM Dose=1uM, 4-(7,7-Dimethyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-8-yl)benzonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B1, CYP11B2
JF-14-JC89_0.01uM Dose=0.01uM, Halicin, SAPK1c (JNK1) Inhibitors targeting MAPK8
JF-14-JC89_0.1uM Dose=0.1uM, Halicin, SAPK1c (JNK1) Inhibitors targeting MAPK8
JF-14-JC89_10uM Dose=10uM, Halicin, SAPK1c (JNK1) Inhibitors targeting MAPK8
JF-14-JC89_1uM Dose=1uM, Halicin, SAPK1c (JNK1) Inhibitors targeting MAPK8
JF-15-IJ23_0.01uM Dose=0.01uM, 5-[(2R)-2-[4-(5-aminopyrazin-2-yl)phenyl]oxolan-2-yl]-N-(2-hydroxy-2-methylpropyl)pyridine-2-carboxamide, ALOX5AP gene inhibitor targeting ALOX5AP
JF-15-IJ23_0.1uM Dose=0.1uM, 5-[(2R)-2-[4-(5-aminopyrazin-2-yl)phenyl]oxolan-2-yl]-N-(2-hydroxy-2-methylpropyl)pyridine-2-carboxamide, ALOX5AP gene inhibitor targeting ALOX5AP
JF-15-IJ23_10uM Dose=10uM, 5-[(2R)-2-[4-(5-aminopyrazin-2-yl)phenyl]oxolan-2-yl]-N-(2-hydroxy-2-methylpropyl)pyridine-2-carboxamide, ALOX5AP gene inhibitor targeting ALOX5AP
JF-16-BD66_0.01uM Dose=0.01uM, Gsk-690693, PKB gamma/Akt3 Inhibitors;Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors targeting AKT1, AKT2, DAPK3, PRKG1, PRKX, AKT3, PAK6
JF-16-BD66_0.1uM Dose=0.1uM, Gsk-690693, PKB gamma/Akt3 Inhibitors;Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors targeting AKT1, AKT2, DAPK3, PRKG1, PRKX, AKT3, PAK6
JF-16-BD66_10uM Dose=10uM, Gsk-690693, PKB gamma/Akt3 Inhibitors;Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors targeting AKT1, AKT2, DAPK3, PRKG1, PRKX, AKT3, PAK6
JF-16-BD66_1uM Dose=1uM, Gsk-690693, PKB gamma/Akt3 Inhibitors;Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors targeting AKT1, AKT2, DAPK3, PRKG1, PRKX, AKT3, PAK6
JF-25-NM40_0.01uM Dose=0.01uM
JF-25-NM40_0.1uM Dose=0.1uM
JF-25-NM40_10uM Dose=10uM
JF-25-NM40_1uM Dose=1uM
JF-30-FM28_0.01uM Dose=0.01uM, BX-471 free base, Chemokine CCR1 Antagonists targeting CCR1
JF-30-FM28_0.1uM Dose=0.1uM, BX-471 free base, Chemokine CCR1 Antagonists targeting CCR1
JF-30-FM28_10uM Dose=10uM, BX-471 free base, Chemokine CCR1 Antagonists targeting CCR1
JF-30-FM28_1uM Dose=1uM, BX-471 free base, Chemokine CCR1 Antagonists targeting CCR1
JF-30-FW92_0.01uM Dose=0.01uM, 3-(Trifluoromethyl)-2-[(5-methyl-1,3,4-thiadiazole-2-yl)thio]-6,7-dichloroquinoxaline, GLP-1 Receptor Agonists;Insulin Secretagogues targeting GLP1R
JF-30-FW92_0.1uM Dose=0.1uM, 3-(Trifluoromethyl)-2-[(5-methyl-1,3,4-thiadiazole-2-yl)thio]-6,7-dichloroquinoxaline, GLP-1 Receptor Agonists;Insulin Secretagogues targeting GLP1R
JF-30-FW92_10uM Dose=10uM, 3-(Trifluoromethyl)-2-[(5-methyl-1,3,4-thiadiazole-2-yl)thio]-6,7-dichloroquinoxaline, GLP-1 Receptor Agonists;Insulin Secretagogues targeting GLP1R
JF-30-FW92_1uM Dose=1uM, 3-(Trifluoromethyl)-2-[(5-methyl-1,3,4-thiadiazole-2-yl)thio]-6,7-dichloroquinoxaline, GLP-1 Receptor Agonists;Insulin Secretagogues targeting GLP1R
JF-37-AR97_0.01uM Dose=0.01uM, {4'-[3-Methyl-4-((s)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid
JF-37-AR97_0.1uM Dose=0.1uM, {4'-[3-Methyl-4-((s)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid
JF-37-AR97_10uM Dose=10uM, {4'-[3-Methyl-4-((s)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid
JF-37-AR97_1uM Dose=1uM, {4'-[3-Methyl-4-((s)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid
JF-39-BZ76_0.01uM Dose=0.01uM, Vs-4718, FAK inhibitor targeting PTK2
JF-39-BZ76_0.1uM Dose=0.1uM, Vs-4718, FAK inhibitor targeting PTK2
JF-39-BZ76_10uM Dose=10uM, Vs-4718, FAK inhibitor targeting PTK2
JF-39-BZ76_1uM Dose=1uM, Vs-4718, FAK inhibitor targeting PTK2
JF-45-JM50_0.01uM Dose=0.01uM, Rauwolscine, alpha-Adrenoceptor Antagonists targeting ADRA1B
JF-45-JM50_0.1uM Dose=0.1uM, Rauwolscine, alpha-Adrenoceptor Antagonists targeting ADRA1B
JF-45-JM50_10uM Dose=10uM, Rauwolscine, alpha-Adrenoceptor Antagonists targeting ADRA1B
JF-45-JM50_1uM Dose=1uM, Rauwolscine, alpha-Adrenoceptor Antagonists targeting ADRA1B
JF-55-EN33_0.01uM Dose=0.01uM, 3-[6-Amino-5-(3,4,5-Trimethoxyphenyl)pyridin-3-Yl]phenol, ACVRL1 gene inhibitor targeting ACVRL1
JF-55-EN33_0.1uM Dose=0.1uM, 3-[6-Amino-5-(3,4,5-Trimethoxyphenyl)pyridin-3-Yl]phenol, ACVRL1 gene inhibitor targeting ACVRL1
JF-55-EN33_10uM Dose=10uM, 3-[6-Amino-5-(3,4,5-Trimethoxyphenyl)pyridin-3-Yl]phenol, ACVRL1 gene inhibitor targeting ACVRL1
JF-55-EN33_1uM Dose=1uM, 3-[6-Amino-5-(3,4,5-Trimethoxyphenyl)pyridin-3-Yl]phenol, ACVRL1 gene inhibitor targeting ACVRL1
JF-62-LU77_0.01uM Dose=0.01uM, Darapladib, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors targeting PLA2G7, OPTN
JF-62-LU77_0.1uM Dose=0.1uM, Darapladib, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors targeting PLA2G7, OPTN
JF-62-LU77_10uM Dose=10uM, Darapladib, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors targeting PLA2G7, OPTN
JF-62-LU77_1uM Dose=1uM, Darapladib, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors targeting PLA2G7, OPTN
JF-74-GS02_0.01uM Dose=0.01uM, alpha-Trifluoromethyl-alpha-hydroxybenzeneacetamide, T-Type Calcium Channel Blockers targeting KCNK3, KCNK9
JF-74-GS02_0.1uM Dose=0.1uM, alpha-Trifluoromethyl-alpha-hydroxybenzeneacetamide, T-Type Calcium Channel Blockers targeting KCNK3, KCNK9
JF-74-GS02_10uM Dose=10uM, alpha-Trifluoromethyl-alpha-hydroxybenzeneacetamide, T-Type Calcium Channel Blockers targeting KCNK3, KCNK9
JF-74-GS02_1uM Dose=1uM, alpha-Trifluoromethyl-alpha-hydroxybenzeneacetamide, T-Type Calcium Channel Blockers targeting KCNK3, KCNK9
JF-76-BD96_0.01uM Dose=0.01uM, 1-(4-Chlorophenyl)-N-[3-cyano-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-5-methyl-1H-pyrazole-4-carboxamide
JF-76-BD96_0.1uM Dose=0.1uM, 1-(4-Chlorophenyl)-N-[3-cyano-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-5-methyl-1H-pyrazole-4-carboxamide
JF-76-BD96_10uM Dose=10uM, 1-(4-Chlorophenyl)-N-[3-cyano-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-5-methyl-1H-pyrazole-4-carboxamide
JF-76-BD96_1uM Dose=1uM, 1-(4-Chlorophenyl)-N-[3-cyano-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-5-methyl-1H-pyrazole-4-carboxamide
JF-79-OI50_0.01uM Dose=0.01uM, FK 409, Soluble Guanylyl Cyclase (sGC) Activators;Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1
JF-79-OI50_0.1uM Dose=0.1uM, FK 409, Soluble Guanylyl Cyclase (sGC) Activators;Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1
JF-79-OI50_10uM Dose=10uM, FK 409, Soluble Guanylyl Cyclase (sGC) Activators;Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1
JF-79-OI50_1uM Dose=1uM, FK 409, Soluble Guanylyl Cyclase (sGC) Activators;Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1
JF-84-QZ64_0.01uM Dose=0.01uM, CID 9837238, Neutral Sphingomyelinase (N-SMase) Inhibitors;Antiinflammatory Drugs targeting SMPD2
JF-84-QZ64_0.1uM Dose=0.1uM, CID 9837238, Neutral Sphingomyelinase (N-SMase) Inhibitors;Antiinflammatory Drugs targeting SMPD2
JF-84-QZ64_10uM Dose=10uM, CID 9837238, Neutral Sphingomyelinase (N-SMase) Inhibitors;Antiinflammatory Drugs targeting SMPD2
JF-84-QZ64_1uM Dose=1uM, CID 9837238, Neutral Sphingomyelinase (N-SMase) Inhibitors;Antiinflammatory Drugs targeting SMPD2
JF-91-IG96_0.01uM Dose=0.01uM, 2-[2-(Morpholin-4-yl)-5-(morpholine-4-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one
JF-91-IG96_0.1uM Dose=0.1uM, 2-[2-(Morpholin-4-yl)-5-(morpholine-4-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one
JF-91-IG96_10uM Dose=10uM, 2-[2-(Morpholin-4-yl)-5-(morpholine-4-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one
JF-91-IG96_1uM Dose=1uM, 2-[2-(Morpholin-4-yl)-5-(morpholine-4-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one
JF-93-EL43_0.01uM Dose=0.01uM, Shp2 IN-1, SHP2 inhibitor targeting PTPN11
JF-93-EL43_0.1uM Dose=0.1uM, Shp2 IN-1, SHP2 inhibitor targeting PTPN11
JF-93-EL43_10uM Dose=10uM, Shp2 IN-1, SHP2 inhibitor targeting PTPN11
JF-93-EL43_1uM Dose=1uM, Shp2 IN-1, SHP2 inhibitor targeting PTPN11
JF-96-HH81_0.01uM Dose=0.01uM, PF-06649298, inhibitor of sodium-coupled citrate transporter targeting SLC13A5
JF-96-HH81_0.1uM Dose=0.1uM, PF-06649298, inhibitor of sodium-coupled citrate transporter targeting SLC13A5
JF-96-HH81_10uM Dose=10uM, PF-06649298, inhibitor of sodium-coupled citrate transporter targeting SLC13A5
JF-96-HH81_1uM Dose=1uM, PF-06649298, inhibitor of sodium-coupled citrate transporter targeting SLC13A5
KA-00-HF91_0.01uM Dose=0.01uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] 3-methylthiophene-2-carboxylate
KA-00-HF91_0.1uM Dose=0.1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] 3-methylthiophene-2-carboxylate
KA-00-HF91_10uM Dose=10uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] 3-methylthiophene-2-carboxylate
KA-00-HF91_1uM Dose=1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] 3-methylthiophene-2-carboxylate
KA-09-PB43_0.01uM Dose=0.01uM, 1,2,3,4-Tetrahydroisoquinoline-7-sulfonamide targeting PNMT
KA-09-PB43_1uM Dose=1uM, 1,2,3,4-Tetrahydroisoquinoline-7-sulfonamide targeting PNMT
KA-14-VZ39_0.01uM Dose=0.01uM, Diphenyleneiodonium, Cytochrome P450 Inhibitors;Xanthine Oxidase Inhibitors;Nitric Oxide Synthase Inhibitors;Electron Transport Chain Inhibitor;NADPH Oxidase Inhibitors targeting XDH, NOX1, NOX4, NOX3
KA-14-VZ39_0.1uM Dose=0.1uM, Diphenyleneiodonium, Cytochrome P450 Inhibitors;Xanthine Oxidase Inhibitors;Nitric Oxide Synthase Inhibitors;Electron Transport Chain Inhibitor;NADPH Oxidase Inhibitors targeting XDH, NOX1, NOX4, NOX3
KA-14-VZ39_10uM Dose=10uM, Diphenyleneiodonium, Cytochrome P450 Inhibitors;Xanthine Oxidase Inhibitors;Nitric Oxide Synthase Inhibitors;Electron Transport Chain Inhibitor;NADPH Oxidase Inhibitors targeting XDH, NOX1, NOX4, NOX3
KA-14-VZ39_1uM Dose=1uM, Diphenyleneiodonium, Cytochrome P450 Inhibitors;Xanthine Oxidase Inhibitors;Nitric Oxide Synthase Inhibitors;Electron Transport Chain Inhibitor;NADPH Oxidase Inhibitors targeting XDH, NOX1, NOX4, NOX3
KA-27-KH73_0.01uM Dose=0.01uM, 3-(6-Ethoxynaphthalen-2-Yl)-1-(Piperidin-4-Ylmethyl)-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine, camk1 gene inhibitor targeting CAMK1, CAMK1D, CAMK1G
KA-27-KH73_0.1uM Dose=0.1uM, 3-(6-Ethoxynaphthalen-2-Yl)-1-(Piperidin-4-Ylmethyl)-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine, camk1 gene inhibitor targeting CAMK1, CAMK1D, CAMK1G
KA-27-KH73_10uM Dose=10uM, 3-(6-Ethoxynaphthalen-2-Yl)-1-(Piperidin-4-Ylmethyl)-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine, camk1 gene inhibitor targeting CAMK1, CAMK1D, CAMK1G
KA-29-AB08_0.01uM Dose=0.01uM, 4-(2-aminopyridin-4-yl)-N-(3-chlorophenyl)pyrimidin-2-amine, CDK1 Inhibitors targeting CDK1
KA-29-AB08_0.1uM Dose=0.1uM, 4-(2-aminopyridin-4-yl)-N-(3-chlorophenyl)pyrimidin-2-amine, CDK1 Inhibitors targeting CDK1
KA-29-AB08_10uM Dose=10uM, 4-(2-aminopyridin-4-yl)-N-(3-chlorophenyl)pyrimidin-2-amine, CDK1 Inhibitors targeting CDK1
KA-29-AB08_1uM Dose=1uM, 4-(2-aminopyridin-4-yl)-N-(3-chlorophenyl)pyrimidin-2-amine, CDK1 Inhibitors targeting CDK1
KA-35-YF58_0.01uM Dose=0.01uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]naphthalen-1-yl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KA-35-YF58_0.1uM Dose=0.1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]naphthalen-1-yl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KA-35-YF58_10uM Dose=10uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]naphthalen-1-yl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KA-35-YF58_1uM Dose=1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]naphthalen-1-yl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KA-37-GD83_0.01uM Dose=0.01uM, 2-(2-Hydroxyethoxy)ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate
KA-37-GD83_0.1uM Dose=0.1uM, 2-(2-Hydroxyethoxy)ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate
KA-37-GD83_10uM Dose=10uM, 2-(2-Hydroxyethoxy)ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate
KA-37-GD83_1uM Dose=1uM, 2-(2-Hydroxyethoxy)ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate
KA-46-YG68_0.01uM Dose=0.01uM, 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors targeting CAMK2A, CAMK2B, FYN, MAPK13, CAMK2G
KA-46-YG68_0.1uM Dose=0.1uM, 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors targeting CAMK2A, CAMK2B, FYN, MAPK13, CAMK2G
KA-46-YG68_10uM Dose=10uM, 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors targeting CAMK2A, CAMK2B, FYN, MAPK13, CAMK2G
KA-46-YG68_1uM Dose=1uM, 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors targeting CAMK2A, CAMK2B, FYN, MAPK13, CAMK2G
KA-50-OP35_0.01uM Dose=0.01uM
KA-50-OP35_0.1uM Dose=0.1uM
KA-50-OP35_10uM Dose=10uM
KA-50-OP35_1uM Dose=1uM
KA-51-CQ55_0.01uM Dose=0.01uM, N-Cyclohexyl-4-(4-phenyl-1-(piperazin-1-yl)-2,6-naphthyridin-3-yl)pyridin-2-amine, PKD inhibitor targeting PRKD1
KA-51-CQ55_0.1uM Dose=0.1uM, N-Cyclohexyl-4-(4-phenyl-1-(piperazin-1-yl)-2,6-naphthyridin-3-yl)pyridin-2-amine, PKD inhibitor targeting PRKD1
KA-51-CQ55_10uM Dose=10uM, N-Cyclohexyl-4-(4-phenyl-1-(piperazin-1-yl)-2,6-naphthyridin-3-yl)pyridin-2-amine, PKD inhibitor targeting PRKD1
KA-51-CQ55_1uM Dose=1uM, N-Cyclohexyl-4-(4-phenyl-1-(piperazin-1-yl)-2,6-naphthyridin-3-yl)pyridin-2-amine, PKD inhibitor targeting PRKD1
KA-52-MX24_0.01uM Dose=0.01uM
KA-52-MX24_0.1uM Dose=0.1uM
KA-52-MX24_10uM Dose=10uM
KA-52-MX24_1uM Dose=1uM
KA-53-KV02_0.01uM Dose=0.01uM, 3-(phenylsulfonyl)-N-((tetrahydrofuran-2-yl)methyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine, HTR6 antagonist;5-HT6 Antagonists targeting HTR6
KA-53-KV02_0.1uM Dose=0.1uM, 3-(phenylsulfonyl)-N-((tetrahydrofuran-2-yl)methyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine, HTR6 antagonist;5-HT6 Antagonists targeting HTR6
KA-53-KV02_10uM Dose=10uM, 3-(phenylsulfonyl)-N-((tetrahydrofuran-2-yl)methyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine, HTR6 antagonist;5-HT6 Antagonists targeting HTR6
KA-53-KV02_1uM Dose=1uM, 3-(phenylsulfonyl)-N-((tetrahydrofuran-2-yl)methyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine, HTR6 antagonist;5-HT6 Antagonists targeting HTR6
KA-54-MB31_0.01uM Dose=0.01uM, 3-Amino-3,4-dihydro-1-hydroxy-2(1H)-quinolinone, Kynurenine Aminotransferase II (KAT II) Inhibitors targeting AADAT
KA-54-MB31_0.1uM Dose=0.1uM, 3-Amino-3,4-dihydro-1-hydroxy-2(1H)-quinolinone, Kynurenine Aminotransferase II (KAT II) Inhibitors targeting AADAT
KA-54-MB31_10uM Dose=10uM, 3-Amino-3,4-dihydro-1-hydroxy-2(1H)-quinolinone, Kynurenine Aminotransferase II (KAT II) Inhibitors targeting AADAT
KA-54-MB31_1uM Dose=1uM, 3-Amino-3,4-dihydro-1-hydroxy-2(1H)-quinolinone, Kynurenine Aminotransferase II (KAT II) Inhibitors targeting AADAT
KA-54-QW27_0.01uM Dose=0.01uM, Phosphodiesterase V (PDE5A) Inhibitors;GPR35 agonist targeting GPR35, PDE6A, PDE5A, ENPP6
KA-54-QW27_0.1uM Dose=0.1uM, Phosphodiesterase V (PDE5A) Inhibitors;GPR35 agonist targeting GPR35, PDE6A, PDE5A, ENPP6
KA-54-QW27_10uM Dose=10uM, Phosphodiesterase V (PDE5A) Inhibitors;GPR35 agonist targeting GPR35, PDE6A, PDE5A, ENPP6
KA-54-QW27_1uM Dose=1uM, Phosphodiesterase V (PDE5A) Inhibitors;GPR35 agonist targeting GPR35, PDE6A, PDE5A, ENPP6
KA-58-YE68_0.01uM Dose=0.01uM, 6-(3-aminophenyl)-3-anilino-2H-isoquinolin-1-one, Cdc25B dual specificity phosphatase inhibitor targeting CDC25B
KA-58-YE68_0.1uM Dose=0.1uM, 6-(3-aminophenyl)-3-anilino-2H-isoquinolin-1-one, Cdc25B dual specificity phosphatase inhibitor targeting CDC25B
KA-58-YE68_10uM Dose=10uM, 6-(3-aminophenyl)-3-anilino-2H-isoquinolin-1-one, Cdc25B dual specificity phosphatase inhibitor targeting CDC25B
KA-58-YE68_1uM Dose=1uM, 6-(3-aminophenyl)-3-anilino-2H-isoquinolin-1-one, Cdc25B dual specificity phosphatase inhibitor targeting CDC25B
KA-60-LC14_0.01uM Dose=0.01uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-3,3-dimethyl-2-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]amino]butanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
KA-60-LC14_0.1uM Dose=0.1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-3,3-dimethyl-2-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]amino]butanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
KA-60-LC14_10uM Dose=10uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-3,3-dimethyl-2-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]amino]butanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
KA-60-LC14_1uM Dose=1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-3,3-dimethyl-2-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]amino]butanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
KA-62-FE69_0.01uM Dose=0.01uM, 2-Methoxy-N-(3-Methyl-2-Oxo-1,2,3,4-Tetrahydroquinazolin-6-Yl)benzenesulfonamide, BRD2/3/4/T BET familiy inhibitor targeting BRD4
KA-62-FE69_0.1uM Dose=0.1uM, 2-Methoxy-N-(3-Methyl-2-Oxo-1,2,3,4-Tetrahydroquinazolin-6-Yl)benzenesulfonamide, BRD2/3/4/T BET familiy inhibitor targeting BRD4
KA-62-FE69_10uM Dose=10uM, 2-Methoxy-N-(3-Methyl-2-Oxo-1,2,3,4-Tetrahydroquinazolin-6-Yl)benzenesulfonamide, BRD2/3/4/T BET familiy inhibitor targeting BRD4
KA-62-FE69_1uM Dose=1uM, 2-Methoxy-N-(3-Methyl-2-Oxo-1,2,3,4-Tetrahydroquinazolin-6-Yl)benzenesulfonamide, BRD2/3/4/T BET familiy inhibitor targeting BRD4
KA-62-IU97_0.1uM Dose=0.1uM, (2S,3R)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-[(propan-2-yl)amino]butan-2-ol, ADRB2 antagonist targeting ADRB2
KA-62-IU97_10uM Dose=10uM, (2S,3R)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-[(propan-2-yl)amino]butan-2-ol, ADRB2 antagonist targeting ADRB2
KA-62-IU97_1uM Dose=1uM, (2S,3R)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-[(propan-2-yl)amino]butan-2-ol, ADRB2 antagonist targeting ADRB2
KA-63-FH23_0.01uM Dose=0.01uM, Cgp 77675, Src Kinase Inhibitors targeting SRC
KA-63-FH23_0.1uM Dose=0.1uM, Cgp 77675, Src Kinase Inhibitors targeting SRC
KA-63-FH23_10uM Dose=10uM, Cgp 77675, Src Kinase Inhibitors targeting SRC
KA-63-FH23_1uM Dose=1uM, Cgp 77675, Src Kinase Inhibitors targeting SRC
KA-71-CQ25_0.01uM Dose=0.01uM, Di-p-tolylethanedione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KA-71-CQ25_1uM Dose=1uM, Di-p-tolylethanedione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KA-71-CQ35_0.01uM Dose=0.01uM, 1-(4-tert.Butyl-benzenesulfonyl)-5-chloro-1H-indole-2-carboxylic acid, CCR9 chemokine antagonist targeting CCR9
KA-71-CQ35_0.1uM Dose=0.1uM, 1-(4-tert.Butyl-benzenesulfonyl)-5-chloro-1H-indole-2-carboxylic acid, CCR9 chemokine antagonist targeting CCR9
KA-71-CQ35_10uM Dose=10uM, 1-(4-tert.Butyl-benzenesulfonyl)-5-chloro-1H-indole-2-carboxylic acid, CCR9 chemokine antagonist targeting CCR9
KA-71-CQ35_1uM Dose=1uM, 1-(4-tert.Butyl-benzenesulfonyl)-5-chloro-1H-indole-2-carboxylic acid, CCR9 chemokine antagonist targeting CCR9
KA-72-WY22_0.1uM Dose=0.1uM, (S)-benzyl [1-benzyl-3-chloro-2-oxopropyl]carbamate, ATG4B gene Inhibitor targeting ATG4B
KA-72-WY22_10uM Dose=10uM, (S)-benzyl [1-benzyl-3-chloro-2-oxopropyl]carbamate, ATG4B gene Inhibitor targeting ATG4B
KA-72-WY22_1uM Dose=1uM, (S)-benzyl [1-benzyl-3-chloro-2-oxopropyl]carbamate, ATG4B gene Inhibitor targeting ATG4B
KA-73-PR92_0.01uM Dose=0.01uM
KA-73-PR92_0.1uM Dose=0.1uM
KA-73-PR92_10uM Dose=10uM
KA-73-PR92_1uM Dose=1uM
KA-75-LP02_0.01uM Dose=0.01uM
KA-75-LP02_0.1uM Dose=0.1uM
KA-75-LP02_10uM Dose=10uM
KA-75-LP02_1uM Dose=1uM
KA-78-TY66_0.01uM Dose=0.01uM, 7-[(5-aminopentyl)oxy]-N~4~-[1-(5-aminopentyl)piperidin-4-yl]-N~2~-[3-(dimethylamino)propyl]-6-methoxyquinazoline-2,4-diamine, Histone-Lysine N-Methyltransferase EHMT2 (H3-K9-HMTase 3;G9a) Inhibitors targeting EHMT2, EHMT1
KA-78-TY66_0.1uM Dose=0.1uM, 7-[(5-aminopentyl)oxy]-N~4~-[1-(5-aminopentyl)piperidin-4-yl]-N~2~-[3-(dimethylamino)propyl]-6-methoxyquinazoline-2,4-diamine, Histone-Lysine N-Methyltransferase EHMT2 (H3-K9-HMTase 3;G9a) Inhibitors targeting EHMT2, EHMT1
KA-78-TY66_10uM Dose=10uM, 7-[(5-aminopentyl)oxy]-N~4~-[1-(5-aminopentyl)piperidin-4-yl]-N~2~-[3-(dimethylamino)propyl]-6-methoxyquinazoline-2,4-diamine, Histone-Lysine N-Methyltransferase EHMT2 (H3-K9-HMTase 3;G9a) Inhibitors targeting EHMT2, EHMT1
KA-78-TY66_1uM Dose=1uM, 7-[(5-aminopentyl)oxy]-N~4~-[1-(5-aminopentyl)piperidin-4-yl]-N~2~-[3-(dimethylamino)propyl]-6-methoxyquinazoline-2,4-diamine, Histone-Lysine N-Methyltransferase EHMT2 (H3-K9-HMTase 3;G9a) Inhibitors targeting EHMT2, EHMT1
KA-81-AG66_0.01uM Dose=0.01uM, Alvocidib, CDK9 inhibitor targeting CDK9, CCNB2
KA-81-AG66_0.1uM Dose=0.1uM, Alvocidib, CDK9 inhibitor targeting CDK9, CCNB2
KA-81-AG66_10uM Dose=10uM, Alvocidib, CDK9 inhibitor targeting CDK9, CCNB2
KA-81-AG66_1uM Dose=1uM, Alvocidib, CDK9 inhibitor targeting CDK9, CCNB2
KA-82-CN45_0.01uM Dose=0.01uM, morpholinocarbonyl-Phe-hPhe-CH2F, m-Calpain (Calpain-2) Inhibitors;Cathepsin B Inhibitors;Cathepsin L Inhibitors targeting CAPN2, CTSB, CTSL
KA-82-CN45_0.1uM Dose=0.1uM, morpholinocarbonyl-Phe-hPhe-CH2F, m-Calpain (Calpain-2) Inhibitors;Cathepsin B Inhibitors;Cathepsin L Inhibitors targeting CAPN2, CTSB, CTSL
KA-82-CN45_10uM Dose=10uM, morpholinocarbonyl-Phe-hPhe-CH2F, m-Calpain (Calpain-2) Inhibitors;Cathepsin B Inhibitors;Cathepsin L Inhibitors targeting CAPN2, CTSB, CTSL
KA-82-CN45_1uM Dose=1uM, morpholinocarbonyl-Phe-hPhe-CH2F, m-Calpain (Calpain-2) Inhibitors;Cathepsin B Inhibitors;Cathepsin L Inhibitors targeting CAPN2, CTSB, CTSL
KA-92-WY22_0.01uM Dose=0.01uM, Rimcazole, sigma Receptor Antagonists targeting SIGMAR1
KA-92-WY22_0.1uM Dose=0.1uM, Rimcazole, sigma Receptor Antagonists targeting SIGMAR1
KA-92-WY22_10uM Dose=10uM, Rimcazole, sigma Receptor Antagonists targeting SIGMAR1
KA-92-WY22_1uM Dose=1uM, Rimcazole, sigma Receptor Antagonists targeting SIGMAR1
KB-00-DM33_0.01uM Dose=0.01uM
KB-00-DM33_0.1uM Dose=0.1uM
KB-00-DM33_10uM Dose=10uM
KB-00-DM33_1uM Dose=1uM
KB-04-AF26_0.01uM Dose=0.01uM
KB-04-AF26_0.1uM Dose=0.1uM
KB-04-AF26_10uM Dose=10uM
KB-04-AF26_1uM Dose=1uM
KB-05-VJ83_0.01uM Dose=0.01uM, 2-Chloro-N-[(9H-fluoren-9-ylamino)carbonyl]-6-fluorobenzamide, PPIA gene inhibitor targeting PPIA
KB-05-VJ83_0.1uM Dose=0.1uM, 2-Chloro-N-[(9H-fluoren-9-ylamino)carbonyl]-6-fluorobenzamide, PPIA gene inhibitor targeting PPIA
KB-05-VJ83_10uM Dose=10uM, 2-Chloro-N-[(9H-fluoren-9-ylamino)carbonyl]-6-fluorobenzamide, PPIA gene inhibitor targeting PPIA
KB-05-VJ83_1uM Dose=1uM, 2-Chloro-N-[(9H-fluoren-9-ylamino)carbonyl]-6-fluorobenzamide, PPIA gene inhibitor targeting PPIA
KB-17-DU74_0.01uM Dose=0.01uM, SR8278, REV-ERB anatagonist targeting NR1D1
KB-17-DU74_0.1uM Dose=0.1uM, SR8278, REV-ERB anatagonist targeting NR1D1
KB-17-DU74_10uM Dose=10uM, SR8278, REV-ERB anatagonist targeting NR1D1
KB-17-DU74_1uM Dose=1uM, SR8278, REV-ERB anatagonist targeting NR1D1
KB-17-PN92_0.01uM Dose=0.01uM, methyl (4S,5Z,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate
KB-17-PN92_0.1uM Dose=0.1uM, methyl (4S,5Z,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate
KB-17-PN92_10uM Dose=10uM, methyl (4S,5Z,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate
KB-17-PN92_1uM Dose=1uM, methyl (4S,5Z,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate
KB-24-KS32_0.01uM Dose=0.01uM, {3,5-Dimethyl-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenoxy}-acetic acid
KB-24-KS32_0.1uM Dose=0.1uM, {3,5-Dimethyl-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenoxy}-acetic acid
KB-24-KS32_10uM Dose=10uM, {3,5-Dimethyl-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenoxy}-acetic acid
KB-24-KS32_1uM Dose=1uM, {3,5-Dimethyl-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenoxy}-acetic acid
KB-24-RB56_0.01uM Dose=0.01uM, Lauryl sulfate
KB-24-RB56_0.1uM Dose=0.1uM, Lauryl sulfate
KB-24-RB56_10uM Dose=10uM, Lauryl sulfate
KB-24-RB56_1uM Dose=1uM, Lauryl sulfate
KB-25-KP22_0.01uM Dose=0.01uM, 4-(5,6-Dimethoxy-2-benzofuranyl)-piperidine, Serotonin Antagonists targeting HTR1A, MAOA, MAOB
KB-25-KP22_0.1uM Dose=0.1uM, 4-(5,6-Dimethoxy-2-benzofuranyl)-piperidine, Serotonin Antagonists targeting HTR1A, MAOA, MAOB
KB-25-KP22_10uM Dose=10uM, 4-(5,6-Dimethoxy-2-benzofuranyl)-piperidine, Serotonin Antagonists targeting HTR1A, MAOA, MAOB
KB-25-KP22_1uM Dose=1uM, 4-(5,6-Dimethoxy-2-benzofuranyl)-piperidine, Serotonin Antagonists targeting HTR1A, MAOA, MAOB
KB-37-OO25_0.01uM Dose=0.01uM, Tovinontrine targeting PDE9A
KB-37-OO25_0.1uM Dose=0.1uM, Tovinontrine targeting PDE9A
KB-37-OO25_10uM Dose=10uM, Tovinontrine targeting PDE9A
KB-37-OO25_1uM Dose=1uM, Tovinontrine targeting PDE9A
KB-39-DB68_0.01uM Dose=0.01uM, 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KB-39-DB68_0.1uM Dose=0.1uM, 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KB-39-DB68_10uM Dose=10uM, 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KB-39-DB68_1uM Dose=1uM, 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A
KB-45-CF78_0.01uM Dose=0.01uM, 2-Benzyl-4H-3,1-benzoxazin-4-one
KB-45-CF78_0.1uM Dose=0.1uM, 2-Benzyl-4H-3,1-benzoxazin-4-one
KB-45-CF78_10uM Dose=10uM, 2-Benzyl-4H-3,1-benzoxazin-4-one
KB-45-CF78_1uM Dose=1uM, 2-Benzyl-4H-3,1-benzoxazin-4-one
KB-46-EJ60_0.01uM Dose=0.01uM
KB-46-EJ60_0.1uM Dose=0.1uM
KB-46-EJ60_10uM Dose=10uM
KB-46-EJ60_1uM Dose=1uM
KB-48-GH25_0.01uM Dose=0.01uM, 2-[3-[(4-Methylphenyl)carbamoyl]-4-piperidin-1-ylphenyl]indazole-6-carboxylic acid
KB-48-GH25_0.1uM Dose=0.1uM, 2-[3-[(4-Methylphenyl)carbamoyl]-4-piperidin-1-ylphenyl]indazole-6-carboxylic acid
KB-48-GH25_10uM Dose=10uM, 2-[3-[(4-Methylphenyl)carbamoyl]-4-piperidin-1-ylphenyl]indazole-6-carboxylic acid
KB-48-GH25_1uM Dose=1uM, 2-[3-[(4-Methylphenyl)carbamoyl]-4-piperidin-1-ylphenyl]indazole-6-carboxylic acid
KB-49-NF63_0.01uM Dose=0.01uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-phenylpropanamide, VPAC1 (VIP1) Antagonists targeting VIPR1
KB-49-NF63_0.1uM Dose=0.1uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-phenylpropanamide, VPAC1 (VIP1) Antagonists targeting VIPR1
KB-49-NF63_10uM Dose=10uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-phenylpropanamide, VPAC1 (VIP1) Antagonists targeting VIPR1
KB-49-NF63_1uM Dose=1uM, N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-phenylpropanamide, VPAC1 (VIP1) Antagonists targeting VIPR1
KB-56-XG08_0.01uM Dose=0.01uM
KB-56-XG08_0.1uM Dose=0.1uM
KB-56-XG08_10uM Dose=10uM
KB-56-XG08_1uM Dose=1uM
KB-57-TK65_0.01uM Dose=0.01uM, Altenusin, Neutral Sphingomyelinase (N-SMase) Inhibitors;HIV Integrase Inhibitors targeting SMPD2
KB-57-TK65_0.1uM Dose=0.1uM, Altenusin, Neutral Sphingomyelinase (N-SMase) Inhibitors;HIV Integrase Inhibitors targeting SMPD2
KB-57-TK65_10uM Dose=10uM, Altenusin, Neutral Sphingomyelinase (N-SMase) Inhibitors;HIV Integrase Inhibitors targeting SMPD2
KB-57-TK65_1uM Dose=1uM, Altenusin, Neutral Sphingomyelinase (N-SMase) Inhibitors;HIV Integrase Inhibitors targeting SMPD2
KB-58-XI48_0.01uM Dose=0.01uM, Diosmin, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR
KB-58-XI48_0.1uM Dose=0.1uM, Diosmin, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR
KB-58-XI48_1uM Dose=1uM, Diosmin, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR
KB-59-KM40_0.1uM Dose=0.1uM
KB-59-KM40_10uM Dose=10uM
KB-65-GP42_0.01uM Dose=0.01uM, 4-[(4-Amino-5-cyanopyrimidin-2-yl)amino]benzenesulfonamide, CDK2 Inhibitors targeting CDK2
KB-65-GP42_0.1uM Dose=0.1uM, 4-[(4-Amino-5-cyanopyrimidin-2-yl)amino]benzenesulfonamide, CDK2 Inhibitors targeting CDK2
KB-65-GP42_10uM Dose=10uM, 4-[(4-Amino-5-cyanopyrimidin-2-yl)amino]benzenesulfonamide, CDK2 Inhibitors targeting CDK2
KB-65-GP42_1uM Dose=1uM, 4-[(4-Amino-5-cyanopyrimidin-2-yl)amino]benzenesulfonamide, CDK2 Inhibitors targeting CDK2
KB-71-QJ23_0.01uM Dose=0.01uM, N-(3-chlorophenyl)-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-9-ethylpurin-6-amine
KB-71-QJ23_0.1uM Dose=0.1uM, N-(3-chlorophenyl)-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-9-ethylpurin-6-amine
KB-71-QJ23_10uM Dose=10uM, N-(3-chlorophenyl)-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-9-ethylpurin-6-amine
KB-71-QJ23_1uM Dose=1uM, N-(3-chlorophenyl)-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-9-ethylpurin-6-amine
KB-72-ID36_0.01uM Dose=0.01uM, Tolimidone, Lyn kinase activator;Lyn Kinase Activators targeting LYN
KB-72-ID36_0.1uM Dose=0.1uM, Tolimidone, Lyn kinase activator;Lyn Kinase Activators targeting LYN
KB-72-ID36_10uM Dose=10uM, Tolimidone, Lyn kinase activator;Lyn Kinase Activators targeting LYN
KB-72-ID36_1uM Dose=1uM, Tolimidone, Lyn kinase activator;Lyn Kinase Activators targeting LYN
KB-77-BA46_0.01uM Dose=0.01uM, 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide, p38 MAPK Inhibitors targeting MAPK14
KB-77-BA46_0.1uM Dose=0.1uM, 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide, p38 MAPK Inhibitors targeting MAPK14
KB-77-BA46_10uM Dose=10uM, 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide, p38 MAPK Inhibitors targeting MAPK14
KB-77-BA46_1uM Dose=1uM, 3-(5-amino-4-benzoyl-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide, p38 MAPK Inhibitors targeting MAPK14
KB-78-BE93_0.01uM Dose=0.01uM, Mivebresib, Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors targeting BRD4
KB-78-BE93_0.1uM Dose=0.1uM, Mivebresib, Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors targeting BRD4
KB-78-BE93_10uM Dose=10uM, Mivebresib, Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors targeting BRD4
KB-78-BE93_1uM Dose=1uM, Mivebresib, Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors targeting BRD4
KB-84-OL45_0.01uM Dose=0.01uM, Cgs 26393, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME, ECE1, ECE2
KB-84-OL45_0.1uM Dose=0.1uM, Cgs 26393, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME, ECE1, ECE2
KB-84-OL45_10uM Dose=10uM, Cgs 26393, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME, ECE1, ECE2
KB-84-OL45_1uM Dose=1uM, Cgs 26393, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME, ECE1, ECE2
KB-85-KP82_0.01uM Dose=0.01uM, Sch 33303, Mediator Release Inhibitors;Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1
KB-85-KP82_0.1uM Dose=0.1uM, Sch 33303, Mediator Release Inhibitors;Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1
KB-85-KP82_10uM Dose=10uM, Sch 33303, Mediator Release Inhibitors;Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1
KB-85-KP82_1uM Dose=1uM, Sch 33303, Mediator Release Inhibitors;Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1
KB-88-OR49_0.01uM Dose=0.01uM, (1S,2R)-2-[[9-ethyl-6-[4-(2-methylpropylsulfamoyl)anilino]purin-2-yl]amino]cyclohexane-1-carboxamide
KB-88-OR49_0.1uM Dose=0.1uM, (1S,2R)-2-[[9-ethyl-6-[4-(2-methylpropylsulfamoyl)anilino]purin-2-yl]amino]cyclohexane-1-carboxamide
KB-88-OR49_10uM Dose=10uM, (1S,2R)-2-[[9-ethyl-6-[4-(2-methylpropylsulfamoyl)anilino]purin-2-yl]amino]cyclohexane-1-carboxamide
KB-88-OR49_1uM Dose=1uM, (1S,2R)-2-[[9-ethyl-6-[4-(2-methylpropylsulfamoyl)anilino]purin-2-yl]amino]cyclohexane-1-carboxamide
KB-92-MK13_0.01uM Dose=0.01uM, 4-Cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonitrile, TNF-alpha Production Inhibitors;Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8
KB-92-MK13_0.1uM Dose=0.1uM, 4-Cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonitrile, TNF-alpha Production Inhibitors;Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8
KB-92-MK13_10uM Dose=10uM, 4-Cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonitrile, TNF-alpha Production Inhibitors;Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8
KB-92-MK13_1uM Dose=1uM, 4-Cycloheptylamino-6-[(pyridin-3-ylmethyl)-amino]-[1,7]naphthyridine-3-carbonitrile, TNF-alpha Production Inhibitors;Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8
KC-07-HN67_0.01uM Dose=0.01uM, Ormetoprim, P2X2/3 Receptor Antagonists;P2X3 Receptor Antagonists targeting P2RX3
KC-07-HN67_0.1uM Dose=0.1uM, Ormetoprim, P2X2/3 Receptor Antagonists;P2X3 Receptor Antagonists targeting P2RX3
KC-07-HN67_10uM Dose=10uM, Ormetoprim, P2X2/3 Receptor Antagonists;P2X3 Receptor Antagonists targeting P2RX3
KC-07-HN67_1uM Dose=1uM, Ormetoprim, P2X2/3 Receptor Antagonists;P2X3 Receptor Antagonists targeting P2RX3
KC-10-GC29_0.01uM Dose=0.01uM, Apoptosis Inducers;Antioxidants;Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
KC-10-GC29_0.1uM Dose=0.1uM, Apoptosis Inducers;Antioxidants;Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
KC-10-GC29_10uM Dose=10uM, Apoptosis Inducers;Antioxidants;Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
KC-10-GC29_1uM Dose=1uM, Apoptosis Inducers;Antioxidants;Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
KC-11-TJ63_1uM Dose=1uM, Pentetrazol, GABA(A) Receptor Antagonists targeting GABRA1
KC-15-HM70_0.01uM Dose=0.01uM, Talarozole, An inhibitor of CYP26 targeting CYP26A1
KC-15-HM70_0.1uM Dose=0.1uM, Talarozole, An inhibitor of CYP26 targeting CYP26A1
KC-15-HM70_10uM Dose=10uM, Talarozole, An inhibitor of CYP26 targeting CYP26A1
KC-15-HM70_1uM Dose=1uM, Talarozole, An inhibitor of CYP26 targeting CYP26A1
KC-17-YN77_0.01uM Dose=0.01uM, N-(adamantan-1-yl)quinoxaline-2-carboxamide, mgluR1 Antagonists;mgluR5 Antagonists targeting GRM1, GRM5
KC-17-YN77_0.1uM Dose=0.1uM, N-(adamantan-1-yl)quinoxaline-2-carboxamide, mgluR1 Antagonists;mgluR5 Antagonists targeting GRM1, GRM5
KC-17-YN77_10uM Dose=10uM, N-(adamantan-1-yl)quinoxaline-2-carboxamide, mgluR1 Antagonists;mgluR5 Antagonists targeting GRM1, GRM5
KC-17-YN77_1uM Dose=1uM, N-(adamantan-1-yl)quinoxaline-2-carboxamide, mgluR1 Antagonists;mgluR5 Antagonists targeting GRM1, GRM5
KC-21-PG56_0.01uM Dose=0.01uM, N-[4-[[3-(hydroxyamino)-3-oxopropyl]-[2-(4-methoxyphenyl)ethyl]sulfamoyl]phenyl]benzamide, Mammalian Tolloid-like 1 Protein (TLL1) inhibitor;Procollagen C Peptidase (BMP1) inhibitor;Mammalian Tolloid-like 2 Protein (TLL2) Inhibitor targeting BMP1
KC-21-PG56_0.1uM Dose=0.1uM, N-[4-[[3-(hydroxyamino)-3-oxopropyl]-[2-(4-methoxyphenyl)ethyl]sulfamoyl]phenyl]benzamide, Mammalian Tolloid-like 1 Protein (TLL1) inhibitor;Procollagen C Peptidase (BMP1) inhibitor;Mammalian Tolloid-like 2 Protein (TLL2) Inhibitor targeting BMP1
KC-21-PG56_10uM Dose=10uM, N-[4-[[3-(hydroxyamino)-3-oxopropyl]-[2-(4-methoxyphenyl)ethyl]sulfamoyl]phenyl]benzamide, Mammalian Tolloid-like 1 Protein (TLL1) inhibitor;Procollagen C Peptidase (BMP1) inhibitor;Mammalian Tolloid-like 2 Protein (TLL2) Inhibitor targeting BMP1
KC-21-PG56_1uM Dose=1uM, N-[4-[[3-(hydroxyamino)-3-oxopropyl]-[2-(4-methoxyphenyl)ethyl]sulfamoyl]phenyl]benzamide, Mammalian Tolloid-like 1 Protein (TLL1) inhibitor;Procollagen C Peptidase (BMP1) inhibitor;Mammalian Tolloid-like 2 Protein (TLL2) Inhibitor targeting BMP1
KC-26-JQ92_0.01uM Dose=0.01uM, Gsk-923295a, Centromere protein E inhibitor targeting CENPE
KC-26-JQ92_0.1uM Dose=0.1uM, Gsk-923295a, Centromere protein E inhibitor targeting CENPE
KC-26-JQ92_10uM Dose=10uM, Gsk-923295a, Centromere protein E inhibitor targeting CENPE
KC-26-JQ92_1uM Dose=1uM, Gsk-923295a, Centromere protein E inhibitor targeting CENPE
KC-32-GO33_0.01uM Dose=0.01uM, 6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide targeting USP7
KC-32-GO33_0.1uM Dose=0.1uM, 6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide targeting USP7
KC-32-GO33_10uM Dose=10uM, 6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide targeting USP7
KC-32-GO33_1uM Dose=1uM, 6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide targeting USP7
KC-35-MF93_0.01uM Dose=0.01uM
KC-35-MF93_0.1uM Dose=0.1uM
KC-35-MF93_10uM Dose=10uM
KC-35-MF93_1uM Dose=1uM
KC-36-DK23_0.01uM Dose=0.01uM, (3s)-3-(7-Methoxy-1-Methyl-1h-Benzo[d][1,2,3]triazol-5-Yl)-3-(4-Methyl-3-(((R)-4-Methyl-1,1-Dioxido-3,4-Dihydro-2h-Benzo[b][1,4,5]oxathiazepin-2-Yl)methyl)phenyl)propanoic Acid, Inhibitor of KEAP1-Nrf2 PPI targeting KEAP1
KC-36-DK23_0.1uM Dose=0.1uM, (3s)-3-(7-Methoxy-1-Methyl-1h-Benzo[d][1,2,3]triazol-5-Yl)-3-(4-Methyl-3-(((R)-4-Methyl-1,1-Dioxido-3,4-Dihydro-2h-Benzo[b][1,4,5]oxathiazepin-2-Yl)methyl)phenyl)propanoic Acid, Inhibitor of KEAP1-Nrf2 PPI targeting KEAP1
KC-36-DK23_10uM Dose=10uM, (3s)-3-(7-Methoxy-1-Methyl-1h-Benzo[d][1,2,3]triazol-5-Yl)-3-(4-Methyl-3-(((R)-4-Methyl-1,1-Dioxido-3,4-Dihydro-2h-Benzo[b][1,4,5]oxathiazepin-2-Yl)methyl)phenyl)propanoic Acid, Inhibitor of KEAP1-Nrf2 PPI targeting KEAP1
KC-36-DK23_1uM Dose=1uM, (3s)-3-(7-Methoxy-1-Methyl-1h-Benzo[d][1,2,3]triazol-5-Yl)-3-(4-Methyl-3-(((R)-4-Methyl-1,1-Dioxido-3,4-Dihydro-2h-Benzo[b][1,4,5]oxathiazepin-2-Yl)methyl)phenyl)propanoic Acid, Inhibitor of KEAP1-Nrf2 PPI targeting KEAP1
KC-43-HY29_0.01uM Dose=0.01uM, (2R)-2-amino-3-[[4-(2-ethylphenyl)-1H-indole-2-carbonyl]amino]propanoic acid, NMDA Glycine-Site Modulators;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR4, GRIN1
KC-43-HY29_0.1uM Dose=0.1uM, (2R)-2-amino-3-[[4-(2-ethylphenyl)-1H-indole-2-carbonyl]amino]propanoic acid, NMDA Glycine-Site Modulators;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR4, GRIN1
KC-43-HY29_10uM Dose=10uM, (2R)-2-amino-3-[[4-(2-ethylphenyl)-1H-indole-2-carbonyl]amino]propanoic acid, NMDA Glycine-Site Modulators;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR4, GRIN1
KC-43-HY29_1uM Dose=1uM, (2R)-2-amino-3-[[4-(2-ethylphenyl)-1H-indole-2-carbonyl]amino]propanoic acid, NMDA Glycine-Site Modulators;Lysophospholipid edg6 (S1P4) Receptor Agonists targeting S1PR4, GRIN1
KC-45-DZ26_0.01uM Dose=0.01uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-5-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN
KC-45-DZ26_0.1uM Dose=0.1uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-5-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN
KC-45-DZ26_10uM Dose=10uM, 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-5-hydroxy-, E3 ligase inhibitor;CRBN neomorph targeting CRBN
KC-48-OO62_0.1uM Dose=0.1uM, PKC theta inhibitor targeting PRKCQ
KC-48-OO62_10uM Dose=10uM, PKC theta inhibitor targeting PRKCQ
KC-48-OO62_1uM Dose=1uM, PKC theta inhibitor targeting PRKCQ
KC-54-AS32_0.01uM Dose=0.01uM, Miridesap, Antiamyloidogenic Agents;Anti-Human Serum Amyloid P (Anti-SAP) targeting APCS
KC-54-AS32_0.1uM Dose=0.1uM, Miridesap, Antiamyloidogenic Agents;Anti-Human Serum Amyloid P (Anti-SAP) targeting APCS
KC-54-AS32_10uM Dose=10uM, Miridesap, Antiamyloidogenic Agents;Anti-Human Serum Amyloid P (Anti-SAP) targeting APCS
KC-67-HN97_0.01uM Dose=0.01uM, 2,2-Dimethyl-6-[(4,6-diphenyl-2-pyridyl)oxy]hexanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
KC-67-HN97_0.1uM Dose=0.1uM, 2,2-Dimethyl-6-[(4,6-diphenyl-2-pyridyl)oxy]hexanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
KC-67-HN97_10uM Dose=10uM, 2,2-Dimethyl-6-[(4,6-diphenyl-2-pyridyl)oxy]hexanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
KC-67-HN97_1uM Dose=1uM, 2,2-Dimethyl-6-[(4,6-diphenyl-2-pyridyl)oxy]hexanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
KC-71-KK26_0.01uM Dose=0.01uM, Gabazine free base, GABA(A) Receptor Antagonists targeting GABRA1, GABRB3, GABRG2
KC-71-KK26_0.1uM Dose=0.1uM, Gabazine free base, GABA(A) Receptor Antagonists targeting GABRA1, GABRB3, GABRG2
KC-71-KK26_10uM Dose=10uM, Gabazine free base, GABA(A) Receptor Antagonists targeting GABRA1, GABRB3, GABRG2
KC-71-KK26_1uM Dose=1uM, Gabazine free base, GABA(A) Receptor Antagonists targeting GABRA1, GABRB3, GABRG2
KC-77-HN47_0.01uM Dose=0.01uM, GABA(A) BZ Site Receptor Partial Agonists
KC-77-HN47_0.1uM Dose=0.1uM, GABA(A) BZ Site Receptor Partial Agonists
KC-77-HN47_1uM Dose=1uM, GABA(A) BZ Site Receptor Partial Agonists
KC-86-UD16_0.01uM Dose=0.01uM
KC-86-UD16_0.1uM Dose=0.1uM
KC-86-UD16_10uM Dose=10uM
KC-86-UD16_1uM Dose=1uM
KC-87-DN47_0.01uM Dose=0.01uM, 3-Aminonorharman, CCKAR antagonist targeting CCKAR
KC-87-DN47_0.1uM Dose=0.1uM, 3-Aminonorharman, CCKAR antagonist targeting CCKAR
KC-87-DN47_10uM Dose=10uM, 3-Aminonorharman, CCKAR antagonist targeting CCKAR
KC-87-DN47_1uM Dose=1uM, 3-Aminonorharman, CCKAR antagonist targeting CCKAR
KC-93-NH98_0.01uM Dose=0.01uM, Acea 1011, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1
KC-93-NH98_0.1uM Dose=0.1uM, Acea 1011, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1
KC-93-NH98_10uM Dose=10uM, Acea 1011, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1
KC-93-NH98_1uM Dose=1uM, Acea 1011, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1
KC-95-ZW49_0.1uM Dose=0.1uM, 2-thiophen-2-ylethyl (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoate, 12-Lipoxygenase Inhibitors targeting ALOX12
KC-95-ZW49_10uM Dose=10uM, 2-thiophen-2-ylethyl (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoate, 12-Lipoxygenase Inhibitors targeting ALOX12
KC-95-ZW49_1uM Dose=1uM, 2-thiophen-2-ylethyl (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoate, 12-Lipoxygenase Inhibitors targeting ALOX12
KC-96-UA29_0.01uM Dose=0.01uM, 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol, ADRB3 agonist targeting ADRB3
KC-96-UA29_0.1uM Dose=0.1uM, 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol, ADRB3 agonist targeting ADRB3
KC-96-UA29_10uM Dose=10uM, 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol, ADRB3 agonist targeting ADRB3
KC-96-UA29_1uM Dose=1uM, 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol, ADRB3 agonist targeting ADRB3
KC-97-AA46_0.01uM Dose=0.01uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-[[(2S)-1-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)-3,3-dimethylbutan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
KC-97-AA46_0.1uM Dose=0.1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-[[(2S)-1-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)-3,3-dimethylbutan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
KC-97-AA46_10uM Dose=10uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-[[(2S)-1-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)-3,3-dimethylbutan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
KC-97-AA46_1uM Dose=1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-[[(2S)-1-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)-3,3-dimethylbutan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide
KC-99-BS89_0.01uM Dose=0.01uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,2-a]pyridin-8-amine
KC-99-BS89_0.1uM Dose=0.1uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,2-a]pyridin-8-amine
KC-99-BS89_10uM Dose=10uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,2-a]pyridin-8-amine
KC-99-BS89_1uM Dose=1uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-(1-oxo-1,4-thiazinan-4-yl)imidazo[1,2-a]pyridin-8-amine
KD-00-UJ81_0.01uM Dose=0.01uM, 3-anilinoisoquinolin-1(2H)-one
KD-00-UJ81_0.1uM Dose=0.1uM, 3-anilinoisoquinolin-1(2H)-one
KD-00-UJ81_10uM Dose=10uM, 3-anilinoisoquinolin-1(2H)-one
KD-00-UJ81_1uM Dose=1uM, 3-anilinoisoquinolin-1(2H)-one
KD-04-TL80_0.01uM Dose=0.01uM
KD-04-TL80_0.1uM Dose=0.1uM
KD-04-TL80_10uM Dose=10uM
KD-04-TL80_1uM Dose=1uM
KD-14-RS67_0.01uM Dose=0.01uM, 1-[4-(2,3-Dimethoxybenzoyl)piperazin-1-yl]-2-(3-methylphenoxy)ethanone, antagonist of CBX7ChD/methyl-lysine binding by blocking H3K27me3 binding;CBX7ChD antagonist targeting CBX7
KD-14-RS67_0.1uM Dose=0.1uM, 1-[4-(2,3-Dimethoxybenzoyl)piperazin-1-yl]-2-(3-methylphenoxy)ethanone, antagonist of CBX7ChD/methyl-lysine binding by blocking H3K27me3 binding;CBX7ChD antagonist targeting CBX7
KD-14-RS67_10uM Dose=10uM, 1-[4-(2,3-Dimethoxybenzoyl)piperazin-1-yl]-2-(3-methylphenoxy)ethanone, antagonist of CBX7ChD/methyl-lysine binding by blocking H3K27me3 binding;CBX7ChD antagonist targeting CBX7
KD-14-RS67_1uM Dose=1uM, 1-[4-(2,3-Dimethoxybenzoyl)piperazin-1-yl]-2-(3-methylphenoxy)ethanone, antagonist of CBX7ChD/methyl-lysine binding by blocking H3K27me3 binding;CBX7ChD antagonist targeting CBX7
KD-17-MR02_0.01uM Dose=0.01uM, 4-[2-[5-(Chloromethyl)-4-[4-(trifluoromethoxy)phenyl]triazol-1-yl]ethyl]-3,5-dimethyl-1,2-oxazole, MGMT gene inhibitor targeting MGMT
KD-17-MR02_0.1uM Dose=0.1uM, 4-[2-[5-(Chloromethyl)-4-[4-(trifluoromethoxy)phenyl]triazol-1-yl]ethyl]-3,5-dimethyl-1,2-oxazole, MGMT gene inhibitor targeting MGMT
KD-17-MR02_10uM Dose=10uM, 4-[2-[5-(Chloromethyl)-4-[4-(trifluoromethoxy)phenyl]triazol-1-yl]ethyl]-3,5-dimethyl-1,2-oxazole, MGMT gene inhibitor targeting MGMT
KD-17-MR02_1uM Dose=1uM, 4-[2-[5-(Chloromethyl)-4-[4-(trifluoromethoxy)phenyl]triazol-1-yl]ethyl]-3,5-dimethyl-1,2-oxazole, MGMT gene inhibitor targeting MGMT
KD-30-SM33_0.01uM Dose=0.01uM, Pyridoxamine
KD-30-SM33_0.1uM Dose=0.1uM, Pyridoxamine
KD-30-SM33_10uM Dose=10uM, Pyridoxamine
KD-30-SM33_1uM Dose=1uM, Pyridoxamine
KD-31-TU05_0.01uM Dose=0.01uM, Lesinurad targeting SLC22A11, SLC22A12
KD-31-TU05_0.1uM Dose=0.1uM, Lesinurad targeting SLC22A11, SLC22A12
KD-31-TU05_10uM Dose=10uM, Lesinurad targeting SLC22A11, SLC22A12
KD-31-TU05_1uM Dose=1uM, Lesinurad targeting SLC22A11, SLC22A12
KD-36-KT24_0.01uM Dose=0.01uM, (2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide
KD-36-KT24_0.1uM Dose=0.1uM, (2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide
KD-36-KT24_10uM Dose=10uM, (2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide
KD-36-KT24_1uM Dose=1uM, (2R,3R,4S,5R,6E)-3,4,5-Trihydroxy-N-[(3S,6R)-6-hydroxy-2-oxo-3-azepanyl]-2-methoxy-8,8-dimethyl-6-nonenamide
KD-38-KY71_0.01uM Dose=0.01uM, CID 44542178, NPFFR2 agonist, GIRK 1/4 blocker targeting NPFFR2
KD-38-KY71_0.1uM Dose=0.1uM, CID 44542178, NPFFR2 agonist, GIRK 1/4 blocker targeting NPFFR2
KD-38-KY71_10uM Dose=10uM, CID 44542178, NPFFR2 agonist, GIRK 1/4 blocker targeting NPFFR2
KD-38-KY71_1uM Dose=1uM, CID 44542178, NPFFR2 agonist, GIRK 1/4 blocker targeting NPFFR2
KD-42-UK08_0.01uM Dose=0.01uM, AZ11657312 (salt free), P2X7 Receptor Antagonists targeting P2RX7
KD-42-UK08_0.1uM Dose=0.1uM, AZ11657312 (salt free), P2X7 Receptor Antagonists targeting P2RX7
KD-42-UK08_10uM Dose=10uM, AZ11657312 (salt free), P2X7 Receptor Antagonists targeting P2RX7
KD-42-UK08_1uM Dose=1uM, AZ11657312 (salt free), P2X7 Receptor Antagonists targeting P2RX7
KD-44-PB06_0.01uM Dose=0.01uM, CID 10461016
KD-44-PB06_0.1uM Dose=0.1uM, CID 10461016
KD-44-PB06_10uM Dose=10uM, CID 10461016
KD-44-PB06_1uM Dose=1uM, CID 10461016
KD-50-WP70_0.01uM Dose=0.01uM, N-(3,4-dichlorophenyl)guanidine, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
KD-50-WP70_0.1uM Dose=0.1uM, N-(3,4-dichlorophenyl)guanidine, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
KD-50-WP70_10uM Dose=10uM, N-(3,4-dichlorophenyl)guanidine, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
KD-50-WP70_1uM Dose=1uM, N-(3,4-dichlorophenyl)guanidine, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
KD-54-IS22_0.01uM Dose=0.01uM, N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide, STAT-3 Inhibitors targeting STAT3
KD-54-IS22_0.1uM Dose=0.1uM, N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide, STAT-3 Inhibitors targeting STAT3
KD-54-IS22_10uM Dose=10uM, N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide, STAT-3 Inhibitors targeting STAT3
KD-54-IS22_1uM Dose=1uM, N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide, STAT-3 Inhibitors targeting STAT3
KD-68-JH25_0.01uM Dose=0.01uM, Devazepide, CCK1 (CCKA) Antagonists targeting CCKAR
KD-68-JH25_0.1uM Dose=0.1uM, Devazepide, CCK1 (CCKA) Antagonists targeting CCKAR
KD-68-JH25_10uM Dose=10uM, Devazepide, CCK1 (CCKA) Antagonists targeting CCKAR
KD-68-JH25_1uM Dose=1uM, Devazepide, CCK1 (CCKA) Antagonists targeting CCKAR
KD-75-HW99_0.01uM Dose=0.01uM, 3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;PDGFR Inhibitors;EGFR (HER1| erbB1) Inhibitors targeting EGFR, FGFR1, FGFR3, FLT4, KDR, DDR2, RET, TEK
KD-75-HW99_0.1uM Dose=0.1uM, 3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;PDGFR Inhibitors;EGFR (HER1| erbB1) Inhibitors targeting EGFR, FGFR1, FGFR3, FLT4, KDR, DDR2, RET, TEK
KD-75-HW99_1uM Dose=1uM, 3-((4-Bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;PDGFR Inhibitors;EGFR (HER1| erbB1) Inhibitors targeting EGFR, FGFR1, FGFR3, FLT4, KDR, DDR2, RET, TEK
KD-86-AJ75_0.01uM Dose=0.01uM, 2-((10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)methyl)-N,5-dimethylbenzenesulfonamide, Glucocorticoid Receptor (GR) Antagonists;Mineralocorticoid Receptor (MR) Antagonists targeting NR3C1, NR3C2
KD-86-AJ75_0.1uM Dose=0.1uM, 2-((10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)methyl)-N,5-dimethylbenzenesulfonamide, Glucocorticoid Receptor (GR) Antagonists;Mineralocorticoid Receptor (MR) Antagonists targeting NR3C1, NR3C2
KD-86-AJ75_10uM Dose=10uM, 2-((10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)methyl)-N,5-dimethylbenzenesulfonamide, Glucocorticoid Receptor (GR) Antagonists;Mineralocorticoid Receptor (MR) Antagonists targeting NR3C1, NR3C2
KD-86-AJ75_1uM Dose=1uM, 2-((10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)methyl)-N,5-dimethylbenzenesulfonamide, Glucocorticoid Receptor (GR) Antagonists;Mineralocorticoid Receptor (MR) Antagonists targeting NR3C1, NR3C2
KD-88-RE18_0.01uM Dose=0.01uM
KD-88-RE18_0.1uM Dose=0.1uM
KD-88-RE18_10uM Dose=10uM
KD-88-RE18_1uM Dose=1uM
KE-02-TK48_0.01uM Dose=0.01uM, 3,5-Bis(trifluoromethyl)benzyl N-acetyltryptophan, TACR1 antagonist targeting TACR1
KE-02-TK48_0.1uM Dose=0.1uM, 3,5-Bis(trifluoromethyl)benzyl N-acetyltryptophan, TACR1 antagonist targeting TACR1
KE-02-TK48_10uM Dose=10uM, 3,5-Bis(trifluoromethyl)benzyl N-acetyltryptophan, TACR1 antagonist targeting TACR1
KE-04-OV29_0.01uM Dose=0.01uM, 2-Cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)-
KE-04-OV29_0.1uM Dose=0.1uM, 2-Cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)-
KE-04-OV29_10uM Dose=10uM, 2-Cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)-
KE-04-OV29_1uM Dose=1uM, 2-Cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)-
KE-06-DQ22_0.01uM Dose=0.01uM, 3-(2-carboxyethyl)-4-iodo-1H-indole-2-carboxylic acid
KE-06-DQ22_0.1uM Dose=0.1uM, 3-(2-carboxyethyl)-4-iodo-1H-indole-2-carboxylic acid
KE-06-DQ22_10uM Dose=10uM, 3-(2-carboxyethyl)-4-iodo-1H-indole-2-carboxylic acid
KE-06-DQ22_1uM Dose=1uM, 3-(2-carboxyethyl)-4-iodo-1H-indole-2-carboxylic acid
KE-07-JX81_0.01uM Dose=0.01uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-[(2,6-difluorophenyl)methoxy]phenoxy]acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2
KE-07-JX81_0.1uM Dose=0.1uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-[(2,6-difluorophenyl)methoxy]phenoxy]acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2
KE-07-JX81_10uM Dose=10uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-[(2,6-difluorophenyl)methoxy]phenoxy]acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2
KE-07-JX81_1uM Dose=1uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-[(2,6-difluorophenyl)methoxy]phenoxy]acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2
KE-18-XY06_0.01uM Dose=0.01uM, Ibopamine, Dopamine D1 Agonists targeting DRD1
KE-18-XY06_0.1uM Dose=0.1uM, Ibopamine, Dopamine D1 Agonists targeting DRD1
KE-18-XY06_10uM Dose=10uM, Ibopamine, Dopamine D1 Agonists targeting DRD1
KE-18-XY06_1uM Dose=1uM, Ibopamine, Dopamine D1 Agonists targeting DRD1
KE-24-RZ94_0.01uM Dose=0.01uM, Yoda-1, Piezo1 channel activator;GlyT-2 Inhibitors targeting SLC6A5, PIEZO1
KE-24-RZ94_0.1uM Dose=0.1uM, Yoda-1, Piezo1 channel activator;GlyT-2 Inhibitors targeting SLC6A5, PIEZO1
KE-24-RZ94_10uM Dose=10uM, Yoda-1, Piezo1 channel activator;GlyT-2 Inhibitors targeting SLC6A5, PIEZO1
KE-24-RZ94_1uM Dose=1uM, Yoda-1, Piezo1 channel activator;GlyT-2 Inhibitors targeting SLC6A5, PIEZO1
KE-28-DL25_0.01uM Dose=0.01uM, Methyl 4-[[2,3-dioxo-4-propan-2-yl-7-(trifluoromethyl)quinoxalin-1-yl]methyl]benzoate, Phosphodiesterase PDE4B Inhibitors targeting PDE4B
KE-28-DL25_0.1uM Dose=0.1uM, Methyl 4-[[2,3-dioxo-4-propan-2-yl-7-(trifluoromethyl)quinoxalin-1-yl]methyl]benzoate, Phosphodiesterase PDE4B Inhibitors targeting PDE4B
KE-28-DL25_1uM Dose=1uM, Methyl 4-[[2,3-dioxo-4-propan-2-yl-7-(trifluoromethyl)quinoxalin-1-yl]methyl]benzoate, Phosphodiesterase PDE4B Inhibitors targeting PDE4B
KE-28-MO72_0.01uM Dose=0.01uM, N-[3-[[1-[6-[2-(dimethylamino)ethylamino]pyrimidin-4-yl]imidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide
KE-28-MO72_0.1uM Dose=0.1uM, N-[3-[[1-[6-[2-(dimethylamino)ethylamino]pyrimidin-4-yl]imidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide
KE-28-MO72_10uM Dose=10uM, N-[3-[[1-[6-[2-(dimethylamino)ethylamino]pyrimidin-4-yl]imidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide
KE-28-MO72_1uM Dose=1uM, N-[3-[[1-[6-[2-(dimethylamino)ethylamino]pyrimidin-4-yl]imidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide
KE-30-PJ81_0.01uM Dose=0.01uM, 1-(4-Fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)pyrrole, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
KE-30-PJ81_0.1uM Dose=0.1uM, 1-(4-Fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)pyrrole, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
KE-30-PJ81_10uM Dose=10uM, 1-(4-Fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)pyrrole, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
KE-30-PJ81_1uM Dose=1uM, 1-(4-Fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)pyrrole, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D
KE-37-MN32_0.01uM Dose=0.01uM, Psammaplin D, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
KE-37-MN32_10uM Dose=10uM, Psammaplin D, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
KE-37-MN32_1uM Dose=1uM, Psammaplin D, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
KE-41-JG66_0.01uM Dose=0.01uM, 6-[(2-{[4-(4-Bromo-2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile
KE-41-JG66_0.1uM Dose=0.1uM, 6-[(2-{[4-(4-Bromo-2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile
KE-41-JG66_10uM Dose=10uM, 6-[(2-{[4-(4-Bromo-2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile
KE-41-JG66_1uM Dose=1uM, 6-[(2-{[4-(4-Bromo-2-chlorophenyl)-5-imidazol-2-ylpyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile
KE-47-IA01_0.01uM Dose=0.01uM, Pci-34051, HDAC8 inhibitor targeting HDAC8
KE-47-IA01_0.1uM Dose=0.1uM, Pci-34051, HDAC8 inhibitor targeting HDAC8
KE-47-IA01_10uM Dose=10uM, Pci-34051, HDAC8 inhibitor targeting HDAC8
KE-47-IA01_1uM Dose=1uM, Pci-34051, HDAC8 inhibitor targeting HDAC8
KE-53-DB74_0.01uM Dose=0.01uM, N-[4-Methyl-2-(morpholin-4-YL)quinolin-6-YL]furan-2-carboxamide
KE-53-DB74_0.1uM Dose=0.1uM, N-[4-Methyl-2-(morpholin-4-YL)quinolin-6-YL]furan-2-carboxamide
KE-53-DB74_10uM Dose=10uM, N-[4-Methyl-2-(morpholin-4-YL)quinolin-6-YL]furan-2-carboxamide
KE-53-DB74_1uM Dose=1uM, N-[4-Methyl-2-(morpholin-4-YL)quinolin-6-YL]furan-2-carboxamide
KE-58-BO47_0.01uM Dose=0.01uM, Bms 433771
KE-58-BO47_10uM Dose=10uM, Bms 433771
KE-58-BO47_1uM Dose=1uM, Bms 433771
KE-68-FV64_0.01uM Dose=0.01uM, 1-(4-Tert-butylphenyl)sulfonylindole-5-carbonitrile, CCR9 antagonist targeting CCR9
KE-68-FV64_0.1uM Dose=0.1uM, 1-(4-Tert-butylphenyl)sulfonylindole-5-carbonitrile, CCR9 antagonist targeting CCR9
KE-68-FV64_10uM Dose=10uM, 1-(4-Tert-butylphenyl)sulfonylindole-5-carbonitrile, CCR9 antagonist targeting CCR9
KE-68-FV64_1uM Dose=1uM, 1-(4-Tert-butylphenyl)sulfonylindole-5-carbonitrile, CCR9 antagonist targeting CCR9
KE-73-XV62_0.01uM Dose=0.01uM, Tubercidin
KE-73-XV62_0.1uM Dose=0.1uM, Tubercidin
KE-73-XV62_10uM Dose=10uM, Tubercidin
KE-73-XV62_1uM Dose=1uM, Tubercidin
KE-74-EB71_0.01uM Dose=0.01uM, 2,3-Dihydroxypropyl dodecanoate
KE-74-EB71_0.1uM Dose=0.1uM, 2,3-Dihydroxypropyl dodecanoate
KE-74-EB71_1uM Dose=1uM, 2,3-Dihydroxypropyl dodecanoate
KE-74-OZ09_0.01uM Dose=0.01uM, N-[(4-chloro-2-methylphenyl)methyl]-1-(4-chlorophenyl)-N-[(5-nitrothiophen-2-yl)methyl]methanamine, REV-ERB agonist targeting NR1D1
KE-74-OZ09_0.1uM Dose=0.1uM, N-[(4-chloro-2-methylphenyl)methyl]-1-(4-chlorophenyl)-N-[(5-nitrothiophen-2-yl)methyl]methanamine, REV-ERB agonist targeting NR1D1
KE-74-OZ09_10uM Dose=10uM, N-[(4-chloro-2-methylphenyl)methyl]-1-(4-chlorophenyl)-N-[(5-nitrothiophen-2-yl)methyl]methanamine, REV-ERB agonist targeting NR1D1
KE-86-QG38_0.01uM Dose=0.01uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-thiomorpholin-4-ylimidazo[1,2-a]pyridin-8-amine, dipeptidyl-peptidase II (DPP7) inhibitor;Fibroblast Activation Protein alpha subunit (FAP) Inhibitor;dipeptidyl-peptidase IV (DPP4) inhibitor targeting DPP4
KE-86-QG38_0.1uM Dose=0.1uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-thiomorpholin-4-ylimidazo[1,2-a]pyridin-8-amine, dipeptidyl-peptidase II (DPP7) inhibitor;Fibroblast Activation Protein alpha subunit (FAP) Inhibitor;dipeptidyl-peptidase IV (DPP4) inhibitor targeting DPP4
KE-86-QG38_10uM Dose=10uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-thiomorpholin-4-ylimidazo[1,2-a]pyridin-8-amine, dipeptidyl-peptidase II (DPP7) inhibitor;Fibroblast Activation Protein alpha subunit (FAP) Inhibitor;dipeptidyl-peptidase IV (DPP4) inhibitor targeting DPP4
KE-86-QG38_1uM Dose=1uM, 7-(Aminomethyl)-6-(2,4-dichlorophenyl)-3-thiomorpholin-4-ylimidazo[1,2-a]pyridin-8-amine, dipeptidyl-peptidase II (DPP7) inhibitor;Fibroblast Activation Protein alpha subunit (FAP) Inhibitor;dipeptidyl-peptidase IV (DPP4) inhibitor targeting DPP4
KE-89-DV96_0.01uM Dose=0.01uM, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1
KE-89-DV96_0.1uM Dose=0.1uM, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1
KE-89-DV96_10uM Dose=10uM, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1
KE-89-DV96_1uM Dose=1uM, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1
KE-89-TF43_0.1uM Dose=0.1uM, 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one, PDE9A gene inhibitor targeting PDE9A
KE-89-TF43_10uM Dose=10uM, 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one, PDE9A gene inhibitor targeting PDE9A
KE-89-TF43_1uM Dose=1uM, 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one, PDE9A gene inhibitor targeting PDE9A
KE-91-GT92_0.01uM Dose=0.01uM
KE-91-GT92_0.1uM Dose=0.1uM
KE-91-GT92_10uM Dose=10uM
KE-91-GT92_1uM Dose=1uM
KE-93-TR02_0.01uM Dose=0.01uM, Emate, Steryl Sulfatase Inhibitors;Estrogen Receptor (ER) Agonists targeting STS
KE-93-TR02_0.1uM Dose=0.1uM, Emate, Steryl Sulfatase Inhibitors;Estrogen Receptor (ER) Agonists targeting STS
KE-93-TR02_10uM Dose=10uM, Emate, Steryl Sulfatase Inhibitors;Estrogen Receptor (ER) Agonists targeting STS
KE-97-MN12_0.01uM Dose=0.01uM, Angiogenesis Inhibitors
KE-97-MN12_10uM Dose=10uM, Angiogenesis Inhibitors
KE-97-TA46_0.01uM Dose=0.01uM, 5-R-Rivaroxaban, Known FactorXa inhibitor targeting F10
KE-97-TA46_0.1uM Dose=0.1uM, 5-R-Rivaroxaban, Known FactorXa inhibitor targeting F10
KE-97-TA46_10uM Dose=10uM, 5-R-Rivaroxaban, Known FactorXa inhibitor targeting F10
KE-97-TA46_1uM Dose=1uM, 5-R-Rivaroxaban, Known FactorXa inhibitor targeting F10
KF-00-NW62_0.01uM Dose=0.01uM, 6-[(2-Aminopyridin-3-yl)methylamino]-1,3-bis[(4-methoxyphenyl)methyl]-1,3,5-triazine-2,4-dione, Prokineticin 1 Receptor (PKR1) Antagonist targeting PROKR1
KF-00-NW62_0.1uM Dose=0.1uM, 6-[(2-Aminopyridin-3-yl)methylamino]-1,3-bis[(4-methoxyphenyl)methyl]-1,3,5-triazine-2,4-dione, Prokineticin 1 Receptor (PKR1) Antagonist targeting PROKR1
KF-00-NW62_10uM Dose=10uM, 6-[(2-Aminopyridin-3-yl)methylamino]-1,3-bis[(4-methoxyphenyl)methyl]-1,3,5-triazine-2,4-dione, Prokineticin 1 Receptor (PKR1) Antagonist targeting PROKR1
KF-00-NW62_1uM Dose=1uM, 6-[(2-Aminopyridin-3-yl)methylamino]-1,3-bis[(4-methoxyphenyl)methyl]-1,3,5-triazine-2,4-dione, Prokineticin 1 Receptor (PKR1) Antagonist targeting PROKR1
KF-07-OX36_0.01uM Dose=0.01uM, 4-[8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-yl]benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE2A
KF-07-OX36_0.1uM Dose=0.1uM, 4-[8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-yl]benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE2A
KF-07-OX36_1uM Dose=1uM, 4-[8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-yl]benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE2A
KF-09-GB83_0.01uM Dose=0.01uM, (+)-Nomifensine
KF-09-GB83_0.1uM Dose=0.1uM, (+)-Nomifensine
KF-09-GB83_10uM Dose=10uM, (+)-Nomifensine
KF-09-GB83_1uM Dose=1uM, (+)-Nomifensine
KF-18-RY71_0.01uM Dose=0.01uM, 4-(1H-Indol-4-yl)-5-methyl-N-(3-(methylsulfonyl)phenyl)pyrimidin-2-amine, CDK gene inhibitor targeting CDK2, CDK5, CDK7, CDK9, CDK4
KF-18-RY71_0.1uM Dose=0.1uM, 4-(1H-Indol-4-yl)-5-methyl-N-(3-(methylsulfonyl)phenyl)pyrimidin-2-amine, CDK gene inhibitor targeting CDK2, CDK5, CDK7, CDK9, CDK4
KF-18-RY71_10uM Dose=10uM, 4-(1H-Indol-4-yl)-5-methyl-N-(3-(methylsulfonyl)phenyl)pyrimidin-2-amine, CDK gene inhibitor targeting CDK2, CDK5, CDK7, CDK9, CDK4
KF-18-RY71_1uM Dose=1uM, 4-(1H-Indol-4-yl)-5-methyl-N-(3-(methylsulfonyl)phenyl)pyrimidin-2-amine, CDK gene inhibitor targeting CDK2, CDK5, CDK7, CDK9, CDK4
KF-37-OX16_0.01uM Dose=0.01uM, N-[4-(3-methylphenyl)-5-pyridin-4-yl-1,3-thiazol-2-yl]acetamide, TNF-alpha Production Inhibitors;Inhibitors of Signal Transduction Pathways;Adenosine A3 Antagonists;p38 MAPK Inhibitors targeting ADORA3, MAPK13
KF-37-OX16_0.1uM Dose=0.1uM, N-[4-(3-methylphenyl)-5-pyridin-4-yl-1,3-thiazol-2-yl]acetamide, TNF-alpha Production Inhibitors;Inhibitors of Signal Transduction Pathways;Adenosine A3 Antagonists;p38 MAPK Inhibitors targeting ADORA3, MAPK13
KF-37-OX16_10uM Dose=10uM, N-[4-(3-methylphenyl)-5-pyridin-4-yl-1,3-thiazol-2-yl]acetamide, TNF-alpha Production Inhibitors;Inhibitors of Signal Transduction Pathways;Adenosine A3 Antagonists;p38 MAPK Inhibitors targeting ADORA3, MAPK13
KF-37-OX16_1uM Dose=1uM, N-[4-(3-methylphenyl)-5-pyridin-4-yl-1,3-thiazol-2-yl]acetamide, TNF-alpha Production Inhibitors;Inhibitors of Signal Transduction Pathways;Adenosine A3 Antagonists;p38 MAPK Inhibitors targeting ADORA3, MAPK13
KF-38-DH25_0.01uM Dose=0.01uM, (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide, Bradykinin B2 Antagonists;Antiinflammatory Drugs targeting BDKRB2
KF-38-DH25_0.1uM Dose=0.1uM, (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide, Bradykinin B2 Antagonists;Antiinflammatory Drugs targeting BDKRB2
KF-38-DH25_10uM Dose=10uM, (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide, Bradykinin B2 Antagonists;Antiinflammatory Drugs targeting BDKRB2
KF-38-DH25_1uM Dose=1uM, (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide, Bradykinin B2 Antagonists;Antiinflammatory Drugs targeting BDKRB2
KF-70-DC09_0.01uM Dose=0.01uM, Methioprim, CDK Inhibitors targeting CCND2, CCND3
KF-70-DC09_0.1uM Dose=0.1uM, Methioprim, CDK Inhibitors targeting CCND2, CCND3
KF-70-DC09_10uM Dose=10uM, Methioprim, CDK Inhibitors targeting CCND2, CCND3
KF-73-PY04_0.01uM Dose=0.01uM, Gsk 932121, P. falciparum Cytochrome b-c1 Complex (Complex III subunit 3) Inhibitors;Electron Transport Chain Inhibitors targeting UQCRC1
KF-73-PY04_0.1uM Dose=0.1uM, Gsk 932121, P. falciparum Cytochrome b-c1 Complex (Complex III subunit 3) Inhibitors;Electron Transport Chain Inhibitors targeting UQCRC1
KF-73-PY04_10uM Dose=10uM, Gsk 932121, P. falciparum Cytochrome b-c1 Complex (Complex III subunit 3) Inhibitors;Electron Transport Chain Inhibitors targeting UQCRC1
LA-09-SS14_0.01uM Dose=0.01uM, Pcera-1, TNF-alpha Production Inhibitors;IL-10 Production Enhancers;cPLA2a activator targeting PLA2G4A
LA-09-SS14_0.1uM Dose=0.1uM, Pcera-1, TNF-alpha Production Inhibitors;IL-10 Production Enhancers;cPLA2a activator targeting PLA2G4A
LA-09-SS14_10uM Dose=10uM, Pcera-1, TNF-alpha Production Inhibitors;IL-10 Production Enhancers;cPLA2a activator targeting PLA2G4A
LA-09-SS14_1uM Dose=1uM, Pcera-1, TNF-alpha Production Inhibitors;IL-10 Production Enhancers;cPLA2a activator targeting PLA2G4A
LA-10-VZ79_0.01uM Dose=0.01uM, AZ-628, Raf kinase B Inhibitors;Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Raf kinase C Inhibitors targeting BRAF, RAF1
LA-10-VZ79_0.1uM Dose=0.1uM, AZ-628, Raf kinase B Inhibitors;Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Raf kinase C Inhibitors targeting BRAF, RAF1
LA-10-VZ79_10uM Dose=10uM, AZ-628, Raf kinase B Inhibitors;Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Raf kinase C Inhibitors targeting BRAF, RAF1
LA-10-VZ79_1uM Dose=1uM, AZ-628, Raf kinase B Inhibitors;Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Raf kinase C Inhibitors targeting BRAF, RAF1
LA-21-GQ75_0.01uM Dose=0.01uM, Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-, Prostacyclin agonist;PTGIR agonist targeting PTGIR
LA-21-GQ75_0.1uM Dose=0.1uM, Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-, Prostacyclin agonist;PTGIR agonist targeting PTGIR
LA-21-GQ75_10uM Dose=10uM, Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-, Prostacyclin agonist;PTGIR agonist targeting PTGIR
LA-21-GQ75_1uM Dose=1uM, Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-, Prostacyclin agonist;PTGIR agonist targeting PTGIR
LA-24-RZ79_0.1uM Dose=0.1uM, (2S,3R,4R,5S,6R)-2-[4-cyclopropyl-3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2
LA-24-RZ79_10uM Dose=10uM, (2S,3R,4R,5S,6R)-2-[4-cyclopropyl-3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2
LA-24-RZ79_1uM Dose=1uM, (2S,3R,4R,5S,6R)-2-[4-cyclopropyl-3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2
LA-25-VT07_0.01uM Dose=0.01uM, Dmxb-A, Nicotinic alpha7 Partial Agonists targeting CHRNA7
LA-25-VT07_0.1uM Dose=0.1uM, Dmxb-A, Nicotinic alpha7 Partial Agonists targeting CHRNA7
LA-25-VT07_10uM Dose=10uM, Dmxb-A, Nicotinic alpha7 Partial Agonists targeting CHRNA7
LA-25-VT07_1uM Dose=1uM, Dmxb-A, Nicotinic alpha7 Partial Agonists targeting CHRNA7
LA-27-FR67_0.01uM Dose=0.01uM, Acamprosate, mgluR);Drugs Acting on Glutamate Receptors (Metabotropic;NMDA Antagonists targeting GRIN2A, GRIN2B, GRM1
LA-27-FR67_0.1uM Dose=0.1uM, Acamprosate, mgluR);Drugs Acting on Glutamate Receptors (Metabotropic;NMDA Antagonists targeting GRIN2A, GRIN2B, GRM1
LA-27-FR67_10uM Dose=10uM, Acamprosate, mgluR);Drugs Acting on Glutamate Receptors (Metabotropic;NMDA Antagonists targeting GRIN2A, GRIN2B, GRM1
LA-27-FR67_1uM Dose=1uM, Acamprosate, mgluR);Drugs Acting on Glutamate Receptors (Metabotropic;NMDA Antagonists targeting GRIN2A, GRIN2B, GRM1
LA-31-YT57_0.01uM Dose=0.01uM, 9-Chloro-2-(2-fluorophenyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-ol, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG1, GABRG2, GABRG3
LA-31-YT57_0.1uM Dose=0.1uM, 9-Chloro-2-(2-fluorophenyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-ol, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG1, GABRG2, GABRG3
LA-31-YT57_10uM Dose=10uM, 9-Chloro-2-(2-fluorophenyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-ol, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG1, GABRG2, GABRG3
LA-31-YT57_1uM Dose=1uM, 9-Chloro-2-(2-fluorophenyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-ol, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG1, GABRG2, GABRG3
LA-36-XT39_0.01uM Dose=0.01uM, P-Toluenesulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type III Inhibitors targeting CA2, CA3
LA-36-XT39_10uM Dose=10uM, P-Toluenesulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type III Inhibitors targeting CA2, CA3
LA-36-XT39_1uM Dose=1uM, P-Toluenesulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type III Inhibitors targeting CA2, CA3
LA-42-CN75_0.01uM Dose=0.01uM, 5-[3-Hydroxy-7-[3-(2,3,4,5,6-pentafluorophenyl)propyl]naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
LA-42-CN75_0.1uM Dose=0.1uM, 5-[3-Hydroxy-7-[3-(2,3,4,5,6-pentafluorophenyl)propyl]naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
LA-42-CN75_10uM Dose=10uM, 5-[3-Hydroxy-7-[3-(2,3,4,5,6-pentafluorophenyl)propyl]naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
LA-42-CN75_1uM Dose=1uM, 5-[3-Hydroxy-7-[3-(2,3,4,5,6-pentafluorophenyl)propyl]naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
LA-42-ER00_0.01uM Dose=0.01uM, Arenobufagin, Arenobufagin, SMUT targeting PSMB1, PSMB2, PSMB5, ATP1B4
LA-42-ER00_0.1uM Dose=0.1uM, Arenobufagin, Arenobufagin, SMUT targeting PSMB1, PSMB2, PSMB5, ATP1B4
LA-42-ER00_10uM Dose=10uM, Arenobufagin, Arenobufagin, SMUT targeting PSMB1, PSMB2, PSMB5, ATP1B4
LA-42-ER00_1uM Dose=1uM, Arenobufagin, Arenobufagin, SMUT targeting PSMB1, PSMB2, PSMB5, ATP1B4
LA-44-KW22_0.01uM Dose=0.01uM, targeting GSK3B
LA-44-KW22_0.1uM Dose=0.1uM, targeting GSK3B
LA-44-KW22_10uM Dose=10uM, targeting GSK3B
LA-44-KW22_1uM Dose=1uM, targeting GSK3B
LA-57-ZX71_0.01uM Dose=0.01uM, Epz015666, PRMT5 gene inhibitor;SAM-cooperative (uncompetitive) inhibition of methyltransferase function;Epizyme SAM cooperative PRMT5 inhibitor (aka EPZ01566 / GSK3235025) targeting PRMT5
LA-57-ZX71_0.1uM Dose=0.1uM, Epz015666, PRMT5 gene inhibitor;SAM-cooperative (uncompetitive) inhibition of methyltransferase function;Epizyme SAM cooperative PRMT5 inhibitor (aka EPZ01566 / GSK3235025) targeting PRMT5
LA-57-ZX71_10uM Dose=10uM, Epz015666, PRMT5 gene inhibitor;SAM-cooperative (uncompetitive) inhibition of methyltransferase function;Epizyme SAM cooperative PRMT5 inhibitor (aka EPZ01566 / GSK3235025) targeting PRMT5
LA-57-ZX71_1uM Dose=1uM, Epz015666, PRMT5 gene inhibitor;SAM-cooperative (uncompetitive) inhibition of methyltransferase function;Epizyme SAM cooperative PRMT5 inhibitor (aka EPZ01566 / GSK3235025) targeting PRMT5
LA-66-RT74_0.01uM Dose=0.01uM, (4-Propan-2-ylphenyl)-[4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-yl]methanone, Parathyroid Hormone Secretion Stimulants targeting CASR
LA-66-RT74_0.1uM Dose=0.1uM, (4-Propan-2-ylphenyl)-[4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-yl]methanone, Parathyroid Hormone Secretion Stimulants targeting CASR
LA-66-RT74_10uM Dose=10uM, (4-Propan-2-ylphenyl)-[4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-yl]methanone, Parathyroid Hormone Secretion Stimulants targeting CASR
LA-66-RT74_1uM Dose=1uM, (4-Propan-2-ylphenyl)-[4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-yl]methanone, Parathyroid Hormone Secretion Stimulants targeting CASR
LA-69-OL77_0.01uM Dose=0.01uM, 5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one, NR2B Antagonists targeting GRIN2B
LA-69-OL77_0.1uM Dose=0.1uM, 5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one, NR2B Antagonists targeting GRIN2B
LA-69-OL77_10uM Dose=10uM, 5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one, NR2B Antagonists targeting GRIN2B
LA-86-XT29_0.01uM Dose=0.01uM, Ro 15-4513, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2
LA-86-XT29_0.1uM Dose=0.1uM, Ro 15-4513, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2
LA-86-XT29_10uM Dose=10uM, Ro 15-4513, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2
LA-86-XT29_1uM Dose=1uM, Ro 15-4513, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB2, GABRB3, GABRG2
LA-93-IR67_0.1uM Dose=0.1uM, N-(6-Tetradecanamidobenzo[d]thiazol-2-yl)benzamide, Ceramide Kinase Inhibitors targeting CERK
LA-93-IR67_10uM Dose=10uM, N-(6-Tetradecanamidobenzo[d]thiazol-2-yl)benzamide, Ceramide Kinase Inhibitors targeting CERK
LA-93-IR67_1uM Dose=1uM, N-(6-Tetradecanamidobenzo[d]thiazol-2-yl)benzamide, Ceramide Kinase Inhibitors targeting CERK
LA-96-VT14_0.01uM Dose=0.01uM
LA-96-VT14_10uM Dose=10uM
LA-96-VT14_1uM Dose=1uM
LA-99-FV41_0.01uM Dose=0.01uM, Dabigatran, Known Thrombin inhibitor targeting F2
LA-99-FV41_0.1uM Dose=0.1uM, Dabigatran, Known Thrombin inhibitor targeting F2
LA-99-FV41_10uM Dose=10uM, Dabigatran, Known Thrombin inhibitor targeting F2
LA-99-FV41_1uM Dose=1uM, Dabigatran, Known Thrombin inhibitor targeting F2
LB-00-NP55_0.01uM Dose=0.01uM, (2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-1-benzofuran-3-one, Sphingosine Kinase Inhibitors targeting SPHK2
LB-00-NP55_0.1uM Dose=0.1uM, (2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-1-benzofuran-3-one, Sphingosine Kinase Inhibitors targeting SPHK2
LB-00-NP55_10uM Dose=10uM, (2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-1-benzofuran-3-one, Sphingosine Kinase Inhibitors targeting SPHK2
LB-00-NP55_1uM Dose=1uM, (2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-1-benzofuran-3-one, Sphingosine Kinase Inhibitors targeting SPHK2
LB-03-JV32_0.01uM Dose=0.01uM, 1-carbamimidamido-N-(4-methylphenyl)methanimidamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
LB-03-JV32_10uM Dose=10uM, 1-carbamimidamido-N-(4-methylphenyl)methanimidamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
LB-03-JV32_1uM Dose=1uM, 1-carbamimidamido-N-(4-methylphenyl)methanimidamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
LB-03-WL18_0.01uM Dose=0.01uM, Larazotide, Zonulin Receptor Antagonists targeting HP
LB-03-WL18_10uM Dose=10uM, Larazotide, Zonulin Receptor Antagonists targeting HP
LB-03-WL18_1uM Dose=1uM, Larazotide, Zonulin Receptor Antagonists targeting HP
LB-04-KP05_0.01uM Dose=0.01uM, 1-Ethyl-2-benzimidazolinone, SK2 Potassium Channel Activators targeting KCNN2
LB-04-KP05_10uM Dose=10uM, 1-Ethyl-2-benzimidazolinone, SK2 Potassium Channel Activators targeting KCNN2
LB-04-KP05_1uM Dose=1uM, 1-Ethyl-2-benzimidazolinone, SK2 Potassium Channel Activators targeting KCNN2
LB-11-CG51_0.01uM Dose=0.01uM, Ibrutinib Racemate, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
LB-11-CG51_0.1uM Dose=0.1uM, Ibrutinib Racemate, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
LB-11-CG51_10uM Dose=10uM, Ibrutinib Racemate, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
LB-14-EI63_0.01uM Dose=0.01uM, Tolcapone, COMT Inhibitors targeting COMT
LB-14-EI63_0.1uM Dose=0.1uM, Tolcapone, COMT Inhibitors targeting COMT
LB-14-EI63_10uM Dose=10uM, Tolcapone, COMT Inhibitors targeting COMT
LB-14-EI63_1uM Dose=1uM, Tolcapone, COMT Inhibitors targeting COMT
LB-17-PD08_0.01uM Dose=0.01uM, Chromeno[4,3,2-de]phthalazin-3(2H)-one, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1
LB-17-PD08_0.1uM Dose=0.1uM, Chromeno[4,3,2-de]phthalazin-3(2H)-one, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1
LB-17-PD08_10uM Dose=10uM, Chromeno[4,3,2-de]phthalazin-3(2H)-one, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1
LB-17-PD08_1uM Dose=1uM, Chromeno[4,3,2-de]phthalazin-3(2H)-one, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1
LB-18-LH35_0.1uM Dose=0.1uM, Flobufen, Lipoxygenase Inhibitors;Leukotriene BLT (LTB4) Antagonists;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, LTB4R, PTGS1, PTGS2, LTB4R2
LB-18-LH35_10uM Dose=10uM, Flobufen, Lipoxygenase Inhibitors;Leukotriene BLT (LTB4) Antagonists;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, LTB4R, PTGS1, PTGS2, LTB4R2
LB-18-LH35_1uM Dose=1uM, Flobufen, Lipoxygenase Inhibitors;Leukotriene BLT (LTB4) Antagonists;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, LTB4R, PTGS1, PTGS2, LTB4R2
LB-24-DV44_0.01uM Dose=0.01uM
LB-24-DV44_0.1uM Dose=0.1uM
LB-24-DV44_10uM Dose=10uM
LB-24-DV44_1uM Dose=1uM
LB-24-KP05_0.01uM Dose=0.01uM, Oxalylglycine, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
LB-24-KP05_0.1uM Dose=0.1uM, Oxalylglycine, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
LB-24-KP05_10uM Dose=10uM, Oxalylglycine, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
LB-24-KP05_1uM Dose=1uM, Oxalylglycine, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
LB-49-UZ91_0.01uM Dose=0.01uM, 1-Methyl-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole
LB-49-UZ91_0.1uM Dose=0.1uM, 1-Methyl-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole
LB-49-UZ91_10uM Dose=10uM, 1-Methyl-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole
LB-49-UZ91_1uM Dose=1uM, 1-Methyl-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole
LB-54-MZ19_0.01uM Dose=0.01uM, Cetilistat, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Pancreatic Triacylglycerol Lipase Inhibitors targeting LIPC, LIPE, PNLIP, LIPG, LIPF
LB-54-MZ19_0.1uM Dose=0.1uM, Cetilistat, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Pancreatic Triacylglycerol Lipase Inhibitors targeting LIPC, LIPE, PNLIP, LIPG, LIPF
LB-54-MZ19_10uM Dose=10uM, Cetilistat, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Pancreatic Triacylglycerol Lipase Inhibitors targeting LIPC, LIPE, PNLIP, LIPG, LIPF
LB-55-UZ51_0.1uM Dose=0.1uM, Benzaldehyde semicarbazone
LB-55-UZ51_10uM Dose=10uM, Benzaldehyde semicarbazone
LB-58-KL25_0.01uM Dose=0.01uM, 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenylpiperidin-3-yl]amino]pyridazin-3-one, KAT2A, KAT2B inhibitor targeting KAT2A, KAT2B
LB-58-KL25_0.1uM Dose=0.1uM, 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenylpiperidin-3-yl]amino]pyridazin-3-one, KAT2A, KAT2B inhibitor targeting KAT2A, KAT2B
LB-58-KL25_10uM Dose=10uM, 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenylpiperidin-3-yl]amino]pyridazin-3-one, KAT2A, KAT2B inhibitor targeting KAT2A, KAT2B
LB-58-KL25_1uM Dose=1uM, 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenylpiperidin-3-yl]amino]pyridazin-3-one, KAT2A, KAT2B inhibitor targeting KAT2A, KAT2B
LB-58-WE43_0.01uM Dose=0.01uM, Laquinimod, Immunomodulator targeting AHR
LB-58-WE43_10uM Dose=10uM, Laquinimod, Immunomodulator targeting AHR
LB-58-WE43_1uM Dose=1uM, Laquinimod, Immunomodulator targeting AHR
LB-60-OF61_0.01uM Dose=0.01uM, CID 134692422
LB-60-OF61_0.1uM Dose=0.1uM, CID 134692422
LB-60-OF61_10uM Dose=10uM, CID 134692422
LB-60-OF61_1uM Dose=1uM, CID 134692422
LB-65-SM65_0.01uM Dose=0.01uM, Imd-0354, NF-kappaB (NFKB) Activation Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting IKBKB
LB-65-SM65_0.1uM Dose=0.1uM, Imd-0354, NF-kappaB (NFKB) Activation Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting IKBKB
LB-65-SM65_10uM Dose=10uM, Imd-0354, NF-kappaB (NFKB) Activation Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting IKBKB
LB-65-SM65_1uM Dose=1uM, Imd-0354, NF-kappaB (NFKB) Activation Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting IKBKB
LB-67-FA06_0.01uM Dose=0.01uM
LB-67-FA06_0.1uM Dose=0.1uM
LB-67-FA06_10uM Dose=10uM
LB-67-FA06_1uM Dose=1uM
LB-67-JK40_0.01uM Dose=0.01uM
LB-67-JK40_0.1uM Dose=0.1uM
LB-67-JK40_10uM Dose=10uM
LB-67-JK40_1uM Dose=1uM
LB-68-SH80_0.01uM Dose=0.01uM, (2S,4R)-1-acetyl-N-(1-(benzo[d]thiazol-2-yl)-5-guanidino-1-oxopentan-2-yl)-4-hydroxypyrrolidine-2-carboxamide, Trypsin Inhibitors;Tryptase Inhibitors targeting PRSS1, PRSS2, PRSS3, TPSAB1, TPSD1, TPSG1, TPSB2
LB-68-SH80_0.1uM Dose=0.1uM, (2S,4R)-1-acetyl-N-(1-(benzo[d]thiazol-2-yl)-5-guanidino-1-oxopentan-2-yl)-4-hydroxypyrrolidine-2-carboxamide, Trypsin Inhibitors;Tryptase Inhibitors targeting PRSS1, PRSS2, PRSS3, TPSAB1, TPSD1, TPSG1, TPSB2
LB-68-SH80_10uM Dose=10uM, (2S,4R)-1-acetyl-N-(1-(benzo[d]thiazol-2-yl)-5-guanidino-1-oxopentan-2-yl)-4-hydroxypyrrolidine-2-carboxamide, Trypsin Inhibitors;Tryptase Inhibitors targeting PRSS1, PRSS2, PRSS3, TPSAB1, TPSD1, TPSG1, TPSB2
LB-68-SH80_1uM Dose=1uM, (2S,4R)-1-acetyl-N-(1-(benzo[d]thiazol-2-yl)-5-guanidino-1-oxopentan-2-yl)-4-hydroxypyrrolidine-2-carboxamide, Trypsin Inhibitors;Tryptase Inhibitors targeting PRSS1, PRSS2, PRSS3, TPSAB1, TPSD1, TPSG1, TPSB2
LB-70-YM83_0.01uM Dose=0.01uM
LB-70-YM83_0.1uM Dose=0.1uM
LB-70-YM83_10uM Dose=10uM
LB-70-YM83_1uM Dose=1uM
LB-72-WN85_0.01uM Dose=0.01uM
LB-72-WN85_0.1uM Dose=0.1uM
LB-72-WN85_10uM Dose=10uM
LB-72-WN85_1uM Dose=1uM
LB-76-JJ80_0.01uM Dose=0.01uM, 1H-Isoindol-1-one, 2-[1-(3,3-diphenylpropyl)-4-piperidinyl]-2,3-dihydro-, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP
LB-76-JJ80_0.1uM Dose=0.1uM, 1H-Isoindol-1-one, 2-[1-(3,3-diphenylpropyl)-4-piperidinyl]-2,3-dihydro-, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP
LB-76-JJ80_10uM Dose=10uM, 1H-Isoindol-1-one, 2-[1-(3,3-diphenylpropyl)-4-piperidinyl]-2,3-dihydro-, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP
LB-76-JJ80_1uM Dose=1uM, 1H-Isoindol-1-one, 2-[1-(3,3-diphenylpropyl)-4-piperidinyl]-2,3-dihydro-, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP
LB-90-DC89_0.01uM Dose=0.01uM, (S)-Albuterol
LB-90-DC89_0.1uM Dose=0.1uM, (S)-Albuterol
LB-90-DC89_10uM Dose=10uM, (S)-Albuterol
LB-90-DC89_1uM Dose=1uM, (S)-Albuterol
LC-03-KY64_0.01uM Dose=0.01uM, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[4-isopropyl-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-phenyl]-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2
LC-03-KY64_0.1uM Dose=0.1uM, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[4-isopropyl-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-phenyl]-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2
LC-03-KY64_10uM Dose=10uM, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[4-isopropyl-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-phenyl]-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2
LC-03-KY64_1uM Dose=1uM, (2R,3S,4R,5R,6S)-2-Hydroxymethyl-6-[4-isopropyl-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-phenyl]-tetrahydro-pyran-3,4,5-triol, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A2
LC-05-JF28_0.01uM Dose=0.01uM, Obelin, Somatostatin SRIF2A (sst1) Antagonists targeting SSTR1
LC-05-JF28_0.1uM Dose=0.1uM, Obelin, Somatostatin SRIF2A (sst1) Antagonists targeting SSTR1
LC-05-JF28_10uM Dose=10uM, Obelin, Somatostatin SRIF2A (sst1) Antagonists targeting SSTR1
LC-05-JF28_1uM Dose=1uM, Obelin, Somatostatin SRIF2A (sst1) Antagonists targeting SSTR1
LC-11-GG16_0.01uM Dose=0.01uM
LC-11-GG16_0.1uM Dose=0.1uM
LC-11-GG16_10uM Dose=10uM
LC-11-GG16_1uM Dose=1uM
LC-11-KD29_0.01uM Dose=0.01uM, 1,4-Dimethylpyridinium
LC-11-KD29_0.1uM Dose=0.1uM, 1,4-Dimethylpyridinium
LC-11-KD29_10uM Dose=10uM, 1,4-Dimethylpyridinium
LC-11-KD29_1uM Dose=1uM, 1,4-Dimethylpyridinium
LC-12-VN85_0.01uM Dose=0.01uM, (E)-N-hydroxy-3-[4-[(3-phenylpropylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
LC-12-VN85_0.1uM Dose=0.1uM, (E)-N-hydroxy-3-[4-[(3-phenylpropylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
LC-12-VN85_10uM Dose=10uM, (E)-N-hydroxy-3-[4-[(3-phenylpropylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
LC-12-VN85_1uM Dose=1uM, (E)-N-hydroxy-3-[4-[(3-phenylpropylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
LC-19-SF48_0.01uM Dose=0.01uM, N-[5-(Adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin, Glucosylceramidase inhibitor targeting GBA2
LC-19-SF48_0.1uM Dose=0.1uM, N-[5-(Adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin, Glucosylceramidase inhibitor targeting GBA2
LC-19-SF48_10uM Dose=10uM, N-[5-(Adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin, Glucosylceramidase inhibitor targeting GBA2
LC-19-SF48_1uM Dose=1uM, N-[5-(Adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin, Glucosylceramidase inhibitor targeting GBA2
LC-20-LZ39_0.01uM Dose=0.01uM, 2,4-Dichlorobenzyl carbamimidothioate, Angiogenesis Inhibitors;MreB Polymerization Inhibitors targeting IDO1
LC-20-LZ39_0.1uM Dose=0.1uM, 2,4-Dichlorobenzyl carbamimidothioate, Angiogenesis Inhibitors;MreB Polymerization Inhibitors targeting IDO1
LC-20-LZ39_10uM Dose=10uM, 2,4-Dichlorobenzyl carbamimidothioate, Angiogenesis Inhibitors;MreB Polymerization Inhibitors targeting IDO1
LC-20-LZ39_1uM Dose=1uM, 2,4-Dichlorobenzyl carbamimidothioate, Angiogenesis Inhibitors;MreB Polymerization Inhibitors targeting IDO1
LC-21-LG46_0.01uM Dose=0.01uM
LC-21-LG46_0.1uM Dose=0.1uM
LC-21-LG46_10uM Dose=10uM
LC-21-LG46_1uM Dose=1uM
LC-40-KC29_0.01uM Dose=0.01uM
LC-40-KC29_0.1uM Dose=0.1uM
LC-40-KC29_10uM Dose=10uM
LC-40-KC29_1uM Dose=1uM
LC-42-WU67_0.01uM Dose=0.01uM, Acadesine, AMP activated protein kinase stimulator;AMPK Activator targeting PRKAG1, PRKAG2, PRKAG3
LC-42-WU67_0.1uM Dose=0.1uM, Acadesine, AMP activated protein kinase stimulator;AMPK Activator targeting PRKAG1, PRKAG2, PRKAG3
LC-42-WU67_10uM Dose=10uM, Acadesine, AMP activated protein kinase stimulator;AMPK Activator targeting PRKAG1, PRKAG2, PRKAG3
LC-42-WU67_1uM Dose=1uM, Acadesine, AMP activated protein kinase stimulator;AMPK Activator targeting PRKAG1, PRKAG2, PRKAG3
LC-43-SE41_0.01uM Dose=0.01uM, PRX-08066 free base, 5-HT2B Antagonists targeting HTR2B
LC-43-SE41_0.1uM Dose=0.1uM, PRX-08066 free base, 5-HT2B Antagonists targeting HTR2B
LC-43-SE41_10uM Dose=10uM, PRX-08066 free base, 5-HT2B Antagonists targeting HTR2B
LC-43-SE41_1uM Dose=1uM, PRX-08066 free base, 5-HT2B Antagonists targeting HTR2B
LC-54-XS57_0.01uM Dose=0.01uM
LC-54-XS57_0.1uM Dose=0.1uM
LC-54-XS57_10uM Dose=10uM
LC-54-XS57_1uM Dose=1uM
LC-57-RH78_0.01uM Dose=0.01uM, K(ATP) Channel Blockers targeting ABCC8, ABCC9, KCNJ8, KCNJ11
LC-57-RH78_0.1uM Dose=0.1uM, K(ATP) Channel Blockers targeting ABCC8, ABCC9, KCNJ8, KCNJ11
LC-57-RH78_10uM Dose=10uM, K(ATP) Channel Blockers targeting ABCC8, ABCC9, KCNJ8, KCNJ11
LC-57-RH78_1uM Dose=1uM, K(ATP) Channel Blockers targeting ABCC8, ABCC9, KCNJ8, KCNJ11
LC-62-AU42_0.01uM Dose=0.01uM
LC-62-AU42_0.1uM Dose=0.1uM
LC-62-AU42_10uM Dose=10uM
LC-62-AU42_1uM Dose=1uM
LC-78-EV09_0.01uM Dose=0.01uM
LC-78-EV09_0.1uM Dose=0.1uM
LC-78-EV09_10uM Dose=10uM
LC-78-EV09_1uM Dose=1uM
LC-83-NR62_0.01uM Dose=0.01uM, (3R)-N~2~-(cyclopropylmethyl)-N~1~-hydroxy-3-(3-hydroxybenzyl)-N~4~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-L-aspartamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5
LC-83-NR62_10uM Dose=10uM, (3R)-N~2~-(cyclopropylmethyl)-N~1~-hydroxy-3-(3-hydroxybenzyl)-N~4~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-L-aspartamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5
LC-83-NR62_1uM Dose=1uM, (3R)-N~2~-(cyclopropylmethyl)-N~1~-hydroxy-3-(3-hydroxybenzyl)-N~4~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-L-aspartamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5
LC-96-WR85_0.01uM Dose=0.01uM, Asn04885796, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17
LC-96-WR85_0.1uM Dose=0.1uM, Asn04885796, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17
LC-96-WR85_10uM Dose=10uM, Asn04885796, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17
LC-96-WR85_1uM Dose=1uM, Asn04885796, UDP/CysLT Receptor (GPR17, P2Y-like) Modulators targeting GPR17
LD-00-HM58_0.01uM Dose=0.01uM, 5-[2,3-Bis(Chloranyl)phenyl]-2-[(3~{r},5~{s})-3,5-Dimethylpiperazin-1-Yl]pyrimidin-4-Amine, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A
LD-00-HM58_0.1uM Dose=0.1uM, 5-[2,3-Bis(Chloranyl)phenyl]-2-[(3~{r},5~{s})-3,5-Dimethylpiperazin-1-Yl]pyrimidin-4-Amine, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A
LD-00-HM58_10uM Dose=10uM, 5-[2,3-Bis(Chloranyl)phenyl]-2-[(3~{r},5~{s})-3,5-Dimethylpiperazin-1-Yl]pyrimidin-4-Amine, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A
LD-00-HM58_1uM Dose=1uM, 5-[2,3-Bis(Chloranyl)phenyl]-2-[(3~{r},5~{s})-3,5-Dimethylpiperazin-1-Yl]pyrimidin-4-Amine, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A
LD-12-GA99_0.01uM Dose=0.01uM, Diacetyldiphenylurea bisguanylhydrazone, Ribonuclease P Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2
LD-12-GA99_0.1uM Dose=0.1uM, Diacetyldiphenylurea bisguanylhydrazone, Ribonuclease P Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2
LD-12-GA99_10uM Dose=10uM, Diacetyldiphenylurea bisguanylhydrazone, Ribonuclease P Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2
LD-12-GA99_1uM Dose=1uM, Diacetyldiphenylurea bisguanylhydrazone, Ribonuclease P Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2
LD-14-PB06_0.01uM Dose=0.01uM, 1-phenyl-8-(3-piperazin-1-yl-phenyl)-1H-imidazo[4,5-c]quinoline, RET inhibitor targeting RET
LD-14-PB06_0.1uM Dose=0.1uM, 1-phenyl-8-(3-piperazin-1-yl-phenyl)-1H-imidazo[4,5-c]quinoline, RET inhibitor targeting RET
LD-14-PB06_10uM Dose=10uM, 1-phenyl-8-(3-piperazin-1-yl-phenyl)-1H-imidazo[4,5-c]quinoline, RET inhibitor targeting RET
LD-14-PB06_1uM Dose=1uM, 1-phenyl-8-(3-piperazin-1-yl-phenyl)-1H-imidazo[4,5-c]quinoline, RET inhibitor targeting RET
LD-22-SA99_0.01uM Dose=0.01uM, (S)-Crizotinib, ALK gene inhibitor,ROS1 gene inhibitor, MET gene inhibitor, NUDT1 gene inhibitor;NUDT1 gene inhibitor targeting NUDT1
LD-22-SA99_10uM Dose=10uM, (S)-Crizotinib, ALK gene inhibitor,ROS1 gene inhibitor, MET gene inhibitor, NUDT1 gene inhibitor;NUDT1 gene inhibitor targeting NUDT1
LD-22-SA99_1uM Dose=1uM, (S)-Crizotinib, ALK gene inhibitor,ROS1 gene inhibitor, MET gene inhibitor, NUDT1 gene inhibitor;NUDT1 gene inhibitor targeting NUDT1
LD-23-UR32_0.01uM Dose=0.01uM, (2R)-[[4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]methyl]-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol
LD-23-UR32_1uM Dose=1uM, (2R)-[[4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]methyl]-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol
LD-30-MF71_0.01uM Dose=0.01uM
LD-30-MF71_0.1uM Dose=0.1uM
LD-30-MF71_10uM Dose=10uM
LD-30-MF71_1uM Dose=1uM
LD-36-DG33_0.1uM Dose=0.1uM
LD-36-DG33_10uM Dose=10uM
LD-36-DG33_1uM Dose=1uM
LD-37-JE11_0.01uM Dose=0.01uM, SR7826, Limk1 inhibitor targeting LIMK1
LD-37-JE11_0.1uM Dose=0.1uM, SR7826, Limk1 inhibitor targeting LIMK1
LD-37-JE11_10uM Dose=10uM, SR7826, Limk1 inhibitor targeting LIMK1
LD-37-JE11_1uM Dose=1uM, SR7826, Limk1 inhibitor targeting LIMK1
LD-37-KX01_0.01uM Dose=0.01uM, PPARalpha Agonists
LD-37-KX01_0.1uM Dose=0.1uM, PPARalpha Agonists
LD-39-FL02_0.01uM Dose=0.01uM, (8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside
LD-39-FL02_0.1uM Dose=0.1uM, (8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside
LD-39-FL02_10uM Dose=10uM, (8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside
LD-39-FL02_1uM Dose=1uM, (8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside
LD-47-RN92_0.01uM Dose=0.01uM, 1-(3,3-Dimethylbutyl)-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
LD-47-RN92_0.1uM Dose=0.1uM, 1-(3,3-Dimethylbutyl)-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
LD-47-RN92_10uM Dose=10uM, 1-(3,3-Dimethylbutyl)-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
LD-47-RN92_1uM Dose=1uM, 1-(3,3-Dimethylbutyl)-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR
LD-48-CY61_0.01uM Dose=0.01uM, 4,6-Dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide, Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI2, ORAI1, ORAI3
LD-48-CY61_0.1uM Dose=0.1uM, 4,6-Dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide, Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI2, ORAI1, ORAI3
LD-48-CY61_10uM Dose=10uM, 4,6-Dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide, Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI2, ORAI1, ORAI3
LD-48-CY61_1uM Dose=1uM, 4,6-Dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide, Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI2, ORAI1, ORAI3
LD-50-SF36_0.01uM Dose=0.01uM, Ro64-5229, GRM2 antagonist targeting GRM2
LD-50-SF36_0.1uM Dose=0.1uM, Ro64-5229, GRM2 antagonist targeting GRM2
LD-50-SF36_10uM Dose=10uM, Ro64-5229, GRM2 antagonist targeting GRM2
LD-50-SF36_1uM Dose=1uM, Ro64-5229, GRM2 antagonist targeting GRM2
LD-67-CX31_10uM Dose=10uM, 4-(3-(Benzotriazol-1-yl)propyl)-1-(2-methoxyphenyl)piperazine, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A
LD-67-CX31_1uM Dose=1uM, 4-(3-(Benzotriazol-1-yl)propyl)-1-(2-methoxyphenyl)piperazine, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A
LD-69-TV81_0.01uM Dose=0.01uM, 7-[3-(4-Acetyl-2-ethyl-5-hydroxy-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
LD-69-TV81_0.1uM Dose=0.1uM, 7-[3-(4-Acetyl-2-ethyl-5-hydroxy-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
LD-69-TV81_1uM Dose=1uM, 7-[3-(4-Acetyl-2-ethyl-5-hydroxy-phenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2
LD-69-ZV56_0.01uM Dose=0.01uM, 11-Desethyl Irinotecan
LD-69-ZV56_0.1uM Dose=0.1uM, 11-Desethyl Irinotecan
LD-69-ZV56_10uM Dose=10uM, 11-Desethyl Irinotecan
LD-69-ZV56_1uM Dose=1uM, 11-Desethyl Irinotecan
LD-96-DG13_0.1uM Dose=0.1uM, Tcs OX2 29, HCRTR2 antagonist;Orexin OX-2 Antagonists targeting HCRTR2
LD-96-DG13_10uM Dose=10uM, Tcs OX2 29, HCRTR2 antagonist;Orexin OX-2 Antagonists targeting HCRTR2
LD-96-DG13_1uM Dose=1uM, Tcs OX2 29, HCRTR2 antagonist;Orexin OX-2 Antagonists targeting HCRTR2
LD-98-CY91_0.01uM Dose=0.01uM, 2-(4-Chlorophenoxy)-N-(2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl)acetamide, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Ligands targeting MCHR1
LD-98-CY91_0.1uM Dose=0.1uM, 2-(4-Chlorophenoxy)-N-(2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl)acetamide, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Ligands targeting MCHR1
LD-98-CY91_10uM Dose=10uM, 2-(4-Chlorophenoxy)-N-(2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl)acetamide, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Ligands targeting MCHR1
LD-98-VO32_0.01uM Dose=0.01uM, Gsk2830371, WIP1 inhibitor targeting PPM1D
LD-98-VO32_0.1uM Dose=0.1uM, Gsk2830371, WIP1 inhibitor targeting PPM1D
LD-98-VO32_10uM Dose=10uM, Gsk2830371, WIP1 inhibitor targeting PPM1D
LD-98-VO32_1uM Dose=1uM, Gsk2830371, WIP1 inhibitor targeting PPM1D
LE-01-MT37_0.1uM Dose=0.1uM, N-[5-[[6-(2-hydroxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide, CDK1/2 inhibitor targeting CCNA1
LE-01-MT37_10uM Dose=10uM, N-[5-[[6-(2-hydroxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide, CDK1/2 inhibitor targeting CCNA1
LE-01-MT37_1uM Dose=1uM, N-[5-[[6-(2-hydroxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide, CDK1/2 inhibitor targeting CCNA1
LE-08-BO67_0.01uM Dose=0.01uM, 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide, Muscarinic M5 receptor antagonist targeting CHRM5
LE-08-BO67_0.1uM Dose=0.1uM, 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide, Muscarinic M5 receptor antagonist targeting CHRM5
LE-08-BO67_10uM Dose=10uM, 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide, Muscarinic M5 receptor antagonist targeting CHRM5
LE-08-BO67_1uM Dose=1uM, 2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide, Muscarinic M5 receptor antagonist targeting CHRM5
LE-31-QT97_0.01uM Dose=0.01uM, N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide, Melatonin Antagonists targeting MTNR1B, MTNR1A
LE-31-QT97_0.1uM Dose=0.1uM, N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide, Melatonin Antagonists targeting MTNR1B, MTNR1A
LE-31-QT97_10uM Dose=10uM, N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide, Melatonin Antagonists targeting MTNR1B, MTNR1A
LE-31-QT97_1uM Dose=1uM, N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide, Melatonin Antagonists targeting MTNR1B, MTNR1A
LE-33-GL18_0.01uM Dose=0.01uM, 3-(4-Tert-butylbenzenesulfonamido)thiophene-2-carboxylic acid, Chemokine CCR9 Receptor Antagonists targeting CCR9
LE-33-GL18_0.1uM Dose=0.1uM, 3-(4-Tert-butylbenzenesulfonamido)thiophene-2-carboxylic acid, Chemokine CCR9 Receptor Antagonists targeting CCR9
LE-33-GL18_10uM Dose=10uM, 3-(4-Tert-butylbenzenesulfonamido)thiophene-2-carboxylic acid, Chemokine CCR9 Receptor Antagonists targeting CCR9
LE-33-GL18_1uM Dose=1uM, 3-(4-Tert-butylbenzenesulfonamido)thiophene-2-carboxylic acid, Chemokine CCR9 Receptor Antagonists targeting CCR9
LE-39-LB33_0.01uM Dose=0.01uM, Chlorothiazide, SLC12A3 inhibitor;CA4 inhibitor;CA1 inhibitor;CA2 inhibitor targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, SLC12A3, CA5B, CA10
LE-39-LB33_0.1uM Dose=0.1uM, Chlorothiazide, SLC12A3 inhibitor;CA4 inhibitor;CA1 inhibitor;CA2 inhibitor targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, SLC12A3, CA5B, CA10
LE-39-LB33_10uM Dose=10uM, Chlorothiazide, SLC12A3 inhibitor;CA4 inhibitor;CA1 inhibitor;CA2 inhibitor targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, SLC12A3, CA5B, CA10
LE-39-LB33_1uM Dose=1uM, Chlorothiazide, SLC12A3 inhibitor;CA4 inhibitor;CA1 inhibitor;CA2 inhibitor targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, SLC12A3, CA5B, CA10
LE-40-JW92_0.01uM Dose=0.01uM
LE-40-JW92_0.1uM Dose=0.1uM
LE-40-JW92_10uM Dose=10uM
LE-40-JW92_1uM Dose=1uM
LE-41-QT17_0.01uM Dose=0.01uM, 2,2-dimethyl-5-(morpholin-4-yl)-N-(pyridin-3-ylmethyl)-1,4-dihydro-2H-pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-8-amine, Phosphodiesterase PDE4D Inhibitors;Phosphodiesterase PDE4B Inhibitors;Phosphodiesterase PDE4A Inhibitors targeting PDE4A, PDE4B, PDE4D
LE-41-QT17_0.1uM Dose=0.1uM, 2,2-dimethyl-5-(morpholin-4-yl)-N-(pyridin-3-ylmethyl)-1,4-dihydro-2H-pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-8-amine, Phosphodiesterase PDE4D Inhibitors;Phosphodiesterase PDE4B Inhibitors;Phosphodiesterase PDE4A Inhibitors targeting PDE4A, PDE4B, PDE4D
LE-41-QT17_10uM Dose=10uM, 2,2-dimethyl-5-(morpholin-4-yl)-N-(pyridin-3-ylmethyl)-1,4-dihydro-2H-pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-8-amine, Phosphodiesterase PDE4D Inhibitors;Phosphodiesterase PDE4B Inhibitors;Phosphodiesterase PDE4A Inhibitors targeting PDE4A, PDE4B, PDE4D
LE-41-QT17_1uM Dose=1uM, 2,2-dimethyl-5-(morpholin-4-yl)-N-(pyridin-3-ylmethyl)-1,4-dihydro-2H-pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-8-amine, Phosphodiesterase PDE4D Inhibitors;Phosphodiesterase PDE4B Inhibitors;Phosphodiesterase PDE4A Inhibitors targeting PDE4A, PDE4B, PDE4D
LE-43-AR77_0.01uM Dose=0.01uM, N-hydroxy-4-phenylbutanamide
LE-43-AR77_0.1uM Dose=0.1uM, N-hydroxy-4-phenylbutanamide
LE-43-AR77_10uM Dose=10uM, N-hydroxy-4-phenylbutanamide
LE-43-AR77_1uM Dose=1uM, N-hydroxy-4-phenylbutanamide
LE-48-SO37_0.01uM Dose=0.01uM, 4-[(3-chlorophenyl)methoxy]-1-methyl-5-pyridin-3-yl-3H-indol-2-one
LE-48-SO37_0.1uM Dose=0.1uM, 4-[(3-chlorophenyl)methoxy]-1-methyl-5-pyridin-3-yl-3H-indol-2-one
LE-48-SO37_10uM Dose=10uM, 4-[(3-chlorophenyl)methoxy]-1-methyl-5-pyridin-3-yl-3H-indol-2-one
LE-48-SO37_1uM Dose=1uM, 4-[(3-chlorophenyl)methoxy]-1-methyl-5-pyridin-3-yl-3H-indol-2-one
LE-50-AP60_0.01uM Dose=0.01uM
LE-50-AP60_0.1uM Dose=0.1uM
LE-50-AP60_10uM Dose=10uM
LE-50-AP60_1uM Dose=1uM
LE-50-NZ39_0.01uM Dose=0.01uM
LE-50-NZ39_0.1uM Dose=0.1uM
LE-50-NZ39_10uM Dose=10uM
LE-50-NZ39_1uM Dose=1uM
LE-55-RW34_0.01uM Dose=0.01uM, [(E)-[9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-ylidene]amino] 5-bromothiophene-2-carboxylate, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TNF-alpha Production Inhibitors targeting PTGS1, PTGS2
LE-55-RW34_0.1uM Dose=0.1uM, [(E)-[9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-ylidene]amino] 5-bromothiophene-2-carboxylate, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TNF-alpha Production Inhibitors targeting PTGS1, PTGS2
LE-55-RW34_10uM Dose=10uM, [(E)-[9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-ylidene]amino] 5-bromothiophene-2-carboxylate, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TNF-alpha Production Inhibitors targeting PTGS1, PTGS2
LE-55-RW34_1uM Dose=1uM, [(E)-[9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-ylidene]amino] 5-bromothiophene-2-carboxylate, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TNF-alpha Production Inhibitors targeting PTGS1, PTGS2
LE-60-VC29_0.01uM Dose=0.01uM, N-(2,4-dichlorobenzyl)-1-benzyl-5-oxopyrrolidine-3-carboxamide, P2X7 Receptor Antagonists targeting P2RX7
LE-60-VC29_0.1uM Dose=0.1uM, N-(2,4-dichlorobenzyl)-1-benzyl-5-oxopyrrolidine-3-carboxamide, P2X7 Receptor Antagonists targeting P2RX7
LE-60-VC29_10uM Dose=10uM, N-(2,4-dichlorobenzyl)-1-benzyl-5-oxopyrrolidine-3-carboxamide, P2X7 Receptor Antagonists targeting P2RX7
LE-60-VC29_1uM Dose=1uM, N-(2,4-dichlorobenzyl)-1-benzyl-5-oxopyrrolidine-3-carboxamide, P2X7 Receptor Antagonists targeting P2RX7
LE-65-RW44_0.01uM Dose=0.01uM, (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Agonists targeting FFAR2, FFAR3
LE-65-RW44_0.1uM Dose=0.1uM, (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Agonists targeting FFAR2, FFAR3
LE-65-RW44_10uM Dose=10uM, (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Agonists targeting FFAR2, FFAR3
LE-65-RW44_1uM Dose=1uM, (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Agonists targeting FFAR2, FFAR3
LE-80-BM08_0.01uM Dose=0.01uM, CID 10481388 targeting ACAT2
LE-80-BM08_0.1uM Dose=0.1uM, CID 10481388 targeting ACAT2
LE-80-BM08_10uM Dose=10uM, CID 10481388 targeting ACAT2
LE-80-BM08_1uM Dose=1uM, CID 10481388 targeting ACAT2
LE-80-QM43_0.01uM Dose=0.01uM, Bz(4-Br)-Phe-Val-Tyr-Lys(Me3)-Ser-Glu-NH2, CBX6 inhibitor targeting CBX6
LE-80-QM43_0.1uM Dose=0.1uM, Bz(4-Br)-Phe-Val-Tyr-Lys(Me3)-Ser-Glu-NH2, CBX6 inhibitor targeting CBX6
LE-80-QM43_10uM Dose=10uM, Bz(4-Br)-Phe-Val-Tyr-Lys(Me3)-Ser-Glu-NH2, CBX6 inhibitor targeting CBX6
LE-80-QM43_1uM Dose=1uM, Bz(4-Br)-Phe-Val-Tyr-Lys(Me3)-Ser-Glu-NH2, CBX6 inhibitor targeting CBX6
LE-81-PG11_0.01uM Dose=0.01uM, N-Methyl-N-((2-(1-(2-(methylamino)ethyl)piperidin-4-yl)pyridin-4-yl)methyl)-3-phenoxybenzamide, inhibitor of PRMT4 targeting CARM1
LE-81-PG11_0.1uM Dose=0.1uM, N-Methyl-N-((2-(1-(2-(methylamino)ethyl)piperidin-4-yl)pyridin-4-yl)methyl)-3-phenoxybenzamide, inhibitor of PRMT4 targeting CARM1
LE-81-PG11_10uM Dose=10uM, N-Methyl-N-((2-(1-(2-(methylamino)ethyl)piperidin-4-yl)pyridin-4-yl)methyl)-3-phenoxybenzamide, inhibitor of PRMT4 targeting CARM1
LE-81-PG11_1uM Dose=1uM, N-Methyl-N-((2-(1-(2-(methylamino)ethyl)piperidin-4-yl)pyridin-4-yl)methyl)-3-phenoxybenzamide, inhibitor of PRMT4 targeting CARM1
LE-83-PR92_0.01uM Dose=0.01uM
LE-83-PR92_0.1uM Dose=0.1uM
LE-83-PR92_10uM Dose=10uM
LE-83-PR92_1uM Dose=1uM
LE-94-HL75_0.01uM Dose=0.01uM, 10,25-Dimethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol, nicotinic acetylcholine receptor antagonist;Relaxant targeting CHRNA2
LE-94-HL75_0.1uM Dose=0.1uM, 10,25-Dimethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol, nicotinic acetylcholine receptor antagonist;Relaxant targeting CHRNA2
LE-94-HL75_10uM Dose=10uM, 10,25-Dimethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol, nicotinic acetylcholine receptor antagonist;Relaxant targeting CHRNA2
LE-94-HL75_1uM Dose=1uM, 10,25-Dimethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol, nicotinic acetylcholine receptor antagonist;Relaxant targeting CHRNA2
LF-14-KL05_0.01uM Dose=0.01uM, 1-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamine, Urotensin II receptor inhibitor targeting UTS2R
LF-14-KL05_0.1uM Dose=0.1uM, 1-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamine, Urotensin II receptor inhibitor targeting UTS2R
LF-14-KL05_10uM Dose=10uM, 1-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamine, Urotensin II receptor inhibitor targeting UTS2R
LF-14-KL05_1uM Dose=1uM, 1-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamine, Urotensin II receptor inhibitor targeting UTS2R
LF-18-HE58_0.01uM Dose=0.01uM
LF-18-HE58_0.1uM Dose=0.1uM
LF-18-HE58_10uM Dose=10uM
LF-18-HE58_1uM Dose=1uM
LF-27-NX16_0.01uM Dose=0.01uM, Olitigaltin, Galectin-3 inhibitor;Galectin 3 Inhibitors targeting LGALS3
LF-27-NX16_0.1uM Dose=0.1uM, Olitigaltin, Galectin-3 inhibitor;Galectin 3 Inhibitors targeting LGALS3
LF-27-NX16_10uM Dose=10uM, Olitigaltin, Galectin-3 inhibitor;Galectin 3 Inhibitors targeting LGALS3
LF-30-FP85_0.01uM Dose=0.01uM, 2-Chloro-5-[3-(5-chloro-2-methoxy-pyridin-4-yl)-1h-indole-6-carbonyl]-benzenesulfonamide
LF-30-FP85_0.1uM Dose=0.1uM, 2-Chloro-5-[3-(5-chloro-2-methoxy-pyridin-4-yl)-1h-indole-6-carbonyl]-benzenesulfonamide
LF-30-FP85_10uM Dose=10uM, 2-Chloro-5-[3-(5-chloro-2-methoxy-pyridin-4-yl)-1h-indole-6-carbonyl]-benzenesulfonamide
LF-30-FP85_1uM Dose=1uM, 2-Chloro-5-[3-(5-chloro-2-methoxy-pyridin-4-yl)-1h-indole-6-carbonyl]-benzenesulfonamide
LF-33-KO15_0.01uM Dose=0.01uM, 9-Isopropyl-N-[3-(trifluoromethyl)benzyl]-9H-purin-6-amine, Casein kinase-I alpha inhibitor;Casein kinase-I delta inhibitor targeting CSNK1A1, CSNK1D
LF-33-KO15_0.1uM Dose=0.1uM, 9-Isopropyl-N-[3-(trifluoromethyl)benzyl]-9H-purin-6-amine, Casein kinase-I alpha inhibitor;Casein kinase-I delta inhibitor targeting CSNK1A1, CSNK1D
LF-33-KO15_10uM Dose=10uM, 9-Isopropyl-N-[3-(trifluoromethyl)benzyl]-9H-purin-6-amine, Casein kinase-I alpha inhibitor;Casein kinase-I delta inhibitor targeting CSNK1A1, CSNK1D
LF-33-KO15_1uM Dose=1uM, 9-Isopropyl-N-[3-(trifluoromethyl)benzyl]-9H-purin-6-amine, Casein kinase-I alpha inhibitor;Casein kinase-I delta inhibitor targeting CSNK1A1, CSNK1D
LF-35-CP32_0.01uM Dose=0.01uM, Adinazolam, Peripheral-type benzodiazepine receptors potentiator targeting TSPO
LF-35-CP32_0.1uM Dose=0.1uM, Adinazolam, Peripheral-type benzodiazepine receptors potentiator targeting TSPO
LF-35-CP32_10uM Dose=10uM, Adinazolam, Peripheral-type benzodiazepine receptors potentiator targeting TSPO
LF-35-CP32_1uM Dose=1uM, Adinazolam, Peripheral-type benzodiazepine receptors potentiator targeting TSPO
LF-37-AX51_0.01uM Dose=0.01uM, 2'-Hydroxy-4'-Methoxychalcone
LF-37-AX51_0.1uM Dose=0.1uM, 2'-Hydroxy-4'-Methoxychalcone
LF-37-AX51_10uM Dose=10uM, 2'-Hydroxy-4'-Methoxychalcone
LF-37-AX51_1uM Dose=1uM, 2'-Hydroxy-4'-Methoxychalcone
LF-45-MW04_0.01uM Dose=0.01uM, SB-408124, Orexin 1 receptor antagonist targeting HCRTR1
LF-45-MW04_0.1uM Dose=0.1uM, SB-408124, Orexin 1 receptor antagonist targeting HCRTR1
LF-45-MW04_10uM Dose=10uM, SB-408124, Orexin 1 receptor antagonist targeting HCRTR1
LF-45-MW04_1uM Dose=1uM, SB-408124, Orexin 1 receptor antagonist targeting HCRTR1
LF-50-IZ49_0.01uM Dose=0.01uM, Alendronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors;Protein Tyrosine Phosphatase (PTP) Inhibitors targeting FDPS, FDFT1
LF-50-IZ49_0.1uM Dose=0.1uM, Alendronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors;Protein Tyrosine Phosphatase (PTP) Inhibitors targeting FDPS, FDFT1
LF-50-IZ49_10uM Dose=10uM, Alendronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors;Protein Tyrosine Phosphatase (PTP) Inhibitors targeting FDPS, FDFT1
LF-50-IZ49_1uM Dose=1uM, Alendronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors;Protein Tyrosine Phosphatase (PTP) Inhibitors targeting FDPS, FDFT1
LF-56-QX74_0.01uM Dose=0.01uM, 4-Heptyloxyphenol, steroidogenic factor inhibitor targeting NR5A1
LF-56-QX74_0.1uM Dose=0.1uM, 4-Heptyloxyphenol, steroidogenic factor inhibitor targeting NR5A1
LF-56-QX74_10uM Dose=10uM, 4-Heptyloxyphenol, steroidogenic factor inhibitor targeting NR5A1
LF-56-QX74_1uM Dose=1uM, 4-Heptyloxyphenol, steroidogenic factor inhibitor targeting NR5A1
LF-64-NB46_0.01uM Dose=0.01uM, Fti 277, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB
LF-64-NB46_0.1uM Dose=0.1uM, Fti 277, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB
LF-64-NB46_10uM Dose=10uM, Fti 277, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB
LF-64-NB46_1uM Dose=1uM, Fti 277, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB
LF-85-QP07_0.01uM Dose=0.01uM, (5,6-Dimethyl-thieno[2,3-d]pyrimidin-4-ylsulfanyl)-acetic acid, Palmitoleoyl-Protein Carboxylesterase NOTUM Inhibitors targeting NOTUM
LF-85-QP07_0.1uM Dose=0.1uM, (5,6-Dimethyl-thieno[2,3-d]pyrimidin-4-ylsulfanyl)-acetic acid, Palmitoleoyl-Protein Carboxylesterase NOTUM Inhibitors targeting NOTUM
LF-85-QP07_10uM Dose=10uM, (5,6-Dimethyl-thieno[2,3-d]pyrimidin-4-ylsulfanyl)-acetic acid, Palmitoleoyl-Protein Carboxylesterase NOTUM Inhibitors targeting NOTUM
LF-85-QP07_1uM Dose=1uM, (5,6-Dimethyl-thieno[2,3-d]pyrimidin-4-ylsulfanyl)-acetic acid, Palmitoleoyl-Protein Carboxylesterase NOTUM Inhibitors targeting NOTUM
LF-86-EA69_0.01uM Dose=0.01uM, N-(3,5-dichlorophenyl)benzenesulfonamide, Dedicator of cytokenesis protein 5 inhibitor targeting DOCK5
LF-86-EA69_0.1uM Dose=0.1uM, N-(3,5-dichlorophenyl)benzenesulfonamide, Dedicator of cytokenesis protein 5 inhibitor targeting DOCK5
LF-86-EA69_10uM Dose=10uM, N-(3,5-dichlorophenyl)benzenesulfonamide, Dedicator of cytokenesis protein 5 inhibitor targeting DOCK5
LF-86-EA69_1uM Dose=1uM, N-(3,5-dichlorophenyl)benzenesulfonamide, Dedicator of cytokenesis protein 5 inhibitor targeting DOCK5
LF-92-IK63_0.01uM Dose=0.01uM, 2-{[4-Amino-3-(3-Fluoro-4-Hydroxyphenyl)-1h-Pyrazolo[3,4-D]pyrimidin-1-Yl]methyl}-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD, PIK3CG
LF-92-IK63_0.1uM Dose=0.1uM, 2-{[4-Amino-3-(3-Fluoro-4-Hydroxyphenyl)-1h-Pyrazolo[3,4-D]pyrimidin-1-Yl]methyl}-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD, PIK3CG
LF-92-IK63_10uM Dose=10uM, 2-{[4-Amino-3-(3-Fluoro-4-Hydroxyphenyl)-1h-Pyrazolo[3,4-D]pyrimidin-1-Yl]methyl}-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD, PIK3CG
LF-92-IK63_1uM Dose=1uM, 2-{[4-Amino-3-(3-Fluoro-4-Hydroxyphenyl)-1h-Pyrazolo[3,4-D]pyrimidin-1-Yl]methyl}-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD, PIK3CG
LF-94-HB11_0.01uM Dose=0.01uM, Apicidin, HDAC inhibitor targeting HDAC3, HDAC4
LF-94-HB11_0.1uM Dose=0.1uM, Apicidin, HDAC inhibitor targeting HDAC3, HDAC4
LF-94-HB11_10uM Dose=10uM, Apicidin, HDAC inhibitor targeting HDAC3, HDAC4
LF-94-HB11_1uM Dose=1uM, Apicidin, HDAC inhibitor targeting HDAC3, HDAC4
MA-06-DJ95_0.01uM Dose=0.01uM, 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CDC7
MA-06-DJ95_0.1uM Dose=0.1uM, 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CDC7
MA-06-DJ95_10uM Dose=10uM, 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CDC7
MA-06-DJ95_1uM Dose=1uM, 2-Pyridin-4-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one, Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CDC7
MA-08-KH70_0.01uM Dose=0.01uM, LY 295427, INSIG-1 Expression Enhancers;LDL-Receptor Up-Regulators targeting LDLR
MA-08-KH70_0.1uM Dose=0.1uM, LY 295427, INSIG-1 Expression Enhancers;LDL-Receptor Up-Regulators targeting LDLR
MA-08-KH70_10uM Dose=10uM, LY 295427, INSIG-1 Expression Enhancers;LDL-Receptor Up-Regulators targeting LDLR
MA-08-KH70_1uM Dose=1uM, LY 295427, INSIG-1 Expression Enhancers;LDL-Receptor Up-Regulators targeting LDLR
MA-16-HJ95_0.01uM Dose=0.01uM
MA-16-HJ95_0.1uM Dose=0.1uM
MA-16-HJ95_10uM Dose=10uM
MA-17-XU09_0.01uM Dose=0.01uM
MA-17-XU09_10uM Dose=10uM
MA-20-ZI33_0.01uM Dose=0.01uM
MA-20-ZI33_0.1uM Dose=0.1uM
MA-20-ZI33_10uM Dose=10uM
MA-20-ZI33_1uM Dose=1uM
MA-25-RP17_0.1uM Dose=0.1uM, 4-{3-[2-(7-Methyl-1H-indol-3-yl)-ethylsulfanyl]-5-quinolin-2-yl-[1,2,4]triazol-4-yl}-butylamine, Somatostatin SRIF1B (sst5) Agonists;Somatostatin SRIF1A (sst2) Agonists targeting SSTR2, SSTR5
MA-25-RP17_10uM Dose=10uM, 4-{3-[2-(7-Methyl-1H-indol-3-yl)-ethylsulfanyl]-5-quinolin-2-yl-[1,2,4]triazol-4-yl}-butylamine, Somatostatin SRIF1B (sst5) Agonists;Somatostatin SRIF1A (sst2) Agonists targeting SSTR2, SSTR5
MA-25-RP17_1uM Dose=1uM, 4-{3-[2-(7-Methyl-1H-indol-3-yl)-ethylsulfanyl]-5-quinolin-2-yl-[1,2,4]triazol-4-yl}-butylamine, Somatostatin SRIF1B (sst5) Agonists;Somatostatin SRIF1A (sst2) Agonists targeting SSTR2, SSTR5
MA-31-VM30_0.01uM Dose=0.01uM, Sabeluzole
MA-31-VM30_0.1uM Dose=0.1uM, Sabeluzole
MA-31-VM30_10uM Dose=10uM, Sabeluzole
MA-31-VM30_1uM Dose=1uM, Sabeluzole
MA-32-UX14_0.01uM Dose=0.01uM, (S)-2-Amino-N-(1-((5-chloro-1H-indol-3-yl)methyl)piperidin-4-yl)-3-(1H-indol-3-yl)propanamide, RAS-SOS molecular glue targeting SOS1
MA-32-UX14_0.1uM Dose=0.1uM, (S)-2-Amino-N-(1-((5-chloro-1H-indol-3-yl)methyl)piperidin-4-yl)-3-(1H-indol-3-yl)propanamide, RAS-SOS molecular glue targeting SOS1
MA-32-UX14_10uM Dose=10uM, (S)-2-Amino-N-(1-((5-chloro-1H-indol-3-yl)methyl)piperidin-4-yl)-3-(1H-indol-3-yl)propanamide, RAS-SOS molecular glue targeting SOS1
MA-32-UX14_1uM Dose=1uM, (S)-2-Amino-N-(1-((5-chloro-1H-indol-3-yl)methyl)piperidin-4-yl)-3-(1H-indol-3-yl)propanamide, RAS-SOS molecular glue targeting SOS1
MA-42-UX14_0.01uM Dose=0.01uM
MA-42-UX14_0.1uM Dose=0.1uM
MA-42-UX14_10uM Dose=10uM
MA-42-UX14_1uM Dose=1uM
MA-42-XG98_0.01uM Dose=0.01uM, 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepin-7-ol
MA-42-XG98_0.1uM Dose=0.1uM, 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepin-7-ol
MA-42-XG98_1uM Dose=1uM, 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepin-7-ol
MA-43-MR37_0.01uM Dose=0.01uM
MA-43-MR37_0.1uM Dose=0.1uM
MA-43-MR37_10uM Dose=10uM
MA-43-MR37_1uM Dose=1uM
MA-45-US84_0.01uM Dose=0.01uM, 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine, SUV420H1/H2 inhibitor;kmt5b and kmt5c inhibitor targeting KMT5B, KMT5C
MA-45-US84_0.1uM Dose=0.1uM, 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine, SUV420H1/H2 inhibitor;kmt5b and kmt5c inhibitor targeting KMT5B, KMT5C
MA-45-US84_10uM Dose=10uM, 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine, SUV420H1/H2 inhibitor;kmt5b and kmt5c inhibitor targeting KMT5B, KMT5C
MA-45-US84_1uM Dose=1uM, 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine, SUV420H1/H2 inhibitor;kmt5b and kmt5c inhibitor targeting KMT5B, KMT5C
MA-58-RR04_0.01uM Dose=0.01uM, VU-0238429, M5 positive allosteric modulator targeting CHRM5
MA-58-RR04_0.1uM Dose=0.1uM, VU-0238429, M5 positive allosteric modulator targeting CHRM5
MA-58-RR04_10uM Dose=10uM, VU-0238429, M5 positive allosteric modulator targeting CHRM5
MA-58-RR04_1uM Dose=1uM, VU-0238429, M5 positive allosteric modulator targeting CHRM5
MA-64-FB16_0.01uM Dose=0.01uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-2-[4-(2-methyltetrazol-5-yl)phenyl]-N-[5-(trifluoromethyl)pyrazin-2-yl]acetamide
MA-64-FB16_0.1uM Dose=0.1uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-2-[4-(2-methyltetrazol-5-yl)phenyl]-N-[5-(trifluoromethyl)pyrazin-2-yl]acetamide
MA-64-FB16_10uM Dose=10uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-2-[4-(2-methyltetrazol-5-yl)phenyl]-N-[5-(trifluoromethyl)pyrazin-2-yl]acetamide
MA-64-FB16_1uM Dose=1uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-2-[4-(2-methyltetrazol-5-yl)phenyl]-N-[5-(trifluoromethyl)pyrazin-2-yl]acetamide
MA-67-FQ44_0.01uM Dose=0.01uM, 1-Hydroxy-2-naphthoyl-Arg-Pro amide targeting TPSAB1, TPSD1, TPSG1, TPSB2
MA-67-FQ44_0.1uM Dose=0.1uM, 1-Hydroxy-2-naphthoyl-Arg-Pro amide targeting TPSAB1, TPSD1, TPSG1, TPSB2
MA-67-FQ44_10uM Dose=10uM, 1-Hydroxy-2-naphthoyl-Arg-Pro amide targeting TPSAB1, TPSD1, TPSG1, TPSB2
MA-67-FQ44_1uM Dose=1uM, 1-Hydroxy-2-naphthoyl-Arg-Pro amide targeting TPSAB1, TPSD1, TPSG1, TPSB2
MA-88-CA03_0.01uM Dose=0.01uM, 6,7,4'-Trihydroxyisoflavan
MA-88-CA03_0.1uM Dose=0.1uM, 6,7,4'-Trihydroxyisoflavan
MA-88-CA03_10uM Dose=10uM, 6,7,4'-Trihydroxyisoflavan
MA-88-CA03_1uM Dose=1uM, 6,7,4'-Trihydroxyisoflavan
MA-96-GW26_0.01uM Dose=0.01uM
MA-96-GW26_0.1uM Dose=0.1uM
MA-96-GW26_10uM Dose=10uM
MA-96-GW26_1uM Dose=1uM
MB-01-IW99_0.01uM Dose=0.01uM, (1-Amino-3-methylbutyl)phosphonic acid targeting LAP3
MB-01-IW99_0.1uM Dose=0.1uM, (1-Amino-3-methylbutyl)phosphonic acid targeting LAP3
MB-01-IW99_10uM Dose=10uM, (1-Amino-3-methylbutyl)phosphonic acid targeting LAP3
MB-13-WR12_0.01uM Dose=0.01uM, N-(1,3-benzodioxol-5-ylmethyl)-2-[5-[2-(3-methoxyanilino)-2-oxoethyl]sulfanyl-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]acetamide
MB-13-WR12_0.1uM Dose=0.1uM, N-(1,3-benzodioxol-5-ylmethyl)-2-[5-[2-(3-methoxyanilino)-2-oxoethyl]sulfanyl-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]acetamide
MB-13-WR12_10uM Dose=10uM, N-(1,3-benzodioxol-5-ylmethyl)-2-[5-[2-(3-methoxyanilino)-2-oxoethyl]sulfanyl-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]acetamide
MB-15-ZF03_0.01uM Dose=0.01uM
MB-15-ZF03_0.1uM Dose=0.1uM
MB-15-ZF03_10uM Dose=10uM
MB-15-ZF03_1uM Dose=1uM
MB-32-LQ97_0.01uM Dose=0.01uM, 3-Pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, Uridine Phosphorylase Inhibitors targeting UPP1
MB-32-LQ97_0.1uM Dose=0.1uM, 3-Pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, Uridine Phosphorylase Inhibitors targeting UPP1
MB-32-LQ97_10uM Dose=10uM, 3-Pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, Uridine Phosphorylase Inhibitors targeting UPP1
MB-32-LQ97_1uM Dose=1uM, 3-Pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-, Uridine Phosphorylase Inhibitors targeting UPP1
MB-35-NZ76_0.01uM Dose=0.01uM, 1,4-Phenylenebis(1,4'-bipiperidin-1'-ylmethanone)
MB-35-NZ76_0.1uM Dose=0.1uM, 1,4-Phenylenebis(1,4'-bipiperidin-1'-ylmethanone)
MB-35-NZ76_10uM Dose=10uM, 1,4-Phenylenebis(1,4'-bipiperidin-1'-ylmethanone)
MB-35-NZ76_1uM Dose=1uM, 1,4-Phenylenebis(1,4'-bipiperidin-1'-ylmethanone)
MB-46-BT89_0.01uM Dose=0.01uM, 4-Hydroxy-3,5-dimethoxycinnamic acid, GABA(A) Receptor Agonists;Alleviation of Cartilage Destruction;Antioxidants targeting KEAP1
MB-46-BT89_0.1uM Dose=0.1uM, 4-Hydroxy-3,5-dimethoxycinnamic acid, GABA(A) Receptor Agonists;Alleviation of Cartilage Destruction;Antioxidants targeting KEAP1
MB-46-BT89_10uM Dose=10uM, 4-Hydroxy-3,5-dimethoxycinnamic acid, GABA(A) Receptor Agonists;Alleviation of Cartilage Destruction;Antioxidants targeting KEAP1
MB-46-BT89_1uM Dose=1uM, 4-Hydroxy-3,5-dimethoxycinnamic acid, GABA(A) Receptor Agonists;Alleviation of Cartilage Destruction;Antioxidants targeting KEAP1
MB-48-VA23_0.01uM Dose=0.01uM, 9-Benzyl-2-methyl-4-phenyl-5-oxa-1,2,9-triazaspiro[5.5]undecane, Vascular adhesion molecule antagonists targeting AOC3
MB-48-VA23_0.1uM Dose=0.1uM, 9-Benzyl-2-methyl-4-phenyl-5-oxa-1,2,9-triazaspiro[5.5]undecane, Vascular adhesion molecule antagonists targeting AOC3
MB-48-VA23_10uM Dose=10uM, 9-Benzyl-2-methyl-4-phenyl-5-oxa-1,2,9-triazaspiro[5.5]undecane, Vascular adhesion molecule antagonists targeting AOC3
MB-48-VA23_1uM Dose=1uM, 9-Benzyl-2-methyl-4-phenyl-5-oxa-1,2,9-triazaspiro[5.5]undecane, Vascular adhesion molecule antagonists targeting AOC3
MB-49-LL22_0.01uM Dose=0.01uM, Pinometostat, Dot1L / KMT4;Dot1L inhibitor targeting DOT1L
MB-49-LL22_0.1uM Dose=0.1uM, Pinometostat, Dot1L / KMT4;Dot1L inhibitor targeting DOT1L
MB-49-LL22_10uM Dose=10uM, Pinometostat, Dot1L / KMT4;Dot1L inhibitor targeting DOT1L
MB-49-LL22_1uM Dose=1uM, Pinometostat, Dot1L / KMT4;Dot1L inhibitor targeting DOT1L
MB-50-ZI28_0.01uM Dose=0.01uM, (4S)-4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dimethyl-4H-pyrrolo[3,4-c]pyrazol-6-one
MB-50-ZI28_0.1uM Dose=0.1uM, (4S)-4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dimethyl-4H-pyrrolo[3,4-c]pyrazol-6-one
MB-50-ZI28_10uM Dose=10uM, (4S)-4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dimethyl-4H-pyrrolo[3,4-c]pyrazol-6-one
MB-50-ZI28_1uM Dose=1uM, (4S)-4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-2,3-dimethyl-4H-pyrrolo[3,4-c]pyrazol-6-one
MB-53-WO35_0.01uM Dose=0.01uM, N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-2-[4-(2-methylpropanoyl)piperazin-1-yl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide, PRMT5 inhibitor targeting PRMT5
MB-53-WO35_0.1uM Dose=0.1uM, N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-2-[4-(2-methylpropanoyl)piperazin-1-yl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide, PRMT5 inhibitor targeting PRMT5
MB-53-WO35_10uM Dose=10uM, N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-2-[4-(2-methylpropanoyl)piperazin-1-yl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide, PRMT5 inhibitor targeting PRMT5
MB-53-WO35_1uM Dose=1uM, N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-2-[4-(2-methylpropanoyl)piperazin-1-yl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide, PRMT5 inhibitor targeting PRMT5
MB-67-UU04_0.01uM Dose=0.01uM, 6-[4-[2-(3-Fluoropyridin-4-yl)imidazo[4,5-b]pyridin-3-yl]piperidin-1-yl]sulfonyl-2-methyl-1,3-benzoxazole, CFTR Modulator targeting CFTR
MB-67-UU04_0.1uM Dose=0.1uM, 6-[4-[2-(3-Fluoropyridin-4-yl)imidazo[4,5-b]pyridin-3-yl]piperidin-1-yl]sulfonyl-2-methyl-1,3-benzoxazole, CFTR Modulator targeting CFTR
MB-67-UU04_10uM Dose=10uM, 6-[4-[2-(3-Fluoropyridin-4-yl)imidazo[4,5-b]pyridin-3-yl]piperidin-1-yl]sulfonyl-2-methyl-1,3-benzoxazole, CFTR Modulator targeting CFTR
MB-67-UU04_1uM Dose=1uM, 6-[4-[2-(3-Fluoropyridin-4-yl)imidazo[4,5-b]pyridin-3-yl]piperidin-1-yl]sulfonyl-2-methyl-1,3-benzoxazole, CFTR Modulator targeting CFTR
MB-72-YK93_0.01uM Dose=0.01uM
MB-72-YK93_0.1uM Dose=0.1uM
MB-72-YK93_10uM Dose=10uM
MB-72-YK93_1uM Dose=1uM
MB-78-HH35_0.01uM Dose=0.01uM, (2E)-2-[[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]-3-(2-nitrophenyl)propanoic acid, eiF4F complex assembly inhibitor;EIF4E-EIF6G interaction inhibitor targeting EIF4E, EIF4G1
MB-78-HH35_10uM Dose=10uM, (2E)-2-[[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]-3-(2-nitrophenyl)propanoic acid, eiF4F complex assembly inhibitor;EIF4E-EIF6G interaction inhibitor targeting EIF4E, EIF4G1
MB-83-RV32_0.1uM Dose=0.1uM, N-1,2,3-Benzothiadiazol-6-yl-N'-[2-oxo-2-(1-piperidinyl)ethyl]urea, allosteric PRMT3 inhibitor;PRMT3 targeting PRMT3
MB-83-RV32_10uM Dose=10uM, N-1,2,3-Benzothiadiazol-6-yl-N'-[2-oxo-2-(1-piperidinyl)ethyl]urea, allosteric PRMT3 inhibitor;PRMT3 targeting PRMT3
MB-86-VG83_0.01uM Dose=0.01uM, N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide, BRD7/9 inhbitor;BRD9 inhibitor;BRD7/9 Bromodomain Inhibitor targeting BRD7, BRD9
MB-86-VG83_0.1uM Dose=0.1uM, N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide, BRD7/9 inhbitor;BRD9 inhibitor;BRD7/9 Bromodomain Inhibitor targeting BRD7, BRD9
MB-86-VG83_10uM Dose=10uM, N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide, BRD7/9 inhbitor;BRD9 inhibitor;BRD7/9 Bromodomain Inhibitor targeting BRD7, BRD9
MB-86-VG83_1uM Dose=1uM, N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide, BRD7/9 inhbitor;BRD9 inhibitor;BRD7/9 Bromodomain Inhibitor targeting BRD7, BRD9
MB-93-BH38_0.01uM Dose=0.01uM, 4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]pyridine, Glucagon Receptor (GCGR) Antagonists;GCGR antagonist targeting GCGR
MB-93-BH38_0.1uM Dose=0.1uM, 4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]pyridine, Glucagon Receptor (GCGR) Antagonists;GCGR antagonist targeting GCGR
MB-93-BH38_10uM Dose=10uM, 4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]pyridine, Glucagon Receptor (GCGR) Antagonists;GCGR antagonist targeting GCGR
MB-95-VI30_0.01uM Dose=0.01uM
MB-95-VI30_0.1uM Dose=0.1uM
MB-95-VI30_10uM Dose=10uM
MB-95-VI30_1uM Dose=1uM
MC-30-BS07_0.01uM Dose=0.01uM, (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoic acid targeting PLG
MC-30-BS07_0.1uM Dose=0.1uM, (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoic acid targeting PLG
MC-30-BS07_10uM Dose=10uM, (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoic acid targeting PLG
MC-30-BS07_1uM Dose=1uM, (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoic acid targeting PLG
MC-36-PM07_0.01uM Dose=0.01uM, Pd 150606, Calpain Inhibitors targeting CAPN1
MC-36-PM07_0.1uM Dose=0.1uM, Pd 150606, Calpain Inhibitors targeting CAPN1
MC-36-PM07_10uM Dose=10uM, Pd 150606, Calpain Inhibitors targeting CAPN1
MC-36-PM07_1uM Dose=1uM, Pd 150606, Calpain Inhibitors targeting CAPN1
MC-40-IP75_0.01uM Dose=0.01uM, Milnacipran, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4
MC-40-IP75_0.1uM Dose=0.1uM, Milnacipran, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4
MC-40-IP75_10uM Dose=10uM, Milnacipran, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4
MC-40-IP75_1uM Dose=1uM, Milnacipran, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4
MC-40-KF76_0.1uM Dose=0.1uM
MC-40-KF76_10uM Dose=10uM
MC-40-KF76_1uM Dose=1uM
MC-43-PK30_0.1uM Dose=0.1uM, Acebilustat, inhibition of leukotriene A4 hydrolase targeting LTA4H
MC-43-PK30_10uM Dose=10uM, Acebilustat, inhibition of leukotriene A4 hydrolase targeting LTA4H
MC-43-PK30_1uM Dose=1uM, Acebilustat, inhibition of leukotriene A4 hydrolase targeting LTA4H
MC-51-BT07_0.01uM Dose=0.01uM, Cx516, AMPA Receptor Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4
MC-51-BT07_0.1uM Dose=0.1uM, Cx516, AMPA Receptor Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4
MC-51-BT07_10uM Dose=10uM, Cx516, AMPA Receptor Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4
MC-51-BT07_1uM Dose=1uM, Cx516, AMPA Receptor Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4
MC-60-AC74_0.01uM Dose=0.01uM, 1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid, IGFBP1-6 Inhibitor targeting IGFBP4
MC-60-AC74_0.1uM Dose=0.1uM, 1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid, IGFBP1-6 Inhibitor targeting IGFBP4
MC-60-AC74_10uM Dose=10uM, 1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid, IGFBP1-6 Inhibitor targeting IGFBP4
MC-60-AC74_1uM Dose=1uM, 1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid, IGFBP1-6 Inhibitor targeting IGFBP4
MC-69-RB13_0.1uM Dose=0.1uM, Raclopride, Dopamine D2 Antagonists;Dopamine D3 Antagonists targeting DRD2, DRD3
MC-69-RB13_10uM Dose=10uM, Raclopride, Dopamine D2 Antagonists;Dopamine D3 Antagonists targeting DRD2, DRD3
MC-82-RG58_0.01uM Dose=0.01uM, (2E, 6E)-farnesylbisphosphonate, Squalene Synthase Inhibitors targeting FDFT1, GGPS1
MC-82-RG58_0.1uM Dose=0.1uM, (2E, 6E)-farnesylbisphosphonate, Squalene Synthase Inhibitors targeting FDFT1, GGPS1
MC-82-RG58_10uM Dose=10uM, (2E, 6E)-farnesylbisphosphonate, Squalene Synthase Inhibitors targeting FDFT1, GGPS1
MC-82-RG58_1uM Dose=1uM, (2E, 6E)-farnesylbisphosphonate, Squalene Synthase Inhibitors targeting FDFT1, GGPS1
MC-92-JU67_0.01uM Dose=0.01uM, US10946019, Example 3 targeting NR4A2
MC-92-JU67_0.1uM Dose=0.1uM, US10946019, Example 3 targeting NR4A2
MC-92-JU67_10uM Dose=10uM, US10946019, Example 3 targeting NR4A2
MC-92-JU67_1uM Dose=1uM, US10946019, Example 3 targeting NR4A2
MD-03-GH73_0.01uM Dose=0.01uM, Diacerein, IL-1 Inhibitors targeting IL1B
MD-03-GH73_0.1uM Dose=0.1uM, Diacerein, IL-1 Inhibitors targeting IL1B
MD-03-NA01_0.01uM Dose=0.01uM, 5,7-Dihydroxyflavanone, Androgen Receptor Ligands;Steroid 5alpha-Reductase Inhibitors targeting AR, SRD5A1, SRD5A2
MD-03-NA01_0.1uM Dose=0.1uM, 5,7-Dihydroxyflavanone, Androgen Receptor Ligands;Steroid 5alpha-Reductase Inhibitors targeting AR, SRD5A1, SRD5A2
MD-03-NA01_10uM Dose=10uM, 5,7-Dihydroxyflavanone, Androgen Receptor Ligands;Steroid 5alpha-Reductase Inhibitors targeting AR, SRD5A1, SRD5A2
MD-03-NA01_1uM Dose=1uM, 5,7-Dihydroxyflavanone, Androgen Receptor Ligands;Steroid 5alpha-Reductase Inhibitors targeting AR, SRD5A1, SRD5A2
MD-06-ZJ05_0.01uM Dose=0.01uM, Deoxycytidine
MD-06-ZJ05_0.1uM Dose=0.1uM, Deoxycytidine
MD-06-ZJ05_10uM Dose=10uM, Deoxycytidine
MD-06-ZJ05_1uM Dose=1uM, Deoxycytidine
MD-09-FE75_0.01uM Dose=0.01uM, 4-(benzenesulfinylmethyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]piperidin-4-ol, TACR2 antagonist targeting TACR2
MD-09-FE75_0.1uM Dose=0.1uM, 4-(benzenesulfinylmethyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]piperidin-4-ol, TACR2 antagonist targeting TACR2
MD-09-FE75_10uM Dose=10uM, 4-(benzenesulfinylmethyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]piperidin-4-ol, TACR2 antagonist targeting TACR2
MD-09-FE75_1uM Dose=1uM, 4-(benzenesulfinylmethyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]piperidin-4-ol, TACR2 antagonist targeting TACR2
MD-17-VD78_0.01uM Dose=0.01uM
MD-17-VD78_0.1uM Dose=0.1uM
MD-17-VD78_10uM Dose=10uM
MD-17-VD78_1uM Dose=1uM
MD-40-FM63_0.01uM Dose=0.01uM, nor-NOHA targeting ARG1
MD-40-FM63_0.1uM Dose=0.1uM, nor-NOHA targeting ARG1
MD-40-FM63_10uM Dose=10uM, nor-NOHA targeting ARG1
MD-40-FM63_1uM Dose=1uM, nor-NOHA targeting ARG1
MD-49-BL92_0.01uM Dose=0.01uM, N-[5-(7-chloroquinolin-4-yl)sulfanyl-1,3,4-thiadiazol-2-yl]acetamide
MD-49-BL92_0.1uM Dose=0.1uM, N-[5-(7-chloroquinolin-4-yl)sulfanyl-1,3,4-thiadiazol-2-yl]acetamide
MD-49-BL92_10uM Dose=10uM, N-[5-(7-chloroquinolin-4-yl)sulfanyl-1,3,4-thiadiazol-2-yl]acetamide
MD-51-EC81_0.01uM Dose=0.01uM, 3,4,5-Piperidinetriol, 2-methyl-, (2S,3R,4S,5R)- targeting FUCA1
MD-51-EC81_0.1uM Dose=0.1uM, 3,4,5-Piperidinetriol, 2-methyl-, (2S,3R,4S,5R)- targeting FUCA1
MD-51-HM45_0.01uM Dose=0.01uM, 2-[(4-Benzoyl-1-piperazinyl)carbonyl]-5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-A]pyrimidine
MD-51-HM45_0.1uM Dose=0.1uM, 2-[(4-Benzoyl-1-piperazinyl)carbonyl]-5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-A]pyrimidine
MD-51-HM45_10uM Dose=10uM, 2-[(4-Benzoyl-1-piperazinyl)carbonyl]-5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-A]pyrimidine
MD-51-HM45_1uM Dose=1uM, 2-[(4-Benzoyl-1-piperazinyl)carbonyl]-5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-A]pyrimidine
MD-60-WI93_0.01uM Dose=0.01uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR-1 (Flt-1) Inhibitors targeting FLT1
MD-60-WI93_0.1uM Dose=0.1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR-1 (Flt-1) Inhibitors targeting FLT1
MD-60-WI93_10uM Dose=10uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR-1 (Flt-1) Inhibitors targeting FLT1
MD-60-WI93_1uM Dose=1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR-1 (Flt-1) Inhibitors targeting FLT1
MD-61-RW54_0.01uM Dose=0.01uM, Sulthiame, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VII Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA1, CA4, CA5A, CA5B
MD-61-RW54_1uM Dose=1uM, Sulthiame, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VII Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA1, CA4, CA5A, CA5B
MD-70-GS72_0.1uM Dose=0.1uM, 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid
MD-70-GS72_10uM Dose=10uM, 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid
MD-73-OU29_0.01uM Dose=0.01uM, 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester, Lipase inhibitor targeting LIPA
MD-73-OU29_0.1uM Dose=0.1uM, 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester, Lipase inhibitor targeting LIPA
MD-73-OU29_10uM Dose=10uM, 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester, Lipase inhibitor targeting LIPA
MD-73-OU29_1uM Dose=1uM, 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester, Lipase inhibitor targeting LIPA
MD-84-YS12_0.01uM Dose=0.01uM, 2,4-dichloro-N-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamoyl]benzamide, PCTP (StARD2) Inhibitor targeting PCTP
MD-84-YS12_0.1uM Dose=0.1uM, 2,4-dichloro-N-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamoyl]benzamide, PCTP (StARD2) Inhibitor targeting PCTP
MD-84-YS12_10uM Dose=10uM, 2,4-dichloro-N-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamoyl]benzamide, PCTP (StARD2) Inhibitor targeting PCTP
MD-84-YS12_1uM Dose=1uM, 2,4-dichloro-N-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamoyl]benzamide, PCTP (StARD2) Inhibitor targeting PCTP
MD-86-UW46_0.01uM Dose=0.01uM, N-[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanamide
MD-86-UW46_0.1uM Dose=0.1uM, N-[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanamide
MD-86-UW46_10uM Dose=10uM, N-[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanamide
MD-86-UW46_1uM Dose=1uM, N-[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanamide
MD-91-HM15_0.01uM Dose=0.01uM, MMP-9 (Gelatinase B) Inhibitors targeting MMP9
MD-91-HM15_0.1uM Dose=0.1uM, MMP-9 (Gelatinase B) Inhibitors targeting MMP9
MD-91-HM15_10uM Dose=10uM, MMP-9 (Gelatinase B) Inhibitors targeting MMP9
MD-91-HM15_1uM Dose=1uM, MMP-9 (Gelatinase B) Inhibitors targeting MMP9
MD-91-JM80_0.01uM Dose=0.01uM, N-methyl-2-(4-phenylmethoxypiperidin-1-yl)ethanamine, PRMT4/6 inhibitor;PRMT4 and PRMT6 inhibitor targeting CARM1, PRMT6
MD-91-JM80_0.1uM Dose=0.1uM, N-methyl-2-(4-phenylmethoxypiperidin-1-yl)ethanamine, PRMT4/6 inhibitor;PRMT4 and PRMT6 inhibitor targeting CARM1, PRMT6
MD-91-JM80_10uM Dose=10uM, N-methyl-2-(4-phenylmethoxypiperidin-1-yl)ethanamine, PRMT4/6 inhibitor;PRMT4 and PRMT6 inhibitor targeting CARM1, PRMT6
MD-91-JM80_1uM Dose=1uM, N-methyl-2-(4-phenylmethoxypiperidin-1-yl)ethanamine, PRMT4/6 inhibitor;PRMT4 and PRMT6 inhibitor targeting CARM1, PRMT6
MD-92-KD16_0.01uM Dose=0.01uM, 1-Methyl-2-[(2-methyl-6-propan-2-ylphenyl)methylcarbamoyl]-3-oxoindazole-7-carboxylic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF
MD-92-KD16_0.1uM Dose=0.1uM, 1-Methyl-2-[(2-methyl-6-propan-2-ylphenyl)methylcarbamoyl]-3-oxoindazole-7-carboxylic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF
MD-92-KD16_10uM Dose=10uM, 1-Methyl-2-[(2-methyl-6-propan-2-ylphenyl)methylcarbamoyl]-3-oxoindazole-7-carboxylic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF
MD-92-LN15_0.01uM Dose=0.01uM, 1-[(1s)-1-(4-Chloro-3-Fluorophenyl)-2-Hydroxyethyl]-4-[2-(Tetrahydro-2h-Pyran-4-Ylamino)pyrimidin-4-Yl]pyridin-2(1h)-One, ERK1/2 inhibitor targeting MAPK1, MAPK3
MD-92-LN15_10uM Dose=10uM, 1-[(1s)-1-(4-Chloro-3-Fluorophenyl)-2-Hydroxyethyl]-4-[2-(Tetrahydro-2h-Pyran-4-Ylamino)pyrimidin-4-Yl]pyridin-2(1h)-One, ERK1/2 inhibitor targeting MAPK1, MAPK3
ME-11-OJ38_0.01uM Dose=0.01uM, H-Cys(1)-Asn-Ser-Asn-Gln-Ile-Cys(1)-OH, Anti-CD4 targeting CD4
ME-11-OJ38_0.1uM Dose=0.1uM, H-Cys(1)-Asn-Ser-Asn-Gln-Ile-Cys(1)-OH, Anti-CD4 targeting CD4
ME-11-OJ38_10uM Dose=10uM, H-Cys(1)-Asn-Ser-Asn-Gln-Ile-Cys(1)-OH, Anti-CD4 targeting CD4
ME-11-OJ38_1uM Dose=1uM, H-Cys(1)-Asn-Ser-Asn-Gln-Ile-Cys(1)-OH, Anti-CD4 targeting CD4
ME-14-LE68_0.01uM Dose=0.01uM, 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Tyrosine Kinase Inhibitors targeting FYN
ME-14-LE68_0.1uM Dose=0.1uM, 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Tyrosine Kinase Inhibitors targeting FYN
ME-14-LE68_10uM Dose=10uM, 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, Tyrosine Kinase Inhibitors targeting FYN
ME-16-XW76_0.01uM Dose=0.01uM, 1-(3-Benzoylpropyl)-4-benzamidopiperidine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
ME-16-XW76_0.1uM Dose=0.1uM, 1-(3-Benzoylpropyl)-4-benzamidopiperidine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
ME-16-XW76_10uM Dose=10uM, 1-(3-Benzoylpropyl)-4-benzamidopiperidine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
ME-16-XW76_1uM Dose=1uM, 1-(3-Benzoylpropyl)-4-benzamidopiperidine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
ME-31-RM40_0.01uM Dose=0.01uM, (E)-3-[4-[(2-carbazol-9-ylethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
ME-31-RM40_0.1uM Dose=0.1uM, (E)-3-[4-[(2-carbazol-9-ylethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
ME-31-RM40_10uM Dose=10uM, (E)-3-[4-[(2-carbazol-9-ylethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
ME-31-RM40_1uM Dose=1uM, (E)-3-[4-[(2-carbazol-9-ylethylamino)methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
ME-36-FM27_0.01uM Dose=0.01uM, 7-[2-(4-Benzhydrylpiperazin-1-yl)ethyl]-1,3-dimethylpurine-2,6-dione, HRH1 antagonist targeting HRH1
ME-42-RD46_0.01uM Dose=0.01uM, 2-[2-[[3-amino-5-[3-[(1S)-1-amino-2-hydroxyethyl]phenyl]phenyl]methoxy]phenyl]acetic acid, Complement factor D inhibitor targeting CFD
ME-42-RD46_0.1uM Dose=0.1uM, 2-[2-[[3-amino-5-[3-[(1S)-1-amino-2-hydroxyethyl]phenyl]phenyl]methoxy]phenyl]acetic acid, Complement factor D inhibitor targeting CFD
ME-42-RD46_10uM Dose=10uM, 2-[2-[[3-amino-5-[3-[(1S)-1-amino-2-hydroxyethyl]phenyl]phenyl]methoxy]phenyl]acetic acid, Complement factor D inhibitor targeting CFD
ME-42-RD46_1uM Dose=1uM, 2-[2-[[3-amino-5-[3-[(1S)-1-amino-2-hydroxyethyl]phenyl]phenyl]methoxy]phenyl]acetic acid, Complement factor D inhibitor targeting CFD
ME-47-CY39_0.01uM Dose=0.01uM, Crisaborole, PDE4 inhibitor use for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D
ME-47-CY39_0.1uM Dose=0.1uM, Crisaborole, PDE4 inhibitor use for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D
ME-47-CY39_10uM Dose=10uM, Crisaborole, PDE4 inhibitor use for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D
ME-47-KQ59_0.01uM Dose=0.01uM, 4-(3-benzyl-4-{[5-(2-fluorophenyl)furan-2-yl]methylidene}-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid targeting BTRC
ME-47-KQ59_10uM Dose=10uM, 4-(3-benzyl-4-{[5-(2-fluorophenyl)furan-2-yl]methylidene}-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid targeting BTRC
ME-47-KQ59_1uM Dose=1uM, 4-(3-benzyl-4-{[5-(2-fluorophenyl)furan-2-yl]methylidene}-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid targeting BTRC
ME-49-AE45_0.01uM Dose=0.01uM, (2S)-1-[2-(tert-butylamino)acetyl]pyrrolidine-2-carbonitrile
ME-49-AE45_0.1uM Dose=0.1uM, (2S)-1-[2-(tert-butylamino)acetyl]pyrrolidine-2-carbonitrile
ME-49-AE45_10uM Dose=10uM, (2S)-1-[2-(tert-butylamino)acetyl]pyrrolidine-2-carbonitrile
ME-49-AE45_1uM Dose=1uM, (2S)-1-[2-(tert-butylamino)acetyl]pyrrolidine-2-carbonitrile
ME-54-JY76_0.01uM Dose=0.01uM
ME-54-JY76_0.1uM Dose=0.1uM
ME-54-JY76_10uM Dose=10uM
ME-54-JY76_1uM Dose=1uM
ME-60-RF56_0.01uM Dose=0.01uM, N-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamothioyl]benzamide, Serotonin Antagonists targeting HTR1A
ME-60-RF56_0.1uM Dose=0.1uM, N-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamothioyl]benzamide, Serotonin Antagonists targeting HTR1A
ME-60-RF56_10uM Dose=10uM, N-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamothioyl]benzamide, Serotonin Antagonists targeting HTR1A
ME-60-RF56_1uM Dose=1uM, N-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamothioyl]benzamide, Serotonin Antagonists targeting HTR1A
ME-61-RC56_10uM Dose=10uM, Suronacrine, Acetylcholinesterase Inhibitors;Norepinephrine Reuptake Inhibitors targeting ACHE
ME-62-IQ37_0.01uM Dose=0.01uM, WY 47288, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5
ME-62-IQ37_0.1uM Dose=0.1uM, WY 47288, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5
ME-62-IQ37_10uM Dose=10uM, WY 47288, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5
ME-62-IQ37_1uM Dose=1uM, WY 47288, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5
ME-64-LE18_0.1uM Dose=0.1uM, Brl 41992, ADRA2B antagonist targeting ADRA2B
ME-64-LE18_10uM Dose=10uM, Brl 41992, ADRA2B antagonist targeting ADRA2B
ME-73-FK70_0.01uM Dose=0.01uM, 5-Iodo-6-amino-1,2-benzopyrone, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1
ME-73-FK70_0.1uM Dose=0.1uM, 5-Iodo-6-amino-1,2-benzopyrone, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1
ME-73-FK70_10uM Dose=10uM, 5-Iodo-6-amino-1,2-benzopyrone, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1
ME-73-FK70_1uM Dose=1uM, 5-Iodo-6-amino-1,2-benzopyrone, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1
ME-77-JX81_0.01uM Dose=0.01uM, PF-514273, Cannabinoid CB1 Antagonists targeting CNR1
ME-77-JX81_10uM Dose=10uM, PF-514273, Cannabinoid CB1 Antagonists targeting CNR1
ME-77-JX81_1uM Dose=1uM, PF-514273, Cannabinoid CB1 Antagonists targeting CNR1
ME-77-TQ29_0.01uM Dose=0.01uM, N,N'-bis-(2-hydroxybenzyl)-2,5-diamino-2,5-dimethyl-hexane, TRPA1 Antagonists targeting TRPA1
ME-77-TQ29_0.1uM Dose=0.1uM, N,N'-bis-(2-hydroxybenzyl)-2,5-diamino-2,5-dimethyl-hexane, TRPA1 Antagonists targeting TRPA1
ME-77-TQ29_10uM Dose=10uM, N,N'-bis-(2-hydroxybenzyl)-2,5-diamino-2,5-dimethyl-hexane, TRPA1 Antagonists targeting TRPA1
ME-77-TQ29_1uM Dose=1uM, N,N'-bis-(2-hydroxybenzyl)-2,5-diamino-2,5-dimethyl-hexane, TRPA1 Antagonists targeting TRPA1
ME-77-XX06_0.01uM Dose=0.01uM, N-[6-[(4-aminoquinazolin-2-yl)amino]hex-3-ynyl]naphthalene-1-sulfonamide
ME-77-XX06_0.1uM Dose=0.1uM, N-[6-[(4-aminoquinazolin-2-yl)amino]hex-3-ynyl]naphthalene-1-sulfonamide
ME-77-XX06_10uM Dose=10uM, N-[6-[(4-aminoquinazolin-2-yl)amino]hex-3-ynyl]naphthalene-1-sulfonamide
ME-77-XX06_1uM Dose=1uM, N-[6-[(4-aminoquinazolin-2-yl)amino]hex-3-ynyl]naphthalene-1-sulfonamide
ME-90-FS02_0.01uM Dose=0.01uM, L 156373, Vasopressin (AVP) V1a Antagonists;Vasopressin (AVP) V2 Antagonists targeting AVPR1A, AVPR2
ME-90-FS02_10uM Dose=10uM, L 156373, Vasopressin (AVP) V1a Antagonists;Vasopressin (AVP) V2 Antagonists targeting AVPR1A, AVPR2
ME-90-FS02_1uM Dose=1uM, L 156373, Vasopressin (AVP) V1a Antagonists;Vasopressin (AVP) V2 Antagonists targeting AVPR1A, AVPR2
ME-93-CO85_0.01uM Dose=0.01uM, 1-[4-[3-(Difluoromethyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl]phenyl]cyclobutan-1-amine
ME-93-CO85_0.1uM Dose=0.1uM, 1-[4-[3-(Difluoromethyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl]phenyl]cyclobutan-1-amine
ME-93-CO85_10uM Dose=10uM, 1-[4-[3-(Difluoromethyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl]phenyl]cyclobutan-1-amine
ME-93-CO85_1uM Dose=1uM, 1-[4-[3-(Difluoromethyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-8-yl]phenyl]cyclobutan-1-amine
MF-04-HB41_0.01uM Dose=0.01uM, L 741742, DRD4 antagonist;Dopamine D4 Antagonists targeting DRD4, CACNA1A, CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNB1, CACNB4, CACNG1
MF-04-HB41_0.1uM Dose=0.1uM, L 741742, DRD4 antagonist;Dopamine D4 Antagonists targeting DRD4, CACNA1A, CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNB1, CACNB4, CACNG1
MF-04-HB41_10uM Dose=10uM, L 741742, DRD4 antagonist;Dopamine D4 Antagonists targeting DRD4, CACNA1A, CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNB1, CACNB4, CACNG1
MF-04-HB41_1uM Dose=1uM, L 741742, DRD4 antagonist;Dopamine D4 Antagonists targeting DRD4, CACNA1A, CACNA1C, CACNA1D, CACNA1E, CACNA1S, CACNB1, CACNB4, CACNG1
MF-11-EW49_0.01uM Dose=0.01uM, Biochanin A, PPARgamma Agonists;Androgen Receptor Antagonists;Steroid 5alpha-Reductase Inhibitors;PPARalpha Agonists targeting AR, PPARA, PPARG, SRD5A1, SRD5A2
MF-11-EW49_0.1uM Dose=0.1uM, Biochanin A, PPARgamma Agonists;Androgen Receptor Antagonists;Steroid 5alpha-Reductase Inhibitors;PPARalpha Agonists targeting AR, PPARA, PPARG, SRD5A1, SRD5A2
MF-11-EW49_10uM Dose=10uM, Biochanin A, PPARgamma Agonists;Androgen Receptor Antagonists;Steroid 5alpha-Reductase Inhibitors;PPARalpha Agonists targeting AR, PPARA, PPARG, SRD5A1, SRD5A2
MF-11-EW49_1uM Dose=1uM, Biochanin A, PPARgamma Agonists;Androgen Receptor Antagonists;Steroid 5alpha-Reductase Inhibitors;PPARalpha Agonists targeting AR, PPARA, PPARG, SRD5A1, SRD5A2
MF-17-BD63_0.01uM Dose=0.01uM, N-[4'-Methyl-2-(pyridin-3-ylamino)-[4,5]bithiazolyl-2'-yl]-acetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
MF-17-BD63_0.1uM Dose=0.1uM, N-[4'-Methyl-2-(pyridin-3-ylamino)-[4,5]bithiazolyl-2'-yl]-acetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
MF-17-BD63_10uM Dose=10uM, N-[4'-Methyl-2-(pyridin-3-ylamino)-[4,5]bithiazolyl-2'-yl]-acetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
MF-17-BD63_1uM Dose=1uM, N-[4'-Methyl-2-(pyridin-3-ylamino)-[4,5]bithiazolyl-2'-yl]-acetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
MF-20-QI53_0.01uM Dose=0.01uM, TAK-779 cation, HIV Attachment Inhibitors;Chemokine CXCR3 Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CXCR3, CCR2
MF-20-QI53_0.1uM Dose=0.1uM, TAK-779 cation, HIV Attachment Inhibitors;Chemokine CXCR3 Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CXCR3, CCR2
MF-20-QI53_10uM Dose=10uM, TAK-779 cation, HIV Attachment Inhibitors;Chemokine CXCR3 Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CXCR3, CCR2
MF-20-QI53_1uM Dose=1uM, TAK-779 cation, HIV Attachment Inhibitors;Chemokine CXCR3 Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CXCR3, CCR2
MF-31-FM25_0.01uM Dose=0.01uM, 1-methyl-3-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]thiourea
MF-31-FM25_0.1uM Dose=0.1uM, 1-methyl-3-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]thiourea
MF-31-FM25_10uM Dose=10uM, 1-methyl-3-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]thiourea
MF-31-FM25_1uM Dose=1uM, 1-methyl-3-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]thiourea
MF-37-KQ09_0.01uM Dose=0.01uM, 7alpha-Hydroxydehydroepiandrosterone, Estrogen Receptor (ER) beta Ligands targeting ESR2
MF-37-KQ09_0.1uM Dose=0.1uM, 7alpha-Hydroxydehydroepiandrosterone, Estrogen Receptor (ER) beta Ligands targeting ESR2
MF-37-KQ09_10uM Dose=10uM, 7alpha-Hydroxydehydroepiandrosterone, Estrogen Receptor (ER) beta Ligands targeting ESR2
MF-37-KQ09_1uM Dose=1uM, 7alpha-Hydroxydehydroepiandrosterone, Estrogen Receptor (ER) beta Ligands targeting ESR2
MF-41-QM60_0.01uM Dose=0.01uM, Dpp-IV-IN-2, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP8, DPP9
MF-41-QM60_0.1uM Dose=0.1uM, Dpp-IV-IN-2, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP8, DPP9
MF-41-QM60_10uM Dose=10uM, Dpp-IV-IN-2, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP8, DPP9
MF-41-QM60_1uM Dose=1uM, Dpp-IV-IN-2, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP8, DPP9
MF-62-JR25_0.01uM Dose=0.01uM, Oxybutynin, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
MF-62-JR25_0.1uM Dose=0.1uM, Oxybutynin, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
MF-62-JR25_10uM Dose=10uM, Oxybutynin, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
MF-62-JR25_1uM Dose=1uM, Oxybutynin, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
MF-65-HS14_0.01uM Dose=0.01uM, (3Z)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-1,1,1-trifluoropropan-2-one
MF-65-HS14_0.1uM Dose=0.1uM, (3Z)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-1,1,1-trifluoropropan-2-one
MF-65-HS14_10uM Dose=10uM, (3Z)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-1,1,1-trifluoropropan-2-one
MF-65-HS14_1uM Dose=1uM, (3Z)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-1,1,1-trifluoropropan-2-one
MF-81-RJ18_0.01uM Dose=0.01uM
MF-81-RJ18_0.1uM Dose=0.1uM
MF-81-RJ18_10uM Dose=10uM
MF-81-RJ18_1uM Dose=1uM
NA-00-YS67_0.01uM Dose=0.01uM, CID 9829299, Cysteine Protease Inhibitors targeting CTSS
NA-00-YS67_0.1uM Dose=0.1uM, CID 9829299, Cysteine Protease Inhibitors targeting CTSS
NA-00-YS67_10uM Dose=10uM, CID 9829299, Cysteine Protease Inhibitors targeting CTSS
NA-00-YS67_1uM Dose=1uM, CID 9829299, Cysteine Protease Inhibitors targeting CTSS
NA-07-JX31_0.01uM Dose=0.01uM
NA-07-JX31_0.1uM Dose=0.1uM
NA-07-JX31_10uM Dose=10uM
NA-07-JX31_1uM Dose=1uM
NA-16-OJ70_0.01uM Dose=0.01uM, (4~{S})-4-(4-chloranyl-2-methyl-phenyl)-5-(5-chloranyl-2-methyl-phenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one, Mdm2 p53-binding protein inhibitor targeting MDM2
NA-16-OJ70_0.1uM Dose=0.1uM, (4~{S})-4-(4-chloranyl-2-methyl-phenyl)-5-(5-chloranyl-2-methyl-phenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one, Mdm2 p53-binding protein inhibitor targeting MDM2
NA-16-OJ70_10uM Dose=10uM, (4~{S})-4-(4-chloranyl-2-methyl-phenyl)-5-(5-chloranyl-2-methyl-phenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one, Mdm2 p53-binding protein inhibitor targeting MDM2
NA-16-OJ70_1uM Dose=1uM, (4~{S})-4-(4-chloranyl-2-methyl-phenyl)-5-(5-chloranyl-2-methyl-phenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one, Mdm2 p53-binding protein inhibitor targeting MDM2
NA-22-BX39_0.01uM Dose=0.01uM, 5,8-Dihydroxy-3-methyl-4-(9H)-naphtho(2,3-c)furanone, ELAVL1 gene inhibitor targeting ELAVL1, MYLK
NA-22-BX39_0.1uM Dose=0.1uM, 5,8-Dihydroxy-3-methyl-4-(9H)-naphtho(2,3-c)furanone, ELAVL1 gene inhibitor targeting ELAVL1, MYLK
NA-22-BX39_10uM Dose=10uM, 5,8-Dihydroxy-3-methyl-4-(9H)-naphtho(2,3-c)furanone, ELAVL1 gene inhibitor targeting ELAVL1, MYLK
NA-29-UI75_0.01uM Dose=0.01uM, Casp8-IN-1, covalent modifier of catalytic cysteine of pro-CASP8 targeting CASP8
NA-29-UI75_0.1uM Dose=0.1uM, Casp8-IN-1, covalent modifier of catalytic cysteine of pro-CASP8 targeting CASP8
NA-29-UI75_10uM Dose=10uM, Casp8-IN-1, covalent modifier of catalytic cysteine of pro-CASP8 targeting CASP8
NA-29-UI75_1uM Dose=1uM, Casp8-IN-1, covalent modifier of catalytic cysteine of pro-CASP8 targeting CASP8
NA-30-EF36_0.01uM Dose=0.01uM, Oicr-9429, WDR5 Inhibitor;WDR5 inhibitor targeting WDR5
NA-30-EF36_0.1uM Dose=0.1uM, Oicr-9429, WDR5 Inhibitor;WDR5 inhibitor targeting WDR5
NA-30-EF36_10uM Dose=10uM, Oicr-9429, WDR5 Inhibitor;WDR5 inhibitor targeting WDR5
NA-30-HS87_0.01uM Dose=0.01uM, Gsk-J4, KDM6A gene inhibitor, KDM6B gene inhibitor;pan-KDM6 family (KDM6A / KDM6B / UTY);Histone demethylation inhibitors targeting KDM6A, KDM6B
NA-30-HS87_0.1uM Dose=0.1uM, Gsk-J4, KDM6A gene inhibitor, KDM6B gene inhibitor;pan-KDM6 family (KDM6A / KDM6B / UTY);Histone demethylation inhibitors targeting KDM6A, KDM6B
NA-30-HS87_10uM Dose=10uM, Gsk-J4, KDM6A gene inhibitor, KDM6B gene inhibitor;pan-KDM6 family (KDM6A / KDM6B / UTY);Histone demethylation inhibitors targeting KDM6A, KDM6B
NA-30-HS87_1uM Dose=1uM, Gsk-J4, KDM6A gene inhibitor, KDM6B gene inhibitor;pan-KDM6 family (KDM6A / KDM6B / UTY);Histone demethylation inhibitors targeting KDM6A, KDM6B
NA-42-JG03_0.01uM Dose=0.01uM, (3S,6S,8aS)-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-(2-phenylethyl)-2,3,6,7,8,8a-hexahydro-1H-indolizine-3-carboxamide
NA-42-JG03_0.1uM Dose=0.1uM, (3S,6S,8aS)-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-(2-phenylethyl)-2,3,6,7,8,8a-hexahydro-1H-indolizine-3-carboxamide
NA-42-JG03_10uM Dose=10uM, (3S,6S,8aS)-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-(2-phenylethyl)-2,3,6,7,8,8a-hexahydro-1H-indolizine-3-carboxamide
NA-42-JG03_1uM Dose=1uM, (3S,6S,8aS)-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-(2-phenylethyl)-2,3,6,7,8,8a-hexahydro-1H-indolizine-3-carboxamide
NB-05-VI80_0.01uM Dose=0.01uM
NB-05-VI80_0.1uM Dose=0.1uM
NB-05-VI80_10uM Dose=10uM
NB-05-VI80_1uM Dose=1uM
NB-06-IJ80_0.1uM Dose=0.1uM, Ac-VEID-CHO, CASP6 Inhibitor targeting CASP6
NB-06-IJ80_10uM Dose=10uM, Ac-VEID-CHO, CASP6 Inhibitor targeting CASP6
NB-12-ZK38_0.01uM Dose=0.01uM, 4-[(2s,4r)-1-Acetyl-4-[(4-Chlorophenyl)amino]-2-Methyl-1,2,3,4-Tetrahydroquinolin-6-Yl]benzoic Acid, BET bromodomain inhibitor targeting BRDT, BRD2, BRD3, BRD4
NB-12-ZK38_0.1uM Dose=0.1uM, 4-[(2s,4r)-1-Acetyl-4-[(4-Chlorophenyl)amino]-2-Methyl-1,2,3,4-Tetrahydroquinolin-6-Yl]benzoic Acid, BET bromodomain inhibitor targeting BRDT, BRD2, BRD3, BRD4
NB-12-ZK38_10uM Dose=10uM, 4-[(2s,4r)-1-Acetyl-4-[(4-Chlorophenyl)amino]-2-Methyl-1,2,3,4-Tetrahydroquinolin-6-Yl]benzoic Acid, BET bromodomain inhibitor targeting BRDT, BRD2, BRD3, BRD4
NB-12-ZK38_1uM Dose=1uM, 4-[(2s,4r)-1-Acetyl-4-[(4-Chlorophenyl)amino]-2-Methyl-1,2,3,4-Tetrahydroquinolin-6-Yl]benzoic Acid, BET bromodomain inhibitor targeting BRDT, BRD2, BRD3, BRD4
NB-17-SQ59_0.01uM Dose=0.01uM, SDZ-62-434 free, Platelet-Activating Factor Receptor (PAFR) Antagonists targeting PTAFR
NB-17-SQ59_0.1uM Dose=0.1uM, SDZ-62-434 free, Platelet-Activating Factor Receptor (PAFR) Antagonists targeting PTAFR
NB-17-SQ59_10uM Dose=10uM, SDZ-62-434 free, Platelet-Activating Factor Receptor (PAFR) Antagonists targeting PTAFR
NB-17-SQ59_1uM Dose=1uM, SDZ-62-434 free, Platelet-Activating Factor Receptor (PAFR) Antagonists targeting PTAFR
NB-21-MW29_0.01uM Dose=0.01uM
NB-21-MW29_0.1uM Dose=0.1uM
NB-21-MW29_10uM Dose=10uM
NB-21-MW29_1uM Dose=1uM
NB-24-VE53_0.01uM Dose=0.01uM, Tebanicline, Nicotinic Receptor Agonists targeting CHRNA3, CHRNA4
NB-24-VE53_0.1uM Dose=0.1uM, Tebanicline, Nicotinic Receptor Agonists targeting CHRNA3, CHRNA4
NB-24-VE53_10uM Dose=10uM, Tebanicline, Nicotinic Receptor Agonists targeting CHRNA3, CHRNA4
NB-24-VE53_1uM Dose=1uM, Tebanicline, Nicotinic Receptor Agonists targeting CHRNA3, CHRNA4
NB-31-SG91_0.01uM Dose=0.01uM, 6-O-Methyl Mycophenolic Acid Methyl Ester
NB-31-SG91_0.1uM Dose=0.1uM, 6-O-Methyl Mycophenolic Acid Methyl Ester
NB-31-SG91_10uM Dose=10uM, 6-O-Methyl Mycophenolic Acid Methyl Ester
NB-31-SG91_1uM Dose=1uM, 6-O-Methyl Mycophenolic Acid Methyl Ester
NB-37-AN17_0.01uM Dose=0.01uM
NB-37-AN17_0.1uM Dose=0.1uM
NB-37-AN17_10uM Dose=10uM
NB-37-AN17_1uM Dose=1uM
NB-37-LA11_0.01uM Dose=0.01uM, PLAUR gene inhibitor targeting PLAUR
NB-37-LA11_0.1uM Dose=0.1uM, PLAUR gene inhibitor targeting PLAUR
NB-37-LA11_10uM Dose=10uM, PLAUR gene inhibitor targeting PLAUR
NB-37-LA11_1uM Dose=1uM, PLAUR gene inhibitor targeting PLAUR
NB-48-NL30_0.1uM Dose=0.1uM, 4-[[3-(4-cyanophenyl)-5-methylpyrazol-1-yl]methyl]-N-ethylbenzamide targeting AR
NB-48-NL30_10uM Dose=10uM, 4-[[3-(4-cyanophenyl)-5-methylpyrazol-1-yl]methyl]-N-ethylbenzamide targeting AR
NB-48-NL30_1uM Dose=1uM, 4-[[3-(4-cyanophenyl)-5-methylpyrazol-1-yl]methyl]-N-ethylbenzamide targeting AR
NB-53-OL78_0.01uM Dose=0.01uM, Abt 702, Adenylate kinase inhibitor targeting AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK9, AK6
NB-53-OL78_0.1uM Dose=0.1uM, Abt 702, Adenylate kinase inhibitor targeting AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK9, AK6
NB-53-OL78_10uM Dose=10uM, Abt 702, Adenylate kinase inhibitor targeting AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK9, AK6
NB-53-OL78_1uM Dose=1uM, Abt 702, Adenylate kinase inhibitor targeting AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK9, AK6
NB-58-SA13_0.01uM Dose=0.01uM
NB-58-SA13_0.1uM Dose=0.1uM
NB-58-SA13_10uM Dose=10uM
NB-58-SA13_1uM Dose=1uM
NB-61-FT12_0.01uM Dose=0.01uM, N-Salicyloyltryptamine, Potassium Channel Modulators;Sodium Channel Blockers;L-Type Calcium Channel Blockers targeting KCND3
NB-61-FT12_0.1uM Dose=0.1uM, N-Salicyloyltryptamine, Potassium Channel Modulators;Sodium Channel Blockers;L-Type Calcium Channel Blockers targeting KCND3
NB-61-FT12_10uM Dose=10uM, N-Salicyloyltryptamine, Potassium Channel Modulators;Sodium Channel Blockers;L-Type Calcium Channel Blockers targeting KCND3
NB-61-FT12_1uM Dose=1uM, N-Salicyloyltryptamine, Potassium Channel Modulators;Sodium Channel Blockers;L-Type Calcium Channel Blockers targeting KCND3
NB-62-DN30_0.01uM Dose=0.01uM, Razuprotafib, Protein Tyrosine Phosphatase beta (PTPRB) Inhibitors targeting PTPN1, PTPRB
NB-62-DN30_0.1uM Dose=0.1uM, Razuprotafib, Protein Tyrosine Phosphatase beta (PTPRB) Inhibitors targeting PTPN1, PTPRB
NB-62-DN30_10uM Dose=10uM, Razuprotafib, Protein Tyrosine Phosphatase beta (PTPRB) Inhibitors targeting PTPN1, PTPRB
NB-62-DN30_1uM Dose=1uM, Razuprotafib, Protein Tyrosine Phosphatase beta (PTPRB) Inhibitors targeting PTPN1, PTPRB
NB-73-CA61_0.01uM Dose=0.01uM
NB-73-CA61_0.1uM Dose=0.1uM
NB-73-CA61_10uM Dose=10uM
NB-73-CA61_1uM Dose=1uM
NB-73-PA21_0.01uM Dose=0.01uM, {4-[4-(4-Isopropoxy-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazol-2-ylmethoxy]-2-methyl-phenoxy}-acetic acid targeting PPARD
NB-73-PA21_10uM Dose=10uM, {4-[4-(4-Isopropoxy-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazol-2-ylmethoxy]-2-methyl-phenoxy}-acetic acid targeting PPARD
NB-73-PA21_1uM Dose=1uM, {4-[4-(4-Isopropoxy-phenyl)-5-(4-trifluoromethyl-phenyl)-thiazol-2-ylmethoxy]-2-methyl-phenoxy}-acetic acid targeting PPARD
NB-75-RF23_0.01uM Dose=0.01uM
NB-75-RF23_0.1uM Dose=0.1uM
NB-75-RF23_10uM Dose=10uM
NB-75-RF23_1uM Dose=1uM
NB-79-SE70_0.01uM Dose=0.01uM, N-(4-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine
NB-79-SE70_10uM Dose=10uM, N-(4-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine
NB-79-SE70_1uM Dose=1uM, N-(4-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine
NB-80-IM48_0.01uM Dose=0.01uM, 1-(2-Fluorophenyl)-8-pyridin-4-ylimidazo[4,5-c]quinoline targeting RET
NB-80-IM48_0.1uM Dose=0.1uM, 1-(2-Fluorophenyl)-8-pyridin-4-ylimidazo[4,5-c]quinoline targeting RET
NB-80-IM48_10uM Dose=10uM, 1-(2-Fluorophenyl)-8-pyridin-4-ylimidazo[4,5-c]quinoline targeting RET
NB-80-IM48_1uM Dose=1uM, 1-(2-Fluorophenyl)-8-pyridin-4-ylimidazo[4,5-c]quinoline targeting RET
NB-89-OV56_0.01uM Dose=0.01uM, PF 04802367, GSK3a/b inhibitor targeting GSK3B, GSK3A
NB-89-OV56_0.1uM Dose=0.1uM, PF 04802367, GSK3a/b inhibitor targeting GSK3B, GSK3A
NB-89-OV56_10uM Dose=10uM, PF 04802367, GSK3a/b inhibitor targeting GSK3B, GSK3A
NB-92-BG38_0.01uM Dose=0.01uM, 5-HT7 agonist 2, HTR7 agonist targeting HTR7
NB-92-BG38_0.1uM Dose=0.1uM, 5-HT7 agonist 2, HTR7 agonist targeting HTR7
NB-92-BG38_10uM Dose=10uM, 5-HT7 agonist 2, HTR7 agonist targeting HTR7
NB-92-BG38_1uM Dose=1uM, 5-HT7 agonist 2, HTR7 agonist targeting HTR7
NC-01-ET52_0.01uM Dose=0.01uM, 5-{4-[3-(4-Acetylpiperazine-1-Carbonyl)phenyl]quinazolin-6-Yl}-2-Methoxypyridine-3-Carbonitrile, lipid kinase inhibitor targeting PIK3CD
NC-01-ET52_0.1uM Dose=0.1uM, 5-{4-[3-(4-Acetylpiperazine-1-Carbonyl)phenyl]quinazolin-6-Yl}-2-Methoxypyridine-3-Carbonitrile, lipid kinase inhibitor targeting PIK3CD
NC-01-ET52_10uM Dose=10uM, 5-{4-[3-(4-Acetylpiperazine-1-Carbonyl)phenyl]quinazolin-6-Yl}-2-Methoxypyridine-3-Carbonitrile, lipid kinase inhibitor targeting PIK3CD
NC-01-ET52_1uM Dose=1uM, 5-{4-[3-(4-Acetylpiperazine-1-Carbonyl)phenyl]quinazolin-6-Yl}-2-Methoxypyridine-3-Carbonitrile, lipid kinase inhibitor targeting PIK3CD
NC-05-TZ21_0.01uM Dose=0.01uM
NC-05-TZ21_1uM Dose=1uM
NC-06-IT89_0.01uM Dose=0.01uM, Trientine, Chelating Agents;Telomerase Inhibitors targeting TERT
NC-06-IT89_0.1uM Dose=0.1uM, Trientine, Chelating Agents;Telomerase Inhibitors targeting TERT
NC-06-IT89_10uM Dose=10uM, Trientine, Chelating Agents;Telomerase Inhibitors targeting TERT
NC-06-IT89_1uM Dose=1uM, Trientine, Chelating Agents;Telomerase Inhibitors targeting TERT
NC-11-BC71_10uM Dose=10uM, Lck Kinase Inhibitors;IL-2 Production Inhibitors;Inhibitors of Signal Transduction Pathways targeting IL2, LCK
NC-14-ES72_0.01uM Dose=0.01uM
NC-14-ES72_0.1uM Dose=0.1uM
NC-14-ES72_10uM Dose=10uM
NC-14-ES72_1uM Dose=1uM
NC-27-AD53_0.01uM Dose=0.01uM, Azd-1480, Jak2 Inhibitors targeting JAK1, JAK2
NC-27-AD53_0.1uM Dose=0.1uM, Azd-1480, Jak2 Inhibitors targeting JAK1, JAK2
NC-27-AD53_10uM Dose=10uM, Azd-1480, Jak2 Inhibitors targeting JAK1, JAK2
NC-27-AD53_1uM Dose=1uM, Azd-1480, Jak2 Inhibitors targeting JAK1, JAK2
NC-28-YK77_0.01uM Dose=0.01uM, (4S)-4-[(1R)-2-[[1-(4-tert-butylpyridin-2-yl)cyclopropyl]amino]-1-hydroxyethyl]-18-methyl-3,15,17-triazatricyclo[14.3.1.16,10]henicosa-1(20),6,8,10(21),16,18-hexaen-2-one
NC-28-YK77_0.1uM Dose=0.1uM, (4S)-4-[(1R)-2-[[1-(4-tert-butylpyridin-2-yl)cyclopropyl]amino]-1-hydroxyethyl]-18-methyl-3,15,17-triazatricyclo[14.3.1.16,10]henicosa-1(20),6,8,10(21),16,18-hexaen-2-one
NC-28-YK77_10uM Dose=10uM, (4S)-4-[(1R)-2-[[1-(4-tert-butylpyridin-2-yl)cyclopropyl]amino]-1-hydroxyethyl]-18-methyl-3,15,17-triazatricyclo[14.3.1.16,10]henicosa-1(20),6,8,10(21),16,18-hexaen-2-one
NC-28-YK77_1uM Dose=1uM, (4S)-4-[(1R)-2-[[1-(4-tert-butylpyridin-2-yl)cyclopropyl]amino]-1-hydroxyethyl]-18-methyl-3,15,17-triazatricyclo[14.3.1.16,10]henicosa-1(20),6,8,10(21),16,18-hexaen-2-one
NC-29-PY58_0.01uM Dose=0.01uM, N-[5-[[6-(3-aminophenyl)pyrimidin-4-yl]amino]-2-methylphenyl]-1-methylimidazole-4-sulfonamide, CDK inhibitor targeting CDK2, CCNA1
NC-29-PY58_0.1uM Dose=0.1uM, N-[5-[[6-(3-aminophenyl)pyrimidin-4-yl]amino]-2-methylphenyl]-1-methylimidazole-4-sulfonamide, CDK inhibitor targeting CDK2, CCNA1
NC-29-PY58_10uM Dose=10uM, N-[5-[[6-(3-aminophenyl)pyrimidin-4-yl]amino]-2-methylphenyl]-1-methylimidazole-4-sulfonamide, CDK inhibitor targeting CDK2, CCNA1
NC-29-PY58_1uM Dose=1uM, N-[5-[[6-(3-aminophenyl)pyrimidin-4-yl]amino]-2-methylphenyl]-1-methylimidazole-4-sulfonamide, CDK inhibitor targeting CDK2, CCNA1
NC-35-BF58_0.01uM Dose=0.01uM, 4-[6-(4-Piperidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
NC-35-BF58_0.1uM Dose=0.1uM, 4-[6-(4-Piperidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
NC-35-BF58_10uM Dose=10uM, 4-[6-(4-Piperidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
NC-35-BF58_1uM Dose=1uM, 4-[6-(4-Piperidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
NC-39-KP22_0.01uM Dose=0.01uM, A-1210477, Mcl-1 inhibitor targeting MCL1
NC-39-KP22_0.1uM Dose=0.1uM, A-1210477, Mcl-1 inhibitor targeting MCL1
NC-39-KP22_1uM Dose=1uM, A-1210477, Mcl-1 inhibitor targeting MCL1
NC-42-UX09_0.01uM Dose=0.01uM
NC-42-UX09_0.1uM Dose=0.1uM
NC-42-UX09_10uM Dose=10uM
NC-42-UX09_1uM Dose=1uM
NC-52-AG88_0.01uM Dose=0.01uM, (Z)-N'-(3-chlorophenyl)-N-(4-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1
NC-52-AG88_0.1uM Dose=0.1uM, (Z)-N'-(3-chlorophenyl)-N-(4-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1
NC-52-AG88_10uM Dose=10uM, (Z)-N'-(3-chlorophenyl)-N-(4-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1
NC-52-AG88_1uM Dose=1uM, (Z)-N'-(3-chlorophenyl)-N-(4-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1
NC-52-HX69_0.01uM Dose=0.01uM, Nalmefene, kappa-Opioid Antagonists targeting OPRD1, OPRK1
NC-52-HX69_0.1uM Dose=0.1uM, Nalmefene, kappa-Opioid Antagonists targeting OPRD1, OPRK1
NC-52-HX69_10uM Dose=10uM, Nalmefene, kappa-Opioid Antagonists targeting OPRD1, OPRK1
NC-52-HX69_1uM Dose=1uM, Nalmefene, kappa-Opioid Antagonists targeting OPRD1, OPRK1
NC-54-XY91_0.01uM Dose=0.01uM, 1-(4-Chlorophenyl)-5-cyclohexylpyrazolo[3,4-d]pyrimidin-4-one
NC-54-XY91_0.1uM Dose=0.1uM, 1-(4-Chlorophenyl)-5-cyclohexylpyrazolo[3,4-d]pyrimidin-4-one
NC-54-XY91_10uM Dose=10uM, 1-(4-Chlorophenyl)-5-cyclohexylpyrazolo[3,4-d]pyrimidin-4-one
NC-54-XY91_1uM Dose=1uM, 1-(4-Chlorophenyl)-5-cyclohexylpyrazolo[3,4-d]pyrimidin-4-one
NC-62-VG98_0.01uM Dose=0.01uM, 5-Chloro-2-(mesitylamino)benzamide, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR4, S1PR5
NC-62-VG98_0.1uM Dose=0.1uM, 5-Chloro-2-(mesitylamino)benzamide, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR4, S1PR5
NC-62-VG98_10uM Dose=10uM, 5-Chloro-2-(mesitylamino)benzamide, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR4, S1PR5
NC-62-VG98_1uM Dose=1uM, 5-Chloro-2-(mesitylamino)benzamide, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR4, S1PR5
NC-73-QU79_0.01uM Dose=0.01uM, 3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
NC-73-QU79_0.1uM Dose=0.1uM, 3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
NC-73-QU79_10uM Dose=10uM, 3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
NC-73-QU79_1uM Dose=1uM, 3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1
NC-76-YX69_0.01uM Dose=0.01uM, 2-Amino-4-methylbenzothiazole
NC-76-YX69_0.1uM Dose=0.1uM, 2-Amino-4-methylbenzothiazole
NC-76-YX69_10uM Dose=10uM, 2-Amino-4-methylbenzothiazole
NC-76-YX69_1uM Dose=1uM, 2-Amino-4-methylbenzothiazole
NC-85-PZ41_0.01uM Dose=0.01uM, Mln-4760, Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors targeting ACE2
NC-85-PZ41_0.1uM Dose=0.1uM, Mln-4760, Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors targeting ACE2
NC-85-PZ41_10uM Dose=10uM, Mln-4760, Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors targeting ACE2
NC-85-PZ41_1uM Dose=1uM, Mln-4760, Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors targeting ACE2
NC-94-LE33_0.01uM Dose=0.01uM, Lomeguatrib, MGMT gene inhibitor targeting MGMT
NC-94-LE33_0.1uM Dose=0.1uM, Lomeguatrib, MGMT gene inhibitor targeting MGMT
NC-94-LE33_10uM Dose=10uM, Lomeguatrib, MGMT gene inhibitor targeting MGMT
ND-03-LH88_0.01uM Dose=0.01uM, Gsk-2636771, PI3Kbeta inhibitor targeting PIK3CB
ND-03-LH88_0.1uM Dose=0.1uM, Gsk-2636771, PI3Kbeta inhibitor targeting PIK3CB
ND-03-LH88_10uM Dose=10uM, Gsk-2636771, PI3Kbeta inhibitor targeting PIK3CB
ND-03-LH88_1uM Dose=1uM, Gsk-2636771, PI3Kbeta inhibitor targeting PIK3CB
ND-06-AJ85_0.01uM Dose=0.01uM, N-[7-[1-[[2-(4-chlorophenyl)-6-fluorophenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2
ND-06-AJ85_0.1uM Dose=0.1uM, N-[7-[1-[[2-(4-chlorophenyl)-6-fluorophenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2
ND-06-AJ85_10uM Dose=10uM, N-[7-[1-[[2-(4-chlorophenyl)-6-fluorophenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2
ND-06-AJ85_1uM Dose=1uM, N-[7-[1-[[2-(4-chlorophenyl)-6-fluorophenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2
ND-07-WN37_0.01uM Dose=0.01uM, Padnarsertib, Allosteric inhibitor that degrades PAK4 targeting PAK4
ND-07-WN37_0.1uM Dose=0.1uM, Padnarsertib, Allosteric inhibitor that degrades PAK4 targeting PAK4
ND-07-WN37_10uM Dose=10uM, Padnarsertib, Allosteric inhibitor that degrades PAK4 targeting PAK4
ND-07-WN37_1uM Dose=1uM, Padnarsertib, Allosteric inhibitor that degrades PAK4 targeting PAK4
ND-15-RC31_0.01uM Dose=0.01uM, 6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid, POLA1 inhibitor targeting POLA1
ND-15-RC31_0.1uM Dose=0.1uM, 6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid, POLA1 inhibitor targeting POLA1
ND-15-RC31_10uM Dose=10uM, 6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid, POLA1 inhibitor targeting POLA1
ND-15-RC31_1uM Dose=1uM, 6-(4-Hydroxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid, POLA1 inhibitor targeting POLA1
ND-20-AS37_0.01uM Dose=0.01uM, 4-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
ND-20-AS37_0.1uM Dose=0.1uM, 4-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
ND-20-AS37_10uM Dose=10uM, 4-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
ND-20-AS37_1uM Dose=1uM, 4-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
ND-27-UQ99_0.01uM Dose=0.01uM, (3S,4S,5R)-3-(3-Bromo-4-hydroxy-benzyl)-5-(3-tert-butyl-benzylamino)-1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-ol, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting CTSE, BACE1, BACE2
ND-27-UQ99_0.1uM Dose=0.1uM, (3S,4S,5R)-3-(3-Bromo-4-hydroxy-benzyl)-5-(3-tert-butyl-benzylamino)-1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-ol, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting CTSE, BACE1, BACE2
ND-27-UQ99_10uM Dose=10uM, (3S,4S,5R)-3-(3-Bromo-4-hydroxy-benzyl)-5-(3-tert-butyl-benzylamino)-1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-ol, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting CTSE, BACE1, BACE2
ND-27-UQ99_1uM Dose=1uM, (3S,4S,5R)-3-(3-Bromo-4-hydroxy-benzyl)-5-(3-tert-butyl-benzylamino)-1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-ol, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting CTSE, BACE1, BACE2
ND-33-UV62_0.01uM Dose=0.01uM, Tasquinimod, Histone Deacetylase 4 (HDAC4) Inhibitors;S100A9 Inhibitors targeting S100A9, HDAC4
ND-33-UV62_0.1uM Dose=0.1uM, Tasquinimod, Histone Deacetylase 4 (HDAC4) Inhibitors;S100A9 Inhibitors targeting S100A9, HDAC4
ND-33-UV62_10uM Dose=10uM, Tasquinimod, Histone Deacetylase 4 (HDAC4) Inhibitors;S100A9 Inhibitors targeting S100A9, HDAC4
ND-33-UV62_1uM Dose=1uM, Tasquinimod, Histone Deacetylase 4 (HDAC4) Inhibitors;S100A9 Inhibitors targeting S100A9, HDAC4
ND-35-VF18_0.01uM Dose=0.01uM, (4-{[(5-{[(3-Chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, PTGER4 agonist;Prostanoid EP4 Agonists targeting PTGER4
ND-35-VF18_0.1uM Dose=0.1uM, (4-{[(5-{[(3-Chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, PTGER4 agonist;Prostanoid EP4 Agonists targeting PTGER4
ND-35-VF18_1uM Dose=1uM, (4-{[(5-{[(3-Chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, PTGER4 agonist;Prostanoid EP4 Agonists targeting PTGER4
ND-35-ZI55_10uM Dose=10uM, Cariporide, Na+/H+ Exchanger type 1 (NHE-1) Inhibitors targeting SLC9A1
ND-36-VC68_0.01uM Dose=0.01uM
ND-36-VC68_0.1uM Dose=0.1uM
ND-36-VC68_10uM Dose=10uM
ND-36-VC68_1uM Dose=1uM
ND-39-PO34_0.1uM Dose=0.1uM, n-(1-Methylbenzo[f]quinazolin-3-yl)guanidine targeting NPY1R, NPFFR1
ND-39-PO34_10uM Dose=10uM, n-(1-Methylbenzo[f]quinazolin-3-yl)guanidine targeting NPY1R, NPFFR1
ND-39-PO34_1uM Dose=1uM, n-(1-Methylbenzo[f]quinazolin-3-yl)guanidine targeting NPY1R, NPFFR1
ND-48-XK57_0.01uM Dose=0.01uM
ND-48-XK57_0.1uM Dose=0.1uM
ND-48-XK57_10uM Dose=10uM
ND-48-XK57_1uM Dose=1uM
ND-54-FY31_0.01uM Dose=0.01uM, 2-Nitrobenzenesulfonamide
ND-54-FY31_0.1uM Dose=0.1uM, 2-Nitrobenzenesulfonamide
ND-54-FY31_10uM Dose=10uM, 2-Nitrobenzenesulfonamide
ND-54-FY31_1uM Dose=1uM, 2-Nitrobenzenesulfonamide
ND-54-NO97_0.01uM Dose=0.01uM, 3-Epioleanolic acid
ND-54-NO97_0.1uM Dose=0.1uM, 3-Epioleanolic acid
ND-54-NO97_10uM Dose=10uM, 3-Epioleanolic acid
ND-54-NO97_1uM Dose=1uM, 3-Epioleanolic acid
ND-56-OT44_0.01uM Dose=0.01uM, Benzamide, N-[(1S)-3-[4-(2-aminocyclopropyl)phenoxy]-1-[[(phenylmethyl)amino]carbonyl]propyl]-, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A
ND-56-OT44_0.1uM Dose=0.1uM, Benzamide, N-[(1S)-3-[4-(2-aminocyclopropyl)phenoxy]-1-[[(phenylmethyl)amino]carbonyl]propyl]-, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A
ND-56-OT44_10uM Dose=10uM, Benzamide, N-[(1S)-3-[4-(2-aminocyclopropyl)phenoxy]-1-[[(phenylmethyl)amino]carbonyl]propyl]-, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A
ND-56-OT44_1uM Dose=1uM, Benzamide, N-[(1S)-3-[4-(2-aminocyclopropyl)phenoxy]-1-[[(phenylmethyl)amino]carbonyl]propyl]-, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A
ND-57-WU44_0.01uM Dose=0.01uM, (2S,3R,4R)-3-hydroxy-4-[(4-phenylphenyl)methoxy]pyrrolidine-2-carboxylic acid, Anti-ASCT2 (Neutral Amino Acid Transporter) targeting SLC1A4, SLC1A5
ND-57-WU44_0.1uM Dose=0.1uM, (2S,3R,4R)-3-hydroxy-4-[(4-phenylphenyl)methoxy]pyrrolidine-2-carboxylic acid, Anti-ASCT2 (Neutral Amino Acid Transporter) targeting SLC1A4, SLC1A5
ND-57-WU44_10uM Dose=10uM, (2S,3R,4R)-3-hydroxy-4-[(4-phenylphenyl)methoxy]pyrrolidine-2-carboxylic acid, Anti-ASCT2 (Neutral Amino Acid Transporter) targeting SLC1A4, SLC1A5
ND-57-WU44_1uM Dose=1uM, (2S,3R,4R)-3-hydroxy-4-[(4-phenylphenyl)methoxy]pyrrolidine-2-carboxylic acid, Anti-ASCT2 (Neutral Amino Acid Transporter) targeting SLC1A4, SLC1A5
ND-66-KW81_0.01uM Dose=0.01uM, A-161906, TNF-alpha Production Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
ND-66-KW81_0.1uM Dose=0.1uM, A-161906, TNF-alpha Production Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
ND-66-KW81_10uM Dose=10uM, A-161906, TNF-alpha Production Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
ND-66-KW81_1uM Dose=1uM, A-161906, TNF-alpha Production Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
ND-68-CU31_0.01uM Dose=0.01uM, MR 16728, Acetylcholine Release Enhancers targeting KCNN4
ND-68-CU31_0.1uM Dose=0.1uM, MR 16728, Acetylcholine Release Enhancers targeting KCNN4
ND-68-CU31_10uM Dose=10uM, MR 16728, Acetylcholine Release Enhancers targeting KCNN4
ND-68-CU31_1uM Dose=1uM, MR 16728, Acetylcholine Release Enhancers targeting KCNN4
ND-85-OJ63_0.01uM Dose=0.01uM, Ezutromid, UTRN (Utrophin gene) Expression Enhancers targeting AHR
ND-85-OJ63_0.1uM Dose=0.1uM, Ezutromid, UTRN (Utrophin gene) Expression Enhancers targeting AHR
ND-85-OJ63_10uM Dose=10uM, Ezutromid, UTRN (Utrophin gene) Expression Enhancers targeting AHR
ND-85-OJ63_1uM Dose=1uM, Ezutromid, UTRN (Utrophin gene) Expression Enhancers targeting AHR
ND-86-GT24_0.01uM Dose=0.01uM, 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-, Histamine H4 Receptor Antagonists;HRH4 antagonist targeting HRH4
ND-86-GT24_0.1uM Dose=0.1uM, 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-, Histamine H4 Receptor Antagonists;HRH4 antagonist targeting HRH4
ND-86-GT24_10uM Dose=10uM, 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-, Histamine H4 Receptor Antagonists;HRH4 antagonist targeting HRH4
ND-86-GT24_1uM Dose=1uM, 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-, Histamine H4 Receptor Antagonists;HRH4 antagonist targeting HRH4
NE-00-JZ19_0.01uM Dose=0.01uM, 4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile, Protein Kinase PKC theta Inhibitors targeting PRKCQ
NE-00-JZ19_0.1uM Dose=0.1uM, 4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile, Protein Kinase PKC theta Inhibitors targeting PRKCQ
NE-00-JZ19_10uM Dose=10uM, 4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile, Protein Kinase PKC theta Inhibitors targeting PRKCQ
NE-00-JZ19_1uM Dose=1uM, 4-(4-methyl-1H-indol-5-ylamino)-5-(5-((4-methylpiperazin-1-yl)methyl)benzofuran-2-yl)nicotinonitrile, Protein Kinase PKC theta Inhibitors targeting PRKCQ
NE-14-AO67_0.01uM Dose=0.01uM
NE-14-AO67_0.1uM Dose=0.1uM
NE-14-AO67_10uM Dose=10uM
NE-14-AO67_1uM Dose=1uM
NE-20-WM78_0.01uM Dose=0.01uM, Cct-241533, Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2
NE-20-WM78_0.1uM Dose=0.1uM, Cct-241533, Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2
NE-20-WM78_10uM Dose=10uM, Cct-241533, Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2
NE-20-WM78_1uM Dose=1uM, Cct-241533, Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK2
NE-24-ZO47_0.01uM Dose=0.01uM, N-[5-bromo-3-[[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]methoxy]pyrazin-2-yl]-4-methylbenzenesulfonamide, Chemokine CCR4 Antagonists targeting CCR4
NE-24-ZO47_0.1uM Dose=0.1uM, N-[5-bromo-3-[[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]methoxy]pyrazin-2-yl]-4-methylbenzenesulfonamide, Chemokine CCR4 Antagonists targeting CCR4
NE-24-ZO47_10uM Dose=10uM, N-[5-bromo-3-[[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]methoxy]pyrazin-2-yl]-4-methylbenzenesulfonamide, Chemokine CCR4 Antagonists targeting CCR4
NE-24-ZO47_1uM Dose=1uM, N-[5-bromo-3-[[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]methoxy]pyrazin-2-yl]-4-methylbenzenesulfonamide, Chemokine CCR4 Antagonists targeting CCR4
NE-27-MD08_0.01uM Dose=0.01uM, N-[1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide, Motilin Receptor Antagonist targeting MLNR
NE-27-MD08_0.1uM Dose=0.1uM, N-[1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide, Motilin Receptor Antagonist targeting MLNR
NE-27-MD08_10uM Dose=10uM, N-[1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide, Motilin Receptor Antagonist targeting MLNR
NE-27-MD08_1uM Dose=1uM, N-[1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide, Motilin Receptor Antagonist targeting MLNR
NE-29-VB58_0.01uM Dose=0.01uM, L 692429, GHS Receptor Antagonists;GHSR agonist targeting GHSR
NE-29-VB58_0.1uM Dose=0.1uM, L 692429, GHS Receptor Antagonists;GHSR agonist targeting GHSR
NE-29-VB58_10uM Dose=10uM, L 692429, GHS Receptor Antagonists;GHSR agonist targeting GHSR
NE-29-VB58_1uM Dose=1uM, L 692429, GHS Receptor Antagonists;GHSR agonist targeting GHSR
NE-34-OZ69_0.01uM Dose=0.01uM, (S)-2-((9-([1,1'-biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol, ADP ribosylation factor 1 inhibitor targeting ARFGAP1
NE-34-OZ69_0.1uM Dose=0.1uM, (S)-2-((9-([1,1'-biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol, ADP ribosylation factor 1 inhibitor targeting ARFGAP1
NE-34-OZ69_10uM Dose=10uM, (S)-2-((9-([1,1'-biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol, ADP ribosylation factor 1 inhibitor targeting ARFGAP1
NE-34-OZ69_1uM Dose=1uM, (S)-2-((9-([1,1'-biphenyl]-4-ylmethyl)-2-((2,3-dihydro-1H-inden-5-yl)oxy)-9H-purin-6-yl)amino)-3-phenylpropan-1-ol, ADP ribosylation factor 1 inhibitor targeting ARFGAP1
NE-37-BQ24_0.01uM Dose=0.01uM, (S) FTY720 Phosphate, S1PR3 agonist targeting S1PR3
NE-37-BQ24_10uM Dose=10uM, (S) FTY720 Phosphate, S1PR3 agonist targeting S1PR3
NE-37-BQ24_1uM Dose=1uM, (S) FTY720 Phosphate, S1PR3 agonist targeting S1PR3
NE-37-JX51_0.01uM Dose=0.01uM
NE-37-JX51_0.1uM Dose=0.1uM
NE-37-JX51_10uM Dose=10uM
NE-37-JX51_1uM Dose=1uM
NE-42-YQ17_0.01uM Dose=0.01uM
NE-42-YQ17_0.1uM Dose=0.1uM
NE-42-YQ17_10uM Dose=10uM
NE-42-YQ17_1uM Dose=1uM
NE-45-SF73_0.01uM Dose=0.01uM
NE-45-SF73_0.1uM Dose=0.1uM
NE-45-SF73_10uM Dose=10uM
NE-45-SF73_1uM Dose=1uM
NE-55-KI60_0.01uM Dose=0.01uM, Matrix Metalloproteinase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
NE-55-KI60_0.1uM Dose=0.1uM, Matrix Metalloproteinase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
NE-55-KI60_10uM Dose=10uM, Matrix Metalloproteinase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
NE-55-KI60_1uM Dose=1uM, Matrix Metalloproteinase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
NE-92-EU87_0.01uM Dose=0.01uM, Abl127, Protein Phosphatase Methylesterase 1 Inhibitor targeting PPME1
NE-92-EU87_0.1uM Dose=0.1uM, Abl127, Protein Phosphatase Methylesterase 1 Inhibitor targeting PPME1
NE-92-EU87_10uM Dose=10uM, Abl127, Protein Phosphatase Methylesterase 1 Inhibitor targeting PPME1
NE-92-EU87_1uM Dose=1uM, Abl127, Protein Phosphatase Methylesterase 1 Inhibitor targeting PPME1
NE-93-AH13_0.01uM Dose=0.01uM, 5-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyridin-2-one
NE-93-AH13_0.1uM Dose=0.1uM, 5-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyridin-2-one
NE-93-AH13_10uM Dose=10uM, 5-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyridin-2-one
NE-93-AH13_1uM Dose=1uM, 5-(1H-pyrazol-4-yl)-1-[4-(trifluoromethoxy)phenyl]pyridin-2-one
NE-94-VE83_0.01uM Dose=0.01uM
NE-94-VE83_0.1uM Dose=0.1uM
NE-94-VE83_10uM Dose=10uM
NE-94-VE83_1uM Dose=1uM
NE-95-RP07_0.01uM Dose=0.01uM, N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea, ACAT Inhibitors;Lipid Lowering Agents targeting ACAT1, ACAT2, SOAT1
NE-95-RP07_0.1uM Dose=0.1uM, N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea, ACAT Inhibitors;Lipid Lowering Agents targeting ACAT1, ACAT2, SOAT1
NE-95-RP07_10uM Dose=10uM, N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea, ACAT Inhibitors;Lipid Lowering Agents targeting ACAT1, ACAT2, SOAT1
NE-95-RP07_1uM Dose=1uM, N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea, ACAT Inhibitors;Lipid Lowering Agents targeting ACAT1, ACAT2, SOAT1
NF-07-NX76_0.01uM Dose=0.01uM, example 166 [WO2014154727], Cathepsin A inhibitor targeting CTSA
NF-07-NX76_10uM Dose=10uM, example 166 [WO2014154727], Cathepsin A inhibitor targeting CTSA
NF-07-NX76_1uM Dose=1uM, example 166 [WO2014154727], Cathepsin A inhibitor targeting CTSA
NF-10-JP55_0.01uM Dose=0.01uM
NF-10-JP55_0.1uM Dose=0.1uM
NF-10-JP55_10uM Dose=10uM
NF-10-JP55_1uM Dose=1uM
NF-19-JL47_0.01uM Dose=0.01uM, 2-Amino-5-[(1-Methoxy-2-Methylindolizin-3-Yl)carbonyl]benzoic Acid, Allosteric inhibitor binding extracellular domain targeting FGFR3, FGFR2, FGFR4
NF-19-JL47_0.1uM Dose=0.1uM, 2-Amino-5-[(1-Methoxy-2-Methylindolizin-3-Yl)carbonyl]benzoic Acid, Allosteric inhibitor binding extracellular domain targeting FGFR3, FGFR2, FGFR4
NF-19-JL47_10uM Dose=10uM, 2-Amino-5-[(1-Methoxy-2-Methylindolizin-3-Yl)carbonyl]benzoic Acid, Allosteric inhibitor binding extracellular domain targeting FGFR3, FGFR2, FGFR4
NF-19-JL47_1uM Dose=1uM, 2-Amino-5-[(1-Methoxy-2-Methylindolizin-3-Yl)carbonyl]benzoic Acid, Allosteric inhibitor binding extracellular domain targeting FGFR3, FGFR2, FGFR4
NF-21-HQ00_0.01uM Dose=0.01uM, Cct251236 targeting PIR
NF-21-HQ00_0.1uM Dose=0.1uM, Cct251236 targeting PIR
NF-21-HQ00_10uM Dose=10uM, Cct251236 targeting PIR
NF-21-HQ00_1uM Dose=1uM, Cct251236 targeting PIR
NF-24-NB76_0.01uM Dose=0.01uM, N-(3-(5-Amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-chloropicolinamide, beta-Secretase 1 (BACE1) Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting BACE1, BACE2
NF-24-NB76_0.1uM Dose=0.1uM, N-(3-(5-Amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-chloropicolinamide, beta-Secretase 1 (BACE1) Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting BACE1, BACE2
NF-24-NB76_10uM Dose=10uM, N-(3-(5-Amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-chloropicolinamide, beta-Secretase 1 (BACE1) Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting BACE1, BACE2
NF-24-NB76_1uM Dose=1uM, N-(3-(5-Amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-chloropicolinamide, beta-Secretase 1 (BACE1) Inhibitors;beta-Secretase 2 (BACE2) Inhibitors targeting BACE1, BACE2
NF-27-AQ24_0.01uM Dose=0.01uM, GR 46611, HTR1D agonist targeting HTR1D
NF-27-AQ24_0.1uM Dose=0.1uM, GR 46611, HTR1D agonist targeting HTR1D
NF-27-AQ24_10uM Dose=10uM, GR 46611, HTR1D agonist targeting HTR1D
NF-27-AQ24_1uM Dose=1uM, GR 46611, HTR1D agonist targeting HTR1D
NF-51-FT62_0.01uM Dose=0.01uM
NF-51-FT62_0.1uM Dose=0.1uM
NF-51-FT62_1uM Dose=1uM
NF-53-AH73_0.01uM Dose=0.01uM, Riociguat, Guanylate Cyclase Activators targeting GUCY1A2
NF-53-AH73_0.1uM Dose=0.1uM, Riociguat, Guanylate Cyclase Activators targeting GUCY1A2
NF-53-AH73_10uM Dose=10uM, Riociguat, Guanylate Cyclase Activators targeting GUCY1A2
NF-53-AH73_1uM Dose=1uM, Riociguat, Guanylate Cyclase Activators targeting GUCY1A2
NF-64-RE03_0.01uM Dose=0.01uM, 3-(3-Bromo-5-methoxy-4-(octyloxy)benzylamino)propylphosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5
NF-64-RE03_0.1uM Dose=0.1uM, 3-(3-Bromo-5-methoxy-4-(octyloxy)benzylamino)propylphosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5
NF-64-RE03_10uM Dose=10uM, 3-(3-Bromo-5-methoxy-4-(octyloxy)benzylamino)propylphosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5
NF-77-LG65_0.01uM Dose=0.01uM, 3-Biphenyl-4-yl-2-{[1-(2-mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2
NF-77-LG65_0.1uM Dose=0.1uM, 3-Biphenyl-4-yl-2-{[1-(2-mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2
NF-77-LG65_10uM Dose=10uM, 3-Biphenyl-4-yl-2-{[1-(2-mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2
NF-77-LG65_1uM Dose=1uM, 3-Biphenyl-4-yl-2-{[1-(2-mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2
OA-10-AB96_0.1uM Dose=0.1uM, (2S)-4-methyl-2-[[4-phenyl-2-(sulfanylmethyl)butanoyl]amino]pentanamide, Collagenase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
OA-10-AB96_10uM Dose=10uM, (2S)-4-methyl-2-[[4-phenyl-2-(sulfanylmethyl)butanoyl]amino]pentanamide, Collagenase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
OA-10-AB96_1uM Dose=1uM, (2S)-4-methyl-2-[[4-phenyl-2-(sulfanylmethyl)butanoyl]amino]pentanamide, Collagenase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
OA-10-PB21_0.01uM Dose=0.01uM, Tiospirone, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
OA-10-PB21_0.1uM Dose=0.1uM, Tiospirone, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
OA-10-PB21_10uM Dose=10uM, Tiospirone, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
OA-10-PB21_1uM Dose=1uM, Tiospirone, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F
OA-12-SU22_0.01uM Dose=0.01uM, Sc-560, Cyclooxygenase-1 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
OA-12-SU22_0.1uM Dose=0.1uM, Sc-560, Cyclooxygenase-1 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
OA-12-SU22_10uM Dose=10uM, Sc-560, Cyclooxygenase-1 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
OA-12-SU22_1uM Dose=1uM, Sc-560, Cyclooxygenase-1 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2
OA-15-DB28_0.01uM Dose=0.01uM
OA-15-DB28_0.1uM Dose=0.1uM
OA-15-DB28_10uM Dose=10uM
OA-15-DB28_1uM Dose=1uM
OA-16-KC73_0.01uM Dose=0.01uM, Ponalrestat, Aldose Reductase Inhibitors targeting AKR1B1, AKR1A1
OA-16-KC73_0.1uM Dose=0.1uM, Ponalrestat, Aldose Reductase Inhibitors targeting AKR1B1, AKR1A1
OA-16-KC73_10uM Dose=10uM, Ponalrestat, Aldose Reductase Inhibitors targeting AKR1B1, AKR1A1
OA-16-KC73_1uM Dose=1uM, Ponalrestat, Aldose Reductase Inhibitors targeting AKR1B1, AKR1A1
OA-39-IH02_0.01uM Dose=0.01uM, Rasagiline, MAO-B Inhibitors targeting MAOB
OA-39-IH02_0.1uM Dose=0.1uM, Rasagiline, MAO-B Inhibitors targeting MAOB
OA-39-IH02_1uM Dose=1uM, Rasagiline, MAO-B Inhibitors targeting MAOB
OA-45-SS39_0.01uM Dose=0.01uM, (4-((5S,7R)-5-(3,4-Dimethoxyphenyl)-7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-2-yl)phenyl)(piperazin-1-yl)methanone, Toll-like receptor 7, toll-like receptor 8 targeting TLR7, TLR8
OA-45-SS39_1uM Dose=1uM, (4-((5S,7R)-5-(3,4-Dimethoxyphenyl)-7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-2-yl)phenyl)(piperazin-1-yl)methanone, Toll-like receptor 7, toll-like receptor 8 targeting TLR7, TLR8
OA-46-YF15_0.01uM Dose=0.01uM, H-Asp-Glu-Val-Asp-al, Apoptosis Inhibitors;Caspase 3 Inhibitors;Caspase 8 Inhibitors targeting CASP3, CASP8
OA-46-YF15_0.1uM Dose=0.1uM, H-Asp-Glu-Val-Asp-al, Apoptosis Inhibitors;Caspase 3 Inhibitors;Caspase 8 Inhibitors targeting CASP3, CASP8
OA-46-YF15_1uM Dose=1uM, H-Asp-Glu-Val-Asp-al, Apoptosis Inhibitors;Caspase 3 Inhibitors;Caspase 8 Inhibitors targeting CASP3, CASP8
OA-51-KF88_0.01uM Dose=0.01uM, Lodoxamide targeting ARRB2, GPR35
OA-51-KF88_0.1uM Dose=0.1uM, Lodoxamide targeting ARRB2, GPR35
OA-51-KF88_1uM Dose=1uM, Lodoxamide targeting ARRB2, GPR35
OA-54-FL10_0.01uM Dose=0.01uM
OA-54-FL10_0.1uM Dose=0.1uM
OA-54-FL10_10uM Dose=10uM
OA-54-FL10_1uM Dose=1uM
OA-62-NJ00_0.01uM Dose=0.01uM
OA-62-NJ00_0.1uM Dose=0.1uM
OA-62-NJ00_10uM Dose=10uM
OA-62-NJ00_1uM Dose=1uM
OA-73-DX11_0.01uM Dose=0.01uM, Imipramine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors;Sodium Channel Blockers targeting ADRA1A, HRH1, HTR2A, SLC6A2, SLC6A4
OA-73-DX11_0.1uM Dose=0.1uM, Imipramine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors;Sodium Channel Blockers targeting ADRA1A, HRH1, HTR2A, SLC6A2, SLC6A4
OA-73-DX11_1uM Dose=1uM, Imipramine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors;Sodium Channel Blockers targeting ADRA1A, HRH1, HTR2A, SLC6A2, SLC6A4
OA-74-FH10_0.01uM Dose=0.01uM, Losartan Carboxaldehyde, Cyclooxygenase-2 Inhibitors;Angiotensin AT1 Antagonists targeting AGTR1, PTGS2
OA-74-FH10_0.1uM Dose=0.1uM, Losartan Carboxaldehyde, Cyclooxygenase-2 Inhibitors;Angiotensin AT1 Antagonists targeting AGTR1, PTGS2
OA-74-FH10_10uM Dose=10uM, Losartan Carboxaldehyde, Cyclooxygenase-2 Inhibitors;Angiotensin AT1 Antagonists targeting AGTR1, PTGS2
OA-80-YT10_0.01uM Dose=0.01uM, (2S)-1-(3-Azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide targeting SMYD3
OA-80-YT10_0.1uM Dose=0.1uM, (2S)-1-(3-Azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide targeting SMYD3
OA-80-YT10_10uM Dose=10uM, (2S)-1-(3-Azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide targeting SMYD3
OA-80-YT10_1uM Dose=1uM, (2S)-1-(3-Azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide targeting SMYD3
OA-86-XP09_0.01uM Dose=0.01uM, 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B
OA-86-XP09_0.1uM Dose=0.1uM, 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B
OA-86-XP09_10uM Dose=10uM, 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B
OA-86-XP09_1uM Dose=1uM, 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B
OA-89-EE65_0.01uM Dose=0.01uM, N-[4-chloro-2-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-4-(trifluoromethoxy)benzenesulfonamide
OA-89-EE65_0.1uM Dose=0.1uM, N-[4-chloro-2-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-4-(trifluoromethoxy)benzenesulfonamide
OA-89-EE65_10uM Dose=10uM, N-[4-chloro-2-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-4-(trifluoromethoxy)benzenesulfonamide
OA-89-EE65_1uM Dose=1uM, N-[4-chloro-2-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-4-(trifluoromethoxy)benzenesulfonamide
OB-01-DJ93_0.01uM Dose=0.01uM, Mardepodect, Phosphodiesterase 10A Inhibitors targeting PDE10A
OB-01-DJ93_10uM Dose=10uM, Mardepodect, Phosphodiesterase 10A Inhibitors targeting PDE10A
OB-01-DJ93_1uM Dose=1uM, Mardepodect, Phosphodiesterase 10A Inhibitors targeting PDE10A
OB-06-WW76_0.01uM Dose=0.01uM, Roxatidine acetate, HRH2 antagonist targeting HRH2
OB-06-WW76_0.1uM Dose=0.1uM, Roxatidine acetate, HRH2 antagonist targeting HRH2
OB-06-WW76_10uM Dose=10uM, Roxatidine acetate, HRH2 antagonist targeting HRH2
OB-06-WW76_1uM Dose=1uM, Roxatidine acetate, HRH2 antagonist targeting HRH2
OB-15-UL37_0.01uM Dose=0.01uM, [(1S)-1-[ethyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]ethyl]phosphonic acid targeting GRIA4
OB-15-UL37_10uM Dose=10uM, [(1S)-1-[ethyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]ethyl]phosphonic acid targeting GRIA4
OB-15-UL37_1uM Dose=1uM, [(1S)-1-[ethyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]ethyl]phosphonic acid targeting GRIA4
OB-17-DQ74_0.01uM Dose=0.01uM, Selinexor, Exportin 1 inhibitor targeting XPO1
OB-17-DQ74_0.1uM Dose=0.1uM, Selinexor, Exportin 1 inhibitor targeting XPO1
OB-17-DQ74_10uM Dose=10uM, Selinexor, Exportin 1 inhibitor targeting XPO1
OB-17-DQ74_1uM Dose=1uM, Selinexor, Exportin 1 inhibitor targeting XPO1
OB-20-LP90_0.01uM Dose=0.01uM, CID 11957585, OXTR antagonist targeting OXTR
OB-20-LP90_0.1uM Dose=0.1uM, CID 11957585, OXTR antagonist targeting OXTR
OB-20-LP90_10uM Dose=10uM, CID 11957585, OXTR antagonist targeting OXTR
OB-20-LP90_1uM Dose=1uM, CID 11957585, OXTR antagonist targeting OXTR
OB-22-TT14_0.01uM Dose=0.01uM, 3,4-Dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone, Influenza A virus RNA Promoter Binder;PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
OB-22-TT14_0.1uM Dose=0.1uM, 3,4-Dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone, Influenza A virus RNA Promoter Binder;PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
OB-22-TT14_10uM Dose=10uM, 3,4-Dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone, Influenza A virus RNA Promoter Binder;PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
OB-22-TT14_1uM Dose=1uM, 3,4-Dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone, Influenza A virus RNA Promoter Binder;PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1
OB-28-LD05_0.01uM Dose=0.01uM, 1-Amino-4-[4-[(4-aminophenyl)methyl]anilino]-9,10-dioxoanthracene-2-sulfonic acid
OB-28-LD05_0.1uM Dose=0.1uM, 1-Amino-4-[4-[(4-aminophenyl)methyl]anilino]-9,10-dioxoanthracene-2-sulfonic acid
OB-28-LD05_10uM Dose=10uM, 1-Amino-4-[4-[(4-aminophenyl)methyl]anilino]-9,10-dioxoanthracene-2-sulfonic acid
OB-28-LD05_1uM Dose=1uM, 1-Amino-4-[4-[(4-aminophenyl)methyl]anilino]-9,10-dioxoanthracene-2-sulfonic acid
OB-41-EW79_0.01uM Dose=0.01uM, Liranaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE
OB-41-EW79_0.1uM Dose=0.1uM, Liranaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE
OB-41-EW79_10uM Dose=10uM, Liranaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE
OB-41-EW79_1uM Dose=1uM, Liranaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE
OB-44-HO47_0.01uM Dose=0.01uM
OB-44-HO47_0.1uM Dose=0.1uM
OB-44-HO47_10uM Dose=10uM
OB-44-HO47_1uM Dose=1uM
OB-46-IM27_0.01uM Dose=0.01uM, N-[2-[[3-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]ethyl]acetamide
OB-46-IM27_0.1uM Dose=0.1uM, N-[2-[[3-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]ethyl]acetamide
OB-46-IM27_10uM Dose=10uM, N-[2-[[3-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]ethyl]acetamide
OB-46-IM27_1uM Dose=1uM, N-[2-[[3-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]ethyl]acetamide
OB-61-XZ91_0.01uM Dose=0.01uM, Neurotrophic Agents targeting ADA, PNP
OB-61-XZ91_0.1uM Dose=0.1uM, Neurotrophic Agents targeting ADA, PNP
OB-61-XZ91_10uM Dose=10uM, Neurotrophic Agents targeting ADA, PNP
OB-61-XZ91_1uM Dose=1uM, Neurotrophic Agents targeting ADA, PNP
OB-65-AI50_0.01uM Dose=0.01uM, Rgfp966, HDAC3 active-site competitive inhibitor;HDAC3 targeting HDAC3
OB-65-AI50_0.1uM Dose=0.1uM, Rgfp966, HDAC3 active-site competitive inhibitor;HDAC3 targeting HDAC3
OB-65-AI50_10uM Dose=10uM, Rgfp966, HDAC3 active-site competitive inhibitor;HDAC3 targeting HDAC3
OB-65-AI50_1uM Dose=1uM, Rgfp966, HDAC3 active-site competitive inhibitor;HDAC3 targeting HDAC3
OB-71-IZ36_0.01uM Dose=0.01uM, 5-m-Tolyloxyuracil, Lyn Kinase Activators targeting LYN
OB-71-IZ36_0.1uM Dose=0.1uM, 5-m-Tolyloxyuracil, Lyn Kinase Activators targeting LYN
OB-71-IZ36_10uM Dose=10uM, 5-m-Tolyloxyuracil, Lyn Kinase Activators targeting LYN
OB-71-IZ36_1uM Dose=1uM, 5-m-Tolyloxyuracil, Lyn Kinase Activators targeting LYN
OB-75-VS99_0.01uM Dose=0.01uM, 3-(Tetrahydrofuran-3-yl oxy)-4-(thieno[3,2-d]pyrimidin-4-yl amino)-benzamide, MAPK-Interacting Kinase (MNK) Inhibitors targeting MKNK2, SGK1, MKNK1
OB-75-VS99_10uM Dose=10uM, 3-(Tetrahydrofuran-3-yl oxy)-4-(thieno[3,2-d]pyrimidin-4-yl amino)-benzamide, MAPK-Interacting Kinase (MNK) Inhibitors targeting MKNK2, SGK1, MKNK1
OB-75-VS99_1uM Dose=1uM, 3-(Tetrahydrofuran-3-yl oxy)-4-(thieno[3,2-d]pyrimidin-4-yl amino)-benzamide, MAPK-Interacting Kinase (MNK) Inhibitors targeting MKNK2, SGK1, MKNK1
OB-77-XJ02_0.01uM Dose=0.01uM, Erythrodiol, IL-1beta Production Inhibitors;IL-6 Production Inhibitors targeting IL1B, IL6
OB-77-XJ02_0.1uM Dose=0.1uM, Erythrodiol, IL-1beta Production Inhibitors;IL-6 Production Inhibitors targeting IL1B, IL6
OB-77-XJ02_10uM Dose=10uM, Erythrodiol, IL-1beta Production Inhibitors;IL-6 Production Inhibitors targeting IL1B, IL6
OB-77-XJ02_1uM Dose=1uM, Erythrodiol, IL-1beta Production Inhibitors;IL-6 Production Inhibitors targeting IL1B, IL6
OB-78-PA58_0.01uM Dose=0.01uM, Teglarinad, Glycerol-3-Phosphate Dehydrogenase (NAD+) Inhibitors;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Signal Transduction Modulators;Inhibitory kappaB Kinase (IKK) Inhibitors targeting GPD1, NAMPT, CHUK
OB-78-PA58_10uM Dose=10uM, Teglarinad, Glycerol-3-Phosphate Dehydrogenase (NAD+) Inhibitors;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Signal Transduction Modulators;Inhibitory kappaB Kinase (IKK) Inhibitors targeting GPD1, NAMPT, CHUK
OB-78-PA58_1uM Dose=1uM, Teglarinad, Glycerol-3-Phosphate Dehydrogenase (NAD+) Inhibitors;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Signal Transduction Modulators;Inhibitory kappaB Kinase (IKK) Inhibitors targeting GPD1, NAMPT, CHUK
OB-83-EA66_0.1uM Dose=0.1uM, (S)-2-[((S)-3-Acetyl-thiazolidine-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid, Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGB1
OB-83-EA66_10uM Dose=10uM, (S)-2-[((S)-3-Acetyl-thiazolidine-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid, Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGB1
OB-83-EA66_1uM Dose=1uM, (S)-2-[((S)-3-Acetyl-thiazolidine-4-carbonyl)-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid, Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGB1
OC-10-FB51_0.01uM Dose=0.01uM
OC-10-FB51_0.1uM Dose=0.1uM
OC-10-FB51_10uM Dose=10uM
OC-10-FB51_1uM Dose=1uM
OC-12-KT94_0.01uM Dose=0.01uM, Sch 40120, Lipoxygenase Inhibitors;Mediator Release Inhibitors targeting ALOX5
OC-12-KT94_0.1uM Dose=0.1uM, Sch 40120, Lipoxygenase Inhibitors;Mediator Release Inhibitors targeting ALOX5
OC-12-KT94_10uM Dose=10uM, Sch 40120, Lipoxygenase Inhibitors;Mediator Release Inhibitors targeting ALOX5
OC-12-KT94_1uM Dose=1uM, Sch 40120, Lipoxygenase Inhibitors;Mediator Release Inhibitors targeting ALOX5
OC-14-JE78_0.01uM Dose=0.01uM, (2R,3S)-1-(Phenanthrene-2-carbonyl)-piperazine-2,3-dicarboxylic acid, NR2D Antagonists;NR2C Antagonists targeting GRIN2C, GRIN2D
OC-14-JE78_0.1uM Dose=0.1uM, (2R,3S)-1-(Phenanthrene-2-carbonyl)-piperazine-2,3-dicarboxylic acid, NR2D Antagonists;NR2C Antagonists targeting GRIN2C, GRIN2D
OC-14-JE78_10uM Dose=10uM, (2R,3S)-1-(Phenanthrene-2-carbonyl)-piperazine-2,3-dicarboxylic acid, NR2D Antagonists;NR2C Antagonists targeting GRIN2C, GRIN2D
OC-14-JE78_1uM Dose=1uM, (2R,3S)-1-(Phenanthrene-2-carbonyl)-piperazine-2,3-dicarboxylic acid, NR2D Antagonists;NR2C Antagonists targeting GRIN2C, GRIN2D
OC-14-JE88_0.01uM Dose=0.01uM, Sergliflozin Etabonate, SGLT-2 Inhibitors targeting SLC5A2
OC-14-JE88_0.1uM Dose=0.1uM, Sergliflozin Etabonate, SGLT-2 Inhibitors targeting SLC5A2
OC-14-JE88_10uM Dose=10uM, Sergliflozin Etabonate, SGLT-2 Inhibitors targeting SLC5A2
OC-14-JE88_1uM Dose=1uM, Sergliflozin Etabonate, SGLT-2 Inhibitors targeting SLC5A2
OC-15-PM40_0.01uM Dose=0.01uM, Rheb inhibitor NR1 targeting RHEB
OC-15-PM40_0.1uM Dose=0.1uM, Rheb inhibitor NR1 targeting RHEB
OC-15-PM40_10uM Dose=10uM, Rheb inhibitor NR1 targeting RHEB
OC-15-PM40_1uM Dose=1uM, Rheb inhibitor NR1 targeting RHEB
OC-21-IP52_0.01uM Dose=0.01uM, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]-2-phenylacetamide
OC-21-IP52_0.1uM Dose=0.1uM, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]-2-phenylacetamide
OC-21-IP52_10uM Dose=10uM, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]-2-phenylacetamide
OC-21-IP52_1uM Dose=1uM, N-[4-[2-(hydroxyamino)-2-oxoethyl]phenyl]-2-phenylacetamide
OC-23-QX66_0.01uM Dose=0.01uM, 3,5-Dihydroxy-4-methoxybenzoic acid, NF-kappaB (NFKB) Activation Inhibitors;Free Radical Scavengers targeting RELA
OC-23-QX66_0.1uM Dose=0.1uM, 3,5-Dihydroxy-4-methoxybenzoic acid, NF-kappaB (NFKB) Activation Inhibitors;Free Radical Scavengers targeting RELA
OC-23-QX66_10uM Dose=10uM, 3,5-Dihydroxy-4-methoxybenzoic acid, NF-kappaB (NFKB) Activation Inhibitors;Free Radical Scavengers targeting RELA
OC-23-QX66_1uM Dose=1uM, 3,5-Dihydroxy-4-methoxybenzoic acid, NF-kappaB (NFKB) Activation Inhibitors;Free Radical Scavengers targeting RELA
OC-25-TL77_0.01uM Dose=0.01uM, Methyl 3-(2-phenylacetamido)thiophene-2-carboxylate
OC-25-TL77_0.1uM Dose=0.1uM, Methyl 3-(2-phenylacetamido)thiophene-2-carboxylate
OC-25-TL77_10uM Dose=10uM, Methyl 3-(2-phenylacetamido)thiophene-2-carboxylate
OC-36-DG23_0.01uM Dose=0.01uM, 1-[3-[(2R)-2,3-dihydroxypropyl]-5-[3-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]cyclopropane-1-carbonitrile, PKC epsilon inhibitor targeting PRKCE
OC-36-DG23_10uM Dose=10uM, 1-[3-[(2R)-2,3-dihydroxypropyl]-5-[3-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]cyclopropane-1-carbonitrile, PKC epsilon inhibitor targeting PRKCE
OC-36-DG23_1uM Dose=1uM, 1-[3-[(2R)-2,3-dihydroxypropyl]-5-[3-(trifluoromethyl)-2H-pyrazolo[3,4-b]pyridin-4-yl]phenyl]cyclopropane-1-carbonitrile, PKC epsilon inhibitor targeting PRKCE
OC-40-XI13_0.01uM Dose=0.01uM, N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase PARP) Inhibitors;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors targeting PARP1, P2RY12
OC-40-XI13_0.1uM Dose=0.1uM, N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase PARP) Inhibitors;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors targeting PARP1, P2RY12
OC-40-XI13_10uM Dose=10uM, N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase PARP) Inhibitors;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors targeting PARP1, P2RY12
OC-40-XI13_1uM Dose=1uM, N~2~,N~2~-Dimethyl-N~1~-(6-oxo-5,6-dihydrophenanthridin-2-YL)glycinamide, NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase PARP) Inhibitors;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors targeting PARP1, P2RY12
OC-41-DF58_0.01uM Dose=0.01uM, Oprea1_571617, inhibitor of dna ligase IV targeting LIG4
OC-41-DF58_0.1uM Dose=0.1uM, Oprea1_571617, inhibitor of dna ligase IV targeting LIG4
OC-41-DF58_10uM Dose=10uM, Oprea1_571617, inhibitor of dna ligase IV targeting LIG4
OC-53-QX76_0.01uM Dose=0.01uM, N-[2-(3-chlorophenyl)ethyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
OC-53-QX76_0.1uM Dose=0.1uM, N-[2-(3-chlorophenyl)ethyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
OC-53-QX76_10uM Dose=10uM, N-[2-(3-chlorophenyl)ethyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
OC-53-QX76_1uM Dose=1uM, N-[2-(3-chlorophenyl)ethyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
OC-55-QZ56_0.01uM Dose=0.01uM, Icrf 193
OC-55-QZ56_0.1uM Dose=0.1uM, Icrf 193
OC-55-QZ56_10uM Dose=10uM, Icrf 193
OC-55-QZ56_1uM Dose=1uM, Icrf 193
OC-56-RM62_0.01uM Dose=0.01uM, ethyl 1-benzyl-4-(3,4-dimethoxyphenyl)-4H-quinoline-3-carboxylate targeting ABCB1
OC-56-RM62_0.1uM Dose=0.1uM, ethyl 1-benzyl-4-(3,4-dimethoxyphenyl)-4H-quinoline-3-carboxylate targeting ABCB1
OC-56-RM62_10uM Dose=10uM, ethyl 1-benzyl-4-(3,4-dimethoxyphenyl)-4H-quinoline-3-carboxylate targeting ABCB1
OC-59-JO99_0.01uM Dose=0.01uM, N-[(2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-methoxybut-2-ynoxy)benzamide
OC-59-JO99_0.1uM Dose=0.1uM, N-[(2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-methoxybut-2-ynoxy)benzamide
OC-59-JO99_10uM Dose=10uM, N-[(2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-methoxybut-2-ynoxy)benzamide
OC-59-JO99_1uM Dose=1uM, N-[(2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-methoxybut-2-ynoxy)benzamide
OC-71-BZ81_0.01uM Dose=0.01uM
OC-71-BZ81_0.1uM Dose=0.1uM
OC-71-BZ81_10uM Dose=10uM
OC-71-BZ81_1uM Dose=1uM
OD-03-CA36_0.01uM Dose=0.01uM, N-[3-[6-(2-chloro-6-methylanilino)pyrazin-2-yl]benzimidazol-5-yl]prop-2-enamide
OD-03-CA36_0.1uM Dose=0.1uM, N-[3-[6-(2-chloro-6-methylanilino)pyrazin-2-yl]benzimidazol-5-yl]prop-2-enamide
OD-03-CA36_10uM Dose=10uM, N-[3-[6-(2-chloro-6-methylanilino)pyrazin-2-yl]benzimidazol-5-yl]prop-2-enamide
OD-03-CA36_1uM Dose=1uM, N-[3-[6-(2-chloro-6-methylanilino)pyrazin-2-yl]benzimidazol-5-yl]prop-2-enamide
OD-07-NJ52_0.01uM Dose=0.01uM, 5-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-2,2-diphenyl-pentanenitrile, CCR1 antagonist;Chemokine US28 Receptor Inverse Agonists targeting CCR1
OD-07-NJ52_10uM Dose=10uM, 5-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-2,2-diphenyl-pentanenitrile, CCR1 antagonist;Chemokine US28 Receptor Inverse Agonists targeting CCR1
OD-07-NJ52_1uM Dose=1uM, 5-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-2,2-diphenyl-pentanenitrile, CCR1 antagonist;Chemokine US28 Receptor Inverse Agonists targeting CCR1
OD-09-LH57_0.01uM Dose=0.01uM, (S)-3-(4-Methoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid ethyl ester
OD-09-LH57_0.1uM Dose=0.1uM, (S)-3-(4-Methoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid ethyl ester
OD-09-LH57_10uM Dose=10uM, (S)-3-(4-Methoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid ethyl ester
OD-09-LH57_1uM Dose=1uM, (S)-3-(4-Methoxy-phenyl)-3-[2-((3-methoxy-propyl)-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-acetylamino]-propionic acid ethyl ester
OD-13-IE31_0.01uM Dose=0.01uM
OD-13-IE31_0.1uM Dose=0.1uM
OD-13-IE31_10uM Dose=10uM
OD-13-IE31_1uM Dose=1uM
OD-23-MK85_0.01uM Dose=0.01uM, 2-(Benzyl(methyl)amino)-N-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-yl)acetamide, Prostanoid EP4 Antagonists targeting PTGER4
OD-23-MK85_0.1uM Dose=0.1uM, 2-(Benzyl(methyl)amino)-N-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-yl)acetamide, Prostanoid EP4 Antagonists targeting PTGER4
OD-23-MK85_1uM Dose=1uM, 2-(Benzyl(methyl)amino)-N-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-yl)acetamide, Prostanoid EP4 Antagonists targeting PTGER4
OD-28-MX63_0.01uM Dose=0.01uM, N-methyl-2-(1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine, HTR2C antagonist targeting HTR2C
OD-28-MX63_0.1uM Dose=0.1uM, N-methyl-2-(1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine, HTR2C antagonist targeting HTR2C
OD-28-MX63_10uM Dose=10uM, N-methyl-2-(1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine, HTR2C antagonist targeting HTR2C
OD-30-JC39_0.01uM Dose=0.01uM, S-propyl 3-(3,4-dihydroxyphenyl)propanethioate, NFE2L2 stimulator/agonist targeting NFE2L2
OD-30-JC39_0.1uM Dose=0.1uM, S-propyl 3-(3,4-dihydroxyphenyl)propanethioate, NFE2L2 stimulator/agonist targeting NFE2L2
OD-30-JC39_10uM Dose=10uM, S-propyl 3-(3,4-dihydroxyphenyl)propanethioate, NFE2L2 stimulator/agonist targeting NFE2L2
OD-30-JC39_1uM Dose=1uM, S-propyl 3-(3,4-dihydroxyphenyl)propanethioate, NFE2L2 stimulator/agonist targeting NFE2L2
OD-30-UF61_0.01uM Dose=0.01uM
OD-30-UF61_0.1uM Dose=0.1uM
OD-30-UF61_10uM Dose=10uM
OD-30-UF61_1uM Dose=1uM
OD-32-FK33_0.01uM Dose=0.01uM, 3,4-Dimethoxy-N-[6-(4-Methoxyphenoxy)-1,3-Dimethyl-2-Oxo-2,3-Dihydro-1h-Benzimidazol-5-Yl]benzenesulfonamide, TRIM24/BRPF1B dual inhibitor;TRIM24/BRPF1/2 dual inhibitor targeting BRPF1, TRIM24, BRD1
OD-32-FK33_0.1uM Dose=0.1uM, 3,4-Dimethoxy-N-[6-(4-Methoxyphenoxy)-1,3-Dimethyl-2-Oxo-2,3-Dihydro-1h-Benzimidazol-5-Yl]benzenesulfonamide, TRIM24/BRPF1B dual inhibitor;TRIM24/BRPF1/2 dual inhibitor targeting BRPF1, TRIM24, BRD1
OD-32-FK33_10uM Dose=10uM, 3,4-Dimethoxy-N-[6-(4-Methoxyphenoxy)-1,3-Dimethyl-2-Oxo-2,3-Dihydro-1h-Benzimidazol-5-Yl]benzenesulfonamide, TRIM24/BRPF1B dual inhibitor;TRIM24/BRPF1/2 dual inhibitor targeting BRPF1, TRIM24, BRD1
OD-32-FK33_1uM Dose=1uM, 3,4-Dimethoxy-N-[6-(4-Methoxyphenoxy)-1,3-Dimethyl-2-Oxo-2,3-Dihydro-1h-Benzimidazol-5-Yl]benzenesulfonamide, TRIM24/BRPF1B dual inhibitor;TRIM24/BRPF1/2 dual inhibitor targeting BRPF1, TRIM24, BRD1
OD-39-RY38_0.01uM Dose=0.01uM, (1z)-1-(3-Ethyl-5-Hydroxy-1,3-Benzothiazol-2(3h)-Ylidene)propan-2-One
OD-39-RY38_0.1uM Dose=0.1uM, (1z)-1-(3-Ethyl-5-Hydroxy-1,3-Benzothiazol-2(3h)-Ylidene)propan-2-One
OD-39-RY38_10uM Dose=10uM, (1z)-1-(3-Ethyl-5-Hydroxy-1,3-Benzothiazol-2(3h)-Ylidene)propan-2-One
OD-39-RY38_1uM Dose=1uM, (1z)-1-(3-Ethyl-5-Hydroxy-1,3-Benzothiazol-2(3h)-Ylidene)propan-2-One
OD-47-WT51_0.01uM Dose=0.01uM, Ecopipam, selective dopamine D1/D5 receptor antagonist targeting DRD1
OD-47-WT51_0.1uM Dose=0.1uM, Ecopipam, selective dopamine D1/D5 receptor antagonist targeting DRD1
OD-47-WT51_10uM Dose=10uM, Ecopipam, selective dopamine D1/D5 receptor antagonist targeting DRD1
OD-47-WT51_1uM Dose=1uM, Ecopipam, selective dopamine D1/D5 receptor antagonist targeting DRD1
OD-48-HX53_0.01uM Dose=0.01uM, Castanospermine, Alpha glucosidase inhibitor targeting GAA, GANC, MOGS
OD-48-HX53_0.1uM Dose=0.1uM, Castanospermine, Alpha glucosidase inhibitor targeting GAA, GANC, MOGS
OD-48-HX53_10uM Dose=10uM, Castanospermine, Alpha glucosidase inhibitor targeting GAA, GANC, MOGS
OD-48-HX53_1uM Dose=1uM, Castanospermine, Alpha glucosidase inhibitor targeting GAA, GANC, MOGS
OD-55-ZL32_0.01uM Dose=0.01uM, 1-(4-Aminophenyl)piperidin-4-ol, CDK Inhibitors targeting CCND2, CCND3
OD-55-ZL32_0.1uM Dose=0.1uM, 1-(4-Aminophenyl)piperidin-4-ol, CDK Inhibitors targeting CCND2, CCND3
OD-55-ZL32_10uM Dose=10uM, 1-(4-Aminophenyl)piperidin-4-ol, CDK Inhibitors targeting CCND2, CCND3
OD-55-ZL32_1uM Dose=1uM, 1-(4-Aminophenyl)piperidin-4-ol, CDK Inhibitors targeting CCND2, CCND3
OD-56-KP44_0.01uM Dose=0.01uM, 2-({3-Nitrobenzoyl}amino)benzamide
OD-56-KP44_0.1uM Dose=0.1uM, 2-({3-Nitrobenzoyl}amino)benzamide
OD-56-KP44_1uM Dose=1uM, 2-({3-Nitrobenzoyl}amino)benzamide
OD-77-AG95_0.01uM Dose=0.01uM, VE-821, ATR gene inhibitor targeting ATR, ATRIP
OD-77-AG95_0.1uM Dose=0.1uM, VE-821, ATR gene inhibitor targeting ATR, ATRIP
OD-77-AG95_10uM Dose=10uM, VE-821, ATR gene inhibitor targeting ATR, ATRIP
OD-77-AG95_1uM Dose=1uM, VE-821, ATR gene inhibitor targeting ATR, ATRIP
OD-78-OU01_0.01uM Dose=0.01uM
OD-78-OU01_0.1uM Dose=0.1uM
OD-78-OU01_10uM Dose=10uM
OD-96-OP94_0.01uM Dose=0.01uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
OD-96-OP94_0.1uM Dose=0.1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
OD-96-OP94_10uM Dose=10uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
OD-96-OP94_1uM Dose=1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP
OD-96-TZ83_0.01uM Dose=0.01uM, BAY 598-Bio-X, SMYD2 inhibitor targeting SMYD2
OD-96-TZ83_0.1uM Dose=0.1uM, BAY 598-Bio-X, SMYD2 inhibitor targeting SMYD2
OD-96-TZ83_10uM Dose=10uM, BAY 598-Bio-X, SMYD2 inhibitor targeting SMYD2
OD-96-TZ83_1uM Dose=1uM, BAY 598-Bio-X, SMYD2 inhibitor targeting SMYD2
OD-96-ZC58_0.01uM Dose=0.01uM, Mdl-29951, NMDA Glycine-Site Antagonists;Fructose-1,6-Bisphosphatase Inhibitors;GPR17 gene modulator targeting FBP1, GPR17
OD-96-ZC58_10uM Dose=10uM, Mdl-29951, NMDA Glycine-Site Antagonists;Fructose-1,6-Bisphosphatase Inhibitors;GPR17 gene modulator targeting FBP1, GPR17
OD-96-ZC58_1uM Dose=1uM, Mdl-29951, NMDA Glycine-Site Antagonists;Fructose-1,6-Bisphosphatase Inhibitors;GPR17 gene modulator targeting FBP1, GPR17
OE-03-IU44_0.01uM Dose=0.01uM, 6-(3-chlorophenyl)-3-[5-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-fluorophenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
OE-03-IU44_0.1uM Dose=0.1uM, 6-(3-chlorophenyl)-3-[5-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-fluorophenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
OE-03-IU44_10uM Dose=10uM, 6-(3-chlorophenyl)-3-[5-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-fluorophenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
OE-03-IU44_1uM Dose=1uM, 6-(3-chlorophenyl)-3-[5-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-fluorophenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
OE-04-VO07_0.01uM Dose=0.01uM, 2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylsulfinyl)pyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists targeting CASR
OE-04-VO07_0.1uM Dose=0.1uM, 2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylsulfinyl)pyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists targeting CASR
OE-04-VO07_10uM Dose=10uM, 2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylsulfinyl)pyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists targeting CASR
OE-04-VO07_1uM Dose=1uM, 2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylsulfinyl)pyridin-3-yl)methyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists targeting CASR
OE-18-ZX28_0.01uM Dose=0.01uM
OE-18-ZX28_0.1uM Dose=0.1uM
OE-18-ZX28_10uM Dose=10uM
OE-18-ZX28_1uM Dose=1uM
OE-23-XH48_0.01uM Dose=0.01uM, Glpg-1837, CFTR modulator targeting CFTR
OE-23-XH48_0.1uM Dose=0.1uM, Glpg-1837, CFTR modulator targeting CFTR
OE-23-XH48_10uM Dose=10uM, Glpg-1837, CFTR modulator targeting CFTR
OE-23-XH48_1uM Dose=1uM, Glpg-1837, CFTR modulator targeting CFTR
OE-31-YC41_0.01uM Dose=0.01uM, benzoic acid N'-[2-(3,5-difluoro-2'-trifluoromethoxy-biphenyl-2-yloxy)-acetyl]-N'-isopropyl hydrazide, Diacylglycerol Acyltransferase (DGAT) Inhibitors targeting DGAT1, DGAT2
OE-31-YC41_0.1uM Dose=0.1uM, benzoic acid N'-[2-(3,5-difluoro-2'-trifluoromethoxy-biphenyl-2-yloxy)-acetyl]-N'-isopropyl hydrazide, Diacylglycerol Acyltransferase (DGAT) Inhibitors targeting DGAT1, DGAT2
OE-31-YC41_10uM Dose=10uM, benzoic acid N'-[2-(3,5-difluoro-2'-trifluoromethoxy-biphenyl-2-yloxy)-acetyl]-N'-isopropyl hydrazide, Diacylglycerol Acyltransferase (DGAT) Inhibitors targeting DGAT1, DGAT2
OE-31-YC41_1uM Dose=1uM, benzoic acid N'-[2-(3,5-difluoro-2'-trifluoromethoxy-biphenyl-2-yloxy)-acetyl]-N'-isopropyl hydrazide, Diacylglycerol Acyltransferase (DGAT) Inhibitors targeting DGAT1, DGAT2
OE-34-NH10_0.01uM Dose=0.01uM, 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one, TIC10 inactivates Akt and ERK and induces TRAIL expression targeting TNFSF10
OE-34-NH10_0.1uM Dose=0.1uM, 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one, TIC10 inactivates Akt and ERK and induces TRAIL expression targeting TNFSF10
OE-34-NH10_10uM Dose=10uM, 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one, TIC10 inactivates Akt and ERK and induces TRAIL expression targeting TNFSF10
OE-34-NH10_1uM Dose=1uM, 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one, TIC10 inactivates Akt and ERK and induces TRAIL expression targeting TNFSF10
OE-41-RC56_0.01uM Dose=0.01uM, 4-chloro-N-(4-ethoxyphenyl)benzenesulfonamide
OE-41-RC56_0.1uM Dose=0.1uM, 4-chloro-N-(4-ethoxyphenyl)benzenesulfonamide
OE-41-RC56_10uM Dose=10uM, 4-chloro-N-(4-ethoxyphenyl)benzenesulfonamide
OE-41-RC56_1uM Dose=1uM, 4-chloro-N-(4-ethoxyphenyl)benzenesulfonamide
OE-50-VB46_0.01uM Dose=0.01uM, 4-hydroxy7-(1-hydroxy-2-{2-[4-(4-phenyl-butoxy)-phenyl]-ethylamino}-ethyl)-3H-benzothiazol-2-one, beta2-Adrenoceptor Agonists targeting ADRB2
OE-50-VB46_0.1uM Dose=0.1uM, 4-hydroxy7-(1-hydroxy-2-{2-[4-(4-phenyl-butoxy)-phenyl]-ethylamino}-ethyl)-3H-benzothiazol-2-one, beta2-Adrenoceptor Agonists targeting ADRB2
OE-50-VB46_10uM Dose=10uM, 4-hydroxy7-(1-hydroxy-2-{2-[4-(4-phenyl-butoxy)-phenyl]-ethylamino}-ethyl)-3H-benzothiazol-2-one, beta2-Adrenoceptor Agonists targeting ADRB2
OE-50-VB46_1uM Dose=1uM, 4-hydroxy7-(1-hydroxy-2-{2-[4-(4-phenyl-butoxy)-phenyl]-ethylamino}-ethyl)-3H-benzothiazol-2-one, beta2-Adrenoceptor Agonists targeting ADRB2
OE-67-XG40_0.01uM Dose=0.01uM, Benzamide, N-[4-methyl-3-[[4-(6-methyl-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KIT
OE-67-XG40_0.1uM Dose=0.1uM, Benzamide, N-[4-methyl-3-[[4-(6-methyl-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KIT
OE-67-XG40_10uM Dose=10uM, Benzamide, N-[4-methyl-3-[[4-(6-methyl-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KIT
OE-67-XG40_1uM Dose=1uM, Benzamide, N-[4-methyl-3-[[4-(6-methyl-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KIT
OE-68-FR64_0.01uM Dose=0.01uM, n-(2,6-Diethylphenyl)-homophthalimide, Puromycin-Sensitive Aminopeptidase Inhibitors targeting ANPEP, NPEPPS
OE-68-FR64_0.1uM Dose=0.1uM, n-(2,6-Diethylphenyl)-homophthalimide, Puromycin-Sensitive Aminopeptidase Inhibitors targeting ANPEP, NPEPPS
OE-68-FR64_10uM Dose=10uM, n-(2,6-Diethylphenyl)-homophthalimide, Puromycin-Sensitive Aminopeptidase Inhibitors targeting ANPEP, NPEPPS
OE-68-FR64_1uM Dose=1uM, n-(2,6-Diethylphenyl)-homophthalimide, Puromycin-Sensitive Aminopeptidase Inhibitors targeting ANPEP, NPEPPS
OE-75-WF43_0.01uM Dose=0.01uM, 8-(2-(3,5-Dimethylpiperazin-1-yl)-4- targeting EED
OE-75-WF43_0.1uM Dose=0.1uM, 8-(2-(3,5-Dimethylpiperazin-1-yl)-4- targeting EED
OE-75-WF43_10uM Dose=10uM, 8-(2-(3,5-Dimethylpiperazin-1-yl)-4- targeting EED
OE-75-WF43_1uM Dose=1uM, 8-(2-(3,5-Dimethylpiperazin-1-yl)-4- targeting EED
OE-78-TD20_0.01uM Dose=0.01uM, Ici 174865, delta-Opioid Inverse Agonists targeting OPRD1
OE-78-TD20_0.1uM Dose=0.1uM, Ici 174865, delta-Opioid Inverse Agonists targeting OPRD1
OE-78-TD20_10uM Dose=10uM, Ici 174865, delta-Opioid Inverse Agonists targeting OPRD1
OE-78-TD20_1uM Dose=1uM, Ici 174865, delta-Opioid Inverse Agonists targeting OPRD1
OE-78-XD40_0.01uM Dose=0.01uM, (+)-Dibenzoyl-D-tartaric acid, Dopamine D3 Antagonists targeting DRD3
OE-78-XD40_0.1uM Dose=0.1uM, (+)-Dibenzoyl-D-tartaric acid, Dopamine D3 Antagonists targeting DRD3
OE-78-XD40_10uM Dose=10uM, (+)-Dibenzoyl-D-tartaric acid, Dopamine D3 Antagonists targeting DRD3
OE-78-XD40_1uM Dose=1uM, (+)-Dibenzoyl-D-tartaric acid, Dopamine D3 Antagonists targeting DRD3
OE-84-HO42_0.01uM Dose=0.01uM, 2-((5,6-Diphenylfuro(2,3-D)pyrimidin-4-YL)amino)ethanol, Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs targeting AURKA
OE-84-HO42_0.1uM Dose=0.1uM, 2-((5,6-Diphenylfuro(2,3-D)pyrimidin-4-YL)amino)ethanol, Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs targeting AURKA
OE-84-HO42_10uM Dose=10uM, 2-((5,6-Diphenylfuro(2,3-D)pyrimidin-4-YL)amino)ethanol, Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs targeting AURKA
OE-84-HO42_1uM Dose=1uM, 2-((5,6-Diphenylfuro(2,3-D)pyrimidin-4-YL)amino)ethanol, Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs targeting AURKA
OE-89-FS84_0.01uM Dose=0.01uM, Glycolysis pathway inhibitor targeting PFKFB3, PFKFB4
OE-89-FS84_0.1uM Dose=0.1uM, Glycolysis pathway inhibitor targeting PFKFB3, PFKFB4
OE-89-FS84_10uM Dose=10uM, Glycolysis pathway inhibitor targeting PFKFB3, PFKFB4
OE-89-FS84_1uM Dose=1uM, Glycolysis pathway inhibitor targeting PFKFB3, PFKFB4
OE-91-GF88_0.01uM Dose=0.01uM, 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-nicotinic acid, Retinoid RXR Agonists targeting RXRA, RXRB, RXRG
OE-91-GF88_0.1uM Dose=0.1uM, 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-nicotinic acid, Retinoid RXR Agonists targeting RXRA, RXRB, RXRG
OE-91-GF88_10uM Dose=10uM, 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-nicotinic acid, Retinoid RXR Agonists targeting RXRA, RXRB, RXRG
OE-91-GF88_1uM Dose=1uM, 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-nicotinic acid, Retinoid RXR Agonists targeting RXRA, RXRB, RXRG
OF-02-BG78_0.01uM Dose=0.01uM
OF-02-BG78_0.1uM Dose=0.1uM
OF-02-BG78_10uM Dose=10uM
OF-02-BG78_1uM Dose=1uM
OF-05-CB18_0.01uM Dose=0.01uM
OF-05-CB18_0.1uM Dose=0.1uM
OF-05-CB18_10uM Dose=10uM
OF-05-CB18_1uM Dose=1uM
OF-19-JH77_0.01uM Dose=0.01uM, 2-[1-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-2,2-diphenyl-ethylamino]-acetamide, TACR1 antagonist targeting TACR1
OF-19-JH77_0.1uM Dose=0.1uM, 2-[1-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-2,2-diphenyl-ethylamino]-acetamide, TACR1 antagonist targeting TACR1
OF-19-JH77_10uM Dose=10uM, 2-[1-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-2,2-diphenyl-ethylamino]-acetamide, TACR1 antagonist targeting TACR1
OF-19-JH77_1uM Dose=1uM, 2-[1-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-2,2-diphenyl-ethylamino]-acetamide, TACR1 antagonist targeting TACR1
OF-28-PH15_0.01uM Dose=0.01uM, 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one, beta3-Adrenoceptor Agonists targeting ADRB3
OF-28-PH15_0.1uM Dose=0.1uM, 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one, beta3-Adrenoceptor Agonists targeting ADRB3
OF-28-PH15_10uM Dose=10uM, 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one, beta3-Adrenoceptor Agonists targeting ADRB3
OF-28-PH15_1uM Dose=1uM, 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one, beta3-Adrenoceptor Agonists targeting ADRB3
OF-32-PT74_0.01uM Dose=0.01uM, 18-Methyl-8-thia-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2,4,6,9,11,13-heptaene
OF-32-PT74_0.1uM Dose=0.1uM, 18-Methyl-8-thia-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2,4,6,9,11,13-heptaene
OF-32-PT74_10uM Dose=10uM, 18-Methyl-8-thia-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2,4,6,9,11,13-heptaene
OF-32-PT74_1uM Dose=1uM, 18-Methyl-8-thia-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2,4,6,9,11,13-heptaene
OF-37-IT01_0.01uM Dose=0.01uM
OF-37-IT01_0.1uM Dose=0.1uM
OF-37-IT01_10uM Dose=10uM
OF-37-IT01_1uM Dose=1uM
OF-47-EQ74_0.01uM Dose=0.01uM
OF-47-EQ74_0.1uM Dose=0.1uM
OF-47-EQ74_10uM Dose=10uM
OF-47-EQ74_1uM Dose=1uM
OF-63-KD88_0.01uM Dose=0.01uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethyl ethyl carbonate
OF-63-KD88_0.1uM Dose=0.1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethyl ethyl carbonate
OF-63-KD88_10uM Dose=10uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethyl ethyl carbonate
OF-63-KD88_1uM Dose=1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethyl ethyl carbonate
OF-97-MQ74_0.01uM Dose=0.01uM
OF-97-MQ74_0.1uM Dose=0.1uM
OF-97-MQ74_10uM Dose=10uM
OF-97-MQ74_1uM Dose=1uM
OF-98-RK57_0.01uM Dose=0.01uM, Propiverine, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
OF-98-RK57_0.1uM Dose=0.1uM, Propiverine, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
OF-98-RK57_10uM Dose=10uM, Propiverine, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
OF-98-RK57_1uM Dose=1uM, Propiverine, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3
PA-09-IB98_0.01uM Dose=0.01uM, 5-(3-Chlorophenyl)-1-(4-propan-2-yloxyphenyl)pyridin-2-one
PA-09-IB98_0.1uM Dose=0.1uM, 5-(3-Chlorophenyl)-1-(4-propan-2-yloxyphenyl)pyridin-2-one
PA-09-IB98_10uM Dose=10uM, 5-(3-Chlorophenyl)-1-(4-propan-2-yloxyphenyl)pyridin-2-one
PA-09-IB98_1uM Dose=1uM, 5-(3-Chlorophenyl)-1-(4-propan-2-yloxyphenyl)pyridin-2-one
PA-15-CI45_0.01uM Dose=0.01uM, ethyl 4-[[(2S)-2-aminopropanoyl]amino]-5-[4-(3,5-dichlorophenyl)phenyl]-2,3-dihydroxypentanoate, Ubiquitin-Conjugating Enzyme E2 R1 (CDC34) Inhibitors targeting CDC34
PA-15-CI45_0.1uM Dose=0.1uM, ethyl 4-[[(2S)-2-aminopropanoyl]amino]-5-[4-(3,5-dichlorophenyl)phenyl]-2,3-dihydroxypentanoate, Ubiquitin-Conjugating Enzyme E2 R1 (CDC34) Inhibitors targeting CDC34
PA-15-CI45_10uM Dose=10uM, ethyl 4-[[(2S)-2-aminopropanoyl]amino]-5-[4-(3,5-dichlorophenyl)phenyl]-2,3-dihydroxypentanoate, Ubiquitin-Conjugating Enzyme E2 R1 (CDC34) Inhibitors targeting CDC34
PA-15-CI45_1uM Dose=1uM, ethyl 4-[[(2S)-2-aminopropanoyl]amino]-5-[4-(3,5-dichlorophenyl)phenyl]-2,3-dihydroxypentanoate, Ubiquitin-Conjugating Enzyme E2 R1 (CDC34) Inhibitors targeting CDC34
PA-15-CP52_0.01uM Dose=0.01uM, (3aS,9bS)-2-(1-benzofuran-5-sulfonyl)-5-methyl-1H,2H,3H,3aH,4H,5H,9bH-pyrrolo[3,4-c]1,6-naphthyridin-4-one targeting GLRA1, GLRA2, GLRA3, GLRA4
PA-15-CP52_0.1uM Dose=0.1uM, (3aS,9bS)-2-(1-benzofuran-5-sulfonyl)-5-methyl-1H,2H,3H,3aH,4H,5H,9bH-pyrrolo[3,4-c]1,6-naphthyridin-4-one targeting GLRA1, GLRA2, GLRA3, GLRA4
PA-15-CP52_10uM Dose=10uM, (3aS,9bS)-2-(1-benzofuran-5-sulfonyl)-5-methyl-1H,2H,3H,3aH,4H,5H,9bH-pyrrolo[3,4-c]1,6-naphthyridin-4-one targeting GLRA1, GLRA2, GLRA3, GLRA4
PA-15-CP52_1uM Dose=1uM, (3aS,9bS)-2-(1-benzofuran-5-sulfonyl)-5-methyl-1H,2H,3H,3aH,4H,5H,9bH-pyrrolo[3,4-c]1,6-naphthyridin-4-one targeting GLRA1, GLRA2, GLRA3, GLRA4
PA-25-OV46_0.01uM Dose=0.01uM, Bjb-432
PA-25-OV46_0.1uM Dose=0.1uM, Bjb-432
PA-25-OV46_10uM Dose=10uM, Bjb-432
PA-25-OV46_1uM Dose=1uM, Bjb-432
PA-31-HP87_0.01uM Dose=0.01uM, Ethyl 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate, KDM6 inhibitor targeting KDM6A, UTY, KDM6B
PA-31-HP87_0.1uM Dose=0.1uM, Ethyl 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate, KDM6 inhibitor targeting KDM6A, UTY, KDM6B
PA-31-HP87_10uM Dose=10uM, Ethyl 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate, KDM6 inhibitor targeting KDM6A, UTY, KDM6B
PA-31-HP87_1uM Dose=1uM, Ethyl 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate, KDM6 inhibitor targeting KDM6A, UTY, KDM6B
PA-39-SH87_0.01uM Dose=0.01uM, 2-[6-[(Quinolin-2-yl)methoxy]naphthalen-2-yl]propanoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs;Leukotriene Antagonists targeting ALOX5
PA-39-SH87_0.1uM Dose=0.1uM, 2-[6-[(Quinolin-2-yl)methoxy]naphthalen-2-yl]propanoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs;Leukotriene Antagonists targeting ALOX5
PA-39-SH87_10uM Dose=10uM, 2-[6-[(Quinolin-2-yl)methoxy]naphthalen-2-yl]propanoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs;Leukotriene Antagonists targeting ALOX5
PA-39-SH87_1uM Dose=1uM, 2-[6-[(Quinolin-2-yl)methoxy]naphthalen-2-yl]propanoic acid, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs;Leukotriene Antagonists targeting ALOX5
PA-40-HC94_0.01uM Dose=0.01uM
PA-40-HC94_0.1uM Dose=0.1uM
PA-40-HC94_10uM Dose=10uM
PA-40-HC94_1uM Dose=1uM
PA-40-NS72_0.01uM Dose=0.01uM, Oseltamivir Acid
PA-40-NS72_0.1uM Dose=0.1uM, Oseltamivir Acid
PA-40-NS72_10uM Dose=10uM, Oseltamivir Acid
PA-40-NS72_1uM Dose=1uM, Oseltamivir Acid
PA-53-BA36_0.01uM Dose=0.01uM, Wx-uk1 free base, Urokinase (u-PA) Inhibitors targeting PLAU, PLG
PA-53-BA36_0.1uM Dose=0.1uM, Wx-uk1 free base, Urokinase (u-PA) Inhibitors targeting PLAU, PLG
PA-53-BA36_10uM Dose=10uM, Wx-uk1 free base, Urokinase (u-PA) Inhibitors targeting PLAU, PLG
PA-57-FX61_0.01uM Dose=0.01uM, N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide
PA-57-FX61_0.1uM Dose=0.1uM, N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide
PA-57-FX61_10uM Dose=10uM, N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide
PA-57-FX61_1uM Dose=1uM, N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide
PA-57-TT36_0.01uM Dose=0.01uM, Ethyl 2-(3-methyl-4-oxo-5-piperidin-1-yl-1,3-thiazolidin-2-ylidene)acetate, Drugs Acting on Potassium Channels targeting SLC12A1
PA-57-TT36_10uM Dose=10uM, Ethyl 2-(3-methyl-4-oxo-5-piperidin-1-yl-1,3-thiazolidin-2-ylidene)acetate, Drugs Acting on Potassium Channels targeting SLC12A1
PA-57-TT36_1uM Dose=1uM, Ethyl 2-(3-methyl-4-oxo-5-piperidin-1-yl-1,3-thiazolidin-2-ylidene)acetate, Drugs Acting on Potassium Channels targeting SLC12A1
PA-60-HV24_0.01uM Dose=0.01uM, Cutamesine, Acetylcholine Release Enhancers;sigma1 Receptor Agonists targeting SIGMAR1
PA-60-HV24_1uM Dose=1uM, Cutamesine, Acetylcholine Release Enhancers;sigma1 Receptor Agonists targeting SIGMAR1
PA-63-TR22_0.1uM Dose=0.1uM, N-[1-[1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methylbenzimidazol-2-yl]-2-ethoxypyridine-4-carboxamide
PA-63-TR22_1uM Dose=1uM, N-[1-[1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methylbenzimidazol-2-yl]-2-ethoxypyridine-4-carboxamide
PA-64-LE28_0.01uM Dose=0.01uM, BN-82451, Lipid Peroxidation Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants;Sodium Channel Blockers targeting PTGS1, PTGS2, SCN1A, SCN2A, SCN3A
PA-64-LE28_0.1uM Dose=0.1uM, BN-82451, Lipid Peroxidation Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants;Sodium Channel Blockers targeting PTGS1, PTGS2, SCN1A, SCN2A, SCN3A
PA-64-LE28_10uM Dose=10uM, BN-82451, Lipid Peroxidation Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants;Sodium Channel Blockers targeting PTGS1, PTGS2, SCN1A, SCN2A, SCN3A
PA-64-LE28_1uM Dose=1uM, BN-82451, Lipid Peroxidation Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants;Sodium Channel Blockers targeting PTGS1, PTGS2, SCN1A, SCN2A, SCN3A
PA-70-ZC89_0.01uM Dose=0.01uM
PA-70-ZC89_0.1uM Dose=0.1uM
PA-70-ZC89_10uM Dose=10uM
PA-70-ZC89_1uM Dose=1uM
PA-75-VL17_0.01uM Dose=0.01uM
PA-75-VL17_0.1uM Dose=0.1uM
PA-75-VL17_10uM Dose=10uM
PA-75-VL17_1uM Dose=1uM
PA-75-VS64_0.01uM Dose=0.01uM, 1G244, Known DPP8, DPP9 inhibitor targeting DPP8, DPP9
PA-75-VS64_10uM Dose=10uM, 1G244, Known DPP8, DPP9 inhibitor targeting DPP8, DPP9
PA-75-VS64_1uM Dose=1uM, 1G244, Known DPP8, DPP9 inhibitor targeting DPP8, DPP9
PA-80-RV09_0.01uM Dose=0.01uM, (1-Hydroxy-1-phosphonodecyl)phosphonic acid targeting GGPS1
PA-80-RV09_0.1uM Dose=0.1uM, (1-Hydroxy-1-phosphonodecyl)phosphonic acid targeting GGPS1
PA-80-RV09_10uM Dose=10uM, (1-Hydroxy-1-phosphonodecyl)phosphonic acid targeting GGPS1
PA-80-RV09_1uM Dose=1uM, (1-Hydroxy-1-phosphonodecyl)phosphonic acid targeting GGPS1
PA-84-RB96_0.01uM Dose=0.01uM, 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one
PA-84-RB96_0.1uM Dose=0.1uM, 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one
PA-84-RB96_10uM Dose=10uM, 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one
PA-84-RB96_1uM Dose=1uM, 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one
PA-93-BD53_0.01uM Dose=0.01uM, (2S)-2-[[[(2S)-2-aminobutanoyl]amino]carbamoylamino]-N-[(2S)-1-amino-3-(3-fluorophenyl)-1-oxopropan-2-yl]-4-phenylbutanamide, Cathepsin C (Dipeptidyl Peptidase I) Inhibitors targeting CTSC
PA-93-BD53_0.1uM Dose=0.1uM, (2S)-2-[[[(2S)-2-aminobutanoyl]amino]carbamoylamino]-N-[(2S)-1-amino-3-(3-fluorophenyl)-1-oxopropan-2-yl]-4-phenylbutanamide, Cathepsin C (Dipeptidyl Peptidase I) Inhibitors targeting CTSC
PA-93-BD53_10uM Dose=10uM, (2S)-2-[[[(2S)-2-aminobutanoyl]amino]carbamoylamino]-N-[(2S)-1-amino-3-(3-fluorophenyl)-1-oxopropan-2-yl]-4-phenylbutanamide, Cathepsin C (Dipeptidyl Peptidase I) Inhibitors targeting CTSC
PA-93-BD53_1uM Dose=1uM, (2S)-2-[[[(2S)-2-aminobutanoyl]amino]carbamoylamino]-N-[(2S)-1-amino-3-(3-fluorophenyl)-1-oxopropan-2-yl]-4-phenylbutanamide, Cathepsin C (Dipeptidyl Peptidase I) Inhibitors targeting CTSC
PB-05-XP37_0.01uM Dose=0.01uM, (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid, allosteric PDK1 activator targeting PDK1
PB-05-XP37_0.1uM Dose=0.1uM, (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid, allosteric PDK1 activator targeting PDK1
PB-05-XP37_10uM Dose=10uM, (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid, allosteric PDK1 activator targeting PDK1
PB-09-OE00_0.01uM Dose=0.01uM, 4-[1-(3-chloro-1-methylpyrazol-4-yl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-8-yl]-N-methylbenzamide, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CB, PIK3CD
PB-09-OE00_0.1uM Dose=0.1uM, 4-[1-(3-chloro-1-methylpyrazol-4-yl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-8-yl]-N-methylbenzamide, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CB, PIK3CD
PB-09-OE00_10uM Dose=10uM, 4-[1-(3-chloro-1-methylpyrazol-4-yl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-8-yl]-N-methylbenzamide, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CB, PIK3CD
PB-09-OE00_1uM Dose=1uM, 4-[1-(3-chloro-1-methylpyrazol-4-yl)-3-methyl-2-oxoimidazo[4,5-c]quinolin-8-yl]-N-methylbenzamide, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CB, PIK3CD
PB-13-ZD03_0.01uM Dose=0.01uM, 1-N,3-N-bis(1-methylquinolin-1-ium-6-yl)benzene-1,3-dicarboxamide, DNA G-quadruplex (G4) Ligands;Telomerase Inhibitors targeting TERT
PB-13-ZD03_0.1uM Dose=0.1uM, 1-N,3-N-bis(1-methylquinolin-1-ium-6-yl)benzene-1,3-dicarboxamide, DNA G-quadruplex (G4) Ligands;Telomerase Inhibitors targeting TERT
PB-13-ZD03_10uM Dose=10uM, 1-N,3-N-bis(1-methylquinolin-1-ium-6-yl)benzene-1,3-dicarboxamide, DNA G-quadruplex (G4) Ligands;Telomerase Inhibitors targeting TERT
PB-18-HD85_0.01uM Dose=0.01uM
PB-18-HD85_0.1uM Dose=0.1uM
PB-18-HD85_10uM Dose=10uM
PB-18-HD85_1uM Dose=1uM
PB-34-EE63_0.01uM Dose=0.01uM, Cinacalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR
PB-34-EE63_10uM Dose=10uM, Cinacalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR
PB-34-EE63_1uM Dose=1uM, Cinacalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR
PB-40-CS17_0.01uM Dose=0.01uM
PB-40-CS17_0.1uM Dose=0.1uM
PB-40-CS17_10uM Dose=10uM
PB-40-CS17_1uM Dose=1uM
PB-40-YB26_0.01uM Dose=0.01uM, SIRT1 gene inhibitor;Histone Deacetylase SIRT2 Inhibitors targeting SIRT2, SIRT1
PB-40-YB26_0.1uM Dose=0.1uM, SIRT1 gene inhibitor;Histone Deacetylase SIRT2 Inhibitors targeting SIRT2, SIRT1
PB-40-YB26_10uM Dose=10uM, SIRT1 gene inhibitor;Histone Deacetylase SIRT2 Inhibitors targeting SIRT2, SIRT1
PB-40-YB26_1uM Dose=1uM, SIRT1 gene inhibitor;Histone Deacetylase SIRT2 Inhibitors targeting SIRT2, SIRT1
PB-59-HH22_0.01uM Dose=0.01uM, 4-[[(4-Fluorophenyl)sulfonylamino]methyl]-~{n}-(Pyridin-3-Ylmethyl)benzamide, NR2A Antagonists targeting GRIN2A
PB-59-HH22_0.1uM Dose=0.1uM, 4-[[(4-Fluorophenyl)sulfonylamino]methyl]-~{n}-(Pyridin-3-Ylmethyl)benzamide, NR2A Antagonists targeting GRIN2A
PB-59-HH22_10uM Dose=10uM, 4-[[(4-Fluorophenyl)sulfonylamino]methyl]-~{n}-(Pyridin-3-Ylmethyl)benzamide, NR2A Antagonists targeting GRIN2A
PB-59-HH22_1uM Dose=1uM, 4-[[(4-Fluorophenyl)sulfonylamino]methyl]-~{n}-(Pyridin-3-Ylmethyl)benzamide, NR2A Antagonists targeting GRIN2A
PB-63-WH18_0.01uM Dose=0.01uM
PB-63-WH18_0.1uM Dose=0.1uM
PB-63-WH18_10uM Dose=10uM
PB-63-WH18_1uM Dose=1uM
PB-66-RW16_0.01uM Dose=0.01uM, PRMT6 gene inhibitor;PRMT6 inhibitor targeting PRMT6
PB-66-RW16_0.1uM Dose=0.1uM, PRMT6 gene inhibitor;PRMT6 inhibitor targeting PRMT6
PB-66-RW16_10uM Dose=10uM, PRMT6 gene inhibitor;PRMT6 inhibitor targeting PRMT6
PB-66-RW16_1uM Dose=1uM, PRMT6 gene inhibitor;PRMT6 inhibitor targeting PRMT6
PC-04-TO77_0.01uM Dose=0.01uM
PC-04-TO77_0.1uM Dose=0.1uM
PC-04-TO77_10uM Dose=10uM
PC-04-TO77_1uM Dose=1uM
PC-05-MI00_0.01uM Dose=0.01uM, Tavaborole, Leucyl-tRNA Synthetase Inhibitors targeting LARS2
PC-05-MI00_0.1uM Dose=0.1uM, Tavaborole, Leucyl-tRNA Synthetase Inhibitors targeting LARS2
PC-05-MI00_10uM Dose=10uM, Tavaborole, Leucyl-tRNA Synthetase Inhibitors targeting LARS2
PC-05-MI00_1uM Dose=1uM, Tavaborole, Leucyl-tRNA Synthetase Inhibitors targeting LARS2
PC-18-VX23_0.01uM Dose=0.01uM, PDK1 inhibitor AR-12, PDK1 inhibitor targeting PDK1
PC-18-VX23_0.1uM Dose=0.1uM, PDK1 inhibitor AR-12, PDK1 inhibitor targeting PDK1
PC-18-VX23_10uM Dose=10uM, PDK1 inhibitor AR-12, PDK1 inhibitor targeting PDK1
PC-18-VX23_1uM Dose=1uM, PDK1 inhibitor AR-12, PDK1 inhibitor targeting PDK1
PC-34-YF76_0.01uM Dose=0.01uM, 1-[2-(2-Tert-butylanilino)pyridin-3-yl]-3-[4-(trifluoromethoxy)phenyl]urea, P2Y Antagonist targeting P2RY1
PC-34-YF76_0.1uM Dose=0.1uM, 1-[2-(2-Tert-butylanilino)pyridin-3-yl]-3-[4-(trifluoromethoxy)phenyl]urea, P2Y Antagonist targeting P2RY1
PC-34-YF76_10uM Dose=10uM, 1-[2-(2-Tert-butylanilino)pyridin-3-yl]-3-[4-(trifluoromethoxy)phenyl]urea, P2Y Antagonist targeting P2RY1
PC-34-YF76_1uM Dose=1uM, 1-[2-(2-Tert-butylanilino)pyridin-3-yl]-3-[4-(trifluoromethoxy)phenyl]urea, P2Y Antagonist targeting P2RY1
PC-44-DH10_0.01uM Dose=0.01uM, (1R,3S,6S,10S,11R)-7-[(dimethylamino)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA
PC-44-DH10_0.1uM Dose=0.1uM, (1R,3S,6S,10S,11R)-7-[(dimethylamino)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA
PC-44-DH10_10uM Dose=10uM, (1R,3S,6S,10S,11R)-7-[(dimethylamino)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA
PC-44-DH10_1uM Dose=1uM, (1R,3S,6S,10S,11R)-7-[(dimethylamino)methyl]-3,12-dimethyl-2,9-dioxatetracyclo[9.3.0.01,3.06,10]tetradec-12-en-8-one, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA
PC-49-XP02_0.01uM Dose=0.01uM
PC-49-XP02_0.1uM Dose=0.1uM
PC-49-XP02_10uM Dose=10uM
PC-49-XP02_1uM Dose=1uM
PC-62-AQ92_0.01uM Dose=0.01uM, (2S,4R)-4-(1H-benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide, Inhibitor of pyrimidine biosynthesis targeting CAD
PC-62-AQ92_0.1uM Dose=0.1uM, (2S,4R)-4-(1H-benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide, Inhibitor of pyrimidine biosynthesis targeting CAD
PC-62-AQ92_10uM Dose=10uM, (2S,4R)-4-(1H-benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide, Inhibitor of pyrimidine biosynthesis targeting CAD
PC-62-AQ92_1uM Dose=1uM, (2S,4R)-4-(1H-benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide, Inhibitor of pyrimidine biosynthesis targeting CAD
PC-63-CH43_0.01uM Dose=0.01uM, 1-[(1,3-Dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide, PARG inhibitor targeting PARG
PC-63-CH43_0.1uM Dose=0.1uM, 1-[(1,3-Dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide, PARG inhibitor targeting PARG
PC-63-CH43_10uM Dose=10uM, 1-[(1,3-Dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide, PARG inhibitor targeting PARG
PC-63-CH43_1uM Dose=1uM, 1-[(1,3-Dimethyl-1H-pyrazol-5-yl)methyl]-1,2,3,4-tetrahydro-N-(1-methylcyclopropyl)-3-[(2-methyl-5-thiazolyl)methyl]-2,4-dioxo-6-quinazolinesulfonamide, PARG inhibitor targeting PARG
PC-68-DU31_0.01uM Dose=0.01uM, N-(3-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-5-yl)-4-((3R)-3,4-dimethylpiperazin-1-yl)benzamide (IUPAC) OR N-(5-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-3-yl)-4-((3R)-3,4-dimethyl-1-piperazinyl)-benzamide, FGFR1 Inhibitors;Angiogenesis Inhibitors targeting FGFR1
PC-68-DU31_0.1uM Dose=0.1uM, N-(3-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-5-yl)-4-((3R)-3,4-dimethylpiperazin-1-yl)benzamide (IUPAC) OR N-(5-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-3-yl)-4-((3R)-3,4-dimethyl-1-piperazinyl)-benzamide, FGFR1 Inhibitors;Angiogenesis Inhibitors targeting FGFR1
PC-68-DU31_10uM Dose=10uM, N-(3-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-5-yl)-4-((3R)-3,4-dimethylpiperazin-1-yl)benzamide (IUPAC) OR N-(5-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-3-yl)-4-((3R)-3,4-dimethyl-1-piperazinyl)-benzamide, FGFR1 Inhibitors;Angiogenesis Inhibitors targeting FGFR1
PC-68-DU31_1uM Dose=1uM, N-(3-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-5-yl)-4-((3R)-3,4-dimethylpiperazin-1-yl)benzamide (IUPAC) OR N-(5-(2-(3,5-dimethoxyphenyl)ethyl)-1H-pyrazol-3-yl)-4-((3R)-3,4-dimethyl-1-piperazinyl)-benzamide, FGFR1 Inhibitors;Angiogenesis Inhibitors targeting FGFR1
PC-68-HN64_0.01uM Dose=0.01uM, 3-(6-fluoro-1H-1,3-benzodiazol-2-yl)-5-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrazin-2-amine, c-Met) Inhibitors;AXL Kinase Inhibitors;HGFR (MET targeting AXL, MET
PC-68-HN64_0.1uM Dose=0.1uM, 3-(6-fluoro-1H-1,3-benzodiazol-2-yl)-5-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrazin-2-amine, c-Met) Inhibitors;AXL Kinase Inhibitors;HGFR (MET targeting AXL, MET
PC-68-HN64_10uM Dose=10uM, 3-(6-fluoro-1H-1,3-benzodiazol-2-yl)-5-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrazin-2-amine, c-Met) Inhibitors;AXL Kinase Inhibitors;HGFR (MET targeting AXL, MET
PC-68-HN64_1uM Dose=1uM, 3-(6-fluoro-1H-1,3-benzodiazol-2-yl)-5-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)pyrazin-2-amine, c-Met) Inhibitors;AXL Kinase Inhibitors;HGFR (MET targeting AXL, MET
PC-74-OR34_0.01uM Dose=0.01uM, CaV1.3 antagonist-1, CACNA1D calcium channel subunit inhibitor targeting CACNA1D
PC-74-OR34_0.1uM Dose=0.1uM, CaV1.3 antagonist-1, CACNA1D calcium channel subunit inhibitor targeting CACNA1D
PC-74-OR34_10uM Dose=10uM, CaV1.3 antagonist-1, CACNA1D calcium channel subunit inhibitor targeting CACNA1D
PC-80-LV29_0.01uM Dose=0.01uM, N-(4-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide
PC-80-LV29_0.1uM Dose=0.1uM, N-(4-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide
PC-80-LV29_10uM Dose=10uM, N-(4-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide
PC-80-LV29_1uM Dose=1uM, N-(4-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide
PC-85-EL52_0.01uM Dose=0.01uM, Jnj-63533054, potent and selective agonist of hGPR139 with an EC50 = 16 nM;GPR139 inhibitor targeting GPR139
PC-85-EL52_0.1uM Dose=0.1uM, Jnj-63533054, potent and selective agonist of hGPR139 with an EC50 = 16 nM;GPR139 inhibitor targeting GPR139
PC-85-EL52_10uM Dose=10uM, Jnj-63533054, potent and selective agonist of hGPR139 with an EC50 = 16 nM;GPR139 inhibitor targeting GPR139
PC-85-EL52_1uM Dose=1uM, Jnj-63533054, potent and selective agonist of hGPR139 with an EC50 = 16 nM;GPR139 inhibitor targeting GPR139
PC-86-EW46_0.01uM Dose=0.01uM, FG-2216, EGLN1 gene inhibitor targeting EGLN1, P4HA1, P4HB, P4HA2, P4HA3
PC-86-EW46_0.1uM Dose=0.1uM, FG-2216, EGLN1 gene inhibitor targeting EGLN1, P4HA1, P4HB, P4HA2, P4HA3
PC-86-EW46_10uM Dose=10uM, FG-2216, EGLN1 gene inhibitor targeting EGLN1, P4HA1, P4HB, P4HA2, P4HA3
PC-86-EW46_1uM Dose=1uM, FG-2216, EGLN1 gene inhibitor targeting EGLN1, P4HA1, P4HB, P4HA2, P4HA3
PC-87-OG75_0.01uM Dose=0.01uM, 5-[2-(3-aminophenyl)ethynyl]-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carbonitrile
PC-87-OG75_0.1uM Dose=0.1uM, 5-[2-(3-aminophenyl)ethynyl]-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carbonitrile
PC-87-OG75_10uM Dose=10uM, 5-[2-(3-aminophenyl)ethynyl]-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carbonitrile
PC-87-OG75_1uM Dose=1uM, 5-[2-(3-aminophenyl)ethynyl]-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carbonitrile
PD-05-HV36_0.01uM Dose=0.01uM, N-[1-[[(1S,9aR)-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl]methyl]piperidin-4-yl]-4-[(5-chloro-1-benzofuran-3-yl)methoxy]-1H-indole-2-carboxamide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2
PD-05-HV36_10uM Dose=10uM, N-[1-[[(1S,9aR)-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl]methyl]piperidin-4-yl]-4-[(5-chloro-1-benzofuran-3-yl)methoxy]-1H-indole-2-carboxamide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2
PD-05-HV36_1uM Dose=1uM, N-[1-[[(1S,9aR)-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl]methyl]piperidin-4-yl]-4-[(5-chloro-1-benzofuran-3-yl)methoxy]-1H-indole-2-carboxamide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2
PD-11-LM65_0.01uM Dose=0.01uM, Acifluorfen
PD-11-LM65_0.1uM Dose=0.1uM, Acifluorfen
PD-11-LM65_10uM Dose=10uM, Acifluorfen
PD-11-LM65_1uM Dose=1uM, Acifluorfen
PD-14-CH80_0.01uM Dose=0.01uM
PD-14-CH80_0.1uM Dose=0.1uM
PD-14-CH80_10uM Dose=10uM
PD-14-CH80_1uM Dose=1uM
PD-14-WO27_0.01uM Dose=0.01uM
PD-14-WO27_0.1uM Dose=0.1uM
PD-14-WO27_10uM Dose=10uM
PD-14-WO27_1uM Dose=1uM
PD-26-DC63_0.01uM Dose=0.01uM, Diazepinomicin, 5-Lipoxygenase Inhibitors;Apoptosis Inducers;MAPK-Activated Protein Kinase Inhibitors;Peripheral Benzodiazepine Receptor (PBR) Ligands targeting ALOX5, TSPO
PD-26-DC63_0.1uM Dose=0.1uM, Diazepinomicin, 5-Lipoxygenase Inhibitors;Apoptosis Inducers;MAPK-Activated Protein Kinase Inhibitors;Peripheral Benzodiazepine Receptor (PBR) Ligands targeting ALOX5, TSPO
PD-26-DC63_10uM Dose=10uM, Diazepinomicin, 5-Lipoxygenase Inhibitors;Apoptosis Inducers;MAPK-Activated Protein Kinase Inhibitors;Peripheral Benzodiazepine Receptor (PBR) Ligands targeting ALOX5, TSPO
PD-26-DC63_1uM Dose=1uM, Diazepinomicin, 5-Lipoxygenase Inhibitors;Apoptosis Inducers;MAPK-Activated Protein Kinase Inhibitors;Peripheral Benzodiazepine Receptor (PBR) Ligands targeting ALOX5, TSPO
PD-30-OV49_0.01uM Dose=0.01uM, Jnj-5207787, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
PD-30-OV49_0.1uM Dose=0.1uM, Jnj-5207787, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
PD-30-OV49_10uM Dose=10uM, Jnj-5207787, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
PD-30-OV49_1uM Dose=1uM, Jnj-5207787, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R
PD-31-RP17_0.01uM Dose=0.01uM
PD-31-RP17_0.1uM Dose=0.1uM
PD-31-RP17_10uM Dose=10uM
PD-31-RP17_1uM Dose=1uM
PD-34-SO87_0.01uM Dose=0.01uM, N-(2-((3-(dimethylamino)propyl)(methyl)amino)-5-(trifluoromethyl)phenyl)-2-fluoro-5-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)benzamide, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK
PD-34-SO87_10uM Dose=10uM, N-(2-((3-(dimethylamino)propyl)(methyl)amino)-5-(trifluoromethyl)phenyl)-2-fluoro-5-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)benzamide, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK
PD-34-SO87_1uM Dose=1uM, N-(2-((3-(dimethylamino)propyl)(methyl)amino)-5-(trifluoromethyl)phenyl)-2-fluoro-5-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)benzamide, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK
PD-40-ZV44_0.01uM Dose=0.01uM, GW842166, Cannabinoid CB2 Agonists targeting CNR2
PD-40-ZV44_0.1uM Dose=0.1uM, GW842166, Cannabinoid CB2 Agonists targeting CNR2
PD-40-ZV44_10uM Dose=10uM, GW842166, Cannabinoid CB2 Agonists targeting CNR2
PD-40-ZV44_1uM Dose=1uM, GW842166, Cannabinoid CB2 Agonists targeting CNR2
PD-50-SI33_0.01uM Dose=0.01uM, N-(1-(3-methoxypropyl)-5-((phenylamino)methyl)-1H-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK
PD-50-SI33_0.1uM Dose=0.1uM, N-(1-(3-methoxypropyl)-5-((phenylamino)methyl)-1H-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK
PD-50-SI33_10uM Dose=10uM, N-(1-(3-methoxypropyl)-5-((phenylamino)methyl)-1H-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK
PD-50-SI33_1uM Dose=1uM, N-(1-(3-methoxypropyl)-5-((phenylamino)methyl)-1H-benzo[d]imidazol-2-yl)isoxazole-5-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK
PD-58-VA68_0.01uM Dose=0.01uM
PD-58-VA68_10uM Dose=10uM
PD-58-VA68_1uM Dose=1uM
PD-60-FM93_0.1uM Dose=0.1uM, Cathepsin G Inhibitor I, Dual mast cell chymase, Cathepsin G inhibitor targeting CMA1, CTSG
PD-60-FM93_10uM Dose=10uM, Cathepsin G Inhibitor I, Dual mast cell chymase, Cathepsin G inhibitor targeting CMA1, CTSG
PD-60-FM93_1uM Dose=1uM, Cathepsin G Inhibitor I, Dual mast cell chymase, Cathepsin G inhibitor targeting CMA1, CTSG
PD-70-VS77_0.01uM Dose=0.01uM, (E)-3-[4-[[2-(2-tert-butyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide
PD-70-VS77_0.1uM Dose=0.1uM, (E)-3-[4-[[2-(2-tert-butyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide
PD-70-VS77_10uM Dose=10uM, (E)-3-[4-[[2-(2-tert-butyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide
PD-70-VS77_1uM Dose=1uM, (E)-3-[4-[[2-(2-tert-butyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide
PD-71-MW24_0.01uM Dose=0.01uM, PI4KIIIbeta-IN-9, PI4K inhibitor targeting PI4KA
PD-71-MW24_0.1uM Dose=0.1uM, PI4KIIIbeta-IN-9, PI4K inhibitor targeting PI4KA
PD-71-MW24_10uM Dose=10uM, PI4KIIIbeta-IN-9, PI4K inhibitor targeting PI4KA
PD-71-MW24_1uM Dose=1uM, PI4KIIIbeta-IN-9, PI4K inhibitor targeting PI4KA
PD-74-GP60_0.01uM Dose=0.01uM, 2-[3-[2-Chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecan-9-yl]acetic acid, GPR120 agonist targeting FFAR4
PD-74-GP60_0.1uM Dose=0.1uM, 2-[3-[2-Chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecan-9-yl]acetic acid, GPR120 agonist targeting FFAR4
PD-74-GP60_10uM Dose=10uM, 2-[3-[2-Chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecan-9-yl]acetic acid, GPR120 agonist targeting FFAR4
PD-74-VS77_0.01uM Dose=0.01uM
PD-74-VS77_10uM Dose=10uM
PD-74-VS77_1uM Dose=1uM
PD-94-WO47_0.01uM Dose=0.01uM, 2-[9-(3-methoxy-4-nitrophenyl)-6-oxo-5,11-dihydrobenzo[b][1,4]benzodiazepin-3-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, Checkpoint Kinase 1 (Chk1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CHEK1
PD-94-WO47_0.1uM Dose=0.1uM, 2-[9-(3-methoxy-4-nitrophenyl)-6-oxo-5,11-dihydrobenzo[b][1,4]benzodiazepin-3-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, Checkpoint Kinase 1 (Chk1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CHEK1
PD-94-WO47_10uM Dose=10uM, 2-[9-(3-methoxy-4-nitrophenyl)-6-oxo-5,11-dihydrobenzo[b][1,4]benzodiazepin-3-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, Checkpoint Kinase 1 (Chk1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CHEK1
PD-94-WO47_1uM Dose=1uM, 2-[9-(3-methoxy-4-nitrophenyl)-6-oxo-5,11-dihydrobenzo[b][1,4]benzodiazepin-3-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, Checkpoint Kinase 1 (Chk1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting CHEK1
PE-00-US47_0.01uM Dose=0.01uM, Epoxyquinomicin D, Antiinflammatory Drugs;Histidine Decarboxylase Inhibitors targeting HDC
PE-00-US47_0.1uM Dose=0.1uM, Epoxyquinomicin D, Antiinflammatory Drugs;Histidine Decarboxylase Inhibitors targeting HDC
PE-00-US47_10uM Dose=10uM, Epoxyquinomicin D, Antiinflammatory Drugs;Histidine Decarboxylase Inhibitors targeting HDC
PE-00-US47_1uM Dose=1uM, Epoxyquinomicin D, Antiinflammatory Drugs;Histidine Decarboxylase Inhibitors targeting HDC
PE-25-KB33_0.01uM Dose=0.01uM, SOAT2 inhibitor;ACAT 2 Inhibitors
PE-25-KB33_10uM Dose=10uM, SOAT2 inhibitor;ACAT 2 Inhibitors
PE-25-KB33_1uM Dose=1uM, SOAT2 inhibitor;ACAT 2 Inhibitors
PE-39-HL72_0.1uM Dose=0.1uM, 8-(1-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-3-acetic acid Methyl Ester, OPRL1 (Nociceptin Receptor) agonist targeting OPRL1
PE-39-HL72_10uM Dose=10uM, 8-(1-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-3-acetic acid Methyl Ester, OPRL1 (Nociceptin Receptor) agonist targeting OPRL1
PE-39-HL72_1uM Dose=1uM, 8-(1-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-3-acetic acid Methyl Ester, OPRL1 (Nociceptin Receptor) agonist targeting OPRL1
PE-49-CB03_0.1uM Dose=0.1uM, 2-[4-[[(3,5-Dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid, LPA1 antagonist targeting LPAR1
PE-49-CB03_1uM Dose=1uM, 2-[4-[[(3,5-Dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid, LPA1 antagonist targeting LPAR1
PE-58-WU11_0.01uM Dose=0.01uM
PE-58-WU11_0.1uM Dose=0.1uM
PE-58-WU11_10uM Dose=10uM
PE-58-WU11_1uM Dose=1uM
PE-63-ER67_0.1uM Dose=0.1uM
PE-63-ER67_10uM Dose=10uM
PE-63-ER67_1uM Dose=1uM
PE-68-QD35_0.01uM Dose=0.01uM, Ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate, TGFBR2 degrador targeting TGFBR2
PE-68-QD35_0.1uM Dose=0.1uM, Ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate, TGFBR2 degrador targeting TGFBR2
PE-68-QD35_10uM Dose=10uM, Ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate, TGFBR2 degrador targeting TGFBR2
PE-68-QD35_1uM Dose=1uM, Ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate, TGFBR2 degrador targeting TGFBR2
PE-69-DO79_0.01uM Dose=0.01uM, N-phenylaminosulfonamide, carbonic anhydrase inhibitor targeting CA1
PE-69-DO79_0.1uM Dose=0.1uM, N-phenylaminosulfonamide, carbonic anhydrase inhibitor targeting CA1
PE-69-DO79_10uM Dose=10uM, N-phenylaminosulfonamide, carbonic anhydrase inhibitor targeting CA1
PE-69-DO79_1uM Dose=1uM, N-phenylaminosulfonamide, carbonic anhydrase inhibitor targeting CA1
PE-82-OK78_0.01uM Dose=0.01uM, 1-Cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine targeting SIGMAR1, TMEM97
PE-82-OK78_0.1uM Dose=0.1uM, 1-Cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine targeting SIGMAR1, TMEM97
PE-82-OK78_10uM Dose=10uM, 1-Cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine targeting SIGMAR1, TMEM97
PE-82-OK78_1uM Dose=1uM, 1-Cyclohexyl-4-[3-(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)propyl]piperazine targeting SIGMAR1, TMEM97
PE-86-SC73_0.01uM Dose=0.01uM, PF-543, SPHK1 inhibitor targeting SPHK1
PE-86-SC73_0.1uM Dose=0.1uM, PF-543, SPHK1 inhibitor targeting SPHK1
PE-86-SC73_10uM Dose=10uM, PF-543, SPHK1 inhibitor targeting SPHK1
PE-86-SC73_1uM Dose=1uM, PF-543, SPHK1 inhibitor targeting SPHK1
PF-39-DY68_0.01uM Dose=0.01uM, 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione
PF-39-DY68_0.1uM Dose=0.1uM, 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione
PF-39-DY68_10uM Dose=10uM, 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione
PF-39-DY68_1uM Dose=1uM, 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione
PF-59-CY33_0.01uM Dose=0.01uM, 8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-1-(3-methyl-1-propan-2-ylpyrazol-4-yl)imidazo[4,5-c]quinolin-2-one, dual mTOR PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD
PF-59-CY33_0.1uM Dose=0.1uM, 8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-1-(3-methyl-1-propan-2-ylpyrazol-4-yl)imidazo[4,5-c]quinolin-2-one, dual mTOR PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD
PF-59-CY33_10uM Dose=10uM, 8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-1-(3-methyl-1-propan-2-ylpyrazol-4-yl)imidazo[4,5-c]quinolin-2-one, dual mTOR PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD
PF-59-CY33_1uM Dose=1uM, 8-(2,4-Dimethoxypyrimidin-5-yl)-3-methyl-1-(3-methyl-1-propan-2-ylpyrazol-4-yl)imidazo[4,5-c]quinolin-2-one, dual mTOR PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD
PF-72-IT39_0.01uM Dose=0.01uM
PF-72-IT39_0.1uM Dose=0.1uM
PF-72-IT39_10uM Dose=10uM
PF-72-IT39_1uM Dose=1uM
PF-84-RH50_0.01uM Dose=0.01uM
PF-84-RH50_0.1uM Dose=0.1uM
PF-84-RH50_10uM Dose=10uM
PF-84-RH50_1uM Dose=1uM
QA-07-KC40_0.01uM Dose=0.01uM, (E)-N-hydroxy-3-[4-[[3-(1H-indol-3-yl)propylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
QA-07-KC40_0.1uM Dose=0.1uM, (E)-N-hydroxy-3-[4-[[3-(1H-indol-3-yl)propylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
QA-07-KC40_10uM Dose=10uM, (E)-N-hydroxy-3-[4-[[3-(1H-indol-3-yl)propylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
QA-07-KC40_1uM Dose=1uM, (E)-N-hydroxy-3-[4-[[3-(1H-indol-3-yl)propylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
QA-14-AU91_0.01uM Dose=0.01uM, Cephalochromin, Phosphodiesterase Inhibitors;NOS2 Expression Inhibitors targeting NOS2
QA-14-AU91_10uM Dose=10uM, Cephalochromin, Phosphodiesterase Inhibitors;NOS2 Expression Inhibitors targeting NOS2
QA-14-AU91_1uM Dose=1uM, Cephalochromin, Phosphodiesterase Inhibitors;NOS2 Expression Inhibitors targeting NOS2
QA-24-ZK07_0.01uM Dose=0.01uM, Docarpamine, Dopamine Receptor Agonists;Dopamine Precursors targeting DRD2, DRD3
QA-24-ZK07_0.1uM Dose=0.1uM, Docarpamine, Dopamine Receptor Agonists;Dopamine Precursors targeting DRD2, DRD3
QA-24-ZK07_10uM Dose=10uM, Docarpamine, Dopamine Receptor Agonists;Dopamine Precursors targeting DRD2, DRD3
QA-25-HL62_0.01uM Dose=0.01uM, 4-({3-chloro-4-[(1-methyl-1H-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinoline-3-carbonitrile, Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors targeting MAP2K1
QA-25-HL62_0.1uM Dose=0.1uM, 4-({3-chloro-4-[(1-methyl-1H-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinoline-3-carbonitrile, Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors targeting MAP2K1
QA-25-HL62_10uM Dose=10uM, 4-({3-chloro-4-[(1-methyl-1H-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinoline-3-carbonitrile, Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors targeting MAP2K1
QA-25-HL62_1uM Dose=1uM, 4-({3-chloro-4-[(1-methyl-1H-imidazol-2-yl)sulfanyl]phenyl}amino)-6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinoline-3-carbonitrile, Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors targeting MAP2K1
QA-27-XW03_0.01uM Dose=0.01uM, 1-[2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl]ethanone
QA-27-XW03_0.1uM Dose=0.1uM, 1-[2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl]ethanone
QA-27-XW03_10uM Dose=10uM, 1-[2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl]ethanone
QA-27-XW03_1uM Dose=1uM, 1-[2-methyl-4-(phenylamino)-3,4-dihydroquinolin-1(2H)-yl]ethanone
QA-30-EV79_0.01uM Dose=0.01uM, Lusutrombopag, Thrombopoietin Receptor (c-MPL) agonist;Signal Transduction Modulators targeting MPL
QA-30-EV79_0.1uM Dose=0.1uM, Lusutrombopag, Thrombopoietin Receptor (c-MPL) agonist;Signal Transduction Modulators targeting MPL
QA-30-EV79_10uM Dose=10uM, Lusutrombopag, Thrombopoietin Receptor (c-MPL) agonist;Signal Transduction Modulators targeting MPL
QA-30-EV79_1uM Dose=1uM, Lusutrombopag, Thrombopoietin Receptor (c-MPL) agonist;Signal Transduction Modulators targeting MPL
QA-34-BH60_0.01uM Dose=0.01uM, rac-2-(4-chlorophenyl)-3-methyl-N-(pyridin-3-yl)butanamide
QA-34-BH60_0.1uM Dose=0.1uM, rac-2-(4-chlorophenyl)-3-methyl-N-(pyridin-3-yl)butanamide
QA-34-BH60_10uM Dose=10uM, rac-2-(4-chlorophenyl)-3-methyl-N-(pyridin-3-yl)butanamide
QA-34-BH60_1uM Dose=1uM, rac-2-(4-chlorophenyl)-3-methyl-N-(pyridin-3-yl)butanamide
QA-34-PH05_0.01uM Dose=0.01uM, Rigosertib, Antagonist of Raf-Ras interaction targeting BRAF, RAF1, ZHX2
QA-34-PH05_0.1uM Dose=0.1uM, Rigosertib, Antagonist of Raf-Ras interaction targeting BRAF, RAF1, ZHX2
QA-34-PH05_10uM Dose=10uM, Rigosertib, Antagonist of Raf-Ras interaction targeting BRAF, RAF1, ZHX2
QA-34-PH05_1uM Dose=1uM, Rigosertib, Antagonist of Raf-Ras interaction targeting BRAF, RAF1, ZHX2
QA-50-YO37_0.01uM Dose=0.01uM, Semapimod, inhibits TNF-alpha - proposed NO inhibitor and/or p38 MAPK pathway; proposed to act via vagus nerve targeting DHPS
QA-50-YO37_0.1uM Dose=0.1uM, Semapimod, inhibits TNF-alpha - proposed NO inhibitor and/or p38 MAPK pathway; proposed to act via vagus nerve targeting DHPS
QA-50-YO37_10uM Dose=10uM, Semapimod, inhibits TNF-alpha - proposed NO inhibitor and/or p38 MAPK pathway; proposed to act via vagus nerve targeting DHPS
QA-50-YO37_1uM Dose=1uM, Semapimod, inhibits TNF-alpha - proposed NO inhibitor and/or p38 MAPK pathway; proposed to act via vagus nerve targeting DHPS
QA-58-CX23_0.1uM Dose=0.1uM, N-hydroxy-2-[(1-naphthalen-2-ylsulfonylpiperidin-3-yl)methylamino]pyrimidine-5-carboxamide
QA-58-CX23_10uM Dose=10uM, N-hydroxy-2-[(1-naphthalen-2-ylsulfonylpiperidin-3-yl)methylamino]pyrimidine-5-carboxamide
QA-58-CX23_1uM Dose=1uM, N-hydroxy-2-[(1-naphthalen-2-ylsulfonylpiperidin-3-yl)methylamino]pyrimidine-5-carboxamide
QA-67-IM54_0.01uM Dose=0.01uM, CID 118626505
QA-67-IM54_0.1uM Dose=0.1uM, CID 118626505
QA-67-IM54_10uM Dose=10uM, CID 118626505
QA-67-IM54_1uM Dose=1uM, CID 118626505
QA-73-SR92_0.01uM Dose=0.01uM
QA-73-SR92_0.1uM Dose=0.1uM
QA-73-SR92_10uM Dose=10uM
QA-73-SR92_1uM Dose=1uM
QA-76-ZM47_0.1uM Dose=0.1uM, N-(Carboxymethyl)-N-(3-Phenylpropyl)glycyl-N-Methyl-L-Histidinamide, IDE gene inhibitor targeting IDE
QA-76-ZM47_10uM Dose=10uM, N-(Carboxymethyl)-N-(3-Phenylpropyl)glycyl-N-Methyl-L-Histidinamide, IDE gene inhibitor targeting IDE
QA-76-ZM47_1uM Dose=1uM, N-(Carboxymethyl)-N-(3-Phenylpropyl)glycyl-N-Methyl-L-Histidinamide, IDE gene inhibitor targeting IDE
QA-81-IM40_0.01uM Dose=0.01uM, 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine targeting KMT5A
QA-81-IM40_0.1uM Dose=0.1uM, 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine targeting KMT5A
QA-81-IM40_10uM Dose=10uM, 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine targeting KMT5A
QA-81-IM40_1uM Dose=1uM, 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine targeting KMT5A
QA-87-NQ04_0.01uM Dose=0.01uM, 5-(Methylamino)-2-(naphthalen-1-yl)-1,3-oxazole-4-carbonitrile, ALOX15 gene inhibitor targeting ALOX15
QA-87-NQ04_0.1uM Dose=0.1uM, 5-(Methylamino)-2-(naphthalen-1-yl)-1,3-oxazole-4-carbonitrile, ALOX15 gene inhibitor targeting ALOX15
QA-87-NQ04_10uM Dose=10uM, 5-(Methylamino)-2-(naphthalen-1-yl)-1,3-oxazole-4-carbonitrile, ALOX15 gene inhibitor targeting ALOX15
QA-87-NQ04_1uM Dose=1uM, 5-(Methylamino)-2-(naphthalen-1-yl)-1,3-oxazole-4-carbonitrile, ALOX15 gene inhibitor targeting ALOX15
QA-98-TQ46_0.01uM Dose=0.01uM, 5-Amino-6h-anthra[1,9-cd]pyrazol-6-one
QA-98-TQ46_0.1uM Dose=0.1uM, 5-Amino-6h-anthra[1,9-cd]pyrazol-6-one
QA-98-TQ46_10uM Dose=10uM, 5-Amino-6h-anthra[1,9-cd]pyrazol-6-one
QA-98-TQ46_1uM Dose=1uM, 5-Amino-6h-anthra[1,9-cd]pyrazol-6-one
QB-00-CS87_0.01uM Dose=0.01uM
QB-00-CS87_0.1uM Dose=0.1uM
QB-00-CS87_10uM Dose=10uM
QB-00-CS87_1uM Dose=1uM
QB-06-VC83_0.01uM Dose=0.01uM, 4-(furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide, GPR41 agonist targeting FFAR3
QB-06-VC83_0.1uM Dose=0.1uM, 4-(furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide, GPR41 agonist targeting FFAR3
QB-06-VC83_10uM Dose=10uM, 4-(furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide, GPR41 agonist targeting FFAR3
QB-06-VC83_1uM Dose=1uM, 4-(furan-2-yl)-2-methyl-5-oxo-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide, GPR41 agonist targeting FFAR3
QB-07-YT91_0.01uM Dose=0.01uM, PARP3 inhibitor targeting PARP3
QB-07-YT91_0.1uM Dose=0.1uM, PARP3 inhibitor targeting PARP3
QB-07-YT91_10uM Dose=10uM, PARP3 inhibitor targeting PARP3
QB-29-GK19_0.01uM Dose=0.01uM, Diethyl (4-oxo-2-phenyl-4H-chromen-6-yl) phosphate, Cholesterol Esterase Inhibitors targeting CEL
QB-29-GK19_0.1uM Dose=0.1uM, Diethyl (4-oxo-2-phenyl-4H-chromen-6-yl) phosphate, Cholesterol Esterase Inhibitors targeting CEL
QB-29-GK19_10uM Dose=10uM, Diethyl (4-oxo-2-phenyl-4H-chromen-6-yl) phosphate, Cholesterol Esterase Inhibitors targeting CEL
QB-29-GK19_1uM Dose=1uM, Diethyl (4-oxo-2-phenyl-4H-chromen-6-yl) phosphate, Cholesterol Esterase Inhibitors targeting CEL
QB-34-NU46_0.01uM Dose=0.01uM, (3R,4aR,10aR)-1-methyl-3-[(4-methylpyrimidin-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol
QB-34-NU46_0.1uM Dose=0.1uM, (3R,4aR,10aR)-1-methyl-3-[(4-methylpyrimidin-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol
QB-34-NU46_10uM Dose=10uM, (3R,4aR,10aR)-1-methyl-3-[(4-methylpyrimidin-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol
QB-34-NU46_1uM Dose=1uM, (3R,4aR,10aR)-1-methyl-3-[(4-methylpyrimidin-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol
QB-35-FO29_0.01uM Dose=0.01uM, (2S)-2-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-sulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid, MMP-12 (Macrophage Elastase) Inhibitors targeting MMP12
QB-35-FO29_0.1uM Dose=0.1uM, (2S)-2-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-sulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid, MMP-12 (Macrophage Elastase) Inhibitors targeting MMP12
QB-35-FO29_10uM Dose=10uM, (2S)-2-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-sulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid, MMP-12 (Macrophage Elastase) Inhibitors targeting MMP12
QB-35-FO29_1uM Dose=1uM, (2S)-2-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-sulfanylbutanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid, MMP-12 (Macrophage Elastase) Inhibitors targeting MMP12
QB-42-ET79_0.01uM Dose=0.01uM, Ecabet, Mucin Production, Enhancers;Urease Inhibitors targeting NOXO1
QB-42-ET79_0.1uM Dose=0.1uM, Ecabet, Mucin Production, Enhancers;Urease Inhibitors targeting NOXO1
QB-42-ET79_10uM Dose=10uM, Ecabet, Mucin Production, Enhancers;Urease Inhibitors targeting NOXO1
QB-42-ET79_1uM Dose=1uM, Ecabet, Mucin Production, Enhancers;Urease Inhibitors targeting NOXO1
QB-42-MC63_0.01uM Dose=0.01uM, [4-[4-[[Methyl(prop-2-enyl)amino]methyl]phenyl]phenyl]-phenylmethanone, Lanosterol Synthase Inhibitors targeting LSS
QB-42-MC63_10uM Dose=10uM, [4-[4-[[Methyl(prop-2-enyl)amino]methyl]phenyl]phenyl]-phenylmethanone, Lanosterol Synthase Inhibitors targeting LSS
QB-42-MC63_1uM Dose=1uM, [4-[4-[[Methyl(prop-2-enyl)amino]methyl]phenyl]phenyl]-phenylmethanone, Lanosterol Synthase Inhibitors targeting LSS
QB-69-AR11_0.01uM Dose=0.01uM, N-[(1S,2R,3S,4R)-4-(2-Chloro-6-cyclopentylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide, Adenosine A1 Agonists targeting ADORA1
QB-69-AR11_0.1uM Dose=0.1uM, N-[(1S,2R,3S,4R)-4-(2-Chloro-6-cyclopentylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide, Adenosine A1 Agonists targeting ADORA1
QB-69-AR11_10uM Dose=10uM, N-[(1S,2R,3S,4R)-4-(2-Chloro-6-cyclopentylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide, Adenosine A1 Agonists targeting ADORA1
QB-69-AR11_1uM Dose=1uM, N-[(1S,2R,3S,4R)-4-(2-Chloro-6-cyclopentylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide, Adenosine A1 Agonists targeting ADORA1
QB-69-QH67_0.01uM Dose=0.01uM, 1,3-Benzothiazol-2-yl-[5-(4-chlorophenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone, TOP2A catalytic inhibitor targeting TOP2A
QB-69-QH67_0.1uM Dose=0.1uM, 1,3-Benzothiazol-2-yl-[5-(4-chlorophenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone, TOP2A catalytic inhibitor targeting TOP2A
QB-69-QH67_10uM Dose=10uM, 1,3-Benzothiazol-2-yl-[5-(4-chlorophenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone, TOP2A catalytic inhibitor targeting TOP2A
QB-69-QH67_1uM Dose=1uM, 1,3-Benzothiazol-2-yl-[5-(4-chlorophenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone, TOP2A catalytic inhibitor targeting TOP2A
QB-72-LM87_0.01uM Dose=0.01uM, NMDA Glycine B Receptor Antagonists targeting GRIN1
QB-72-LM87_10uM Dose=10uM, NMDA Glycine B Receptor Antagonists targeting GRIN1
QB-72-LM87_1uM Dose=1uM, NMDA Glycine B Receptor Antagonists targeting GRIN1
QB-87-TC65_0.01uM Dose=0.01uM, PD-166866, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Basic Fibroblast Growth Factor (bFGF;FGF2) Inhibitors;Tyrosine Kinase Inhibitors targeting FGF2, FGFR3P1
QB-87-TC65_0.1uM Dose=0.1uM, PD-166866, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Basic Fibroblast Growth Factor (bFGF;FGF2) Inhibitors;Tyrosine Kinase Inhibitors targeting FGF2, FGFR3P1
QB-87-TC65_10uM Dose=10uM, PD-166866, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Basic Fibroblast Growth Factor (bFGF;FGF2) Inhibitors;Tyrosine Kinase Inhibitors targeting FGF2, FGFR3P1
QB-87-TC65_1uM Dose=1uM, PD-166866, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Basic Fibroblast Growth Factor (bFGF;FGF2) Inhibitors;Tyrosine Kinase Inhibitors targeting FGF2, FGFR3P1
QB-88-PG52_0.01uM Dose=0.01uM, 2-Benzyloxy-4H-3,1-benzoxazin-4-one, Cathepsin G inhibitor targeting CTSG
QB-88-PG52_0.1uM Dose=0.1uM, 2-Benzyloxy-4H-3,1-benzoxazin-4-one, Cathepsin G inhibitor targeting CTSG
QB-88-PG52_10uM Dose=10uM, 2-Benzyloxy-4H-3,1-benzoxazin-4-one, Cathepsin G inhibitor targeting CTSG
QB-88-PG52_1uM Dose=1uM, 2-Benzyloxy-4H-3,1-benzoxazin-4-one, Cathepsin G inhibitor targeting CTSG
QB-99-OU03_0.01uM Dose=0.01uM, 2-(s)Cyano-1-isoleucylpyrrolidine, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
QB-99-OU03_0.1uM Dose=0.1uM, 2-(s)Cyano-1-isoleucylpyrrolidine, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
QB-99-OU03_10uM Dose=10uM, 2-(s)Cyano-1-isoleucylpyrrolidine, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
QB-99-OU03_1uM Dose=1uM, 2-(s)Cyano-1-isoleucylpyrrolidine, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
QC-10-TY16_0.01uM Dose=0.01uM, Ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate, Carnitine O-Palmitoyltransferase Inhibitors;Antioxidants targeting CPT1A, CPT1B
QC-10-TY16_0.1uM Dose=0.1uM, Ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate, Carnitine O-Palmitoyltransferase Inhibitors;Antioxidants targeting CPT1A, CPT1B
QC-10-TY16_10uM Dose=10uM, Ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate, Carnitine O-Palmitoyltransferase Inhibitors;Antioxidants targeting CPT1A, CPT1B
QC-10-TY16_1uM Dose=1uM, Ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate, Carnitine O-Palmitoyltransferase Inhibitors;Antioxidants targeting CPT1A, CPT1B
QC-12-DW06_0.01uM Dose=0.01uM, 4-Phenyl-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]piperidine-4-carboxamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1
QC-12-DW06_0.1uM Dose=0.1uM, 4-Phenyl-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]piperidine-4-carboxamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1
QC-12-DW06_10uM Dose=10uM, 4-Phenyl-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]piperidine-4-carboxamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1
QC-12-DW06_1uM Dose=1uM, 4-Phenyl-1-[2-[3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]piperidine-4-carboxamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1
QC-15-WY38_0.1uM Dose=0.1uM, TRKA Inhibitors targeting NTRK1
QC-15-WY38_10uM Dose=10uM, TRKA Inhibitors targeting NTRK1
QC-15-WY38_1uM Dose=1uM, TRKA Inhibitors targeting NTRK1
QC-22-LC33_0.01uM Dose=0.01uM, 4-fluoro-N-[4-(piperidin-1-ylcarbonyl)phenyl]benzamide
QC-22-LC33_10uM Dose=10uM, 4-fluoro-N-[4-(piperidin-1-ylcarbonyl)phenyl]benzamide
QC-22-LC33_1uM Dose=1uM, 4-fluoro-N-[4-(piperidin-1-ylcarbonyl)phenyl]benzamide
QC-32-ZC28_0.01uM Dose=0.01uM, 4-[Methyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]butylphosphonic acid
QC-32-ZC28_0.1uM Dose=0.1uM, 4-[Methyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]butylphosphonic acid
QC-32-ZC28_10uM Dose=10uM, 4-[Methyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]butylphosphonic acid
QC-32-ZC28_1uM Dose=1uM, 4-[Methyl-[(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]amino]butylphosphonic acid
QC-49-CA55_0.01uM Dose=0.01uM
QC-49-CA55_0.1uM Dose=0.1uM
QC-49-CA55_10uM Dose=10uM
QC-49-CA55_1uM Dose=1uM
QC-55-WY28_0.01uM Dose=0.01uM
QC-55-WY28_0.1uM Dose=0.1uM
QC-55-WY28_10uM Dose=10uM
QC-55-WY28_1uM Dose=1uM
QC-63-VN72_0.01uM Dose=0.01uM
QC-63-VN72_10uM Dose=10uM
QC-63-VN72_1uM Dose=1uM
QC-76-GI57_10uM Dose=10uM
QC-76-GI57_1uM Dose=1uM
QC-78-XX98_0.01uM Dose=0.01uM, Alogliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
QC-78-XX98_0.1uM Dose=0.1uM, Alogliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
QC-78-XX98_10uM Dose=10uM, Alogliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
QC-78-XX98_1uM Dose=1uM, Alogliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
QC-80-MO42_0.01uM Dose=0.01uM
QC-80-MO42_0.1uM Dose=0.1uM
QC-80-MO42_10uM Dose=10uM
QC-80-MO42_1uM Dose=1uM
QC-90-PV99_0.01uM Dose=0.01uM, 2-(Morpholinomethyl)-5-((5-((7-(trifluoromethyl)quinolin-4-yl)thio)pentyl)oxy)-4H-pyran-4-one, Rac1 GTPase Inhibitors;Angiogenesis Inhibitors targeting RAC1
QC-90-PV99_0.1uM Dose=0.1uM, 2-(Morpholinomethyl)-5-((5-((7-(trifluoromethyl)quinolin-4-yl)thio)pentyl)oxy)-4H-pyran-4-one, Rac1 GTPase Inhibitors;Angiogenesis Inhibitors targeting RAC1
QC-90-PV99_10uM Dose=10uM, 2-(Morpholinomethyl)-5-((5-((7-(trifluoromethyl)quinolin-4-yl)thio)pentyl)oxy)-4H-pyran-4-one, Rac1 GTPase Inhibitors;Angiogenesis Inhibitors targeting RAC1
QC-90-PV99_1uM Dose=1uM, 2-(Morpholinomethyl)-5-((5-((7-(trifluoromethyl)quinolin-4-yl)thio)pentyl)oxy)-4H-pyran-4-one, Rac1 GTPase Inhibitors;Angiogenesis Inhibitors targeting RAC1
QC-95-TO14_0.1uM Dose=0.1uM, Lazabemide, MAO-B Inhibitors targeting MAOB
QC-95-TO14_10uM Dose=10uM, Lazabemide, MAO-B Inhibitors targeting MAOB
QC-95-TO14_1uM Dose=1uM, Lazabemide, MAO-B Inhibitors targeting MAOB
QD-13-FQ44_0.01uM Dose=0.01uM, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, PDCD1, PDE1A, PDE1C, PDE4C, PDE6A, PDE6C, PDE6D, PDE6G, PDE6H, PDE8A, PDE9A, PDE6B, PDE8B
QD-13-FQ44_0.1uM Dose=0.1uM, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, PDCD1, PDE1A, PDE1C, PDE4C, PDE6A, PDE6C, PDE6D, PDE6G, PDE6H, PDE8A, PDE9A, PDE6B, PDE8B
QD-13-FQ44_10uM Dose=10uM, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, PDCD1, PDE1A, PDE1C, PDE4C, PDE6A, PDE6C, PDE6D, PDE6G, PDE6H, PDE8A, PDE9A, PDE6B, PDE8B
QD-13-FQ44_1uM Dose=1uM, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, PDCD1, PDE1A, PDE1C, PDE4C, PDE6A, PDE6C, PDE6D, PDE6G, PDE6H, PDE8A, PDE9A, PDE6B, PDE8B
QD-32-CW16_0.01uM Dose=0.01uM, DW-1350, Leukotriene BLT (LTB4) Antagonists targeting LTB4R
QD-32-CW16_0.1uM Dose=0.1uM, DW-1350, Leukotriene BLT (LTB4) Antagonists targeting LTB4R
QD-32-CW16_10uM Dose=10uM, DW-1350, Leukotriene BLT (LTB4) Antagonists targeting LTB4R
QD-32-CW16_1uM Dose=1uM, DW-1350, Leukotriene BLT (LTB4) Antagonists targeting LTB4R
QD-39-YV36_0.01uM Dose=0.01uM, (1S,3S)-3-amino-4-(2,2,2-trifluoro-1-trifluoromethylethylidene)cyclopentane, OAT inhibitor targeting OAT
QD-39-YV36_0.1uM Dose=0.1uM, (1S,3S)-3-amino-4-(2,2,2-trifluoro-1-trifluoromethylethylidene)cyclopentane, OAT inhibitor targeting OAT
QD-39-YV36_10uM Dose=10uM, (1S,3S)-3-amino-4-(2,2,2-trifluoro-1-trifluoromethylethylidene)cyclopentane, OAT inhibitor targeting OAT
QD-39-YV36_1uM Dose=1uM, (1S,3S)-3-amino-4-(2,2,2-trifluoro-1-trifluoromethylethylidene)cyclopentane, OAT inhibitor targeting OAT
QD-57-GT11_0.01uM Dose=0.01uM
QD-57-GT11_0.1uM Dose=0.1uM
QD-57-GT11_10uM Dose=10uM
QD-57-GT11_1uM Dose=1uM
QD-61-CS49_0.01uM Dose=0.01uM, (2S)-2-[[2-[(2R,3S,4R,5S,6R)-6-(hexadecoxymethyl)-3,4,5-trihydroxyoxan-2-yl]acetyl]amino]pentanedioic acid, E-Selectin Inhibitors targeting SELE
QD-61-CS49_0.1uM Dose=0.1uM, (2S)-2-[[2-[(2R,3S,4R,5S,6R)-6-(hexadecoxymethyl)-3,4,5-trihydroxyoxan-2-yl]acetyl]amino]pentanedioic acid, E-Selectin Inhibitors targeting SELE
QD-61-CS49_10uM Dose=10uM, (2S)-2-[[2-[(2R,3S,4R,5S,6R)-6-(hexadecoxymethyl)-3,4,5-trihydroxyoxan-2-yl]acetyl]amino]pentanedioic acid, E-Selectin Inhibitors targeting SELE
QD-75-XB03_0.01uM Dose=0.01uM
QD-75-XB03_0.1uM Dose=0.1uM
QD-75-XB03_10uM Dose=10uM
QD-75-XB03_1uM Dose=1uM
QD-85-OO24_0.01uM Dose=0.01uM, Agn-PC-0O4rya, Na+/Ca2+ Exchanger (NCX) Inhibitors;L-Type Calcium Channel Blockers targeting SLC8A2, SLC8A1
QD-85-OO24_0.1uM Dose=0.1uM, Agn-PC-0O4rya, Na+/Ca2+ Exchanger (NCX) Inhibitors;L-Type Calcium Channel Blockers targeting SLC8A2, SLC8A1
QD-85-OO24_1uM Dose=1uM, Agn-PC-0O4rya, Na+/Ca2+ Exchanger (NCX) Inhibitors;L-Type Calcium Channel Blockers targeting SLC8A2, SLC8A1
QE-00-EB96_0.01uM Dose=0.01uM, MERTK gene inhibitor targeting MERTK
QE-00-EB96_0.1uM Dose=0.1uM, MERTK gene inhibitor targeting MERTK
QE-00-EB96_10uM Dose=10uM, MERTK gene inhibitor targeting MERTK
QE-00-EB96_1uM Dose=1uM, MERTK gene inhibitor targeting MERTK
QE-03-UA61_0.01uM Dose=0.01uM, 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile, Menin inhibitor targeting MEN1
QE-03-UA61_0.1uM Dose=0.1uM, 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile, Menin inhibitor targeting MEN1
QE-03-UA61_10uM Dose=10uM, 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile, Menin inhibitor targeting MEN1
QE-03-UA61_1uM Dose=1uM, 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile, Menin inhibitor targeting MEN1
QE-04-BY06_0.01uM Dose=0.01uM, (5,5-Dioxo-4H-thieno[3,2-c]thiochromen-2-yl)-[4-(4-methoxyphenyl)piperazin-1-yl]methanone, LYPLA2 gene inhibitor targeting LYPLA2
QE-04-BY06_0.1uM Dose=0.1uM, (5,5-Dioxo-4H-thieno[3,2-c]thiochromen-2-yl)-[4-(4-methoxyphenyl)piperazin-1-yl]methanone, LYPLA2 gene inhibitor targeting LYPLA2
QE-04-BY06_10uM Dose=10uM, (5,5-Dioxo-4H-thieno[3,2-c]thiochromen-2-yl)-[4-(4-methoxyphenyl)piperazin-1-yl]methanone, LYPLA2 gene inhibitor targeting LYPLA2
QE-04-BY06_1uM Dose=1uM, (5,5-Dioxo-4H-thieno[3,2-c]thiochromen-2-yl)-[4-(4-methoxyphenyl)piperazin-1-yl]methanone, LYPLA2 gene inhibitor targeting LYPLA2
QE-11-DP47_0.01uM Dose=0.01uM, 9-Hydroxycalabaxanthone
QE-11-DP47_0.1uM Dose=0.1uM, 9-Hydroxycalabaxanthone
QE-11-DP47_10uM Dose=10uM, 9-Hydroxycalabaxanthone
QE-11-DP47_1uM Dose=1uM, 9-Hydroxycalabaxanthone
QE-18-WG07_0.01uM Dose=0.01uM, CXCR2 antagonist 8, Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR1, CXCR2
QE-18-WG07_0.1uM Dose=0.1uM, CXCR2 antagonist 8, Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR1, CXCR2
QE-18-WG07_10uM Dose=10uM, CXCR2 antagonist 8, Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR1, CXCR2
QE-18-WG07_1uM Dose=1uM, CXCR2 antagonist 8, Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR1, CXCR2
QE-35-YE15_0.01uM Dose=0.01uM, 1-(4-tert-Butyl-anilino)-4-[6-hydroxy-(pyridin-3-yl)methyl]-phthalazine
QE-35-YE15_0.1uM Dose=0.1uM, 1-(4-tert-Butyl-anilino)-4-[6-hydroxy-(pyridin-3-yl)methyl]-phthalazine
QE-35-YE15_10uM Dose=10uM, 1-(4-tert-Butyl-anilino)-4-[6-hydroxy-(pyridin-3-yl)methyl]-phthalazine
QE-35-YE15_1uM Dose=1uM, 1-(4-tert-Butyl-anilino)-4-[6-hydroxy-(pyridin-3-yl)methyl]-phthalazine
QE-48-NG07_0.01uM Dose=0.01uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-[4-[[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-(diaminomethylideneamino)-1,3,5-triazin-2-yl]amino]anilino]-1,3,5-triazin-2-yl]guanidine, NPR1 agonist of the extracellular domain targeting NPR1
QE-48-NG07_0.1uM Dose=0.1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-[4-[[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-(diaminomethylideneamino)-1,3,5-triazin-2-yl]amino]anilino]-1,3,5-triazin-2-yl]guanidine, NPR1 agonist of the extracellular domain targeting NPR1
QE-48-NG07_10uM Dose=10uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-[4-[[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-(diaminomethylideneamino)-1,3,5-triazin-2-yl]amino]anilino]-1,3,5-triazin-2-yl]guanidine, NPR1 agonist of the extracellular domain targeting NPR1
QE-48-NG07_1uM Dose=1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-[4-[[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-(diaminomethylideneamino)-1,3,5-triazin-2-yl]amino]anilino]-1,3,5-triazin-2-yl]guanidine, NPR1 agonist of the extracellular domain targeting NPR1
QE-76-HF95_0.01uM Dose=0.01uM, S 8921, Ileal sodium bile acid cotransporter inhibitor targeting SLC10A2
QE-76-HF95_0.1uM Dose=0.1uM, S 8921, Ileal sodium bile acid cotransporter inhibitor targeting SLC10A2
QE-76-HF95_10uM Dose=10uM, S 8921, Ileal sodium bile acid cotransporter inhibitor targeting SLC10A2
QE-76-HF95_1uM Dose=1uM, S 8921, Ileal sodium bile acid cotransporter inhibitor targeting SLC10A2
QE-76-ST29_0.01uM Dose=0.01uM, 5-Amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one
QE-76-ST29_0.1uM Dose=0.1uM, 5-Amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one
QE-76-ST29_10uM Dose=10uM, 5-Amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one
QE-76-ST29_1uM Dose=1uM, 5-Amino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one
QE-79-XO29_0.01uM Dose=0.01uM, Harringtonine, Translation Inititiation Inhibitor targeting RPL3
QE-79-XO29_0.1uM Dose=0.1uM, Harringtonine, Translation Inititiation Inhibitor targeting RPL3
QE-79-XO29_10uM Dose=10uM, Harringtonine, Translation Inititiation Inhibitor targeting RPL3
QE-79-XO29_1uM Dose=1uM, Harringtonine, Translation Inititiation Inhibitor targeting RPL3
QE-83-LG95_10uM Dose=10uM, Zotepine, Dopamine D2 Antagonists;Adrenergic receptor modulator;Serotonin Antagonists targeting ADRA1B, HTR1E, HTR1F
QE-83-LG95_1uM Dose=1uM, Zotepine, Dopamine D2 Antagonists;Adrenergic receptor modulator;Serotonin Antagonists targeting ADRA1B, HTR1E, HTR1F
QE-87-XW53_0.01uM Dose=0.01uM, Dopexamine, Dopamine D1 Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, DRD1
QE-87-XW53_0.1uM Dose=0.1uM, Dopexamine, Dopamine D1 Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, DRD1
QE-87-XW53_10uM Dose=10uM, Dopexamine, Dopamine D1 Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, DRD1
QE-87-XW53_1uM Dose=1uM, Dopexamine, Dopamine D1 Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, DRD1
QE-93-PG25_0.01uM Dose=0.01uM, 3-(8-(Hydroxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
QE-93-PG25_10uM Dose=10uM, 3-(8-(Hydroxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
QE-93-PG25_1uM Dose=1uM, 3-(8-(Hydroxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
QE-98-XD90_0.01uM Dose=0.01uM, N,N-dimethyl-3-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]prop-2-yn-1-amine
QE-98-XD90_0.1uM Dose=0.1uM, N,N-dimethyl-3-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]prop-2-yn-1-amine
QE-98-XD90_10uM Dose=10uM, N,N-dimethyl-3-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]prop-2-yn-1-amine
QE-98-XD90_1uM Dose=1uM, N,N-dimethyl-3-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]prop-2-yn-1-amine
QF-00-CY91_0.01uM Dose=0.01uM, 3-Phenylacetylamino-2,6-piperidinedione
QF-00-CY91_0.1uM Dose=0.1uM, 3-Phenylacetylamino-2,6-piperidinedione
QF-00-CY91_10uM Dose=10uM, 3-Phenylacetylamino-2,6-piperidinedione
QF-00-CY91_1uM Dose=1uM, 3-Phenylacetylamino-2,6-piperidinedione
QF-00-NO42_0.01uM Dose=0.01uM
QF-00-NO42_0.1uM Dose=0.1uM
QF-00-NO42_10uM Dose=10uM
QF-00-NO42_1uM Dose=1uM
QF-05-OL72_0.01uM Dose=0.01uM
QF-05-OL72_0.1uM Dose=0.1uM
QF-05-OL72_10uM Dose=10uM
QF-05-OL72_1uM Dose=1uM
QF-09-IK44_0.01uM Dose=0.01uM, Aryl carbamate analog 1
QF-09-IK44_0.1uM Dose=0.1uM, Aryl carbamate analog 1
QF-09-IK44_10uM Dose=10uM, Aryl carbamate analog 1
QF-09-IK44_1uM Dose=1uM, Aryl carbamate analog 1
QF-14-JU46_0.01uM Dose=0.01uM, 3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid, Thyroid Hormone Receptor beta Agonists targeting THRA, THRB
QF-14-JU46_10uM Dose=10uM, 3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid, Thyroid Hormone Receptor beta Agonists targeting THRA, THRB
QF-41-QW99_0.01uM Dose=0.01uM, Fdl169, CFTR corrector targeting CFTR
QF-41-QW99_0.1uM Dose=0.1uM, Fdl169, CFTR corrector targeting CFTR
QF-41-QW99_10uM Dose=10uM, Fdl169, CFTR corrector targeting CFTR
QF-41-QW99_1uM Dose=1uM, Fdl169, CFTR corrector targeting CFTR
QF-45-KI95_0.01uM Dose=0.01uM, 4-Bromanyl-~{n}-(6-Methoxy-1,3-Dimethyl-2-Oxidanylidene-Benzimidazol-5-Yl)-2-Methyl-Benzenesulfonamide, BRPF1B and BRPF2 inhibitor targeting BRPF1, BRD1
QF-45-KI95_0.1uM Dose=0.1uM, 4-Bromanyl-~{n}-(6-Methoxy-1,3-Dimethyl-2-Oxidanylidene-Benzimidazol-5-Yl)-2-Methyl-Benzenesulfonamide, BRPF1B and BRPF2 inhibitor targeting BRPF1, BRD1
QF-45-KI95_10uM Dose=10uM, 4-Bromanyl-~{n}-(6-Methoxy-1,3-Dimethyl-2-Oxidanylidene-Benzimidazol-5-Yl)-2-Methyl-Benzenesulfonamide, BRPF1B and BRPF2 inhibitor targeting BRPF1, BRD1
QF-45-KI95_1uM Dose=1uM, 4-Bromanyl-~{n}-(6-Methoxy-1,3-Dimethyl-2-Oxidanylidene-Benzimidazol-5-Yl)-2-Methyl-Benzenesulfonamide, BRPF1B and BRPF2 inhibitor targeting BRPF1, BRD1
QF-55-QV81_0.01uM Dose=0.01uM
QF-55-QV81_0.1uM Dose=0.1uM
QF-55-QV81_10uM Dose=10uM
QF-55-QV81_1uM Dose=1uM
QF-63-EA36_0.01uM Dose=0.01uM
QF-63-EA36_10uM Dose=10uM
QF-63-EA36_1uM Dose=1uM
QF-71-QI30_0.01uM Dose=0.01uM, 4-Dimethylamino-N-(7-hydroxycarbamoyl-heptyl)-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
QF-71-QI30_10uM Dose=10uM, 4-Dimethylamino-N-(7-hydroxycarbamoyl-heptyl)-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
QF-71-QI30_1uM Dose=1uM, 4-Dimethylamino-N-(7-hydroxycarbamoyl-heptyl)-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
QF-97-LC45_0.1uM Dose=0.1uM
QF-97-LC45_10uM Dose=10uM
QF-97-LC45_1uM Dose=1uM
RA-00-KI98_0.01uM Dose=0.01uM, N-[1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methylbenzimidazol-2-yl]-5-methoxypyridine-3-carboxamide, Blk tyrosine kinase inhibitor targeting EGFR
RA-00-KI98_0.1uM Dose=0.1uM, N-[1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methylbenzimidazol-2-yl]-5-methoxypyridine-3-carboxamide, Blk tyrosine kinase inhibitor targeting EGFR
RA-00-KI98_10uM Dose=10uM, N-[1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methylbenzimidazol-2-yl]-5-methoxypyridine-3-carboxamide, Blk tyrosine kinase inhibitor targeting EGFR
RA-00-KI98_1uM Dose=1uM, N-[1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methylbenzimidazol-2-yl]-5-methoxypyridine-3-carboxamide, Blk tyrosine kinase inhibitor targeting EGFR
RA-01-US54_0.01uM Dose=0.01uM
RA-01-US54_10uM Dose=10uM
RA-01-US54_1uM Dose=1uM
RA-02-OJ95_0.01uM Dose=0.01uM, (3R,4S)-1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol, Methylthioadenosine Phosphorylase (MTAP) Inhibitors targeting MTAP
RA-02-OJ95_0.1uM Dose=0.1uM, (3R,4S)-1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol, Methylthioadenosine Phosphorylase (MTAP) Inhibitors targeting MTAP
RA-02-OJ95_10uM Dose=10uM, (3R,4S)-1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol, Methylthioadenosine Phosphorylase (MTAP) Inhibitors targeting MTAP
RA-02-OJ95_1uM Dose=1uM, (3R,4S)-1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol, Methylthioadenosine Phosphorylase (MTAP) Inhibitors targeting MTAP
RA-03-RQ19_0.01uM Dose=0.01uM, 3-(6-fluoropyridin-3-yl)-2-(4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl)pyridine, QPCT inhibitor targeting QPCT
RA-03-RQ19_0.1uM Dose=0.1uM, 3-(6-fluoropyridin-3-yl)-2-(4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl)pyridine, QPCT inhibitor targeting QPCT
RA-03-RQ19_10uM Dose=10uM, 3-(6-fluoropyridin-3-yl)-2-(4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl)pyridine, QPCT inhibitor targeting QPCT
RA-03-RQ19_1uM Dose=1uM, 3-(6-fluoropyridin-3-yl)-2-(4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl)pyridine, QPCT inhibitor targeting QPCT
RA-14-EK87_0.01uM Dose=0.01uM, 3-(4-hydroxyphenyl)-7-methoxy-4H-1,3-benzoxazin-2-one
RA-14-EK87_0.1uM Dose=0.1uM, 3-(4-hydroxyphenyl)-7-methoxy-4H-1,3-benzoxazin-2-one
RA-14-EK87_10uM Dose=10uM, 3-(4-hydroxyphenyl)-7-methoxy-4H-1,3-benzoxazin-2-one
RA-14-EK87_1uM Dose=1uM, 3-(4-hydroxyphenyl)-7-methoxy-4H-1,3-benzoxazin-2-one
RA-18-CU16_0.01uM Dose=0.01uM
RA-18-CU16_0.1uM Dose=0.1uM
RA-18-CU16_10uM Dose=10uM
RA-18-CU16_1uM Dose=1uM
RA-23-IX31_0.01uM Dose=0.01uM, (2R,3S)-1-(2-Chlorobenzoyl)-2-(4-(cyclopentylamino)phenyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, C5a Antagonists targeting C5AR1
RA-23-IX31_0.1uM Dose=0.1uM, (2R,3S)-1-(2-Chlorobenzoyl)-2-(4-(cyclopentylamino)phenyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, C5a Antagonists targeting C5AR1
RA-23-IX31_10uM Dose=10uM, (2R,3S)-1-(2-Chlorobenzoyl)-2-(4-(cyclopentylamino)phenyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, C5a Antagonists targeting C5AR1
RA-23-IX31_1uM Dose=1uM, (2R,3S)-1-(2-Chlorobenzoyl)-2-(4-(cyclopentylamino)phenyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, C5a Antagonists targeting C5AR1
RA-25-SB63_0.01uM Dose=0.01uM, N-[(4-carbamimidoylphenyl)methyl]-1-(naphthalen-2-ylmethyl)pyrazole-4-carboxamide, Known PlasmaKallikrein inhibitor targeting KLKB1
RA-25-SB63_0.1uM Dose=0.1uM, N-[(4-carbamimidoylphenyl)methyl]-1-(naphthalen-2-ylmethyl)pyrazole-4-carboxamide, Known PlasmaKallikrein inhibitor targeting KLKB1
RA-25-SB63_10uM Dose=10uM, N-[(4-carbamimidoylphenyl)methyl]-1-(naphthalen-2-ylmethyl)pyrazole-4-carboxamide, Known PlasmaKallikrein inhibitor targeting KLKB1
RA-25-SB63_1uM Dose=1uM, N-[(4-carbamimidoylphenyl)methyl]-1-(naphthalen-2-ylmethyl)pyrazole-4-carboxamide, Known PlasmaKallikrein inhibitor targeting KLKB1
RA-25-VV91_0.01uM Dose=0.01uM
RA-25-VV91_0.1uM Dose=0.1uM
RA-25-VV91_10uM Dose=10uM
RA-25-VV91_1uM Dose=1uM
RA-27-ST16_0.01uM Dose=0.01uM, Istaroxime, Na+/K+-ATPase Inhibitors;SERCA2a Activator targeting ATP2A2, ATP1B1, ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B2, ATP1B3, FXYD2, ATP1B4
RA-27-ST16_10uM Dose=10uM, Istaroxime, Na+/K+-ATPase Inhibitors;SERCA2a Activator targeting ATP2A2, ATP1B1, ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B2, ATP1B3, FXYD2, ATP1B4
RA-42-CM42_0.01uM Dose=0.01uM, Lestaurtinib
RA-42-CM42_0.1uM Dose=0.1uM, Lestaurtinib
RA-42-CM42_10uM Dose=10uM, Lestaurtinib
RA-42-CM42_1uM Dose=1uM, Lestaurtinib
RA-44-SU16_0.01uM Dose=0.01uM, H4 Receptor antagonist 1, HRH4 antagonist targeting HRH4
RA-44-SU16_0.1uM Dose=0.1uM, H4 Receptor antagonist 1, HRH4 antagonist targeting HRH4
RA-44-SU16_10uM Dose=10uM, H4 Receptor antagonist 1, HRH4 antagonist targeting HRH4
RA-49-ZB08_0.01uM Dose=0.01uM
RA-49-ZB08_0.1uM Dose=0.1uM
RA-49-ZB08_10uM Dose=10uM
RA-49-ZB08_1uM Dose=1uM
RA-53-JG50_0.01uM Dose=0.01uM, (S)-N-(2,6-Dioxopiperidin-3-yl)undec-10-enamide, Broad Spectrum Chemokine Inhibitors (BSCI) targeting CCR2, CRBN
RA-53-JG50_10uM Dose=10uM, (S)-N-(2,6-Dioxopiperidin-3-yl)undec-10-enamide, Broad Spectrum Chemokine Inhibitors (BSCI) targeting CCR2, CRBN
RA-53-JG50_1uM Dose=1uM, (S)-N-(2,6-Dioxopiperidin-3-yl)undec-10-enamide, Broad Spectrum Chemokine Inhibitors (BSCI) targeting CCR2, CRBN
RA-55-DY98_0.01uM Dose=0.01uM
RA-55-DY98_0.1uM Dose=0.1uM
RA-55-DY98_10uM Dose=10uM
RA-55-DY98_1uM Dose=1uM
RA-57-TJ22_0.01uM Dose=0.01uM, K(ir) 6.2/SUR1 Blockers;Insulin Secretagogues targeting KCNJ11, ABCC8
RA-60-MZ29_0.01uM Dose=0.01uM, KDM5A pan Inhibitor targeting KDM5A
RA-60-MZ29_0.1uM Dose=0.1uM, KDM5A pan Inhibitor targeting KDM5A
RA-60-MZ29_10uM Dose=10uM, KDM5A pan Inhibitor targeting KDM5A
RA-60-MZ29_1uM Dose=1uM, KDM5A pan Inhibitor targeting KDM5A
RA-63-FK60_0.01uM Dose=0.01uM, Cysmethynil, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT
RA-63-FK60_10uM Dose=10uM, Cysmethynil, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT
RA-63-FK60_1uM Dose=1uM, Cysmethynil, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT
RA-81-JZ66_0.01uM Dose=0.01uM, 3-(Carboxymethyl)-5-fluoro-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1
RA-81-JZ66_0.1uM Dose=0.1uM, 3-(Carboxymethyl)-5-fluoro-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1
RA-81-JZ66_10uM Dose=10uM, 3-(Carboxymethyl)-5-fluoro-1-(naphthalen-1-ylmethyl)-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1
RA-86-LI22_0.01uM Dose=0.01uM, Bromosporine
RA-86-LI22_10uM Dose=10uM, Bromosporine
RA-86-LI22_1uM Dose=1uM, Bromosporine
RA-89-RR01_0.01uM Dose=0.01uM, Bms-906024, Gamma-secretase inhibitor;gamma secretase inhibitor targeting PSEN1
RA-89-RR01_0.1uM Dose=0.1uM, Bms-906024, Gamma-secretase inhibitor;gamma secretase inhibitor targeting PSEN1
RA-89-RR01_10uM Dose=10uM, Bms-906024, Gamma-secretase inhibitor;gamma secretase inhibitor targeting PSEN1
RA-89-RR01_1uM Dose=1uM, Bms-906024, Gamma-secretase inhibitor;gamma secretase inhibitor targeting PSEN1
RB-06-YP44_0.01uM Dose=0.01uM, m-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
RB-06-YP44_0.1uM Dose=0.1uM, m-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
RB-06-YP44_10uM Dose=10uM, m-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
RB-06-YP44_1uM Dose=1uM, m-Chlorophenylbiguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
RB-18-SX73_0.01uM Dose=0.01uM
RB-18-SX73_0.1uM Dose=0.1uM
RB-18-SX73_10uM Dose=10uM
RB-18-SX73_1uM Dose=1uM
RB-22-TT44_0.1uM Dose=0.1uM, (2E)-3-{4-[bicyclo[3.3.1]non-9-ylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;Selective Estrogen Receptor Destabilizers (SERD) targeting ESR1, ESR2
RB-22-TT44_10uM Dose=10uM, (2E)-3-{4-[bicyclo[3.3.1]non-9-ylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;Selective Estrogen Receptor Destabilizers (SERD) targeting ESR1, ESR2
RB-22-TT44_1uM Dose=1uM, (2E)-3-{4-[bicyclo[3.3.1]non-9-ylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;Selective Estrogen Receptor Destabilizers (SERD) targeting ESR1, ESR2
RB-34-TO07_0.01uM Dose=0.01uM, N'-[4-[[4-[Hydroxybis[4-(trifluoromethyl)phenyl]methyl]-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-urea, EHMT2 inhibitor targeting EHMT2
RB-34-TO07_0.1uM Dose=0.1uM, N'-[4-[[4-[Hydroxybis[4-(trifluoromethyl)phenyl]methyl]-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-urea, EHMT2 inhibitor targeting EHMT2
RB-34-TO07_10uM Dose=10uM, N'-[4-[[4-[Hydroxybis[4-(trifluoromethyl)phenyl]methyl]-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-urea, EHMT2 inhibitor targeting EHMT2
RB-34-TO07_1uM Dose=1uM, N'-[4-[[4-[Hydroxybis[4-(trifluoromethyl)phenyl]methyl]-1-piperidinyl]methyl]phenyl]-N,N-dimethyl-urea, EHMT2 inhibitor targeting EHMT2
RB-42-MC53_0.1uM Dose=0.1uM, 4-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-indol-1-yl}-piperidine-1-carboxylic acid tert-butyl ester, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
RB-42-MC53_10uM Dose=10uM, 4-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-indol-1-yl}-piperidine-1-carboxylic acid tert-butyl ester, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
RB-42-MC53_1uM Dose=1uM, 4-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]-indol-1-yl}-piperidine-1-carboxylic acid tert-butyl ester, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ
RB-43-AX96_0.01uM Dose=0.01uM, PC-190723
RB-43-AX96_0.1uM Dose=0.1uM, PC-190723
RB-43-AX96_10uM Dose=10uM, PC-190723
RB-43-AX96_1uM Dose=1uM, PC-190723
RB-48-AN54_0.01uM Dose=0.01uM, Gsk984
RB-48-AN54_0.1uM Dose=0.1uM, Gsk984
RB-48-AN54_10uM Dose=10uM, Gsk984
RB-48-AN54_1uM Dose=1uM, Gsk984
RB-55-KL42_0.01uM Dose=0.01uM
RB-55-KL42_0.1uM Dose=0.1uM
RB-55-KL42_10uM Dose=10uM
RB-55-KL42_1uM Dose=1uM
RB-55-WB28_0.01uM Dose=0.01uM, Verproside, TNFa - NFkB pathway inhibitor;TRADD-TRAF2 PPI inhibitor targeting TRAF2, TRADD
RB-55-WB28_0.1uM Dose=0.1uM, Verproside, TNFa - NFkB pathway inhibitor;TRADD-TRAF2 PPI inhibitor targeting TRAF2, TRADD
RB-55-WB28_10uM Dose=10uM, Verproside, TNFa - NFkB pathway inhibitor;TRADD-TRAF2 PPI inhibitor targeting TRAF2, TRADD
RB-55-WB28_1uM Dose=1uM, Verproside, TNFa - NFkB pathway inhibitor;TRADD-TRAF2 PPI inhibitor targeting TRAF2, TRADD
RB-56-FZ63_0.01uM Dose=0.01uM, 3-[[3-Methyl-2-[[2,3,4-Tris(Fluoranyl)phenoxy]methyl]-1-Benzofuran-4-Yl]oxy]-N-(Pyridin-3-Ylmethyl)propan-1-Amine, N-Myristoyltransferase Inhibitors targeting NMT1
RB-56-FZ63_0.1uM Dose=0.1uM, 3-[[3-Methyl-2-[[2,3,4-Tris(Fluoranyl)phenoxy]methyl]-1-Benzofuran-4-Yl]oxy]-N-(Pyridin-3-Ylmethyl)propan-1-Amine, N-Myristoyltransferase Inhibitors targeting NMT1
RB-56-FZ63_10uM Dose=10uM, 3-[[3-Methyl-2-[[2,3,4-Tris(Fluoranyl)phenoxy]methyl]-1-Benzofuran-4-Yl]oxy]-N-(Pyridin-3-Ylmethyl)propan-1-Amine, N-Myristoyltransferase Inhibitors targeting NMT1
RB-56-FZ63_1uM Dose=1uM, 3-[[3-Methyl-2-[[2,3,4-Tris(Fluoranyl)phenoxy]methyl]-1-Benzofuran-4-Yl]oxy]-N-(Pyridin-3-Ylmethyl)propan-1-Amine, N-Myristoyltransferase Inhibitors targeting NMT1
RB-61-DW99_0.01uM Dose=0.01uM, N-Methyl-1-(5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl)methanamine, ATP4A blocker, ATP4B blocker targeting ATP4A, ATP4B
RB-61-DW99_0.1uM Dose=0.1uM, N-Methyl-1-(5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl)methanamine, ATP4A blocker, ATP4B blocker targeting ATP4A, ATP4B
RB-61-DW99_10uM Dose=10uM, N-Methyl-1-(5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl)methanamine, ATP4A blocker, ATP4B blocker targeting ATP4A, ATP4B
RB-61-DW99_1uM Dose=1uM, N-Methyl-1-(5-phenyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl)methanamine, ATP4A blocker, ATP4B blocker targeting ATP4A, ATP4B
RB-74-JO32_0.01uM Dose=0.01uM, 4',4''-Methylenebis(acetanilide)
RB-74-JO32_0.1uM Dose=0.1uM, 4',4''-Methylenebis(acetanilide)
RB-74-JO32_10uM Dose=10uM, 4',4''-Methylenebis(acetanilide)
RB-74-JO32_1uM Dose=1uM, 4',4''-Methylenebis(acetanilide)
RB-80-II48_0.01uM Dose=0.01uM, 8-(2,5-Dimethoxyphenyl)-1-(2-fluorophenyl)imidazo[4,5-c]quinoline, RET inhibitor targeting RET
RB-80-II48_0.1uM Dose=0.1uM, 8-(2,5-Dimethoxyphenyl)-1-(2-fluorophenyl)imidazo[4,5-c]quinoline, RET inhibitor targeting RET
RB-80-II48_10uM Dose=10uM, 8-(2,5-Dimethoxyphenyl)-1-(2-fluorophenyl)imidazo[4,5-c]quinoline, RET inhibitor targeting RET
RB-80-II48_1uM Dose=1uM, 8-(2,5-Dimethoxyphenyl)-1-(2-fluorophenyl)imidazo[4,5-c]quinoline, RET inhibitor targeting RET
RB-80-RO52_0.01uM Dose=0.01uM, Dexamethasone, Antiinflammatory Drugs targeting NR3C1
RB-80-RO52_0.1uM Dose=0.1uM, Dexamethasone, Antiinflammatory Drugs targeting NR3C1
RB-80-RO52_10uM Dose=10uM, Dexamethasone, Antiinflammatory Drugs targeting NR3C1
RB-80-RO52_1uM Dose=1uM, Dexamethasone, Antiinflammatory Drugs targeting NR3C1
RC-08-UN34_0.01uM Dose=0.01uM, 4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)benzonitrile
RC-08-UN34_0.1uM Dose=0.1uM, 4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)benzonitrile
RC-08-UN34_10uM Dose=10uM, 4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)benzonitrile
RC-08-UN34_1uM Dose=1uM, 4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)benzonitrile
RC-14-PH60_0.01uM Dose=0.01uM, Lin28-let-7a antagonist 1 targeting LIN28A
RC-14-PH60_0.1uM Dose=0.1uM, Lin28-let-7a antagonist 1 targeting LIN28A
RC-14-PH60_10uM Dose=10uM, Lin28-let-7a antagonist 1 targeting LIN28A
RC-14-PH60_1uM Dose=1uM, Lin28-let-7a antagonist 1 targeting LIN28A
RC-18-AD40_0.01uM Dose=0.01uM, N-(3,5-dimethylphenyl)-4-(thiazol-2-yl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors;Syk Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting SYK, AURKB, GSK3A
RC-18-AD40_0.1uM Dose=0.1uM, N-(3,5-dimethylphenyl)-4-(thiazol-2-yl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors;Syk Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting SYK, AURKB, GSK3A
RC-18-AD40_10uM Dose=10uM, N-(3,5-dimethylphenyl)-4-(thiazol-2-yl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors;Syk Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting SYK, AURKB, GSK3A
RC-18-AD40_1uM Dose=1uM, N-(3,5-dimethylphenyl)-4-(thiazol-2-yl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors;Syk Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting SYK, AURKB, GSK3A
RC-21-IF98_0.01uM Dose=0.01uM
RC-21-IF98_0.1uM Dose=0.1uM
RC-21-IF98_10uM Dose=10uM
RC-21-IF98_1uM Dose=1uM
RC-47-HT31_0.01uM Dose=0.01uM, CID 9804834, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
RC-47-HT31_0.1uM Dose=0.1uM, CID 9804834, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
RC-47-HT31_10uM Dose=10uM, CID 9804834, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
RC-47-HT31_1uM Dose=1uM, CID 9804834, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB
RC-47-LT41_0.01uM Dose=0.01uM
RC-47-LT41_0.1uM Dose=0.1uM
RC-47-LT41_10uM Dose=10uM
RC-47-LT41_1uM Dose=1uM
RC-52-AC88_0.01uM Dose=0.01uM, (Z)-N-(4-bromophenyl)-N'-(3-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1
RC-52-AC88_0.1uM Dose=0.1uM, (Z)-N-(4-bromophenyl)-N'-(3-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1
RC-52-AC88_10uM Dose=10uM, (Z)-N-(4-bromophenyl)-N'-(3-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1
RC-52-AC88_1uM Dose=1uM, (Z)-N-(4-bromophenyl)-N'-(3-chlorophenyl)but-2-enediamide, XPO1 (CRM1) inhibitor targeting XPO1
RC-62-LC43_0.01uM Dose=0.01uM, (2r)-2-Amino-3-(2,4-Dichlorophenyl)-1-(1,3-Dihydro-2h-Isoindol-2-Yl)propan-1-One
RC-62-LC43_0.1uM Dose=0.1uM, (2r)-2-Amino-3-(2,4-Dichlorophenyl)-1-(1,3-Dihydro-2h-Isoindol-2-Yl)propan-1-One
RC-62-LC43_10uM Dose=10uM, (2r)-2-Amino-3-(2,4-Dichlorophenyl)-1-(1,3-Dihydro-2h-Isoindol-2-Yl)propan-1-One
RC-62-LC43_1uM Dose=1uM, (2r)-2-Amino-3-(2,4-Dichlorophenyl)-1-(1,3-Dihydro-2h-Isoindol-2-Yl)propan-1-One
RC-65-VL12_0.01uM Dose=0.01uM, (E)-N-[(1R)-1-[3-(cyclopropylmethoxy)phenyl]ethyl]-5-(2,4-dioxopyrimidin-1-yl)pent-3-ene-1-sulfonamide, Deoxyuridine Nucleotidohydrolase (dUTPase) Inhibitors targeting DUT
RC-65-VL12_0.1uM Dose=0.1uM, (E)-N-[(1R)-1-[3-(cyclopropylmethoxy)phenyl]ethyl]-5-(2,4-dioxopyrimidin-1-yl)pent-3-ene-1-sulfonamide, Deoxyuridine Nucleotidohydrolase (dUTPase) Inhibitors targeting DUT
RC-65-VL12_10uM Dose=10uM, (E)-N-[(1R)-1-[3-(cyclopropylmethoxy)phenyl]ethyl]-5-(2,4-dioxopyrimidin-1-yl)pent-3-ene-1-sulfonamide, Deoxyuridine Nucleotidohydrolase (dUTPase) Inhibitors targeting DUT
RC-65-VL12_1uM Dose=1uM, (E)-N-[(1R)-1-[3-(cyclopropylmethoxy)phenyl]ethyl]-5-(2,4-dioxopyrimidin-1-yl)pent-3-ene-1-sulfonamide, Deoxyuridine Nucleotidohydrolase (dUTPase) Inhibitors targeting DUT
RC-74-NK42_0.01uM Dose=0.01uM
RC-74-NK42_0.1uM Dose=0.1uM
RC-74-NK42_10uM Dose=10uM
RC-74-NK42_1uM Dose=1uM
RC-92-EM42_0.01uM Dose=0.01uM, CDK4 Inhibitors;CDK2 Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2, CDK4
RC-92-EM42_0.1uM Dose=0.1uM, CDK4 Inhibitors;CDK2 Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2, CDK4
RC-92-EM42_10uM Dose=10uM, CDK4 Inhibitors;CDK2 Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2, CDK4
RC-92-EM42_1uM Dose=1uM, CDK4 Inhibitors;CDK2 Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2, CDK4
RD-35-DE45_0.01uM Dose=0.01uM, N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-((1-methylpiperidin-4-yl)oxy)benzamide, SLC5A7 gene inhibitor targeting SLC5A7
RD-35-DE45_0.1uM Dose=0.1uM, N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-((1-methylpiperidin-4-yl)oxy)benzamide, SLC5A7 gene inhibitor targeting SLC5A7
RD-35-DE45_10uM Dose=10uM, N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-((1-methylpiperidin-4-yl)oxy)benzamide, SLC5A7 gene inhibitor targeting SLC5A7
RD-35-DE45_1uM Dose=1uM, N-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-((1-methylpiperidin-4-yl)oxy)benzamide, SLC5A7 gene inhibitor targeting SLC5A7
RD-37-PW33_0.01uM Dose=0.01uM, BAX activator targeting BAX
RD-37-PW33_0.1uM Dose=0.1uM, BAX activator targeting BAX
RD-37-PW33_10uM Dose=10uM, BAX activator targeting BAX
RD-37-PW33_1uM Dose=1uM, BAX activator targeting BAX
RD-39-ZE95_0.01uM Dose=0.01uM, 3,4-Dichloro-1-benzothiophene-2-carbohydrazide, inhibitor of OGG1 targeting OGG1
RD-39-ZE95_0.1uM Dose=0.1uM, 3,4-Dichloro-1-benzothiophene-2-carbohydrazide, inhibitor of OGG1 targeting OGG1
RD-39-ZE95_10uM Dose=10uM, 3,4-Dichloro-1-benzothiophene-2-carbohydrazide, inhibitor of OGG1 targeting OGG1
RD-39-ZE95_1uM Dose=1uM, 3,4-Dichloro-1-benzothiophene-2-carbohydrazide, inhibitor of OGG1 targeting OGG1
RD-50-EO07_0.1uM Dose=0.1uM, Efipladib, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A
RD-50-EO07_10uM Dose=10uM, Efipladib, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A
RD-50-EO07_1uM Dose=1uM, Efipladib, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A
RD-57-WQ44_0.01uM Dose=0.01uM, VU0650786, selective mGlu3 NAM targeting GRM3
RD-57-WQ44_0.1uM Dose=0.1uM, VU0650786, selective mGlu3 NAM targeting GRM3
RD-57-WQ44_10uM Dose=10uM, VU0650786, selective mGlu3 NAM targeting GRM3
RD-57-WQ44_1uM Dose=1uM, VU0650786, selective mGlu3 NAM targeting GRM3
RD-64-KA33_0.01uM Dose=0.01uM, Gsk983, Inhibitor of pyrimidine biosynthesis targeting DHODH
RD-64-KA33_0.1uM Dose=0.1uM, Gsk983, Inhibitor of pyrimidine biosynthesis targeting DHODH
RD-64-KA33_10uM Dose=10uM, Gsk983, Inhibitor of pyrimidine biosynthesis targeting DHODH
RD-64-KA33_1uM Dose=1uM, Gsk983, Inhibitor of pyrimidine biosynthesis targeting DHODH
RD-66-DP49_0.01uM Dose=0.01uM, 2-[(1-Methyl-2-Oxidanyl-4-Oxidanylidene-Quinolin-3-Yl)carbonylamino]ethanoic Acid, Prolyl 4-Hydroxylase Inhibitors;Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
RD-66-DP49_0.1uM Dose=0.1uM, 2-[(1-Methyl-2-Oxidanyl-4-Oxidanylidene-Quinolin-3-Yl)carbonylamino]ethanoic Acid, Prolyl 4-Hydroxylase Inhibitors;Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
RD-66-DP49_10uM Dose=10uM, 2-[(1-Methyl-2-Oxidanyl-4-Oxidanylidene-Quinolin-3-Yl)carbonylamino]ethanoic Acid, Prolyl 4-Hydroxylase Inhibitors;Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
RD-66-DP49_1uM Dose=1uM, 2-[(1-Methyl-2-Oxidanyl-4-Oxidanylidene-Quinolin-3-Yl)carbonylamino]ethanoic Acid, Prolyl 4-Hydroxylase Inhibitors;Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1
RD-79-FH72_0.01uM Dose=0.01uM, 4-(4-Chlorophenyl)-2-[(5-nitrofuran-2-carbonyl)amino]thiophene-3-carboxylic acid
RD-79-FH72_0.1uM Dose=0.1uM, 4-(4-Chlorophenyl)-2-[(5-nitrofuran-2-carbonyl)amino]thiophene-3-carboxylic acid
RD-79-FH72_10uM Dose=10uM, 4-(4-Chlorophenyl)-2-[(5-nitrofuran-2-carbonyl)amino]thiophene-3-carboxylic acid
RD-79-FH72_1uM Dose=1uM, 4-(4-Chlorophenyl)-2-[(5-nitrofuran-2-carbonyl)amino]thiophene-3-carboxylic acid
RD-89-FH52_0.01uM Dose=0.01uM
RD-89-FH52_0.1uM Dose=0.1uM
RD-89-FH52_10uM Dose=10uM
RD-89-FH52_1uM Dose=1uM
RD-90-DS77_0.01uM Dose=0.01uM, Genistin
RD-90-DS77_0.1uM Dose=0.1uM, Genistin
RD-90-DS77_10uM Dose=10uM, Genistin
RD-90-DS77_1uM Dose=1uM, Genistin
RD-90-OY66_0.01uM Dose=0.01uM, Benzeneacetamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-(((2-hydroxy-1-(hydroxymethyl)ethyl)amino)methyl)-, CDK4 Inhibitors;CDK1 Inhibitors;CDK2/Cyclin E Inhibitors targeting CCNE1, CDK1, CDK2, CDK4, CCNE2
RD-90-OY66_0.1uM Dose=0.1uM, Benzeneacetamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-(((2-hydroxy-1-(hydroxymethyl)ethyl)amino)methyl)-, CDK4 Inhibitors;CDK1 Inhibitors;CDK2/Cyclin E Inhibitors targeting CCNE1, CDK1, CDK2, CDK4, CCNE2
RD-90-OY66_10uM Dose=10uM, Benzeneacetamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-(((2-hydroxy-1-(hydroxymethyl)ethyl)amino)methyl)-, CDK4 Inhibitors;CDK1 Inhibitors;CDK2/Cyclin E Inhibitors targeting CCNE1, CDK1, CDK2, CDK4, CCNE2
RD-90-OY66_1uM Dose=1uM, Benzeneacetamide, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-(((2-hydroxy-1-(hydroxymethyl)ethyl)amino)methyl)-, CDK4 Inhibitors;CDK1 Inhibitors;CDK2/Cyclin E Inhibitors targeting CCNE1, CDK1, CDK2, CDK4, CCNE2
RD-92-QT24_0.01uM Dose=0.01uM, Autophinib targeting PIK3C3
RD-92-QT24_0.1uM Dose=0.1uM, Autophinib targeting PIK3C3
RD-92-QT24_10uM Dose=10uM, Autophinib targeting PIK3C3
RD-92-QT24_1uM Dose=1uM, Autophinib targeting PIK3C3
RD-96-AM02_0.01uM Dose=0.01uM
RD-96-AM02_0.1uM Dose=0.1uM
RD-96-AM02_10uM Dose=10uM
RD-96-AM02_1uM Dose=1uM
RE-04-MV24_0.01uM Dose=0.01uM, Catpb, GPR43 antagonist targeting FFAR2
RE-04-MV24_0.1uM Dose=0.1uM, Catpb, GPR43 antagonist targeting FFAR2
RE-04-MV24_10uM Dose=10uM, Catpb, GPR43 antagonist targeting FFAR2
RE-04-MV24_1uM Dose=1uM, Catpb, GPR43 antagonist targeting FFAR2
RE-21-BF58_0.01uM Dose=0.01uM, Glycogen Phosphorylase Inhibitor, phosphorylase, glycogen, liver Inhibitor targeting PYGL
RE-21-BF58_0.1uM Dose=0.1uM, Glycogen Phosphorylase Inhibitor, phosphorylase, glycogen, liver Inhibitor targeting PYGL
RE-21-BF58_1uM Dose=1uM, Glycogen Phosphorylase Inhibitor, phosphorylase, glycogen, liver Inhibitor targeting PYGL
RE-22-MW21_0.01uM Dose=0.01uM, HTR1A agonist
RE-22-MW21_10uM Dose=10uM, HTR1A agonist
RE-22-MW21_1uM Dose=1uM, HTR1A agonist
RE-35-JB13_0.01uM Dose=0.01uM, MEK5/ERK5 Inhibitor targeting MAP2K5
RE-35-JB13_10uM Dose=10uM, MEK5/ERK5 Inhibitor targeting MAP2K5
RE-35-JB13_1uM Dose=1uM, MEK5/ERK5 Inhibitor targeting MAP2K5
RE-44-GR79_0.01uM Dose=0.01uM, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
RE-44-GR79_0.1uM Dose=0.1uM, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
RE-44-GR79_1uM Dose=1uM, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10
RE-51-AF63_0.1uM Dose=0.1uM, Voglibose, alpha-Glucosidase Inhibitors;inhibits digestion and absorption of glucose from intestine targeting GAA, SI
RE-51-AF63_10uM Dose=10uM, Voglibose, alpha-Glucosidase Inhibitors;inhibits digestion and absorption of glucose from intestine targeting GAA, SI
RE-51-AF63_1uM Dose=1uM, Voglibose, alpha-Glucosidase Inhibitors;inhibits digestion and absorption of glucose from intestine targeting GAA, SI
RE-62-FC93_0.01uM Dose=0.01uM, 6-(3-Chlorophenyl)-3-[5-[4-(diethylamino)piperidin-1-yl]-2-methoxyphenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
RE-62-FC93_0.1uM Dose=0.1uM, 6-(3-Chlorophenyl)-3-[5-[4-(diethylamino)piperidin-1-yl]-2-methoxyphenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
RE-62-FC93_10uM Dose=10uM, 6-(3-Chlorophenyl)-3-[5-[4-(diethylamino)piperidin-1-yl]-2-methoxyphenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
RE-62-FC93_1uM Dose=1uM, 6-(3-Chlorophenyl)-3-[5-[4-(diethylamino)piperidin-1-yl]-2-methoxyphenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine
RE-72-IT14_0.01uM Dose=0.01uM, 3-{4-[(E)-3-(4-tert-Butyl-piperazin-1-yl)-propenyl]-benzyl}-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
RE-72-IT14_0.1uM Dose=0.1uM, 3-{4-[(E)-3-(4-tert-Butyl-piperazin-1-yl)-propenyl]-benzyl}-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
RE-72-IT14_10uM Dose=10uM, 3-{4-[(E)-3-(4-tert-Butyl-piperazin-1-yl)-propenyl]-benzyl}-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
RE-72-IT14_1uM Dose=1uM, 3-{4-[(E)-3-(4-tert-Butyl-piperazin-1-yl)-propenyl]-benzyl}-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
RE-97-MC55_0.01uM Dose=0.01uM, 3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCG
RE-97-MC55_0.1uM Dose=0.1uM, 3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCG
RE-97-MC55_10uM Dose=10uM, 3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCG
RE-97-MC55_1uM Dose=1uM, 3-[1-(3-Dimethylamino-propyl)-1H-indazol-3-yl]-4-[1-(1,4,4a,8a-tetrahydro-naphthalen-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCG
RE-99-TA30_0.01uM Dose=0.01uM, (3,4-dihydro-1H-isochromen-1-ylmethyl)amine, MC4R antagonist targeting MC4R
RE-99-TA30_0.1uM Dose=0.1uM, (3,4-dihydro-1H-isochromen-1-ylmethyl)amine, MC4R antagonist targeting MC4R
RE-99-TA30_10uM Dose=10uM, (3,4-dihydro-1H-isochromen-1-ylmethyl)amine, MC4R antagonist targeting MC4R
RE-99-TA30_1uM Dose=1uM, (3,4-dihydro-1H-isochromen-1-ylmethyl)amine, MC4R antagonist targeting MC4R
RF-04-GI28_0.01uM Dose=0.01uM
RF-04-GI28_0.1uM Dose=0.1uM
RF-04-GI28_10uM Dose=10uM
RF-04-GI28_1uM Dose=1uM
RF-05-PV01_0.01uM Dose=0.01uM, 6-Chloro-3-((4-methylpiperazin-1-yl)methylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one, SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4, PBRM1
RF-05-PV01_0.1uM Dose=0.1uM, 6-Chloro-3-((4-methylpiperazin-1-yl)methylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one, SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4, PBRM1
RF-05-PV01_10uM Dose=10uM, 6-Chloro-3-((4-methylpiperazin-1-yl)methylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one, SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4, PBRM1
RF-05-PV01_1uM Dose=1uM, 6-Chloro-3-((4-methylpiperazin-1-yl)methylene)-2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one, SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4, PBRM1
RF-07-FC20_0.1uM Dose=0.1uM, AR-C118925XX, An antagonist of the P2Y2 Receptor, apparently first identified by AZ;P2RY2 antagonist targeting P2RY2
RF-07-FC20_10uM Dose=10uM, AR-C118925XX, An antagonist of the P2Y2 Receptor, apparently first identified by AZ;P2RY2 antagonist targeting P2RY2
RF-07-FC20_1uM Dose=1uM, AR-C118925XX, An antagonist of the P2Y2 Receptor, apparently first identified by AZ;P2RY2 antagonist targeting P2RY2
RF-36-EI47_0.01uM Dose=0.01uM, (R)-4-hydroxy-7-(1-hydroxy-2-(2-methyl-1-phenylpropan-2-ylamino)ethyl)benzo[d]thiazol-2(3H)-one, beta1-Adrenoceptor Ligands;beta2-Adrenoceptor Ligands targeting ADRB1, ADRB2
RF-36-EI47_0.1uM Dose=0.1uM, (R)-4-hydroxy-7-(1-hydroxy-2-(2-methyl-1-phenylpropan-2-ylamino)ethyl)benzo[d]thiazol-2(3H)-one, beta1-Adrenoceptor Ligands;beta2-Adrenoceptor Ligands targeting ADRB1, ADRB2
RF-36-EI47_10uM Dose=10uM, (R)-4-hydroxy-7-(1-hydroxy-2-(2-methyl-1-phenylpropan-2-ylamino)ethyl)benzo[d]thiazol-2(3H)-one, beta1-Adrenoceptor Ligands;beta2-Adrenoceptor Ligands targeting ADRB1, ADRB2
RF-36-EI47_1uM Dose=1uM, (R)-4-hydroxy-7-(1-hydroxy-2-(2-methyl-1-phenylpropan-2-ylamino)ethyl)benzo[d]thiazol-2(3H)-one, beta1-Adrenoceptor Ligands;beta2-Adrenoceptor Ligands targeting ADRB1, ADRB2
RF-47-PC15_0.01uM Dose=0.01uM, 4,6-Dinitro-2,1,3-benzothiadiazole
RF-47-PC15_0.1uM Dose=0.1uM, 4,6-Dinitro-2,1,3-benzothiadiazole
RF-47-PC15_10uM Dose=10uM, 4,6-Dinitro-2,1,3-benzothiadiazole
RF-47-PC15_1uM Dose=1uM, 4,6-Dinitro-2,1,3-benzothiadiazole
RF-57-OJ02_0.01uM Dose=0.01uM, N-(4-chloro-2-isopropoxybenzyl)-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, GPR3 inverse agonist targeting GPR3
RF-57-OJ02_0.1uM Dose=0.1uM, N-(4-chloro-2-isopropoxybenzyl)-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, GPR3 inverse agonist targeting GPR3
RF-57-OJ02_10uM Dose=10uM, N-(4-chloro-2-isopropoxybenzyl)-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, GPR3 inverse agonist targeting GPR3
RF-57-OJ02_1uM Dose=1uM, N-(4-chloro-2-isopropoxybenzyl)-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, GPR3 inverse agonist targeting GPR3
RF-58-GQ76_0.01uM Dose=0.01uM
RF-58-GQ76_0.1uM Dose=0.1uM
RF-58-GQ76_10uM Dose=10uM
RF-58-GQ76_1uM Dose=1uM
RF-70-HE33_0.01uM Dose=0.01uM
RF-70-HE33_10uM Dose=10uM
RF-70-HE33_1uM Dose=1uM
RF-95-QO64_0.01uM Dose=0.01uM
RF-95-QO64_0.1uM Dose=0.1uM
RF-95-QO64_10uM Dose=10uM
RF-95-QO64_1uM Dose=1uM
S0-EE-TZAB_0.01uM Dose=0.01uM
S0-EE-TZAB_0.1uM Dose=0.1uM
S0-EE-TZAB_10uM Dose=10uM
S0-EE-TZAB_1uM Dose=1uM
S0-EE-U3YG_0.01uM Dose=0.01uM, ACMSD inhibitor targeting ACMSD
S0-EE-U3YG_0.1uM Dose=0.1uM, ACMSD inhibitor targeting ACMSD
S0-EE-U3YG_10uM Dose=10uM, ACMSD inhibitor targeting ACMSD
S0-EE-U3YG_1uM Dose=1uM, ACMSD inhibitor targeting ACMSD
S0-EE-WH3B_0.01uM Dose=0.01uM, 1-(4-cyanophenyl)-N-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxamide targeting ALDH1A2
S0-EE-WH3B_0.1uM Dose=0.1uM, 1-(4-cyanophenyl)-N-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxamide targeting ALDH1A2
S0-EE-WH3B_10uM Dose=10uM, 1-(4-cyanophenyl)-N-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxamide targeting ALDH1A2
S0-EE-WH3B_1uM Dose=1uM, 1-(4-cyanophenyl)-N-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxamide targeting ALDH1A2
S0-EE-WHDK_0.01uM Dose=0.01uM, 2-(6-aminopurin-9-yl)-N-[(4-sulfamoylphenyl)methyl]acetamide targeting CA2, CA9
S0-EE-WHDK_0.1uM Dose=0.1uM, 2-(6-aminopurin-9-yl)-N-[(4-sulfamoylphenyl)methyl]acetamide targeting CA2, CA9
S0-EE-WHDK_10uM Dose=10uM, 2-(6-aminopurin-9-yl)-N-[(4-sulfamoylphenyl)methyl]acetamide targeting CA2, CA9
S0-EE-WIZB_0.01uM Dose=0.01uM, Glpg-2451 targeting CFTR
S0-EE-WIZB_0.1uM Dose=0.1uM, Glpg-2451 targeting CFTR
S0-EE-WIZB_10uM Dose=10uM, Glpg-2451 targeting CFTR
S0-EE-WIZB_1uM Dose=1uM, Glpg-2451 targeting CFTR
S0-EE-WJKI_0.01uM Dose=0.01uM, 3-[3-(3-hydroxyphenyl)prop-2-yn-1-yl]-8-methanesulfonyl-1,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione targeting MLKL
S0-EE-WJKI_0.1uM Dose=0.1uM, 3-[3-(3-hydroxyphenyl)prop-2-yn-1-yl]-8-methanesulfonyl-1,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione targeting MLKL
S0-EE-WJKI_10uM Dose=10uM, 3-[3-(3-hydroxyphenyl)prop-2-yn-1-yl]-8-methanesulfonyl-1,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione targeting MLKL
S0-EE-WJKI_1uM Dose=1uM, 3-[3-(3-hydroxyphenyl)prop-2-yn-1-yl]-8-methanesulfonyl-1,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione targeting MLKL
S0-EE-WNJ9_0.01uM Dose=0.01uM, 2-N-methyl-6-[(1S)-1-phenylethyl]-4-N-(1H-pyrazol-4-yl)pyridine-2,4-dicarboxamide targeting BRD4
S0-EE-WNJ9_0.1uM Dose=0.1uM, 2-N-methyl-6-[(1S)-1-phenylethyl]-4-N-(1H-pyrazol-4-yl)pyridine-2,4-dicarboxamide targeting BRD4
S0-EE-WNJ9_10uM Dose=10uM, 2-N-methyl-6-[(1S)-1-phenylethyl]-4-N-(1H-pyrazol-4-yl)pyridine-2,4-dicarboxamide targeting BRD4
S0-EE-WNJ9_1uM Dose=1uM, 2-N-methyl-6-[(1S)-1-phenylethyl]-4-N-(1H-pyrazol-4-yl)pyridine-2,4-dicarboxamide targeting BRD4
S0-EE-WNJC_0.01uM Dose=0.01uM
S0-EE-WNJC_10uM Dose=10uM
S0-EE-WNJC_1uM Dose=1uM
S0-EE-WW6E_0.1uM Dose=0.1uM, N-(3-((Cyclopentylthio)methyl)-4-methoxyphenyl)benzimidamide targeting QRFPR
S0-EE-WW6E_10uM Dose=10uM, N-(3-((Cyclopentylthio)methyl)-4-methoxyphenyl)benzimidamide targeting QRFPR
S0-EE-WW6E_1uM Dose=1uM, N-(3-((Cyclopentylthio)methyl)-4-methoxyphenyl)benzimidamide targeting QRFPR
S0-EE-WW96_0.01uM Dose=0.01uM, eCF506 targeting FYN, SRC, YES1
S0-EE-WW96_0.1uM Dose=0.1uM, eCF506 targeting FYN, SRC, YES1
S0-EE-WW96_10uM Dose=10uM, eCF506 targeting FYN, SRC, YES1
S0-EE-WW96_1uM Dose=1uM, eCF506 targeting FYN, SRC, YES1
S0-EE-WYIH_0.01uM Dose=0.01uM, CID 56603175 targeting DGAT1
S0-EE-WYIH_0.1uM Dose=0.1uM, CID 56603175 targeting DGAT1
S0-EE-WYIH_10uM Dose=10uM, CID 56603175 targeting DGAT1
S0-EE-WYIH_1uM Dose=1uM, CID 56603175 targeting DGAT1
S0-EE-X3XU_0.01uM Dose=0.01uM, NAcM-OPT targeting UBE2M, DCUN1D1, NEDD8
S0-EE-X3XU_10uM Dose=10uM, NAcM-OPT targeting UBE2M, DCUN1D1, NEDD8
S0-EE-X3XU_1uM Dose=1uM, NAcM-OPT targeting UBE2M, DCUN1D1, NEDD8
S0-EE-X3ZT_0.01uM Dose=0.01uM, 4-ethyl-N-[(2S)-4-methyl-1-oxo-1-pyrrolidin-1-ylpentan-2-yl]benzamide targeting MYD88
S0-EE-X3ZT_10uM Dose=10uM, 4-ethyl-N-[(2S)-4-methyl-1-oxo-1-pyrrolidin-1-ylpentan-2-yl]benzamide targeting MYD88
S0-EE-X3ZZ_0.1uM Dose=0.1uM, Pesampator targeting GRIA1
S0-EE-X3ZZ_10uM Dose=10uM, Pesampator targeting GRIA1
S0-EE-X3ZZ_1uM Dose=1uM, Pesampator targeting GRIA1
S0-EE-X7LX_0.01uM Dose=0.01uM, (R)-2-(6-(4-(1-Hydroxypropan-2-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-isopropoxyisoindolin-1-one, ASK1 targeting MAP3K5
S0-EE-X7LX_0.1uM Dose=0.1uM, (R)-2-(6-(4-(1-Hydroxypropan-2-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-isopropoxyisoindolin-1-one, ASK1 targeting MAP3K5
S0-EE-X7LX_10uM Dose=10uM, (R)-2-(6-(4-(1-Hydroxypropan-2-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-isopropoxyisoindolin-1-one, ASK1 targeting MAP3K5
S0-EE-X7LX_1uM Dose=1uM, (R)-2-(6-(4-(1-Hydroxypropan-2-yl)-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-6-isopropoxyisoindolin-1-one, ASK1 targeting MAP3K5
S0-EE-X9LZ_0.01uM Dose=0.01uM, N-[1-[6-(3-methoxyphenyl)pyrimidin-4-yl]piperidin-4-yl]-N-methyl-7-oxo-6-prop-2-enyl-1H-pyrrolo[2,3-c]pyridine-4-carboxamide, Inhibitor of CERC2 targeting CECR2
S0-EE-X9LZ_10uM Dose=10uM, N-[1-[6-(3-methoxyphenyl)pyrimidin-4-yl]piperidin-4-yl]-N-methyl-7-oxo-6-prop-2-enyl-1H-pyrrolo[2,3-c]pyridine-4-carboxamide, Inhibitor of CERC2 targeting CECR2
S0-EE-X9NZ_0.01uM Dose=0.01uM, Methyl 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoate, Retinol-Binding Protein 4 Inhibitors targeting RBP4
S0-EE-X9NZ_0.1uM Dose=0.1uM, Methyl 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoate, Retinol-Binding Protein 4 Inhibitors targeting RBP4
S0-EE-X9NZ_10uM Dose=10uM, Methyl 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoate, Retinol-Binding Protein 4 Inhibitors targeting RBP4
S0-EE-XFA6_0.01uM Dose=0.01uM, P2Y13 (GPR86; GPR94) Receptor Agonists targeting P2RY13
S0-EE-XFA6_10uM Dose=10uM, P2Y13 (GPR86; GPR94) Receptor Agonists targeting P2RY13
S0-EE-XFA6_1uM Dose=1uM, P2Y13 (GPR86; GPR94) Receptor Agonists targeting P2RY13
S0-EE-XFDA_0.01uM Dose=0.01uM, Unii-4P8laf78C2, ClC-7 Channel Blockers;Bone Resorption Inhibitors targeting CLCN7
S0-EE-XFDA_0.1uM Dose=0.1uM, Unii-4P8laf78C2, ClC-7 Channel Blockers;Bone Resorption Inhibitors targeting CLCN7
S0-EE-XFDA_10uM Dose=10uM, Unii-4P8laf78C2, ClC-7 Channel Blockers;Bone Resorption Inhibitors targeting CLCN7
S0-EE-XFDA_1uM Dose=1uM, Unii-4P8laf78C2, ClC-7 Channel Blockers;Bone Resorption Inhibitors targeting CLCN7
S0-EE-XGEL_0.01uM Dose=0.01uM, L-Moses, KAT2B, KAT2A inhibitor targeting KAT2B
S0-EE-XGEL_0.1uM Dose=0.1uM, L-Moses, KAT2B, KAT2A inhibitor targeting KAT2B
S0-EE-XGEL_10uM Dose=10uM, L-Moses, KAT2B, KAT2A inhibitor targeting KAT2B
S0-EE-XGEL_1uM Dose=1uM, L-Moses, KAT2B, KAT2A inhibitor targeting KAT2B
S0-EE-XGII_0.01uM Dose=0.01uM, 2-[2-[(4-carbamimidoylanilino)-(5-ethoxy-2-fluoro-3-propan-2-yloxyphenyl)methyl]-1H-imidazol-5-yl]benzamide, F7 gene inhibitor targeting F7
S0-EE-XGII_0.1uM Dose=0.1uM, 2-[2-[(4-carbamimidoylanilino)-(5-ethoxy-2-fluoro-3-propan-2-yloxyphenyl)methyl]-1H-imidazol-5-yl]benzamide, F7 gene inhibitor targeting F7
S0-EE-XGII_10uM Dose=10uM, 2-[2-[(4-carbamimidoylanilino)-(5-ethoxy-2-fluoro-3-propan-2-yloxyphenyl)methyl]-1H-imidazol-5-yl]benzamide, F7 gene inhibitor targeting F7
S0-EE-XGII_1uM Dose=1uM, 2-[2-[(4-carbamimidoylanilino)-(5-ethoxy-2-fluoro-3-propan-2-yloxyphenyl)methyl]-1H-imidazol-5-yl]benzamide, F7 gene inhibitor targeting F7
S0-EE-XKW4_0.01uM Dose=0.01uM, NFATc1-IN-1, RANKL inhibitor targeting TNFSF11
S0-EE-XKW4_10uM Dose=10uM, NFATc1-IN-1, RANKL inhibitor targeting TNFSF11
S0-EE-XMWH_0.01uM Dose=0.01uM, 4-[4-(1-Benzofuran-5-Yl)phenyl]-5-{[(3s)-1-(Cyclopropylcarbonyl)pyrrolidin-3-Yl]methyl}-2,4-Dihydro-3h-1,2,4-Triazol-3-One, FAS inhibitor targeting FASN
S0-EE-XMWH_0.1uM Dose=0.1uM, 4-[4-(1-Benzofuran-5-Yl)phenyl]-5-{[(3s)-1-(Cyclopropylcarbonyl)pyrrolidin-3-Yl]methyl}-2,4-Dihydro-3h-1,2,4-Triazol-3-One, FAS inhibitor targeting FASN
S0-EE-XMWH_10uM Dose=10uM, 4-[4-(1-Benzofuran-5-Yl)phenyl]-5-{[(3s)-1-(Cyclopropylcarbonyl)pyrrolidin-3-Yl]methyl}-2,4-Dihydro-3h-1,2,4-Triazol-3-One, FAS inhibitor targeting FASN
S0-EE-XMWH_1uM Dose=1uM, 4-[4-(1-Benzofuran-5-Yl)phenyl]-5-{[(3s)-1-(Cyclopropylcarbonyl)pyrrolidin-3-Yl]methyl}-2,4-Dihydro-3h-1,2,4-Triazol-3-One, FAS inhibitor targeting FASN
S0-EE-XMXE_0.01uM Dose=0.01uM, (4R)-4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide targeting DDR1, DDR2
S0-EE-XMXE_0.1uM Dose=0.1uM, (4R)-4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide targeting DDR1, DDR2
S0-EE-XMXE_10uM Dose=10uM, (4R)-4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide targeting DDR1, DDR2
S0-EE-XMXE_1uM Dose=1uM, (4R)-4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide targeting DDR1, DDR2
S0-EE-XNAL_0.01uM Dose=0.01uM, Venuloside A, SLC43A1 gene inhibitor targeting SLC43A1
S0-EE-XNAL_0.1uM Dose=0.1uM, Venuloside A, SLC43A1 gene inhibitor targeting SLC43A1
S0-EE-XNAL_10uM Dose=10uM, Venuloside A, SLC43A1 gene inhibitor targeting SLC43A1
S0-EE-XNAL_1uM Dose=1uM, Venuloside A, SLC43A1 gene inhibitor targeting SLC43A1
S0-EE-XPGU_0.01uM Dose=0.01uM, 2-Hydroxy-6-(2-naphthalen-2-yl-ethyl)-benzoic acid targeting SOX18
S0-EE-XPGU_0.1uM Dose=0.1uM, 2-Hydroxy-6-(2-naphthalen-2-yl-ethyl)-benzoic acid targeting SOX18
S0-EE-XPGU_10uM Dose=10uM, 2-Hydroxy-6-(2-naphthalen-2-yl-ethyl)-benzoic acid targeting SOX18
S0-EE-XPGU_1uM Dose=1uM, 2-Hydroxy-6-(2-naphthalen-2-yl-ethyl)-benzoic acid targeting SOX18
S0-EE-XXLY_0.01uM Dose=0.01uM, 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(3S)-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)pyrrolidin-3-yl]urea, CDK8 inhibitor targeting CDK8
S0-EE-XXLY_0.1uM Dose=0.1uM, 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(3S)-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)pyrrolidin-3-yl]urea, CDK8 inhibitor targeting CDK8
S0-EE-XXLY_10uM Dose=10uM, 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(3S)-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)pyrrolidin-3-yl]urea, CDK8 inhibitor targeting CDK8
S0-EE-XXLY_1uM Dose=1uM, 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[(3S)-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)pyrrolidin-3-yl]urea, CDK8 inhibitor targeting CDK8
S0-EE-XYMJ_0.01uM Dose=0.01uM, Gsk1331268, mgluR2 Positive Allosteric Modulator;postive allosteric modulator targeting GRM2
S0-EE-XYMJ_0.1uM Dose=0.1uM, Gsk1331268, mgluR2 Positive Allosteric Modulator;postive allosteric modulator targeting GRM2
S0-EE-XYMJ_10uM Dose=10uM, Gsk1331268, mgluR2 Positive Allosteric Modulator;postive allosteric modulator targeting GRM2
S0-EE-XYMJ_1uM Dose=1uM, Gsk1331268, mgluR2 Positive Allosteric Modulator;postive allosteric modulator targeting GRM2
S0-EE-XZUM_0.01uM Dose=0.01uM, targeting KDM5B, KDM4B, KDM5A
S0-EE-XZUM_0.1uM Dose=0.1uM, targeting KDM5B, KDM4B, KDM5A
S0-EE-XZUM_10uM Dose=10uM, targeting KDM5B, KDM4B, KDM5A
S0-EE-XZUM_1uM Dose=1uM, targeting KDM5B, KDM4B, KDM5A
S0-EE-Y00Z_0.01uM Dose=0.01uM, T-98475, GnRH (LHRH) Antagonists targeting GNRHR
S0-EE-Y00Z_10uM Dose=10uM, T-98475, GnRH (LHRH) Antagonists targeting GNRHR
S0-EE-Y4UM_0.01uM Dose=0.01uM, (1R)-1-(3,4-dichlorophenyl)-2-[2-imino-3-[(2-methylphenyl)methyl]benzimidazol-1-yl]ethanol, small-molecule antogonist of CBX7ChD binding to H3K27me3 when the protein is bound to RNA targeting CBX7
S0-EE-Y4UM_0.1uM Dose=0.1uM, (1R)-1-(3,4-dichlorophenyl)-2-[2-imino-3-[(2-methylphenyl)methyl]benzimidazol-1-yl]ethanol, small-molecule antogonist of CBX7ChD binding to H3K27me3 when the protein is bound to RNA targeting CBX7
S0-EE-Y4UM_10uM Dose=10uM, (1R)-1-(3,4-dichlorophenyl)-2-[2-imino-3-[(2-methylphenyl)methyl]benzimidazol-1-yl]ethanol, small-molecule antogonist of CBX7ChD binding to H3K27me3 when the protein is bound to RNA targeting CBX7
S0-EE-Y4UM_1uM Dose=1uM, (1R)-1-(3,4-dichlorophenyl)-2-[2-imino-3-[(2-methylphenyl)methyl]benzimidazol-1-yl]ethanol, small-molecule antogonist of CBX7ChD binding to H3K27me3 when the protein is bound to RNA targeting CBX7
S0-EE-Y6LH_0.01uM Dose=0.01uM, PF 6767832, M1 postive allosteric modulator targeting CHRM1
S0-EE-Y6LH_0.1uM Dose=0.1uM, PF 6767832, M1 postive allosteric modulator targeting CHRM1
S0-EE-Y6LH_10uM Dose=10uM, PF 6767832, M1 postive allosteric modulator targeting CHRM1
S0-EE-Y6LH_1uM Dose=1uM, PF 6767832, M1 postive allosteric modulator targeting CHRM1
S0-EE-Y6WJ_0.01uM Dose=0.01uM, 4-(2-Amino-1,3-benzothiazol-6-yl)-1-(cyclopropylmethyl)pyridin-2-one, PI4KA gene inhibitor targeting PI4KA
S0-EE-Y6WJ_0.1uM Dose=0.1uM, 4-(2-Amino-1,3-benzothiazol-6-yl)-1-(cyclopropylmethyl)pyridin-2-one, PI4KA gene inhibitor targeting PI4KA
S0-EE-Y6WJ_10uM Dose=10uM, 4-(2-Amino-1,3-benzothiazol-6-yl)-1-(cyclopropylmethyl)pyridin-2-one, PI4KA gene inhibitor targeting PI4KA
S0-EE-Y6WJ_1uM Dose=1uM, 4-(2-Amino-1,3-benzothiazol-6-yl)-1-(cyclopropylmethyl)pyridin-2-one, PI4KA gene inhibitor targeting PI4KA
S0-EE-Y6Y9_0.01uM Dose=0.01uM, 6-chloro-N-(1-ethylpiperidin-4-yl)-1,2,3,4-tetrahydroacridin-9-amine
S0-EE-Y6Y9_0.1uM Dose=0.1uM, 6-chloro-N-(1-ethylpiperidin-4-yl)-1,2,3,4-tetrahydroacridin-9-amine
S0-EE-Y6Y9_10uM Dose=10uM, 6-chloro-N-(1-ethylpiperidin-4-yl)-1,2,3,4-tetrahydroacridin-9-amine
S0-EE-Y6Y9_1uM Dose=1uM, 6-chloro-N-(1-ethylpiperidin-4-yl)-1,2,3,4-tetrahydroacridin-9-amine
S0-EE-Y6YC_0.01uM Dose=0.01uM, N-[5-({[(3-Fluorophenyl)carbamoyl]amino}methyl)-2-Methylphenyl]imidazo[1,2-A]pyridine-3-Carboxamide, DDR2 inhibitor targeting DDR2
S0-EE-Y6YC_0.1uM Dose=0.1uM, N-[5-({[(3-Fluorophenyl)carbamoyl]amino}methyl)-2-Methylphenyl]imidazo[1,2-A]pyridine-3-Carboxamide, DDR2 inhibitor targeting DDR2
S0-EE-Y6YC_10uM Dose=10uM, N-[5-({[(3-Fluorophenyl)carbamoyl]amino}methyl)-2-Methylphenyl]imidazo[1,2-A]pyridine-3-Carboxamide, DDR2 inhibitor targeting DDR2
S0-EE-Y6YC_1uM Dose=1uM, N-[5-({[(3-Fluorophenyl)carbamoyl]amino}methyl)-2-Methylphenyl]imidazo[1,2-A]pyridine-3-Carboxamide, DDR2 inhibitor targeting DDR2
S0-EE-Y737_0.01uM Dose=0.01uM, Benzamide, N-[[(4S)-1,4-dihydro-2-oxo-6-(1H-pyrazol-3-yl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-4-yl]methyl]-4-fluoro-, Long Chain Fatty Acid Elongase 6 Inhibitor targeting ELOVL6
S0-EE-Y737_0.1uM Dose=0.1uM, Benzamide, N-[[(4S)-1,4-dihydro-2-oxo-6-(1H-pyrazol-3-yl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-4-yl]methyl]-4-fluoro-, Long Chain Fatty Acid Elongase 6 Inhibitor targeting ELOVL6
S0-EE-Y737_10uM Dose=10uM, Benzamide, N-[[(4S)-1,4-dihydro-2-oxo-6-(1H-pyrazol-3-yl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-4-yl]methyl]-4-fluoro-, Long Chain Fatty Acid Elongase 6 Inhibitor targeting ELOVL6
S0-EE-Y737_1uM Dose=1uM, Benzamide, N-[[(4S)-1,4-dihydro-2-oxo-6-(1H-pyrazol-3-yl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-4-yl]methyl]-4-fluoro-, Long Chain Fatty Acid Elongase 6 Inhibitor targeting ELOVL6
S0-EE-Y79N_0.01uM Dose=0.01uM, (2e)-3-[(6s,9r)-4-(Cyclopropylamino)-6,7,8,9-Tetrahydro-5h-6,9-Epiminocyclohepta[d]pyrimidin-10-Yl]-1-(2-Hydroxyphenyl)prop-2-En-1-One, N-Ac Lysine competitive SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4
S0-EE-Y79N_0.1uM Dose=0.1uM, (2e)-3-[(6s,9r)-4-(Cyclopropylamino)-6,7,8,9-Tetrahydro-5h-6,9-Epiminocyclohepta[d]pyrimidin-10-Yl]-1-(2-Hydroxyphenyl)prop-2-En-1-One, N-Ac Lysine competitive SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4
S0-EE-Y79N_10uM Dose=10uM, (2e)-3-[(6s,9r)-4-(Cyclopropylamino)-6,7,8,9-Tetrahydro-5h-6,9-Epiminocyclohepta[d]pyrimidin-10-Yl]-1-(2-Hydroxyphenyl)prop-2-En-1-One, N-Ac Lysine competitive SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4
S0-EE-Y79N_1uM Dose=1uM, (2e)-3-[(6s,9r)-4-(Cyclopropylamino)-6,7,8,9-Tetrahydro-5h-6,9-Epiminocyclohepta[d]pyrimidin-10-Yl]-1-(2-Hydroxyphenyl)prop-2-En-1-One, N-Ac Lysine competitive SMARCA2/4 inhibitor targeting SMARCA2, SMARCA4
S0-EE-Y7IR_0.01uM Dose=0.01uM, 4-(((6S,9AS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, Wnt signaling inhibitor, Inhibitor of beta-catenin/TCF transcription targeting CTNNB1
S0-EE-Y7IR_0.1uM Dose=0.1uM, 4-(((6S,9AS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, Wnt signaling inhibitor, Inhibitor of beta-catenin/TCF transcription targeting CTNNB1
S0-EE-Y7IR_10uM Dose=10uM, 4-(((6S,9AS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, Wnt signaling inhibitor, Inhibitor of beta-catenin/TCF transcription targeting CTNNB1
S0-EE-Y7IR_1uM Dose=1uM, 4-(((6S,9AS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, Wnt signaling inhibitor, Inhibitor of beta-catenin/TCF transcription targeting CTNNB1
S0-EE-Y7SS_0.01uM Dose=0.01uM
S0-EE-Y7SS_0.1uM Dose=0.1uM
S0-EE-Y7SS_10uM Dose=10uM
S0-EE-Y7SS_1uM Dose=1uM
S0-EE-Y96T_0.01uM Dose=0.01uM, (s)-N-(1-propyl-1h-benzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide, Selective allosteric inhibitor for HSPA1A/Hsp70i targeting HSPA1A
S0-EE-Y96T_0.1uM Dose=0.1uM, (s)-N-(1-propyl-1h-benzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide, Selective allosteric inhibitor for HSPA1A/Hsp70i targeting HSPA1A
S0-EE-Y96T_10uM Dose=10uM, (s)-N-(1-propyl-1h-benzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide, Selective allosteric inhibitor for HSPA1A/Hsp70i targeting HSPA1A
S0-EE-Y96T_1uM Dose=1uM, (s)-N-(1-propyl-1h-benzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide, Selective allosteric inhibitor for HSPA1A/Hsp70i targeting HSPA1A
S0-EE-Y96U_0.01uM Dose=0.01uM, Jnj-42165279, FAAH inhibitor targeting FAAH
S0-EE-Y96U_0.1uM Dose=0.1uM, Jnj-42165279, FAAH inhibitor targeting FAAH
S0-EE-Y96U_10uM Dose=10uM, Jnj-42165279, FAAH inhibitor targeting FAAH
S0-EE-Y96U_1uM Dose=1uM, Jnj-42165279, FAAH inhibitor targeting FAAH
S0-EE-Y97N_0.01uM Dose=0.01uM, 4-(4-(3-(1H-Pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)morpholine, ALK2 inhibitor targeting TGFBR2
S0-EE-Y97N_0.1uM Dose=0.1uM, 4-(4-(3-(1H-Pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)morpholine, ALK2 inhibitor targeting TGFBR2
S0-EE-Y97N_10uM Dose=10uM, 4-(4-(3-(1H-Pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)morpholine, ALK2 inhibitor targeting TGFBR2
S0-EE-Y97N_1uM Dose=1uM, 4-(4-(3-(1H-Pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)morpholine, ALK2 inhibitor targeting TGFBR2
S0-EE-Y9JI_0.01uM Dose=0.01uM, Spt-IN-1, Serine Palmitoyl Transferase inhibitor targeting SPTLC1
S0-EE-Y9JI_0.1uM Dose=0.1uM, Spt-IN-1, Serine Palmitoyl Transferase inhibitor targeting SPTLC1
S0-EE-Y9JI_10uM Dose=10uM, Spt-IN-1, Serine Palmitoyl Transferase inhibitor targeting SPTLC1
S0-EE-Y9JI_1uM Dose=1uM, Spt-IN-1, Serine Palmitoyl Transferase inhibitor targeting SPTLC1
S0-EE-Y9S3_0.01uM Dose=0.01uM, PF-06471553, MOGAT 3 inhibitor targeting MOGAT3
S0-EE-Y9S3_0.1uM Dose=0.1uM, PF-06471553, MOGAT 3 inhibitor targeting MOGAT3
S0-EE-Y9S3_10uM Dose=10uM, PF-06471553, MOGAT 3 inhibitor targeting MOGAT3
S0-EE-Y9S3_1uM Dose=1uM, PF-06471553, MOGAT 3 inhibitor targeting MOGAT3
S0-EE-Y9YA_0.01uM Dose=0.01uM, 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-5-methoxy-N-pyridin-4-ylpyrimidin-4-amine, BUB1 mitotic checkpoint serine/threonine kinase inhibitor targeting BUB1
S0-EE-Y9YA_0.1uM Dose=0.1uM, 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-5-methoxy-N-pyridin-4-ylpyrimidin-4-amine, BUB1 mitotic checkpoint serine/threonine kinase inhibitor targeting BUB1
S0-EE-Y9YA_10uM Dose=10uM, 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-5-methoxy-N-pyridin-4-ylpyrimidin-4-amine, BUB1 mitotic checkpoint serine/threonine kinase inhibitor targeting BUB1
S0-EE-Y9YA_1uM Dose=1uM, 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl]-5-methoxy-N-pyridin-4-ylpyrimidin-4-amine, BUB1 mitotic checkpoint serine/threonine kinase inhibitor targeting BUB1
S0-EE-YAXR_0.01uM Dose=0.01uM, 6-Nonylpyridine-2,4-diol, GPR84 agonist;Potent GPR84 Agonists targeting GPR84
S0-EE-YAXR_0.1uM Dose=0.1uM, 6-Nonylpyridine-2,4-diol, GPR84 agonist;Potent GPR84 Agonists targeting GPR84
S0-EE-YAXR_10uM Dose=10uM, 6-Nonylpyridine-2,4-diol, GPR84 agonist;Potent GPR84 Agonists targeting GPR84
S0-EE-YAXR_1uM Dose=1uM, 6-Nonylpyridine-2,4-diol, GPR84 agonist;Potent GPR84 Agonists targeting GPR84
S0-EE-YC7H_0.01uM Dose=0.01uM, 4-[[1-(4-chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino]-N-hydroxybenzamide targeting HDAC6
S0-EE-YC7H_0.1uM Dose=0.1uM, 4-[[1-(4-chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino]-N-hydroxybenzamide targeting HDAC6
S0-EE-YC7H_10uM Dose=10uM, 4-[[1-(4-chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino]-N-hydroxybenzamide targeting HDAC6
S0-EE-YC7H_1uM Dose=1uM, 4-[[1-(4-chlorophenyl)-3-methyl-2-oxopyrrolidin-3-yl]amino]-N-hydroxybenzamide targeting HDAC6
S0-EE-YEKU_0.01uM Dose=0.01uM, (E)-6-Chloro-3-(3-(5-fluoropyridin-3-yl)acryloyl)-4-phenylquinolin-2(1H)-one, EIF4G gene inhibitor targeting EIF4G1
S0-EE-YEKU_0.1uM Dose=0.1uM, (E)-6-Chloro-3-(3-(5-fluoropyridin-3-yl)acryloyl)-4-phenylquinolin-2(1H)-one, EIF4G gene inhibitor targeting EIF4G1
S0-EE-YEKU_10uM Dose=10uM, (E)-6-Chloro-3-(3-(5-fluoropyridin-3-yl)acryloyl)-4-phenylquinolin-2(1H)-one, EIF4G gene inhibitor targeting EIF4G1
S0-EE-YEKU_1uM Dose=1uM, (E)-6-Chloro-3-(3-(5-fluoropyridin-3-yl)acryloyl)-4-phenylquinolin-2(1H)-one, EIF4G gene inhibitor targeting EIF4G1
S0-EE-YEL3_0.01uM Dose=0.01uM, N-(4-{5-[3-(Acetylamino)phenyl]-2-(2-Aminopyridin-3-Yl)-3h-Imidazo[4,5-B]pyridin-3-Yl}benzyl)-3-Fluorobenzamide, allosteric AKT inhbitor targeting AKT1
S0-EE-YEL3_0.1uM Dose=0.1uM, N-(4-{5-[3-(Acetylamino)phenyl]-2-(2-Aminopyridin-3-Yl)-3h-Imidazo[4,5-B]pyridin-3-Yl}benzyl)-3-Fluorobenzamide, allosteric AKT inhbitor targeting AKT1
S0-EE-YEL3_10uM Dose=10uM, N-(4-{5-[3-(Acetylamino)phenyl]-2-(2-Aminopyridin-3-Yl)-3h-Imidazo[4,5-B]pyridin-3-Yl}benzyl)-3-Fluorobenzamide, allosteric AKT inhbitor targeting AKT1
S0-EE-YEL3_1uM Dose=1uM, N-(4-{5-[3-(Acetylamino)phenyl]-2-(2-Aminopyridin-3-Yl)-3h-Imidazo[4,5-B]pyridin-3-Yl}benzyl)-3-Fluorobenzamide, allosteric AKT inhbitor targeting AKT1
S0-EE-YFM9_0.01uM Dose=0.01uM, 3-((9H-Purin-6-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide, troponin 1 interacting kinase inhibitor targeting TNNI3K
S0-EE-YFM9_0.1uM Dose=0.1uM, 3-((9H-Purin-6-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide, troponin 1 interacting kinase inhibitor targeting TNNI3K
S0-EE-YFM9_10uM Dose=10uM, 3-((9H-Purin-6-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide, troponin 1 interacting kinase inhibitor targeting TNNI3K
S0-EE-YFM9_1uM Dose=1uM, 3-((9H-Purin-6-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide, troponin 1 interacting kinase inhibitor targeting TNNI3K
S0-EE-YFUH_10uM Dose=10uM, 4-[2-Amino-4-Methyl-3-(2-Methylquinolin-6-Yl)benzoyl]-1-Methyl-2,5-Diphenyl-1,2-Dihydro-3h-Pyrazol-3-One, PERK kinase inhibitor targeting EIF2AK3
S0-EE-YFUH_1uM Dose=1uM, 4-[2-Amino-4-Methyl-3-(2-Methylquinolin-6-Yl)benzoyl]-1-Methyl-2,5-Diphenyl-1,2-Dihydro-3h-Pyrazol-3-One, PERK kinase inhibitor targeting EIF2AK3
S0-EE-YGIT_0.01uM Dose=0.01uM, 1-(4-Chlorophenoxy)-3-[[1-[(2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]methyl-methylamino]propan-2-ol, TLR-4 antagonist targeting TLR4
S0-EE-YGIT_0.1uM Dose=0.1uM, 1-(4-Chlorophenoxy)-3-[[1-[(2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]methyl-methylamino]propan-2-ol, TLR-4 antagonist targeting TLR4
S0-EE-YGIT_10uM Dose=10uM, 1-(4-Chlorophenoxy)-3-[[1-[(2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]methyl-methylamino]propan-2-ol, TLR-4 antagonist targeting TLR4
S0-EE-YGIT_1uM Dose=1uM, 1-(4-Chlorophenoxy)-3-[[1-[(2-chlorophenyl)methyl]-3,5-dimethylpyrazol-4-yl]methyl-methylamino]propan-2-ol, TLR-4 antagonist targeting TLR4
S0-EE-YLU9_0.01uM Dose=0.01uM, PAK1 inhibitor targeting PAK1
S0-EE-YLU9_10uM Dose=10uM, PAK1 inhibitor targeting PAK1
S0-EE-YLU9_1uM Dose=1uM, PAK1 inhibitor targeting PAK1
S0-EE-YMWJ_0.01uM Dose=0.01uM, TX1-85-1, ERBB3 covalent inhibitor targeting ERBB3
S0-EE-YMWJ_0.1uM Dose=0.1uM, TX1-85-1, ERBB3 covalent inhibitor targeting ERBB3
S0-EE-YMWJ_10uM Dose=10uM, TX1-85-1, ERBB3 covalent inhibitor targeting ERBB3
S0-EE-YMWJ_1uM Dose=1uM, TX1-85-1, ERBB3 covalent inhibitor targeting ERBB3
S0-EE-YNU4_0.01uM Dose=0.01uM, (E)-4-(4-methyl-1H-indol-5-ylamino)-5-(2-(6-(morpholinomethyl)pyridin-2-yl)vinyl)nicotinonitrile, PKC theta inhibitor targeting PRKCQ
S0-EE-YNU4_0.1uM Dose=0.1uM, (E)-4-(4-methyl-1H-indol-5-ylamino)-5-(2-(6-(morpholinomethyl)pyridin-2-yl)vinyl)nicotinonitrile, PKC theta inhibitor targeting PRKCQ
S0-EE-YNU4_10uM Dose=10uM, (E)-4-(4-methyl-1H-indol-5-ylamino)-5-(2-(6-(morpholinomethyl)pyridin-2-yl)vinyl)nicotinonitrile, PKC theta inhibitor targeting PRKCQ
S0-EE-YNU4_1uM Dose=1uM, (E)-4-(4-methyl-1H-indol-5-ylamino)-5-(2-(6-(morpholinomethyl)pyridin-2-yl)vinyl)nicotinonitrile, PKC theta inhibitor targeting PRKCQ
S0-EE-YRH3_0.01uM Dose=0.01uM, [3-[[4-(aminomethyl)-1-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate, LIMK2 gene inhibitor;LIMK1 gene inhibitor targeting LIMK1, LIMK2
S0-EE-YRH3_0.1uM Dose=0.1uM, [3-[[4-(aminomethyl)-1-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate, LIMK2 gene inhibitor;LIMK1 gene inhibitor targeting LIMK1, LIMK2
S0-EE-YRH3_10uM Dose=10uM, [3-[[4-(aminomethyl)-1-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate, LIMK2 gene inhibitor;LIMK1 gene inhibitor targeting LIMK1, LIMK2
S0-EE-YRH3_1uM Dose=1uM, [3-[[4-(aminomethyl)-1-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate, LIMK2 gene inhibitor;LIMK1 gene inhibitor targeting LIMK1, LIMK2
SA-01-QC36_0.01uM Dose=0.01uM, methyl 2-[1-[(3R)-1-benzoylpiperidin-3-yl]triazol-4-yl]pyridine-4-carboxylate, KDM2A inhibitor targeting KDM2A
SA-01-QC36_0.1uM Dose=0.1uM, methyl 2-[1-[(3R)-1-benzoylpiperidin-3-yl]triazol-4-yl]pyridine-4-carboxylate, KDM2A inhibitor targeting KDM2A
SA-01-QC36_10uM Dose=10uM, methyl 2-[1-[(3R)-1-benzoylpiperidin-3-yl]triazol-4-yl]pyridine-4-carboxylate, KDM2A inhibitor targeting KDM2A
SA-01-QC36_1uM Dose=1uM, methyl 2-[1-[(3R)-1-benzoylpiperidin-3-yl]triazol-4-yl]pyridine-4-carboxylate, KDM2A inhibitor targeting KDM2A
SA-03-IQ14_0.01uM Dose=0.01uM
SA-03-IQ14_0.1uM Dose=0.1uM
SA-03-IQ14_10uM Dose=10uM
SA-03-IQ14_1uM Dose=1uM
SA-28-ZT78_0.01uM Dose=0.01uM, Gavestinel, NMDA Glycine-Site Antagonists targeting GRIN1
SA-28-ZT78_0.1uM Dose=0.1uM, Gavestinel, NMDA Glycine-Site Antagonists targeting GRIN1
SA-28-ZT78_10uM Dose=10uM, Gavestinel, NMDA Glycine-Site Antagonists targeting GRIN1
SA-28-ZT78_1uM Dose=1uM, Gavestinel, NMDA Glycine-Site Antagonists targeting GRIN1
SA-31-AZ46_0.01uM Dose=0.01uM, PKM2 activator 3, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM
SA-31-AZ46_0.1uM Dose=0.1uM, PKM2 activator 3, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM
SA-31-AZ46_10uM Dose=10uM, PKM2 activator 3, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM
SA-31-VB03_0.01uM Dose=0.01uM, Ascochlorin, Electron Transport Chain Inhibitors;AP-1 Inhibitors targeting JUN, UQCRC1
SA-31-VB03_0.1uM Dose=0.1uM, Ascochlorin, Electron Transport Chain Inhibitors;AP-1 Inhibitors targeting JUN, UQCRC1
SA-31-VB03_10uM Dose=10uM, Ascochlorin, Electron Transport Chain Inhibitors;AP-1 Inhibitors targeting JUN, UQCRC1
SA-31-VB03_1uM Dose=1uM, Ascochlorin, Electron Transport Chain Inhibitors;AP-1 Inhibitors targeting JUN, UQCRC1
SA-32-CC58_0.01uM Dose=0.01uM, Piperidin-4-yl-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-amine, CDK inhibitors targeting CCNB2, CCNB3
SA-32-CC58_0.1uM Dose=0.1uM, Piperidin-4-yl-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-amine, CDK inhibitors targeting CCNB2, CCNB3
SA-32-CC58_10uM Dose=10uM, Piperidin-4-yl-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-amine, CDK inhibitors targeting CCNB2, CCNB3
SA-32-CC58_1uM Dose=1uM, Piperidin-4-yl-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-amine, CDK inhibitors targeting CCNB2, CCNB3
SA-37-YW78_0.01uM Dose=0.01uM, 1,4-Bis(4-(pyrrolidinyl)piperidinyl)benzamide, Selective antagonist of L3MBTL3 targeting L3MBTL1, L3MBTL3, L3MBTL4
SA-37-YW78_0.1uM Dose=0.1uM, 1,4-Bis(4-(pyrrolidinyl)piperidinyl)benzamide, Selective antagonist of L3MBTL3 targeting L3MBTL1, L3MBTL3, L3MBTL4
SA-37-YW78_10uM Dose=10uM, 1,4-Bis(4-(pyrrolidinyl)piperidinyl)benzamide, Selective antagonist of L3MBTL3 targeting L3MBTL1, L3MBTL3, L3MBTL4
SA-37-YW78_1uM Dose=1uM, 1,4-Bis(4-(pyrrolidinyl)piperidinyl)benzamide, Selective antagonist of L3MBTL3 targeting L3MBTL1, L3MBTL3, L3MBTL4
SA-40-VR29_0.01uM Dose=0.01uM, Phosphonic acid, (1-amino-3-phenylpropyl)- targeting LAP3
SA-40-VR29_0.1uM Dose=0.1uM, Phosphonic acid, (1-amino-3-phenylpropyl)- targeting LAP3
SA-40-VR29_10uM Dose=10uM, Phosphonic acid, (1-amino-3-phenylpropyl)- targeting LAP3
SA-40-VR29_1uM Dose=1uM, Phosphonic acid, (1-amino-3-phenylpropyl)- targeting LAP3
SA-43-QT61_0.01uM Dose=0.01uM, 2-Benzyl-5-(2,5-dichloro-phenyl)-2H-[1,2,4]triazole-3-thiol, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
SA-43-QT61_0.1uM Dose=0.1uM, 2-Benzyl-5-(2,5-dichloro-phenyl)-2H-[1,2,4]triazole-3-thiol, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
SA-43-QT61_10uM Dose=10uM, 2-Benzyl-5-(2,5-dichloro-phenyl)-2H-[1,2,4]triazole-3-thiol, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
SA-43-QT61_1uM Dose=1uM, 2-Benzyl-5-(2,5-dichloro-phenyl)-2H-[1,2,4]triazole-3-thiol, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
SA-49-SD47_0.01uM Dose=0.01uM, (3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, ADORA2A agonist;ADORA2B agonist targeting ADORA2A, ADORA2B
SA-49-SD47_0.1uM Dose=0.1uM, (3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, ADORA2A agonist;ADORA2B agonist targeting ADORA2A, ADORA2B
SA-49-SD47_10uM Dose=10uM, (3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, ADORA2A agonist;ADORA2B agonist targeting ADORA2A, ADORA2B
SA-49-SD47_1uM Dose=1uM, (3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, ADORA2A agonist;ADORA2B agonist targeting ADORA2A, ADORA2B
SA-53-XG95_0.01uM Dose=0.01uM, N-(1S-[2-{4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]-1-piperazinyl}-5-chlorophenyl]-3-methylbutyl)-3-(dimethylamino)propionamide, Melanocortin MC4 Receptor Antagonists targeting MC4R
SA-53-XG95_0.1uM Dose=0.1uM, N-(1S-[2-{4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]-1-piperazinyl}-5-chlorophenyl]-3-methylbutyl)-3-(dimethylamino)propionamide, Melanocortin MC4 Receptor Antagonists targeting MC4R
SA-53-XG95_10uM Dose=10uM, N-(1S-[2-{4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]-1-piperazinyl}-5-chlorophenyl]-3-methylbutyl)-3-(dimethylamino)propionamide, Melanocortin MC4 Receptor Antagonists targeting MC4R
SA-63-NG30_0.01uM Dose=0.01uM, N-[4-(3-Chlorophenyl)-5-(2-chlorobenzoyl)thiazole-2-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide, Retinoid receptor modulator targeting RORB, RORC
SA-63-NG30_0.1uM Dose=0.1uM, N-[4-(3-Chlorophenyl)-5-(2-chlorobenzoyl)thiazole-2-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide, Retinoid receptor modulator targeting RORB, RORC
SA-63-NG30_10uM Dose=10uM, N-[4-(3-Chlorophenyl)-5-(2-chlorobenzoyl)thiazole-2-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide, Retinoid receptor modulator targeting RORB, RORC
SA-63-NG30_1uM Dose=1uM, N-[4-(3-Chlorophenyl)-5-(2-chlorobenzoyl)thiazole-2-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide, Retinoid receptor modulator targeting RORB, RORC
SA-87-MW08_0.01uM Dose=0.01uM, N-((2S,4S,5S,7S)-7-(2-(1-acetylpiperidin-4-yl)ethylcarbamoyl)-4-amino-5-hydroxy-2-isopropyl-8-methylnonyl)-2-(4-methoxybutoxy)benzamide, Renin Inhibitor targeting REN
SA-87-MW08_0.1uM Dose=0.1uM, N-((2S,4S,5S,7S)-7-(2-(1-acetylpiperidin-4-yl)ethylcarbamoyl)-4-amino-5-hydroxy-2-isopropyl-8-methylnonyl)-2-(4-methoxybutoxy)benzamide, Renin Inhibitor targeting REN
SA-87-MW08_10uM Dose=10uM, N-((2S,4S,5S,7S)-7-(2-(1-acetylpiperidin-4-yl)ethylcarbamoyl)-4-amino-5-hydroxy-2-isopropyl-8-methylnonyl)-2-(4-methoxybutoxy)benzamide, Renin Inhibitor targeting REN
SA-87-MW08_1uM Dose=1uM, N-((2S,4S,5S,7S)-7-(2-(1-acetylpiperidin-4-yl)ethylcarbamoyl)-4-amino-5-hydroxy-2-isopropyl-8-methylnonyl)-2-(4-methoxybutoxy)benzamide, Renin Inhibitor targeting REN
SB-09-JU93_0.01uM Dose=0.01uM, D-Phenylalaninamide, N-acetyl-D-tyrosyl-D-arginyl-, GADD45Beta/ MKK7 complex disruptor targeting MAP2K7
SB-09-JU93_0.1uM Dose=0.1uM, D-Phenylalaninamide, N-acetyl-D-tyrosyl-D-arginyl-, GADD45Beta/ MKK7 complex disruptor targeting MAP2K7
SB-09-JU93_10uM Dose=10uM, D-Phenylalaninamide, N-acetyl-D-tyrosyl-D-arginyl-, GADD45Beta/ MKK7 complex disruptor targeting MAP2K7
SB-16-SI72_0.01uM Dose=0.01uM, 8-pCPT-2'-O-Me-cAMP, PDE2A Inhibitor;RAPGEF3 activator;Activator of Epac targeting RAPGEF3, PDE2A
SB-16-SI72_0.1uM Dose=0.1uM, 8-pCPT-2'-O-Me-cAMP, PDE2A Inhibitor;RAPGEF3 activator;Activator of Epac targeting RAPGEF3, PDE2A
SB-16-SI72_10uM Dose=10uM, 8-pCPT-2'-O-Me-cAMP, PDE2A Inhibitor;RAPGEF3 activator;Activator of Epac targeting RAPGEF3, PDE2A
SB-26-NB80_0.01uM Dose=0.01uM, 1-(4-Chlorophenyl)-5-phenyl-4,5-dihydro-1h-pyrazol-3-amine, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO
SB-26-NB80_0.1uM Dose=0.1uM, 1-(4-Chlorophenyl)-5-phenyl-4,5-dihydro-1h-pyrazol-3-amine, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO
SB-26-NB80_10uM Dose=10uM, 1-(4-Chlorophenyl)-5-phenyl-4,5-dihydro-1h-pyrazol-3-amine, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO
SB-26-NB80_1uM Dose=1uM, 1-(4-Chlorophenyl)-5-phenyl-4,5-dihydro-1h-pyrazol-3-amine, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO
SB-28-EJ14_0.01uM Dose=0.01uM, 4-(1,2,3,4-Tetrahydroquinolin-1-yl)-6-(4amino-phenyl)-7H-pyrrolo[2.3-d]-pyrimidine, EGFR (HER1;Abl Kinase Inhibitors;Protein Kinase C (PKC) Inhibitors;erbB1) Inhibitors targeting ABL1, EGFR, SRC, ABL2, ERBB2
SB-28-EJ14_0.1uM Dose=0.1uM, 4-(1,2,3,4-Tetrahydroquinolin-1-yl)-6-(4amino-phenyl)-7H-pyrrolo[2.3-d]-pyrimidine, EGFR (HER1;Abl Kinase Inhibitors;Protein Kinase C (PKC) Inhibitors;erbB1) Inhibitors targeting ABL1, EGFR, SRC, ABL2, ERBB2
SB-28-EJ14_10uM Dose=10uM, 4-(1,2,3,4-Tetrahydroquinolin-1-yl)-6-(4amino-phenyl)-7H-pyrrolo[2.3-d]-pyrimidine, EGFR (HER1;Abl Kinase Inhibitors;Protein Kinase C (PKC) Inhibitors;erbB1) Inhibitors targeting ABL1, EGFR, SRC, ABL2, ERBB2
SB-28-EJ14_1uM Dose=1uM, 4-(1,2,3,4-Tetrahydroquinolin-1-yl)-6-(4amino-phenyl)-7H-pyrrolo[2.3-d]-pyrimidine, EGFR (HER1;Abl Kinase Inhibitors;Protein Kinase C (PKC) Inhibitors;erbB1) Inhibitors targeting ABL1, EGFR, SRC, ABL2, ERBB2
SB-29-AN01_0.01uM Dose=0.01uM, benzyl (2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carboxylate, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
SB-29-AN01_0.1uM Dose=0.1uM, benzyl (2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carboxylate, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
SB-29-AN01_1uM Dose=1uM, benzyl (2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carboxylate, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
SB-29-ZH97_0.01uM Dose=0.01uM, Tetrahydrouridine, CDA gene inhibitor targeting CDA
SB-29-ZH97_0.1uM Dose=0.1uM, Tetrahydrouridine, CDA gene inhibitor targeting CDA
SB-29-ZH97_10uM Dose=10uM, Tetrahydrouridine, CDA gene inhibitor targeting CDA
SB-29-ZH97_1uM Dose=1uM, Tetrahydrouridine, CDA gene inhibitor targeting CDA
SB-74-OD45_0.01uM Dose=0.01uM, N-1-(Fur-3-ylethyl)-N-hydroxyurea, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
SB-74-OD45_0.1uM Dose=0.1uM, N-1-(Fur-3-ylethyl)-N-hydroxyurea, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
SB-74-OD45_10uM Dose=10uM, N-1-(Fur-3-ylethyl)-N-hydroxyurea, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
SB-74-OD45_1uM Dose=1uM, N-1-(Fur-3-ylethyl)-N-hydroxyurea, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
SB-75-TY18_0.01uM Dose=0.01uM
SB-75-TY18_0.1uM Dose=0.1uM
SB-75-TY18_10uM Dose=10uM
SB-75-TY18_1uM Dose=1uM
SB-75-UH17_0.01uM Dose=0.01uM, Osanetant, Tachykinin NK3 Antagonists targeting TACR3
SB-75-UH17_0.1uM Dose=0.1uM, Osanetant, Tachykinin NK3 Antagonists targeting TACR3
SB-75-UH17_10uM Dose=10uM, Osanetant, Tachykinin NK3 Antagonists targeting TACR3
SB-75-UH17_1uM Dose=1uM, Osanetant, Tachykinin NK3 Antagonists targeting TACR3
SB-80-CR34_0.01uM Dose=0.01uM
SB-80-CR34_0.1uM Dose=0.1uM
SB-80-CR34_10uM Dose=10uM
SB-80-CR34_1uM Dose=1uM
SB-87-LQ34_0.01uM Dose=0.01uM, GI254023X, ADAM10 gene inhibitor targeting ADAM10
SB-87-LQ34_0.1uM Dose=0.1uM, GI254023X, ADAM10 gene inhibitor targeting ADAM10
SB-87-LQ34_10uM Dose=10uM, GI254023X, ADAM10 gene inhibitor targeting ADAM10
SB-87-LQ34_1uM Dose=1uM, GI254023X, ADAM10 gene inhibitor targeting ADAM10
SB-89-QK94_0.01uM Dose=0.01uM
SB-89-QK94_0.1uM Dose=0.1uM
SB-89-QK94_10uM Dose=10uM
SB-89-QK94_1uM Dose=1uM
SB-92-FF15_0.01uM Dose=0.01uM, 1-[2-(1-Hydroxymethyl-cyclopentylamino)-acetyl]-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
SB-92-FF15_0.1uM Dose=0.1uM, 1-[2-(1-Hydroxymethyl-cyclopentylamino)-acetyl]-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
SB-92-FF15_10uM Dose=10uM, 1-[2-(1-Hydroxymethyl-cyclopentylamino)-acetyl]-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
SB-92-FF15_1uM Dose=1uM, 1-[2-(1-Hydroxymethyl-cyclopentylamino)-acetyl]-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4
SB-94-ZA83_0.01uM Dose=0.01uM, (3R)-6-cyclohexyl-N-hydroxy-3-[3-(1-methylsulfonylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]hexanamide, Procollagen C-Proteinase Inhibitors targeting BMP1
SB-94-ZA83_0.1uM Dose=0.1uM, (3R)-6-cyclohexyl-N-hydroxy-3-[3-(1-methylsulfonylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]hexanamide, Procollagen C-Proteinase Inhibitors targeting BMP1
SB-94-ZA83_10uM Dose=10uM, (3R)-6-cyclohexyl-N-hydroxy-3-[3-(1-methylsulfonylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]hexanamide, Procollagen C-Proteinase Inhibitors targeting BMP1
SB-94-ZA83_1uM Dose=1uM, (3R)-6-cyclohexyl-N-hydroxy-3-[3-(1-methylsulfonylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl]hexanamide, Procollagen C-Proteinase Inhibitors targeting BMP1
SC-02-RZ08_0.01uM Dose=0.01uM, N-[(E)-[4-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]phenyl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine, CXCR4 antagonist targeting CXCR4
SC-02-RZ08_0.1uM Dose=0.1uM, N-[(E)-[4-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]phenyl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine, CXCR4 antagonist targeting CXCR4
SC-02-RZ08_10uM Dose=10uM, N-[(E)-[4-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]phenyl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine, CXCR4 antagonist targeting CXCR4
SC-02-RZ08_1uM Dose=1uM, N-[(E)-[4-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]phenyl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine, CXCR4 antagonist targeting CXCR4
SC-09-QD27_0.1uM Dose=0.1uM
SC-09-QD27_10uM Dose=10uM
SC-09-QD27_1uM Dose=1uM
SC-17-WW78_0.01uM Dose=0.01uM, 2-[[4-(4-cyano-1-methylpiperidin-4-yl)-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile, MAP3K12 (DLK) Inhibitors targeting MAP3K12
SC-17-WW78_0.1uM Dose=0.1uM, 2-[[4-(4-cyano-1-methylpiperidin-4-yl)-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile, MAP3K12 (DLK) Inhibitors targeting MAP3K12
SC-17-WW78_10uM Dose=10uM, 2-[[4-(4-cyano-1-methylpiperidin-4-yl)-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile, MAP3K12 (DLK) Inhibitors targeting MAP3K12
SC-17-WW78_1uM Dose=1uM, 2-[[4-(4-cyano-1-methylpiperidin-4-yl)-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile, MAP3K12 (DLK) Inhibitors targeting MAP3K12
SC-25-HE80_0.01uM Dose=0.01uM, 4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]-4-methylphenyl]-3-(trifluoromethyl)benzamide, DDR tyrosine kinase receptor inhibitor targeting DDR1, DDR2
SC-25-HE80_0.1uM Dose=0.1uM, 4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]-4-methylphenyl]-3-(trifluoromethyl)benzamide, DDR tyrosine kinase receptor inhibitor targeting DDR1, DDR2
SC-25-HE80_10uM Dose=10uM, 4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]-4-methylphenyl]-3-(trifluoromethyl)benzamide, DDR tyrosine kinase receptor inhibitor targeting DDR1, DDR2
SC-25-HE80_1uM Dose=1uM, 4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]-4-methylphenyl]-3-(trifluoromethyl)benzamide, DDR tyrosine kinase receptor inhibitor targeting DDR1, DDR2
SC-50-ME48_0.01uM Dose=0.01uM
SC-50-ME48_0.1uM Dose=0.1uM
SC-50-ME48_10uM Dose=10uM
SC-50-ME48_1uM Dose=1uM
SC-59-TX35_0.01uM Dose=0.01uM
SC-59-TX35_0.1uM Dose=0.1uM
SC-59-TX35_10uM Dose=10uM
SC-59-TX35_1uM Dose=1uM
SC-64-CU21_0.1uM Dose=0.1uM, 3-cyano-N-(6-methoxy-1,3-dimethyl-2-oxobenzimidazol-5-yl)benzenesulfonamide
SC-64-CU21_1uM Dose=1uM, 3-cyano-N-(6-methoxy-1,3-dimethyl-2-oxobenzimidazol-5-yl)benzenesulfonamide
SC-68-JQ26_0.01uM Dose=0.01uM, N-(2-Chloro-phenyl)-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
SC-68-JQ26_0.1uM Dose=0.1uM, N-(2-Chloro-phenyl)-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
SC-68-JQ26_1uM Dose=1uM, N-(2-Chloro-phenyl)-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
SC-71-IB68_0.01uM Dose=0.01uM, Sah 41-178, Carbonic anhydrase inhibitor targeting CA1, CA2
SC-71-IB68_0.1uM Dose=0.1uM, Sah 41-178, Carbonic anhydrase inhibitor targeting CA1, CA2
SC-71-IB68_1uM Dose=1uM, Sah 41-178, Carbonic anhydrase inhibitor targeting CA1, CA2
SC-72-YW56_0.01uM Dose=0.01uM, 4'-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5',13',17'-triazaspiro(cyclopropane-1,15'-tetracyclo(8.7.0.0^(2,7).0^(11,16))heptadecane)-1'(10'),2'(7'),3',5',11'(16')-pentaen-12'-one, MAPKAPK5 inhibitor targeting MAPKAPK5
SC-72-YW56_0.1uM Dose=0.1uM, 4'-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5',13',17'-triazaspiro(cyclopropane-1,15'-tetracyclo(8.7.0.0^(2,7).0^(11,16))heptadecane)-1'(10'),2'(7'),3',5',11'(16')-pentaen-12'-one, MAPKAPK5 inhibitor targeting MAPKAPK5
SC-72-YW56_10uM Dose=10uM, 4'-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5',13',17'-triazaspiro(cyclopropane-1,15'-tetracyclo(8.7.0.0^(2,7).0^(11,16))heptadecane)-1'(10'),2'(7'),3',5',11'(16')-pentaen-12'-one, MAPKAPK5 inhibitor targeting MAPKAPK5
SC-72-YW56_1uM Dose=1uM, 4'-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-5',13',17'-triazaspiro(cyclopropane-1,15'-tetracyclo(8.7.0.0^(2,7).0^(11,16))heptadecane)-1'(10'),2'(7'),3',5',11'(16')-pentaen-12'-one, MAPKAPK5 inhibitor targeting MAPKAPK5
SC-76-YF40_0.01uM Dose=0.01uM
SC-76-YF40_0.1uM Dose=0.1uM
SC-76-YF40_10uM Dose=10uM
SC-76-YF40_1uM Dose=1uM
SD-12-UF05_0.01uM Dose=0.01uM, Phenylsulfamate, Carbonic anhydrase inhibitor targeting CA2
SD-12-UF05_0.1uM Dose=0.1uM, Phenylsulfamate, Carbonic anhydrase inhibitor targeting CA2
SD-12-UF05_10uM Dose=10uM, Phenylsulfamate, Carbonic anhydrase inhibitor targeting CA2
SD-12-UF05_1uM Dose=1uM, Phenylsulfamate, Carbonic anhydrase inhibitor targeting CA2
SD-15-WR01_0.01uM Dose=0.01uM, 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoic acid, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
SD-15-WR01_0.1uM Dose=0.1uM, 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoic acid, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
SD-15-WR01_10uM Dose=10uM, 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoic acid, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
SD-15-WR01_1uM Dose=1uM, 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoic acid, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
SD-51-LL22_0.01uM Dose=0.01uM, 3-(2-(4-(3-chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)-1H-indazole, Calmodulin Antagonists targeting CALM1
SD-51-LL22_0.1uM Dose=0.1uM, 3-(2-(4-(3-chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)-1H-indazole, Calmodulin Antagonists targeting CALM1
SD-51-LL22_10uM Dose=10uM, 3-(2-(4-(3-chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)-1H-indazole, Calmodulin Antagonists targeting CALM1
SD-51-LL22_1uM Dose=1uM, 3-(2-(4-(3-chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)-1H-indazole, Calmodulin Antagonists targeting CALM1
SD-61-RL57_0.01uM Dose=0.01uM, P38 alpha MAP kinase inhibitor
SD-69-IX30_0.01uM Dose=0.01uM, Etomoxir
SD-69-IX30_0.1uM Dose=0.1uM, Etomoxir
SD-69-IX30_10uM Dose=10uM, Etomoxir
SD-69-IX30_1uM Dose=1uM, Etomoxir
SD-69-QA40_0.01uM Dose=0.01uM, (5Z)-5-(6-fluoro-2,3-dihydrochromen-4-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
SD-69-QA40_0.1uM Dose=0.1uM, (5Z)-5-(6-fluoro-2,3-dihydrochromen-4-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
SD-69-QA40_10uM Dose=10uM, (5Z)-5-(6-fluoro-2,3-dihydrochromen-4-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
SD-69-QA40_1uM Dose=1uM, (5Z)-5-(6-fluoro-2,3-dihydrochromen-4-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD
SD-82-GT69_0.01uM Dose=0.01uM, N~4~-Cyclopropyl-6-(2,3-Dichlorophenyl)pyrimidine-2,4-Diamine, NUDT1 gene inhibitor targeting NUDT1
SD-82-GT69_0.1uM Dose=0.1uM, N~4~-Cyclopropyl-6-(2,3-Dichlorophenyl)pyrimidine-2,4-Diamine, NUDT1 gene inhibitor targeting NUDT1
SD-82-GT69_10uM Dose=10uM, N~4~-Cyclopropyl-6-(2,3-Dichlorophenyl)pyrimidine-2,4-Diamine, NUDT1 gene inhibitor targeting NUDT1
SD-82-GT69_1uM Dose=1uM, N~4~-Cyclopropyl-6-(2,3-Dichlorophenyl)pyrimidine-2,4-Diamine, NUDT1 gene inhibitor targeting NUDT1
SE-15-AV21_0.01uM Dose=0.01uM, 1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea, Eukaryotic Translation Initiation Factor 2-alpha Kinase 1 (HRI) Activators targeting EIF2AK1
SE-15-AV21_0.1uM Dose=0.1uM, 1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea, Eukaryotic Translation Initiation Factor 2-alpha Kinase 1 (HRI) Activators targeting EIF2AK1
SE-15-AV21_10uM Dose=10uM, 1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea, Eukaryotic Translation Initiation Factor 2-alpha Kinase 1 (HRI) Activators targeting EIF2AK1
SE-15-AV21_1uM Dose=1uM, 1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(3,4-dichlorophenyl)urea, Eukaryotic Translation Initiation Factor 2-alpha Kinase 1 (HRI) Activators targeting EIF2AK1
SE-21-NB93_0.01uM Dose=0.01uM, Stiripentol, GABA Reuptake Inhibitors;GABA Aminotransferase Inhibitors targeting ABAT
SE-21-NB93_0.1uM Dose=0.1uM, Stiripentol, GABA Reuptake Inhibitors;GABA Aminotransferase Inhibitors targeting ABAT
SE-21-NB93_1uM Dose=1uM, Stiripentol, GABA Reuptake Inhibitors;GABA Aminotransferase Inhibitors targeting ABAT
SE-29-ZA15_0.01uM Dose=0.01uM, UT-B-IN-1, Urea transporter inhibitor targeting SLC14A1, SLC14A2
SE-29-ZA15_0.1uM Dose=0.1uM, UT-B-IN-1, Urea transporter inhibitor targeting SLC14A1, SLC14A2
SE-29-ZA15_10uM Dose=10uM, UT-B-IN-1, Urea transporter inhibitor targeting SLC14A1, SLC14A2
SE-29-ZA15_1uM Dose=1uM, UT-B-IN-1, Urea transporter inhibitor targeting SLC14A1, SLC14A2
SE-76-JI27_0.01uM Dose=0.01uM, Pyridine-2-carboxylic acid {(S)-3-[(3,5-bis-trifluoromethyl-benzoyl)-methyl-amino]-4-phenyl-butyl}-amide, Orexin OX-2 Antagonists targeting HCRTR2
SE-76-JI27_0.1uM Dose=0.1uM, Pyridine-2-carboxylic acid {(S)-3-[(3,5-bis-trifluoromethyl-benzoyl)-methyl-amino]-4-phenyl-butyl}-amide, Orexin OX-2 Antagonists targeting HCRTR2
SE-76-JI27_10uM Dose=10uM, Pyridine-2-carboxylic acid {(S)-3-[(3,5-bis-trifluoromethyl-benzoyl)-methyl-amino]-4-phenyl-butyl}-amide, Orexin OX-2 Antagonists targeting HCRTR2
SE-76-JI27_1uM Dose=1uM, Pyridine-2-carboxylic acid {(S)-3-[(3,5-bis-trifluoromethyl-benzoyl)-methyl-amino]-4-phenyl-butyl}-amide, Orexin OX-2 Antagonists targeting HCRTR2
SE-81-RI20_0.01uM Dose=0.01uM
SE-81-RI20_0.1uM Dose=0.1uM
SE-81-RI20_10uM Dose=10uM
SE-81-RI20_1uM Dose=1uM
SE-89-DO49_0.01uM Dose=0.01uM, [4-[[(3R)-7-(5-cyanofuran-2-yl)-4-(4-methoxyphenyl)sulfonyl-1-[(3-methylimidazol-4-yl)methyl]-3,5-dihydro-2H-1,4-benzodiazepin-3-yl]methyl]phenyl] N-benzylcarbamate, Rab GGTase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting RABGGTA, RABGGTB
SE-89-DO49_0.1uM Dose=0.1uM, [4-[[(3R)-7-(5-cyanofuran-2-yl)-4-(4-methoxyphenyl)sulfonyl-1-[(3-methylimidazol-4-yl)methyl]-3,5-dihydro-2H-1,4-benzodiazepin-3-yl]methyl]phenyl] N-benzylcarbamate, Rab GGTase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting RABGGTA, RABGGTB
SE-89-DO49_10uM Dose=10uM, [4-[[(3R)-7-(5-cyanofuran-2-yl)-4-(4-methoxyphenyl)sulfonyl-1-[(3-methylimidazol-4-yl)methyl]-3,5-dihydro-2H-1,4-benzodiazepin-3-yl]methyl]phenyl] N-benzylcarbamate, Rab GGTase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting RABGGTA, RABGGTB
SE-89-DO49_1uM Dose=1uM, [4-[[(3R)-7-(5-cyanofuran-2-yl)-4-(4-methoxyphenyl)sulfonyl-1-[(3-methylimidazol-4-yl)methyl]-3,5-dihydro-2H-1,4-benzodiazepin-3-yl]methyl]phenyl] N-benzylcarbamate, Rab GGTase Inhibitors;Geranylgeranyl Transferase Type I (GGTase-I) Inhibitors targeting RABGGTA, RABGGTB
SE-91-VW19_0.01uM Dose=0.01uM, Pimavanserin, SELECTIVE inverse agonist on the serotonin receptor subtype 5-HT2A;HTR2A (5HT2A) inverse agonist targeting HTR2A, HTR5A
SE-91-VW19_0.1uM Dose=0.1uM, Pimavanserin, SELECTIVE inverse agonist on the serotonin receptor subtype 5-HT2A;HTR2A (5HT2A) inverse agonist targeting HTR2A, HTR5A
SE-91-VW19_10uM Dose=10uM, Pimavanserin, SELECTIVE inverse agonist on the serotonin receptor subtype 5-HT2A;HTR2A (5HT2A) inverse agonist targeting HTR2A, HTR5A
SE-91-VW19_1uM Dose=1uM, Pimavanserin, SELECTIVE inverse agonist on the serotonin receptor subtype 5-HT2A;HTR2A (5HT2A) inverse agonist targeting HTR2A, HTR5A
SE-92-BP29_0.01uM Dose=0.01uM
SE-92-BP29_0.1uM Dose=0.1uM
SE-92-BP29_10uM Dose=10uM
SE-92-BP29_1uM Dose=1uM
SF-32-RC78_0.01uM Dose=0.01uM, MAP3K5 gene inhibitor targeting MAP3K5
SF-32-RC78_0.1uM Dose=0.1uM, MAP3K5 gene inhibitor targeting MAP3K5
SF-32-RC78_10uM Dose=10uM, MAP3K5 gene inhibitor targeting MAP3K5
SF-32-RC78_1uM Dose=1uM, MAP3K5 gene inhibitor targeting MAP3K5
SF-48-KT63_0.01uM Dose=0.01uM, 4-((Aminosulfonyl)amino)benzenesulfonamide
SF-48-KT63_0.1uM Dose=0.1uM, 4-((Aminosulfonyl)amino)benzenesulfonamide
SF-48-KT63_10uM Dose=10uM, 4-((Aminosulfonyl)amino)benzenesulfonamide
SF-48-KT63_1uM Dose=1uM, 4-((Aminosulfonyl)amino)benzenesulfonamide
SF-52-LP14_0.01uM Dose=0.01uM, (2R,3S,7R,8R,8aS)-6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3H-1-benzofuran]-7'-carboxylic acid, Complement Inhibitors targeting C3
SF-52-LP14_10uM Dose=10uM, (2R,3S,7R,8R,8aS)-6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3H-1-benzofuran]-7'-carboxylic acid, Complement Inhibitors targeting C3
SF-52-LP14_1uM Dose=1uM, (2R,3S,7R,8R,8aS)-6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3H-1-benzofuran]-7'-carboxylic acid, Complement Inhibitors targeting C3
SF-67-CJ22_10uM Dose=10uM
SF-67-CJ22_1uM Dose=1uM
SF-77-LC15_0.01uM Dose=0.01uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-10,10-dimethyl-2-oxa-7-azadispiro[3.0.45.14]decane-8-carboxamide
SF-77-LC15_0.1uM Dose=0.1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-10,10-dimethyl-2-oxa-7-azadispiro[3.0.45.14]decane-8-carboxamide
SF-77-LC15_10uM Dose=10uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-10,10-dimethyl-2-oxa-7-azadispiro[3.0.45.14]decane-8-carboxamide
SF-77-LC15_1uM Dose=1uM, (5R,8S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-7-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-10,10-dimethyl-2-oxa-7-azadispiro[3.0.45.14]decane-8-carboxamide
TA-10-KH35_0.01uM Dose=0.01uM, 3-Chloro-1-(3,4-dichlorophenyl)-4-(4-methylpiperazin-1-yl)pyrrole-2,5-dione targeting BCL2A1
TA-10-KH35_0.1uM Dose=0.1uM, 3-Chloro-1-(3,4-dichlorophenyl)-4-(4-methylpiperazin-1-yl)pyrrole-2,5-dione targeting BCL2A1
TA-10-KH35_10uM Dose=10uM, 3-Chloro-1-(3,4-dichlorophenyl)-4-(4-methylpiperazin-1-yl)pyrrole-2,5-dione targeting BCL2A1
TA-10-KH35_1uM Dose=1uM, 3-Chloro-1-(3,4-dichlorophenyl)-4-(4-methylpiperazin-1-yl)pyrrole-2,5-dione targeting BCL2A1
TA-19-GU13_0.01uM Dose=0.01uM, 6-Ethylguanine
TA-19-GU13_0.1uM Dose=0.1uM, 6-Ethylguanine
TA-19-GU13_10uM Dose=10uM, 6-Ethylguanine
TA-19-GU13_1uM Dose=1uM, 6-Ethylguanine
TA-19-YA45_0.01uM Dose=0.01uM, N-{[5-(1H-benzimidazol-2-yl)-2-methylphenyl]carbamothioyl}-2,3-dihydro-1,4-benzodioxine-6-carboxamide, antagonist of neuropilin-1 receptor targeting NRP1
TA-19-YA45_0.1uM Dose=0.1uM, N-{[5-(1H-benzimidazol-2-yl)-2-methylphenyl]carbamothioyl}-2,3-dihydro-1,4-benzodioxine-6-carboxamide, antagonist of neuropilin-1 receptor targeting NRP1
TA-19-YA45_10uM Dose=10uM, N-{[5-(1H-benzimidazol-2-yl)-2-methylphenyl]carbamothioyl}-2,3-dihydro-1,4-benzodioxine-6-carboxamide, antagonist of neuropilin-1 receptor targeting NRP1
TA-19-YA45_1uM Dose=1uM, N-{[5-(1H-benzimidazol-2-yl)-2-methylphenyl]carbamothioyl}-2,3-dihydro-1,4-benzodioxine-6-carboxamide, antagonist of neuropilin-1 receptor targeting NRP1
TA-20-FO62_0.01uM Dose=0.01uM
TA-20-FO62_0.1uM Dose=0.1uM
TA-20-FO62_10uM Dose=10uM
TA-20-FO62_1uM Dose=1uM
TA-21-GI75_0.01uM Dose=0.01uM, 2-[[5-(2,6-Dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid, NTSR1 antagonist;NTSR2 antagonist;Neurotensin Antagonists targeting NTSR1, NTSR2
TA-21-GI75_0.1uM Dose=0.1uM, 2-[[5-(2,6-Dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid, NTSR1 antagonist;NTSR2 antagonist;Neurotensin Antagonists targeting NTSR1, NTSR2
TA-21-GI75_10uM Dose=10uM, 2-[[5-(2,6-Dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid, NTSR1 antagonist;NTSR2 antagonist;Neurotensin Antagonists targeting NTSR1, NTSR2
TA-21-GI75_1uM Dose=1uM, 2-[[5-(2,6-Dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid, NTSR1 antagonist;NTSR2 antagonist;Neurotensin Antagonists targeting NTSR1, NTSR2
TA-25-KO99_0.01uM Dose=0.01uM, 2,3-difluoro-N-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide, TRPM4 Agonists;Cytokine Production Inhibitors targeting TRPM4
TA-25-KO99_0.1uM Dose=0.1uM, 2,3-difluoro-N-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide, TRPM4 Agonists;Cytokine Production Inhibitors targeting TRPM4
TA-25-KO99_10uM Dose=10uM, 2,3-difluoro-N-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide, TRPM4 Agonists;Cytokine Production Inhibitors targeting TRPM4
TA-25-KO99_1uM Dose=1uM, 2,3-difluoro-N-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide, TRPM4 Agonists;Cytokine Production Inhibitors targeting TRPM4
TA-25-ZO44_0.01uM Dose=0.01uM, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, Protein Kinase B (PKB/Akt) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting PDPK1
TA-25-ZO44_0.1uM Dose=0.1uM, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, Protein Kinase B (PKB/Akt) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting PDPK1
TA-25-ZO44_10uM Dose=10uM, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, Protein Kinase B (PKB/Akt) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting PDPK1
TA-25-ZO44_1uM Dose=1uM, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, Protein Kinase B (PKB/Akt) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting PDPK1
TA-34-CK62_0.01uM Dose=0.01uM, 3-[[4-[2-(3-Chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propanamide, CDK1 Inhibitors targeting CDK1
TA-34-CK62_0.1uM Dose=0.1uM, 3-[[4-[2-(3-Chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propanamide, CDK1 Inhibitors targeting CDK1
TA-34-CK62_10uM Dose=10uM, 3-[[4-[2-(3-Chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propanamide, CDK1 Inhibitors targeting CDK1
TA-34-CK62_1uM Dose=1uM, 3-[[4-[2-(3-Chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propanamide, CDK1 Inhibitors targeting CDK1
TA-36-GV23_0.01uM Dose=0.01uM, Kynurenic Acid, a7 nicotinic acetylcholine receptor Inhibitor;NMDA Antagonists;AMPA Receptor Modulators targeting CHRNA7
TA-36-GV23_0.1uM Dose=0.1uM, Kynurenic Acid, a7 nicotinic acetylcholine receptor Inhibitor;NMDA Antagonists;AMPA Receptor Modulators targeting CHRNA7
TA-36-GV23_1uM Dose=1uM, Kynurenic Acid, a7 nicotinic acetylcholine receptor Inhibitor;NMDA Antagonists;AMPA Receptor Modulators targeting CHRNA7
TA-36-PC58_0.01uM Dose=0.01uM, 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin Dimerization Inhibitors targeting BIRC5
TA-36-PC58_0.1uM Dose=0.1uM, 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin Dimerization Inhibitors targeting BIRC5
TA-36-PC58_10uM Dose=10uM, 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin Dimerization Inhibitors targeting BIRC5
TA-36-PC58_1uM Dose=1uM, 4-[3,5-Bis(benzyloxy)phenyl]-6-(5-chloro-2-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile, Survivin Dimerization Inhibitors targeting BIRC5
TA-48-MG12_0.01uM Dose=0.01uM
TA-48-MG12_0.1uM Dose=0.1uM
TA-48-MG12_10uM Dose=10uM
TA-48-MG12_1uM Dose=1uM
TA-57-FF07_0.01uM Dose=0.01uM, Mes-D-Ala-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl
TA-57-FF07_0.1uM Dose=0.1uM, Mes-D-Ala-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl
TA-57-FF07_10uM Dose=10uM, Mes-D-Ala-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl
TA-57-FF07_1uM Dose=1uM, Mes-D-Ala-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl
TA-82-BQ12_0.01uM Dose=0.01uM, CU-Cpt22, TLR1/2 complex inhibitor targeting TLR1, TLR2
TA-82-BQ12_0.1uM Dose=0.1uM, CU-Cpt22, TLR1/2 complex inhibitor targeting TLR1, TLR2
TA-82-BQ12_10uM Dose=10uM, CU-Cpt22, TLR1/2 complex inhibitor targeting TLR1, TLR2
TA-82-BQ12_1uM Dose=1uM, CU-Cpt22, TLR1/2 complex inhibitor targeting TLR1, TLR2
TB-06-VB30_0.01uM Dose=0.01uM, pan PLK inhibitor targeting PLK3, PLK1, PLK2
TB-06-VB30_0.1uM Dose=0.1uM, pan PLK inhibitor targeting PLK3, PLK1, PLK2
TB-06-VB30_10uM Dose=10uM, pan PLK inhibitor targeting PLK3, PLK1, PLK2
TB-06-VB30_1uM Dose=1uM, pan PLK inhibitor targeting PLK3, PLK1, PLK2
TB-55-WY28_0.01uM Dose=0.01uM, SB 204990, ATP citrate lyase inhibitor targeting ACLY
TB-55-WY28_0.1uM Dose=0.1uM, SB 204990, ATP citrate lyase inhibitor targeting ACLY
TB-55-WY28_10uM Dose=10uM, SB 204990, ATP citrate lyase inhibitor targeting ACLY
TB-55-WY28_1uM Dose=1uM, SB 204990, ATP citrate lyase inhibitor targeting ACLY
TC-02-NZ28_0.01uM Dose=0.01uM
TC-02-NZ28_10uM Dose=10uM
TC-02-NZ28_1uM Dose=1uM
TC-16-ZS56_0.1uM Dose=0.1uM, Recilisib
TC-16-ZS56_10uM Dose=10uM, Recilisib
TC-16-ZS56_1uM Dose=1uM, Recilisib
TC-22-OM27_0.01uM Dose=0.01uM
TC-22-OM27_0.1uM Dose=0.1uM
TC-22-OM27_10uM Dose=10uM
TC-22-OM27_1uM Dose=1uM
TC-25-MR66_0.01uM Dose=0.01uM, Xct790, Estrogen-Related Receptor alpha (ERRalpha, ERR1) Inverse Agonists targeting ESRRA
TC-25-MR66_0.1uM Dose=0.1uM, Xct790, Estrogen-Related Receptor alpha (ERRalpha, ERR1) Inverse Agonists targeting ESRRA
TC-25-MR66_10uM Dose=10uM, Xct790, Estrogen-Related Receptor alpha (ERRalpha, ERR1) Inverse Agonists targeting ESRRA
TC-25-MR66_1uM Dose=1uM, Xct790, Estrogen-Related Receptor alpha (ERRalpha, ERR1) Inverse Agonists targeting ESRRA
TC-25-NY68_0.01uM Dose=0.01uM, US10730870, Example 65 targeting VHL
TC-25-NY68_0.1uM Dose=0.1uM, US10730870, Example 65 targeting VHL
TC-32-HZ53_0.1uM Dose=0.1uM, N-[2-[2-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetamide, CCR1 antagonist targeting CCR1
TC-32-HZ53_10uM Dose=10uM, N-[2-[2-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetamide, CCR1 antagonist targeting CCR1
TC-32-HZ53_1uM Dose=1uM, N-[2-[2-[4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetamide, CCR1 antagonist targeting CCR1
TC-36-AL79_0.01uM Dose=0.01uM, Duloxetine, Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting CYP2D6, SLC6A2, SLC6A4
TC-36-AL79_0.1uM Dose=0.1uM, Duloxetine, Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting CYP2D6, SLC6A2, SLC6A4
TC-36-AL79_10uM Dose=10uM, Duloxetine, Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting CYP2D6, SLC6A2, SLC6A4
TC-36-AL79_1uM Dose=1uM, Duloxetine, Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting CYP2D6, SLC6A2, SLC6A4
TC-45-JH72_0.01uM Dose=0.01uM, Vesamicol targeting SLC18A3
TC-45-JH72_0.1uM Dose=0.1uM, Vesamicol targeting SLC18A3
TC-45-JH72_10uM Dose=10uM, Vesamicol targeting SLC18A3
TC-45-JH72_1uM Dose=1uM, Vesamicol targeting SLC18A3
TC-59-QN21_0.01uM Dose=0.01uM, SB-332235, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
TC-59-QN21_0.1uM Dose=0.1uM, SB-332235, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
TC-59-QN21_10uM Dose=10uM, SB-332235, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
TC-59-QN21_1uM Dose=1uM, SB-332235, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2
TC-66-CI47_0.01uM Dose=0.01uM
TC-66-CI47_0.1uM Dose=0.1uM
TC-66-CI47_10uM Dose=10uM
TC-66-CI47_1uM Dose=1uM
TC-67-HF87_0.01uM Dose=0.01uM
TC-67-HF87_0.1uM Dose=0.1uM
TC-67-HF87_1uM Dose=1uM
TC-69-EY43_0.01uM Dose=0.01uM, PF-06761281 targeting SLC13A5
TC-69-EY43_0.1uM Dose=0.1uM, PF-06761281 targeting SLC13A5
TC-69-EY43_10uM Dose=10uM, PF-06761281 targeting SLC13A5
TC-80-LY86_0.01uM Dose=0.01uM, 4-[[3-[3-(Trifluoromethyl)phenyl]-2,4-dioxo-5-thiazolidinylidene]methyl]benzoic acid
TC-80-LY86_0.1uM Dose=0.1uM, 4-[[3-[3-(Trifluoromethyl)phenyl]-2,4-dioxo-5-thiazolidinylidene]methyl]benzoic acid
TC-80-LY86_10uM Dose=10uM, 4-[[3-[3-(Trifluoromethyl)phenyl]-2,4-dioxo-5-thiazolidinylidene]methyl]benzoic acid
TC-80-LY86_1uM Dose=1uM, 4-[[3-[3-(Trifluoromethyl)phenyl]-2,4-dioxo-5-thiazolidinylidene]methyl]benzoic acid
TC-91-SL57_0.01uM Dose=0.01uM
TC-91-SL57_0.1uM Dose=0.1uM
TC-91-SL57_10uM Dose=10uM
TC-91-SL57_1uM Dose=1uM
TC-94-QN39_0.01uM Dose=0.01uM, Iferanserin
TC-94-QN39_0.1uM Dose=0.1uM, Iferanserin
TC-94-QN39_10uM Dose=10uM, Iferanserin
TC-94-QN39_1uM Dose=1uM, Iferanserin
TC-95-IR96_0.01uM Dose=0.01uM, T-226296, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists targeting MCHR1, MCHR2
TC-95-IR96_0.1uM Dose=0.1uM, T-226296, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists targeting MCHR1, MCHR2
TC-95-IR96_10uM Dose=10uM, T-226296, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists targeting MCHR1, MCHR2
TC-95-IR96_1uM Dose=1uM, T-226296, Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists targeting MCHR1, MCHR2
TD-09-SX65_0.01uM Dose=0.01uM, N-(3-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine, CDK Inhibitors targeting CDK2, CCNE2
TD-09-SX65_0.1uM Dose=0.1uM, N-(3-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine, CDK Inhibitors targeting CDK2, CCNE2
TD-09-SX65_10uM Dose=10uM, N-(3-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine, CDK Inhibitors targeting CDK2, CCNE2
TD-09-SX65_1uM Dose=1uM, N-(3-chlorophenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine, CDK Inhibitors targeting CDK2, CCNE2
TD-17-NF32_0.01uM Dose=0.01uM
TD-17-NF32_0.1uM Dose=0.1uM
TD-17-NF32_10uM Dose=10uM
TD-17-NF32_1uM Dose=1uM
TD-18-FT48_0.1uM Dose=0.1uM, Ethyl 1-[5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carbonyl]piperidine-2-carboxylate, F2RL1 antagonist targeting F2RL1
TD-18-FT48_10uM Dose=10uM, Ethyl 1-[5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carbonyl]piperidine-2-carboxylate, F2RL1 antagonist targeting F2RL1
TD-18-FT48_1uM Dose=1uM, Ethyl 1-[5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carbonyl]piperidine-2-carboxylate, F2RL1 antagonist targeting F2RL1
TD-29-IN36_0.01uM Dose=0.01uM
TD-29-IN36_0.1uM Dose=0.1uM
TD-29-IN36_10uM Dose=10uM
TD-29-IN36_1uM Dose=1uM
TD-31-KS49_0.1uM Dose=0.1uM, Sertindole, Dopamine D2 Antagonists;5-HT2A Antagonists targeting ADRA1B, HTR1E, HTR1F
TD-31-KS49_10uM Dose=10uM, Sertindole, Dopamine D2 Antagonists;5-HT2A Antagonists targeting ADRA1B, HTR1E, HTR1F
TD-31-KS49_1uM Dose=1uM, Sertindole, Dopamine D2 Antagonists;5-HT2A Antagonists targeting ADRA1B, HTR1E, HTR1F
TD-33-TT56_0.01uM Dose=0.01uM
TD-33-TT56_0.1uM Dose=0.1uM
TD-33-TT56_10uM Dose=10uM
TD-33-TT56_1uM Dose=1uM
TD-35-IE25_0.01uM Dose=0.01uM, Z-321, Prolyl Endopeptidase (prolyl oligopeptidase;POP) Inhibitors targeting PREP
TD-35-IE25_0.1uM Dose=0.1uM, Z-321, Prolyl Endopeptidase (prolyl oligopeptidase;POP) Inhibitors targeting PREP
TD-35-IE25_10uM Dose=10uM, Z-321, Prolyl Endopeptidase (prolyl oligopeptidase;POP) Inhibitors targeting PREP
TD-35-IE25_1uM Dose=1uM, Z-321, Prolyl Endopeptidase (prolyl oligopeptidase;POP) Inhibitors targeting PREP
TD-36-JP74_0.01uM Dose=0.01uM, N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide, Glucosylceramidase inhibitor targeting GBA
TD-36-JP74_0.1uM Dose=0.1uM, N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide, Glucosylceramidase inhibitor targeting GBA
TD-36-JP74_10uM Dose=10uM, N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide, Glucosylceramidase inhibitor targeting GBA
TD-36-JP74_1uM Dose=1uM, N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide, Glucosylceramidase inhibitor targeting GBA
TD-40-ZR64_0.01uM Dose=0.01uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-cyclopropylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
TD-40-ZR64_0.1uM Dose=0.1uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-cyclopropylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
TD-40-ZR64_10uM Dose=10uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-cyclopropylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
TD-40-ZR64_1uM Dose=1uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-cyclopropylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
TD-48-MJ89_0.01uM Dose=0.01uM, 7-Chloro-5-(2-chlorophenyl)-4,4-dioxo-1,5-dihydro-4lambda6,1-benzothiazepin-2-one, Na+/Ca2+ Exchanger (NCX) Inhibitors targeting SLC8A2, SLC8A1
TD-48-MJ89_0.1uM Dose=0.1uM, 7-Chloro-5-(2-chlorophenyl)-4,4-dioxo-1,5-dihydro-4lambda6,1-benzothiazepin-2-one, Na+/Ca2+ Exchanger (NCX) Inhibitors targeting SLC8A2, SLC8A1
TD-48-MJ89_10uM Dose=10uM, 7-Chloro-5-(2-chlorophenyl)-4,4-dioxo-1,5-dihydro-4lambda6,1-benzothiazepin-2-one, Na+/Ca2+ Exchanger (NCX) Inhibitors targeting SLC8A2, SLC8A1
TD-48-XJ84_0.01uM Dose=0.01uM, 4-[2-Methoxy-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]benzonitrile
TD-48-XJ84_10uM Dose=10uM, 4-[2-Methoxy-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]benzonitrile
TD-48-XJ84_1uM Dose=1uM, 4-[2-Methoxy-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]benzonitrile
TD-49-MO89_0.01uM Dose=0.01uM
TD-49-MO89_0.1uM Dose=0.1uM
TD-49-MO89_10uM Dose=10uM
TD-49-MO89_1uM Dose=1uM
TD-57-NZ75_0.01uM Dose=0.01uM
TD-57-NZ75_0.1uM Dose=0.1uM
TD-57-NZ75_10uM Dose=10uM
TD-57-NZ75_1uM Dose=1uM
TD-69-UA90_0.01uM Dose=0.01uM, N-{1-[4-(Benzothiazol-2-yloxy)-benzyl]-piperidin-4-yl}-2-hydroxy-acetamide, Leukotriene A4 Hydrolase Inhibitors targeting LTA4H
TD-69-UA90_0.1uM Dose=0.1uM, N-{1-[4-(Benzothiazol-2-yloxy)-benzyl]-piperidin-4-yl}-2-hydroxy-acetamide, Leukotriene A4 Hydrolase Inhibitors targeting LTA4H
TD-69-UA90_10uM Dose=10uM, N-{1-[4-(Benzothiazol-2-yloxy)-benzyl]-piperidin-4-yl}-2-hydroxy-acetamide, Leukotriene A4 Hydrolase Inhibitors targeting LTA4H
TD-69-UA90_1uM Dose=1uM, N-{1-[4-(Benzothiazol-2-yloxy)-benzyl]-piperidin-4-yl}-2-hydroxy-acetamide, Leukotriene A4 Hydrolase Inhibitors targeting LTA4H
TD-91-KV46_0.01uM Dose=0.01uM
TD-91-KV46_1uM Dose=1uM
TE-12-BW46_10uM Dose=10uM, F16357, PAR1) Antagonist;Proteinase-Activated Receptor 1 (F2R targeting F2R
TE-12-BW46_1uM Dose=1uM, F16357, PAR1) Antagonist;Proteinase-Activated Receptor 1 (F2R targeting F2R
TE-15-RO34_0.01uM Dose=0.01uM, N-[1-[[5-chloro-2-(cyclopropylmethoxy)phenyl]methyl]-5-methylpyrazol-3-yl]-1,2,3,4-tetrahydroisoquinoline-6-carboxamide, SCD gene inhibitor targeting SCD
TE-15-RO34_10uM Dose=10uM, N-[1-[[5-chloro-2-(cyclopropylmethoxy)phenyl]methyl]-5-methylpyrazol-3-yl]-1,2,3,4-tetrahydroisoquinoline-6-carboxamide, SCD gene inhibitor targeting SCD
TE-15-RO34_1uM Dose=1uM, N-[1-[[5-chloro-2-(cyclopropylmethoxy)phenyl]methyl]-5-methylpyrazol-3-yl]-1,2,3,4-tetrahydroisoquinoline-6-carboxamide, SCD gene inhibitor targeting SCD
TE-16-VT54_0.01uM Dose=0.01uM, Atglistatin, Patatin like phospholipase protein inhibitor targeting PNPLA2
TE-16-VT54_0.1uM Dose=0.1uM, Atglistatin, Patatin like phospholipase protein inhibitor targeting PNPLA2
TE-16-VT54_10uM Dose=10uM, Atglistatin, Patatin like phospholipase protein inhibitor targeting PNPLA2
TE-16-VT54_1uM Dose=1uM, Atglistatin, Patatin like phospholipase protein inhibitor targeting PNPLA2
TE-25-NH87_0.1uM Dose=0.1uM, 3-(2-(naphthalen-2-ylmethyl)phenyl)-N-(thiophen-2-ylsulfonyl)acrylamide, Prostanoid EP3 Antagonists targeting PTGER3
TE-25-NH87_10uM Dose=10uM, 3-(2-(naphthalen-2-ylmethyl)phenyl)-N-(thiophen-2-ylsulfonyl)acrylamide, Prostanoid EP3 Antagonists targeting PTGER3
TE-25-NH87_1uM Dose=1uM, 3-(2-(naphthalen-2-ylmethyl)phenyl)-N-(thiophen-2-ylsulfonyl)acrylamide, Prostanoid EP3 Antagonists targeting PTGER3
TE-26-XS06_0.01uM Dose=0.01uM, Brivudine, Heat Shock Protein 27 (hsp27) Inhibitors;Reverse Transcriptase Inhibitors targeting HSPB1
TE-26-XS06_0.1uM Dose=0.1uM, Brivudine, Heat Shock Protein 27 (hsp27) Inhibitors;Reverse Transcriptase Inhibitors targeting HSPB1
TE-26-XS06_10uM Dose=10uM, Brivudine, Heat Shock Protein 27 (hsp27) Inhibitors;Reverse Transcriptase Inhibitors targeting HSPB1
TE-26-XS06_1uM Dose=1uM, Brivudine, Heat Shock Protein 27 (hsp27) Inhibitors;Reverse Transcriptase Inhibitors targeting HSPB1
TE-27-FF87_0.01uM Dose=0.01uM, 6-[(8-Benzyl-1,3-dioxo-2,8-diazaspiro[4.5]decan-2-yl)methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors;Cathepsin S Inhibitors targeting CTSK, CTSS
TE-27-FF87_0.1uM Dose=0.1uM, 6-[(8-Benzyl-1,3-dioxo-2,8-diazaspiro[4.5]decan-2-yl)methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors;Cathepsin S Inhibitors targeting CTSK, CTSS
TE-27-FF87_10uM Dose=10uM, 6-[(8-Benzyl-1,3-dioxo-2,8-diazaspiro[4.5]decan-2-yl)methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors;Cathepsin S Inhibitors targeting CTSK, CTSS
TE-27-FF87_1uM Dose=1uM, 6-[(8-Benzyl-1,3-dioxo-2,8-diazaspiro[4.5]decan-2-yl)methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors;Cathepsin S Inhibitors targeting CTSK, CTSS
TE-32-AC63_0.01uM Dose=0.01uM, Bay-299, Bromodomain inhibitor targeting TAF1, BRD1, TAF1L
TE-32-AC63_0.1uM Dose=0.1uM, Bay-299, Bromodomain inhibitor targeting TAF1, BRD1, TAF1L
TE-32-AC63_10uM Dose=10uM, Bay-299, Bromodomain inhibitor targeting TAF1, BRD1, TAF1L
TE-32-AC63_1uM Dose=1uM, Bay-299, Bromodomain inhibitor targeting TAF1, BRD1, TAF1L
TE-42-FZ03_0.01uM Dose=0.01uM
TE-42-FZ03_0.1uM Dose=0.1uM
TE-42-FZ03_10uM Dose=10uM
TE-42-FZ03_1uM Dose=1uM
TE-67-XP56_0.01uM Dose=0.01uM, Bms-561392, ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors) targeting ADAM17
TE-67-XP56_0.1uM Dose=0.1uM, Bms-561392, ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors) targeting ADAM17
TE-67-XP56_10uM Dose=10uM, Bms-561392, ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors) targeting ADAM17
TE-67-XP56_1uM Dose=1uM, Bms-561392, ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors) targeting ADAM17
TE-76-FI57_0.01uM Dose=0.01uM, N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(3-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2
TE-76-FI57_0.1uM Dose=0.1uM, N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(3-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2
TE-76-FI57_10uM Dose=10uM, N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(3-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2
TE-76-FI57_1uM Dose=1uM, N-[7-[1-[[2-(4-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-1-(3-chlorophenyl)sulfanyl-4-(dimethylamino)butan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide, Apoptosis Inducers;BCL2 gene inhibitor targeting BCL2
TE-87-FM14_0.01uM Dose=0.01uM, (2S)-2-amino-3-[4-(2-amino-6-phenylpyrimidin-4-yl)phenyl]propanoic acid
TE-87-FM14_0.1uM Dose=0.1uM, (2S)-2-amino-3-[4-(2-amino-6-phenylpyrimidin-4-yl)phenyl]propanoic acid
TE-87-FM14_10uM Dose=10uM, (2S)-2-amino-3-[4-(2-amino-6-phenylpyrimidin-4-yl)phenyl]propanoic acid
TE-87-FM14_1uM Dose=1uM, (2S)-2-amino-3-[4-(2-amino-6-phenylpyrimidin-4-yl)phenyl]propanoic acid
TF-04-RX73_0.01uM Dose=0.01uM, 3-[4-[2-Methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile
TF-04-RX73_0.1uM Dose=0.1uM, 3-[4-[2-Methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile
TF-04-RX73_10uM Dose=10uM, 3-[4-[2-Methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile
TF-04-RX73_1uM Dose=1uM, 3-[4-[2-Methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile
TF-09-RD17_0.01uM Dose=0.01uM, Avasimibe, ACAT Inhibitor targeting SOAT1, SOAT2
TF-09-RD17_0.1uM Dose=0.1uM, Avasimibe, ACAT Inhibitor targeting SOAT1, SOAT2
TF-09-RD17_10uM Dose=10uM, Avasimibe, ACAT Inhibitor targeting SOAT1, SOAT2
TF-09-RD17_1uM Dose=1uM, Avasimibe, ACAT Inhibitor targeting SOAT1, SOAT2
TF-23-DD23_0.01uM Dose=0.01uM, PF-4708671, Antagonist of S6K targeting RPS6KB1
TF-23-DD23_0.1uM Dose=0.1uM, PF-4708671, Antagonist of S6K targeting RPS6KB1
TF-23-DD23_10uM Dose=10uM, PF-4708671, Antagonist of S6K targeting RPS6KB1
TF-23-DD23_1uM Dose=1uM, PF-4708671, Antagonist of S6K targeting RPS6KB1
TF-29-QU48_0.01uM Dose=0.01uM
TF-29-QU48_10uM Dose=10uM
TF-29-QU48_1uM Dose=1uM
TF-36-BS66_0.01uM Dose=0.01uM, (3S,8S,9S,10R,13S,14S,17R)-17-[(2S)-1-hydroxypropan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol, Cholesterol Biosynthesis Inhibitors; Delta(24)-Sterol Reductase (DHCR24) Inhibitors targeting DHCR24
TF-36-BS66_0.1uM Dose=0.1uM, (3S,8S,9S,10R,13S,14S,17R)-17-[(2S)-1-hydroxypropan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol, Cholesterol Biosynthesis Inhibitors; Delta(24)-Sterol Reductase (DHCR24) Inhibitors targeting DHCR24
TF-36-BS66_10uM Dose=10uM, (3S,8S,9S,10R,13S,14S,17R)-17-[(2S)-1-hydroxypropan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol, Cholesterol Biosynthesis Inhibitors; Delta(24)-Sterol Reductase (DHCR24) Inhibitors targeting DHCR24
TF-36-BS66_1uM Dose=1uM, (3S,8S,9S,10R,13S,14S,17R)-17-[(2S)-1-hydroxypropan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol, Cholesterol Biosynthesis Inhibitors; Delta(24)-Sterol Reductase (DHCR24) Inhibitors targeting DHCR24
TF-43-DT71_0.01uM Dose=0.01uM
TF-43-DT71_0.1uM Dose=0.1uM
TF-43-DT71_10uM Dose=10uM
TF-43-DT71_1uM Dose=1uM
TF-60-NH65_0.01uM Dose=0.01uM, Insulin Secretagogues;K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9
TF-60-NH65_0.1uM Dose=0.1uM, Insulin Secretagogues;K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9
TF-60-NH65_10uM Dose=10uM, Insulin Secretagogues;K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9
TF-77-DW08_0.01uM Dose=0.01uM, 3-[5-(4-chlorophenyl)-6-methoxyimidazo[1,2-b]isoindol-5-yl]-N,N-diethylpropanamide, Neuropeptide S Receptor 1 (NPSR1) Antagonists;NPSR1 antagonist targeting NPSR1
TF-77-DW08_0.1uM Dose=0.1uM, 3-[5-(4-chlorophenyl)-6-methoxyimidazo[1,2-b]isoindol-5-yl]-N,N-diethylpropanamide, Neuropeptide S Receptor 1 (NPSR1) Antagonists;NPSR1 antagonist targeting NPSR1
TF-77-DW08_10uM Dose=10uM, 3-[5-(4-chlorophenyl)-6-methoxyimidazo[1,2-b]isoindol-5-yl]-N,N-diethylpropanamide, Neuropeptide S Receptor 1 (NPSR1) Antagonists;NPSR1 antagonist targeting NPSR1
TF-77-DW08_1uM Dose=1uM, 3-[5-(4-chlorophenyl)-6-methoxyimidazo[1,2-b]isoindol-5-yl]-N,N-diethylpropanamide, Neuropeptide S Receptor 1 (NPSR1) Antagonists;NPSR1 antagonist targeting NPSR1
UA-06-UV98_0.01uM Dose=0.01uM, Tandutinib, Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Angiogenesis Inhibitors;PDGFRbeta Inhibitors targeting FLT3, KIT, PDGFRB
UA-06-UV98_0.1uM Dose=0.1uM, Tandutinib, Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Angiogenesis Inhibitors;PDGFRbeta Inhibitors targeting FLT3, KIT, PDGFRB
UA-06-UV98_10uM Dose=10uM, Tandutinib, Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Angiogenesis Inhibitors;PDGFRbeta Inhibitors targeting FLT3, KIT, PDGFRB
UA-06-UV98_1uM Dose=1uM, Tandutinib, Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Angiogenesis Inhibitors;PDGFRbeta Inhibitors targeting FLT3, KIT, PDGFRB
UA-17-QS18_0.01uM Dose=0.01uM, (2S)-2-[[1-[(4-aminophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-4-cyclohexylbutanoic acid, AGTR2 antagonist targeting AGTR2
UA-17-QS18_0.1uM Dose=0.1uM, (2S)-2-[[1-[(4-aminophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-4-cyclohexylbutanoic acid, AGTR2 antagonist targeting AGTR2
UA-17-QS18_10uM Dose=10uM, (2S)-2-[[1-[(4-aminophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-4-cyclohexylbutanoic acid, AGTR2 antagonist targeting AGTR2
UA-17-QS18_1uM Dose=1uM, (2S)-2-[[1-[(4-aminophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-4-cyclohexylbutanoic acid, AGTR2 antagonist targeting AGTR2
UA-20-YK17_0.01uM Dose=0.01uM, (2R)-1-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-3,3,3-trifluoro-2-hydroxy-2-methylpropan-1-one, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
UA-20-YK17_0.1uM Dose=0.1uM, (2R)-1-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-3,3,3-trifluoro-2-hydroxy-2-methylpropan-1-one, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
UA-20-YK17_10uM Dose=10uM, (2R)-1-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-3,3,3-trifluoro-2-hydroxy-2-methylpropan-1-one, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
UA-20-YK17_1uM Dose=1uM, (2R)-1-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-3,3,3-trifluoro-2-hydroxy-2-methylpropan-1-one, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
UA-25-LA05_0.01uM Dose=0.01uM, N-(4-aminobutyl)-5-chloronaphthalene-1-sulfonamide
UA-25-LA05_0.1uM Dose=0.1uM, N-(4-aminobutyl)-5-chloronaphthalene-1-sulfonamide
UA-25-LA05_10uM Dose=10uM, N-(4-aminobutyl)-5-chloronaphthalene-1-sulfonamide
UA-25-LA05_1uM Dose=1uM, N-(4-aminobutyl)-5-chloronaphthalene-1-sulfonamide
UA-39-TN76_0.01uM Dose=0.01uM, Cindunistat, Inositol Monophosphatase Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators targeting IMPA1, NOS2
UA-39-TN76_0.1uM Dose=0.1uM, Cindunistat, Inositol Monophosphatase Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators targeting IMPA1, NOS2
UA-39-TN76_10uM Dose=10uM, Cindunistat, Inositol Monophosphatase Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators targeting IMPA1, NOS2
UA-39-TN76_1uM Dose=1uM, Cindunistat, Inositol Monophosphatase Inhibitors;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators targeting IMPA1, NOS2
UA-44-EN14_0.01uM Dose=0.01uM, Cyclohexyl[4-(2-naphthalenylsulfonyl)-1-piperazinyl]methanone
UA-44-EN14_0.1uM Dose=0.1uM, Cyclohexyl[4-(2-naphthalenylsulfonyl)-1-piperazinyl]methanone
UA-44-EN14_10uM Dose=10uM, Cyclohexyl[4-(2-naphthalenylsulfonyl)-1-piperazinyl]methanone
UA-44-EN14_1uM Dose=1uM, Cyclohexyl[4-(2-naphthalenylsulfonyl)-1-piperazinyl]methanone
UA-56-RO11_0.01uM Dose=0.01uM, N2-[(1S,2R)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethylpurine-2,6-diamine, CDK inhibitor targeting CDK1, CDK2, CCNA1, CCNB2, CCNB3
UA-56-RO11_0.1uM Dose=0.1uM, N2-[(1S,2R)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethylpurine-2,6-diamine, CDK inhibitor targeting CDK1, CDK2, CCNA1, CCNB2, CCNB3
UA-56-RO11_10uM Dose=10uM, N2-[(1S,2R)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethylpurine-2,6-diamine, CDK inhibitor targeting CDK1, CDK2, CCNA1, CCNB2, CCNB3
UA-56-RO11_1uM Dose=1uM, N2-[(1S,2R)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-ethylpurine-2,6-diamine, CDK inhibitor targeting CDK1, CDK2, CCNA1, CCNB2, CCNB3
UA-91-HL97_0.01uM Dose=0.01uM
UA-91-HL97_0.1uM Dose=0.1uM
UA-91-HL97_10uM Dose=10uM
UA-91-HL97_1uM Dose=1uM
UB-21-MV06_0.01uM Dose=0.01uM, 7-amino-6-(1H-benzo[d]imidazol-2-yl)-3H-imidazo[4,5-b]pyridin-5(4H)-one, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK
UB-21-MV06_0.1uM Dose=0.1uM, 7-amino-6-(1H-benzo[d]imidazol-2-yl)-3H-imidazo[4,5-b]pyridin-5(4H)-one, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK
UB-21-MV06_10uM Dose=10uM, 7-amino-6-(1H-benzo[d]imidazol-2-yl)-3H-imidazo[4,5-b]pyridin-5(4H)-one, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK
UB-21-MV06_1uM Dose=1uM, 7-amino-6-(1H-benzo[d]imidazol-2-yl)-3H-imidazo[4,5-b]pyridin-5(4H)-one, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK
UB-28-WW60_0.01uM Dose=0.01uM, 6-(Trifluoromethyl)-1,2-benzoxazol-3-ol
UB-28-WW60_0.1uM Dose=0.1uM, 6-(Trifluoromethyl)-1,2-benzoxazol-3-ol
UB-28-WW60_10uM Dose=10uM, 6-(Trifluoromethyl)-1,2-benzoxazol-3-ol
UB-28-WW60_1uM Dose=1uM, 6-(Trifluoromethyl)-1,2-benzoxazol-3-ol
UB-30-TL20_0.1uM Dose=0.1uM, 1-Amino-4-[4-(2,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid targeting P2RY4
UB-30-TL20_10uM Dose=10uM, 1-Amino-4-[4-(2,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid targeting P2RY4
UB-30-TL20_1uM Dose=1uM, 1-Amino-4-[4-(2,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid targeting P2RY4
UB-40-KU41_0.01uM Dose=0.01uM, (1R,2S,3R,4S)-4-(6-amino-2-anilinopurin-9-yl)-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
UB-40-KU41_0.1uM Dose=0.1uM, (1R,2S,3R,4S)-4-(6-amino-2-anilinopurin-9-yl)-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
UB-40-KU41_10uM Dose=10uM, (1R,2S,3R,4S)-4-(6-amino-2-anilinopurin-9-yl)-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
UB-40-KU41_1uM Dose=1uM, (1R,2S,3R,4S)-4-(6-amino-2-anilinopurin-9-yl)-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
UB-40-NK72_0.01uM Dose=0.01uM
UB-40-NK72_0.1uM Dose=0.1uM
UB-40-NK72_10uM Dose=10uM
UB-40-NK72_1uM Dose=1uM
UB-41-DY23_0.01uM Dose=0.01uM
UB-41-DY23_0.1uM Dose=0.1uM
UB-41-DY23_10uM Dose=10uM
UB-41-DY23_1uM Dose=1uM
UB-62-DF90_0.01uM Dose=0.01uM
UB-62-DF90_0.1uM Dose=0.1uM
UB-62-DF90_10uM Dose=10uM
UB-62-DF90_1uM Dose=1uM
UB-76-QL04_0.01uM Dose=0.01uM, 3-[[2-[6-(2-methoxyethylamino)pyrimidin-4-yl]-1,2,4-triazol-3-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide
UB-76-QL04_0.1uM Dose=0.1uM, 3-[[2-[6-(2-methoxyethylamino)pyrimidin-4-yl]-1,2,4-triazol-3-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide
UB-76-QL04_10uM Dose=10uM, 3-[[2-[6-(2-methoxyethylamino)pyrimidin-4-yl]-1,2,4-triazol-3-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide
UB-76-QL04_1uM Dose=1uM, 3-[[2-[6-(2-methoxyethylamino)pyrimidin-4-yl]-1,2,4-triazol-3-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide
UB-79-KN96_0.01uM Dose=0.01uM
UB-79-KN96_0.1uM Dose=0.1uM
UB-79-KN96_10uM Dose=10uM
UB-83-HM84_0.01uM Dose=0.01uM, Dexamethasone Pivalate
UB-83-HM84_0.1uM Dose=0.1uM, Dexamethasone Pivalate
UB-83-HM84_10uM Dose=10uM, Dexamethasone Pivalate
UB-83-HM84_1uM Dose=1uM, Dexamethasone Pivalate
UB-90-TA33_0.01uM Dose=0.01uM, 4-Tert-butyl-2-[[4-[(5-fluoropyridin-3-yl)methyl]phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile
UB-90-TA33_0.1uM Dose=0.1uM, 4-Tert-butyl-2-[[4-[(5-fluoropyridin-3-yl)methyl]phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile
UB-90-TA33_10uM Dose=10uM, 4-Tert-butyl-2-[[4-[(5-fluoropyridin-3-yl)methyl]phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile
UB-90-TA33_1uM Dose=1uM, 4-Tert-butyl-2-[[4-[(5-fluoropyridin-3-yl)methyl]phthalazin-1-yl]amino]-1,3-thiazole-5-carbonitrile
UC-00-QA88_0.01uM Dose=0.01uM, 2-[4-(4-Amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]ethanol
UC-00-QA88_0.1uM Dose=0.1uM, 2-[4-(4-Amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]ethanol
UC-00-QA88_10uM Dose=10uM, 2-[4-(4-Amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]ethanol
UC-00-QA88_1uM Dose=1uM, 2-[4-(4-Amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]ethanol
UC-19-KX65_0.01uM Dose=0.01uM
UC-19-KX65_0.1uM Dose=0.1uM
UC-19-KX65_10uM Dose=10uM
UC-19-KX65_1uM Dose=1uM
UC-20-ZV24_0.01uM Dose=0.01uM, R(+)-Butylindazone, Erythrocyte Cl- transport system inhibitor targeting SLC12A4
UC-20-ZV24_0.1uM Dose=0.1uM, R(+)-Butylindazone, Erythrocyte Cl- transport system inhibitor targeting SLC12A4
UC-20-ZV24_10uM Dose=10uM, R(+)-Butylindazone, Erythrocyte Cl- transport system inhibitor targeting SLC12A4
UC-20-ZV24_1uM Dose=1uM, R(+)-Butylindazone, Erythrocyte Cl- transport system inhibitor targeting SLC12A4
UC-21-PY73_0.01uM Dose=0.01uM, Ro 46-2005, Endothelin Receptor Antagonists targeting EDNRA, EDNRB
UC-21-PY73_0.1uM Dose=0.1uM, Ro 46-2005, Endothelin Receptor Antagonists targeting EDNRA, EDNRB
UC-21-PY73_10uM Dose=10uM, Ro 46-2005, Endothelin Receptor Antagonists targeting EDNRA, EDNRB
UC-21-PY73_1uM Dose=1uM, Ro 46-2005, Endothelin Receptor Antagonists targeting EDNRA, EDNRB
UC-38-AA43_0.01uM Dose=0.01uM, 4-methyl-2-(5-oxo-1-(4-(trifluoromethyl)benzyl)-1H-1,2,4-triazol-4(5H)-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
UC-38-AA43_0.1uM Dose=0.1uM, 4-methyl-2-(5-oxo-1-(4-(trifluoromethyl)benzyl)-1H-1,2,4-triazol-4(5H)-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
UC-38-AA43_10uM Dose=10uM, 4-methyl-2-(5-oxo-1-(4-(trifluoromethyl)benzyl)-1H-1,2,4-triazol-4(5H)-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
UC-38-AA43_1uM Dose=1uM, 4-methyl-2-(5-oxo-1-(4-(trifluoromethyl)benzyl)-1H-1,2,4-triazol-4(5H)-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD
UC-48-CW55_0.01uM Dose=0.01uM
UC-48-CW55_0.1uM Dose=0.1uM
UC-48-CW55_10uM Dose=10uM
UC-52-SS41_0.01uM Dose=0.01uM, 1-(3-(Naphth-2-ylmethoxy)phenyl)-1-(thiazol-2-yl)propyl methyl ether, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
UC-52-SS41_0.1uM Dose=0.1uM, 1-(3-(Naphth-2-ylmethoxy)phenyl)-1-(thiazol-2-yl)propyl methyl ether, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
UC-52-SS41_10uM Dose=10uM, 1-(3-(Naphth-2-ylmethoxy)phenyl)-1-(thiazol-2-yl)propyl methyl ether, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
UC-52-SS41_1uM Dose=1uM, 1-(3-(Naphth-2-ylmethoxy)phenyl)-1-(thiazol-2-yl)propyl methyl ether, Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
UC-58-DM11_0.1uM Dose=0.1uM, Pozanicline, Nicotinic Receptor Partial Agonists targeting CHRNA4, CHRNB2
UC-58-DM11_10uM Dose=10uM, Pozanicline, Nicotinic Receptor Partial Agonists targeting CHRNA4, CHRNB2
UC-58-DM11_1uM Dose=1uM, Pozanicline, Nicotinic Receptor Partial Agonists targeting CHRNA4, CHRNB2
UC-68-LC67_0.01uM Dose=0.01uM, N-Cyclopropyl-N-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine, Known USP14 inhibitor targeting USP14
UC-68-LC67_0.1uM Dose=0.1uM, N-Cyclopropyl-N-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine, Known USP14 inhibitor targeting USP14
UC-68-LC67_10uM Dose=10uM, N-Cyclopropyl-N-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine, Known USP14 inhibitor targeting USP14
UC-68-LC67_1uM Dose=1uM, N-Cyclopropyl-N-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine, Known USP14 inhibitor targeting USP14
UC-80-UO92_0.01uM Dose=0.01uM, Momipp, Methuosis inducer targeting PIKFYVE, PIP5K1C
UC-80-UO92_0.1uM Dose=0.1uM, Momipp, Methuosis inducer targeting PIKFYVE, PIP5K1C
UC-80-UO92_10uM Dose=10uM, Momipp, Methuosis inducer targeting PIKFYVE, PIP5K1C
UC-80-UO92_1uM Dose=1uM, Momipp, Methuosis inducer targeting PIKFYVE, PIP5K1C
UC-83-VC55_0.01uM Dose=0.01uM, N-[4-(trifluoromethyl)phenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
UC-83-VC55_0.1uM Dose=0.1uM, N-[4-(trifluoromethyl)phenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
UC-83-VC55_1uM Dose=1uM, N-[4-(trifluoromethyl)phenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
UD-03-SW43_0.01uM Dose=0.01uM
UD-03-SW43_0.1uM Dose=0.1uM
UD-03-SW43_10uM Dose=10uM
UD-03-SW43_1uM Dose=1uM
UD-04-WN64_0.01uM Dose=0.01uM, [1-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperidin-4-yl] N-tert-butylcarbamate
UD-04-WN64_0.1uM Dose=0.1uM, [1-[6-[6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]piperidin-4-yl] N-tert-butylcarbamate
UD-07-US73_0.01uM Dose=0.01uM, (15E)-4-(4-hydroxyphenyl)-7-(1H-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone, Actin stabilizer targeting ACTB
UD-07-US73_0.1uM Dose=0.1uM, (15E)-4-(4-hydroxyphenyl)-7-(1H-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone, Actin stabilizer targeting ACTB
UD-07-US73_10uM Dose=10uM, (15E)-4-(4-hydroxyphenyl)-7-(1H-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone, Actin stabilizer targeting ACTB
UD-07-US73_1uM Dose=1uM, (15E)-4-(4-hydroxyphenyl)-7-(1H-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone, Actin stabilizer targeting ACTB
UD-09-TN01_0.01uM Dose=0.01uM, Anta XV, Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
UD-09-TN01_0.1uM Dose=0.1uM, Anta XV, Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
UD-09-TN01_10uM Dose=10uM, Anta XV, Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
UD-09-TN01_1uM Dose=1uM, Anta XV, Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
UD-16-YL39_0.01uM Dose=0.01uM, 3-amino-N-(5-benzoyl-2-piperazin-1-ylphenyl)pyrazine-2-carboxamide
UD-16-YL39_0.1uM Dose=0.1uM, 3-amino-N-(5-benzoyl-2-piperazin-1-ylphenyl)pyrazine-2-carboxamide
UD-16-YL39_10uM Dose=10uM, 3-amino-N-(5-benzoyl-2-piperazin-1-ylphenyl)pyrazine-2-carboxamide
UD-16-YL39_1uM Dose=1uM, 3-amino-N-(5-benzoyl-2-piperazin-1-ylphenyl)pyrazine-2-carboxamide
UD-20-ER54_0.01uM Dose=0.01uM, Paprazine, uncompetitive inhibitor targeting GAA
UD-20-ER54_0.1uM Dose=0.1uM, Paprazine, uncompetitive inhibitor targeting GAA
UD-20-ER54_10uM Dose=10uM, Paprazine, uncompetitive inhibitor targeting GAA
UD-20-ER54_1uM Dose=1uM, Paprazine, uncompetitive inhibitor targeting GAA
UD-27-FS48_0.01uM Dose=0.01uM, Neuropeptide Y1 (NPY Y1) Antagonists;NPY1R antagonist targeting NPY1R
UD-27-FS48_10uM Dose=10uM, Neuropeptide Y1 (NPY Y1) Antagonists;NPY1R antagonist targeting NPY1R
UD-27-FS48_1uM Dose=1uM, Neuropeptide Y1 (NPY Y1) Antagonists;NPY1R antagonist targeting NPY1R
UD-49-HQ53_0.01uM Dose=0.01uM, 6-[(1S)-1-hydroxy-2-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methoxypyridine-3-carbonitrile, KCNJ1 inhibitor;KCNJ1 gene inhibitor targeting KCNJ1
UD-49-HQ53_0.1uM Dose=0.1uM, 6-[(1S)-1-hydroxy-2-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methoxypyridine-3-carbonitrile, KCNJ1 inhibitor;KCNJ1 gene inhibitor targeting KCNJ1
UD-49-HQ53_10uM Dose=10uM, 6-[(1S)-1-hydroxy-2-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methoxypyridine-3-carbonitrile, KCNJ1 inhibitor;KCNJ1 gene inhibitor targeting KCNJ1
UD-49-HQ53_1uM Dose=1uM, 6-[(1S)-1-hydroxy-2-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methoxypyridine-3-carbonitrile, KCNJ1 inhibitor;KCNJ1 gene inhibitor targeting KCNJ1
UD-50-IU51_0.01uM Dose=0.01uM, Geranyl biphosphonate
UD-50-IU51_0.1uM Dose=0.1uM, Geranyl biphosphonate
UD-50-IU51_10uM Dose=10uM, Geranyl biphosphonate
UD-50-IU51_1uM Dose=1uM, Geranyl biphosphonate
UD-70-IO77_0.1uM Dose=0.1uM, 1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, PDE10A inhibitor targeting PDE10A
UD-70-IO77_10uM Dose=10uM, 1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, PDE10A inhibitor targeting PDE10A
UD-70-IO77_1uM Dose=1uM, 1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, PDE10A inhibitor targeting PDE10A
UD-78-YQ06_0.01uM Dose=0.01uM, CID 91826512, Tip60 (KAT5) inhibitor targeting KAT5
UD-78-YQ06_0.1uM Dose=0.1uM, CID 91826512, Tip60 (KAT5) inhibitor targeting KAT5
UD-78-YQ06_10uM Dose=10uM, CID 91826512, Tip60 (KAT5) inhibitor targeting KAT5
UD-78-YQ06_1uM Dose=1uM, CID 91826512, Tip60 (KAT5) inhibitor targeting KAT5
UD-85-WR81_0.01uM Dose=0.01uM, Gardiquimod
UD-85-WR81_0.1uM Dose=0.1uM, Gardiquimod
UD-85-WR81_10uM Dose=10uM, Gardiquimod
UD-85-WR81_1uM Dose=1uM, Gardiquimod
UD-99-XG44_0.01uM Dose=0.01uM, (1,2-Diphenyl-ethyl)-phosphonic acid
UD-99-XG44_0.1uM Dose=0.1uM, (1,2-Diphenyl-ethyl)-phosphonic acid
UD-99-XG44_10uM Dose=10uM, (1,2-Diphenyl-ethyl)-phosphonic acid
UD-99-XG44_1uM Dose=1uM, (1,2-Diphenyl-ethyl)-phosphonic acid
UE-01-HV71_0.01uM Dose=0.01uM
UE-01-HV71_0.1uM Dose=0.1uM
UE-01-HV71_10uM Dose=10uM
UE-01-HV71_1uM Dose=1uM
UE-02-UW61_0.01uM Dose=0.01uM, 4-Methyl-1-(1h-Pyrazol-4-Ylmethyl)-5-[(4-{[6-(2,2,2-Trifluoroethyl)thieno[2,3-D]pyrimidin-4-Yl]amino}piperidin-1-Yl)methyl]-1h-Indole-2-Carbonitrile, Menin inhibitor targeting MEN1
UE-02-UW61_0.1uM Dose=0.1uM, 4-Methyl-1-(1h-Pyrazol-4-Ylmethyl)-5-[(4-{[6-(2,2,2-Trifluoroethyl)thieno[2,3-D]pyrimidin-4-Yl]amino}piperidin-1-Yl)methyl]-1h-Indole-2-Carbonitrile, Menin inhibitor targeting MEN1
UE-02-UW61_10uM Dose=10uM, 4-Methyl-1-(1h-Pyrazol-4-Ylmethyl)-5-[(4-{[6-(2,2,2-Trifluoroethyl)thieno[2,3-D]pyrimidin-4-Yl]amino}piperidin-1-Yl)methyl]-1h-Indole-2-Carbonitrile, Menin inhibitor targeting MEN1
UE-02-UW61_1uM Dose=1uM, 4-Methyl-1-(1h-Pyrazol-4-Ylmethyl)-5-[(4-{[6-(2,2,2-Trifluoroethyl)thieno[2,3-D]pyrimidin-4-Yl]amino}piperidin-1-Yl)methyl]-1h-Indole-2-Carbonitrile, Menin inhibitor targeting MEN1
UE-09-SD17_0.01uM Dose=0.01uM
UE-09-SD17_0.1uM Dose=0.1uM
UE-09-SD17_10uM Dose=10uM
UE-09-SD17_1uM Dose=1uM
UE-13-LK75_0.01uM Dose=0.01uM, RN486, reversible BTK inhibitor targeting BTK
UE-13-LK75_0.1uM Dose=0.1uM, RN486, reversible BTK inhibitor targeting BTK
UE-13-LK75_10uM Dose=10uM, RN486, reversible BTK inhibitor targeting BTK
UE-13-LK75_1uM Dose=1uM, RN486, reversible BTK inhibitor targeting BTK
UE-20-KA68_0.01uM Dose=0.01uM, Z-FA-Fmk, Cathepsin B Inhibitors targeting CTSB
UE-20-KA68_0.1uM Dose=0.1uM, Z-FA-Fmk, Cathepsin B Inhibitors targeting CTSB
UE-20-KA68_10uM Dose=10uM, Z-FA-Fmk, Cathepsin B Inhibitors targeting CTSB
UE-20-KA68_1uM Dose=1uM, Z-FA-Fmk, Cathepsin B Inhibitors targeting CTSB
UE-41-CL72_0.01uM Dose=0.01uM, N-(7-hydroxy-1-naphthyl)-N'-[3-(methylthio)phenyl]urea, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting P2RX1, TRPV1
UE-41-CL72_0.1uM Dose=0.1uM, N-(7-hydroxy-1-naphthyl)-N'-[3-(methylthio)phenyl]urea, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting P2RX1, TRPV1
UE-41-CL72_10uM Dose=10uM, N-(7-hydroxy-1-naphthyl)-N'-[3-(methylthio)phenyl]urea, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting P2RX1, TRPV1
UE-41-CL72_1uM Dose=1uM, N-(7-hydroxy-1-naphthyl)-N'-[3-(methylthio)phenyl]urea, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting P2RX1, TRPV1
UE-50-KK32_0.1uM Dose=0.1uM, 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile
UE-50-KK32_10uM Dose=10uM, 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile
UE-50-KK32_1uM Dose=1uM, 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile
UE-58-EW15_0.01uM Dose=0.01uM, (E)-1-(4-Hydroxy-3,5-dimethoxyphenyl)-7-phenylhept-1-en-3-one, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
UE-58-EW15_0.1uM Dose=0.1uM, (E)-1-(4-Hydroxy-3,5-dimethoxyphenyl)-7-phenylhept-1-en-3-one, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
UE-58-EW15_10uM Dose=10uM, (E)-1-(4-Hydroxy-3,5-dimethoxyphenyl)-7-phenylhept-1-en-3-one, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
UE-58-EW15_1uM Dose=1uM, (E)-1-(4-Hydroxy-3,5-dimethoxyphenyl)-7-phenylhept-1-en-3-one, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5
UE-76-JL04_0.01uM Dose=0.01uM
UE-76-JL04_0.1uM Dose=0.1uM
UE-76-JL04_10uM Dose=10uM
UE-76-JL04_1uM Dose=1uM
UE-78-EW35_0.01uM Dose=0.01uM, 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole, HTR2A antagonist targeting HTR2A
UE-78-EW35_0.1uM Dose=0.1uM, 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole, HTR2A antagonist targeting HTR2A
UE-78-EW35_10uM Dose=10uM, 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole, HTR2A antagonist targeting HTR2A
UE-78-EW35_1uM Dose=1uM, 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole, HTR2A antagonist targeting HTR2A
UE-90-AA63_0.01uM Dose=0.01uM
UE-90-AA63_0.1uM Dose=0.1uM
UE-90-AA63_10uM Dose=10uM
UE-90-AA63_1uM Dose=1uM
UE-90-KK72_0.01uM Dose=0.01uM
UE-90-KK72_0.1uM Dose=0.1uM
UE-90-KK72_10uM Dose=10uM
UE-90-KK72_1uM Dose=1uM
UE-91-YV71_0.01uM Dose=0.01uM
UE-91-YV71_0.1uM Dose=0.1uM
UE-91-YV71_10uM Dose=10uM
UE-99-BK94_0.01uM Dose=0.01uM, 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide, KCNK3 gene inhibitor targeting KCNK3
UE-99-BK94_0.1uM Dose=0.1uM, 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide, KCNK3 gene inhibitor targeting KCNK3
UE-99-BK94_10uM Dose=10uM, 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide, KCNK3 gene inhibitor targeting KCNK3
UE-99-BK94_1uM Dose=1uM, 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide, KCNK3 gene inhibitor targeting KCNK3
UF-06-JB00_0.1uM Dose=0.1uM, ethyl N-[4-[(E)-3-(4-morpholin-4-ylquinolin-2-yl)prop-2-enoyl]phenyl]carbamate, TNF-alpha Production Inhibitors;Heat Shock Protein 70 (hsp70) Inducers targeting HSPA1A
UF-06-JB00_10uM Dose=10uM, ethyl N-[4-[(E)-3-(4-morpholin-4-ylquinolin-2-yl)prop-2-enoyl]phenyl]carbamate, TNF-alpha Production Inhibitors;Heat Shock Protein 70 (hsp70) Inducers targeting HSPA1A
UF-06-JB00_1uM Dose=1uM, ethyl N-[4-[(E)-3-(4-morpholin-4-ylquinolin-2-yl)prop-2-enoyl]phenyl]carbamate, TNF-alpha Production Inhibitors;Heat Shock Protein 70 (hsp70) Inducers targeting HSPA1A
UF-14-LK87_0.01uM Dose=0.01uM, Metformin, inhibitor of mitochondrial complex I of the electron transport chain;GPD2 gene modulator;adenine deaminase inhibitor;MTTP Inhibitor;mitochondrial repiratory chain 1 inhibitors;AMP-Activated Protein Kinase (AMPK) Activators targeting GPD2, MT-ND1
UF-14-LK87_0.1uM Dose=0.1uM, Metformin, inhibitor of mitochondrial complex I of the electron transport chain;GPD2 gene modulator;adenine deaminase inhibitor;MTTP Inhibitor;mitochondrial repiratory chain 1 inhibitors;AMP-Activated Protein Kinase (AMPK) Activators targeting GPD2, MT-ND1
UF-14-LK87_10uM Dose=10uM, Metformin, inhibitor of mitochondrial complex I of the electron transport chain;GPD2 gene modulator;adenine deaminase inhibitor;MTTP Inhibitor;mitochondrial repiratory chain 1 inhibitors;AMP-Activated Protein Kinase (AMPK) Activators targeting GPD2, MT-ND1
UF-14-LK87_1uM Dose=1uM, Metformin, inhibitor of mitochondrial complex I of the electron transport chain;GPD2 gene modulator;adenine deaminase inhibitor;MTTP Inhibitor;mitochondrial repiratory chain 1 inhibitors;AMP-Activated Protein Kinase (AMPK) Activators targeting GPD2, MT-ND1
UF-27-HS98_0.01uM Dose=0.01uM, Toyocamycin targeting ADK
UF-27-HS98_0.1uM Dose=0.1uM, Toyocamycin targeting ADK
UF-27-HS98_10uM Dose=10uM, Toyocamycin targeting ADK
UF-27-HS98_1uM Dose=1uM, Toyocamycin targeting ADK
UF-27-OP66_0.01uM Dose=0.01uM, 5-[3-(4-Chlorophenyl)-1H-Indazol-5-Yl]-2H-1,2,3,4-Tetrazole, SAPK1a (JNK2) Inhibitors targeting MAPK9
UF-27-OP66_0.1uM Dose=0.1uM, 5-[3-(4-Chlorophenyl)-1H-Indazol-5-Yl]-2H-1,2,3,4-Tetrazole, SAPK1a (JNK2) Inhibitors targeting MAPK9
UF-27-OP66_10uM Dose=10uM, 5-[3-(4-Chlorophenyl)-1H-Indazol-5-Yl]-2H-1,2,3,4-Tetrazole, SAPK1a (JNK2) Inhibitors targeting MAPK9
UF-28-DW05_0.01uM Dose=0.01uM, 5-[3-(5-aminopentyl)-5-(1H-indol-3-ylmethyl)-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(4-aminophenoxy)benzonitrile, Somatostatin SRIF1A (sst2) Agonists targeting SSTR2
UF-28-DW05_0.1uM Dose=0.1uM, 5-[3-(5-aminopentyl)-5-(1H-indol-3-ylmethyl)-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(4-aminophenoxy)benzonitrile, Somatostatin SRIF1A (sst2) Agonists targeting SSTR2
UF-28-DW05_10uM Dose=10uM, 5-[3-(5-aminopentyl)-5-(1H-indol-3-ylmethyl)-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(4-aminophenoxy)benzonitrile, Somatostatin SRIF1A (sst2) Agonists targeting SSTR2
UF-28-DW05_1uM Dose=1uM, 5-[3-(5-aminopentyl)-5-(1H-indol-3-ylmethyl)-2,4-dioxoimidazolidin-1-yl]sulfonyl-2-(4-aminophenoxy)benzonitrile, Somatostatin SRIF1A (sst2) Agonists targeting SSTR2
UF-43-HT41_0.01uM Dose=0.01uM, (S)-3,4-Dcpg, mgluR8 Agonists targeting GRM8
UF-43-HT41_0.1uM Dose=0.1uM, (S)-3,4-Dcpg, mgluR8 Agonists targeting GRM8
UF-43-HT41_10uM Dose=10uM, (S)-3,4-Dcpg, mgluR8 Agonists targeting GRM8
UF-43-HT41_1uM Dose=1uM, (S)-3,4-Dcpg, mgluR8 Agonists targeting GRM8
UF-44-NQ36_0.01uM Dose=0.01uM, Argipressin tannate, AVPR1A agonist targeting AVPR1A
UF-44-NQ36_0.1uM Dose=0.1uM, Argipressin tannate, AVPR1A agonist targeting AVPR1A
UF-44-NQ36_10uM Dose=10uM, Argipressin tannate, AVPR1A agonist targeting AVPR1A
UF-44-NQ36_1uM Dose=1uM, Argipressin tannate, AVPR1A agonist targeting AVPR1A
UF-55-NA30_0.01uM Dose=0.01uM, 3-[[2-(3-Aminophenyl)-[1,3]oxazolo[5,4-d]pyrimidin-7-yl]amino]phenol
UF-55-NA30_0.1uM Dose=0.1uM, 3-[[2-(3-Aminophenyl)-[1,3]oxazolo[5,4-d]pyrimidin-7-yl]amino]phenol
UF-55-NA30_10uM Dose=10uM, 3-[[2-(3-Aminophenyl)-[1,3]oxazolo[5,4-d]pyrimidin-7-yl]amino]phenol
UF-55-NA30_1uM Dose=1uM, 3-[[2-(3-Aminophenyl)-[1,3]oxazolo[5,4-d]pyrimidin-7-yl]amino]phenol
UF-61-QB73_0.01uM Dose=0.01uM, (S)-1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropan-1-ol, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors targeting CYP17A1
UF-61-QB73_0.1uM Dose=0.1uM, (S)-1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropan-1-ol, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors targeting CYP17A1
UF-61-QB73_1uM Dose=1uM, (S)-1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropan-1-ol, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors targeting CYP17A1
UF-85-NE30_0.01uM Dose=0.01uM, 2-[4-[7-Fluoro-2-(hydroxymethyl)-8-(2-methoxy-4-pyridin-2-yloxyphenyl)imidazo[4,5-c]quinolin-1-yl]piperidin-1-yl]acetonitrile
UF-85-NE30_0.1uM Dose=0.1uM, 2-[4-[7-Fluoro-2-(hydroxymethyl)-8-(2-methoxy-4-pyridin-2-yloxyphenyl)imidazo[4,5-c]quinolin-1-yl]piperidin-1-yl]acetonitrile
UF-85-NE30_10uM Dose=10uM, 2-[4-[7-Fluoro-2-(hydroxymethyl)-8-(2-methoxy-4-pyridin-2-yloxyphenyl)imidazo[4,5-c]quinolin-1-yl]piperidin-1-yl]acetonitrile
UF-85-NE30_1uM Dose=1uM, 2-[4-[7-Fluoro-2-(hydroxymethyl)-8-(2-methoxy-4-pyridin-2-yloxyphenyl)imidazo[4,5-c]quinolin-1-yl]piperidin-1-yl]acetonitrile
UF-86-ME07_0.01uM Dose=0.01uM, 2-Mercaptoethylguanidine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Cyclooxygenase (COX) Inhibitors;Antiinflammatory Drugs;Free Radical Scavengers targeting NOS2
UF-86-ME07_0.1uM Dose=0.1uM, 2-Mercaptoethylguanidine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Cyclooxygenase (COX) Inhibitors;Antiinflammatory Drugs;Free Radical Scavengers targeting NOS2
UF-86-ME07_10uM Dose=10uM, 2-Mercaptoethylguanidine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Cyclooxygenase (COX) Inhibitors;Antiinflammatory Drugs;Free Radical Scavengers targeting NOS2
UF-86-ME07_1uM Dose=1uM, 2-Mercaptoethylguanidine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Cyclooxygenase (COX) Inhibitors;Antiinflammatory Drugs;Free Radical Scavengers targeting NOS2
UF-98-OM26_0.01uM Dose=0.01uM, (S)-2-(2-Chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid, Cell Adhesion Inhibitors;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4
UF-98-OM26_0.1uM Dose=0.1uM, (S)-2-(2-Chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid, Cell Adhesion Inhibitors;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4
UF-98-OM26_10uM Dose=10uM, (S)-2-(2-Chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid, Cell Adhesion Inhibitors;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4
UF-98-OM26_1uM Dose=1uM, (S)-2-(2-Chloro-6-methylbenzamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid, Cell Adhesion Inhibitors;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4
VA-03-RM19_0.01uM Dose=0.01uM, N-[(3R)-3-(Dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide, 5-hydroxytryptamine receptor 1F receptor agonist targeting HTR1F
VA-03-RM19_0.1uM Dose=0.1uM, N-[(3R)-3-(Dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide, 5-hydroxytryptamine receptor 1F receptor agonist targeting HTR1F
VA-03-RM19_10uM Dose=10uM, N-[(3R)-3-(Dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide, 5-hydroxytryptamine receptor 1F receptor agonist targeting HTR1F
VA-03-RM19_1uM Dose=1uM, N-[(3R)-3-(Dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide, 5-hydroxytryptamine receptor 1F receptor agonist targeting HTR1F
VA-06-DB75_0.01uM Dose=0.01uM, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA
VA-06-DB75_0.1uM Dose=0.1uM, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA
VA-06-DB75_10uM Dose=10uM, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA
VA-06-DB75_1uM Dose=1uM, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA
VA-11-NO89_0.01uM Dose=0.01uM, 6-Hydroxy-1,3-benzothiazole-2-sulfonamide, Carbonic anhydrase type I inhibitor;carbonic anhydrase type II inhibitor targeting CA1, CA4, CA5A, CA5B, CA3, CA8, CA11, CA10
VA-11-NO89_0.1uM Dose=0.1uM, 6-Hydroxy-1,3-benzothiazole-2-sulfonamide, Carbonic anhydrase type I inhibitor;carbonic anhydrase type II inhibitor targeting CA1, CA4, CA5A, CA5B, CA3, CA8, CA11, CA10
VA-11-NO89_10uM Dose=10uM, 6-Hydroxy-1,3-benzothiazole-2-sulfonamide, Carbonic anhydrase type I inhibitor;carbonic anhydrase type II inhibitor targeting CA1, CA4, CA5A, CA5B, CA3, CA8, CA11, CA10
VA-11-NO89_1uM Dose=1uM, 6-Hydroxy-1,3-benzothiazole-2-sulfonamide, Carbonic anhydrase type I inhibitor;carbonic anhydrase type II inhibitor targeting CA1, CA4, CA5A, CA5B, CA3, CA8, CA11, CA10
VA-15-ZR21_0.01uM Dose=0.01uM
VA-15-ZR21_0.1uM Dose=0.1uM
VA-15-ZR21_10uM Dose=10uM
VA-15-ZR21_1uM Dose=1uM
VA-19-EX85_0.01uM Dose=0.01uM, CID 71716944, Bcl-2 Inhibitors;Apoptosis Inducers targeting BCL2
VA-19-EX85_0.1uM Dose=0.1uM, CID 71716944, Bcl-2 Inhibitors;Apoptosis Inducers targeting BCL2
VA-19-EX85_10uM Dose=10uM, CID 71716944, Bcl-2 Inhibitors;Apoptosis Inducers targeting BCL2
VA-19-EX85_1uM Dose=1uM, CID 71716944, Bcl-2 Inhibitors;Apoptosis Inducers targeting BCL2
VA-27-OT56_0.01uM Dose=0.01uM
VA-27-OT56_0.1uM Dose=0.1uM
VA-27-OT56_10uM Dose=10uM
VA-27-OT56_1uM Dose=1uM
VA-39-AQ18_0.01uM Dose=0.01uM, (2S)-2-Amino-N-[(2R)-1-(4-butanoyl-4-phenylpiperidin-1-yl)-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(3-methylimidazol-4-yl)propanamide, Melanocortin MC1 Receptor Agonists targeting MC1R
VA-39-AQ18_0.1uM Dose=0.1uM, (2S)-2-Amino-N-[(2R)-1-(4-butanoyl-4-phenylpiperidin-1-yl)-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(3-methylimidazol-4-yl)propanamide, Melanocortin MC1 Receptor Agonists targeting MC1R
VA-39-AQ18_10uM Dose=10uM, (2S)-2-Amino-N-[(2R)-1-(4-butanoyl-4-phenylpiperidin-1-yl)-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(3-methylimidazol-4-yl)propanamide, Melanocortin MC1 Receptor Agonists targeting MC1R
VA-39-AQ18_1uM Dose=1uM, (2S)-2-Amino-N-[(2R)-1-(4-butanoyl-4-phenylpiperidin-1-yl)-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(3-methylimidazol-4-yl)propanamide, Melanocortin MC1 Receptor Agonists targeting MC1R
VA-48-RJ44_0.01uM Dose=0.01uM, N-((6 (hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide, HDAC 4/5 targeting HDAC4, HDAC5
VA-48-RJ44_0.1uM Dose=0.1uM, N-((6 (hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide, HDAC 4/5 targeting HDAC4, HDAC5
VA-48-RJ44_10uM Dose=10uM, N-((6 (hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide, HDAC 4/5 targeting HDAC4, HDAC5
VA-48-RJ44_1uM Dose=1uM, N-((6 (hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide, HDAC 4/5 targeting HDAC4, HDAC5
VA-48-TW80_0.01uM Dose=0.01uM, GABA receptor ligand targeting GABRA2
VA-48-TW80_0.1uM Dose=0.1uM, GABA receptor ligand targeting GABRA2
VA-48-TW80_10uM Dose=10uM, GABA receptor ligand targeting GABRA2
VA-48-TW80_1uM Dose=1uM, GABA receptor ligand targeting GABRA2
VA-57-TF22_0.01uM Dose=0.01uM
VA-57-TF22_0.1uM Dose=0.1uM
VA-57-TF22_10uM Dose=10uM
VA-57-TF22_1uM Dose=1uM
VA-71-JY23_0.01uM Dose=0.01uM
VA-71-JY23_0.1uM Dose=0.1uM
VA-71-JY23_10uM Dose=10uM
VA-71-JY23_1uM Dose=1uM
VA-82-XZ88_0.1uM Dose=0.1uM
VA-84-EQ91_0.01uM Dose=0.01uM, [(2R,3R,5R,10S,11R,12R,13R,14S,17R)-2,3,11-trihydroxy-4,4,10,13-tetramethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-12-yl] acetate, Elastase Inhibitors targeting PI3
VA-84-EQ91_0.1uM Dose=0.1uM, [(2R,3R,5R,10S,11R,12R,13R,14S,17R)-2,3,11-trihydroxy-4,4,10,13-tetramethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-12-yl] acetate, Elastase Inhibitors targeting PI3
VA-84-EQ91_10uM Dose=10uM, [(2R,3R,5R,10S,11R,12R,13R,14S,17R)-2,3,11-trihydroxy-4,4,10,13-tetramethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-12-yl] acetate, Elastase Inhibitors targeting PI3
VA-84-EQ91_1uM Dose=1uM, [(2R,3R,5R,10S,11R,12R,13R,14S,17R)-2,3,11-trihydroxy-4,4,10,13-tetramethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-12-yl] acetate, Elastase Inhibitors targeting PI3
VA-92-QP54_0.01uM Dose=0.01uM, Picropodophyllin, CASP3 activator;Apoptosis Inducers;IGF-1R Inhibitors;Caspase 3 Activators;apoptosis inhibitor;IGF1R inhibitor targeting CASP3, IGF1R
VA-92-QP54_0.1uM Dose=0.1uM, Picropodophyllin, CASP3 activator;Apoptosis Inducers;IGF-1R Inhibitors;Caspase 3 Activators;apoptosis inhibitor;IGF1R inhibitor targeting CASP3, IGF1R
VA-92-QP54_10uM Dose=10uM, Picropodophyllin, CASP3 activator;Apoptosis Inducers;IGF-1R Inhibitors;Caspase 3 Activators;apoptosis inhibitor;IGF1R inhibitor targeting CASP3, IGF1R
VA-92-QP54_1uM Dose=1uM, Picropodophyllin, CASP3 activator;Apoptosis Inducers;IGF-1R Inhibitors;Caspase 3 Activators;apoptosis inhibitor;IGF1R inhibitor targeting CASP3, IGF1R
VB-27-PZ25_0.01uM Dose=0.01uM, 4-(3-bromophenyl)-1H-1,2,3-triazole, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2
VB-27-PZ25_0.1uM Dose=0.1uM, 4-(3-bromophenyl)-1H-1,2,3-triazole, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2
VB-27-PZ25_10uM Dose=10uM, 4-(3-bromophenyl)-1H-1,2,3-triazole, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2
VB-27-PZ25_1uM Dose=1uM, 4-(3-bromophenyl)-1H-1,2,3-triazole, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2
VB-48-KG22_0.01uM Dose=0.01uM, 6,8-Dimercapto-2-hydroxypurine
VB-48-KG22_0.1uM Dose=0.1uM, 6,8-Dimercapto-2-hydroxypurine
VB-48-KG22_10uM Dose=10uM, 6,8-Dimercapto-2-hydroxypurine
VB-48-KG22_1uM Dose=1uM, 6,8-Dimercapto-2-hydroxypurine
VB-76-UE47_0.01uM Dose=0.01uM
VB-76-UE47_0.1uM Dose=0.1uM
VB-76-UE47_10uM Dose=10uM
VB-76-UE47_1uM Dose=1uM
VB-88-YT38_0.1uM Dose=0.1uM
VB-88-YT38_1uM Dose=1uM
VB-89-RG34_0.01uM Dose=0.01uM, [(2R)-2-amino-2-methyl-4-[4-[3-(4-phenylphenyl)propanoyl]phenyl]butyl] dihydrogen phosphate, Lysophospholipid Receptor Agonists targeting S1PR1, S1PR5
VB-89-RG34_0.1uM Dose=0.1uM, [(2R)-2-amino-2-methyl-4-[4-[3-(4-phenylphenyl)propanoyl]phenyl]butyl] dihydrogen phosphate, Lysophospholipid Receptor Agonists targeting S1PR1, S1PR5
VB-89-RG34_10uM Dose=10uM, [(2R)-2-amino-2-methyl-4-[4-[3-(4-phenylphenyl)propanoyl]phenyl]butyl] dihydrogen phosphate, Lysophospholipid Receptor Agonists targeting S1PR1, S1PR5
VB-89-RG34_1uM Dose=1uM, [(2R)-2-amino-2-methyl-4-[4-[3-(4-phenylphenyl)propanoyl]phenyl]butyl] dihydrogen phosphate, Lysophospholipid Receptor Agonists targeting S1PR1, S1PR5
VB-92-JQ72_0.01uM Dose=0.01uM, N-[1-[[1-(2-fluoroethyl)piperidin-4-yl]-phenylmethyl]pyrazol-4-yl]-6,6-dimethyl-1,4,5,7-tetrahydroindazole-3-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK
VB-92-JQ72_0.1uM Dose=0.1uM, N-[1-[[1-(2-fluoroethyl)piperidin-4-yl]-phenylmethyl]pyrazol-4-yl]-6,6-dimethyl-1,4,5,7-tetrahydroindazole-3-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK
VB-92-JQ72_10uM Dose=10uM, N-[1-[[1-(2-fluoroethyl)piperidin-4-yl]-phenylmethyl]pyrazol-4-yl]-6,6-dimethyl-1,4,5,7-tetrahydroindazole-3-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK
VB-92-JQ72_1uM Dose=1uM, N-[1-[[1-(2-fluoroethyl)piperidin-4-yl]-phenylmethyl]pyrazol-4-yl]-6,6-dimethyl-1,4,5,7-tetrahydroindazole-3-carboxamide, ITK (EMT) Kinase Inhibitors targeting ITK
VC-14-ND05_0.1uM Dose=0.1uM, 2-[(1H-Benzotriazol-6-ylamino)methyl]-4,6-dichloro-phenol
VC-14-ND05_10uM Dose=10uM, 2-[(1H-Benzotriazol-6-ylamino)methyl]-4,6-dichloro-phenol
VC-14-ND05_1uM Dose=1uM, 2-[(1H-Benzotriazol-6-ylamino)methyl]-4,6-dichloro-phenol
VC-19-YG34_0.01uM Dose=0.01uM, 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, Flt3 (FLK2/STK1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting CHUK, FLT3, IKBKB, IKBKG
VC-19-YG34_0.1uM Dose=0.1uM, 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, Flt3 (FLK2/STK1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting CHUK, FLT3, IKBKB, IKBKG
VC-19-YG34_10uM Dose=10uM, 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, Flt3 (FLK2/STK1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting CHUK, FLT3, IKBKB, IKBKG
VC-19-YG34_1uM Dose=1uM, 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, Flt3 (FLK2/STK1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting CHUK, FLT3, IKBKB, IKBKG
VC-30-QH05_0.01uM Dose=0.01uM, Zucapsaicin, TRPV1 (Vanilloid VR1 Receptor) Agonists targeting TRPV1
VC-30-QH05_0.1uM Dose=0.1uM, Zucapsaicin, TRPV1 (Vanilloid VR1 Receptor) Agonists targeting TRPV1
VC-30-QH05_10uM Dose=10uM, Zucapsaicin, TRPV1 (Vanilloid VR1 Receptor) Agonists targeting TRPV1
VC-30-QH05_1uM Dose=1uM, Zucapsaicin, TRPV1 (Vanilloid VR1 Receptor) Agonists targeting TRPV1
VC-79-JG59_0.01uM Dose=0.01uM, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-(dimethylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, PYK2 inhibitor targeting PTK2B
VC-79-JG59_0.1uM Dose=0.1uM, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-(dimethylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, PYK2 inhibitor targeting PTK2B
VC-79-JG59_10uM Dose=10uM, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-(dimethylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, PYK2 inhibitor targeting PTK2B
VC-79-JG59_1uM Dose=1uM, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-(dimethylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, PYK2 inhibitor targeting PTK2B
VC-94-CG67_0.01uM Dose=0.01uM
VC-94-CG67_0.1uM Dose=0.1uM
VC-94-CG67_10uM Dose=10uM
VC-94-CG67_1uM Dose=1uM
VD-08-TC47_0.01uM Dose=0.01uM, Tesaglitazar, PPARgamma Agonists;Insulin Sensitizers;PPARalpha Agonists targeting PPARA, PPARG
VD-08-TC47_0.1uM Dose=0.1uM, Tesaglitazar, PPARgamma Agonists;Insulin Sensitizers;PPARalpha Agonists targeting PPARA, PPARG
VD-08-TC47_10uM Dose=10uM, Tesaglitazar, PPARgamma Agonists;Insulin Sensitizers;PPARalpha Agonists targeting PPARA, PPARG
VD-08-TC47_1uM Dose=1uM, Tesaglitazar, PPARgamma Agonists;Insulin Sensitizers;PPARalpha Agonists targeting PPARA, PPARG
VD-08-YA83_0.01uM Dose=0.01uM
VD-08-YA83_0.1uM Dose=0.1uM
VD-08-YA83_10uM Dose=10uM
VD-08-YA83_1uM Dose=1uM
VD-09-SX75_0.01uM Dose=0.01uM
VD-09-SX75_0.1uM Dose=0.1uM
VD-09-SX75_10uM Dose=10uM
VD-14-CD80_0.01uM Dose=0.01uM, 6-Chloro-5-methyl-N-(quinolin-5-yl)indoline-1-carboxamide, 5-HT2B Antagonists targeting HTR2B
VD-14-CD80_10uM Dose=10uM, 6-Chloro-5-methyl-N-(quinolin-5-yl)indoline-1-carboxamide, 5-HT2B Antagonists targeting HTR2B
VD-14-CD80_1uM Dose=1uM, 6-Chloro-5-methyl-N-(quinolin-5-yl)indoline-1-carboxamide, 5-HT2B Antagonists targeting HTR2B
VD-20-SR39_0.01uM Dose=0.01uM, 4-{[4-(2,4-Difluorophenyl)-1,3-thiazol-2-yl]amino}phenol
VD-20-SR39_0.1uM Dose=0.1uM, 4-{[4-(2,4-Difluorophenyl)-1,3-thiazol-2-yl]amino}phenol
VD-20-SR39_10uM Dose=10uM, 4-{[4-(2,4-Difluorophenyl)-1,3-thiazol-2-yl]amino}phenol
VD-20-SR39_1uM Dose=1uM, 4-{[4-(2,4-Difluorophenyl)-1,3-thiazol-2-yl]amino}phenol
VD-41-XP62_0.01uM Dose=0.01uM, 3-fluoro-N'-(2-fluorobenzenesulfonyl)-5-(pyridin-2-yl)benzohydrazide targeting KAT6A, KAT6B
VD-41-XP62_0.1uM Dose=0.1uM, 3-fluoro-N'-(2-fluorobenzenesulfonyl)-5-(pyridin-2-yl)benzohydrazide targeting KAT6A, KAT6B
VD-41-XP62_10uM Dose=10uM, 3-fluoro-N'-(2-fluorobenzenesulfonyl)-5-(pyridin-2-yl)benzohydrazide targeting KAT6A, KAT6B
VD-41-XP62_1uM Dose=1uM, 3-fluoro-N'-(2-fluorobenzenesulfonyl)-5-(pyridin-2-yl)benzohydrazide targeting KAT6A, KAT6B
VD-76-SO91_0.01uM Dose=0.01uM, N-[3,5-Bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)-5-pyrimidinecarboxamide, NF-kappaB (NFKB) Activation Inhibitors;Antiinflammatory Drugs targeting NFKB1
VD-76-SO91_0.1uM Dose=0.1uM, N-[3,5-Bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)-5-pyrimidinecarboxamide, NF-kappaB (NFKB) Activation Inhibitors;Antiinflammatory Drugs targeting NFKB1
VD-76-SO91_10uM Dose=10uM, N-[3,5-Bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)-5-pyrimidinecarboxamide, NF-kappaB (NFKB) Activation Inhibitors;Antiinflammatory Drugs targeting NFKB1
VD-76-SO91_1uM Dose=1uM, N-[3,5-Bis(trifluoromethyl)phenyl]-2-chloro-4-(trifluoromethyl)-5-pyrimidinecarboxamide, NF-kappaB (NFKB) Activation Inhibitors;Antiinflammatory Drugs targeting NFKB1
VD-88-MW70_0.1uM Dose=0.1uM, [4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine, CDK Inhibitor;Pan Kinase Inhibitor targeting CDK2, CCNE2
VD-88-MW70_10uM Dose=10uM, [4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine, CDK Inhibitor;Pan Kinase Inhibitor targeting CDK2, CCNE2
VD-88-MW70_1uM Dose=1uM, [4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine, CDK Inhibitor;Pan Kinase Inhibitor targeting CDK2, CCNE2
VE-11-PV61_0.01uM Dose=0.01uM, Tak-259, Orally Active α1D Adrenoceptor targeting ADRA1D
VE-11-PV61_0.1uM Dose=0.1uM, Tak-259, Orally Active α1D Adrenoceptor targeting ADRA1D
VE-11-PV61_10uM Dose=10uM, Tak-259, Orally Active α1D Adrenoceptor targeting ADRA1D
VE-11-PV61_1uM Dose=1uM, Tak-259, Orally Active α1D Adrenoceptor targeting ADRA1D
VE-15-RK04_0.01uM Dose=0.01uM, Eudistomin N targeting CHUK
VE-15-RK04_10uM Dose=10uM, Eudistomin N targeting CHUK
VE-15-RK04_1uM Dose=1uM, Eudistomin N targeting CHUK
VE-22-XI52_0.01uM Dose=0.01uM, 4-((4-((4-Chlorophenyl)amino)phthalazin-1-yl)methyl)-N-methylpicolinamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR
VE-22-XI52_0.1uM Dose=0.1uM, 4-((4-((4-Chlorophenyl)amino)phthalazin-1-yl)methyl)-N-methylpicolinamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR
VE-22-XI52_10uM Dose=10uM, 4-((4-((4-Chlorophenyl)amino)phthalazin-1-yl)methyl)-N-methylpicolinamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR
VE-22-XI52_1uM Dose=1uM, 4-((4-((4-Chlorophenyl)amino)phthalazin-1-yl)methyl)-N-methylpicolinamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR
VE-23-IJ47_0.01uM Dose=0.01uM
VE-23-IJ47_0.1uM Dose=0.1uM
VE-28-FM71_0.01uM Dose=0.01uM, 1-(4-chlorophenyl)-4-(piperidin-1-yl)-1H-imidazol-2(5H)-one, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA4, GABRA5, GABRA3, GABRA6, GABRG1, GABRG2, GABRG3
VE-28-FM71_0.1uM Dose=0.1uM, 1-(4-chlorophenyl)-4-(piperidin-1-yl)-1H-imidazol-2(5H)-one, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA4, GABRA5, GABRA3, GABRA6, GABRG1, GABRG2, GABRG3
VE-28-FM71_10uM Dose=10uM, 1-(4-chlorophenyl)-4-(piperidin-1-yl)-1H-imidazol-2(5H)-one, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA4, GABRA5, GABRA3, GABRA6, GABRG1, GABRG2, GABRG3
VE-28-FM71_1uM Dose=1uM, 1-(4-chlorophenyl)-4-(piperidin-1-yl)-1H-imidazol-2(5H)-one, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA4, GABRA5, GABRA3, GABRA6, GABRG1, GABRG2, GABRG3
VE-33-MT21_0.01uM Dose=0.01uM, Gdc-0834, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
VE-33-MT21_0.1uM Dose=0.1uM, Gdc-0834, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
VE-33-MT21_10uM Dose=10uM, Gdc-0834, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
VE-33-MT21_1uM Dose=1uM, Gdc-0834, Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK
VE-46-XV53_0.01uM Dose=0.01uM, LY466195 Diethyl ester prodrug
VE-46-XV53_0.1uM Dose=0.1uM, LY466195 Diethyl ester prodrug
VE-46-XV53_10uM Dose=10uM, LY466195 Diethyl ester prodrug
VE-46-XV53_1uM Dose=1uM, LY466195 Diethyl ester prodrug
VE-59-SD17_0.01uM Dose=0.01uM, (3-(((6-Phenyl-5-(p-tolyl)pyridin-2-yl)methyl)amino)propyl)phosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists targeting S1PR1, S1PR3
VE-59-SD17_0.1uM Dose=0.1uM, (3-(((6-Phenyl-5-(p-tolyl)pyridin-2-yl)methyl)amino)propyl)phosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists targeting S1PR1, S1PR3
VE-59-SD17_10uM Dose=10uM, (3-(((6-Phenyl-5-(p-tolyl)pyridin-2-yl)methyl)amino)propyl)phosphonic acid, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Antagonists targeting S1PR1, S1PR3
VE-88-XW30_0.01uM Dose=0.01uM
VE-88-XW30_0.1uM Dose=0.1uM
VE-88-XW30_10uM Dose=10uM
VF-03-AC40_0.01uM Dose=0.01uM, 3-chloro-N-[(E)-[1-[4-(trifluoromethoxy)phenyl]pyrrol-2-yl]methylideneamino]-5-(trifluoromethyl)pyridin-2-amine
VF-03-AC40_0.1uM Dose=0.1uM, 3-chloro-N-[(E)-[1-[4-(trifluoromethoxy)phenyl]pyrrol-2-yl]methylideneamino]-5-(trifluoromethyl)pyridin-2-amine
VF-03-AC40_10uM Dose=10uM, 3-chloro-N-[(E)-[1-[4-(trifluoromethoxy)phenyl]pyrrol-2-yl]methylideneamino]-5-(trifluoromethyl)pyridin-2-amine
VF-03-AC40_1uM Dose=1uM, 3-chloro-N-[(E)-[1-[4-(trifluoromethoxy)phenyl]pyrrol-2-yl]methylideneamino]-5-(trifluoromethyl)pyridin-2-amine
VF-06-RV33_0.01uM Dose=0.01uM, 3-[(4-chlorophenyl)methyl]-4-methyl-5,7-bis(2H-tetrazol-5-ylmethoxy)chromen-2-one targeting PLN
VF-06-RV33_0.1uM Dose=0.1uM, 3-[(4-chlorophenyl)methyl]-4-methyl-5,7-bis(2H-tetrazol-5-ylmethoxy)chromen-2-one targeting PLN
VF-06-RV33_10uM Dose=10uM, 3-[(4-chlorophenyl)methyl]-4-methyl-5,7-bis(2H-tetrazol-5-ylmethoxy)chromen-2-one targeting PLN
VF-06-RV33_1uM Dose=1uM, 3-[(4-chlorophenyl)methyl]-4-methyl-5,7-bis(2H-tetrazol-5-ylmethoxy)chromen-2-one targeting PLN
VF-07-NP76_0.01uM Dose=0.01uM, (2s)-N-[4-[3-Cyano-1-[(3,5-Dimethyl-1,2-Oxazol-4-Yl)methyl]indol-5-Yl]oxyphenyl]pyrrolidine-2-Carboxamide, PFKFB3 inhibitor;inhibition of PFKFB3 leads to inhibition of glycolysis targeting PFKFB3
VF-07-NP76_0.1uM Dose=0.1uM, (2s)-N-[4-[3-Cyano-1-[(3,5-Dimethyl-1,2-Oxazol-4-Yl)methyl]indol-5-Yl]oxyphenyl]pyrrolidine-2-Carboxamide, PFKFB3 inhibitor;inhibition of PFKFB3 leads to inhibition of glycolysis targeting PFKFB3
VF-07-NP76_10uM Dose=10uM, (2s)-N-[4-[3-Cyano-1-[(3,5-Dimethyl-1,2-Oxazol-4-Yl)methyl]indol-5-Yl]oxyphenyl]pyrrolidine-2-Carboxamide, PFKFB3 inhibitor;inhibition of PFKFB3 leads to inhibition of glycolysis targeting PFKFB3
VF-07-NP76_1uM Dose=1uM, (2s)-N-[4-[3-Cyano-1-[(3,5-Dimethyl-1,2-Oxazol-4-Yl)methyl]indol-5-Yl]oxyphenyl]pyrrolidine-2-Carboxamide, PFKFB3 inhibitor;inhibition of PFKFB3 leads to inhibition of glycolysis targeting PFKFB3
VF-12-MF80_0.01uM Dose=0.01uM, 2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide, Adenosine A2B Agonists targeting ADORA2B
VF-12-MF80_0.1uM Dose=0.1uM, 2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide, Adenosine A2B Agonists targeting ADORA2B
VF-12-MF80_10uM Dose=10uM, 2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide, Adenosine A2B Agonists targeting ADORA2B
VF-19-KA00_0.01uM Dose=0.01uM, Iso-1, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
VF-19-KA00_0.1uM Dose=0.1uM, Iso-1, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
VF-19-KA00_1uM Dose=1uM, Iso-1, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF
VF-20-LY76_0.01uM Dose=0.01uM, High Temperature Requirement A2 Inhibitor I, Omi/HtrA2 Inhibitor targeting HTRA2
VF-20-LY76_0.1uM Dose=0.1uM, High Temperature Requirement A2 Inhibitor I, Omi/HtrA2 Inhibitor targeting HTRA2
VF-20-LY76_10uM Dose=10uM, High Temperature Requirement A2 Inhibitor I, Omi/HtrA2 Inhibitor targeting HTRA2
VF-49-KA00_0.01uM Dose=0.01uM, 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde, ERN1 gene inhibitor targeting ERN1
VF-49-KA00_0.1uM Dose=0.1uM, 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde, ERN1 gene inhibitor targeting ERN1
VF-49-KA00_10uM Dose=10uM, 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde, ERN1 gene inhibitor targeting ERN1
VF-49-KA00_1uM Dose=1uM, 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde, ERN1 gene inhibitor targeting ERN1
VF-79-GQ03_0.01uM Dose=0.01uM
VF-79-GQ03_0.1uM Dose=0.1uM
VF-79-GQ03_10uM Dose=10uM
VF-79-GQ03_1uM Dose=1uM
WA-00-QY36_0.01uM Dose=0.01uM, US10189788, Example 7, Prostaglandin F2a receptor (PGF2a-DP aka PTGFR) antagnoist targeting PTGFR
WA-00-QY36_10uM Dose=10uM, US10189788, Example 7, Prostaglandin F2a receptor (PGF2a-DP aka PTGFR) antagnoist targeting PTGFR
WA-03-IF37_0.1uM Dose=0.1uM, 5-[[4-(3-bromo-4-ethylanilino)phthalazin-1-yl]methyl]-1H-pyridin-2-one, Cytochrome P450 CYP2C9 Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Angiogenesis Inhibitors targeting CYP2C9, CYP3A4, KDR, MUSK
WA-03-IF37_10uM Dose=10uM, 5-[[4-(3-bromo-4-ethylanilino)phthalazin-1-yl]methyl]-1H-pyridin-2-one, Cytochrome P450 CYP2C9 Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Angiogenesis Inhibitors targeting CYP2C9, CYP3A4, KDR, MUSK
WA-03-IF37_1uM Dose=1uM, 5-[[4-(3-bromo-4-ethylanilino)phthalazin-1-yl]methyl]-1H-pyridin-2-one, Cytochrome P450 CYP2C9 Inhibitors;Inhibitors of Signal Transduction Pathways;VEGFR Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Angiogenesis Inhibitors targeting CYP2C9, CYP3A4, KDR, MUSK
WA-03-KC95_0.01uM Dose=0.01uM, (2,6-Dimethylpyridin-4-yl)methyl tert-butylcarbamate, Leptin Receptor (OBR) Agonists targeting LEPR
WA-03-KC95_0.1uM Dose=0.1uM, (2,6-Dimethylpyridin-4-yl)methyl tert-butylcarbamate, Leptin Receptor (OBR) Agonists targeting LEPR
WA-03-KC95_10uM Dose=10uM, (2,6-Dimethylpyridin-4-yl)methyl tert-butylcarbamate, Leptin Receptor (OBR) Agonists targeting LEPR
WA-03-KC95_1uM Dose=1uM, (2,6-Dimethylpyridin-4-yl)methyl tert-butylcarbamate, Leptin Receptor (OBR) Agonists targeting LEPR
WA-06-QR58_0.01uM Dose=0.01uM, [(E)-(2-hydroxy-5-phenylphenyl)methylideneamino]thiourea targeting CDK5R1
WA-06-QR58_0.1uM Dose=0.1uM, [(E)-(2-hydroxy-5-phenylphenyl)methylideneamino]thiourea targeting CDK5R1
WA-06-QR58_10uM Dose=10uM, [(E)-(2-hydroxy-5-phenylphenyl)methylideneamino]thiourea targeting CDK5R1
WA-06-QR58_1uM Dose=1uM, [(E)-(2-hydroxy-5-phenylphenyl)methylideneamino]thiourea targeting CDK5R1
WA-15-KX40_0.01uM Dose=0.01uM
WA-15-KX40_0.1uM Dose=0.1uM
WA-15-KX40_10uM Dose=10uM
WA-15-KX40_1uM Dose=1uM
WA-36-EE47_0.01uM Dose=0.01uM, 1-{2-[1-(Aminomethyl)cyclohexyl]ethyl}-3-Isoquinolin-6-Ylurea, Allosteric PRMT3 inhibitor targeting PRMT3
WA-36-EE47_0.1uM Dose=0.1uM, 1-{2-[1-(Aminomethyl)cyclohexyl]ethyl}-3-Isoquinolin-6-Ylurea, Allosteric PRMT3 inhibitor targeting PRMT3
WA-36-EE47_10uM Dose=10uM, 1-{2-[1-(Aminomethyl)cyclohexyl]ethyl}-3-Isoquinolin-6-Ylurea, Allosteric PRMT3 inhibitor targeting PRMT3
WA-36-EE47_1uM Dose=1uM, 1-{2-[1-(Aminomethyl)cyclohexyl]ethyl}-3-Isoquinolin-6-Ylurea, Allosteric PRMT3 inhibitor targeting PRMT3
WA-43-MP01_0.01uM Dose=0.01uM, 2-phenyl-1,2-benzisothiazol-3-(2H)-one
WA-43-MP01_0.1uM Dose=0.1uM, 2-phenyl-1,2-benzisothiazol-3-(2H)-one
WA-43-MP01_10uM Dose=10uM, 2-phenyl-1,2-benzisothiazol-3-(2H)-one
WA-43-MP01_1uM Dose=1uM, 2-phenyl-1,2-benzisothiazol-3-(2H)-one
WA-45-ZD47_0.01uM Dose=0.01uM, (R)-2-(N-Benzyl-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide, Leukocyte Elastase Inhibitors targeting ELANE
WA-45-ZD47_0.1uM Dose=0.1uM, (R)-2-(N-Benzyl-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide, Leukocyte Elastase Inhibitors targeting ELANE
WA-45-ZD47_10uM Dose=10uM, (R)-2-(N-Benzyl-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide, Leukocyte Elastase Inhibitors targeting ELANE
WA-45-ZD47_1uM Dose=1uM, (R)-2-(N-Benzyl-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide, Leukocyte Elastase Inhibitors targeting ELANE
WA-53-FZ40_0.01uM Dose=0.01uM
WA-53-FZ40_0.1uM Dose=0.1uM
WA-53-FZ40_10uM Dose=10uM
WA-53-FZ40_1uM Dose=1uM
WA-62-RP29_0.01uM Dose=0.01uM, N4-methyl-N2-{2-methyl-1-[2-({3-methyl-3H-imidazo[4,5-b]pyridin-6-yl}oxy)phenyl]-1H-indol-6-yl}pyrimidine-2,4-diamine, Dot1L inhibitors targeting DOT1L
WA-62-RP29_0.1uM Dose=0.1uM, N4-methyl-N2-{2-methyl-1-[2-({3-methyl-3H-imidazo[4,5-b]pyridin-6-yl}oxy)phenyl]-1H-indol-6-yl}pyrimidine-2,4-diamine, Dot1L inhibitors targeting DOT1L
WA-62-RP29_10uM Dose=10uM, N4-methyl-N2-{2-methyl-1-[2-({3-methyl-3H-imidazo[4,5-b]pyridin-6-yl}oxy)phenyl]-1H-indol-6-yl}pyrimidine-2,4-diamine, Dot1L inhibitors targeting DOT1L
WA-62-RP29_1uM Dose=1uM, N4-methyl-N2-{2-methyl-1-[2-({3-methyl-3H-imidazo[4,5-b]pyridin-6-yl}oxy)phenyl]-1H-indol-6-yl}pyrimidine-2,4-diamine, Dot1L inhibitors targeting DOT1L
WA-80-EA43_0.01uM Dose=0.01uM, N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-3-methoxypyridin-2-yl]-3-fluoro-4-(5-methylfuran-2-yl)benzenesulfonamide, GHS Receptor Agonists targeting GHSR
WA-80-EA43_0.1uM Dose=0.1uM, N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-3-methoxypyridin-2-yl]-3-fluoro-4-(5-methylfuran-2-yl)benzenesulfonamide, GHS Receptor Agonists targeting GHSR
WA-80-EA43_10uM Dose=10uM, N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-3-methoxypyridin-2-yl]-3-fluoro-4-(5-methylfuran-2-yl)benzenesulfonamide, GHS Receptor Agonists targeting GHSR
WA-80-EA43_1uM Dose=1uM, N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-3-methoxypyridin-2-yl]-3-fluoro-4-(5-methylfuran-2-yl)benzenesulfonamide, GHS Receptor Agonists targeting GHSR
WA-90-HU51_0.01uM Dose=0.01uM, 4-oxo-2-pentyl-1H-quinoline-3-carboxylic acid, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
WA-90-HU51_10uM Dose=10uM, 4-oxo-2-pentyl-1H-quinoline-3-carboxylic acid, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
WA-90-HU51_1uM Dose=1uM, 4-oxo-2-pentyl-1H-quinoline-3-carboxylic acid, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1
WA-98-CM36_0.01uM Dose=0.01uM, 5-chloro-N-(5-chloro-2-hydroxy-phenyl)-2-methoxy-benzamide, KCNMA1 gene stimulator;BKca channel opener targeting KCNMA1
WA-98-CM36_10uM Dose=10uM, 5-chloro-N-(5-chloro-2-hydroxy-phenyl)-2-methoxy-benzamide, KCNMA1 gene stimulator;BKca channel opener targeting KCNMA1
WA-98-CM36_1uM Dose=1uM, 5-chloro-N-(5-chloro-2-hydroxy-phenyl)-2-methoxy-benzamide, KCNMA1 gene stimulator;BKca channel opener targeting KCNMA1
WB-17-DI74_0.01uM Dose=0.01uM, IV 2 compound, Thioredoxin 1 competitive irrreversible inhibitor targeting TXN, TXNRD1, TXNRD2
WB-17-DI74_0.1uM Dose=0.1uM, IV 2 compound, Thioredoxin 1 competitive irrreversible inhibitor targeting TXN, TXNRD1, TXNRD2
WB-17-DI74_10uM Dose=10uM, IV 2 compound, Thioredoxin 1 competitive irrreversible inhibitor targeting TXN, TXNRD1, TXNRD2
WB-17-DI74_1uM Dose=1uM, IV 2 compound, Thioredoxin 1 competitive irrreversible inhibitor targeting TXN, TXNRD1, TXNRD2
WB-33-KW88_0.01uM Dose=0.01uM
WB-33-KW88_0.1uM Dose=0.1uM
WB-33-KW88_1uM Dose=1uM
WB-38-DZ32_0.01uM Dose=0.01uM, Isatin Sulfonamide 34, Caspase 7 Inhibitors;Apoptosis Inhibitors;Caspase 3 Inhibitors targeting CASP3, CASP7
WB-38-DZ32_10uM Dose=10uM, Isatin Sulfonamide 34, Caspase 7 Inhibitors;Apoptosis Inhibitors;Caspase 3 Inhibitors targeting CASP3, CASP7
WB-38-DZ32_1uM Dose=1uM, Isatin Sulfonamide 34, Caspase 7 Inhibitors;Apoptosis Inhibitors;Caspase 3 Inhibitors targeting CASP3, CASP7
WB-43-IC00_0.01uM Dose=0.01uM, Opaganib, Sphingosine Kinase 2 (SphK2) Inhibitors;Angiogenesis Inhibitors targeting SPHK2
WB-43-IC00_10uM Dose=10uM, Opaganib, Sphingosine Kinase 2 (SphK2) Inhibitors;Angiogenesis Inhibitors targeting SPHK2
WB-43-IC00_1uM Dose=1uM, Opaganib, Sphingosine Kinase 2 (SphK2) Inhibitors;Angiogenesis Inhibitors targeting SPHK2
WB-44-AA73_0.01uM Dose=0.01uM, Known Tryptase inhibitor
WB-44-AA73_1uM Dose=1uM, Known Tryptase inhibitor
WB-47-FS93_0.01uM Dose=0.01uM, SecinH3, Cytohesin Inhibitors targeting CYTH2, CYTH1
WB-47-FS93_0.1uM Dose=0.1uM, SecinH3, Cytohesin Inhibitors targeting CYTH2, CYTH1
WB-47-FS93_1uM Dose=1uM, SecinH3, Cytohesin Inhibitors targeting CYTH2, CYTH1
WB-48-EF24_0.01uM Dose=0.01uM, Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1
WB-48-EF24_0.1uM Dose=0.1uM, Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1
WB-48-EF24_10uM Dose=10uM, Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1
WB-48-EF24_1uM Dose=1uM, Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1
WB-48-OF09_0.01uM Dose=0.01uM
WB-48-OF09_10uM Dose=10uM
WB-48-OF09_1uM Dose=1uM
WB-54-WD35_0.01uM Dose=0.01uM, Kdoam-25 targeting KDM5A, KDM5C, KDM5D, KDM5B
WB-54-WD35_0.1uM Dose=0.1uM, Kdoam-25 targeting KDM5A, KDM5C, KDM5D, KDM5B
WB-54-WD35_10uM Dose=10uM, Kdoam-25 targeting KDM5A, KDM5C, KDM5D, KDM5B
WB-54-WD35_1uM Dose=1uM, Kdoam-25 targeting KDM5A, KDM5C, KDM5D, KDM5B
WB-82-EL69_0.01uM Dose=0.01uM, [(4R,4aR,8aS)-2-[(2R)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone
WB-82-EL69_0.1uM Dose=0.1uM, [(4R,4aR,8aS)-2-[(2R)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone
WB-82-EL69_10uM Dose=10uM, [(4R,4aR,8aS)-2-[(2R)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone
WB-82-EL69_1uM Dose=1uM, [(4R,4aR,8aS)-2-[(2R)-3-(6-methoxypyridin-3-yl)-2-methylpropyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-4-yl]-[4-(3,4-difluorophenyl)piperazin-1-yl]methanone
WB-92-FB15_0.01uM Dose=0.01uM, (2S)-1-[2-(cyclopentylamino)acetyl]pyrrolidine-2-carbonitrile, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9
WB-92-FB15_0.1uM Dose=0.1uM, (2S)-1-[2-(cyclopentylamino)acetyl]pyrrolidine-2-carbonitrile, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9
WB-92-FB15_10uM Dose=10uM, (2S)-1-[2-(cyclopentylamino)acetyl]pyrrolidine-2-carbonitrile, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9
WB-92-FB15_1uM Dose=1uM, (2S)-1-[2-(cyclopentylamino)acetyl]pyrrolidine-2-carbonitrile, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9
WB-92-TT14_0.01uM Dose=0.01uM
WB-92-TT14_0.1uM Dose=0.1uM
WB-92-TT14_10uM Dose=10uM
WB-92-TT14_1uM Dose=1uM
WC-09-GD62_0.01uM Dose=0.01uM, CID 56946209, EIF4A1 gene inhibitor targeting EIF4A1
WC-09-GD62_0.1uM Dose=0.1uM, CID 56946209, EIF4A1 gene inhibitor targeting EIF4A1
WC-09-GD62_10uM Dose=10uM, CID 56946209, EIF4A1 gene inhibitor targeting EIF4A1
WC-09-GD62_1uM Dose=1uM, CID 56946209, EIF4A1 gene inhibitor targeting EIF4A1
WC-16-IR43_0.01uM Dose=0.01uM, (E)-N-hydroxy-3-[4-[(2-quinolin-3-ylethylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
WC-16-IR43_0.1uM Dose=0.1uM, (E)-N-hydroxy-3-[4-[(2-quinolin-3-ylethylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
WC-16-IR43_10uM Dose=10uM, (E)-N-hydroxy-3-[4-[(2-quinolin-3-ylethylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
WC-16-IR43_1uM Dose=1uM, (E)-N-hydroxy-3-[4-[(2-quinolin-3-ylethylamino)methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10
WC-22-DS16_0.01uM Dose=0.01uM, N-(1-phenylethyl)-3-tosylthieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine
WC-22-DS16_0.1uM Dose=0.1uM, N-(1-phenylethyl)-3-tosylthieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine
WC-22-DS16_10uM Dose=10uM, N-(1-phenylethyl)-3-tosylthieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine
WC-22-DS16_1uM Dose=1uM, N-(1-phenylethyl)-3-tosylthieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-amine
WC-23-DZ10_0.01uM Dose=0.01uM, 7-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine, Histamine H1 Receptor Ligands;Histamine H4 Receptor Agonists targeting HRH1, HRH4
WC-23-DZ10_10uM Dose=10uM, 7-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine, Histamine H1 Receptor Ligands;Histamine H4 Receptor Agonists targeting HRH1, HRH4
WC-23-DZ10_1uM Dose=1uM, 7-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine, Histamine H1 Receptor Ligands;Histamine H4 Receptor Agonists targeting HRH1, HRH4
WC-33-YP46_0.01uM Dose=0.01uM, 9-(1,3-benzodioxol-5-yl)-4-[2-hydroxy-3-[4-(2-methoxyethyl)piperazin-1-yl]propoxy]-6,7-dimethoxy-3H-benzo[f][2]benzofuran-1-one, pan cancer cell killer;Notch pathway inhibitor targeting ATP6V0A2
WC-33-YP46_0.1uM Dose=0.1uM, 9-(1,3-benzodioxol-5-yl)-4-[2-hydroxy-3-[4-(2-methoxyethyl)piperazin-1-yl]propoxy]-6,7-dimethoxy-3H-benzo[f][2]benzofuran-1-one, pan cancer cell killer;Notch pathway inhibitor targeting ATP6V0A2
WC-33-YP46_10uM Dose=10uM, 9-(1,3-benzodioxol-5-yl)-4-[2-hydroxy-3-[4-(2-methoxyethyl)piperazin-1-yl]propoxy]-6,7-dimethoxy-3H-benzo[f][2]benzofuran-1-one, pan cancer cell killer;Notch pathway inhibitor targeting ATP6V0A2
WC-33-YP46_1uM Dose=1uM, 9-(1,3-benzodioxol-5-yl)-4-[2-hydroxy-3-[4-(2-methoxyethyl)piperazin-1-yl]propoxy]-6,7-dimethoxy-3H-benzo[f][2]benzofuran-1-one, pan cancer cell killer;Notch pathway inhibitor targeting ATP6V0A2
WC-38-CZ02_0.01uM Dose=0.01uM, [3-(Hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol
WC-38-CZ02_0.1uM Dose=0.1uM, [3-(Hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol
WC-38-CZ02_10uM Dose=10uM, [3-(Hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol
WC-38-CZ02_1uM Dose=1uM, [3-(Hydroxymethyl)-5-[2-(6-methylpyridin-2-yl)ethynyl]phenyl]methanol
WC-49-TQ48_0.01uM Dose=0.01uM
WC-49-TQ48_0.1uM Dose=0.1uM
WC-49-TQ48_10uM Dose=10uM
WC-49-TQ48_1uM Dose=1uM
WC-54-BJ14_0.01uM Dose=0.01uM, Integrin-antagonist-1, ITGB6 antagonist targeting ITGA6, ITGB6
WC-54-BJ14_0.1uM Dose=0.1uM, Integrin-antagonist-1, ITGB6 antagonist targeting ITGA6, ITGB6
WC-54-BJ14_10uM Dose=10uM, Integrin-antagonist-1, ITGB6 antagonist targeting ITGA6, ITGB6
WC-54-BJ14_1uM Dose=1uM, Integrin-antagonist-1, ITGB6 antagonist targeting ITGA6, ITGB6
WC-59-RG09_0.01uM Dose=0.01uM, Osi-930, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors targeting ABL1, KDR, KIT, PDGFRB
WC-59-RG09_0.1uM Dose=0.1uM, Osi-930, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors targeting ABL1, KDR, KIT, PDGFRB
WC-59-RG09_10uM Dose=10uM, Osi-930, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors targeting ABL1, KDR, KIT, PDGFRB
WC-59-RG09_1uM Dose=1uM, Osi-930, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors targeting ABL1, KDR, KIT, PDGFRB
WC-67-DI84_0.01uM Dose=0.01uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
WC-67-DI84_0.1uM Dose=0.1uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
WC-67-DI84_10uM Dose=10uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
WC-67-DI84_1uM Dose=1uM, 6-(6-acetamidopyrimidin-4-yl)oxy-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
WC-75-IK59_0.01uM Dose=0.01uM, 8-(4-hydroxybutyl)-1-methyl-7-phenyl-1H-imidazo[1,2-a]purine-2,4(3H,8H)-dione, EphB4 Inhibitors targeting EPHB4
WC-75-IK59_0.1uM Dose=0.1uM, 8-(4-hydroxybutyl)-1-methyl-7-phenyl-1H-imidazo[1,2-a]purine-2,4(3H,8H)-dione, EphB4 Inhibitors targeting EPHB4
WC-75-IK59_10uM Dose=10uM, 8-(4-hydroxybutyl)-1-methyl-7-phenyl-1H-imidazo[1,2-a]purine-2,4(3H,8H)-dione, EphB4 Inhibitors targeting EPHB4
WC-81-BR91_0.01uM Dose=0.01uM, Bisanilinopyrimidine, 3d
WC-81-BR91_0.1uM Dose=0.1uM, Bisanilinopyrimidine, 3d
WC-81-BR91_10uM Dose=10uM, Bisanilinopyrimidine, 3d
WC-81-BR91_1uM Dose=1uM, Bisanilinopyrimidine, 3d
WC-82-YS26_0.01uM Dose=0.01uM, 4-[5-(2-methylphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
WC-82-YS26_0.1uM Dose=0.1uM, 4-[5-(2-methylphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
WC-82-YS26_10uM Dose=10uM, 4-[5-(2-methylphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
WC-82-YS26_1uM Dose=1uM, 4-[5-(2-methylphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidine
WC-88-EM46_0.01uM Dose=0.01uM, Macimorelin, FOS Expression Enhancers;Growth Hormone Secretagogues;Signal Transduction Modulators;GHS Receptor Agonists targeting GHSR
WC-89-JT40_0.01uM Dose=0.01uM, 4-Amino-3-iodobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA4, CA3, CA5A, CA5B, CA8, CA11, CA10
WC-89-JT40_0.1uM Dose=0.1uM, 4-Amino-3-iodobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA4, CA3, CA5A, CA5B, CA8, CA11, CA10
WC-89-JT40_10uM Dose=10uM, 4-Amino-3-iodobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA4, CA3, CA5A, CA5B, CA8, CA11, CA10
WC-89-JT40_1uM Dose=1uM, 4-Amino-3-iodobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA4, CA3, CA5A, CA5B, CA8, CA11, CA10
WC-95-BX35_0.01uM Dose=0.01uM, [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-(4z)-ylidene]-acetic acid
WC-95-BX35_0.1uM Dose=0.1uM, [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-(4z)-ylidene]-acetic acid
WC-95-BX35_10uM Dose=10uM, [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-(4z)-ylidene]-acetic acid
WC-95-BX35_1uM Dose=1uM, [2,7-Dichloro-10-methoxy-3-thia-9-aza-benzo[f]azulen-(4z)-ylidene]-acetic acid
WD-08-QT63_0.01uM Dose=0.01uM
WD-08-QT63_0.1uM Dose=0.1uM
WD-08-QT63_10uM Dose=10uM
WD-08-QT63_1uM Dose=1uM
WD-15-WN01_0.01uM Dose=0.01uM, tert-butyl N-[2-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]ethyl]carbamate, ApoB Secretion Inhibitors targeting APOB
WD-15-WN01_0.1uM Dose=0.1uM, tert-butyl N-[2-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]ethyl]carbamate, ApoB Secretion Inhibitors targeting APOB
WD-15-WN01_10uM Dose=10uM, tert-butyl N-[2-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]ethyl]carbamate, ApoB Secretion Inhibitors targeting APOB
WD-26-EB85_0.01uM Dose=0.01uM, Flavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1
WD-26-EB85_0.1uM Dose=0.1uM, Flavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1
WD-26-EB85_10uM Dose=10uM, Flavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1
WD-26-EB85_1uM Dose=1uM, Flavone, Cytochrome P450 CYP1A1 Inhibitors targeting CYP1A1
WD-26-LV83_0.01uM Dose=0.01uM, N-[trans-3-(2-Methoxy-3h-Imidazo[4,5-B]pyridin-3-Yl)cyclobutyl]-1,3-Benzothiazol-2-Amine, Phoshodiesterase 10A Inhibitor targeting PDE10A
WD-26-LV83_0.1uM Dose=0.1uM, N-[trans-3-(2-Methoxy-3h-Imidazo[4,5-B]pyridin-3-Yl)cyclobutyl]-1,3-Benzothiazol-2-Amine, Phoshodiesterase 10A Inhibitor targeting PDE10A
WD-26-LV83_10uM Dose=10uM, N-[trans-3-(2-Methoxy-3h-Imidazo[4,5-B]pyridin-3-Yl)cyclobutyl]-1,3-Benzothiazol-2-Amine, Phoshodiesterase 10A Inhibitor targeting PDE10A
WD-26-LV83_1uM Dose=1uM, N-[trans-3-(2-Methoxy-3h-Imidazo[4,5-B]pyridin-3-Yl)cyclobutyl]-1,3-Benzothiazol-2-Amine, Phoshodiesterase 10A Inhibitor targeting PDE10A
WD-62-UB45_0.01uM Dose=0.01uM, [(Benzylamino)-phenylmethyl]phosphonic acid, prostatic acid phosphatase inhibitor targeting ACP3
WD-62-UB45_0.1uM Dose=0.1uM, [(Benzylamino)-phenylmethyl]phosphonic acid, prostatic acid phosphatase inhibitor targeting ACP3
WD-62-UB45_10uM Dose=10uM, [(Benzylamino)-phenylmethyl]phosphonic acid, prostatic acid phosphatase inhibitor targeting ACP3
WD-62-UB45_1uM Dose=1uM, [(Benzylamino)-phenylmethyl]phosphonic acid, prostatic acid phosphatase inhibitor targeting ACP3
WD-65-PA90_0.01uM Dose=0.01uM, Lafutidine, Histamine H2 Receptor Antagonists targeting HRH2
WD-65-PA90_0.1uM Dose=0.1uM, Lafutidine, Histamine H2 Receptor Antagonists targeting HRH2
WD-65-PA90_10uM Dose=10uM, Lafutidine, Histamine H2 Receptor Antagonists targeting HRH2
WD-65-PA90_1uM Dose=1uM, Lafutidine, Histamine H2 Receptor Antagonists targeting HRH2
WD-73-QC55_0.01uM Dose=0.01uM, Pirenoxine
WD-73-QC55_10uM Dose=10uM, Pirenoxine
WD-73-QC55_1uM Dose=1uM, Pirenoxine
WD-75-LK69_0.01uM Dose=0.01uM, 4-[6-[(2R)-2-(3-fluorophenyl)piperidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]benzonitrile
WD-75-LK69_0.1uM Dose=0.1uM, 4-[6-[(2R)-2-(3-fluorophenyl)piperidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]benzonitrile
WD-75-LK69_10uM Dose=10uM, 4-[6-[(2R)-2-(3-fluorophenyl)piperidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]benzonitrile
WD-75-LK69_1uM Dose=1uM, 4-[6-[(2R)-2-(3-fluorophenyl)piperidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]benzonitrile
WD-86-NH64_0.01uM Dose=0.01uM
WD-86-NH64_0.1uM Dose=0.1uM
WD-86-NH64_10uM Dose=10uM
WD-86-NH64_1uM Dose=1uM
WD-97-SF27_0.1uM Dose=0.1uM, 2-(((2-chloro-3-(2-methylpyridin-3-yl)-1-benzothiophen-5-yl)carbamoyl)amino)-N-(3-(methyl((3R)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-3-yl)amino)propyl)acetamide targeting DOT1L
WD-97-SF27_10uM Dose=10uM, 2-(((2-chloro-3-(2-methylpyridin-3-yl)-1-benzothiophen-5-yl)carbamoyl)amino)-N-(3-(methyl((3R)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-3-yl)amino)propyl)acetamide targeting DOT1L
WD-97-SF27_1uM Dose=1uM, 2-(((2-chloro-3-(2-methylpyridin-3-yl)-1-benzothiophen-5-yl)carbamoyl)amino)-N-(3-(methyl((3R)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-3-yl)amino)propyl)acetamide targeting DOT1L
WE-25-AN91_0.01uM Dose=0.01uM, CP 96345, Tachykinin NK1 Antagonists;Non-Steroidal Antiinflammatory Drugs targeting CACNA1C, CACNA1F, CACNA1S
WE-25-AN91_0.1uM Dose=0.1uM, CP 96345, Tachykinin NK1 Antagonists;Non-Steroidal Antiinflammatory Drugs targeting CACNA1C, CACNA1F, CACNA1S
WE-25-AN91_10uM Dose=10uM, CP 96345, Tachykinin NK1 Antagonists;Non-Steroidal Antiinflammatory Drugs targeting CACNA1C, CACNA1F, CACNA1S
WE-25-AN91_1uM Dose=1uM, CP 96345, Tachykinin NK1 Antagonists;Non-Steroidal Antiinflammatory Drugs targeting CACNA1C, CACNA1F, CACNA1S
WE-41-YO44_0.01uM Dose=0.01uM, N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea, Angiogenesis Inhibitors;Urokinase (u-PA) Inhibitors targeting PLAU
WE-41-YO44_0.1uM Dose=0.1uM, N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea, Angiogenesis Inhibitors;Urokinase (u-PA) Inhibitors targeting PLAU
WE-41-YO44_10uM Dose=10uM, N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea, Angiogenesis Inhibitors;Urokinase (u-PA) Inhibitors targeting PLAU
WE-41-YO44_1uM Dose=1uM, N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea, Angiogenesis Inhibitors;Urokinase (u-PA) Inhibitors targeting PLAU
WE-43-PZ45_0.01uM Dose=0.01uM, [4-Amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3,5-dichloropyridin-4-yl)methanone
WE-43-PZ45_0.1uM Dose=0.1uM, [4-Amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3,5-dichloropyridin-4-yl)methanone
WE-43-PZ45_10uM Dose=10uM, [4-Amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3,5-dichloropyridin-4-yl)methanone
WE-43-PZ45_1uM Dose=1uM, [4-Amino-2-[4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazol-5-yl]-(3,5-dichloropyridin-4-yl)methanone
WE-48-PP43_0.1uM Dose=0.1uM, (1S,2R)-2-[[9-ethyl-6-(4-piperidin-1-ylsulfonylanilino)purin-2-yl]amino]cyclohexane-1-carboxamide, Protein Kinase Inhibitors targeting SRC
WE-48-PP43_10uM Dose=10uM, (1S,2R)-2-[[9-ethyl-6-(4-piperidin-1-ylsulfonylanilino)purin-2-yl]amino]cyclohexane-1-carboxamide, Protein Kinase Inhibitors targeting SRC
WE-48-PP43_1uM Dose=1uM, (1S,2R)-2-[[9-ethyl-6-(4-piperidin-1-ylsulfonylanilino)purin-2-yl]amino]cyclohexane-1-carboxamide, Protein Kinase Inhibitors targeting SRC
WE-69-LT10_0.01uM Dose=0.01uM
WE-69-LT10_0.1uM Dose=0.1uM
WE-69-LT10_10uM Dose=10uM
WE-69-LT10_1uM Dose=1uM
WE-76-XH29_10uM Dose=10uM, 6-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid, Apoptosis Inducers;Caspase 9 Activators;Caspase 3 Activators targeting CASP3, CASP9
WE-97-CV00_0.01uM Dose=0.01uM
WE-97-CV00_0.1uM Dose=0.1uM
WE-97-CV00_1uM Dose=1uM
WF-20-QN39_0.01uM Dose=0.01uM, Diethylstilbestrol Dipropionate, Estrogen Receptor Agonist targeting ESR1
WF-20-QN39_0.1uM Dose=0.1uM, Diethylstilbestrol Dipropionate, Estrogen Receptor Agonist targeting ESR1
WF-20-QN39_10uM Dose=10uM, Diethylstilbestrol Dipropionate, Estrogen Receptor Agonist targeting ESR1
WF-20-QN39_1uM Dose=1uM, Diethylstilbestrol Dipropionate, Estrogen Receptor Agonist targeting ESR1
WF-24-LG17_0.01uM Dose=0.01uM, N-[1-(1h-Indol-3-Ylmethyl)piperidin-4-Yl]-L-Tryptophanamide
WF-24-LG17_0.1uM Dose=0.1uM, N-[1-(1h-Indol-3-Ylmethyl)piperidin-4-Yl]-L-Tryptophanamide
WF-24-LG17_10uM Dose=10uM, N-[1-(1h-Indol-3-Ylmethyl)piperidin-4-Yl]-L-Tryptophanamide
WF-24-LG17_1uM Dose=1uM, N-[1-(1h-Indol-3-Ylmethyl)piperidin-4-Yl]-L-Tryptophanamide
WF-31-RY78_0.01uM Dose=0.01uM, (3H)granisetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E
WF-31-RY78_0.1uM Dose=0.1uM, (3H)granisetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E
WF-31-RY78_10uM Dose=10uM, (3H)granisetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E
WF-31-RY78_1uM Dose=1uM, (3H)granisetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E
WF-76-NV73_0.01uM Dose=0.01uM, Cxl-1020, activation for sGC, oxidation of sulfides for others targeting ATP2A2, CTSB, GAPDH, GUCY1A1, PLN
WF-76-NV73_0.1uM Dose=0.1uM, Cxl-1020, activation for sGC, oxidation of sulfides for others targeting ATP2A2, CTSB, GAPDH, GUCY1A1, PLN
WF-76-NV73_10uM Dose=10uM, Cxl-1020, activation for sGC, oxidation of sulfides for others targeting ATP2A2, CTSB, GAPDH, GUCY1A1, PLN
WF-76-NV73_1uM Dose=1uM, Cxl-1020, activation for sGC, oxidation of sulfides for others targeting ATP2A2, CTSB, GAPDH, GUCY1A1, PLN
WF-85-JN16_0.01uM Dose=0.01uM, 5|A-reductase-IN-1, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
WF-85-JN16_0.1uM Dose=0.1uM, 5|A-reductase-IN-1, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
WF-85-JN16_10uM Dose=10uM, 5|A-reductase-IN-1, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
WF-85-JN16_1uM Dose=1uM, 5|A-reductase-IN-1, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2
WF-96-ME07_0.01uM Dose=0.01uM, Cur 61414, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
WF-96-ME07_0.1uM Dose=0.1uM, Cur 61414, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
WF-96-ME07_10uM Dose=10uM, Cur 61414, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
WF-96-ME07_1uM Dose=1uM, Cur 61414, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH
XA-12-UL84_0.01uM Dose=0.01uM
XA-12-UL84_0.1uM Dose=0.1uM
XA-12-UL84_10uM Dose=10uM
XA-12-UL84_1uM Dose=1uM
XA-35-DA85_0.01uM Dose=0.01uM
XA-35-DA85_0.1uM Dose=0.1uM
XA-35-DA85_10uM Dose=10uM
XA-35-DA85_1uM Dose=1uM
XA-36-WV33_0.01uM Dose=0.01uM, Ethyl 4-(3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
XA-36-WV33_0.1uM Dose=0.1uM, Ethyl 4-(3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
XA-36-WV33_10uM Dose=10uM, Ethyl 4-(3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
XA-36-WV33_1uM Dose=1uM, Ethyl 4-(3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11
XA-39-SG64_0.01uM Dose=0.01uM, MK-0354, GPR109a partial agonist targeting HCAR2
XA-39-SG64_0.1uM Dose=0.1uM, MK-0354, GPR109a partial agonist targeting HCAR2
XA-39-SG64_1uM Dose=1uM, MK-0354, GPR109a partial agonist targeting HCAR2
XA-40-AD40_0.01uM Dose=0.01uM, Methyl (3E)-4-phenyl-3-butenoate targeting PAM
XA-40-AD40_0.1uM Dose=0.1uM, Methyl (3E)-4-phenyl-3-butenoate targeting PAM
XA-40-AD40_10uM Dose=10uM, Methyl (3E)-4-phenyl-3-butenoate targeting PAM
XA-40-AD40_1uM Dose=1uM, Methyl (3E)-4-phenyl-3-butenoate targeting PAM
XA-82-BM12_0.01uM Dose=0.01uM, TLR2/4 pathway antagonist targeting TLR2, TLR4
XA-82-BM12_0.1uM Dose=0.1uM, TLR2/4 pathway antagonist targeting TLR2, TLR4
XA-82-BM12_10uM Dose=10uM, TLR2/4 pathway antagonist targeting TLR2, TLR4
XA-82-BM12_1uM Dose=1uM, TLR2/4 pathway antagonist targeting TLR2, TLR4
XA-88-GW50_0.01uM Dose=0.01uM
XA-88-GW50_0.1uM Dose=0.1uM
XA-88-GW50_10uM Dose=10uM
XA-88-GW50_1uM Dose=1uM
XB-22-LI07_0.01uM Dose=0.01uM
XB-22-LI07_0.1uM Dose=0.1uM
XB-22-LI07_10uM Dose=10uM
XB-22-LI07_1uM Dose=1uM
XB-35-TO54_0.01uM Dose=0.01uM, N-(4-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-(morpholin-4-yl)pyridine-3-carboxamide, BET inhibitor BD1 selective targeting BRD4
XB-35-TO54_0.1uM Dose=0.1uM, N-(4-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-(morpholin-4-yl)pyridine-3-carboxamide, BET inhibitor BD1 selective targeting BRD4
XB-35-TO54_10uM Dose=10uM, N-(4-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-(morpholin-4-yl)pyridine-3-carboxamide, BET inhibitor BD1 selective targeting BRD4
XB-35-TO54_1uM Dose=1uM, N-(4-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-(morpholin-4-yl)pyridine-3-carboxamide, BET inhibitor BD1 selective targeting BRD4
XB-39-YT35_0.01uM Dose=0.01uM, 4-[[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide, OPRD1 agonist targeting OPRD1
XB-39-YT35_0.1uM Dose=0.1uM, 4-[[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide, OPRD1 agonist targeting OPRD1
XB-39-YT35_10uM Dose=10uM, 4-[[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide, OPRD1 agonist targeting OPRD1
XB-39-YT35_1uM Dose=1uM, 4-[[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide, OPRD1 agonist targeting OPRD1
XB-53-OZ95_0.01uM Dose=0.01uM
XB-53-OZ95_0.1uM Dose=0.1uM
XB-53-OZ95_10uM Dose=10uM
XB-53-OZ95_1uM Dose=1uM
XB-70-NK42_0.1uM Dose=0.1uM, SR1001, Retinoid RORalpha Inverse Agonists;Retinoid RORgamma Inverse Agonists targeting RORA
XB-70-NK42_10uM Dose=10uM, SR1001, Retinoid RORalpha Inverse Agonists;Retinoid RORgamma Inverse Agonists targeting RORA
XB-70-NK42_1uM Dose=1uM, SR1001, Retinoid RORalpha Inverse Agonists;Retinoid RORgamma Inverse Agonists targeting RORA
XB-75-YN01_0.01uM Dose=0.01uM, 4-(2-Methylpropoxy)-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin B Inhibitors targeting CTSV
XB-75-YN01_0.1uM Dose=0.1uM, 4-(2-Methylpropoxy)-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin B Inhibitors targeting CTSV
XB-75-YN01_10uM Dose=10uM, 4-(2-Methylpropoxy)-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin B Inhibitors targeting CTSV
XB-75-YN01_1uM Dose=1uM, 4-(2-Methylpropoxy)-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin B Inhibitors targeting CTSV
XC-12-SL04_0.01uM Dose=0.01uM, CP-481,715, Chemokine CCR1 Antagonists targeting CCR1
XC-12-SL04_0.1uM Dose=0.1uM, CP-481,715, Chemokine CCR1 Antagonists targeting CCR1
XC-12-SL04_10uM Dose=10uM, CP-481,715, Chemokine CCR1 Antagonists targeting CCR1
XC-12-SL04_1uM Dose=1uM, CP-481,715, Chemokine CCR1 Antagonists targeting CCR1
XC-13-LW13_0.01uM Dose=0.01uM, 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carbonitrile
XC-13-LW13_0.1uM Dose=0.1uM, 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carbonitrile
XC-13-LW13_10uM Dose=10uM, 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carbonitrile
XC-13-LW13_1uM Dose=1uM, 3-Amino-4-phenyl-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carbonitrile
XC-50-TN39_0.01uM Dose=0.01uM
XC-50-TN39_0.1uM Dose=0.1uM
XC-50-TN39_10uM Dose=10uM
XC-50-TN39_1uM Dose=1uM
XC-61-SE50_0.01uM Dose=0.01uM, A-971432, selective agonist of sphingosine-1-phosphate receptor 5 (S1PR5) targeting S1PR5
XC-61-SE50_0.1uM Dose=0.1uM, A-971432, selective agonist of sphingosine-1-phosphate receptor 5 (S1PR5) targeting S1PR5
XC-61-SE50_10uM Dose=10uM, A-971432, selective agonist of sphingosine-1-phosphate receptor 5 (S1PR5) targeting S1PR5
XC-61-SE50_1uM Dose=1uM, A-971432, selective agonist of sphingosine-1-phosphate receptor 5 (S1PR5) targeting S1PR5
XC-65-XN91_0.01uM Dose=0.01uM, 6-(Propylamino)nicotinic acid, GPR109A agonist targeting HCAR2
XC-65-XN91_0.1uM Dose=0.1uM, 6-(Propylamino)nicotinic acid, GPR109A agonist targeting HCAR2
XC-65-XN91_10uM Dose=10uM, 6-(Propylamino)nicotinic acid, GPR109A agonist targeting HCAR2
XC-65-XN91_1uM Dose=1uM, 6-(Propylamino)nicotinic acid, GPR109A agonist targeting HCAR2
XC-68-NP33_0.01uM Dose=0.01uM, 1-(3-Phenylpropyl)-4-[[(4R)-2-(3-pyridyl)thiazolidin-4-yl]carbonyl]piperazine, PTAFR antagonist targeting PTAFR
XC-68-NP33_0.1uM Dose=0.1uM, 1-(3-Phenylpropyl)-4-[[(4R)-2-(3-pyridyl)thiazolidin-4-yl]carbonyl]piperazine, PTAFR antagonist targeting PTAFR
XC-68-NP33_10uM Dose=10uM, 1-(3-Phenylpropyl)-4-[[(4R)-2-(3-pyridyl)thiazolidin-4-yl]carbonyl]piperazine, PTAFR antagonist targeting PTAFR
XC-68-NP33_1uM Dose=1uM, 1-(3-Phenylpropyl)-4-[[(4R)-2-(3-pyridyl)thiazolidin-4-yl]carbonyl]piperazine, PTAFR antagonist targeting PTAFR
XC-81-LR46_0.01uM Dose=0.01uM
XC-81-LR46_0.1uM Dose=0.1uM
XC-81-LR46_10uM Dose=10uM
XC-81-LR46_1uM Dose=1uM
XC-86-SR58_0.01uM Dose=0.01uM
XC-86-SR58_0.1uM Dose=0.1uM
XC-86-SR58_10uM Dose=10uM
XC-86-SR58_1uM Dose=1uM
XC-88-ZM66_0.01uM Dose=0.01uM
XC-88-ZM66_0.1uM Dose=0.1uM
XC-88-ZM66_10uM Dose=10uM
XC-88-ZM66_1uM Dose=1uM
XD-01-OY13_0.01uM Dose=0.01uM, Cvt-12012, SCD1) Inhibitors;Stearoyl-CoA Desaturase (delta-9 Desaturase;SCD targeting SCD
XD-01-OY13_0.1uM Dose=0.1uM, Cvt-12012, SCD1) Inhibitors;Stearoyl-CoA Desaturase (delta-9 Desaturase;SCD targeting SCD
XD-01-OY13_10uM Dose=10uM, Cvt-12012, SCD1) Inhibitors;Stearoyl-CoA Desaturase (delta-9 Desaturase;SCD targeting SCD
XD-01-OY13_1uM Dose=1uM, Cvt-12012, SCD1) Inhibitors;Stearoyl-CoA Desaturase (delta-9 Desaturase;SCD targeting SCD
XD-03-FM54_0.01uM Dose=0.01uM
XD-03-FM54_0.1uM Dose=0.1uM
XD-03-FM54_10uM Dose=10uM
XD-03-FM54_1uM Dose=1uM
XD-08-ZW85_0.01uM Dose=0.01uM
XD-08-ZW85_0.1uM Dose=0.1uM
XD-08-ZW85_10uM Dose=10uM
XD-08-ZW85_1uM Dose=1uM
XD-18-IF89_0.01uM Dose=0.01uM, Humulone, Apoptosis Inducers;AP-1 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Antioxidants targeting PTGS2, JUN
XD-18-IF89_0.1uM Dose=0.1uM, Humulone, Apoptosis Inducers;AP-1 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Antioxidants targeting PTGS2, JUN
XD-18-IF89_10uM Dose=10uM, Humulone, Apoptosis Inducers;AP-1 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Antioxidants targeting PTGS2, JUN
XD-18-IF89_1uM Dose=1uM, Humulone, Apoptosis Inducers;AP-1 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Antioxidants targeting PTGS2, JUN
XD-27-EB72_0.01uM Dose=0.01uM, PRC2/EZH2 targeting EZH2
XD-27-EB72_0.1uM Dose=0.1uM, PRC2/EZH2 targeting EZH2
XD-27-EB72_10uM Dose=10uM, PRC2/EZH2 targeting EZH2
XD-27-EB72_1uM Dose=1uM, PRC2/EZH2 targeting EZH2
XD-37-GI34_0.01uM Dose=0.01uM
XD-37-GI34_0.1uM Dose=0.1uM
XD-37-GI34_10uM Dose=10uM
XD-37-GI34_1uM Dose=1uM
XD-40-HA98_0.01uM Dose=0.01uM, ;Mammalian Target of Rapamycin (mTOR;FRAP1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting MTOR, IKBKB
XD-40-HA98_0.1uM Dose=0.1uM, ;Mammalian Target of Rapamycin (mTOR;FRAP1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting MTOR, IKBKB
XD-40-HA98_10uM Dose=10uM, ;Mammalian Target of Rapamycin (mTOR;FRAP1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting MTOR, IKBKB
XD-40-HA98_1uM Dose=1uM, ;Mammalian Target of Rapamycin (mTOR;FRAP1) Inhibitors;IKK-2 (IKK-beta) Inhibitors targeting MTOR, IKBKB
XD-44-FJ34_0.01uM Dose=0.01uM, 2-[[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]carbamoylamino]-N,N-dimethylacetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
XD-44-FJ34_0.1uM Dose=0.1uM, 2-[[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]carbamoylamino]-N,N-dimethylacetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
XD-44-FJ34_10uM Dose=10uM, 2-[[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]carbamoylamino]-N,N-dimethylacetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
XD-44-FJ34_1uM Dose=1uM, 2-[[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]carbamoylamino]-N,N-dimethylacetamide, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG
XD-50-BD50_0.01uM Dose=0.01uM, 2-(4-Amylcinnamoyl)amino-4-chlorobenzoic acid, Phospholipase A2 (PLA2) Inhibitors targeting PLA2G10
XD-50-BD50_0.1uM Dose=0.1uM, 2-(4-Amylcinnamoyl)amino-4-chlorobenzoic acid, Phospholipase A2 (PLA2) Inhibitors targeting PLA2G10
XD-50-BD50_10uM Dose=10uM, 2-(4-Amylcinnamoyl)amino-4-chlorobenzoic acid, Phospholipase A2 (PLA2) Inhibitors targeting PLA2G10
XD-50-BD50_1uM Dose=1uM, 2-(4-Amylcinnamoyl)amino-4-chlorobenzoic acid, Phospholipase A2 (PLA2) Inhibitors targeting PLA2G10
XD-53-KC50_0.01uM Dose=0.01uM
XD-53-KC50_0.1uM Dose=0.1uM
XD-53-KC50_10uM Dose=10uM
XD-53-KC50_1uM Dose=1uM
XD-54-WU31_0.01uM Dose=0.01uM, Hydroxycitric acid, ATP citrate lyase inhibitor targeting ACLY
XD-54-WU31_0.1uM Dose=0.1uM, Hydroxycitric acid, ATP citrate lyase inhibitor targeting ACLY
XD-54-WU31_10uM Dose=10uM, Hydroxycitric acid, ATP citrate lyase inhibitor targeting ACLY
XD-60-SU16_0.01uM Dose=0.01uM, Prt-4165, Ubiquitin Protein Ligase E3 Inhibitors targeting RNF2, BMI1, RING1
XD-60-SU16_10uM Dose=10uM, Prt-4165, Ubiquitin Protein Ligase E3 Inhibitors targeting RNF2, BMI1, RING1
XD-60-SU16_1uM Dose=1uM, Prt-4165, Ubiquitin Protein Ligase E3 Inhibitors targeting RNF2, BMI1, RING1
XD-62-HM52_1uM Dose=1uM, N-[4-[[5-[5-hydroxy-4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide, Thyroid stimulating hormone receptor antagonist targeting TSHR
XD-68-MP63_0.01uM Dose=0.01uM, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine
XD-68-MP63_0.1uM Dose=0.1uM, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine
XD-68-MP63_10uM Dose=10uM, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine
XD-68-MP63_1uM Dose=1uM, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine
XD-71-WI50_0.01uM Dose=0.01uM
XD-71-WI50_0.1uM Dose=0.1uM
XD-71-WI50_10uM Dose=10uM
XD-71-WI50_1uM Dose=1uM
XE-18-BC97_0.01uM Dose=0.01uM, 2-Hydroxy-6-[4-methyl-5-(4-methylpiperazine-1-carbonyl)-1,3-thiazol-2-yl]naphthalene-1-carbaldehyde
XE-18-BC97_0.1uM Dose=0.1uM, 2-Hydroxy-6-[4-methyl-5-(4-methylpiperazine-1-carbonyl)-1,3-thiazol-2-yl]naphthalene-1-carbaldehyde
XE-18-BC97_10uM Dose=10uM, 2-Hydroxy-6-[4-methyl-5-(4-methylpiperazine-1-carbonyl)-1,3-thiazol-2-yl]naphthalene-1-carbaldehyde
XE-18-BC97_1uM Dose=1uM, 2-Hydroxy-6-[4-methyl-5-(4-methylpiperazine-1-carbonyl)-1,3-thiazol-2-yl]naphthalene-1-carbaldehyde
XE-29-LT20_0.01uM Dose=0.01uM, 6-Chloro-3-hydroxy-1,2-benzisoxazole, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO
XE-29-LT20_0.1uM Dose=0.1uM, 6-Chloro-3-hydroxy-1,2-benzisoxazole, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO
XE-29-LT20_10uM Dose=10uM, 6-Chloro-3-hydroxy-1,2-benzisoxazole, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO
XE-29-LT20_1uM Dose=1uM, 6-Chloro-3-hydroxy-1,2-benzisoxazole, D-Amino Acid Oxidase (DAAO) Inhibitors targeting DAO
XE-45-YU38_0.01uM Dose=0.01uM
XE-45-YU38_0.1uM Dose=0.1uM
XE-45-YU38_10uM Dose=10uM
XE-45-YU38_1uM Dose=1uM
XE-55-GK99_0.01uM Dose=0.01uM, Trifluoro-methanesulfonic acid 8-chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepin-2-yl ester, Drugs Acting on 5-Hydroxytryptamine Receptors;Drugs Acting on Dopamine Receptors;Drugs Acting on Adrenoceptors targeting DRD2, DRD3, HTR2A, HTR2C, DRD1, ADRB1
XE-55-GK99_0.1uM Dose=0.1uM, Trifluoro-methanesulfonic acid 8-chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepin-2-yl ester, Drugs Acting on 5-Hydroxytryptamine Receptors;Drugs Acting on Dopamine Receptors;Drugs Acting on Adrenoceptors targeting DRD2, DRD3, HTR2A, HTR2C, DRD1, ADRB1
XE-55-GK99_10uM Dose=10uM, Trifluoro-methanesulfonic acid 8-chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepin-2-yl ester, Drugs Acting on 5-Hydroxytryptamine Receptors;Drugs Acting on Dopamine Receptors;Drugs Acting on Adrenoceptors targeting DRD2, DRD3, HTR2A, HTR2C, DRD1, ADRB1
XE-55-GK99_1uM Dose=1uM, Trifluoro-methanesulfonic acid 8-chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepin-2-yl ester, Drugs Acting on 5-Hydroxytryptamine Receptors;Drugs Acting on Dopamine Receptors;Drugs Acting on Adrenoceptors targeting DRD2, DRD3, HTR2A, HTR2C, DRD1, ADRB1
XE-69-AT35_0.01uM Dose=0.01uM, Nocardimicin A
XE-69-AT35_0.1uM Dose=0.1uM, Nocardimicin A
XE-69-AT35_10uM Dose=10uM, Nocardimicin A
XE-69-AT35_1uM Dose=1uM, Nocardimicin A
XE-99-WG54_0.01uM Dose=0.01uM, Bvryltbigiaadd-uhfffaoysa-
XE-99-WG54_0.1uM Dose=0.1uM, Bvryltbigiaadd-uhfffaoysa-
XE-99-WG54_10uM Dose=10uM, Bvryltbigiaadd-uhfffaoysa-
XE-99-WG54_1uM Dose=1uM, Bvryltbigiaadd-uhfffaoysa-
XF-24-NT53_0.01uM Dose=0.01uM, Bms-599626, HER4 (erbB4) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;HER3 (erbB3) Inhibitors targeting EGFR, ERBB2, ERBB3, ERBB4
XF-24-NT53_0.1uM Dose=0.1uM, Bms-599626, HER4 (erbB4) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;HER3 (erbB3) Inhibitors targeting EGFR, ERBB2, ERBB3, ERBB4
XF-24-NT53_10uM Dose=10uM, Bms-599626, HER4 (erbB4) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;HER3 (erbB3) Inhibitors targeting EGFR, ERBB2, ERBB3, ERBB4
XF-24-NT53_1uM Dose=1uM, Bms-599626, HER4 (erbB4) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;HER3 (erbB3) Inhibitors targeting EGFR, ERBB2, ERBB3, ERBB4
XF-42-ES96_0.01uM Dose=0.01uM, (1-(4-Nitrophenyl)piperidin-3-yl)methanol, CDK Inhibitors targeting CCND2, CCND3, CDK6
XF-42-ES96_0.1uM Dose=0.1uM, (1-(4-Nitrophenyl)piperidin-3-yl)methanol, CDK Inhibitors targeting CCND2, CCND3, CDK6
XF-42-ES96_10uM Dose=10uM, (1-(4-Nitrophenyl)piperidin-3-yl)methanol, CDK Inhibitors targeting CCND2, CCND3, CDK6
XF-42-ES96_1uM Dose=1uM, (1-(4-Nitrophenyl)piperidin-3-yl)methanol, CDK Inhibitors targeting CCND2, CCND3, CDK6
XF-76-GE52_0.01uM Dose=0.01uM
XF-76-GE52_0.1uM Dose=0.1uM
XF-76-GE52_10uM Dose=10uM
XF-76-GE52_1uM Dose=1uM
XF-97-DS48_0.1uM Dose=0.1uM, 3-{4-[(2'',6''-Dimethylbiphenyl-3-yl)methoxy]phenyl}propanoic Acid, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1
XF-97-DS48_10uM Dose=10uM, 3-{4-[(2'',6''-Dimethylbiphenyl-3-yl)methoxy]phenyl}propanoic Acid, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1
XF-97-DS48_1uM Dose=1uM, 3-{4-[(2'',6''-Dimethylbiphenyl-3-yl)methoxy]phenyl}propanoic Acid, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1
YA-00-OG62_0.01uM Dose=0.01uM, methyl 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoate, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
YA-00-OG62_0.1uM Dose=0.1uM, methyl 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoate, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
YA-00-OG62_1uM Dose=1uM, methyl 3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]benzoate, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4
YA-21-RR66_0.01uM Dose=0.01uM, (R)-8-chloro-4-(3-(methylamino)pyrrolidin-1-yl)benzofuro[3,2-d]pyrimidin-2-amine, Histamine H4 Receptor Antagonists targeting HRH4
YA-21-RR66_0.1uM Dose=0.1uM, (R)-8-chloro-4-(3-(methylamino)pyrrolidin-1-yl)benzofuro[3,2-d]pyrimidin-2-amine, Histamine H4 Receptor Antagonists targeting HRH4
YA-21-RR66_10uM Dose=10uM, (R)-8-chloro-4-(3-(methylamino)pyrrolidin-1-yl)benzofuro[3,2-d]pyrimidin-2-amine, Histamine H4 Receptor Antagonists targeting HRH4
YA-21-RR66_1uM Dose=1uM, (R)-8-chloro-4-(3-(methylamino)pyrrolidin-1-yl)benzofuro[3,2-d]pyrimidin-2-amine, Histamine H4 Receptor Antagonists targeting HRH4
YA-34-DT48_0.01uM Dose=0.01uM
YA-34-DT48_0.1uM Dose=0.1uM
YA-34-DT48_10uM Dose=10uM
YA-34-DT48_1uM Dose=1uM
YA-39-ZW92_0.01uM Dose=0.01uM, 6-(4-Methyl-piperazin-1-yl)-7,8,9,10-tetrahydro-phenanthridine, 5-HT3 receptor antagonist targeting HTR3B, HTR3C, HTR3D, HTR3E
YA-39-ZW92_0.1uM Dose=0.1uM, 6-(4-Methyl-piperazin-1-yl)-7,8,9,10-tetrahydro-phenanthridine, 5-HT3 receptor antagonist targeting HTR3B, HTR3C, HTR3D, HTR3E
YA-39-ZW92_10uM Dose=10uM, 6-(4-Methyl-piperazin-1-yl)-7,8,9,10-tetrahydro-phenanthridine, 5-HT3 receptor antagonist targeting HTR3B, HTR3C, HTR3D, HTR3E
YA-39-ZW92_1uM Dose=1uM, 6-(4-Methyl-piperazin-1-yl)-7,8,9,10-tetrahydro-phenanthridine, 5-HT3 receptor antagonist targeting HTR3B, HTR3C, HTR3D, HTR3E
YA-44-LW45_0.01uM Dose=0.01uM, 4-(4-Chlorophenyl)-1-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)propyl]piperidin-4-ol, Chemokine CC Antagonists;Antiinflammatory Drugs targeting CCR6, CCR7, CCR8, CCR10, CX3CR1
YA-44-LW45_0.1uM Dose=0.1uM, 4-(4-Chlorophenyl)-1-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)propyl]piperidin-4-ol, Chemokine CC Antagonists;Antiinflammatory Drugs targeting CCR6, CCR7, CCR8, CCR10, CX3CR1
YA-44-LW45_10uM Dose=10uM, 4-(4-Chlorophenyl)-1-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)propyl]piperidin-4-ol, Chemokine CC Antagonists;Antiinflammatory Drugs targeting CCR6, CCR7, CCR8, CCR10, CX3CR1
YA-44-LW45_1uM Dose=1uM, 4-(4-Chlorophenyl)-1-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)propyl]piperidin-4-ol, Chemokine CC Antagonists;Antiinflammatory Drugs targeting CCR6, CCR7, CCR8, CCR10, CX3CR1
YA-52-FO46_10uM Dose=10uM, N-(2-chlorobenzyl)-2-(N-(4-isobutoxy-3-methoxybenzyl)-4-((4-methylpiperazin-1-yl)methyl)phenylsulfonamido)acetamide, BDKRB1 antagonist;Non-Opioid Analgesics targeting BDKRB1
YA-52-FO46_1uM Dose=1uM, N-(2-chlorobenzyl)-2-(N-(4-isobutoxy-3-methoxybenzyl)-4-((4-methylpiperazin-1-yl)methyl)phenylsulfonamido)acetamide, BDKRB1 antagonist;Non-Opioid Analgesics targeting BDKRB1
YA-61-RR36_0.01uM Dose=0.01uM
YA-61-RR36_0.1uM Dose=0.1uM
YA-61-RR36_10uM Dose=10uM
YA-61-RR36_1uM Dose=1uM
YA-71-LR91_0.01uM Dose=0.01uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-2-[4-(2-methyltetrazol-5-yl)phenyl]acetamide
YA-71-LR91_0.1uM Dose=0.1uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-2-[4-(2-methyltetrazol-5-yl)phenyl]acetamide
YA-71-LR91_10uM Dose=10uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-2-[4-(2-methyltetrazol-5-yl)phenyl]acetamide
YA-71-LR91_1uM Dose=1uM, (2S)-2-[(1S)-3,3-difluorocyclopentyl]-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-2-[4-(2-methyltetrazol-5-yl)phenyl]acetamide
YA-78-MS95_0.01uM Dose=0.01uM, 2164U90, Ileal Bile Acid Transporter (IBAT) Inhibitors targeting SLC10A2
YA-78-MS95_0.1uM Dose=0.1uM, 2164U90, Ileal Bile Acid Transporter (IBAT) Inhibitors targeting SLC10A2
YA-78-MS95_10uM Dose=10uM, 2164U90, Ileal Bile Acid Transporter (IBAT) Inhibitors targeting SLC10A2
YA-78-MS95_1uM Dose=1uM, 2164U90, Ileal Bile Acid Transporter (IBAT) Inhibitors targeting SLC10A2
YA-81-YH47_0.01uM Dose=0.01uM
YA-81-YH47_0.1uM Dose=0.1uM
YA-81-YH47_10uM Dose=10uM
YA-81-YH47_1uM Dose=1uM
YA-82-VS66_0.01uM Dose=0.01uM, 2-(4-Chlorobenzoyl)-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-1,2,3,4-tetrahydroisoquinoline, NMDA NR2C Receptor Ligands;NMDA NR2D Receptor Ligands targeting GRIN2C, GRIN2D
YA-82-VS66_0.1uM Dose=0.1uM, 2-(4-Chlorobenzoyl)-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-1,2,3,4-tetrahydroisoquinoline, NMDA NR2C Receptor Ligands;NMDA NR2D Receptor Ligands targeting GRIN2C, GRIN2D
YA-82-VS66_10uM Dose=10uM, 2-(4-Chlorobenzoyl)-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-1,2,3,4-tetrahydroisoquinoline, NMDA NR2C Receptor Ligands;NMDA NR2D Receptor Ligands targeting GRIN2C, GRIN2D
YA-82-VS66_1uM Dose=1uM, 2-(4-Chlorobenzoyl)-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-1,2,3,4-tetrahydroisoquinoline, NMDA NR2C Receptor Ligands;NMDA NR2D Receptor Ligands targeting GRIN2C, GRIN2D
YA-85-VH07_0.01uM Dose=0.01uM, N-(3,4-Dimethoxy-5-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine, TBK1 inhibitor targeting IKBKE, TBK1
YA-85-VH07_0.1uM Dose=0.1uM, N-(3,4-Dimethoxy-5-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine, TBK1 inhibitor targeting IKBKE, TBK1
YA-85-VH07_10uM Dose=10uM, N-(3,4-Dimethoxy-5-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine, TBK1 inhibitor targeting IKBKE, TBK1
YA-85-VH07_1uM Dose=1uM, N-(3,4-Dimethoxy-5-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine, TBK1 inhibitor targeting IKBKE, TBK1
YA-92-YO01_0.01uM Dose=0.01uM, LL-Z 1271alpha
YA-92-YO01_0.1uM Dose=0.1uM, LL-Z 1271alpha
YA-92-YO01_10uM Dose=10uM, LL-Z 1271alpha
YA-92-YO01_1uM Dose=1uM, LL-Z 1271alpha
YB-01-IL62_0.01uM Dose=0.01uM, 4-Methyl-3-[(3-nitrophenyl)methyl]-7-pyrimidin-2-yloxychromen-2-one
YB-01-IL62_0.1uM Dose=0.1uM, 4-Methyl-3-[(3-nitrophenyl)methyl]-7-pyrimidin-2-yloxychromen-2-one
YB-01-IL62_10uM Dose=10uM, 4-Methyl-3-[(3-nitrophenyl)methyl]-7-pyrimidin-2-yloxychromen-2-one
YB-01-IL62_1uM Dose=1uM, 4-Methyl-3-[(3-nitrophenyl)methyl]-7-pyrimidin-2-yloxychromen-2-one
YB-18-SI56_0.01uM Dose=0.01uM
YB-18-SI56_0.1uM Dose=0.1uM
YB-18-SI56_10uM Dose=10uM
YB-18-SI56_1uM Dose=1uM
YB-27-PO08_0.01uM Dose=0.01uM, Abietic acid, Antiinflammatory;Antibacterial;HSD11B1 expression inhibitor targeting HSD11B1, HSD11B2
YB-27-PO08_0.1uM Dose=0.1uM, Abietic acid, Antiinflammatory;Antibacterial;HSD11B1 expression inhibitor targeting HSD11B1, HSD11B2
YB-27-PO08_1uM Dose=1uM, Abietic acid, Antiinflammatory;Antibacterial;HSD11B1 expression inhibitor targeting HSD11B1, HSD11B2
YB-30-EK42_0.01uM Dose=0.01uM
YB-30-EK42_0.1uM Dose=0.1uM
YB-30-EK42_10uM Dose=10uM
YB-30-EK42_1uM Dose=1uM
YB-31-TH67_0.01uM Dose=0.01uM, Estradiol Acetate
YB-31-TH67_0.1uM Dose=0.1uM, Estradiol Acetate
YB-31-TH67_10uM Dose=10uM, Estradiol Acetate
YB-31-TH67_1uM Dose=1uM, Estradiol Acetate
YB-54-ET23_0.01uM Dose=0.01uM, 5-Chloro-2-{2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl}pyridine, JMJD2 Histone Demethylase Inhibitor targeting KDM4C, KDM4E, KDM4B
YB-54-ET23_0.1uM Dose=0.1uM, 5-Chloro-2-{2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl}pyridine, JMJD2 Histone Demethylase Inhibitor targeting KDM4C, KDM4E, KDM4B
YB-54-ET23_10uM Dose=10uM, 5-Chloro-2-{2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl}pyridine, JMJD2 Histone Demethylase Inhibitor targeting KDM4C, KDM4E, KDM4B
YB-54-ET23_1uM Dose=1uM, 5-Chloro-2-{2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl}pyridine, JMJD2 Histone Demethylase Inhibitor targeting KDM4C, KDM4E, KDM4B
YB-58-IZ37_0.01uM Dose=0.01uM, 2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, N-Ac Lysine competitive BET family inhibitor BRD4 targeting BRD4
YB-58-IZ37_0.1uM Dose=0.1uM, 2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, N-Ac Lysine competitive BET family inhibitor BRD4 targeting BRD4
YB-58-IZ37_10uM Dose=10uM, 2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, N-Ac Lysine competitive BET family inhibitor BRD4 targeting BRD4
YB-58-IZ37_1uM Dose=1uM, 2-((6R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, N-Ac Lysine competitive BET family inhibitor BRD4 targeting BRD4
YB-61-MY23_0.1uM Dose=0.1uM, 2-(Morpholin-4-yl)-benzo[h]chromen-4-one, DNA-PK inhibitor targeting PRKDC
YB-61-MY23_10uM Dose=10uM, 2-(Morpholin-4-yl)-benzo[h]chromen-4-one, DNA-PK inhibitor targeting PRKDC
YB-61-MY23_1uM Dose=1uM, 2-(Morpholin-4-yl)-benzo[h]chromen-4-one, DNA-PK inhibitor targeting PRKDC
YB-74-BG62_0.01uM Dose=0.01uM, Dopamine D2/3 receptor partial agonist targeting DRD3
YB-74-BG62_0.1uM Dose=0.1uM, Dopamine D2/3 receptor partial agonist targeting DRD3
YB-74-BG62_10uM Dose=10uM, Dopamine D2/3 receptor partial agonist targeting DRD3
YB-74-BG62_1uM Dose=1uM, Dopamine D2/3 receptor partial agonist targeting DRD3
YB-79-DM48_0.01uM Dose=0.01uM, 3-Octadecyloxy-2-methoxypropylphosphonocholine, Angiogenesis Inhibitors;Lipid Homeostasis Modulator;Membrane Metabolism Inhibitor;CoA-Independent Transacyclase (CoA-IT) Inhibitors targeting PNPLA4, PLCB1, PNPLA2, PNPLA3
YB-79-DM48_0.1uM Dose=0.1uM, 3-Octadecyloxy-2-methoxypropylphosphonocholine, Angiogenesis Inhibitors;Lipid Homeostasis Modulator;Membrane Metabolism Inhibitor;CoA-Independent Transacyclase (CoA-IT) Inhibitors targeting PNPLA4, PLCB1, PNPLA2, PNPLA3
YB-79-DM48_10uM Dose=10uM, 3-Octadecyloxy-2-methoxypropylphosphonocholine, Angiogenesis Inhibitors;Lipid Homeostasis Modulator;Membrane Metabolism Inhibitor;CoA-Independent Transacyclase (CoA-IT) Inhibitors targeting PNPLA4, PLCB1, PNPLA2, PNPLA3
YB-79-DM48_1uM Dose=1uM, 3-Octadecyloxy-2-methoxypropylphosphonocholine, Angiogenesis Inhibitors;Lipid Homeostasis Modulator;Membrane Metabolism Inhibitor;CoA-Independent Transacyclase (CoA-IT) Inhibitors targeting PNPLA4, PLCB1, PNPLA2, PNPLA3
YB-79-RC04_0.01uM Dose=0.01uM, 7-[(1R,2S,3E,5Z)-8-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-(3-methylphenyl)octa-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid, Phospholipase A2 (PLA2) Inhibitors;Leukotriene Antagonists targeting PLA2G10
YB-79-RC04_0.1uM Dose=0.1uM, 7-[(1R,2S,3E,5Z)-8-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-(3-methylphenyl)octa-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid, Phospholipase A2 (PLA2) Inhibitors;Leukotriene Antagonists targeting PLA2G10
YB-79-RC04_10uM Dose=10uM, 7-[(1R,2S,3E,5Z)-8-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-(3-methylphenyl)octa-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid, Phospholipase A2 (PLA2) Inhibitors;Leukotriene Antagonists targeting PLA2G10
YB-79-RC04_1uM Dose=1uM, 7-[(1R,2S,3E,5Z)-8-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-(3-methylphenyl)octa-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid, Phospholipase A2 (PLA2) Inhibitors;Leukotriene Antagonists targeting PLA2G10
YB-80-KQ31_0.01uM Dose=0.01uM, CD80 (B7-1) Inhibitors targeting CD80, CD28
YB-80-KQ31_0.1uM Dose=0.1uM, CD80 (B7-1) Inhibitors targeting CD80, CD28
YB-80-KQ31_10uM Dose=10uM, CD80 (B7-1) Inhibitors targeting CD80, CD28
YB-80-KQ31_1uM Dose=1uM, CD80 (B7-1) Inhibitors targeting CD80, CD28
YB-83-AS93_0.01uM Dose=0.01uM, 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4, PRKCH, PRKCZ
YB-83-AS93_0.1uM Dose=0.1uM, 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4, PRKCH, PRKCZ
YB-83-AS93_10uM Dose=10uM, 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4, PRKCH, PRKCZ
YB-83-AS93_1uM Dose=1uM, 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4, PRKCH, PRKCZ
YC-06-WA22_0.01uM Dose=0.01uM, 2-(4-(Pyrrolidin-1-yl)but-2-ynyl)isoxazolidin-3-one, Muscarinic M2 Agonists;Muscarinic M1 Agonists;Muscarinic M3 Agonists targeting CHRM5
YC-06-WA22_0.1uM Dose=0.1uM, 2-(4-(Pyrrolidin-1-yl)but-2-ynyl)isoxazolidin-3-one, Muscarinic M2 Agonists;Muscarinic M1 Agonists;Muscarinic M3 Agonists targeting CHRM5
YC-11-LU43_0.01uM Dose=0.01uM, CDK2 Inhibitors;CDK1 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1, CDK2
YC-11-LU43_0.1uM Dose=0.1uM, CDK2 Inhibitors;CDK1 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1, CDK2
YC-11-LU43_10uM Dose=10uM, CDK2 Inhibitors;CDK1 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK1, CDK2
YC-27-PB87_0.01uM Dose=0.01uM, 4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid, LPAR5 (alias GPR92) inhibitor targeting LPAR5
YC-27-PB87_0.1uM Dose=0.1uM, 4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid, LPAR5 (alias GPR92) inhibitor targeting LPAR5
YC-27-PB87_10uM Dose=10uM, 4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid, LPAR5 (alias GPR92) inhibitor targeting LPAR5
YC-27-PB87_1uM Dose=1uM, 4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid, LPAR5 (alias GPR92) inhibitor targeting LPAR5
YC-32-MB85_0.01uM Dose=0.01uM, N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Inhibitors of Signal Transduction Pathways;Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2
YC-32-MB85_0.1uM Dose=0.1uM, N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Inhibitors of Signal Transduction Pathways;Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2
YC-32-MB85_10uM Dose=10uM, N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Inhibitors of Signal Transduction Pathways;Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2
YC-32-MB85_1uM Dose=1uM, N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Inhibitors of Signal Transduction Pathways;Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2
YC-45-JD42_0.01uM Dose=0.01uM, Ethyl 2-[2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate
YC-45-JD42_0.1uM Dose=0.1uM, Ethyl 2-[2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate
YC-45-JD42_10uM Dose=10uM, Ethyl 2-[2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate
YC-45-JD42_1uM Dose=1uM, Ethyl 2-[2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate
YC-57-OY42_0.01uM Dose=0.01uM, SB-267268, Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alpha-V/beta-3 antagonist, integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3
YC-57-OY42_0.1uM Dose=0.1uM, SB-267268, Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alpha-V/beta-3 antagonist, integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3
YC-57-OY42_10uM Dose=10uM, SB-267268, Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alpha-V/beta-3 antagonist, integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3
YC-57-OY42_1uM Dose=1uM, SB-267268, Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alpha-V/beta-3 antagonist, integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3
YC-66-WR78_0.01uM Dose=0.01uM
YC-66-WR78_10uM Dose=10uM
YC-66-WR78_1uM Dose=1uM
YC-80-XX73_0.01uM Dose=0.01uM, 3-(Ethoxycarbonyl)-1,3-thiazolidine-4-carboxylic acid, Elastase Inhibitors targeting PI3
YC-80-XX73_0.1uM Dose=0.1uM, 3-(Ethoxycarbonyl)-1,3-thiazolidine-4-carboxylic acid, Elastase Inhibitors targeting PI3
YC-80-XX73_10uM Dose=10uM, 3-(Ethoxycarbonyl)-1,3-thiazolidine-4-carboxylic acid, Elastase Inhibitors targeting PI3
YC-83-VF72_0.01uM Dose=0.01uM
YC-83-VF72_0.1uM Dose=0.1uM
YC-83-VF72_10uM Dose=10uM
YC-83-VF72_1uM Dose=1uM
YD-21-ZR41_0.01uM Dose=0.01uM, Timapiprant, CRTH2 Receptor Antagonists targeting PTGDR2
YD-21-ZR41_0.1uM Dose=0.1uM, Timapiprant, CRTH2 Receptor Antagonists targeting PTGDR2
YD-21-ZR41_10uM Dose=10uM, Timapiprant, CRTH2 Receptor Antagonists targeting PTGDR2
YD-21-ZR41_1uM Dose=1uM, Timapiprant, CRTH2 Receptor Antagonists targeting PTGDR2
YD-32-RO91_0.01uM Dose=0.01uM, Lofepramine
YD-32-RO91_0.1uM Dose=0.1uM, Lofepramine
YD-32-RO91_10uM Dose=10uM, Lofepramine
YD-32-RO91_1uM Dose=1uM, Lofepramine
YD-38-CI01_0.01uM Dose=0.01uM, 4-Amino-5-chloro-2-methoxy-benzoic acid 2-pyrrolidin-1-yl-ethyl ester, HTR4 agonist targeting HTR4
YD-38-CI01_0.1uM Dose=0.1uM, 4-Amino-5-chloro-2-methoxy-benzoic acid 2-pyrrolidin-1-yl-ethyl ester, HTR4 agonist targeting HTR4
YD-38-CI01_10uM Dose=10uM, 4-Amino-5-chloro-2-methoxy-benzoic acid 2-pyrrolidin-1-yl-ethyl ester, HTR4 agonist targeting HTR4
YD-38-CI01_1uM Dose=1uM, 4-Amino-5-chloro-2-methoxy-benzoic acid 2-pyrrolidin-1-yl-ethyl ester, HTR4 agonist targeting HTR4
YD-49-HM53_0.01uM Dose=0.01uM, MELK inhibitor targeting MELK
YD-49-HM53_0.1uM Dose=0.1uM, MELK inhibitor targeting MELK
YD-49-HM53_10uM Dose=10uM, MELK inhibitor targeting MELK
YD-49-HM53_1uM Dose=1uM, MELK inhibitor targeting MELK
YD-59-WM48_0.01uM Dose=0.01uM, 2-Methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane], CHRM1 agonist targeting CHRM1
YD-59-WM48_0.1uM Dose=0.1uM, 2-Methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane], CHRM1 agonist targeting CHRM1
YD-59-WM48_10uM Dose=10uM, 2-Methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane], CHRM1 agonist targeting CHRM1
YD-59-WM48_1uM Dose=1uM, 2-Methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane], CHRM1 agonist targeting CHRM1
YD-71-BE10_0.01uM Dose=0.01uM, Sgk1-IN-1, Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitors targeting SGK1, SGK2
YD-71-BE10_0.1uM Dose=0.1uM, Sgk1-IN-1, Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitors targeting SGK1, SGK2
YD-71-BE10_10uM Dose=10uM, Sgk1-IN-1, Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitors targeting SGK1, SGK2
YD-71-BE10_1uM Dose=1uM, Sgk1-IN-1, Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitors targeting SGK1, SGK2
YD-85-OD87_0.01uM Dose=0.01uM, 4-[[2,6-difluoro-4-[3-(1H-pyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine
YD-85-OD87_0.1uM Dose=0.1uM, 4-[[2,6-difluoro-4-[3-(1H-pyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine
YD-85-OD87_10uM Dose=10uM, 4-[[2,6-difluoro-4-[3-(1H-pyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine
YD-85-OD87_1uM Dose=1uM, 4-[[2,6-difluoro-4-[3-(1H-pyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine
YE-01-JU83_0.01uM Dose=0.01uM, N-p-Tolyl-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
YE-01-JU83_0.1uM Dose=0.1uM, N-p-Tolyl-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
YE-01-JU83_10uM Dose=10uM, N-p-Tolyl-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
YE-01-JU83_1uM Dose=1uM, N-p-Tolyl-guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E
YE-02-BO16_0.01uM Dose=0.01uM, 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester, Anxiolytics targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2
YE-02-BO16_0.1uM Dose=0.1uM, 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester, Anxiolytics targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2
YE-02-BO16_10uM Dose=10uM, 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester, Anxiolytics targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2
YE-02-BO16_1uM Dose=1uM, 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester, Anxiolytics targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2
YE-45-AD07_0.01uM Dose=0.01uM, 6-(4-Fluorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)nicotinamide, Prostaglandin synthase inhibitor targeting PTGDS, HPGDS
YE-45-AD07_0.1uM Dose=0.1uM, 6-(4-Fluorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)nicotinamide, Prostaglandin synthase inhibitor targeting PTGDS, HPGDS
YE-45-AD07_10uM Dose=10uM, 6-(4-Fluorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)nicotinamide, Prostaglandin synthase inhibitor targeting PTGDS, HPGDS
YE-45-AD07_1uM Dose=1uM, 6-(4-Fluorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)nicotinamide, Prostaglandin synthase inhibitor targeting PTGDS, HPGDS
YE-46-YA12_0.01uM Dose=0.01uM, 2-(4-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1
YE-46-YA12_0.1uM Dose=0.1uM, 2-(4-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1
YE-46-YA12_10uM Dose=10uM, 2-(4-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1
YE-46-YA12_1uM Dose=1uM, 2-(4-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide, Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1
YE-55-YX75_0.01uM Dose=0.01uM, methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate, PTGER4 agonist;PTGER2 agonist;PTGER3 agonist targeting PTGER2, PTGER3, PTGER4
YE-55-YX75_0.1uM Dose=0.1uM, methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate, PTGER4 agonist;PTGER2 agonist;PTGER3 agonist targeting PTGER2, PTGER3, PTGER4
YE-55-YX75_10uM Dose=10uM, methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate, PTGER4 agonist;PTGER2 agonist;PTGER3 agonist targeting PTGER2, PTGER3, PTGER4
YE-55-YX75_1uM Dose=1uM, methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate, PTGER4 agonist;PTGER2 agonist;PTGER3 agonist targeting PTGER2, PTGER3, PTGER4
YE-57-WY37_0.01uM Dose=0.01uM, 2-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]benzamide
YE-57-WY37_0.1uM Dose=0.1uM, 2-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]benzamide
YE-57-WY37_10uM Dose=10uM, 2-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]benzamide
YE-57-WY37_1uM Dose=1uM, 2-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]benzamide
YE-80-LN04_0.01uM Dose=0.01uM
YE-80-LN04_0.1uM Dose=0.1uM
YE-80-LN04_10uM Dose=10uM
YE-80-LN04_1uM Dose=1uM
YF-00-IN39_0.01uM Dose=0.01uM
YF-00-IN39_10uM Dose=10uM
YF-00-IN39_1uM Dose=1uM
YF-12-EY30_0.01uM Dose=0.01uM, (2S)-4-methyl-N-phenyl-2-[[4-phenyl-2-(sulfanylmethyl)butanoyl]amino]pentanamide, Collagenase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
YF-12-EY30_0.1uM Dose=0.1uM, (2S)-4-methyl-N-phenyl-2-[[4-phenyl-2-(sulfanylmethyl)butanoyl]amino]pentanamide, Collagenase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
YF-12-EY30_1uM Dose=1uM, (2S)-4-methyl-N-phenyl-2-[[4-phenyl-2-(sulfanylmethyl)butanoyl]amino]pentanamide, Collagenase Inhibitors targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21
YF-35-FN16_0.01uM Dose=0.01uM, N-[2-[2-(cyclohexylamino)pyridin-4-yl]-6-piperazin-1-ylpyridin-4-yl]methanesulfonamide
YF-35-FN16_0.1uM Dose=0.1uM, N-[2-[2-(cyclohexylamino)pyridin-4-yl]-6-piperazin-1-ylpyridin-4-yl]methanesulfonamide
YF-35-FN16_10uM Dose=10uM, N-[2-[2-(cyclohexylamino)pyridin-4-yl]-6-piperazin-1-ylpyridin-4-yl]methanesulfonamide
YF-35-FN16_1uM Dose=1uM, N-[2-[2-(cyclohexylamino)pyridin-4-yl]-6-piperazin-1-ylpyridin-4-yl]methanesulfonamide
YF-46-CA32_0.01uM Dose=0.01uM
YF-46-CA32_0.1uM Dose=0.1uM
YF-46-CA32_10uM Dose=10uM
YF-46-CA32_1uM Dose=1uM
YF-47-HO48_0.01uM Dose=0.01uM, alpha-Fluoromethylhistidine, (S)-, Histidine Decarboxylase Inhibitors targeting HDC
YF-47-HO48_0.1uM Dose=0.1uM, alpha-Fluoromethylhistidine, (S)-, Histidine Decarboxylase Inhibitors targeting HDC
YF-47-HO48_10uM Dose=10uM, alpha-Fluoromethylhistidine, (S)-, Histidine Decarboxylase Inhibitors targeting HDC
YF-47-HO48_1uM Dose=1uM, alpha-Fluoromethylhistidine, (S)-, Histidine Decarboxylase Inhibitors targeting HDC
YF-57-HO38_0.01uM Dose=0.01uM, Abecarnil, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB3, GABRG2
YF-57-HO38_0.1uM Dose=0.1uM, Abecarnil, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB3, GABRG2
YF-57-HO38_10uM Dose=10uM, Abecarnil, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB3, GABRG2
YF-57-HO38_1uM Dose=1uM, Abecarnil, GABA(A) BZ Site Receptor Partial Agonists targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB3, GABRG2
YF-64-PQ11_0.01uM Dose=0.01uM, Nitisinone, 4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitors targeting HPD
YF-64-PQ11_0.1uM Dose=0.1uM, Nitisinone, 4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitors targeting HPD
YF-64-PQ11_10uM Dose=10uM, Nitisinone, 4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitors targeting HPD
YF-77-FV50_0.1uM Dose=0.1uM
YF-77-FV50_10uM Dose=10uM
YF-77-FV50_1uM Dose=1uM
ZA-18-VC47_0.01uM Dose=0.01uM, 2-[[4-(Cyclopropanecarbonyl)piperazin-1-yl]methyl]-1,2-benzothiazol-3-one targeting PDIA3, P4HB
ZA-18-VC47_0.1uM Dose=0.1uM, 2-[[4-(Cyclopropanecarbonyl)piperazin-1-yl]methyl]-1,2-benzothiazol-3-one targeting PDIA3, P4HB
ZA-18-VC47_10uM Dose=10uM, 2-[[4-(Cyclopropanecarbonyl)piperazin-1-yl]methyl]-1,2-benzothiazol-3-one targeting PDIA3, P4HB
ZA-18-VC47_1uM Dose=1uM, 2-[[4-(Cyclopropanecarbonyl)piperazin-1-yl]methyl]-1,2-benzothiazol-3-one targeting PDIA3, P4HB
ZA-25-KN86_0.01uM Dose=0.01uM
ZA-25-KN86_0.1uM Dose=0.1uM
ZA-25-KN86_1uM Dose=1uM
ZA-28-BF44_0.1uM Dose=0.1uM, Amg-458, HGFR (MET;c-Met) Inhibitors targeting MET
ZA-28-BF44_10uM Dose=10uM, Amg-458, HGFR (MET;c-Met) Inhibitors targeting MET
ZA-28-BF44_1uM Dose=1uM, Amg-458, HGFR (MET;c-Met) Inhibitors targeting MET
ZA-63-AC60_0.01uM Dose=0.01uM, [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone targeting GPX4
ZA-63-AC60_0.1uM Dose=0.1uM, [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone targeting GPX4
ZA-63-AC60_10uM Dose=10uM, [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone targeting GPX4
ZA-63-AC60_1uM Dose=1uM, [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone targeting GPX4
ZA-84-ZC97_0.01uM Dose=0.01uM, 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-, Retinoid RXRalpha Agonists targeting RXRA
ZA-84-ZC97_0.1uM Dose=0.1uM, 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-, Retinoid RXRalpha Agonists targeting RXRA
ZA-84-ZC97_10uM Dose=10uM, 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-, Retinoid RXRalpha Agonists targeting RXRA
ZA-84-ZC97_1uM Dose=1uM, 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-, Retinoid RXRalpha Agonists targeting RXRA
ZB-09-RC84_0.01uM Dose=0.01uM, 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2
ZB-09-RC84_0.1uM Dose=0.1uM, 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2
ZB-09-RC84_10uM Dose=10uM, 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2
ZB-09-RC84_1uM Dose=1uM, 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2
ZB-12-BE52_0.01uM Dose=0.01uM, N-(3,4-Dichlorobenzyl)-5-hydroxyindole-2-carboxylic acid, Chemokine CCR2B Receptor Antagonists targeting CCR2
ZB-12-BE52_0.1uM Dose=0.1uM, N-(3,4-Dichlorobenzyl)-5-hydroxyindole-2-carboxylic acid, Chemokine CCR2B Receptor Antagonists targeting CCR2
ZB-12-BE52_10uM Dose=10uM, N-(3,4-Dichlorobenzyl)-5-hydroxyindole-2-carboxylic acid, Chemokine CCR2B Receptor Antagonists targeting CCR2
ZB-16-BR73_0.01uM Dose=0.01uM, N'-(1-(Pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide, p53 tumor suppressor protein inhibitor targeting TP53
ZB-16-BR73_0.1uM Dose=0.1uM, N'-(1-(Pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide, p53 tumor suppressor protein inhibitor targeting TP53
ZB-16-BR73_10uM Dose=10uM, N'-(1-(Pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide, p53 tumor suppressor protein inhibitor targeting TP53
ZB-16-BR73_1uM Dose=1uM, N'-(1-(Pyridin-2-yl)ethylidene)azetidine-1-carbothiohydrazide, p53 tumor suppressor protein inhibitor targeting TP53
ZB-28-SS80_0.01uM Dose=0.01uM, (3-Cyano-4-{3-[(5-methyl-furan-2-ylmethyl)-sulfamoyl]-5-trifluoromethyl-phenyl}-pyrrol-1-yl)-acetic acid, GPR44 antagonist targeting PTGDR2
ZB-28-SS80_0.1uM Dose=0.1uM, (3-Cyano-4-{3-[(5-methyl-furan-2-ylmethyl)-sulfamoyl]-5-trifluoromethyl-phenyl}-pyrrol-1-yl)-acetic acid, GPR44 antagonist targeting PTGDR2
ZB-28-SS80_10uM Dose=10uM, (3-Cyano-4-{3-[(5-methyl-furan-2-ylmethyl)-sulfamoyl]-5-trifluoromethyl-phenyl}-pyrrol-1-yl)-acetic acid, GPR44 antagonist targeting PTGDR2
ZB-28-SS80_1uM Dose=1uM, (3-Cyano-4-{3-[(5-methyl-furan-2-ylmethyl)-sulfamoyl]-5-trifluoromethyl-phenyl}-pyrrol-1-yl)-acetic acid, GPR44 antagonist targeting PTGDR2
ZB-29-GC39_0.01uM Dose=0.01uM
ZB-29-GC39_0.1uM Dose=0.1uM
ZB-29-GC39_10uM Dose=10uM
ZB-29-GC39_1uM Dose=1uM
ZB-33-MZ40_0.01uM Dose=0.01uM, 6-(2,3-Dichlorophenyl)-N4-methylpyrimidine-2,4-diamine, NUDT1 gene inhibitor targeting NUDT1
ZB-33-MZ40_0.1uM Dose=0.1uM, 6-(2,3-Dichlorophenyl)-N4-methylpyrimidine-2,4-diamine, NUDT1 gene inhibitor targeting NUDT1
ZB-33-MZ40_10uM Dose=10uM, 6-(2,3-Dichlorophenyl)-N4-methylpyrimidine-2,4-diamine, NUDT1 gene inhibitor targeting NUDT1
ZB-33-MZ40_1uM Dose=1uM, 6-(2,3-Dichlorophenyl)-N4-methylpyrimidine-2,4-diamine, NUDT1 gene inhibitor targeting NUDT1
ZB-42-PL54_0.01uM Dose=0.01uM
ZB-42-PL54_0.1uM Dose=0.1uM
ZB-42-PL54_10uM Dose=10uM
ZB-42-PL54_1uM Dose=1uM
ZB-45-AK89_0.01uM Dose=0.01uM, Nvp-dky709
ZB-45-AK89_10uM Dose=10uM, Nvp-dky709
ZB-45-AK89_1uM Dose=1uM, Nvp-dky709
ZB-54-WT28_0.01uM Dose=0.01uM, 6-(3-Fluorophenyl)-N-[1-(2,2,2-Trifluoroethyl)piperidin-4-Yl]pyridine-3-Carboxamide, Hematopoietic Prostaglandin D Synthase Inhibitor targeting HPGDS
ZB-54-WT28_0.1uM Dose=0.1uM, 6-(3-Fluorophenyl)-N-[1-(2,2,2-Trifluoroethyl)piperidin-4-Yl]pyridine-3-Carboxamide, Hematopoietic Prostaglandin D Synthase Inhibitor targeting HPGDS
ZB-54-WT28_10uM Dose=10uM, 6-(3-Fluorophenyl)-N-[1-(2,2,2-Trifluoroethyl)piperidin-4-Yl]pyridine-3-Carboxamide, Hematopoietic Prostaglandin D Synthase Inhibitor targeting HPGDS
ZB-54-WT28_1uM Dose=1uM, 6-(3-Fluorophenyl)-N-[1-(2,2,2-Trifluoroethyl)piperidin-4-Yl]pyridine-3-Carboxamide, Hematopoietic Prostaglandin D Synthase Inhibitor targeting HPGDS
ZB-62-QB90_0.01uM Dose=0.01uM, Vidofludimus, Anti-IL-17;Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
ZB-62-QB90_0.1uM Dose=0.1uM, Vidofludimus, Anti-IL-17;Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
ZB-62-QB90_10uM Dose=10uM, Vidofludimus, Anti-IL-17;Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
ZB-62-QB90_1uM Dose=1uM, Vidofludimus, Anti-IL-17;Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH
ZB-67-SE99_0.01uM Dose=0.01uM
ZB-67-SE99_0.1uM Dose=0.1uM
ZB-67-SE99_10uM Dose=10uM
ZB-67-SE99_1uM Dose=1uM
ZB-72-PE17_0.01uM Dose=0.01uM
ZB-72-PE17_0.1uM Dose=0.1uM
ZB-72-PE17_10uM Dose=10uM
ZB-72-PE17_1uM Dose=1uM
ZB-92-PL24_0.01uM Dose=0.01uM, Palonosetron, 5-HT3 Antagonists targeting HTR3A
ZB-92-PL24_0.1uM Dose=0.1uM, Palonosetron, 5-HT3 Antagonists targeting HTR3A
ZB-92-PL24_10uM Dose=10uM, Palonosetron, 5-HT3 Antagonists targeting HTR3A
ZB-93-OS38_0.01uM Dose=0.01uM, 1-(4-methoxyphenyl)-N-[(4-propan-2-ylphenyl)methyl]benzimidazol-5-amine
ZB-93-OS38_0.1uM Dose=0.1uM, 1-(4-methoxyphenyl)-N-[(4-propan-2-ylphenyl)methyl]benzimidazol-5-amine
ZB-93-OS38_10uM Dose=10uM, 1-(4-methoxyphenyl)-N-[(4-propan-2-ylphenyl)methyl]benzimidazol-5-amine
ZB-93-OS38_1uM Dose=1uM, 1-(4-methoxyphenyl)-N-[(4-propan-2-ylphenyl)methyl]benzimidazol-5-amine
ZC-09-IW47_0.01uM Dose=0.01uM, 7-(2,2-Dimethylpropyl)-6-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]pyrrolo[2,3-d]pyrimidine-2-carbonitrile
ZC-09-IW47_0.1uM Dose=0.1uM, 7-(2,2-Dimethylpropyl)-6-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]pyrrolo[2,3-d]pyrimidine-2-carbonitrile
ZC-09-IW47_10uM Dose=10uM, 7-(2,2-Dimethylpropyl)-6-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]pyrrolo[2,3-d]pyrimidine-2-carbonitrile
ZC-09-IW47_1uM Dose=1uM, 7-(2,2-Dimethylpropyl)-6-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]pyrrolo[2,3-d]pyrimidine-2-carbonitrile
ZC-12-OO11_0.01uM Dose=0.01uM, 5-(Pyridin-4-YL)-1H-imidazole-2-thiol, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8
ZC-12-OO11_0.1uM Dose=0.1uM, 5-(Pyridin-4-YL)-1H-imidazole-2-thiol, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8
ZC-12-OO11_10uM Dose=10uM, 5-(Pyridin-4-YL)-1H-imidazole-2-thiol, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8
ZC-12-OO11_1uM Dose=1uM, 5-(Pyridin-4-YL)-1H-imidazole-2-thiol, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8
ZC-47-HL31_0.01uM Dose=0.01uM, 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)cyclohexanecarbonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors;Aromatase Inhibitors targeting CYP11B1, CYP11B2, CYP19A1
ZC-47-HL31_0.1uM Dose=0.1uM, 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)cyclohexanecarbonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors;Aromatase Inhibitors targeting CYP11B1, CYP11B2, CYP19A1
ZC-47-HL31_10uM Dose=10uM, 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)cyclohexanecarbonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors;Aromatase Inhibitors targeting CYP11B1, CYP11B2, CYP19A1
ZC-47-HL31_1uM Dose=1uM, 4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)cyclohexanecarbonitrile, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors;Aromatase Inhibitors targeting CYP11B1, CYP11B2, CYP19A1
ZC-74-FT18_0.01uM Dose=0.01uM, CID 25225521, Orexin 2 receptor antagonist targeting HCRTR2
ZC-74-FT18_0.1uM Dose=0.1uM, CID 25225521, Orexin 2 receptor antagonist targeting HCRTR2
ZC-74-FT18_10uM Dose=10uM, CID 25225521, Orexin 2 receptor antagonist targeting HCRTR2
ZC-74-FT18_1uM Dose=1uM, CID 25225521, Orexin 2 receptor antagonist targeting HCRTR2
ZC-88-KS25_0.01uM Dose=0.01uM
ZC-88-KS25_0.1uM Dose=0.1uM
ZC-88-KS25_10uM Dose=10uM
ZC-88-KS25_1uM Dose=1uM
ZD-09-WT25_0.01uM Dose=0.01uM, 4-(Cyclopropylmethyl)-5-[2-(piperidin-4-ylamino)pyrimidin-4-yl]pyrimidin-2-amine
ZD-09-WT25_0.1uM Dose=0.1uM, 4-(Cyclopropylmethyl)-5-[2-(piperidin-4-ylamino)pyrimidin-4-yl]pyrimidin-2-amine
ZD-09-WT25_10uM Dose=10uM, 4-(Cyclopropylmethyl)-5-[2-(piperidin-4-ylamino)pyrimidin-4-yl]pyrimidin-2-amine
ZD-09-WT25_1uM Dose=1uM, 4-(Cyclopropylmethyl)-5-[2-(piperidin-4-ylamino)pyrimidin-4-yl]pyrimidin-2-amine
ZD-15-SG14_0.01uM Dose=0.01uM, 5,5'-Diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde
ZD-15-SG14_0.1uM Dose=0.1uM, 5,5'-Diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde
ZD-15-SG14_10uM Dose=10uM, 5,5'-Diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde
ZD-15-SG14_1uM Dose=1uM, 5,5'-Diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde
ZD-18-MI26_0.01uM Dose=0.01uM, N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide, Calcitonin Gene-Related Peptides (CGRP) Antagonists targeting CALCRL
ZD-18-MI26_0.1uM Dose=0.1uM, N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide, Calcitonin Gene-Related Peptides (CGRP) Antagonists targeting CALCRL
ZD-18-MI26_10uM Dose=10uM, N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide, Calcitonin Gene-Related Peptides (CGRP) Antagonists targeting CALCRL
ZD-18-MI26_1uM Dose=1uM, N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide, Calcitonin Gene-Related Peptides (CGRP) Antagonists targeting CALCRL
ZD-23-ZF57_0.01uM Dose=0.01uM, (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, LRRK2 inhibitor targeting LRRK2
ZD-23-ZF57_0.1uM Dose=0.1uM, (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, LRRK2 inhibitor targeting LRRK2
ZD-23-ZF57_10uM Dose=10uM, (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, LRRK2 inhibitor targeting LRRK2
ZD-23-ZF57_1uM Dose=1uM, (4-((5-chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone, LRRK2 inhibitor targeting LRRK2
ZD-27-QL96_0.1uM Dose=0.1uM, CDK Inhibitors
ZD-38-GI91_0.01uM Dose=0.01uM
ZD-38-GI91_0.1uM Dose=0.1uM
ZD-38-GI91_10uM Dose=10uM
ZD-38-GI91_1uM Dose=1uM
ZD-43-CS43_0.01uM Dose=0.01uM, 5,8-Dichlorospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7 gene inhibitor targeting PDE7A, PDE7B
ZD-43-CS43_0.1uM Dose=0.1uM, 5,8-Dichlorospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7 gene inhibitor targeting PDE7A, PDE7B
ZD-43-CS43_10uM Dose=10uM, 5,8-Dichlorospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7 gene inhibitor targeting PDE7A, PDE7B
ZD-43-CS43_1uM Dose=1uM, 5,8-Dichlorospiro[1,3-dihydroquinazoline-4,1'-cyclohexane]-2-one, PDE7 gene inhibitor targeting PDE7A, PDE7B
ZD-74-FC07_0.01uM Dose=0.01uM
ZD-74-FC07_0.1uM Dose=0.1uM
ZD-74-FC07_10uM Dose=10uM
ZD-74-FC07_1uM Dose=1uM
ZD-78-BS65_0.01uM Dose=0.01uM
ZD-78-BS65_0.1uM Dose=0.1uM
ZD-78-BS65_10uM Dose=10uM
ZD-78-BS65_1uM Dose=1uM
ZD-84-PM36_10uM Dose=10uM, Cyclopropanecarboxylic acid [4-(3-methoxy-phenoxy)-phenyl]-amide, Melatonin MT2 Receptor Ligands targeting MTNR1B
ZD-85-ID22_0.01uM Dose=0.01uM, 2,6-Difluoro-4-[4-(4-fluorophenyl)pyridin-3-yl]phenol
ZD-85-ID22_0.1uM Dose=0.1uM, 2,6-Difluoro-4-[4-(4-fluorophenyl)pyridin-3-yl]phenol
ZD-85-ID22_10uM Dose=10uM, 2,6-Difluoro-4-[4-(4-fluorophenyl)pyridin-3-yl]phenol
ZD-85-ID22_1uM Dose=1uM, 2,6-Difluoro-4-[4-(4-fluorophenyl)pyridin-3-yl]phenol
ZD-85-ND87_0.01uM Dose=0.01uM
ZD-85-ND87_0.1uM Dose=0.1uM
ZD-85-ND87_10uM Dose=10uM
ZD-93-FI44_0.01uM Dose=0.01uM, J-113863 cation, trans-, CCR3 antagonist targeting CCR1, CCR3
ZD-93-FI44_0.1uM Dose=0.1uM, J-113863 cation, trans-, CCR3 antagonist targeting CCR1, CCR3
ZD-93-FI44_10uM Dose=10uM, J-113863 cation, trans-, CCR3 antagonist targeting CCR1, CCR3
ZD-93-FI44_1uM Dose=1uM, J-113863 cation, trans-, CCR3 antagonist targeting CCR1, CCR3
ZE-11-HK24_0.01uM Dose=0.01uM, methyl (1R,2R,3S,3aR,8bS)-6-[[(2R,3R,6R)-6-[(1S)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate, EIF4A gene modulator targeting EIF4A1, EIF4A2, EIF4A3
ZE-11-HK24_0.1uM Dose=0.1uM, methyl (1R,2R,3S,3aR,8bS)-6-[[(2R,3R,6R)-6-[(1S)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate, EIF4A gene modulator targeting EIF4A1, EIF4A2, EIF4A3
ZE-11-HK24_10uM Dose=10uM, methyl (1R,2R,3S,3aR,8bS)-6-[[(2R,3R,6R)-6-[(1S)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate, EIF4A gene modulator targeting EIF4A1, EIF4A2, EIF4A3
ZE-11-HK24_1uM Dose=1uM, methyl (1R,2R,3S,3aR,8bS)-6-[[(2R,3R,6R)-6-[(1S)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy]-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate, EIF4A gene modulator targeting EIF4A1, EIF4A2, EIF4A3
ZE-11-PR61_0.01uM Dose=0.01uM, 1-[(1r,3s)-3-{[(5-Bromothiophen-2-Yl)carbonyl]amino}cyclohexyl]-N-Methyl-2-(Pyridin-2-Yl)-1h-Benzimidazole-5-Carboxamide, BCAT2 inhibitor targeting BCAT2
ZE-11-PR61_0.1uM Dose=0.1uM, 1-[(1r,3s)-3-{[(5-Bromothiophen-2-Yl)carbonyl]amino}cyclohexyl]-N-Methyl-2-(Pyridin-2-Yl)-1h-Benzimidazole-5-Carboxamide, BCAT2 inhibitor targeting BCAT2
ZE-11-PR61_10uM Dose=10uM, 1-[(1r,3s)-3-{[(5-Bromothiophen-2-Yl)carbonyl]amino}cyclohexyl]-N-Methyl-2-(Pyridin-2-Yl)-1h-Benzimidazole-5-Carboxamide, BCAT2 inhibitor targeting BCAT2
ZE-13-SI09_0.01uM Dose=0.01uM, (1-Amino-2-cyclohexylethyl)phosphonic acid, Leucine Aminopeptidase inhibitor targeting LAP3
ZE-13-SI09_10uM Dose=10uM, (1-Amino-2-cyclohexylethyl)phosphonic acid, Leucine Aminopeptidase inhibitor targeting LAP3
ZE-13-SI09_1uM Dose=1uM, (1-Amino-2-cyclohexylethyl)phosphonic acid, Leucine Aminopeptidase inhibitor targeting LAP3
ZE-14-BN99_0.01uM Dose=0.01uM, Cct251545, type I inhibitor of CDK8 and CDK19;Wnt Pathway Inhibitor;Wnt signalling inhibitor targeting CDK8, CDK19
ZE-14-BN99_0.1uM Dose=0.1uM, Cct251545, type I inhibitor of CDK8 and CDK19;Wnt Pathway Inhibitor;Wnt signalling inhibitor targeting CDK8, CDK19
ZE-14-BN99_10uM Dose=10uM, Cct251545, type I inhibitor of CDK8 and CDK19;Wnt Pathway Inhibitor;Wnt signalling inhibitor targeting CDK8, CDK19
ZE-14-BN99_1uM Dose=1uM, Cct251545, type I inhibitor of CDK8 and CDK19;Wnt Pathway Inhibitor;Wnt signalling inhibitor targeting CDK8, CDK19
ZE-37-PE19_0.01uM Dose=0.01uM, 6,8-Dichloro-7-methoxy-9H-beta-carboline targeting CHUK
ZE-37-PE19_0.1uM Dose=0.1uM, 6,8-Dichloro-7-methoxy-9H-beta-carboline targeting CHUK
ZE-37-PE19_10uM Dose=10uM, 6,8-Dichloro-7-methoxy-9H-beta-carboline targeting CHUK
ZE-37-PE19_1uM Dose=1uM, 6,8-Dichloro-7-methoxy-9H-beta-carboline targeting CHUK
ZE-45-CG69_0.01uM Dose=0.01uM
ZE-45-CG69_0.1uM Dose=0.1uM
ZE-45-CG69_10uM Dose=10uM
ZE-45-CG69_1uM Dose=1uM
ZE-46-XH09_0.01uM Dose=0.01uM, (2S,3R)-2-[4-(Cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
ZE-46-XH09_0.1uM Dose=0.1uM, (2S,3R)-2-[4-(Cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
ZE-46-XH09_10uM Dose=10uM, (2S,3R)-2-[4-(Cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
ZE-46-XH09_1uM Dose=1uM, (2S,3R)-2-[4-(Cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
ZE-53-LS38_0.01uM Dose=0.01uM, N'-benzhydryl-N-(9H-fluoren-9-yl)ethane-1,2-diamine
ZE-53-LS38_0.1uM Dose=0.1uM, N'-benzhydryl-N-(9H-fluoren-9-yl)ethane-1,2-diamine
ZE-53-LS38_10uM Dose=10uM, N'-benzhydryl-N-(9H-fluoren-9-yl)ethane-1,2-diamine
ZE-53-LS38_1uM Dose=1uM, N'-benzhydryl-N-(9H-fluoren-9-yl)ethane-1,2-diamine
ZE-58-ZZ82_0.01uM Dose=0.01uM
ZE-58-ZZ82_0.1uM Dose=0.1uM
ZE-58-ZZ82_10uM Dose=10uM
ZE-58-ZZ82_1uM Dose=1uM
ZE-61-GA95_0.01uM Dose=0.01uM, N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
ZE-61-GA95_0.1uM Dose=0.1uM, N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
ZE-61-GA95_10uM Dose=10uM, N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
ZE-61-GA95_1uM Dose=1uM, N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
ZE-79-HJ46_0.01uM Dose=0.01uM, N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
ZE-79-HJ46_0.1uM Dose=0.1uM, N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
ZE-79-HJ46_10uM Dose=10uM, N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
ZE-79-HJ46_1uM Dose=1uM, N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide
ZF-00-MX33_0.01uM Dose=0.01uM
ZF-00-MX33_0.1uM Dose=0.1uM
ZF-00-MX33_10uM Dose=10uM
ZF-00-MX33_1uM Dose=1uM
ZF-10-JD55_0.01uM Dose=0.01uM
ZF-10-JD55_0.1uM Dose=0.1uM
ZF-10-JD55_10uM Dose=10uM
ZF-10-JD55_1uM Dose=1uM